mesalamine has been researched along with Colitis, Ulcerative in 1715 studies
Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed)
mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.
Colitis, Ulcerative: Inflammation of the COLON that is predominantly confined to the MUCOSA. Its major symptoms include DIARRHEA, rectal BLEEDING, the passage of MUCUS, and ABDOMINAL PAIN.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Some patients with inflammatory bowel disease (IBD) who were under mesalamine treatment develop adverse reactions called "mesalamine allergy," which includes high fever and worsening diarrhea." | 9.22 | Genetic Background of Mesalamine-induced Fever and Diarrhea in Japanese Patients with Inflammatory Bowel Disease. ( Andoh, A; Araki, H; Fujii, T; Fujiya, M; Hanai, H; Hiraoka, S; Hisamatsu, T; Hokari, R; Ishiguro, Y; Kakuta, Y; Katsurada, T; Kawai, Y; Kinouchi, Y; Kobayashi, T; Kudo, H; Kuroha, M; Li, D; Masamune, A; Matsumoto, T; Matsuura, M; McGovern, DPB; Minegishi, N; Moroi, R; Motoya, S; Nagasaki, M; Naito, T; Nakase, H; Noguchi, M; Ohta, Y; Okamoto, D; Onodera, M; Oshima, N; Otsuka, T; Sakuraba, H; Sasaki, M; Sasaki, Y; Sato, Y; Shiga, H; Shimoyama, Y; Shinozaki, M; Suzuki, K; Suzuki, Y; Takagawa, T; Tokunaga, K, 2022) |
| "Mesalamine suppositories are first-line therapy in active ulcerative proctitis; the standard regime still recommends multiple doses per day." | 9.14 | Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. ( Andus, T; Baranovsky, A; Cascorbi, I; Dilger, K; Dorofeyev, AE; Greinwald, R; Kocjan, A; Lozynskyy, YS; Mikhailova, TL; Mohrbacher, R; Müser, M; Stolte, M; Vieth, M; Zvyagintseva, TD, 2010) |
| "This study showed that a daily bedtime dose of a 500 mg mesalamine suppository is safe and efficacious in children with ulcerative proctitis." | 9.14 | Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents. ( Giguere, M; Heyman, MB; Kierkus, J; Shbaklo, H; Spénard, J, 2010) |
| " This article presents a case report of febrile pleuropericarditis in a UC patient treated with balsalazide, and provides a thorough literature review of the rare side effects of 5-ASAs, their incidence, clinical presentation, differential diagnosis and treatment." | 8.90 | Febrile pleuropericarditis, a potentially life-threatening adverse event of balsalazide--case report and literature review of the side effects of 5-aminosalicylates. ( Coman, RM; Gjymishka, A; Glover, SC, 2014) |
| "Mesalamine (MES), also known as 5-aminosalicylic acid, is effective in treating mild to moderate ulcerative colitis (UC)." | 8.12 | Mesalamine-Mediated Amelioration of Experimental Colitis in Piglets Involves Gut Microbiota Modulation and Intestinal Immune Cell Infiltration. ( Huang, Y; Liu, H; Wu, M; Xiao, H; Yang, G, 2022) |
| "Peri-myocarditis has been associated to mesalamine use." | 8.02 | Peri-myocarditis caused by topical rectal mesalamine. ( Koslowsky, B; Orlev, A, 2021) |
| "Myopericarditis has occasionally been reported as a side effect of mesalamine in patients with inflammatory bowel disease." | 7.83 | Mesalamine-induced myopericarditis - A case report. ( Araújo-Correia, L; Bernardo, S; Fernandes, SR, 2016) |
| " We present a case of an 8-year-old female patient with intolerance to mesalamine and proctitis resistant to conventional therapy who responded to rectal tacrolimus treatment." | 7.80 | Successful treatment for ulcerative proctitis with rectal tacrolimus in an 8-year-old girl with intolerance to mesalamine. ( Blasco-Alonso, J; Gallego-Gutiérrez, S; Girón Fernández-Crehuet, F; Luque Pérez, S; Navas-López, VM; Serrano Nieto, MJ; Sierra Salinas, C, 2014) |
| "We prospectively investigated colonoscopic biopsies from five groups of 20 subjects each: patients with ulcerative or indeterminate colitis treated with azathioprine (group 1), azathioprine and 5-ASA (group 2), 5-ASA (group 3), untreated IBD (group 4), and healthy controls." | 7.74 | Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis. ( Bengmark, S; Dörffel, Y; Lochs, H; Loening-Baucke, V; Swidsinski, A, 2007) |
| "We report the case of a patient in whom fever, weight loss and pericarditis developed after 16 years of treatment with sulfasalazine for ulcerative colitis, after increasing the daily dosage from 1 to 3 g." | 7.74 | Sulfasalazine-induced pericarditis in a patient with ulcerative colitis without recurrence when switching to mesalazine. ( Aslangul, E; Gadhoum, H; Le Jeunne, C; Perrot, S; Romnicianu, S; Szwebel, T, 2007) |
| " Within 24 h of receiving intravenous steroids, loperamide, and mesalamine, she developed symptomatic hypotension, severe sinus bradycardia, sinus pauses, and junctional escape beats." | 7.70 | Severe symptomatic sinus bradycardia associated with mesalamine use. ( Asirvatham, S; Sebastian, C; Thadani, U, 1998) |
| "We describe a case of a 25-yr-old woman with ulcerative colitis who developed marked thrombocytopenia during treatment and upon rechallenge with oral mesalamine." | 7.70 | Mesalamine-associated thrombocytopenia. ( Farrell, RJ; Fine, SN; Michetti, P; Peppercorn, MA, 1999) |
| "Marks score or the ulcerative colitis disease-activity index) at two and four weeks." | 6.71 | Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. ( Berlanga-Acosta, J; Nightingale, J; Playford, RJ; Sinha, A; West, KP, 2003) |
| "MMX mesalamine was the causative agent by drug-induced lymphocyte stimulation test." | 5.72 | A Case of Stevens-Johnson Syndrome Complicated with Multimatrix System Mesalamine in Ulcerative Colitis. ( Abe, K; Goda, K; Irisawa, A; Kanamori, A; Kanazawa, M; Masuyama, S; Tanaka, T; Tominaga, K; Watanabe, S; Yamamiya, A, 2022) |
| "Mesalamine was stopped and repeat CXR was obtained on the follow-up visit, which showed no pleural effusion." | 5.56 | Mesalamine-induced eosinophilic pleural effusion. ( Al-Abcha, A; Alratroot, A; Kherallah, S; Raziq, F, 2020) |
| "Drug-induced acute pancreatitis (DIAP) is an often-neglected entity where the disorder is the consequence of the toxic effects of various agents applied to treat potentially life-threatening conditions, such as inflammatory bowel disease." | 5.56 | Recurrent acute pancreatitis induced by 5-ASA and azathioprine in ulcerative colitis. ( Bajor, J; Faluhelyi, N; Hegyi, P; Hegyi, PJ; Németh, BC; Szakács, Z, 2020) |
| "The patient was diagnosed with ulcerative colitis and received remission induction therapy with prednisolone." | 5.51 | Hematemesis due to Drug Allergy to Oral Prednisolone in a Patient with Ulcerative Colitis. ( Arisaka, O; Arisaka, T; Hiraishi, H; Irisawa, A; Kanazawa, M; Sugaya, T; Takahashi, F; Takenaka, K; Tominaga, K, 2019) |
| "Colitis was induced in female swiss mice by adding DSS 3% to the drinking water." | 5.48 | Antioxidant and anti-inflammatory effect of plumieride in dextran sulfate sodium-induced colitis in mice. ( Andrade, SF; Boeing, T; Bonomini, TJ; da Silva, LM; de Souza, P; Lucinda, RM; Malheiros, A; Mariano, LNB; Somensi, LB, 2018) |
| "Mesalamine suppositories have been used widely for the treatment of distal ulcerative colitis and considered to be safer than systemic administration for its limited systemic absorption." | 5.40 | Ulcerative colitis flair induced by mesalamine suppositories hypersensitivity. ( Ding, H; Hu, J; Hu, XY; Liu, XC; Mei, Q; Xu, JM, 2014) |
| "A mesalamine-induced fever was considered, and treatment was stopped, which led to spontaneous resolution of the fever." | 5.39 | Isolated fever induced by mesalamine treatment. ( Amara, J; Daniel, F; Honein, K; Jaoude, JB; Nasnas, R; Sayegh, R; Slim, R; Yaghi, C, 2013) |
| "A 19-year-old Japanese man had been treated for ulcerative colitis for 2 years." | 5.37 | A case of acne fulminans in a patient with ulcerative colitis successfully treated with prednisolone and diaminodiphenylsulfone: a literature review of acne fulminans, rosacea fulminans and neutrophilic dermatoses occurring in the setting of inflammatory ( Danno, K; Fujimoto, N; Tanaka, T; Uenishi, T; Wakabayashi, M, 2011) |
| "Myocarditis was diagnosed and balsalazide therapy was withdrawn, resulting in a full recovery and resolution of abnormalities." | 5.35 | Balsalazide-induced myocarditis. ( Austin, D; Hogg, KJ; Jamieson, N; Robertson, E, 2008) |
| "Colitis was induced by intrarectal administration of OXA solution (7." | 5.32 | Oxazolone-induced colitis in BALB/C mice: a new method to evaluate the efficacy of therapeutic agents for ulcerative colitis. ( Hatakeyama, S; Kojima, R; Kuroda, S; Nakamaru, K; Ohkishi, T, 2004) |
| "We report a case of ulcerative colitis (UC) that occurred during the course of rheumatoid arthritis (RA)." | 5.32 | Ulcerative colitis occurring in the course of rheumatoid arthritis: a case successfully treated with mesalamine enema. ( Fukaya, E; Honma, F; Iwadate, H; Kobayashi, H; Orikasa, H; Saito, H; Sato, K; Sato, Y; Sekine, H; Shio, K; Shioya, Y; Sugisaki, K; Watanabe, H, 2004) |
| "Interstitial nephritis is a recognized side effect." | 5.31 | Interstitial nephritis in patients with inflammatory bowel disease treated with mesalamine. ( Alexopoulou, I; Churchill, DN; Margetts, PJ, 2001) |
| "An 18-year-old woman with ulcerative colitis (UC) developed diffuse pulmonary infiltrates and hypoxemia three months after reinstitution of oral mesalamine." | 5.31 | Bronchiolitis obliterans in a patient with ulcerative colitis receiving mesalamine. ( Gil, J; Haralambou, G; Present, DH; Teirstein, AS, 2001) |
| "A 42-yr-old man with ulcerative colitis was admitted for investigation of prolonged fever associated with cholestatic liver tests." | 5.30 | Mesalamine-induced granulomatous hepatitis. ( Braun, M; Fraser, GM; Kunin, M; Salamon, F; Tur-Kaspa, R, 1999) |
| "Some patients with inflammatory bowel disease (IBD) who were under mesalamine treatment develop adverse reactions called "mesalamine allergy," which includes high fever and worsening diarrhea." | 5.22 | Genetic Background of Mesalamine-induced Fever and Diarrhea in Japanese Patients with Inflammatory Bowel Disease. ( Andoh, A; Araki, H; Fujii, T; Fujiya, M; Hanai, H; Hiraoka, S; Hisamatsu, T; Hokari, R; Ishiguro, Y; Kakuta, Y; Katsurada, T; Kawai, Y; Kinouchi, Y; Kobayashi, T; Kudo, H; Kuroha, M; Li, D; Masamune, A; Matsumoto, T; Matsuura, M; McGovern, DPB; Minegishi, N; Moroi, R; Motoya, S; Nagasaki, M; Naito, T; Nakase, H; Noguchi, M; Ohta, Y; Okamoto, D; Onodera, M; Oshima, N; Otsuka, T; Sakuraba, H; Sasaki, M; Sasaki, Y; Sato, Y; Shiga, H; Shimoyama, Y; Shinozaki, M; Suzuki, K; Suzuki, Y; Takagawa, T; Tokunaga, K, 2022) |
| "Mesalamine suppositories are first-line therapy in active ulcerative proctitis; the standard regime still recommends multiple doses per day." | 5.14 | Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis. ( Andus, T; Baranovsky, A; Cascorbi, I; Dilger, K; Dorofeyev, AE; Greinwald, R; Kocjan, A; Lozynskyy, YS; Mikhailova, TL; Mohrbacher, R; Müser, M; Stolte, M; Vieth, M; Zvyagintseva, TD, 2010) |
| "This study showed that a daily bedtime dose of a 500 mg mesalamine suppository is safe and efficacious in children with ulcerative proctitis." | 5.14 | Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents. ( Giguere, M; Heyman, MB; Kierkus, J; Shbaklo, H; Spénard, J, 2010) |
| "Topical mesalamine appears well tolerated and effective in treating patients with cuffitis, with improvement in symptom as well as endoscopic and histologic inflammation." | 5.11 | Treatment of rectal cuff inflammation (cuffitis) in patients with ulcerative colitis following restorative proctocolectomy and ileal pouch-anal anastomosis. ( Achkar, JP; Bambrick, ML; Bast, J; Bennett, AE; Brzezinski, A; Fazio, VW; Lashner, BA; Remzi, FH; Shen, B, 2004) |
| " Mesalamine is considered safe in pregnancy, excluding formulations with dibutyl phthalate." | 5.05 | Mesalamine in the Initial Therapy of Ulcerative Colitis. ( Chibbar, R; Moss, AC, 2020) |
| " This article presents a case report of febrile pleuropericarditis in a UC patient treated with balsalazide, and provides a thorough literature review of the rare side effects of 5-ASAs, their incidence, clinical presentation, differential diagnosis and treatment." | 4.90 | Febrile pleuropericarditis, a potentially life-threatening adverse event of balsalazide--case report and literature review of the side effects of 5-aminosalicylates. ( Coman, RM; Gjymishka, A; Glover, SC, 2014) |
| "Data from both basic research and clinical experience continue to suggest that mesalamines and thiopurines are effective and efficient for the maintenance of remission of inflammatory bowel diseases." | 4.85 | Individually administered or co-prescribed thiopurines and mesalamines for inflammatory bowel disease. ( Actis, GC; Ayoubi, M; Leone, N; Pazienza, P; Pellicano, R; Rizzetto, M; Rosina, F; Tappero, G, 2009) |
| "Sulfasalazine, consisting of 5-aminosalicylic acid bound to sulfapyridine by a diazo bond, was first used for treatment of ulcerative colitis in the early 1940s and later found effective in placebo-controlled trials for acute disease and for long-term maintenance of remission." | 4.81 | Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications. ( Schroeder, KW, 2002) |
| "Mesalamine (MES), also known as 5-aminosalicylic acid, is effective in treating mild to moderate ulcerative colitis (UC)." | 4.12 | Mesalamine-Mediated Amelioration of Experimental Colitis in Piglets Involves Gut Microbiota Modulation and Intestinal Immune Cell Infiltration. ( Huang, Y; Liu, H; Wu, M; Xiao, H; Yang, G, 2022) |
| "Bronchiectasis was treated with inhaled oral steroids and sputum expectoration while she continued mesalamine and azathioprine for ulcerative colitis." | 4.12 | Ulcerative colitis-associated bronchiectasis: A rare extraintestinal manifestation of inflammatory bowel disease: A case report. ( Abbas, A; Alhalabi, M; Ali Deeb, S; Ali, F, 2022) |
| "Non-adherence to mesalamine was underestimated by physicians in pregnant UC patients and contributed to disease relapse and possibly on pregnancy outcomes." | 4.02 | Non-adherence to Medications in Pregnant Ulcerative Colitis Patients Contributes to Disease Flares and Adverse Pregnancy Outcomes. ( Esaki, M; Fujii, T; Hibi, T; Hokari, R; Ishihara, S; Kitamura, K; Kobayashi, T; Kuji, N; Kunisaki, R; Miura, S; Nagahori, M; Naganuma, M; Nakamura, S; Sakuraba, A; Suzuki, Y; Takashi, K; Watanabe, C; Yamagami, H; Yokoyama, K; Yonezawa, M; Yoshimura, N, 2021) |
| "Although oral mesalamine is the first-choice drug for treating mild-to-moderate ulcerative colitis (UC), some patients show symptoms of intolerance, including exacerbation of diarrhea and abdominal pain." | 4.02 | Multicenter survey on mesalamine intolerance in patients with ulcerative colitis. ( Fujiwara, A; Higashi, R; Hiraoka, S; Inokuchi, T; Kato, J; Matsueda, K; Miyaike, J; Moritou, Y; Okada, H; Suzuki, S; Takagi, S; Takahara, M; Toyokawa, T, 2021) |
| "Peri-myocarditis has been associated to mesalamine use." | 4.02 | Peri-myocarditis caused by topical rectal mesalamine. ( Koslowsky, B; Orlev, A, 2021) |
| "The role of 5-aminosalicylic acid (5-ASA or mesalamine) in the prevention of colorectal cancer in ulcerative colitis (UC) patients was reported, but the effect on molecular targets in UC colon mucosa is unknown." | 3.91 | Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis. ( Alvarez, J; Amenta, PS; Bajpai, M; Cheng, J; Das, KK; Das, KM; Geng, X; Gorin, S; Minacapelli, CD; Poplin, E; Seril, DN; Van Gurp, J, 2019) |
| "Myopericarditis has occasionally been reported as a side effect of mesalamine in patients with inflammatory bowel disease." | 3.83 | Mesalamine-induced myopericarditis - A case report. ( Araújo-Correia, L; Bernardo, S; Fernandes, SR, 2016) |
| " We report a 22 year-old male with ulcerative colitis in treatment with mesalazine and prednisone presenting with headache and speech disturbances." | 3.81 | [Intracranial sinus venous thrombosis in ulcerative colitis. Report of one case]. ( Bagattini, JC; Calcagno, GP; Chiarella, M; Cohen, H; Forster, TA, 2015) |
| " We present a case of an 8-year-old female patient with intolerance to mesalamine and proctitis resistant to conventional therapy who responded to rectal tacrolimus treatment." | 3.80 | Successful treatment for ulcerative proctitis with rectal tacrolimus in an 8-year-old girl with intolerance to mesalamine. ( Blasco-Alonso, J; Gallego-Gutiérrez, S; Girón Fernández-Crehuet, F; Luque Pérez, S; Navas-López, VM; Serrano Nieto, MJ; Sierra Salinas, C, 2014) |
| "Inflammation-targeted treatment of patients with UC is effective and costs less than continuous treatment of all patients with mesalamine, the current standard of care." | 3.78 | Cost utility of inflammation-targeted therapy for patients with ulcerative colitis. ( Higgins, PD; Saini, SD; Waljee, AK, 2012) |
| "In the acute treatment of Crohn's disease, Pentasa and Salofalk seem to be more effective than placebo." | 3.76 | Oral 5-aminosalicylic acid preparations in treatment of inflammatory bowel disease. An update. ( Martin, F, 1987) |
| " The knowledge of the pharmacokinetic properties of 5-ASA from different drug formulations might contribute to a better understanding of its mode of action in IBD." | 3.76 | Pharmacology and pharmacokinetics of 5-aminosalicylic acid. ( Klotz, U; Maier, KE, 1987) |
| "The drug is useful in the treatment of active ulcerative colitis as well as in preventing relapses of the disease in remission." | 3.75 | Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development. ( Peppercorn, MA, 1984) |
| "Some studies have suggested that mesalamine can prevent the development of colorectal cancer in patients with ulcerative colitis (UC)." | 3.74 | Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine. ( Bodian, C; Croog, V; Harpaz, N; Hossain, S; Itzkowitz, S; Kornbluth, A; Ullman, T, 2008) |
| "We prospectively investigated colonoscopic biopsies from five groups of 20 subjects each: patients with ulcerative or indeterminate colitis treated with azathioprine (group 1), azathioprine and 5-ASA (group 2), 5-ASA (group 3), untreated IBD (group 4), and healthy controls." | 3.74 | Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis. ( Bengmark, S; Dörffel, Y; Lochs, H; Loening-Baucke, V; Swidsinski, A, 2007) |
| "We report the case of a patient in whom fever, weight loss and pericarditis developed after 16 years of treatment with sulfasalazine for ulcerative colitis, after increasing the daily dosage from 1 to 3 g." | 3.74 | Sulfasalazine-induced pericarditis in a patient with ulcerative colitis without recurrence when switching to mesalazine. ( Aslangul, E; Gadhoum, H; Le Jeunne, C; Perrot, S; Romnicianu, S; Szwebel, T, 2007) |
| " Clinically, pro-drugs such as olsalazine have been associated with dose-dependent diarrhea, which was likely secondary to ileal secretion induced by the azo linkages, in 17% of patients." | 3.73 | Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum. ( Chang, EB; Hanauer, SB; Kles, KA; Musch, MW; Turner, JR; Vavricka, SR, 2005) |
| " Other data collected included history of primary sclerosing cholangitis, family history of colorectal cancer, and smoking and drug history (mesalamine 5-aminosalicylic acid, azathioprine, and folate)." | 3.72 | Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. ( Forbes, A; Kamm, M; Price, A; Rumbles, S; Rutter, M; Saunders, B; Schofield, G; Talbot, I; Wilkinson, K; Williams, C, 2004) |
| " Within 24 h of receiving intravenous steroids, loperamide, and mesalamine, she developed symptomatic hypotension, severe sinus bradycardia, sinus pauses, and junctional escape beats." | 3.70 | Severe symptomatic sinus bradycardia associated with mesalamine use. ( Asirvatham, S; Sebastian, C; Thadani, U, 1998) |
| "High doses of orally administered prednisolone induced the healing of the pyoderma gangrenosum within 2 months." | 3.70 | [Extra-intestinal manifestations and complications in chronic active ulcerative colitis in childhood and adolescence]. ( Hüppe, D; Schenck, B; Tromm, A, 1999) |
| "We describe a case of a 25-yr-old woman with ulcerative colitis who developed marked thrombocytopenia during treatment and upon rechallenge with oral mesalamine." | 3.70 | Mesalamine-associated thrombocytopenia. ( Farrell, RJ; Fine, SN; Michetti, P; Peppercorn, MA, 1999) |
| " She had been diagnosed 2 months before as having ulcerative proctitis and was treated with mesalamine, which induced a full remission, but 3 antibiotic regimens failed to improve her lung disease." | 3.70 | [Mesalamine-induced hypersensitivity pneumonitis]. ( Fireman, Z; Weiner, P; Weizman, J; Zamir, C; Zamir, D, 1999) |
| "After 2 weeks' treatment with sulfasalazine (SASP) and mesalazine enema, a 32-year-old female with recently diagnosed ulcerative colitis developed bilateral pulmonary infiltrates with peripheral eosinophilia." | 3.70 | [Sulfasalazine-induced pulmonary infiltrates and Legionella pneumonia]. ( Avar, S; Bielecki, JW; Joss, R, 2000) |
| "Amplified chemiluminescence was used to measure reactive oxygen species production by colonic biopsy specimens from rats with acetic acid induced colitis and to assess the in vitro effect of conventional antioxidants, standard therapies and proposed novel therapies for inflammatory bowel disease." | 3.69 | Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis. ( Blades, S; Blake, DR; Chander, CL; Claxson, AW; Coumbe, A; Millar, AD; Morris, CJ; Panetta, J; Rampton, DS, 1996) |
| "A rat model of colitis [dextran sulfate (DSS)] was used to study the permeation of Evans blue (EB) from the lumen into the wall of proximal and distal colonic loops after exposure to the dye for 2 hr." | 3.69 | Influence of topical rectal application of drugs on dextran sulfate-induced colitis in rats. ( Ahlman, H; Björck, S; Dahlström, A; Jennische, E, 1997) |
| "Acute pancreatitis is a known, although rare, complication of mesalamine treatment." | 3.69 | Acute pancreatitis after long-term 5-aminosalicylic acid therapy. ( Fernández, J; Feu, F; Navarro, S; Panés, J; Sala, M; Terés, J, 1997) |
| "Lichen planus is a recognized complication of sulfasalazine therapy." | 3.68 | Lichen planus and mesalazine. ( Alstead, EM; Farthing, MJ; Wilson, AG, 1991) |
| "Despite the extensive use of sulfasalazine (SAS) and/or 5-aminosalicylic acid (5-ASA) in patients with inflammatory bowel disease and, more recently, rheumatoid arthritis, their mode of action has not been elucidated so far." | 3.67 | Possible mode of action of 5-aminosalicylic acid. ( Dreyling, KW; Goebell, H; May, B; Peskar, BM; Schaarschmidt, K, 1987) |
| "AJM300 is an oral, small-molecule α4-integrin antagonist." | 3.11 | AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. ( Hibi, T; Hirai, F; Ishida, T; Ishiguro, Y; Kajioka, T; Kanke, K; Kishida, S; Kobayashi, K; Matsuoka, K; Miura, Y; Mizusawa, H; Nakajima, K; Ohmori, T; Ohta, A; Watanabe, K; Watanabe, M, 2022) |
| "Proctitis is the least extensive type of ulcerative colitis, for which rectal therapy is rarely studied and is underused." | 3.11 | Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial. ( Abdulkhakov, S; Abrahamovych, O; Alexeeva, O; Andreev, P; Baluta, M; Datsenko, O; Delmans, G; Dorofeyev, A; Greinwald, R; Kharchenko, N; Khimion, L; Kolesnik, IP; Kruis, W; Lesniakowski, K; Levchenko, O; Maksyashina, SV; Mihaly, E; Mohrbacher, R; Mostovoy, Y; Mueller, R; Pokrotnieks, J; Sablin, OA; Siegmund, B; Simanenkov, V; Sobon, M; Uspenskiy, Y; Viacheslav, N; Vieth, M, 2022) |
| "5-ASA is used as first-line therapy for ulcerative colitis." | 3.01 | Significance of 5-Aminosalicylic Acid Intolerance in the Clinical Management of Ulcerative Colitis. ( Kanai, T; Kiyohara, H; Mikami, Y; Mizushima, I; Suzuki, S; Tsunoda, J, 2023) |
| " Epidemiologic studies suggest that long-term use of non-steroidal anti-inflammatory drugs (NSAIDs), including mesalazine, has beneficial effects on colitis-associated colorectal cancer." | 3.01 | Molecular Mechanisms of the Antitumor Effects of Mesalazine and Its Preventive Potential in Colorectal Cancer. ( Madej, M; Strzalka-Mrozik, B; Słoka, J, 2023) |
| "Ulcerative colitis is a lifelong inflammatory disease affecting the rectum and colon to a variable extent." | 3.01 | Ulcerative colitis. ( Honap, S; Le Berre, C; Peyrin-Biroulet, L, 2023) |
| "The risk of colorectal cancer after 20 years of disease duration is 4." | 3.01 | Ulcerative Colitis in Adults: A Review. ( Gros, B; Kaplan, GG, 2023) |
| "BACKGROUND Ulcerative colitis (UC) is a chronic immune-mediated disease of the colon." | 3.01 | Upadacitinib as a Rescue Therapy in Acute Severe Ulcerative Colitis: A Case Report and Review of the Literature. ( Ali, NM; Shehab, MA, 2023) |
| " Mesalamine is commonly administered as divided dosing, although once-daily dosing may provide benefits for patients." | 3.01 | Similar pharmacokinetics of three dosing regimens comprising two oral delayed-release mesalamine formulations in healthy adult volunteers: Randomised, open-label, parallel-group study. ( Jakate, A; McNamee, B; Sandborn, WJ; Vande Casteele, N, 2021) |
| " We, therefore, conduct a randomized and controlled trial to evaluate the efficacy and safety of mesalazine enteric-coated tablets combined with Kangfuxin Liquid (KFX) enema for the child-bearing period female with active UC." | 3.01 | Effect of Kangfuxin Liquid enema combined with mesalazine on gestational outcomes and quality of life in child-bearing female with active ulcerative colitis: A protocol for randomized, double-blind, controlled trial. ( Li, F; Lu, H; Wang, T; Zhang, Q, 2021) |
| " Adverse event rates were similar (QCHS granules 38." | 3.01 | Randomised clinical trial: Efficacy and safety of Qing-Chang-Hua-Shi granules in a multicenter, randomized, and double-blind clinical trial of patients with moderately active ulcerative colitis. ( Chen, S; Chen, Y; Cheng, J; Gu, P; Gu, Q; Hu, J; Ke, X; Liu, Y; Ren, S; Shen, H; Shen, Z; Tang, Z; Xie, J; Zhang, L; Zhang, S; Zhao, W; Zheng, K; Zhu, L; Zou, J, 2021) |
| " Treatment-emergent adverse events and morning cortisol levels were assessed throughout the treatment and follow-up phases." | 2.94 | Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1). ( Derova, J; Fellermann, K; Greinwald, R; Jonaitis, L; Nacak, T; Rácz, I; Schiefke, I; Wehrum, S, 2020) |
| "Although proctitis is the most limited form of ulcerative colitis, it causes unpleasant symptoms." | 2.90 | Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis. ( Abdulkhakov, S; Alekseeva, O; Andreev, P; Datsenko, O; Dorofeyev, AE; Greinwald, R; Kruis, W; Levchenko, O; Lozynskyy, Y; Mohrbacher, R; Mostovoy, Y; Neshta, V; Pesegova, M; Siegmund, B; Soloviev, K; Stiess, M; Vieth, M, 2019) |
| " The authors found that the treatment showed slightly adverse events in FAP patients." | 2.90 | Utility of Mesalazine in Familial Adenomatous Polyposis: Clinical Report of Reduction of Polyp Size in Patients with Ulcerative Colitis, and Safety Examination in Familial Adenomatous Polyposis Patients. ( Abe, T; Doyama, H; Ezoe, Y; Ishikawa, H; Mutoh, M; Nakajima, T; Sakai, T; Takeuchi, Y; Wakabayashi, K, 2019) |
| "Medication non-adherence in paediatric ulcerative colitis (UC) has been associated with negative health outcomes including flares in disease activity." | 2.90 | Longitudinal non-adherence predicts treatment escalation in paediatric ulcerative colitis. ( Carmody, JK; Denson, LA; Hommel, KA; Hyams, JS; LeLeiko, NS; Lobato, D; Peugh, JL; Plevinsky, J, 2019) |
| "A final diagnosis, however, indicated ulcerative colitis in 10 children and Crohn disease in 2 children." | 2.87 | Granulocyte and Monocyte Apheresis for Induction of Remission in Children With New-Onset Inflammatory Bowel Colitis. ( Eberhardson, M; Fagerberg, UL; Finkel, Y; Rolandsdotter, H, 2018) |
| " We found large variation in spot (Nac-)5-ASA urinary excretion that was unrelated to brand, dosing schedule or dosage of 5-ASA." | 2.87 | Urinalysis of MMX-mesalazine as a tool to monitor 5-ASA adherence in daily IBD practice. ( Burger, DM; Drenth, JPH; Hoentjen, F; Peters, W; Römkens, TEH; Te Morsche, R, 2018) |
| "Disease activity of patients with ulcerative colitis (UC) predicts health-related quality of life (HRQL) and work-related outcomes (eg, absenteeism, productivity)." | 2.87 | Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study. ( D'Haens, G; Teynor, M; Willian, MK; Yarlas, A, 2018) |
| "Mesalamine response was defined as improvement in Week 6 Physician's Global Assessment (PGA) and non-response as a lack of improvement in Week 6 PGA." | 2.87 | Genetic variants in cellular transport do not affect mesalamine response in ulcerative colitis. ( Daly, MJ; Huang, H; Kaplan, JL; Moran, CJ; Rivas, M; Winter, HS, 2018) |
| "Present investigation is conducted to investigate the clinical efficacy of mesalazine in combination with the Bifid Triple Viable Capsules on the ulcerative colitis (UC) and the resultant effect on the inflammatory factors (TNF-α, IL-8 and IL-10) of UC patients." | 2.87 | Efficacy of mesalazine in combination with bifid triple viable capsules on ulcerative colitis and the resultant effect on the inflammatory factors. ( Chen, J; Chen, Z; Huang, M; Lang, C; Xue, L; Yang, B; Zhang, Y, 2018) |
| "Clinical remission [ulcerative colitis disease activity index rectal bleeding and stool frequency subscale scores of 0] was similar in both groups [p = 0." | 2.84 | Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial. ( Axler, J; Barrett, AC; Bortey, E; Cohen, RD; Forbes, WP; Lichtenstein, GR; Riddell, RH; Rubin, DT; Sandborn, WJ; Zhu, C, 2017) |
| "QD dosing with Asacol is as effective and safe as TID for maintenance of remission in patients with ulcerative colitis." | 2.84 | 2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis: A Randomized, Noninferiority, Multi-center Trial. ( Arai, T; Hibi, T; Iida, M; Ito, H; Nishino, H; Ohmori, T; Okubo, T; Suzuki, Y; Yokoyama, T, 2017) |
| "Paediatric ulcerative colitis [UC] is more extensive than adult disease, and more often refractory to mesalamine." | 2.84 | Mesalamine Enemas for Induction of Remission in Oral Mesalamine-refractory Pediatric Ulcerative Colitis: A Prospective Cohort Study. ( Boaz, M; Broide, E; Cohen, S; Focht, G; Kolho, KL; Kori, M; Ledder, O; Levine, A; Mozer-Glassberg, Y; On, A; Peleg, S; Shabat, CS; Shachmon, E; Shamaly, H; Shaoul, R; Shteyer, E; Turner, D; Yerushalmi, B, 2017) |
| "Trials in adults suggested that, in ulcerative colitis [UC], once-daily [OD] dosing of 5-ASA [5-amino salicylic acid] may be as or more effective than twice-daily [BD] dosing." | 2.84 | Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial. ( Broide, E; Cohen, S; Kolho, KL; Kori, M; Ledder, O; Levine, A; Mozer-Glassberg, Y; On, A; Peleg, S; Shamaly, H; Shaoul, R; Shteyer, E; Turner, D; Yerushalmi, B, 2017) |
| "Approximately 20% of patients with ulcerative colitis become steroid dependent." | 2.84 | Traditional Chinese medicine combination therapy for patients with steroid-dependent ulcerative colitis: study protocol for a randomized controlled trial. ( Jia, J; Lu, Y; Shen, H; Shen, Z; Zhang, L; Zheng, K; Zhu, L, 2017) |
| " The "good adherers" with false-negative urine tests were on a once daily dosing regimen and had collected a spot urine sample shortly before the next dosage." | 2.84 | Simple Urine Test to Evaluate Adherence to Oral 5-ASA in Teenagers With Ulcerative Colitis: Proof of Concept. ( Dijkstra, A; Touw, DJ; van Rheenen, PF, 2017) |
| "Ulcerative proctitis is a common and often highly symptomatic form of inflammatory bowel disease." | 2.82 | Efficacy of Pharmacological Agents for Ulcerative Proctitis: A Systematic Literature Review. ( Caron, B; Danese, S; Hart, A; Panaccione, R; Peyrin-Biroulet, L; Sandborn, WJ; Schreiber, S; Solitano, V, 2022) |
| "The treatment spectrum for ulcerative colitis has greatly increased in recent years." | 2.82 | [Living guideline on ulcerative colitis]. ( Kucharzik, T, 2022) |
| "Antibiotics have been considered to treat ulcerative colitis (UC) due to their antimicrobial properties against intestinal bacteria linked to inflammation." | 2.82 | Antibiotics for the induction and maintenance of remission in ulcerative colitis. ( Akobeng, AK; Gordon, M; Grafton-Clarke, C; Sinopoulou, V, 2022) |
| "RCT studies on Vitamin D in the treatment of ulcerative colitis were searched from CNKI, Wanfang Data, PubMed, Cochrane Library, and Web of Science databases." | 2.82 | Efficacy and Safety of Vitamin D Adjuvant Therapy for Ulcerative Colitis: A Meta-Analysis. ( Guo, X; Huang, Y; Liu, C, 2022) |
| "To systematically assess effectiveness and safety of Bifidobacterium quadruple viable bacteria combined with mesalamine against ulcerative colitis (UC) in the Asian population." | 2.82 | Efficacy and Safety of Bifidobacterium Quadruple Viable Bacteria Combined with Mesalamine against UC Management: A Systematic Review and Meta-Analysis. ( Chen, Y; Fan, Y; Li, S; Li, W; Lv, Q; Sun, X; Xie, F; Yang, X, 2022) |
| "The risk of acute pancreatitis in patients with IBD is increased due to the higher incidence of cholelithiasis and drug-induced pancreatitis in this population." | 2.82 | Pancreatic Disorders in Patients with Inflammatory Bowel Disease. ( Bi, Y; Corral, JE; Farraye, FA; Ji, B; Kröner, PT; Lukens, FJ; Montenegro, ML, 2022) |
| "Mesalamine granules treatment resulted in a significantly longer remission duration versus placebo (P=0." | 2.82 | Once-daily Mesalamine Formulation for Maintenance of Remission in Ulcerative Colitis: A Randomized, Placebo-controlled Clinical Trial. ( Barrett, AC; Bortey, E; Forbes, WP; Gordon, GL; Lichtenstein, GR; Murthy, U; Paterson, C; Pruitt, R; Sedghi, S; Zakko, S, 2016) |
| " Relapse was defined as revised Sutherland Disease Activity Index (SDAI) rectal bleeding score ≥1 and mucosal appearance score ≥2, UC flare, or UC-related adverse event (AE)." | 2.82 | Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors. ( Barrett, AC; Bortey, E; Forbes, WP; Gordon, GL; Lichtenstein, GR; Murthy, U; Paterson, C; Pruitt, R; Sedghi, S; Zakko, SF, 2016) |
| " Treatment-emergent adverse events were reported by ten subjects." | 2.82 | Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis. ( Cuffari, C; Edwards, AY; Fyderek, K; Hossack, S; Korczowski, B; Martin, P; Pierce, D; Van Heusen, H; Wan, H, 2016) |
| "Adalimumab was approved for the treatment of ulcerative colitis refractory to conventional therapy several years later than infliximab in Europe." | 2.82 | [Long-term adalimumab therapy in ulcerative colitis in clinical practice: result of the Hungarian multicenter prospective study]. ( Bálint, A; Bor, R; Csontos, Á; Farkas, K; Gábor, Z; Hegede, G; Horváth, G; Juhász, M; Lakner, L; Miheller, P; Milassin, Á; Molnár, T; Nagy, F; Palatka, K; Rácz, I; Rutka, M; Szabó, A; Szepes, Z; Szűcs, M; Vincze, Á; Zsigmond, F; Zsóri, Á, 2016) |
| " The frequency of adverse events was comparable between groups, regardless of baseline 5-ASA use." | 2.82 | Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies. ( Bosworth, BP; Harper, JR; Rubin, DT; Sandborn, WJ, 2016) |
| "Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 patients received a single daily oral administration of mesalazine 1200 mg and a double daily administration of a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4." | 2.82 | The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study. ( Buscemi, S; Carini, F; Damiani, P; Damiano, G; Gerges-Geagea, A; Jurjus, A; Lo Monte, AI; Marino Gammazza, A; Palumbo, VD; Romeo, M; Tomasello, G, 2016) |
| "A total of 221 patients with active ulcerative colitis were randomized into YNBY group (78 cases) and control group (143 cases)." | 2.82 | [Efficacy of Yunnan Baiyao as an adjuvant treatment for active ulcerative colitis: an open-label randomized controlled study]. ( Diao, N; Gu, YX; Li, MS; Zhao, WZ; Zhu, XT, 2016) |
| "The relapse rate of ulcerative colitis (UC) is high." | 2.80 | Combined diosmectite and mesalazine treatment for mild-to-moderate ulcerative colitis: a randomized, placebo-controlled study. ( Cui, HF; Jiang, XL; Wang, HH, 2015) |
| "Mesalazine is a key drug in the treatment of ulcerative colitis (UC)." | 2.80 | Ulcerative colitis patients with an inflammatory response upon mesalazine cannot be desensitized: a randomized study. ( Buurman, DJ; De Monchy, JG; Dijkstra, G; Kleibeuker, JH; Schellekens, RC; van der Waaij, LA, 2015) |
| "Mesalazine is used as maintenance therapy in ulcerative colitis but the optimal dosage is still controversial." | 2.80 | A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis. ( Avallone, EV; Cassieri, C; Cocco, A; Crispino, P; De Nitto, D; Marcheggiano, A; Occhigrossi, G; Paoluzi, P; Pica, R; Zippi, M, 2015) |
| "A 1-year substudy was conducted alongside a trial that compared 2 different dosing regimens (once daily versus three times daily) of mesalazine for patients in remission with ulcerative colitis." | 2.79 | Electronic monitoring of medication adherence in a 1-year clinical study of 2 dosing regimens of mesalazine for adults in remission with ulcerative colitis. ( Farewell, D; Gillespie, D; Hawthorne, AB; Hood, K; Probert, C; Stenson, R, 2014) |
| "Among patients with quiescent ulcerative colitis (UC), lower fecal concentrations of calprotectin are associated with lower rates of relapse." | 2.79 | Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis. ( Aberra, FN; Brensinger, C; Cross, R; Gilroy, E; Hardi, R; Lewis, JD; Liakos, S; McCabe, R; Nessel, L; Osterman, MT; Shafran, I; Wolf, D, 2014) |
| "To evaluate the potential for pharmacokinetic interactions between MMX mesalamine and amoxicillin, ciprofloxacin extended release (XR), metronidazole, or sulfamethoxazole in four open-label, randomized, placebo-controlled, two-period crossover studies." | 2.79 | Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials. ( Barrett, K; Corcoran, M; Inglis, S; Martin, P; Pierce, D; Preston, P; Thompson, TN; Willsie, SK, 2014) |
| " Safety assessments included monitoring of adverse events (AEs) and clinical laboratory tests." | 2.79 | Long-term safety and tolerability of once-daily mesalamine granules in the maintenance of remission of ulcerative colitis. ( Barrett, AC; Bortey, E; Forbes, WP; Lichtenstein, GR; Paterson, C, 2014) |
| "Japanese ulcerative colitis (UC) patients receiving acute induction therapy with 4." | 2.79 | Efficacy of long-term 4.0 g/day mesalazine (Pentasa) for maintenance therapy in ulcerative colitis. ( Akazawa, Y; Ichikawa, T; Isomoto, H; Makiyama, K; Matsumura, M; Nakao, K; Nishiyama, H; Ohba, K; Ohnita, K; Takeshima, F; Yamaguchi, N; Yamakawa, M; Yamao, T, 2014) |
| " Adverse events at least possibly related to treatment were observed in 23%, 12." | 2.79 | Safety and activity of dersalazine sodium in patients with mild-to-moderate active colitis: double-blind randomized proof of concept study. ( Panés, J; Pontes, C; Torres, F; Vives, R, 2014) |
| "Clinical trials in ulcerative colitis (UC) rely on certain parameters to evaluate responses that are highly subjective or of low sensitivity." | 2.78 | Evaluation of responsive gene expression as a sensitive and specific biomarker in patients with ulcerative colitis. ( Aceituno, M; Balsa, D; Esteller, M; Lozano, JJ; Merlos, M; Panés, J; Planell, N; Pontes, C; Román, J; Salas, A, 2013) |
| "The optimal mesalazine dosing strategy for ulcerative colitis (UC) continues to evolve." | 2.78 | The effect of third-party reporting on adoption of evidence-based mesalazine regimens in ulcerative colitis: an observational study. ( Ceplis-Kastner, S; Kruis, W; Leifeld, L; Morgenstern, J; Pfützer, R; Reimers, B, 2013) |
| " Given the high use of complementary alternative medicines in pediatric IBD, a prospective tolerability study of curcumin, an herbal therapy with known anti-inflammatory effects, was conducted to assess possible dosage in children with IBD." | 2.78 | Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study. ( Burpee, T; Christie, D; Cohen, M; Suskind, DL; Wahbeh, G; Weber, W, 2013) |
| "The primary endpoint was clinical recurrence at Month 6." | 2.77 | Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis. ( Barrett, K; Dolin, B; Jamal, MM; Kane, S; Katz, S; Palmen, M; Safdi, M; Solomon, D, 2012) |
| "Compared with HD, a mesalamine enteric-coated tablet, FCC is similarly effective and safe in the treatment of active UC with TCM pattern of damp-heat accumulation interior pattern." | 2.77 | Efficacy and safety of Fufangkushen colon-coated capsule in the treatment of ulcerative colitis compared with mesalazine: a double-blinded and randomized study. ( Gong, Y; Jiang, M; Li, L; Lin, Y; Liu, L; Liu, Y; Lu, A; Yang, B; Zha, Q, 2012) |
| " Multivariate analysis, however, showed OD dosing was associated with lower relapse risk independently of adherence." | 2.77 | One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis. ( Dhar, A; Gillespie, D; Hawthorne, AB; Hood, K; Kapur, KC; Probert, CS; Stenson, R; Swarbrick, ET, 2012) |
| " The PODIUM study compared a once daily to a twice daily dosing regimen of a slow-release mesalazine (Pentasa®); here we assess the efficacy, in terms of maintenance of remission and mucosal healing, of both regimens in patients with left-sided disease." | 2.77 | Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing. ( Bokemeyer, B; Broberg, P; Dignass, A; Gill, I; Hommes, D, 2012) |
| "Treatment with mesalamine to maintain endoscopic remission (mucosal healing) of ulcerative colitis (UC) has been shown to reduce the risk of relapse and is the recommended first-line maintenance therapy." | 2.77 | Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis. ( Barrett, K; D'Haens, G; Hodgson, I; Sandborn, WJ; Streck, P, 2012) |
| "Primary endpoint was the ulcerative colitis-disease activity index (UC-DAI) score before and after 8 weeks of treatment." | 2.76 | Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. ( Hibi, T; Hiwatashi, N; Mitsuyama, K; Munakata, A; Suzuki, Y, 2011) |
| " dosing of total 1." | 2.76 | Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis. ( Bátovský, M; Dilger, K; Faszczyk, M; Greinwald, R; Horynski, M; Jonaitis, L; Kruis, W; Kull, K; Lozynsky, YS; Mikhailova, TL; Mueller, R; Pokrotnieks, J; Rácz, I; Vcev, A; Zakharash, Y, 2011) |
| " The tailored intervention included educational and motivational components, plus options including simplified dosing regimes and practical reminders such as pill dispensers." | 2.76 | Impact of a tailored patient preference intervention in adherence to 5-aminosalicylic acid medication in ulcerative colitis: results from an exploratory randomized controlled trial. ( Baker, R; Bankart, J; Mayberry, JF; Moshkovska, T; Smith, RM; Stone, MA, 2011) |
| "Mesalamine has been used as the first-line medication for the treatment of ulcerative colitis (UC)." | 2.75 | Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study. ( Aida, Y; Hibi, T; Iida, M; Ito, H; Matsumoto, T; Suzuki, Y; Takano, Y; Yoshida, T, 2010) |
| "6-Mercaptopurine (6-MP) is an effective maintenance medication in patients with ulcerative colitis (UC), but toxic effects like myelosuppression limit its clinical benefit." | 2.75 | Thiopurine maintenance therapy for ulcerative colitis: the clinical significance of monitoring 6-thioguanine nucleotide. ( Abe, J; Arai, O; Hanai, H; Hosoda, Y; Iida, T; Ikeya, K; Kageoka, M; Kubota, T; Maruyama, Y; Miwa, I; Oohata, A; Takeuchi, K; Watanabe, F; Yoshirou, S, 2010) |
| "The practice of dosing mesalamines in divided doses for the treatment of ulcerative colitis (UC) began with sulfasalazine and was driven by sulfapyridine toxicity." | 2.75 | Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis. ( Dunnmon, P; Friedenberg, KA; Kane, S; Korzenik, J; Lashner, B; Leighton, JA; Mahadevan, U; Marion, JF; Patel, RM; Ramsey, D; Safdi, M; Sandborn, WJ; Sninsky, CA, 2010) |
| "Rosiglitazone enema treatment was well tolerated and reduced the Mayo ulcerative colitis score from 8." | 2.75 | Topical rosiglitazone treatment improves ulcerative colitis by restoring peroxisome proliferator-activated receptor-gamma activity. ( Brynskov, J; Pedersen, G, 2010) |
| "Therapy for active left-sided ulcerative colitis usually involves topical application of mesalazine (mesalamine) or budesonide." | 2.75 | Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis. ( Hartmann, F; Stein, J, 2010) |
| "The decrease in ulcerative colitis disease activity index (UCDAI) scores of 50% or more was higher in the VSL#3 group than in the placebo group (63." | 2.75 | Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. ( Annese, V; Brandimarte, G; D'Amico, T; Danese, S; Di Giulio, E; Di Rosa, S; Elisei, W; Forti, G; Gasbarrini, A; Giglio, A; Giorgetti, GM; Hassan, C; Imeneo, M; Larussa, T; Luzza, F; Modeo, ME; Morini, S; Papa, A; Pistoia, MA; Rodino', S; Sacca', N; Sebkova, L; Tursi, A, 2010) |
| "Relapse was defined as SDAI rectal bleeding score ≥1 and a mucosal appearance score ≥2, a UC flare, or initiation of medication to treat a UC flare." | 2.75 | Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial. ( Bortey, E; Forbes, WP; Gordon, GL; Lichtenstein, GR; Merchant, K; Murthy, U; Pruitt, R; Sedghi, S; Shaw, A; Zakko, S, 2010) |
| "The natural history of ulcerative colitis requires continuous monitoring of medical treatment via frequent outpatient visits." | 2.75 | E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach. ( Avnstrøm, S; Bailey, Y; Burisch, J; Elkjaer, M; Langholz, E; Laugesen, B; Lynge, E; Munkholm, P; O'Morain, C; Scherfig, H; Shuhaibar, M, 2010) |
| "Many patients with ulcerative colitis (UC) respond to mesalamine therapy within 8 weeks." | 2.74 | Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis. ( Barrett, K; Joseph, R; Kamm, MA; Lees, K; Lichtenstein, GR; Sandborn, WJ; Schreiber, S, 2009) |
| "To determine the therapeutic equivalence and safety of once daily (OD) versus three times daily (TID) dosing of a total daily dose of 3 g Salofalk (mesalazine) granules in patients with active ulcerative colitis." | 2.74 | Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. ( Batovsky, M; Boehm, S; Gorelov, IA; Greinwald, R; Horynski, M; Kiudelis, G; Kruis, W; Kykal, J; Mueller, R; Pokrotnieks, J; Rácz, I, 2009) |
| " We investigated the efficacy and safety of once daily administration of prolonged-release mesalamine granules in maintenance of remission in patients with quiescent ulcerative colitis, compared with the well established twice daily dosing regimen." | 2.74 | Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis. ( Adamek, H; Bhatt, A; Bokemeyer, B; Börner, N; Dietel, P; Dignass, AU; Klugmann, T; Mross, M; Pool, MO; Silvennoinen, J; Stijnen, T; Tan, G; Veerman, H; Vermeire, S; Vinter-Jensen, L, 2009) |
| " The most common adverse events reported were worsening of UC and headache; both were reported more often in the placebo group." | 2.74 | Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study. ( Forbes, WP; Gordon, GL; Huang, S; Lamet, M; Mareya, S; Pruitt, R; Scherl, EJ; Shaw, A, 2009) |
| " Adverse events and laboratory changes were monitored throughout the study." | 2.74 | Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind study. ( Attard, TM; Bortey, E; Forbes, WP; Heyman, MB; Pieniaszek, HJ; Pohl, JF; Quiros, JA; Walker, K, 2009) |
| "2 g/tablet) is a 5-aminosalicylic acid formulation, designed for once-daily dosing in the treatment of ulcerative colitis." | 2.74 | Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol. ( Ardia, A; Bellinvia, S; Campieri, M; Caprilli, R; Cottone, M; Kohn, A; Pallone, F; Prantera, C; Savarino, V; Sturniolo, GC; Vecchi, M, 2009) |
| "All adverse events were "not serious." | 2.74 | Pharmacokinetics and safety of single and multiple doses of Asacol tablets in Japanese healthy volunteers. ( Furuta, S; Hibi, T; Ito, H; Sasaki, H; Takano, Y; Yoshida, T, 2009) |
| "Nearly 25% of patients with ulcerative colitis (UC) requiring steroids therapy become steroid-dependent after 1 yr, and virtually all develop steroid-related adverse events." | 2.73 | Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study. ( Andriulli, A; Annese, V; Bossa, F; Dallapiccola, B; Damonte, G; De Santo, E; Latiano, A; Magnani, M; Palmieri, O; Rossi, L; Serafini, S, 2008) |
| "MMX mesalamine was generally well-tolerated." | 2.73 | Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. ( Boddu, P; Butler, T; Gubergrits, N; Joseph, RE; Kamm, MA; Lees, K; Lichtenstein, GR; Lyne, A; Sandborn, WJ, 2007) |
| " median relative bioavailability of 60 mL rectal foam: 36%)." | 2.73 | A clinical trial on absorption and N-acetylation of oral and rectal mesalazine. ( Cap, M; Cascorbi, I; Dilger, K; Kreisel, W; Novacek, G; Remmler, C; Rössle, M; Trenk, D; Wacheck, V; Zähringer, A, 2007) |
| " Recently, a high-volume 5-aminosalicylic acid foam has been shown to be as effective and safe as standard 5-aminosalicylic acid enema." | 2.73 | Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis. ( Adamonis, K; Bar-Meir, S; Chermesh, I; Eliakim, R; Greinwald, R; Gross, V; Kupcinskas, L; Lavy, A; Mueller, R; Pokrotnieks, J; Tulassay, Z, 2007) |
| " Following our positive results with nIFN-beta in a previously published open-labeled study, the present study was designed as an extension with the hypothesis that administration of higher dosage of nIFN-beta (1." | 2.73 | Successful treatment of steroid refractory active ulcerative colitis with natural interferon-beta--an open long-term trial. ( Andus, T; Chrissafidou, A; Malek, M; Musch, E; Schulz, M, 2007) |
| " This study evaluated the safety and efficacy of MMX mesalazine dosed once or twice daily as maintenance therapy in patients with ulcerative colitis." | 2.73 | Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis. ( Barrett, K; Joseph, R; Kamm, MA; Lees, K; Lichtenstein, GR; Sandborn, WJ; Schreiber, S, 2008) |
| "In group A (oral NAC combined with mesalamine) contrarily to group B (mesalamine alone), the clinical improvement correlates with a decrease of chemokines such as MCP-1 and IL-8." | 2.73 | N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: randomized, placebo-controlled pilot study. ( Arriaza, E; Castillejo, MS; Delgado, M; Gisbert, JP; Gonzalez Lara, V; Guijarro, LG; Marin-Jimenez, I; Mate, J; Olleros, T; Pena, AS; Perez-Calle, JL; Prieto-Merino, D, 2008) |
| " For the last few decades, scientists have been endeavoring to invent and innovate technologies that can substitute the conventional dosage forms and enable targeted and prolonged drug release at a particular site." | 2.72 | Budding Multi-matrix Technology-a Retrospective Approach, Deep Insights, and Future Perspectives. ( Atmakuri, S; Hoque, S; Khatri, D; Kumar, R; Madan, J; Mahajan, S; Maji, I; Modani, S; Singh, PK; Sriram, A; Srivastava, S; Tangirala, S, 2021) |
| "Inflammatory bowel diseases such as ulcerative colitis (UC) may be complicated by several extraintestinal manifestations." | 2.72 | Recurrent myocarditis in a patient with active ulcerative colitis: a case report and review of the literature. ( Caio, G; Caputo, F; De Giorgio, R; Lungaro, L; Marcello, MC; Muccinelli, M; Volta, U; Zoli, E; Zoli, G, 2021) |
| "001; chi-square test) with no differences in frequency of adverse events." | 2.72 | Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis. ( Bátovský, M; Fixa, B; Florin, TH; Gabalec, L; Gibson, PR; Greinwald, R; Pekárková, B; Radford-Smith, G; Tibitanzl, J, 2006) |
| "Remission ulcerative colitis-disease activity index (UC-DAI) < or =1, a score of 0 for rectal bleeding and stool frequency, and > or =1 -point reduction in sigmoidoscopy score from baseline was the primary end point." | 2.72 | Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study. ( Baert, F; Connor, P; D'Haens, G; Dewit, O; Engels, L; Hommes, D; Joseph, R; Palmen, M; Ramage, J; Stephenson, D; van der Waaij, L, 2006) |
| "Patients with ulcerative colitis have a higher rate of tubular nephropathies." | 2.72 | [Characterization of proteinuria in patients with ulcerative colitis and therapy with aminosalicylates]. ( Aymaz, S; Buschhausen, L; Krakamp, B; Kruis, W; Weber, M, 2006) |
| "Curcumin is a biologically active phytochemical substance present in turmeric and has pharmacologic actions that might benefit patients with ulcerative colitis (UC)." | 2.72 | Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. ( Andoh, A; Arai, H; Fujiyama, Y; Hanai, H; Hiraishi, H; Hirayama, K; Iida, T; Iwaoka, Y; Kanke, K; Koide, Y; Maruyama, Y; Mitsuyama, K; Nagata, T; Sata, M; Takeuchi, K; Tsujikawa, T; Uchijima, M; Watanabe, F; Yamada, M; Yoshii, S, 2006) |
| "The treatment of distal ulcerative colitis, refractory to conventional 5-ASA/steroid treatment, is still a matter of debate." | 2.71 | Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial. ( Annese, V; Bresci, G; Caprilli, R; d'Albasio, G; D'Incà, R; Giaccari, S; Ingrosso, M; Mansi, C; Riegler, G; Valpiani, D; Vernia, P, 2003) |
| "boulardii can be effective in the treatment of ulcerative colitis." | 2.71 | A pilot trial of Saccharomyces boulardii in ulcerative colitis. ( Giollo, P; Guslandi, M; Testoni, PA, 2003) |
| "Marks score or the ulcerative colitis disease-activity index) at two and four weeks." | 2.71 | Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis. ( Berlanga-Acosta, J; Nightingale, J; Playford, RJ; Sinha, A; West, KP, 2003) |
| "To assess the feasibility, safety and efficacy of patient-led dosing using balsalazide in the long-term treatment of ulcerative colitis." | 2.71 | Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3-year prospective observational study. ( Gibson, JA; Green, JR; Kerr, GD; Swan, CH; Swarbrick, ET; Thornton, PC, 2004) |
| "The scheduled oral + topical 5-ASA treatment, at the lowest cumulative topical dosage tested over the longest known observation period, is efficacious in improving clinical outcome and decreasing overall costs in UC patients." | 2.71 | Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis. ( Cermesoni, L; Cesana, BM; Piodi, LP; Ulivieri, FM, 2004) |
| "This study was conducted to assess, in a small sample, the short-term outcomes of once-daily mesalamine versus conventional dosing in maintaining quiescent ulcerative colitis (UC) and to assess adherence rates with both regimens." | 2.71 | A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis. ( Huo, D; Kane, S; Magnanti, K, 2003) |
| "Inclusion criteria were active ulcerative colitis (Clinical Activity Index [CAI] and Endoscopic Index [EI] according to Rachmilewitz, CAI 6-12; EI >/=4)." | 2.71 | The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. ( Bar-Meir, S; Chowers, Y; Faszczyk, M; Feher, J; Greinwald, R; Kovacs, A; Kruis, W; Lakatos, L; Lengyele, G; Mickisch, O; Mlitz, H; Stolte, M; Vieth, M, 2003) |
| "The cumulative recurrence rate in the GBF group with steroid tapering treatment was significantly lower compared with the value in the control group." | 2.71 | Germinated barley foodstuff prolongs remission in patients with ulcerative colitis. ( Andoh, A; Araki, Y; Bamba, T; Fujiyama, Y; Fukuda, M; Hanai, H; Kanauchi, O; Kojima, A; Mitsuyama, K; Sata, M; Takayuki, I; Takeuchi, K; Toyonaga, A, 2004) |
| "Balsalazide/VSL#3 was significantly superior to balsalazide alone and to mesalazine in obtaining remission: 24 patients of group A were in remission [per-protocol: 85." | 2.71 | Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis. ( Brandimarte, G; Forti, G; Gigliobianco, A; Giorgetti, GM; Modeo, ME; Tursi, A, 2004) |
| " Current oral regimens require the use of large tablets and frequent dosing to reach the recommended treatment dose." | 2.71 | Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial. ( Behrens, C; Bias, P; Raedler, A, 2004) |
| "The continuous use of topical mesalazine associated with a high oral dosage significantly improves the clinical course of ulcerative colitis patients at high risk of relapse." | 2.71 | Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis. ( Caprilli, R; Chiaramonte, M; Corrao, G; Frieri, G; Galletti, B; Latella, G; Palumbo, G; Pimpo, M, 2005) |
| "Therapy for active ulcerative colitis (UC) usually involves rectal formulations of corticosteroids (CS), which are characterized by the risk of systemic steroid-related adverse effects." | 2.71 | Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial. ( Annese, V; Balzano, A; Campieri, M; D'Arienzo, A; Gionchetti, P; Iaquinto, G; Lecis, PE; Maieron, R; Manguso, F; Rizzello, F; Valpiani, D; Varoli, G, 2005) |
| "Eighty-eight ulcerative colitis patients with a mild to moderate clinical relapse were randomized to one of the two drugs at a daily dose of 2." | 2.71 | Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis. ( Al-Damluji, A; Ashworth, S; Bramble, M; Forbes, A; Herbert, K; Ho, J; Kang, JY; Przemioslo, R; Shetty, A, 2005) |
| " However, the optimal dosage remains to be defined." | 2.71 | Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study. ( Consolazio, A; Crispino, P; Iacopini, F; Marcheggiano, A; Paoluzi, OA; Paoluzi, P; Pica, R; Rivera, M, 2005) |
| "Current treatment of ulcerative colitis is imperfect." | 2.71 | Trial of trefoil factor 3 enemas, in combination with oral 5-aminosalicylic acid, for the treatment of mild-to-moderate left-sided ulcerative colitis. ( Fitzgerald, AJ; Ghosh, S; Mahmood, A; Melley, L; Playford, RJ, 2005) |
| "Disease activity was assessed using the ulcerative colitis disease activity index, with clinical and endoscopic signs at four and eight weeks." | 2.71 | Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. ( Befrits, R; Dignass, A; Foldager, M; Gassul, M; Lindgren, S; Marteau, P; Midhagen, G; Probert, CS; Rademaker, J; Tan, TG, 2005) |
| "Nicotine enemas cause fewer AEs and were used as supplemental treatment for active UC." | 2.71 | A randomized trial of nicotine enemas for active ulcerative colitis. ( Courtney, E; Evans, BK; Green, JT; Hawkes, ND; Ingram, JR; Newcombe, RG; Pillai, S; Rhodes, J; Srivastava, ED; Swift, JL; Thomas, GA; Williams, GT, 2005) |
| "Preliminary data have shown that delayed release oral mesalamine (Asacol) dosed at 4." | 2.71 | Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. ( Ajayi, F; Hanauer, SB; Katz, S; Kornbluth, A; Regalli, G; Safdi, M; Sandborn, WJ; Smith-Hall, N; Woogen, S; Yeh, C, 2005) |
| "Balsalazide is a novel azo-bonded 5-aminosalicylic acid treatment for mild-to-moderate ulcerative colitis." | 2.70 | Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis. ( Cross, A; Doty, P; Hanson, J; Hardi, R; Johanson, J; Johnson, LK; Koval, G; Pruitt, R; Riff, D; Safdi, M; Winston, B; Wruble, L, 2002) |
| " After this acute therapy, patients were submitted to clinical, endoscopic and histological examinations and those in remission were assigned to a follow-up (maintenance) period with oral mesalazine alone at a dosage of 1." | 2.70 | Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial. ( Ardizzone, S; Bianchi Porro, G; Cottone, M; D'Albasio, G; Miglioli, M; Paoluzi, OA; Paoluzi, P; Pera, A; Pica, R; Prantera, C; Sturniolo, G, 2002) |
| "In patients with mild active ulcerative colitis, mesalazine 4 g orally and 2 g orally plus 2 g enema are equally effective in inducing disease remission." | 2.70 | Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study. ( Beltrami, M; Beretta, L; Campieri, M; de Franchis , R; Di Maurizio , P; Fornaciari, G; Ganio, E; Gionchetti, P; Meucci, G; Usai, P; Vecchi, M, 2001) |
| "High doses of mesalazine usually result in an inconvenient dosage schedule and reduced compliance." | 2.70 | Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis. ( Campieri, M; Farup, PG; Hébuterne, X; Hinterleitner, TA; Keller, R; Lukás, M; Meier, R; Oddsson, E; Rachmilewitz, D; Rathbone, B, 2001) |
| "Ulcerative colitis is managed mainly in secondary care by regular outpatient reviews done by specialist clinicians." | 2.70 | Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial. ( Roberts, C; Robinson, A; Thompson, DG; Wilkin, D, 2001) |
| "Balsalazide is a new 5-aminosalicylic acid (5-ASA) containing prodrug." | 2.70 | Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses. ( Brandes, JW; Ewald, U; Hämling, J; Howaldt, S; Koop, I; Krakamp, B; Kruis, W; Mönnikes, H; Pallant, D; Schreiber, S; Schütz, E; Stolte, M; Theuer, D, 2001) |
| "Balsalazide has been designed to deliver 5-aminosalicylic acid to the colon without the poor tolerability of sulfasalazine." | 2.70 | A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis. ( Gibson, JA; Green, JR; Kerr, GD; Mansfield, JC; Thornton, PC, 2002) |
| "Balsalazide is an azo-bonded pro-drug which also releases 5-aminosalicylic acid into the colon, but uses an inert carrier molecule." | 2.70 | A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis. ( Cann, PA; Giaffer, MH; Holdsworth, CD; Mansfield, JC; McKenna, D; Thornton, PC, 2002) |
| "Forty patients with ulcerative colitis in complete remission for 6 months were randomized to either olsalazine (n=20) or mesalazine (n=20 for nine months)." | 2.70 | Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis. ( Freyne, PJ; Kelleher, D; Mahmud, N; O'Hare, N; O'Toole, D; Weir, DG, 2002) |
| "Patients with active distal ulcerative colitis, diagnosed according to standardized criteria, were treated for 4 weeks." | 2.70 | A new mesalazine foam enema (Claversal Foam) compared with a standard liquid enema in patients with active distal ulcerative colitis. ( Gertz, B; Malchow, H, 2002) |
| "Forty-two patients with severe ulcerative colitis (more than 10 points on the Powell-Tuck scoring system and mucosal disease Heatly grade III or IV)." | 2.70 | Octreotide in patients with active ulcerative colitis treated with high dose corticosteroids (OPUS 1). ( Friis, S; Hoogkamer, JF; Karvonen, AL; Lygren, I; Mulder, CJ; Nielsen, OH; Rädler, A; Tefera, S; van Bergeijk, JD; von Tirpitz, C; Waldum, HL; Wilson, JH, 2002) |
| "Distal ulcerative colitis usually responds to treatment with rectal mesalamine, but the management of refractory cases is poorly defined." | 2.70 | Distal ulcerative colitis refractory to rectal mesalamine: role of transdermal nicotine versus oral mesalamine. ( Frego, R; Guslandi, M; Testoni, PA; Viale, E, 2002) |
| "Balsalazide is a new innovative, mesalamine-containing prodrug that is activated by bacteria in the colon." | 2.70 | A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis. ( Bell, JK; Johnson, LK; Koval, G; Levine, DS; Pruitt, R; Riff, DS; Sales, D; Wruble, L, 2002) |
| "Balsalazide is a novel mesalamine prodrug, activated by colonic bacteria." | 2.69 | Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group. ( Gibson, JA; Green, JR; Hodgson, HJ; Holdsworth, CD; Kerr, GD; Leicester, RJ; Lobo, AJ; Parkins, KJ; Taylor, MD, 1998) |
| " No dose-response relation was demonstrated." | 2.69 | Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group. ( Hanauer, SB, 1998) |
| "Patients with mild to moderate active ulcerative colitis were randomized to receive either olsalazine sodium, 3 g/day (n = 88), or mesalazine, 3 g/day (n = 80), for up to 12 weeks." | 2.69 | Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis. ( Brandes, JW; Ewe, K; Judmaier, G; Krakamp, B; Kruis, W; Lorenz-Mayer, H; Otto, P; Schreiber, S; Schütz, E; Theuer, D, 1998) |
| "Beclomethasone dipropionate enemas combined with oral 5-aminosalicylic acid may be a safe and useful therapeutic approach in the treatment of ulcerative colitis not responsive to oral 5-aminosalicylic acid alone." | 2.69 | Beclomethasone dipropionate (3 mg) enemas combined with oral 5-ASA (2.4 g) in the treatment of ulcerative colitis not responsive to oral 5-ASA alone. ( Bennato, R; Castiglione, GN; D'Arienzo, A; Manguso, F; Mazzacca, G; Sanges, M; Scaglione, G; Vicinanza, G, 1998) |
| "A total of 105 patients with ulcerative colitis who were in remission were randomized into groups to receive oral treatment with Plantago ovata seeds (10 g b." | 2.69 | Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU). ( Domínguez-Abascal, F; Fernández-Bañares, F; García-Pugés, A; Gassull, MA; Giné, JJ; Gomollón, F; González-Huix, F; González-Lara, V; Hinojosa, J; Martínez-Salmerón, JF; Moles, J; Navarro, E; Riera, J; Sánchez-Lombraña, JL, 1999) |
| "Fifteen patients with ulcerative colitis were treated with olsalazine or mesalazine, each for 7 days in an open, randomized, crossover design study." | 2.69 | The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine. ( Florholmen, J; Støa-Birketvedt, G, 1999) |
| "Ulcerative colitis has been suggested to be caused by infection and there is circumstantial evidence linking Escherichia coli with the condition." | 2.69 | Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial. ( Axon, AT; Chalmers, DM; Hawkey, PM; Rembacken, BJ; Snelling, AM, 1999) |
| "Twenty patients with ulcerative colitis, intolerant or allergic to 5-ASA, have been treated with a new probiotic preparation (VSL#3, CSL, Milan, Italy) containing 5x10(11) cells/g of 3 strains of bifidobacteria, 4 strains of lactobacilli and 1 strain of Streptococcus salivarius ssp." | 2.69 | Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. ( Brigidi, P; Campieri, M; Gionchetti, P; Johansson, R; Matteuzzi, D; Rizzello, F; Venturi, A; Zucconi, E, 1999) |
| " UC relapses in the rectal remnant usually are prevented by chronic administration of 5-aminosalicylic acid (5-ASA) in topical formulations." | 2.69 | Scintigraphic imaging and absorption of a 5-aminosalicylic acid enema in patients with ileorectal anastomosis. ( Baldassarri, AR; Benti, R; Bianchi, PA; Bruno, A; Gerundini, P; Lisciandrano, D; Ranzi, T, 1999) |
| "pylori." | 2.69 | Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease. ( Duncan, HD; Green, JR; Pearce, CB; Timmis, L, 2000) |
| "In this pilot study for distal ulcerative colitis budesonide foam is as safe and effective as mesalazine enema." | 2.69 | [Budesonide foam as a new therapeutic principle in distal ulcerative colitis in comparison with mesalazine enema. An open, controlled, randomized and prospective multicenter pilot study]. ( Frühmorgen, P; Huber, W; Kimmig, JM; Rufle, W, 2000) |
| "In biopsies of active ulcerative colitis but not in noninflamed mucosa, activation of NF-kappaB was detected predominantly in macrophages." | 2.69 | Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. ( Bantel, H; Berg, C; Kruis, W; Schulze-Osthoff, K; Stolte, M; Vieth, M, 2000) |
| "Seventy-nine patients with distal ulcerative colitis were stratified on the basis of the extent of the disease (proctitis and proctosigmoiditis) and randomized to one of the treatment groups." | 2.68 | Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis. A comparison of the efficacy and practicality of two topical treatment regimens. ( Brodin, U; Farup, PG; Halvorsen, FA; Hovde, O; Raknerud, N, 1995) |
| "To compare a low dosage (1 g/day) rectal preparation of 5-aminosalicylic acid in slightly acidic, buffered suspension (Pentasa) with a hydrocortisone 100 mg/day enema (Cortenema)." | 2.68 | Low Pentasa dosage versus hydrocortisone in the topical treatment of active ulcerative colitis: a randomized, double-blind study. ( Ardizzone, S; Bianchi Porro, G; Fasoli, A; Imbesi, V; Molteni, P; Petrillo, M, 1995) |
| " Treatment-related adverse events were rare." | 2.68 | Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. ( Arora, S; Hanauer, S; Miner, P; Robinson, M; Schwartz, J, 1995) |
| "The mesalamine tablet was well tolerated, and no clinically significant changes were seen in hematologic, hepatic, or renal laboratory profiles." | 2.68 | An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group. ( , 1996) |
| "We investigated the adverse effects of sulfasalazine in the treatment of inflammatory bowel disease in Japan." | 2.68 | Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine. ( Munakata, A; Nakajima, H; Yoshida, Y, 1995) |
| " No dose-related adverse events were found." | 2.68 | Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group. ( Blok, P; Dekker, W; Ferwerda, J; Fockens, P; Gasthuis, K; Meuwissen, SG; Mulder, CJ; Tuynman, HA; Tytgat, GN; van Hees, PA, 1995) |
| "Fifteen patients with ulcerative colitis in clinical and endoscopical remission were randomized in a cross over design." | 2.68 | Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission. ( Becker, K; Ewe, K; Ueberschaer, B, 1996) |
| "Active ulcerative colitis changes colon motility and this leads to uncertainty about enema spread." | 2.68 | Distribution of mesalazine enemas in active and quiescent ulcerative colitis. ( Boer, RO; Lourens, J; Sindram, JW; Tuynman, HA; van Bodegraven, AA, 1996) |
| "Prednisolone treated patients had significantly fewer days with liquid stools than mesalazine patients, with a median of 0 and 1 days respectively by week 4 (p = 0." | 2.68 | A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis. ( Daniels, S; Grace, RH; Jewell, DP; Keighley, MR; Kingston, RD; Lee, FI; Mani, V; Patterson, J; Record, CO; Smith, K, 1996) |
| "To compare the systemic load of 5-aminosalicylic acid (5-ASA) as a basis for potential long-term toxicity during treatment in usual dosage with olsalazine (Dipentum) and one controlled-release mesalazine preparation (Salofalk) in patients with inactive ulcerative colitis." | 2.68 | Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine. ( Karamanolis, DG; Papatheodoridis, GV; Xourgias, V, 1996) |
| "In patients with ulcerative colitis receiving maintenance 5-ASA therapy there was greater absorption and less acetylation of 5-ASA from mesalazine (Asacol) compared with sulphasalazine or olsalazine, but no evidence from this study that this resulted in increased nephrotoxicity." | 2.68 | 5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine. ( Campbell, BJ; Dwarakanath, AD; Morris, AI; Rhodes, JM; Stevenson, A; Stretch, GL; Yaqoob, M, 1996) |
| "Zileuton (600 mg qid) was not significantly better than placebo in the maintenance of remission of ulcerative colitis in this trial and may have limited potential in the treatment of this condition." | 2.68 | A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis. ( Dube, LM; Hawkey, CJ; Lancaster, JF; Linnen, PJ; Rountree, LV, 1997) |
| "Twelve patients with active ulcerative colitis were administered 4 g of the mesalazine rectal enema labelled with 100 MBq technetium sulphur colloid (99mTc-SC)." | 2.68 | Retrograde colonic spread of a new mesalazine rectal enema in patients with distal ulcerative colitis. ( Boschi, S; Campieri, M; Corbelli, C; Fanti, S; Ferretti, M; Gionchetti, P; Miglioli, M; Rizzello, F; Venturi, A, 1997) |
| "A total of 120 patients with inactive ulcerative colitis were included in a double-blind, double-dummy study comparing mesalazine 500 mg t." | 2.68 | Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis. ( Fixa, B; Fric, P; Judmaier, G; Kruis, W; Schütz, E; Stolte, M, 1997) |
| "Sixty outpatients with ulcerative colitis at least 5 cm above the anal verge and not more than 50 cm, inclusive, and a total disease activity index (DAI) score between 4 and 10, inclusive, were randomized to either mesalamine rectal enema (n = 18) once nightly, oral mesalamine 2." | 2.68 | A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. ( Banks, P; DeMicco, M; Deren, J; Fleishman, C; Koval, G; Nichols, T; Safdi, M; Sninsky, C; Targan, S; Wiita, B; Wruble, L, 1997) |
| "Fifty patients with ulcerative colitis in remission for a minimum period of 1 month participated in the study." | 2.67 | Intermittent versus continuous 5-aminosalicylic acid treatment for maintaining remission in ulcerative colitis. ( Amorosi, A; Bardazzi, G; Bartoletti, L; Bonanomi, AG; d'Albasio, G; Messori, A; Morettini, A; Pacini, F; Trallori, G, 1994) |
| "Patients with ulcerative colitis tend to be young, potentially at peak lifetime productivity levels, and the disease can be devastating in its effects on the quality of life in these individuals." | 2.67 | Mesalamine capsules enhance the quality of life for patients with ulcerative colitis. ( Hanauer, S; Hoop, R; Robinson, M; Wilkinson, C; Zbrozek, A, 1994) |
| "Cyclosporine enemas administered in a dosage of 350 mg/day for 4 weeks are not efficacious in mildly to moderately active left-sided ulcerative colitis." | 2.67 | A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis. ( Batts, KP; Harrison, JM; Lawson, GM; Sandborn, WJ; Schroeder, KW; Steiner, BL; Tremaine, WJ; Zinsmeister, AR, 1994) |
| "Thirty-eight patients had ulcerative colitis (UC) and 25 had Crohn's disease." | 2.67 | Experience with Eudragit-S-coated mesalamine (Asacol) in inflammatory bowel disease. An open study. ( Faber, SM; Korelitz, BI, 1993) |
| "Thirty-eight patients with distal ulcerative colitis (n = 17) or ulcerative proctitis (n = 21) in clinical, endoscopic, and histologic remission were randomly assigned to receive either oral mesalazine (0." | 2.67 | Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis. ( Hatzis, A; Mantzaris, GJ; Petraki, K; Spiliadi, C; Triantaphyllou, G, 1994) |
| "Oral mesalamine capsules were significantly superior to placebo for inducing remission, with 29% of patients at 2 g and 29% at 4 g achieving remission by physician global assessment, compared with 12% on placebo." | 2.67 | Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group. ( Arora, S; Cello, J; Hanauer, S; Robinson, M; Roufail, W; Safdi, M; Schwartz, J, 1993) |
| "Olsalazine was clearly superior to mesalazine in prevention of relapses in ulcerative colitis, especially in patients with left-sided disease." | 2.67 | Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis. ( Bergin, CF; Courtney, MG; Keeling, PW; Nunes, DP; O'Driscoll, M; Trimble, V; Weir, DG, 1992) |
| "The effect of fish oil on the course of ulcerative colitis was investigated in a randomised blinded controlled study." | 2.67 | Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial. ( Belluzzi, A; Daneshmend, TK; Everitt, SJ; Hawkey, CJ; Hawthorne, AB; Holmes, GK; Malkinson, C; Shaheen, MZ; Willars, JE, 1992) |
| " Balsalazide is therefore both highly effective in maintaining remission in ulcerative colitis and well tolerated in both conventional and high dosage (the latter equivalent to 5." | 2.67 | Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months. ( Brown, P; Gibson, JA; Green, JR; Kerr, GD; Rowlinson, A; Swan, CH; Swarbrick, ET; Thornton, P, 1992) |
| "The pharmacokinetic profile of a new 4-g 5-aminosalicyclic acid (5-ASA) retention enema, Mesasal, was investigated." | 2.67 | Steady-state pharmacokinetics of a new 4-gram 5-aminosalicylic acid retention enema in patients with ulcerative colitis in remission. ( Almer, S; Norlander, B; Osterwald, H; Ström, M, 1991) |
| " This study suggests that 1 g 5-ASA (in a 100 ml enema) is a sufficient dosage for patients with a mild to moderate attack of ulcerative colitis." | 2.67 | Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis. ( Barbara, L; Belluzzi, A; Brignola, C; Campieri, M; Gionchetti, P; Iannone, P; Miglioli, M; Tampieri, M, 1991) |
| "Sixty-two patients with ulcerative colitis localised to the distal sigmoid colon and rectum (less than 20 cm) entered the trial." | 2.67 | Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation. A double-blind placebo controlled trial. ( Barbara, L; Belluzzi, A; Brignola, C; Brunetti, G; Campieri, M; Gionchetti, P; Iannone, P; Miglioli, M; Tampieri, M, 1990) |
| "Thirty patients with distal ulcerative colitis in remission (17 proctitis, 13 proctosigmoiditis) were randomly given either 5-aminosalicylic acid (5-ASA) or placebo suppositories, 400 mg bid." | 2.67 | 5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial. ( Boscaino, A; D'Arienzo, A; D'Armiento, FP; Giannattasio, F; Lancia, C; Mazzacca, G; Panarese, A; Quattrone, P, 1990) |
| "Consequently, new alternatives for the treatment of ulcerative colitis are constantly being sought." | 2.66 | Probiotics for maintenance of remission in ulcerative colitis. ( Akobeng, AK; Baines, PA; Gordon, M; Iheozor-Ejiofor, Z; Kaur, L; Sinopoulou, V, 2020) |
| "Consequently, new alternatives for the treatment of ulcerative colitis are constantly being sought." | 2.66 | Probiotics for induction of remission in ulcerative colitis. ( Akobeng, AK; Baines, PA; Gordon, M; Iheozor-Ejiofor, Z; Kaur, L; Sinopoulou, V, 2020) |
| " Time to symptom resolution was defined as the period between first drug dosage date and first 3 consecutive days of induction therapy when the patient achieved a score of 0 [normal] on a modified UC Disease Activity Index for stool frequency and/or rectal bleeding." | 2.66 | Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis. ( Barrett, K; Hanauer, SB; Sandborn, WJ; Schreiber, S, 2020) |
| "Mesalamine is the core treatment of mild‑to‑moderate ulcerative colitis (UC) and corticosteroids are crucial for the induction of remission of moderate‑to‑severe flares in both UC and Crohn's disease (CD)." | 2.66 | Inflammatory Bowel Disease - Non-biological treatment. ( Cordeiro, G; Dias, AM; Estevinho, MM; Magro, F, 2020) |
| "The effectiveness of plants in treating ulcerative colitis has been determined." | 2.66 | A phytopharmacological overview of medicinal plants used for prophylactic and treatment of colitis. ( Akkol, EK; Karpuz, B; Khan, H; Sobarzo-Sánchez, E, 2020) |
| " (5) Optimization of 5-aminosalicylate dosage may be indicated even for quiescent patients with ulcerative colitis if mucosal healing is not obtained, and if patients have multiple risk factors for recurrence." | 2.66 | Solving the questions regarding 5-aminosalitylate formulation in the treatment of ulcerative colitis. ( Naganuma, M, 2020) |
| " A secondary objective was to compare the efficacy and safety of once-daily dosing of oral 5-ASA versus conventional dosing regimens (two or three times daily)." | 2.66 | Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. ( Feagan, BG; MacDonald, JK; Murray, A; Nguyen, TM; Parker, CE, 2020) |
| "To assess the efficacy, dose-responsiveness, and safety of oral 5-ASA compared to placebo, SASP, or 5-ASA comparators for maintenance of remission in quiescent UC and to compare the efficacy and safety of once-daily dosing of oral 5-ASA with conventional (two or three times daily) dosing regimens." | 2.66 | Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. ( Feagan, BG; MacDonald, JK; Murray, A; Nguyen, TM; Parker, CE, 2020) |
| "Ulcerative colitis is a chronic inflammatory bowel disease with an estimated 150 000 patients in Germany alone." | 2.66 | Ulcerative Colitis-Diagnostic and Therapeutic Algorithms. ( Dignass, A; Kannengiesser, K; Koletzko, S; Kucharzik, T, 2020) |
| "Clinical improvement in Crohn's disease was seen in 87% of patients of the 5-aminosalicylic acid group and in 80% of the salazosulfapyridine group." | 2.66 | [Successful acute treatment of chronic inflammatory intestinal diseases with oral 5-aminosalicylic acid]. ( Bode, JC; Frühmorgen, P; Heller, T; Klotz, U; Maier, K; von Gaisberg, U, 1985) |
| "Patients with distal ulcerative colitis may be refractory to standard drug therapy." | 2.66 | Refractory distal ulcerative colitis responsive to 5-aminosalicylate enemas. ( Antonioli, DA; Barber, GB; Lee, DE; Peppercorn, MA, 1985) |
| " Metronidazole and azathioprin are considered to be reserve drugs and can be used in the treatment of fistulae or in order to cut down the dosage of prednisolone during remission." | 2.66 | [Drug therapy of chronic inflammatory intestinal diseases--current status of 5-aminosalicylic acid]. ( Gerok, W; Schölmerich, J, 1986) |
| "Sulfasalazine is an effective drug for maintaining remission in ulcerative colitis, but its use may be precluded by side effects." | 2.66 | Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine. ( Greenberg, GR; Habal, FM, 1988) |
| "Seventy-five patients with ulcerative colitis in remission for between 1 mo and 5 yr were included for analysis." | 2.66 | Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis. ( Blok, P; Dekker, W; Mulder, CJ; Schrijver, M; Tytgat, GN; van der Heide, H; Weterman, IT, 1988) |
| "Balsalazide (BSZ) is a pro-drug which releases 5-aminosalicylic acid (5ASA) and 4-aminobenzoyl-beta-alanine (an inert carrier) in the colon of various species including man." | 2.66 | Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine. ( Baron, JH; Barrison, IG; Lennard-Jones, JE; McIntyre, PB; Rodrigues, CA; Thornton, PC; Walker, JG, 1988) |
| " Long-term use of olsalazine in controlled trials may be considered safe, even in high doses." | 2.66 | Colonic prostaglandin E2 levels and olsalazine metabolism in relapsing ulcerative colitis: implications for controlled trials in the long term. ( Bukhave, K; Lauritsen, K; Laursen, LS; Rask-Madsen, J, 1988) |
| " Specific procedures of preparation and dosage remain to be established." | 2.66 | New enema treatments for inflammatory bowel disease. ( Karp, LC; Targan, SR, 1988) |
| " Patients were randomly assigned to receive 5-ASA at a dosage of either 4." | 2.66 | Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. ( Ilstrup, DM; Schroeder, KW; Tremaine, WJ, 1987) |
| "A controlled trial has been carried out in order to compare the efficacy of enemas containing a high dosage of 5-ASA (4 g) versus enemas containing hydrocortisone 100 mg." | 2.66 | Efficacy of 5-aminosalicylic acid enemas versus hydrocortisone enemas in ulcerative colitis. ( Barbara, L; Bazzocchi, G; Belluzzi, A; Brignola, C; Campieri, M; Gionchetti, P; Migaldi, M; Miglioli, M; Tabanelli, GM, 1987) |
| " Plasma and urine concentrations of 5-AS and its acetylated major metabolite (AcAS) were monitored during one dosing interval." | 2.65 | Disposition of 5-aminosalicylic acid, the active metabolite of sulphasalazine, in man. ( Fischer, C; Klotz, U; Maier, K; Stumpf, E; von Gaisberg, U, 1983) |
| "5-Aminosalicylic acid (5-ASA) is the active component of Salazopyrin and induces a prompt and excellent improvement, when administered as high dosage enema, in patients suffering from active ulcerative colitis." | 2.65 | A double-blind clinical trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis. ( Bazzocchi, G; Bertoni, F; Brignola, C; Campieri, M; Labò, G; Lanfranchi, GA; Minguzzi, MR, 1984) |
| " With several medications (eg, sulfasalazine, diazo-bonded 5-aminosalicylates [ASA], mesalamines, and corticosteroids, including budesonide) and complex dosing formulations, regimens, and routes, to treat a disease with variable anatomic extent, there is considerable practice variability in the management of patients with mild-moderate UC." | 2.61 | AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis. ( Binion, DG; Feuerstein, JD; Singh, S; Tremaine, WJ, 2019) |
| " Also, no obvious difference was found between OD and BD regime dosing of mesalazine regardless of total adverse events, treatment-related adverse events or serious adverse events." | 2.61 | Efficacy and safety of once daily versus twice daily mesalazine for mild-to-moderate ulcerative colitis: A meta-analysis of randomized controlled trials. ( Li, J; Qiu, C; Wang, B; Wang, X; Zhang, Q; Zhang, Z; Zheng, X, 2019) |
| "We searched PubMed, Scopus, Embase, the Cochrane Library, clinical trial registries, regulatory agencies' websites and international conference proceedings, up to July 2018, to identify randomized controlled trials of adult patients with active, mild-to-moderate UC, comparing budesonide-MMX or mesalamine against placebo, or against each other, or different dosing strategies, for induction of remission." | 2.61 | Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis. ( Bonovas, S; Danese, S; González-Lorenzo, M; Lytras, T; Nikolopoulos, GK; Pantavou, K; Peyrin-Biroulet, L; Piovani, D, 2019) |
| "Mesalamine is a first-line drug in the treatment of inflammatory bowel diseases, while its intolerance occasionally occurs in clinical practice." | 2.61 | The culprit of mesalamine intolerance: case series and literature review. ( Fu, Y; Hong, F; Quan, R; Xie, C; Yan, W; Zou, K, 2019) |
| "To summarise adverse drug events to mesalazine and recommend techniques for management." | 2.58 | Systematic review: safety of mesalazine in ulcerative colitis. ( Aboubakr, A; Colombel, JF; Narula, N; Sehgal, P, 2018) |
| " The rates of adverse events (AE), serious AEs, and steroid-related side-effects are similar to placebo and mesalamine and slightly inferior to traditional corticosteroids." | 2.58 | The safety of beclomethasone dipropionate in the treatment of ulcerative colitis. ( Calabrese, C; Calafiore, A; Campieri, M; Gionchetti, P; Mazza, M; Rizzello, F; Salice, M, 2018) |
| "The majority of patients with ulcerative colitis have mildly to moderately active disease." | 2.58 | Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. ( Dulai, PS; Fumery, M; Murad, MH; Nguyen, NH; Prokop, LJ; Sandborn, WJ; Singh, S, 2018) |
| " The occurrence of adverse events was not significantly different between each treatments and placebo." | 2.55 | Efficacy and safety of rectal 5-aminosalicylic acid versus corticosteroids in active distal ulcerative colitis: a systematic review and network meta-analysis. ( Ma, H; Ma, J; Sun, M; Wang, P; Zhang, H; Zhang, Y; Zhao, X; Zhou, C; Zhu, Y, 2017) |
| "Ulcerative colitis (UC) and Crohn's disease (CD) are inflammatory bowel diseases (IBD)." | 2.55 | Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease. ( Derwa, Y; Ford, AC; Gracie, DJ; Hamlin, PJ, 2017) |
| "The genetics of isolated colonic Crohn's disease place it approximately midway between Crohn's disease with small intestinal involvement and UC, making a case for considering it as a separate condition." | 2.55 | Recent advances in clinical practice: a systematic review of isolated colonic Crohn's disease: the third IBD? ( Ekbom, A; Rhodes, JM; Subramanian, S, 2017) |
| "Ulcerative colitis is a chronic inflammatory disease affecting the colon, and its incidence is rising worldwide." | 2.55 | Ulcerative colitis. ( Allen, PB; Colombel, JF; Mehandru, S; Peyrin-Biroulet, L; Ungaro, R, 2017) |
| "Patients with ulcerative colitis (UC) who achieve remission with corticosteroids often relapse after tapering or discontinuation; alternative treatments limiting steroid exposure and UC relapse would be beneficial." | 2.53 | Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission. ( Barrett, AC; Bortey, E; Forbes, WP; Gordon, GL; Lichtenstein, GR; Murthy, U; Paterson, C; Pruitt, R; Sedghi, S; Zakko, S, 2016) |
| " This review summarizes data on pharmacokinetics and applications of oral and topical 5-ASA therapies in active and quiescent, extensive colitis and distal disease, both as monotherapies and in combination and reviews dosing and dosing intervals for oral 5-ASA in both active disease and to maintain remissions." | 2.53 | Oral or Topical 5-ASA in Ulcerative Colitis. ( Hanauer, SB, 2016) |
| " A secondary objective of this systematic review was to compare the efficacy and safety of once daily dosing of oral 5-ASA with conventional (two or three times daily) dosing regimens." | 2.53 | Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. ( Bhanji, T; Feagan, BG; MacDonald, JK; Parker, CE; Wang, Y, 2016) |
| "Its use in ulcerative colitis (UC) was limited to rectal preparations until recently when the new oral budesonide formulation incorporating the multi-matrix system technology was introduced." | 2.53 | Budesonide for the treatment of ulcerative colitis. ( Abdalla, MI; Herfarth, H, 2016) |
| " A secondary objective was to compare the efficacy and safety of once daily dosing of oral 5-ASA with conventional (two or three times daily) dosing regimens." | 2.53 | Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. ( Feagan, BG; MacDonald, JK; Parker, CE; Wang, Y, 2016) |
| "Azathioprine was shown to be significantly superior to placebo for maintenance of remission." | 2.53 | Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. ( Chande, N; MacDonald, JK; McDonald, JW; Patton, PH; Timmer, A, 2016) |
| " Efficacy, safety and adherence to once daily (OD) and multiple daily (MD) dosing of mesalamine for the induction and maintenance of remission in mild to moderate UC were systematically reviewed and compared." | 2.53 | Once daily vs multiple daily mesalamine therapy for mild to moderate ulcerative colitis: a meta-analysis. ( Jiang, XL; Li, W; Zhang, ZM, 2016) |
| "Ulcerative colitis is an immunologic disorder of the intestine which involves the mucosa and sometimes the submucosa." | 2.53 | [Ulcerative colitis]. ( Biedermann, L; D'cunja, J; Roose, L, 2016) |
| " The total numbers of adverse events associated with BDP and 5-ASA treatments for UC were similar (OR = 1." | 2.53 | Efficacy and Safety of Beclomethasone Dipropionate versus 5-Aminosalicylic Acid in the Treatment of Ulcerative Colitis: A Systematic Review and Meta-Analysis. ( Li, N; Ma, T; Ren, Y; Wang, C; Wang, J; You, S; Zhao, X, 2016) |
| "In contrast to other agents used in the treatment of ulcerative colitis, 5-ASA does not have any known anti-inflammatory effect on other organs or other colonic inflammatory diseases like diverticulitis." | 2.52 | 5-Aminosalicylic acid, a specific drug for ulcerative colitis. ( Hauso, Ø; Martinsen, TC; Waldum, H, 2015) |
| "When we look at the natural history of Crohn's disease (CD), it first begins with inflammation of the intestinal mucosa and this inflammatory reaction proceeds to stenosing or penetrating reaction if not adequately controlled." | 2.52 | [Changing paradigm in the management of inflammatory bowel disease]. ( Jang, BI, 2015) |
| "Ulcerative colitis is a chronic inflammatory disease of the colon of unknown cause that is characterized by alternating intervals of active and inactive disease in 80-90% of patients." | 2.50 | Treatment of ulcerative colitis. ( Blonski, W; Buchner, AM; Lichtenstein, GR, 2014) |
| "We present three patients with ulcerative colitis, all treated with mesalazine, in whom unexplained lung disease developed." | 2.50 | Pulmonary pathology in patients with ulcerative colitis treated with mesalazine--a challenging and complex diagnostic problem. Case series and literature review. ( Bestry, I; Kacprzak, A; Kuś, J; Langfort, R; Siemion-Szcześniak, I; Szturmowicz, M, 2014) |
| "Ulcerative colitis is a chronic idiopathic inflammatory bowel disease characterized by continuous mucosal inflammation that starts in the rectum and extends proximally." | 2.50 | Ulcerative colitis: epidemiology, diagnosis, and management. ( Cheifetz, AS; Feuerstein, JD, 2014) |
| "Individuals with ulcerative colitis face an increased risk of developing colorectal cancer and would benefit from early chemopreventive intervention." | 2.49 | Differential response of flat and polypoid colitis-associated colorectal neoplasias to chemopreventive agents and heterocyclic amines. ( Chang, WC; Clapper, ML; Cooper, HS; Zenser, TV, 2013) |
| "Ulcerative colitis (UC) and Crohn's disease (CD) represent a chronic inflammatory condition of the bowel that often require lifelong medical therapy for the induction and maintenance of the remission." | 2.49 | Mesalazine for the treatment of inflammatory bowel disease. ( Cottone, M; Criscuoli, V; Modesto, I; Orlando, A, 2013) |
| "Oral mesalamine is an effective and safe treatment of mild-to-moderate or quiescent ulcerative colitis regardless of the chosen formulation." | 2.49 | Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviews. ( Chande, N; Feagan, BG; MacDonald, JK, 2013) |
| "Treatment for ulcerative colitis includes mostly systemic acting steroids for induction of remission and topically and systemically acting 5-ASA products and TNF antibodies for maintenance of remission." | 2.49 | [Inflammatory bowel disease]. ( Beglinger, C; Patuto, N, 2013) |
| "Patients with ulcerative colitis uniformly have disease involving the distal colon." | 2.48 | Foam preparations for the treatment of ulcerative colitis. ( Loew, BJ; Siegel, CA, 2012) |
| "Mesalamine (mesalazine) is a 5-aminosalicylic acid compound that is the first-line treatment for patients with mild-to-moderate UC." | 2.48 | Mesalamine in the treatment and maintenance of remission of ulcerative colitis. ( Ham, M; Moss, AC, 2012) |
| " OD dosing of mesalamine was shown to be as effective as MD dosing for the maintenance of clinical remission in patients with quiescent UC (RR = 1." | 2.48 | Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: a meta-analysis. ( Huang, ML; Qiao, YQ; Ran, ZH; Tong, JL; Xu, XT, 2012) |
| "Coexistence of systemic lupus erythematosus (SLE) should be considered in patients with inflammatory bowel disease (IBD) and complex extraintestinal manifestations and the diagnosis of IBD could be established either before or after the diagnosis of SLE." | 2.48 | Inflammatory bowel disease and lupus: a systematic review of the literature. ( Katsanos, KH; Tsianos, EV; Voulgari, PV, 2012) |
| "We systematically reviewed and compared the efficacy and safety of once daily (OD) mesalamine to conventional dosing for induction and maintenance of remission in ulcerative colitis (UC)." | 2.48 | Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis. ( Feagan, BG; MacDonald, JK, 2012) |
| "Ulcerative colitis is an idiopathic, chronic inflammatory disorder of the colonic mucosa, which starts in the rectum and generally extends proximally in a continuous manner through part of, or the entire, colon; however, some patients with proctitis or left-sided colitis might have a caecal patch of inflammation." | 2.48 | Ulcerative colitis. ( Baumgart, DC; Eckmann, L; Ordás, I; Sandborn, WJ; Talamini, M, 2012) |
| "Mesalamine is a topically active agent with anti-inflammatory properties." | 2.48 | Multi-Matrix System (MMX®) mesalamine for the treatment of mild-to-moderate ulcerative colitis. ( Horst, SN; Kane, S, 2012) |
| "Azathioprine was shown to be significantly superior to placebo for maintenance of remission." | 2.48 | Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. ( Macdonald, JK; McDonald, JW; Timmer, A; Tsoulis, DJ, 2012) |
| " A secondary objective of this systematic review was to compare the efficacy and safety of once daily dosing of oral 5-ASA with conventional (two or three times daily) dosing regimens." | 2.48 | Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. ( Feagan, BG; Macdonald, JK, 2012) |
| " A secondary objective was to compare the efficacy and safety of once daily dosing of oral 5-ASA with conventional (two or three times daily) dosing regimens." | 2.48 | Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. ( Feagan, BG; Macdonald, JK, 2012) |
| "Curcumin was administered orally in a dose of 2 g/day for six months." | 2.48 | Curcumin for maintenance of remission in ulcerative colitis. ( Ahuja, V; Kumar, A; Kumar, S; Moss, AC; Sankar, MJ, 2012) |
| " Well designed randomized trials are needed to establish the optimal dosing regimen for rectal 5-ASA, to compare rectal 5-ASA with rectal corticosteroids and to identify subgroups of patients who are more or less responsive to specific rectal 5-ASA regimens." | 2.48 | Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. ( Anand, A; Irvine, EJ; Marshall, JK; Newman, JR; Steinhart, AH; Thabane, M, 2012) |
| " Thus, a general recommendation for long-term use of 5-ASA solely for chemopreventive measures is not warranted." | 2.48 | The role of chemoprevention of colorectal cancer with 5-aminosalicylates in ulcerative colitis. ( Herfarth, H, 2012) |
| "Acute severe ulcerative colitis (ASC) is a potentially life-threatening disease." | 2.47 | Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN. ( Alex, G; Baldassano, RN; Benchimol, EI; Bousvaros, A; Cucchiara, S; Dubinsky, M; Escher, JC; Griffiths, AM; Hyams, JS; Langer, JC; Levine, A; Markowitz, J; Ruemmele, FM; Russell, RK; Shamberger, R; Travis, SP; Turner, D; van Assche, G; Wilson, DC, 2011) |
| "The use of topical therapy in the treatment of ulcerative colitis has declined in recent years despite evidence of good efficacy." | 2.47 | Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis. ( Harris, MS; Lichtenstein, GR, 2011) |
| " However, several randomized controlled trials (RCTs) have been published recently, and no previous meta-analysis has studied the effect of 5-ASA dosage used." | 2.47 | Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. ( Achkar, JP; Ford, AC; Kane, SV; Khan, KJ; Marshall, JK; Moayyedi, P; Talley, NJ, 2011) |
| " Traditionally these agents have required a large pill burden and multiple daily dosing regimens which may account for the low adherence rates, especially in patients in remission." | 2.47 | Maintaining remission in ulcerative colitis--role of once daily extended-release mesalamine. ( Cohen, RD; Oliveira, L, 2011) |
| " Some trials evaluated also the efficacy and safety of once-daily dosing of older 5-ASA formulations in maintenance of remission, finding a greater adherence to therapy in the group given the once daily regimen, compared with the classic twice daily groups." | 2.47 | Is 5-ASA still the treatment of choice for ulcerative colitis? ( Cottone, M; Modesto, I; Orlando, A; Renna, S, 2011) |
| "Conventional therapies for ulcerative colitis and Crohn's disease (CD) include aminosalicylates, corticosteroids, thiopurines, methotrexate, and anti-tumor necrosis factor agents." | 2.47 | Conventional medical management of inflammatory bowel disease. ( Burger, D; Travis, S, 2011) |
| "Health care expenditures for ulcerative colitis (UC) are >$2 billion annually." | 2.47 | Cost-effectiveness analysis of adjunct VSL#3 therapy versus standard medical therapy in pediatric ulcerative colitis. ( Bass, D; Garber, A; Honkanen, A; Park, KT; Perez, F; Tsai, R, 2011) |
| " Once-daily dosing may improve adherence, but impact on the relapse of disease activity is unclear as no previous meta-analysis has studied this issue." | 2.47 | Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis. ( Ford, AC; Kane, SV; Khan, KJ; Moayyedi, P; Sandborn, WJ, 2011) |
| "Treatment of patients with ulcerative colitis (UC) has traditionally focused on improving symptoms, with the main objective of inducing and maintaining symptomatic remission." | 2.46 | Importance of mucosal healing in ulcerative colitis. ( Lichtenstein, GR; Rutgeerts, P, 2010) |
| "Crohn's disease and ulcerative colitis, together popularly known as inflammatory bowel disease (IBD), are characterized by a number of extraintestinal manifestations." | 2.46 | Pancreatitis in inflammatory bowel diseases. ( Das, K; Pitchumoni, CS; Rubin, A, 2010) |
| "Due to the frequency of preceding pulmonary disease and the common temporal dissociation regarding intestinal disease, pulmonary manifestations of inflammatory bowel disease are at high risk of being overlooked." | 2.46 | [Pulmonary manifestations of inflammatory bowel disease]. ( Bachmann, O; Länger, F; Rademacher, J, 2010) |
| " New dosage regimens are likely to become standard practice in the near future." | 2.46 | Mesalazine in inflammatory bowel disease: a trendy topic once again? ( de Silva, S; Ghosh, S; Iacucci, M, 2010) |
| " The first-line therapy remains 5-aminosalicylic acid, which is available in several different formulations and dosing schedules." | 2.46 | Insight into the widespread problem of nonadherence to therapy in ulcerative colitis patients. ( Bernick, SJ; Kane, S, 2010) |
| "Optimizing treatment goals in ulcerative colitis requires recognizing the needs of patients." | 2.46 | Best practice in the management of mild-to-moderately active ulcerative colitis and achieving maintenance of remission using mesalazine. ( Elkjaer, M; Marteau, P; Michetti, P; Munkholm, P; Probert, CS, 2010) |
| "Strict clinical remission endpoints in ulcerative colitis (UC) trials produce low remission rates and do not reflect the good outcomes of UC therapy." | 2.45 | Voting With their Feet (VWF) endpoint: a meta-analysis of an alternative endpoint in clinical trials, using 5-ASA induction studies in ulcerative colitis. ( Higgins, PD; Rangwalla, SC; Waljee, AK, 2009) |
| " In addition, the effectiveness of oral therapy relies on good compliance, which may be adversely affected by frequent daily dosing and a large number of tablets." | 2.45 | [Effectiveness of new, once-daily 5-aminosalicylic acid in the treatment of ulcerative colitis]. ( Lakatos, L; Lakatos, PL, 2009) |
| "Mesalamine is a locally acting antiinflammatory agent that is widely used both to maintain and induce remission in inflammatory bowel disease." | 2.45 | Encapsulated mesalamine granules (Apriso) for ulcerative colitis. ( , 2009) |
| " Patients often take only 40 to 80% of their prescribed dosage of medication." | 2.45 | [The problems of compliance and adherence, using the example of chronic inflammatory bowel disease]. ( Siegmund, SV; Singer, MV; Zimmerer, T, 2009) |
| "While assessment of 5-ASA release is important, limitations of individual measurement techniques mean that randomized clinical studies in UC patients remain the best guide for dosing and treatment regimen decisions." | 2.44 | Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis--methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa. ( Kamm, MA; Lichtenstein, GR, 2008) |
| "Balsalazide is a 5-amino salicylic acid prodrug well-tolerated and effective in treating acute ulcerative colitis." | 2.44 | Balsalazide plus high-potency probiotic preparation (VSL[sharp]3) in the treatment of acute mild-to-moderate ulcerative colitis and uncomplicated diverticulitis of the colon. ( Tursi, A, 2008) |
| "Balsalazide is an aminosalicylate prodrug that releases mesalazine in the colon, thus exerting its multiple anti-inflammatory effects in areas of colitis." | 2.44 | Balsalazide disodium for the treatment of ulcerative colitis. ( Moss, AC; Patil, SA, 2008) |
| "ulcerative colitis and Crohn's disease), for both active disease and the control of remission." | 2.44 | Drug insight: aminosalicylates for the treatment of IBD. ( Munck, LK; Nielsen, OH, 2007) |
| "Crohn's disease and ulcerative colitis are two idiopathic inflammatory bowel disorders." | 2.44 | Inflammatory bowel disease: clinical aspects and established and evolving therapies. ( Baumgart, DC; Sandborn, WJ, 2007) |
| "Colorectal cancer is a complication of longstanding inflammatory bowel disease." | 2.44 | [Colorectal cancer in inflammatory bowel disease]. ( Henriksen, M; Moum, B, 2007) |
| " Current mesalamine formulations are not ideal for long-term treatment due to issues with patient adherence secondary to complex dosing regimens and high pill burden." | 2.44 | Multi-matrix system mesalamine: to use or not to use. ( Kale-Pradhan, PB; Pradhan, RS; Wilhelm, SM, 2008) |
| " Consequently, new guidelines for the management of distal colitis have focussed more on rectal delivery and on optimizing 5-ASA dosage than previously." | 2.44 | Management of distal ulcerative colitis: frequently asked questions analysis. ( Gearry, RB; Gibson, PR; Irving, PM; James, SL, 2008) |
| "More than two-thirds of ulcerative colitis patients experience at least one relapse over a period of 10 years." | 2.44 | Review article: evolving concepts in treatment and disease modification in ulcerative colitis. ( Hanauer, SB, 2008) |
| " With the advantage of low pill burden and easy dosing schedule, it may potentially improve patient compliance and treatment success." | 2.44 | MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis. ( Hu, MY; Peppercorn, MA, 2008) |
| " For patients with severe ulcerative colitis (UC), steroid dosing has been clarified, and a mega-analysis of steroid outcomes and toxicities has been reported." | 2.44 | Optimizing drug therapy in inflammatory bowel disease. ( Kornbluth, A; Swaminath, A, 2007) |
| "Medication non-adherence is multifactorial involving factors other than dosing frequency." | 2.44 | Review article: medication non-adherence in ulcerative colitis--strategies to improve adherence with mesalazine and other maintenance therapies. ( Ghosh, S; Hawthorne, AB; Rubin, G, 2008) |
| " Such sharpened indications have reiterated attention to correct dosing: the results of controlled trials have shown mesalamine to be fully effective at twice the traditional daily dosage (4." | 2.44 | Mesalamine for inflammatory bowel disease: recent reappraisals. ( Actis, GC; Pazienza, P; Rosina, F, 2008) |
| " Nonadherence may be affected by such factors as complicated dosing regimens, forgetfulness, male sex, and treatment delivery methods." | 2.44 | Maximizing patient adherence and clinical outcomes with mesalamine in mildly-to-moderately active ulcerative colitis. ( Lichtenstein, GR; Rubin, DT; Sabesin, SM; Velayos, FS; Vitat, P, 2008) |
| "Treatment of ulcerative colitis has changed little in recent years, except for our improved ability to deliver mesalazine to the large bowel via the recent availability of several oral and rectal preparations." | 2.43 | Inflammatory bowel disease. ( Gibson, PR; Iser, J, 2005) |
| "Guidelines for treatment of ulcerative colitis in children have been created by the working group of the Japanese Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Japanese Society for Pediatric Inflammatory Bowel Disease." | 2.43 | [Guidelines for treatment of ulcerative colitis in children]. ( Tomomasa, T, 2005) |
| "Most of these cases had a history of ulcerative colitis (76 patients)." | 2.43 | 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. ( Card, T; Leufkens, HG; Logan, RF; van Staa, TP, 2005) |
| " This review examines the prevalence and impact of non-adherence to 5-aminosalicylic acid therapy among patients with ulcerative colitis, as well as drug delivery strategies that may enhance dosing regimens to improve patient acceptability, adherence and long-term clinical outcomes." | 2.43 | Systematic review: adherence issues in the treatment of ulcerative colitis. ( Kane, SV, 2006) |
| " Additionally, established therapies are attracting renewed interest with novel dosage regimens and new formulations offering improved efficacy whilst maintaining an excellent tolerance profile." | 2.43 | What's new: innovative concepts in inflammatory bowel disease. ( Sandborn, WJ, 2006) |
| " This review highlights how novel formulations and dosing regimens can ensure treatment success at a greater convenience for the patient with no increased risk of adverse effects." | 2.43 | New lessons: classic treatments, expanding options in ulcerative colitis. ( Hanauer, SB, 2006) |
| " A dose-response trend for 5-ASA was also observed." | 2.43 | Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. ( Macdonald, JK; Sutherland, L, 2006) |
| "Sulfasalazine has more frequent side effects than olsalazine, balsalazide, and mesalamine formulations." | 2.43 | Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention. ( Sandborn, WJ, 2006) |
| "Crohn's disease (CD) and ulcerative colitis (UC) are common and heterogeneous chronic inflammatory bowel disorders of childhood that account for up to 25% of all patients with inflammatory bowel disease (IBD)." | 2.43 | Inflammatory bowel disease in children: a pediatrician's perspective. ( Cuffari, C, 2006) |
| "Patients with mild-moderate ulcerative colitis who do not improve within 2 weeks of high-dose 5-aminosalicylic acid should have treatment augmented by oral steroids." | 2.43 | Review article: induction therapy for patients with active ulcerative colitis. ( Travis, SP, 2006) |
| " Similarly, when 5-aminosalicylic acids are used to induce remission, continuing the induction dosage for an extra 4 weeks prolongs remission and reduces the frequency of relapse." | 2.43 | Review article: maintenance therapy in patients with ulcerative colitis. ( Keshav, S; Orchard, T; Probert, CS, 2006) |
| "Sulfasalazine was the first aminosalicylate to be used for induction and maintenance therapy of ulcerative colitis (UC)." | 2.43 | Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis. ( Hanauer, SB, 2006) |
| "The relative risk of colorectal cancer in ulcerative colitis is increased, however, there're marked geographically differences." | 2.43 | [Inflammatory bowel disease and colorectal cancer]. ( Hagymási, K; Tulassay, Z, 2006) |
| ": To quantify through systematic review the pharmacokinetic profiles of the oral delayed release and sustained release mesalazine (5-aminosalicylate, 5ASA) formulations (Asacol, Salofalk, Mesasal, Claversal, Pentasa) and pro-drugs (sulfasalazine, olsalazine, balsalazide) used in the management of ulcerative colitis." | 2.42 | Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. ( Hanauer, SB; Sandborn, WJ, 2003) |
| "Ulcerative colitis is a chronic inflammatory bowel disease." | 2.42 | [Management of ulcerative colitis]. ( Kullak-Ublick, GA; Rammert, Ch, 2003) |
| "The diagnostic work-up of ulcerative colitis at presentation is based on the collection of clinical, microbiological, radiological, endoscopic and histologic data." | 2.42 | Review article: diagnosis, monitoring and treatment of distal colitis. ( De Franchis, R; Devani, M; Rondonotti, E; Saibeni, S; Vecchi, M, 2003) |
| "Ursodeoxycholic acid has been shown to reduce the risk of neoplasia in UC patients with primary sclerosing cholangitis." | 2.42 | Chemoprevention of colorectal cancer in ulcerative colitis. ( Croog, VJ; Itzkowitz, SH; Ullman, TA, 2003) |
| " A dose-response trend for 5-ASA was also observed." | 2.42 | Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. ( MacDonald, JK; Sutherland, L, 2003) |
| "To determine whether there is a difference in short-term adverse events in patients with ulcerative colitis treated with mesalazine, olsalazine or balsalazide." | 2.42 | Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis. ( Bjorkman, D; Kane, SV; Loftus, EV, 2004) |
| "According to the current paradigm both ulcerative colitis (UC) and Crohn's disease (CD) result from a complex interplay of genetic susceptibility factors, environmental factors, alterations of the physiological intestinal flora and a defective regulation of the intestinal immune system." | 2.42 | Current concept of pathophysiological understanding and natural course of ulcerative colitis. ( Galle, PR; Holtmann, MH, 2004) |
| "Ulcerative colitis is characterized by chronic inflammation of the colon." | 2.42 | Ulcerative colitis: conservative management and long-term effects. ( Fölsch, UR; Kühbacher, T; Schreiber, S, 2004) |
| "We confirmed eosinophilic pneumonia by bronchoalveolar lavage and transbronchial lung biopsy." | 2.42 | [A case of eosinophilic pneumonia possibly associated with 5-aminosalicylic acid (5-ASA)]. ( Aoshima, M; Hakoda, Y; Kinoshita, M; Ohyashiki, K; Sakurai, M, 2004) |
| "Left-sided ulcerative colitis is not a distinct entity, but a less extensive form of pancolitis." | 2.42 | Left-sided ulcerative colitis. ( Haghighi, DB; Lashner, BA, 2004) |
| " Adverse events requiring the withdrawal of therapy seem to occur less frequently with balsalazide, mesalamine, and olsalazine compared with sulfasalazine." | 2.42 | The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis. ( Baker, DE; Kane, S, 2004) |
| "Balsalazide is a well tolerated and effective first-line therapeutic option for patients with ulcerative colitis, both for the treatment of active mild-to-moderate disease and as maintenance therapy to prevent disease relapse." | 2.41 | Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis. ( Goa, KL; Muijsers, RB, 2002) |
| "Therapies for patients with ulcerative colitis have, until recently, been limited in scope and efficacy." | 2.41 | Evolving medical therapies for ulcerative colitis. ( Cohen, RD, 2002) |
| "It describes the treatment of ulcerative colitis according to the different groups of patients and the degree of activity." | 2.41 | [Conservative therapy of inflammatory bowel diseases]. ( Nagy, F, 2002) |
| " Induction of clinical and endoscopic remission was achieved in more patients receiving a daily dosage of 4 g/day than in those receiving placebo." | 2.41 | Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease. ( Clemett, D; Markham, A, 2000) |
| " Mesalamine enema dosing intervals between QHS to Q3 days maintained efficacy." | 2.41 | A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis. ( Cohen, RD; Hanauer, SB; Thisted, RA; Woseth, DM, 2000) |
| " The dosage forms available for rectal delivery include suppositories, foams, and liquid enemas, and selection among these preparations should be guided by the proximal extent of disease and patient preference." | 2.41 | Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis. ( Irvine, EJ; Marshall, JK, 2000) |
| " Although significant differences are found between the various aminosalicylates in release patterns and the resulting pharmacokinetic parameters, no differences in therapeutic effects have been found in comparative studies." | 2.41 | Clinical pharmacokinetics of slow release mesalazine. ( De Vos, M, 2000) |
| "Balsalazide is a 5-aminosalicylic acid (mesalazine) pro-drug which has an inert carrier molecule instead of the sulfapyridine moiety of sulfasalazine." | 2.41 | Review article: balsalazide therapy in ulcerative colitis. ( Ragunath, K; Williams, JG, 2001) |
| "Whereas the incidence of ulcerative colitis has remained stable at around 8-9/10(5), the incidence of Crohn's disease has increased from below 1 to more than 5/10(5) per year during the last three decades." | 2.41 | [Therapeutic principles for chronic inflammatory bowel disease]. ( Binder, V; Munkholm, P, 2001) |
| "Treatment of pouchitis is largely empirical and few controlled studies have been carried-out." | 2.41 | Review article: treatment of mild to moderate ulcerative colitis and pouchitis. ( Amadini, C; Campieri, M; Gionchetti, P; Rizzello, F; Venturi, A, 2002) |
| "Seventy percent of patients with ulcerative colitis can expect to experience a relapse over a 12 month period." | 2.41 | Review article: maintenance of remission in ulcerative colitis. ( Kamm, MA, 2002) |
| "The lethality of the severe ulcerative colitis has been markedly reduced in the last decades by drug and surgical therapy." | 2.40 | [Drug therapy of ulcerative colitis]. ( Rückert, Y, 1997) |
| " The optimal dosage of oral 5-ASA in the maintenance therapy of ulcerative colitis in remission is not clear." | 2.40 | Guidelines for the treatment of ulcerative colitis in remission. ( Ardizzone, S; Bianchi Porro, G; Bollani, S; Molteni, P, 1997) |
| "The treatment of ulcerative colitis and Crohn's disease shares certain common principles." | 2.40 | [Therapy of chronic inflammatory bowel diseases]. ( Beglinger, C, 1997) |
| " Although there is controversy concerning dosage or duration of therapy, oral and topical mesalazine is effective in the treatment of mild to moderately active distal ulcerative colitis." | 2.40 | A practical guide to the management of distal ulcerative colitis. ( Ardizzone, S; Bianchi Porro, G, 1998) |
| "Balsalazide is a prodrug of mesalazine which has an inert carrier molecule instead of the sulfapyridine moiety of sulfasalazine." | 2.40 | Balsalazide. ( Prakash, A; Spencer, CM, 1998) |
| "Drugs for the treatment of ulcerative colitis are sulphapyridine, 5-aminosalicylic acid, prednisolone, betamethasone and immunosuppressive drugs." | 2.40 | [Ulcerative colitis and intestinal bleeding]. ( Asakura, H, 1998) |
| "4 g/day, but a higher dosage of oral delayed-release mesalazine 4." | 2.40 | Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease. ( Markham, A; Prakash, A, 1999) |
| "This is the first report of acute pancreatitis developed by oral 5-ASA therapy for the treatment of ulcerative colitis in the literature of Japan." | 2.40 | Acute pancreatitis secondary to 5-aminosalicylic acid therapy in a patient with ulcerative colitis. ( Adachi, E; Chiba, T; Kawanami, C; Matsushima, Y; Nakamura, T; Nakase, H; Okazaki, K; Seno, H; Uchida, K, 1999) |
| "In patients with moderate or severe ulcerative colitis, glucocorticoids which may be given in conjunction with SASP or 5-ASA are beneficial in producing remission." | 2.40 | [Medical therapy in ulcerative colitis]. ( Akiya, T; Kon, Y; Motegi, K; Nagasako, K; Nogawa, H; Sawada, T, 1999) |
| "Selection of treatment for ulcerative colitis is based on the definition of clinical severity." | 2.40 | [Treatment of mild and moderate ulcerative colitis]. ( Fujinuma, S; Nakajima, S; Sakai, K; Sakai, Y, 1999) |
| "Women with ulcerative colitis who are pregnant have many concerns, such as the effect of the gestational period on UC, the effect of UC on the pregnancy, and the safety of drugs used to control the disease." | 2.40 | [Ulcerative colitis and pregnancy]. ( Ida, A; Koyama, K, 1999) |
| "In both ulcerative colitis and Crohn's disease 5-ASA has proved effective in the acute phase of the disease." | 2.39 | Medical management of patients with difficult-to-treat inflammatory bowel disease. ( van Hogezand, RA, 1994) |
| " A dose-response effect for 5-ASA existed (P < 0." | 2.38 | Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis. ( May, GR; Shaffer, EA; Sutherland, LR, 1993) |
| "In severely active Crohn's disease, systemic corticosteroids have to be administered." | 2.38 | [Local or systemic treatment of inflammatory bowel diseases?]. ( Halter, F; Schmassmann, A, 1993) |
| "The standard therapy of ulcerative colitis and Crohn's disease is based on the treatment with corticosteroids, sulfasalazine and 5-aminosalicylic acid (mesalazine)." | 2.38 | [Drug therapy of chronic inflammatory bowel disease--reliable standards and new developments]. ( Fischbach, W, 1992) |
| "The history, pharmacology, pharmacokinetics, clinical uses and efficacy, adverse effects, drug interactions, and dosage and administration of rectal mesalamine and oral olsalazine in the treatment of inflammatory bowel disease (IBD) are reviewed." | 2.38 | Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease. ( Gales, BJ; Segars, LW, 1992) |
| "Sulfasalazine has been used for many years in the management of ulcerative colitis." | 2.38 | Mesalamine in ulcerative colitis. ( Fitzgerald, JM; Marsh, TD, 1991) |
| "Basis treatment of severe ulcerative colitis and Crohn's disease comprises the systemic administration of corticosteroids." | 2.38 | [Conservative therapy of ulcerative colitis and Crohn disease]. ( Kreisel, W; Rasenack, J, 1991) |
| " There are no data to suggest that patients unresponsive to oral sulfasalazine will respond to 5-ASA in any form, although it is possible that better toleration of the 5-ASA formulations will allow more effective dosage levels to be delivered." | 2.38 | New oral salicylates in the therapy of chronic idiopathic inflammatory bowel disease. ( Robinson, MG, 1989) |
| "Mesalamine use was associated with fewer relapses in UC/IBDU patients (aHR, 0." | 1.91 | Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease. ( Akol-Simsek, D; Colombel, JF; de Koning, DB; Fidder, HH; Goetgebuer, R; Hoentjen, F; Horjus-Talabur Horje, CS; Jansen, JM; Jharap, B; Lutgens, MWMD; Mahmmod, N; Mahmoud, R; Mares, W; Minderhoud, I; Oldenburg, B; Römkens, TEH; Savelkoul, EHJ; van Boeckel, PGA; van Schaik, FDM; van Tuyl, SAC; Witteman, BJM, 2023) |
| " Four (8%) developed nonserious adverse reactions and switched to 5-aminosalicylates (5-ASA) by 1 year." | 1.91 | Efficacy and Safety of Sulfasalazine Suspension in Children With Ulcerative Colitis. ( Bousvaros, A; Chan, C; Liu, E; Mansuri, I; Rufo, PA; Wang, S, 2023) |
| "The medical records of patients with Crohn's disease (CD) and ulcerative colitis (UC) diagnosed with IBD-associated intestinal neoplasia (dysplasia or cancer) from 1983 to 2020 were included in this study." | 1.91 | Effect of Biologics on the Risk of Advanced-Stage Inflammatory Bowel Disease-Associated Intestinal Cancer: A Nationwide Study. ( Ajioka, Y; Akagi, Y; Arakaki, J; Daito, K; Futami, K; Goi, T; Hanai, T; Hasegawa, J; Hida, K; Ikeuchi, H; Iseki, Y; Ishida, F; Ishihara, S; Itabashi, M; Kanemitsu, Y; Katsumata, K; Kazama, S; Kimura, H; Kinugasa, Y; Kiyomatsu, T; Komori, K; Koyama, F; Maeda, K; Maemoto, A; Matsuda, K; Nakamura, M; Nezu, R; Noake, T; Noguchi, T; Ogino, T; Ohge, H; Okabayashi, K; Okamoto, K; Okuda, J; Sasaki, S; Sato, Y; Seishima, R; Shida, D; Sugihara, K; Sunami, E; Suto, T; Takahashi, K; Toiyama, Y; Uchino, M; Uehara, K; Ueno, H; Wakai, T; Watanabe, K; Yamada, K; Yamada, T; Yamaguchi, S; Yamamoto, S; Yamamoto, T, 2023) |
| "Adults with ulcerative colitis on oral mesalazine and scheduled for colonoscopy were eligible for inclusion in this cross-sectional study." | 1.91 | Potential of Mesalazine Therapeutic Drug Monitoring by Measuring Fecal Excretion in Patients With Ulcerative Colitis. ( Bouma, G; Fidder, HH; Huitema, ADR; Oldenburg, B; van de Meeberg, MM; Verheij, ER, 2023) |
| "Because intestinal inflammation affects the gut microbiota and 5-ASA can change the severity of inflammation, assessing the impact of inflammation and 5-ASA on the gut microbiota is not feasible in a clinical study of patients with UC." | 1.91 | 5-Aminosalicylic acid alters the gut microbiota and altered microbiota transmitted vertically to offspring have protective effects against colitis. ( Akimoto, Y; Hibi, N; Hibi, T; Hisamatsu, T; Kobayashi, T; Kuronuma, S; Lee, STM; Matsuura, M; Miyoshi, J; Nishinarita, Y; Oguri, N; Takeuchi, O; Wada, H, 2023) |
| " This leads us to establish how rCDI and its resistance to different treatments make this a challenge for the health system, both for hospitals and for outpatients, as well as how time-consuming each treatment is from the first intake of the drug until its total efficacy or until patients reach a dose-response and time-response to the disease." | 1.91 | Recurrent Multidrug-Resistant ( Castells, J; Ibrahimli, S; Jaramillo, AP; Siegel, S, 2023) |
| "A 73-year-old woman developed ulcerative colitis with mesalazine intolerance a year ago." | 1.91 | [A case of ulcerative colitis with mesalazine intolerance complicated with agranulocytosis and septic shock during salazosulfapyridine administration]. ( Eizuka, K; Honta, S; Ikehata, A; Inomata, N; Masuo, T; Ono, S; Sekino, Y, 2023) |
| "Ulcerative colitis is a relapsing and remitting disease that may be associated with flares." | 1.91 | Factors contributing to flares of ulcerative colitis in North India- a case-control study. ( Dutta, U; Jearth, V; Mahajan, G; Patil, AN; Rana, VS; Saroch, A; Sekar, A; Sharma, V; Singh, AK; Singh, H, 2023) |
| "A 45-year-old man with a history of ulcerative colitis (UC) taking mesalazine (5-aminosalicylic acid) visited the emergency room presenting with ataxia, ophthalmoplegia and a progressively worsening cognitive impairment." | 1.91 | Bickerstaff's brainstem encephalitis: a rare case of neurologic complication in Ulcerative Colitis. ( Cho, H; Han, J; Joe, S; Joo, H; Kim, HK; Lee, CS, 2023) |
| "5-ASA-induced myocarditis is a rare side effect, and few cases have been reported." | 1.72 | 5-Aminosalicylic Acid-induced Myocarditis in a Patient with Atypical Ulcerative Colitis. ( Seo, GS; Song, HY, 2022) |
| "Ulcerative colitis was diagnosed 6 months earlier and treated with mesalamine 80 mg/kg/day and azathioprine 2." | 1.72 | SARS-CoV-2 (COVID-19) pneumonia patient treated with two doses of infliximab within 2 weeks for acute severe ulcerative colitis: A case report. ( Abbas, A; Alhalabi, M; Ali, F; Eddin, KA, 2022) |
| "Ulcerative colitis is an inflammatory bowel disease that forms ulcerations in the mucous membrane of the colon and rectum, in which gut microbiota plays a pivotal role in its pathogenesis." | 1.72 | Therapeutic Potential of Metabolites from ( Aljofan, M; Babenko, D; Chulenbayeva, L; Gulyayev, A; Kozhakhmetov, S; Kozhakhmetova, S; Kushugulova, A; Muhanbetganov, N; Nurgaziyev, M; Nurgozhina, A; Sergazy, S; Tuyakova, A, 2022) |
| "Among 10 400 patients, ulcerative colitis (UC) was twice as common as Crohn's disease (CD), with a male predominance (UC 6678, CD 3495, IBD unclassified 227, and 58% male)." | 1.72 | Emerging inflammatory bowel disease demographics, phenotype, and treatment in South Asia, South-East Asia, and Middle East: Preliminary findings from the Inflammatory Bowel Disease-Emerging Nations' Consortium. ( Abdullah, M; Aftab, H; Ahmed, F; Al Awadhi, S; Al Mohannadi, M; Ali, E; Aniwan, S; Aye, TT; Banerjee, R; Bhatia, SJ; Chaudhuri, S; De Silva, AP; de Silva, HJ; Desai, DC; Dutta, U; Fernandopulle, N; Ghoshal, UC; Hilmi, I; Joshi, N; Kieu, TV; Limsrivilai, J; Mohiuddin, SA; Mohsin, MN; Nawarathne, M; Ngoc, PTV; Nguyen, AD; Ni, N; Niriella, MA; Omar, M; Pal, P; Philip, M; Pisespongsa, P; Rahman, MM; Ramesh, GN; Saberi, B; Shastri, YM; Sollano, JD; Travis, SPL; Wai, TM; Zeid, A, 2022) |
| "MMX mesalamine was the causative agent by drug-induced lymphocyte stimulation test." | 1.72 | A Case of Stevens-Johnson Syndrome Complicated with Multimatrix System Mesalamine in Ulcerative Colitis. ( Abe, K; Goda, K; Irisawa, A; Kanamori, A; Kanazawa, M; Masuyama, S; Tanaka, T; Tominaga, K; Watanabe, S; Yamamiya, A, 2022) |
| "However, the PPS-treated colitis group showed higher gene expression of IL-35 EBI3 subunit by 1." | 1.72 | Pentosan Polysulfate Sodium augments the therapeutic effect of 5-Aminosalicylic Acid in DSS colitis model; the role of IL-35 expression. ( AbdElfattah, AA; Ashour, RH; El-Kady, RA; Elmasry, A; Hazem, NM, 2022) |
| "The dose and duration of mesalazine treatment for ulcerative colitis (UC) is a potentially important determinant of effectiveness, with evidence suggesting that continuing the induction dose for 6-12 months may improve outcomes; however, real-world data are lacking." | 1.72 | Lower Risk of Recurrence with a Higher Induction Dose of Mesalazine and Longer Duration of Treatment in Ulcerative Colitis: Results from the Dutch, Non-Interventional, IMPACT Study. ( Bezemer, G; Bodelier, A; Bruin, K; Jansen, J; Keulen, E; Koussoulas, V; Kuijvenhoven, J; Lubbinge, H; Minderhoud, I; Ouwendijk, R; Russel, M; Tang, T; Van der Meulen, A; Van Dobbenburgh, A; Van Nistelrooy, M; Vandebosch, S; West, R; Wolters, L, 2022) |
| " UC patients on oral 5-ASA ≥ 2 g daily for ≥ 1 year with C-reactive protein (CRP) < 10 mg/dL and no 5-ASA dosage escalation, UC-related hospitalization or corticosteroid use in the past year were included." | 1.72 | No increased risk of flare in ulcerative colitis patients in corticosteroid-free remission after stopping 5-aminosalicylic acid: A territory-wide population-based study. ( Chan, FKL; Cheng, CTY; Lam, BKH; Lam, RHM; Mak, JWY; Ng, SC; Wong, GLH; Yip, TCF; Yuen, NTK, 2022) |
| " Through population pharmacokinetic (PK) analysis and in-vitro in-vivo correlation (IVIVC) modeling on the dissolution and BE data of a generic enteric-coated product (EM) and its reference Salofalk® 250 mg tablet (SM), we for the first time revealed the underlying mechanism of the high inter-subject variability for such delayed-release formulation." | 1.72 | Population pharmacokinetics and IVIVC for mesalazine enteric-coated tablets. ( Gao, F; Leng, W; Wo, SK; Yan, X; Zhang, Y; Zuo, Z, 2022) |
| "Olsalazine is a typical 5-aminosalicylic acid (5-ASA) drug that depends on gut microbiota to liberate its anti-inflammatory moiety 5-ASA in the treatment of ulcerative colitis (UC)." | 1.72 | Pharmacokinetic and gut microbiota analyses revealed the effect of Lactobacillus acidophilus on the metabolism of Olsalazine in ulcerative colitis rats. ( Feng, Y; Li, Z; Liu, L; Ma, S; Mei, Q; Wang, J; Wang, S; Wang, X; Wang, Y; Xu, Z; Yan, R; Yang, P, 2022) |
| "Patients with ulcerative colitis (UC) are known to have a significantly poor quality of life due to bowel frequency (night) and urgent defecation." | 1.72 | Bowel frequency (night) and urgent defecation are improved by budesonide foam in patients with ulcerative colitis: a retrospective observational study. ( Akita, Y; Iwashita, Y; Maruyama, Y; Miyashita, H; Miyazaki, R; Sakurai, T; Saruta, M; Shibuya, N; Shimada, M, 2022) |
| "Paternal and maternal use of 5-ASA was safe across offspring outcomes; none of the findings reached statistical significance." | 1.72 | The safety of paternal and maternal use of 5-aminosalicylic acid during conception and pregnancy: a nationwide cohort study. ( Friedman, S; Kjeldsen, J; Nielsen, J; Nørgård, BM, 2022) |
| "Diversion colitis and ulcerative colitis (UC) can be caused by different mechanisms; however, several case reports have described the development of typical UC following diversion colitis." | 1.72 | Progression of ulcerative colitis following diversion colitis. ( Araki, K; Inayama, Y; Kimura, H; Kumagai, J; Kunisaki, R; Maeda, S; Matsune, Y; Yaguchi, K, 2022) |
| "Distal ulcerative colitis (UC) is responsible for distressing symptoms and reduces quality of life (QoL)." | 1.72 | Real-world evidence of quality of life improvement in patients with distal ulcerative colitis treated by mesalazine: the Quartz study. ( Caron, B; Gonzalez, F; Paupard, T; Peyrin-Biroulet, L; Siproudhis, L, 2022) |
| "The long-term outcomes of Ulcerative colitis (UC) after discontinuation of biological therapy are largely unknown." | 1.72 | Prediction of long-term remission in patients following discontinuation of anti-TNF therapy in ulcerative colitis: a 10 year follow up study. ( Beilfuss, J; Florholmen, J; Goll, R; Gundersen, M; Johnsen, KM; Kileng, H; Moe, ØK; Sørbye, SW, 2022) |
| "Ulcerative colitis is a condition of chronic inflammation affecting the large intestine." | 1.72 | Use of Novel Biological Agent in Severe Ulcerative Colitis with Poor Response to Initial Therapy: A Case Report. ( Basnet, BK; Bhandari, A, 2022) |
| "Crohn's disease (CD) and ulcerative colitis (UC) are complex, inflammatory bowel diseases (IBD) with debilitating complications." | 1.72 | Thiopurine Monotherapy Is Effective in Maintenance of Mild-Moderate Inflammatory Bowel Disease. ( Barber, GE; Choe, M; Hendler, S; Keyashian, K; Lechner, S; Limketkai, BN; Limsui, D, 2022) |
| "The onset age of ulcerative colitis has been increasing in several countries." | 1.62 | Clinical Course of Ulcerative Colitis Associated with an Age at Diagnosis: A Recent Japanese Database Survey. ( Iijima, K; Shimodaira, Y; Watanabe, K, 2021) |
| "Infliximab is used for ulcerative colitis but could also be effective against severe DC." | 1.62 | Novel application of infliximab for diversion colitis. ( Kido, M; Okajima, H; Tamura, R; Yasui, Y, 2021) |
| " This case reinforces the possibility of a causal relationship between mesalazine therapy and toxic hepatic injury without systemic hypersensitivity." | 1.62 | "Hepatotoxicity in inflammatory bowel disease: mesalazine, the forgotten drug". ( Garrido, I; Lopes, J; Lopes, S; Macedo, G; Santos, AL, 2021) |
| " Mesalazine at 4,000 mg/day and prednisolone at 60 mg/day were started, and the prednisolone dosage was thereafter gradually reduced and switched to golimumab." | 1.62 | Multiple Cerebral Infarction Associated with Cerebral Vasculitis in a Patient with Ulcerative Colitis. ( Dohi, O; Hasegawa, D; Hirose, R; Inoue, K; Ishikawa, T; Itoh, Y; Kamada, K; Konishi, H; Naito, Y; Takagi, T; Uchiyama, K; Yasuda, T; Yoshida, N, 2021) |
| "This analysis in patients with ulcerative colitis who require treatment with biologics or tofacitinib demonstrates that continuing 5-ASA therapy is not a cost-effective strategy." | 1.62 | Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis. ( Huang, E; Patel, S; Rubin, DT; Shaffer, SR, 2021) |
| "A total of 103 patients (93." | 1.62 | Knowledge of 5-aminosalicylic acid nephrotoxicity and adherence to kidney function monitoring of patients with inflammatory bowel disease. ( Achit, H; Ayav, C; D'Amico, F; Danese, S; Frimat, L; Guillemin, F; Guillo, L; Peyrin-Biroulet, L; Weislinger, L, 2021) |
| "A 50-year-old female with ulcerative colitis (UC) (pancolitis) for 13 years was referred for a screening colonoscopy." | 1.62 | A case of severe diverticulosis in a patient with ulcerative colitis. ( Dias, E; Macedo, G; Santos-Antunes, J, 2021) |
| "The majority of patients had Crohn's disease (CD) (60%) and most of them were in clinical remission." | 1.62 | COVID-19 in IBD: The experience of a single tertiary IBD center. ( Belluzzi, A; Calabrese, C; Calandrini, L; Decorato, A; Dussias, N; Filippone, E; Gionchetti, P; Laureti, S; Melotti, L; Peruzzi, G; Poggioli, G; Privitera, H; Rizzello, F; Rottoli, M; Salice, M; Scaioli, E; Siniscalchi, A, 2021) |
| "Studies of patients with ulcerative colitis (UC) report that reduced clinical symptoms and endoscopic activity predict better health-related quality of life (HRQoL)." | 1.62 | The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine. ( Nag, A; Willian, MK; Yarlas, A, 2021) |
| "Most colorectal cancers (CRC) arise sporadically from precursor lesions: colonic polyps." | 1.62 | 5-Aminosalicylic acid inhibits stem cell function in human adenoma-derived cells: implications for chemoprophylaxis in colorectal tumorigenesis. ( Chambers, AC; Collard, TJ; Creed, TJ; Dixon, SW; Greenhough, A; Legge, DN; Mortensson, EMH; Williams, AC, 2021) |
| "A pregnant woman with severe ulcerative colitis was treated with a dose of mesalazine 4,000 mg/day from early gestation to delivery." | 1.62 | Maternal mesalazine-induced neonatal gastrointestinal bleeding. ( Kuboi, T; Nii, K; Okada, H; Okazaki, K, 2021) |
| "Ulcerative colitis is a common non-specific chronic disease." | 1.62 | Supplemental bifid triple viable capsule treatment improves inflammatory response and T cell frequency in ulcerative colitis patients. ( Li, S; Xiao, D; Yin, Y; Zou, Y, 2021) |
| "Although most patients with ulcerative colitis should be given topical treatment, different studies have shown that they are underused in clinical practice." | 1.56 | Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on topical therapy in ulcerative colitis. ( Barreiro-de Acosta, M; Domènech, E; Esteve, M; Ginard, D; Gisbert, JP; Marín-Jiménez, I; Mínguez, M; Ricart, E, 2020) |
| " Its combination with bifid triple viable could mitigate adverse effects." | 1.56 | Effects of mesalazine combined with bifid triple viable on intestinal flora, immunoglobulin and levels of cal, MMP-9, and MPO in feces of patients with ulcerative colitis. ( Jiang, XE; Yang, SM; Zhang, Y; Zhou, XJ, 2020) |
| "Therefore, in diagnosing and treating ulcerative colitis, noninvasive, low-cost methods for predicting mucosal healing using useful biomarkers are required in the clinical setting." | 1.56 | Serum amyloid A is a better predictive biomarker of mucosal healing than C-reactive protein in ulcerative colitis in clinical remission. ( Chayama, K; Hayashi, R; Ito, M; Kumada, J; Naito, T; Nomura, M; Oka, S; Takigawa, H; Tanaka, S; Ueno, Y; Wakai, M, 2020) |
| "Mesalamine was stopped and repeat CXR was obtained on the follow-up visit, which showed no pleural effusion." | 1.56 | Mesalamine-induced eosinophilic pleural effusion. ( Al-Abcha, A; Alratroot, A; Kherallah, S; Raziq, F, 2020) |
| "Histologic remission in ulcerative colitis (UC) patients may be associated with positive outcomes." | 1.56 | Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission. ( Al-Saedi, M; Alshahrani, AA; Aruljothy, A; Christensen, B; Fadida, M; Marshall, JK; Narula, N; Rubin, DT, 2020) |
| "Drug-induced acute pancreatitis (DIAP) is an often-neglected entity where the disorder is the consequence of the toxic effects of various agents applied to treat potentially life-threatening conditions, such as inflammatory bowel disease." | 1.56 | Recurrent acute pancreatitis induced by 5-ASA and azathioprine in ulcerative colitis. ( Bajor, J; Faluhelyi, N; Hegyi, P; Hegyi, PJ; Németh, BC; Szakács, Z, 2020) |
| "He was suspected of having ulcerative colitis, and administration of 2400mg/day of oral mesalazine was initiated." | 1.56 | [Mesalazine-induced myocarditis]. ( Ikeuchi, H; Kodama, R; Koh, Y; Nagaya, T; Saegusa, H; Ushimaru, H, 2020) |
| "Infliximab can improve DM in the treatment of ulcerative colitis." | 1.56 | Infliximab is effective in the treatment of ulcerative colitis with dermatomyositis: A case report. ( Chen, L; Gu, GL; Han, LC; Huang, BB; Li, SQ; Liu, GF; Lv, XD; Lv, XP; Wang, HQ; Zhan, LL, 2020) |
| "She had ulcerative colitis and had been taking salazosulfapyridine (SASP) for about 30 years." | 1.51 | [DRUG-INDUCED BILATERAL NEPHROLITHIASIS IN AN ULCERATIVE COLITIS PATIENT: A CASE REPORT]. ( Kurosawa, K; Nagamoto, S; Ogawa, K; Oka, S; Okaneya, T; Sakaguchi, K; Urakami, S, 2019) |
| "Mesalamine treatment has an effect on epithelial miRNAs." | 1.51 | miR-206 as a Biomarker for Response to Mesalamine Treatment in Ulcerative Colitis. ( Amenta, PS; Bajpai, M; Brant, SR; Das, KM; Geng, X; Minacapelli, CD; Poplin, E; Van Gurp, J, 2019) |
| "The patient was diagnosed with ulcerative colitis and received remission induction therapy with prednisolone." | 1.51 | Hematemesis due to Drug Allergy to Oral Prednisolone in a Patient with Ulcerative Colitis. ( Arisaka, O; Arisaka, T; Hiraishi, H; Irisawa, A; Kanazawa, M; Sugaya, T; Takahashi, F; Takenaka, K; Tominaga, K, 2019) |
| " The delayed release and the lower bioavailability of 5-ASA from xylan-5-ASA conjugate administration compared to free 5-ASA administration confirmed the successful local colon delivery of 5-ASA using xylan-5-ASA conjugate." | 1.51 | Xylan from Pineapple Stem Waste: a Potential Biopolymer for Colonic Targeting of Anti-inflammatory Agent Mesalamine. ( Anindya, AL; Damayanti, S; Kurniati, NF; Oktaviani, RD; Praevina, BR; Rachmawati, H; Riani, C, 2019) |
| "Men with ulcerative colitis were more likely to undergo treatment consistent with long-term remission or cure, including maintenance medications and definitive surgery." | 1.51 | Sex Differences in Treatment Strategies Among Patients With Ulcerative Colitis: A Retrospective Cohort Analysis of Privately Insured Patients. ( Bundorf, MK; Kin, C; Morris, AM; Park, KT; Sceats, LA, 2019) |
| "Prednisolone treatment successfully induced clinical remission and mucosal healing." | 1.51 | A case of nivolumab-associated colitis, which relapsed after mucosal healing and was then successfully treated with mesalazine. ( Akemoto, Y; Asari, T; Chinda, D; Fukuda, S; Fukutoku, Y; Hasui, K; Hiraga, H; Kikuchi, H; Mikami, T; Murai, Y; Sakuraba, H; Sawaya, M; Tanaka, M; Tatsuta, T, 2019) |
| "Observational, cohort study of ulcerative colitis (UC) patients in clinical remission at least 6 months on 5-ASA monotherapy maintenance prescribed by an electronic management program." | 1.51 | Impact and risk factors of non-adherence to 5-aminosalicylates in quiescent ulcerative colitis evaluated by an electronic management system. ( Anton, R; Ballester, MP; Bosca-Watts, MM; Fullana, M; Marti-Aguado, D; Minguez, M; Mora, F; Navarro-Cortes, P; Romero, E; Sanchez, A; Tosca, J, 2019) |
| "A 35-year-old woman with ulcerative colitis was diagnosed to have acute eosinophilic pneumonia after 29 days of oral mesalazine use and improved after mesalazine and corticosteroid were withdrawn." | 1.51 | Recurrent Eosinophilic Pneumonia Associated with Mesalazine Suppository in a Patient with Ulcerative Colitis. ( Kang, SB; Lee, J; Park, M; Park, Y, 2019) |
| "Post-treatment inflammation distribution can change over time." | 1.51 | Effectiveness of sigmoidoscopy for assessing ulcerative colitis disease activity and therapeutic response. ( Chang, CW; Chen, MJ; Hsu, TC; Lin, WC; Wang, HY, 2019) |
| "Thalidomide was discontinued and orally administered mesalazine was restarted." | 1.51 | Early onset first-episode psychosis during treatment with thalidomide for refractory ulcerative colitis: a case report. ( Ivagnes, S; Margari, F; Margari, L; Palumbi, R; Petruzzelli, MG, 2019) |
| "An increase incidence of ulcerative colitis (UC) has been reported in Mexico." | 1.51 | Ulcerative colitis: epidemiology, clinical features and associated factors with surgical treatment in a tertiary hospital in Mexico. ( Alarcón-Bernés, L; Gracida-Mancilla, NI; Jiménez-Bobadilla, B; León-Rendón, JL; López-Pérez, RY; Villanueva Herrero, JA, 2019) |
| "The therapy of the inflammatory bowel diseases is quite complex." | 1.48 | The adherence to the therapy in inflammatory bowel disease: beyond the number of the tablets. ( Astegiano, M; Caviglia, GP; Finocchiaro, F; Pellicano, R; Ribaldone, DG; Saracco, GM; Vernero, M, 2018) |
| "Colitis was induced in female swiss mice by adding DSS 3% to the drinking water." | 1.48 | Antioxidant and anti-inflammatory effect of plumieride in dextran sulfate sodium-induced colitis in mice. ( Andrade, SF; Boeing, T; Bonomini, TJ; da Silva, LM; de Souza, P; Lucinda, RM; Malheiros, A; Mariano, LNB; Somensi, LB, 2018) |
| "BACKGROUND Ulcerative colitis (UC) is a chronic inflammatory bowel disease, affecting the colon continuously from the rectum proximally." | 1.48 | A Case of Right-Sided Ulcerative Colitis with Mesalamine-Induced Hypersensitivity Reactions. ( Ajioka, Y; Hasegawa, K; Hirono, H; Honma, T; Ohkoshi, S; Watanabe, K, 2018) |
| "Linear IgA bullous dermatosis is a rare bullous disease in children and adults that can be associated with autoimmune conditions, malignancies, infections, or medication exposure." | 1.48 | Linear IgA bullous dermatosis associated with ulcerative proctitis: treatment challenge. ( Burns, C; Yetto, T, 2018) |
| "A 75-year-old female was diagnosed with ulcerative colitis and took mesalazine over a period of 2 years and 8 months." | 1.48 | Mesalazine-related lung disease in a patient with ulcerative colitis: A case report. ( Cheng, YM; Chiu, CT; Hu, HC; Huang, PH; Kuo, CJ; Lin, CW; Lin, CY; Su, MY, 2018) |
| " Headaches initially improved but the dosage could not be decreased under 750 mg a day without recurrence of the symptoms." | 1.48 | Mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis: A case report. ( Hage, A; Hage, R; Khanna, RK; Polin, V; Sené, T; Vignal-Clermont, C, 2018) |
| "Mesalamine was discontinued, and thepatient's skin eruption, renal function, liver functiontests, and leukocytosis subsequently improved." | 1.46 | First report of mesalamine (5-aminosalicylic acid) as the causative agent in a case of acute generalized exanthamous pustulosis. ( Hutchens, K; Park, K; Rocci, E; Winterfield, L, 2017) |
| "Efficacy of maintenance therapy in ulcerative colitis (UC) in the remission stage has been reported to depend on release profile or dosing regimen of oral 5-aminosalicylic acid (5-ASA) products used." | 1.46 | Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study. ( Hanai, H; Hibi, T; Kochi, S; Nagahori, M; Nakamura, S; Omuro, S; Watanabe, M; Yamamoto, T, 2017) |
| "Crohn's disease and ulcerative colitis are the two major types of inflammatory bowel disease, and affect mainly the gastrointestinal tract but also have extraintestinal sequelae, such as arterial and venous thromboembolism." | 1.46 | Use of Novel Oral Anticoagulant to Treat Pulmonary Thromboembolism in Patient with Ulcerative Colitis Superinfected Cytomegalovirus Colitis. ( Jang, S; Kang, SB; Kim, SH; Park, JK; Park, Y; Sung, Y; Yun, J, 2017) |
| "We present a case of a patient with ulcerative colitis and recurrent CD infection successfully treated with FT." | 1.46 | Fecal transplantation as a treatment for Clostridium difficile infection in patients with ulcerative colitis. ( Izquierdo Romero, M; Mancebo Mata, A; Varela Trastoy, P, 2017) |
| "Whether the epidemiology of ulcerative colitis (UC) has changed during recent decades is partly unknown." | 1.46 | Changes in medical management and colectomy rates: a population-based cohort study on the epidemiology and natural history of ulcerative colitis in Örebro, Sweden, 1963-2010. ( Cao, Y; Eriksson, C; Halfvarson, J; Henriksson, I; Montgomery, S; Rundquist, S; Zhulina, Y, 2017) |
| "Guided by the Pediatric Ulcerative Colitis Activity Index (PUCAI), patients received initial standardised treatment with mesalazine (PUCAI 10-30) oral corticosteroids (PUCAI 35-60), or intravenous corticosteroids (PUCAI ≥65)." | 1.46 | Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study. ( Baker, SS; Baldassano, RN; Benkov, K; Boyle, B; Britt, A; Collins, MH; Davis, S; Denson, LA; Dubinsky, M; Evans, J; Gotman, N; Griffiths, AM; Guthery, SL; Heyman, M; Hyams, JS; Kappelman, MD; Keljo, DJ; Kugathasan, S; LeLeiko, NS; Mack, DR; Markowitz, J; Marquis, A; Moulton, D; Noe, J; Oliva-Hemker, M; Otley, A; Patel, A; Pfefferkorn, M; Rosh, J; Rufo, P; Sauer, CG; Saul, B; Serrano, J; Spada, KL; Strople, J; Sudel, B; Sylvester, FA; Tangpricha, V; Venkateswaran, S; Wali, P; Walters, T; Wang, J; Ziring, D, 2017) |
| " Dissolution studies of the prepared formulation conducted in simulated colonic fluid clearly demonstrated its superiority over the marketed, delayed release dosage forms of mesalamine." | 1.46 | Role of synbiotics in polysaccharide assisted colon targeted microspheres of mesalamine for the treatment of ulcerative colitis. ( Gulati, M; Kaur, R; Singh, SK, 2017) |
| "In both Crohn's disease and ulcerative colitis patients in deep remission, the incidence rate of relapse was 19% per patient-year." | 1.46 | Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study. ( Aicart, M; Alcaín, G; Almela, P; Arguelles-Arias, F; Arias-Rivera, ML; Barreiro-de Acosta, M; Barrio, J; Beltrán, B; Benítez, JM; Bermejo, F; Botella, B; Bujanda, L; Busquets, D; Calvet, X; Casanova, MJ; Castaño-Milla, C; Castro, E; Castro, L; Ceballos, D; Chaparro, M; Cortés, X; Domènech, E; Domínguez, M; Domínguez-Antonaya, M; Dueñas, C; Esteve, M; Fernández-Salazar, L; García-Herola, A; García-López, S; García-Planella, E; García-Sánchez, V; García-Sepulcre, MF; Garrido, E; Gisbert, JP; Gómez-García, M; Gomollón, F; González-Lama, Y; Guardiola, J; Gutiérrez, A; Hernández-Martínez, A; Hervías, D; Hinojosa, J; Huguet, JM; Jauregui-Amezaga, A; Khorrami, S; Leo, E; Llaó, J; Lorente-Poyatos, R; Mañosa, M; Marín-Jiménez, I; Marrero, JM; Martín-Arranz, M; Martinez-Montiel, MP; Menacho, M; Merino, O; Monfort, D; Moraleja, I; Muñoz, C; Muñoz, F; Nantes, O; Navarro-Llavat, M; Novella, MT; Opio, V; Pajares, R; Pérez-Calle, JL; Pérez-Martínez, I; Pineda, JR; Ponferrada, A; Ramírez-de la Piscina, P; Ramos, L; Robles-Alonso, V; Rodríguez, C; Rodríguez, GE; Rodríguez-Pérez, A; Rojas-Feria, M; Roncedo, O; Sánchez-Torres, A; Sicilia, B; Taxonera, C; Tosca, J; Van Domselaar, M; Vázquez, JM; Vega-López, AB, 2017) |
| "A man aged 56 years with a history of ulcerative colitis (UC) status postsubtotal colectomy was hospitalised with fevers, dry cough, eye redness and a new bloody, mucoid rectal discharge." | 1.46 | Subcorneal pustular dermatosis and episcleritis associated with poorly controlled ulcerative colitis. ( Adams, M; Trevino, J; Wargo, JJ, 2017) |
| " DAI and colonic histopathology scores in the normal dosage, high dosage and the 5‑ASA‑SiO2 NP groups demonstrated a significant improvement when compared with the model group." | 1.46 | 5-ASA-loaded SiO2 nanoparticles-a novel drug delivery system targeting therapy on ulcerative colitis in mice. ( Mao, J; Tan, X; Tang, H; Wang, F; Wang, Y; Xiang, D, 2017) |
| "Although severe flare of ulcerative colitis (UC) is uncommon, it significantly increases the risk of preterm delivery, low birth weight and other adverse fetal outcomes." | 1.46 | Case Report: Acute Flair of Ulcerative Colitis during Pregnancy Is Still a Major Problem. ( Markovic, S; Protic, M; Tarabar, D, 2017) |
| "We present a case of invasive pulmonary Aspergillosis due to corticosteroid therapy in the context of a severe Ulcerative Colitis flare." | 1.46 | Invasive pulmonary aspergillosis in an immunocompromised patient with severe ulcerative colitis. ( Ballester, MP; Bosca Watts, MM; Marti Aguado, D, 2017) |
| " One comparing two different dosing regimens for the maintenance of remission in people with ulcerative colitis (CODA), and the other comparing an orally administered treatment to an intravenously administered treatment in preventing skeletal-related events in patients with bone metastases from breast cancer (ZICE)." | 1.46 | The use of randomisation-based efficacy estimators in non-inferiority trials. ( Barrett-Lee, P; Casbard, A; Farewell, D; Gillespie, D; Hawthorne, AB; Hood, K; Hurt, C; Murray, N; Probert, C; Stenson, R, 2017) |
| "The prevalence of ulcerative colitis (UC) and its associated economic burden is increasing in Spain." | 1.43 | [Cost-effectiveness assessment through theoretical cost-minimization analysis of the use of two gastro-resistant modified-release mesalazine formulations in the management of ulcerative colitis in Spain]. ( Gisbert, JP; Gomollón, F; Méndez, I, 2016) |
| "Twenty-two patients with ulcerative colitis in clinical relapse and 7 control subjects referred for colonoscopy were enrolled." | 1.43 | Confocal laser endomicroscopy in ulcerative colitis: a longitudinal study of endomicroscopic changes and response to medical therapy (with videos). ( Brynskov, J; Ciocalteu, A; Hendel, J; Karstensen, JG; Klausen, P; Klausen, TW; Riis, LB; Săftoiu, A; Vilmann, P, 2016) |
| "Older ulcerative colitis (UC) patients had similar anti-TNF use (16." | 1.43 | Medication Utilization and the Impact of Continued Corticosteroid Use on Patient-reported Outcomes in Older Patients with Inflammatory Bowel Disease. ( Anton, K; Chen, W; Geisz, M; Ha, C; Kappelman, MD; Long, MD; Martin, CF; Sandler, RS, 2016) |
| "The Achilles tendinitis subsided with conservative management within 2 weeks, despite continuation of mesalazine therapy." | 1.43 | Achilles tendinitis as a rare extraintestinal manifestation of ulcerative colitis. ( Araki, I; Komai, K; Nakamiya, O; Shimada, Y; Taniuchi, Y; Tokuumi, Y; Zenda, T, 2016) |
| "To investigate knowledge and fear of colorectal cancer (CRC) risk in inflammatory bowel disease (IBD) patients." | 1.43 | Patients' knowledge and fear of colorectal cancer risk in inflammatory bowel disease. ( Belle, A; Collet-Fenetrier, B; Lopez, A; Peyrin-Biroulet, L, 2016) |
| "Recurrent Clostridium difficile infection (rCDI) contributes to a significant burden of disease in patients with inflammatory bowel disease (IBD)." | 1.43 | Recurrence of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease: The RECIDIVISM Study. ( Bahreini, Z; McGeer, A; Nguyen, GC; Razik, R; Rumman, A, 2016) |
| "Fatigue was evaluated using the fatigue visual analog scale (fVAS)." | 1.43 | Conventional treatment regimens for ulcerative colitis alleviate fatigue - an observational cohort study. ( Aabakken, L; Carlsen, A; Grimstad, T; Isaksen, K; Karlsen, LN; Kvaløy, JT; Leitao, K; Norheim, KB; Omdal, R, 2016) |
| "Disease relapse was measured at each visit." | 1.43 | The Effects of Active IBD During Pregnancy in the Era of Novel IBD Therapies. ( de Lima-Karagiannis, A; van der Woude, CJ; Zelinkova-Detkova, Z, 2016) |
| "The medical treatment of ulcerative colitis (UC) has seen a change towards a more active attitude during recent years, including both the use of more traditional drugs as well as new biological substances." | 1.43 | Low colectomy rate five years after diagnosis of ulcerative colitis. Results from a prospective population-based cohort in Sweden (ICURE) diagnosed during 2005-2009. ( Holmström, T; Karlbom, U; Rönnblom, A; Sjöberg, D; Tanghöj, H; Thörn, M, 2016) |
| "Half of the Crohn's disease patients were prescribed prolonged oral 5-ASAs during the study, although this decreased between era 3 and 5 from 61." | 1.43 | Steroid dependency and trends in prescribing for inflammatory bowel disease - a 20-year national population-based study. ( Cecil, E; Chhaya, V; Curcin, V; Majeed, A; Pollok, RC; Saxena, S; Subramanian, V, 2016) |
| "The use of immunosuppressants for the treatment of nephrotic syndrome might affect the development of rectal carcinoma." | 1.43 | Ulcerative colitis associated with nephrotic syndrome after treatment with mesalazine developed into rectal carcinoma: a case study. ( Koketsu, S; Kubota, Y; Noie, T; Okuyama, T; Ono, Y; Oya, M; Sameshima, S, 2016) |
| "No significant risk for other intestinal cancers was found, especially for small bowel carcinoma." | 1.43 | Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study. ( Charpentier, C; Cheddani, H; Dauchet, L; Dupas, JL; Fumery, M; Gower-Rousseau, C; Marie Bouvier, A; Pariente, B; Peyrin-Biroulet, L; Savoye, G, 2016) |
| "Forty-four-year-old male with ulcerative colitis (UC) for 11 years reported frequent relapse despite daily sulfasalazine 4 g, azathioprine 125 mg, and rectal 5-aminosalicylic acid." | 1.43 | Successful colonoscopic fecal microbiota transplantation for active ulcerative colitis: First report from India. ( Bagga, R; Jain, P; Rawal, P; Seth, AK, 2016) |
| "Acetic acid ulcerative colitis (UC) is an experimental condition created due to intra-rectal administration of acetic acid which causes inflammation and ulceration in the lining of colon and rectum." | 1.42 | Mesalazine-probiotics beads for acetic acid experimental colitis: formulation and characterization of a promising new therapeutic strategy for ulcerative colitis. ( Bansal, D; Dubey, N; Ganeshpurkar, A; Pandey, V; Vishwakarma, N, 2015) |
| "Curcumin is a polyphenol that is extracted from turmeric (Curcuma longa)." | 1.42 | [Curcumin add-on therapy for ulcerative colitis]. ( Gamus, D; Lang, A; Salomon, N, 2015) |
| "Physicians traditionally treat ulcerative colitis (UC) using a step-up approach." | 1.42 | Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study. ( Fournier, N; Rogler, G; Safroneeva, E; Schoepfer, AM; Straumann, A; Vavricka, SR, 2015) |
| " Physicians who prescribe 5-aminosalicylate to patients with inflammatory bowel disease should be aware of this adverse event." | 1.42 | Chronic tubulointerstitial nephritis induced by 5-aminosalicylate in an ulcerative colitis patient: a rare but serious adverse event. ( Chagas, C; Magalhães-Costa, P; Matos, L, 2015) |
| "Treatment of mesalazine, an anti-ulcerative colitis drug, down-regulated Foxp3 and IL-17 expression in BTLA positive T cells along with attenuated severity for colitis." | 1.42 | BTLA associates with increased Foxp3 expression in CD4(+) T cells in dextran sulfate sodium-induced colitis. ( Fu, XX; Kong, B; Wang, CY; Wang, WD; Xiang, WY; Xu, JF; Zeng, JC; Zhang, HX; Zhang, JA; Zheng, XB; Zhong, J; Zhu, B, 2015) |
| "Identifying ulcerative colitis (UC) patients with increased risk of colectomy is essential for appropriate treatment." | 1.42 | Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study). ( Cvancarova, M; Høivik, ML; Moum, B; Solberg, IC, 2015) |
| "A cohort of patients with ulcerative colitis was prospectively enrolled in this observational study and followed for 12 months." | 1.42 | Adherence to Rectal Mesalamine in Patients with Ulcerative Colitis. ( Boyle, M; Cheifetz, AS; Cury, DB; Moss, A; Nanda, K; Ting, A, 2015) |
| " No serious adverse event, including progressive multifocal leukoencephalopathy, was observed, although more investigations are needed to confirm the safety profile of this drug." | 1.42 | Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis. ( Hibi, T; Iwakiri, R; Matsuoka, K; Motoya, S; Tominaga, K; Watanabe, K; Watanabe, M; Yoshimura, N, 2015) |
| "For patients with ulcerative colitis, adherence to 5-aminosalicylic acid (5-ASA) is generally expected to ensure better maintenance of remission." | 1.42 | [Adherence to oral 5-aminosalicylic acid by patients with quiescent ulcerative colitis: a questionnaire survey]. ( Kani, K; Kato, S; Kobayashi, T; Nagoshi, S; Yakabi, K; Yamamoto, R, 2015) |
| "As seen in active ulcerative colitis (UC), the formation of crypt abscesses was observed in the biopsy." | 1.42 | A case of diverticular colitis with lesions resembling ulcerative colitis and correlation of tumor necrosis factor-alpha staining with clinical manifestations. ( Inui, K; Katano, Y; Kobayashi, T; Kosaka, T; Torii, Y; Wakabayasi, T; Yoshino, J, 2015) |
| "The management of patients with ulcerative colitis who are dependent on corticosteroid for control of symptoms, or refractory to corticosteroids or standard immunosuppressive therapy, is challenging." | 1.42 | New Zealand Society of Gastroenterology Guidelines for the Management of Refractory Ulcerative Colitis. ( Day, AS; Eliadou, E; Gearry, RB; Inns, SJ; Rowbotham, DS; Schultz, M; Thompson-Fawcett, MW; Walmsley, R, 2015) |
| "In the treatment of ulcerative colitis with mesalazine, we should pay attention with patient's cough or fever for early detection of drug-induced pneumonia." | 1.42 | [THREE CASES OF DRUG-INDUCED PNEUMONIA CAUSED BY MESALAZINE]. ( Abe, T; Akiyama, N; Matsui, T; Nozue, T; Suda, T; Yokomura, K, 2015) |
| "Topical treatment in proctitis patients was underused in Switzerland." | 1.40 | Topical therapy is underused in patients with ulcerative colitis. ( Beglinger, C; Fournier, N; Mottet, C; Pittet, V; Rogler, G; Seibold, F, 2014) |
| " To establish whether once daily (OD) mesalazine offers economic advantages over twice daily (BD) dosing in active UC, we evaluated the outcomes and costs of a recently published randomized study." | 1.40 | Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4 g or twice-daily 2g mesalazine dosing. ( Connolly, MP; Kuyvenhoven, JP; Nielsen, SK; Postma, MJ, 2014) |
| "The Pediatric Ulcerative Colitis Activity Index was used to measure various secondary endpoints in the pediatric Remicade trial." | 1.40 | Alternate endpoints and clinical outcome assessments in pediatric ulcerative colitis registration trials. ( Lee, CS; Lee, JJ; Mulberg, AE; Nelson, RM; Papadopoulos, EJ; Rodriguez, WJ; Sachs, HC; Sun, H, 2014) |
| "A total of 174 patients with ulcerative colitis, 99 women and 75 men, were included." | 1.40 | IL23R polymorphisms influence phenotype and response to therapy in patients with ulcerative colitis. ( Brito, M; Correia, LA; Cravo, ML; de Deus, JR; Ferreira, PA; Maio, RF; Ministro, P; Moura-Santos, P; Peixe, P; Sousa, P; Tavares, L; Velho, S; Velosa, JF, 2014) |
| " It is recommended that virtually all children with UC must be treated with some maintenance therapy and 5-ASA requirement and dosing are often higher in children." | 1.40 | Differences in the management of pediatric and adult onset ulcerative colitis--lessons from the joint ECCO and ESPGHAN consensus guidelines for the management of pediatric ulcerative colitis. ( Ruemmele, FM; Turner, D, 2014) |
| "Sera of 110 CD patients, 82 ulcerative colitis (UC), and 150 healthy controls were collected and the presence of antibodies against the mycobacterial protein tyrosine phosphatase PtpA was assayed using ELISA." | 1.40 | Effect of inflammatory bowel disease therapies on immunogenicity of Mycobacterium paratuberculosis proteins. ( Bach, H; Bressler, B; Grist, J; Silverberg, MS; Stempak, JM; Xia, A, 2014) |
| " The overall safety profile was good; no serious adverse events were recorded." | 1.40 | Safety and efficacy of sodium hyaluronate (IBD98E) in the induction of clinical and endoscopic remission in subjects with distal ulcerative colitis. ( Danese, S; Fiorino, G; Gilardi, D; Naccarato, P; Sociale, OR, 2014) |
| "Although some ulcerative colitis (UC) patients are diagnosed when they do not have any UC-related symptoms, clinical features and prognosis of UC diagnosed in asymptomatic patients remain unclear." | 1.40 | Clinical features and course of ulcerative colitis diagnosed in asymptomatic subjects. ( Byeon, JS; Jung, KW; Kim, J; Kim, JH; Kim, JW; Kim, KJ; Kim, SO; Myung, SJ; Park, SH; Park, SK; Yang, DH; Yang, SK; Ye, BD, 2014) |
| "Treatments for Crohn's disease (CD) and ulcerative colitis (UC) are not uniformly effective, thus necessitating dose changes, switching, and augmentation and carry adverse event risk, often requiring discontinuation, which reduces treatment benefits." | 1.40 | Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease. ( Davis, KL; Mody, R; Rubin, DT; Wang, CC, 2014) |
| "Mesalamine suppositories have been used widely for the treatment of distal ulcerative colitis and considered to be safer than systemic administration for its limited systemic absorption." | 1.40 | Ulcerative colitis flair induced by mesalamine suppositories hypersensitivity. ( Ding, H; Hu, J; Hu, XY; Liu, XC; Mei, Q; Xu, JM, 2014) |
| "The rat model of ulcerative colitis was used to evaluate the efficiency of our loaded pellets as a drug carrier." | 1.40 | Preparation and evaluation of colon adhesive pellets of 5-aminosalicylic acid. ( Elamin, ES; Ping, Q; Qiao, H; Sun, M; Xu, M, 2014) |
| "The prevalence rate of Crohn's disease and ulcerative colitis in our male infertile patients was 163 per 100,000 men and 490 per 100,000 men, respectively." | 1.40 | Inflammatory bowel disease in subfertile men and the effect of mesalazine on fertility. ( Arai, G; Iwahata, T; Kobori, Y; Okada, H; Shin, T; Soh, S; Suzuki, K; Yagi, H, 2014) |
| "Infliximab was approved for the treatment of ulcerative colitis (UC) in 2006 and has recently been used as rescue therapy in steroid-refractory UC." | 1.40 | [Differences in the prognosis according to the periods of diagnosis in ulcerative colitis]. ( Chae, HB; Hong, SN; Huh, KC; Jang, HJ; Jung, SA; Jung, Y; Jung, YS; Kim, JH; Kim, YH; Kim, YS; Lee, CK; Park, DI; Shin, JE; Song, HJ, 2014) |
| "Pulmonary complications of ulcerative colitis (UC) are relatively rare." | 1.40 | Ulcerative colitis-associated pulmonary nodules with cavity formation successfully treated with mesalazine and granulocyte-monocyte apheresis. ( Hayashi, Y; Hiyama, S; Kitamura, A; Lefor, AK; Nomoto, H; Ohashi, M; Sasao, W; Shinozaki, S; Sunada, K; Yamamoto, H; Yano, T, 2014) |
| "A mesalamine-induced fever was considered, and treatment was stopped, which led to spontaneous resolution of the fever." | 1.39 | Isolated fever induced by mesalamine treatment. ( Amara, J; Daniel, F; Honein, K; Jaoude, JB; Nasnas, R; Sayegh, R; Slim, R; Yaghi, C, 2013) |
| "Nationwide ulcerative colitis data were obtained from the Veterans Affairs health care system for the period 2001 to 2011." | 1.39 | Long-term mesalamine maintenance in ulcerative colitis: which is more important? Adherence or daily dose. ( Abbas, AM; Bazzano, LA; Khan, N; Koleva, YN, 2013) |
| "Studies have demonstrated that ulcerative colitis patients treated with 5-ASA have an overall decrease in the risk of developing colorectal carcinoma." | 1.39 | Protection against peroxynitrite-induced DNA damage by mesalamine: implications for anti-inflammation and anti-cancer activity. ( Dou, X; Graham, PM; Jia, Z; Li, JZ; Li, Y; Misra, HP; Zhu, H, 2013) |
| "Currently available drugs for the treatment of ulcerative colitis (UC) include salicylates, thiopurines, corticosteroids and new anti-tumour necrosis factor (TNF)-α biologics." | 1.39 | Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications. ( Akagi, M; Goishi, H; Kajihara, T; Miura, T; Sugiyama, S; Tanaka, T, 2013) |
| "Patients with primary sclerosing cholangitis (PSC) and ulcerative colitis (UC) are at an increased risk of colorectal neoplasia, but it is unknown if liver transplantation (LT) alters neoplasia progression." | 1.39 | The fate of indefinite and low-grade dysplasia in ulcerative colitis and primary sclerosing cholangitis colitis before and after liver transplantation. ( Eaton, JE; Imam, M; Loftus, EV; Owens, VL; Pardi, DS; Smyrk, TC; Talwalkar, JA, 2013) |
| "Disease progression was monitored daily by observation of clinical signs and body weight change." | 1.39 | Effectiveness of a hydroxynaphthoquinone fraction from Arnebia euchroma in rats with experimental colitis. ( Che, X; Fan, HY; Liu, K; Lv, WH; Song, WW; Xu, H; Yang, MY; Zhang, ZL, 2013) |
| "A clinical case of combination of ulcerative colitis and alopecia in young woman is presented in the article." | 1.39 | [Clinical case of a combination of ulcerative colitis and alopecia areata]. ( Abdulkhakov, RA; Abdulkhakov, SR; Cheremina, NA; Odintsova, AKh; Safina, DD, 2013) |
| "We report a case of a patient with ulcerative colitis and central serous retinopathy, which is a chronic ophthalmological condition that is frequently aggravated by corticosteroid treatment and may sometimes result in severe visual impairment." | 1.39 | A patient with ulcerative colitis and central serous chorioretinopathy--a therapeutic dilemma. ( Ben-Horin, S; Geyshis, B; Katz, G; Kopylov, U, 2013) |
| " Further pediatric studies will be needed to address whether increased adherence and/or higher dosing schedules will improve outcomes." | 1.39 | Outcome following aminosalicylate therapy in children newly diagnosed as having ulcerative colitis. ( Ashai-Khan, F; Bousvaros, A; Carvalho, R; Evans, J; Faubion, W; Griffiths, A; Grossman, A; Hyams, J; Kappelman, M; Kay, M; Keljo, D; Leleiko, N; Lerer, T; Mack, D; Markowitz, J; Oliva-Hemker, M; Otley, A; Pfefferkorn, M; Rosh, J; Saeed, S; Sudel, B; Zeisler, B, 2013) |
| "Important national differences in ulcerative colitis patients' attitudes and perceptions were observed, which may help physicians improve patient care based on country-specific needs and influence self-assessments in clinical trials." | 1.39 | National differences in ulcerative colitis experience and management among patients from five European countries and Canada: an online survey. ( Buch, M; Holley, D; Louis, E; Panés, J; Paridaens, K; Schreiber, S, 2013) |
| "There were 44 confirmed cases of ulcerative colitis with a prevalence rate of 22/100,000." | 1.39 | The prevalence of inflammatory bowel disease in an Israeli Arab population. ( Birkenfeld, S; Fraser, GM; Niv, Y; Zvidi, I, 2013) |
| "Sulfasalazine was the first aminosalicylic used in the maintenance therapy of this disease." | 1.39 | [Rescue therapy with sulfasalazine prior to immunosuppressive or biological agents in ulcerative colitis poorly controlled with mesalazine]. ( Busto Bea, V; Garrido, E; López San Román, A; Martínez González, J; Mesonero Gismero, F; Parejo Carbonell, S, 2013) |
| "Mesalamine adherence was quantified by patient self-reports at enrollment and pharmacy refills of mesalamine over 6 months." | 1.39 | A random urine test can identify patients at risk of mesalamine non-adherence: a prospective study. ( Berg, AH; Cheifetz, AS; Gifford, AE; Horowitz, G; Lahiff, C; Moss, AC, 2013) |
| "It has been recommended that the treatment of active ulcerative colitis (UC) should be continued until complete healing of endoscopic lesions." | 1.38 | Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study. ( Colombo, E; D'Incà, R; Fasoli, R; Gullotta, R; Lombardi, G; Meucci, G; Saibeni, S; Terpin, M; Valpiani, D, 2012) |
| "Patients with ulcerative colitis (UC) frequently require long-term therapy to prevent relapse." | 1.38 | Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: a discrete-choice experiment. ( Dewilde, S; Hodgkins, P; Lloyd, A; Solomon, D; Swinburn, P; Yen, L, 2012) |
| "Although the early outcomes of ulcerative colitis after a first course of corticosteroids are well known, data on long-term disease evolution in patients responding to a first corticosteroid course are scarce." | 1.38 | Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids. ( Cabré, E; Domènech, E; Garcia-Planella, E; Gordillo, J; López San Román, A; Mañosa, M; Van Domselaar, M; Zabana, Y, 2012) |
| "Typical ulcerative colitis developed in five patients (25 %; four proctitis, one pancolitis) in a mean time of 18." | 1.38 | Long term follow-up of appendiceal and distal right-sided colonic inflammation. ( Byeon, JS; Jung, KW; Kim, JH; Kim, KJ; Kim, MJ; Myung, SJ; Park, SH; Yang, DH; Yang, SK; Ye, BD, 2012) |
| "Subclinical inflammation in ulcerative colitis (UC) can predispose to relapses and biomarkers can detect mucosal inflammation." | 1.38 | Evaluation of fecal myeloperoxidase as a biomarker of disease activity and severity in ulcerative colitis. ( Dutta, U; Hussain, S; Kochhar, R; Masoodi, I; Prasad, KK; Singh, K; Vaiphei, K; Vaishnavi, C, 2012) |
| "Relapses were treated in the same manner as the first attack in both groups." | 1.38 | Long-term clinical impact of early introduction of granulocyte and monocyte adsorptive apheresis in new onset, moderately active, extensive ulcerative colitis. ( Matsumoto, K; Umegae, S; Yamamoto, T, 2012) |
| "Ulcerative colitis was diagnosed in 77 (97." | 1.38 | The effects of liver transplantation on the clinical course of colitis in ulcerative colitis patients with primary sclerosing cholangitis. ( Choudhary, M; Kiran, RP; Lashner, BA; Navaneethan, U; Remzi, FH; Shen, B; Venkatesh, PG, 2012) |
| "Past studies with ulcerative colitis (UC) patients indicate that disease activity strongly predicts health-related quality of life (HRQL)." | 1.38 | The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients. ( Hodgkins, P; Kane, S; Karlstadt, R; Solomon, D; Yarlas, A; Yen, L, 2012) |
| "He was an ulcerative colitis patient and depressed about his illness and routine life traffic." | 1.37 | An unusual case of mesalazine intoxication: oral and rectal overloading of the rectal suppository form. ( Kara, B; Kosenli, O; Koseoglu, Z; Satar, S; Sebe, A, 2011) |
| "hominis in refractory ulcerative colitis." | 1.37 | Six ulcerative colitis patients with refractory symptoms co-infective with Blastocystis hominis in China. ( Hu, PJ; Lin, XC; Tai, WP; Wu, J, 2011) |
| "The two main types, ulcerative colitis (UC) and Crohn's disease (CD), sometimes mimic each other and are not readily distinguishable." | 1.37 | Inflammatory bowel disease unclassified. ( Chen, SH; Chen, WX; Li, YM; Xu, CF; Zhou, N, 2011) |
| "A 19-year-old Japanese man had been treated for ulcerative colitis for 2 years." | 1.37 | A case of acne fulminans in a patient with ulcerative colitis successfully treated with prednisolone and diaminodiphenylsulfone: a literature review of acne fulminans, rosacea fulminans and neutrophilic dermatoses occurring in the setting of inflammatory ( Danno, K; Fujimoto, N; Tanaka, T; Uenishi, T; Wakabayashi, M, 2011) |
| " If adherence and its influence on the remission rates and the risk of developing colorectal cancer were included in the model, the results might have even been more favorable to Mezavant due to its once daily dosing regimen." | 1.37 | Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine. ( Mittendorf, T; Prenzler, A; von der Schulenburg, JM; Yen, L, 2011) |
| "Patients with ulcerative colitis experience various impairments." | 1.37 | [Pharmacotherapy in patients with ulcerative colitis]. ( Blozik, E; Bokemeyer, B; Hardt, J; Hüppe, A; Preiss, JC; Raspe, H; Scherer, M, 2011) |
| "The first case was given a diagnosis of eosinophilic pneumonia by bronchoscopic examination, and responded to steroid therapy after discontinuation of mesalazine." | 1.37 | [Two cases of drug-induced intrathoracic lesions caused by mesalazine in patients with ulcerative colitis]. ( Hatakeyama, N; Hosokawa, E; Inayama, M; Machida, H; Ogushi, F; Shinohara, T, 2011) |
| " dosing in left-sided colitis (CR 73% vs." | 1.37 | Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis. ( Gibson, PR; Greinwald, R; Kruis, W; Leifeld, L; Marakhouski, Y; Morgenstern, J; Mueller, R; Pfützer, R, 2011) |
| " This case indicates that the long-term administration of mesalazine may lead to an adverse pulmonary reaction." | 1.37 | [A case of lung injury induced by long-term administration of mesalazine]. ( Hayashi, K; Horaguchi, R; Iijima, H; Shindoh, C; Shindoh, Y; Suda, Y, 2011) |
| "Only one of them developed proximal disease progression." | 1.37 | Long-term outcome of patients with distal ulcerative colitis and inflammation of the appendiceal orifice. ( Boix, J; Cabré, E; Domènech, E; Lorenzo-Zúñiga, V; Mañosa, M; Marín, L; Moreno, V; Naves, JE; Oller, B; Zabana, Y, 2011) |
| "A total of 20 IBD (14 Crohn's disease, 6 ulcerative colitis) HIV infected patients and 40 matched control seronegative IBD patients (2 controls per case) were compared regarding relapse of their disease." | 1.36 | Course of inflammatory bowel disease in patients infected with human immunodeficiency virus. ( Baraboutis, IG; Georgiadis, D; Georgiou, O; Karamanolis, DG; Papastamopoulos, V; Rodias, M; Skoutelis, A; Viazis, N; Vlachogiannakos, J, 2010) |
| "Mesalamine is a mainstay therapeutic agent in chronic ulcerative colitis (CUC) in which condition it reverses crypt architectural changes and reduces colitis-associated cancer (CAC)." | 1.36 | Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis. ( Barrett, TA; Blatner, NR; Brown, JB; Cheresh, P; Dirisina, R; Goretsky, T; Grimm, GR; Khazaie, K; Lee, G; Li, L; Managlia, E; Yang, GY, 2010) |
| " An Asacol dosage of 800 mg, three times a day, was compared to 2400 mg given once a day." | 1.36 | A dynamic model of once-daily 5-aminosalicylic acid predicts clinical efficacy. ( Ehrenpreis, ED; Hannon, B; Parakkal, D; Putt, KS; Thorpe, MP, 2010) |
| " Participants had better adherence than the expected population rate, with a significant dose-response effect." | 1.36 | Telephone nurse counseling for medication adherence in ulcerative colitis: a preliminary study. ( Cook, PF; El-Hajj, D; Emiliozzi, S; McCabe, MM, 2010) |
| "The treatment of ulcerative colitis (inflammatory bowel disease, IBD) has been achieved by using colon specific drug delivery system bearing 5-ASA and Camylofine dihydrochloride." | 1.36 | Development and characterization of colon specific drug delivery system bearing 5-ASA and Camylofine dihydrochloride for the treatment of ulcerative colitis. ( Dubey, R; Jain, SK; Omrey, P; Vyas, SP, 2010) |
| " The potential effect of dosing frequency on adherence and possible long-term effects of remission maintenance on colorectal cancer (CRC) rates were also investigated." | 1.36 | A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective. ( Akehurst, R; Bodger, K; Brereton, N; Hodgkins, P; Kamm, MA; Yan, S, 2010) |
| "She had past history of ulcerative colitis with the continued medication of mesalazine without success." | 1.36 | Combinational effect of low-dose oral corticosteroid and mizoribine for ulcerative colitis in a patient with systemic sclerosis. ( Ohtsuka, T, 2010) |
| "Mesalazine therapy for ulcerative colitis has been reported to be effective and safe." | 1.36 | Mesalazine-induced multi-organ hypersensitivity. ( Allegri, MP; Carli, T; Chigiotti, S; Cresti, A; Migliorini, MG; Nencioni, C; Perari, MG; Riccardi, MP; Ricciardi, B; Sposato, B; Toti, M, 2010) |
| "We report a case of the daughter with ulcerative colitis and her mother with Crohn's disease who have a -159C/T promoter polymorphism of CD14 gene for IBD." | 1.36 | [A case of ulcerative colitis found in a patient whose parent has Crohn's disease]. ( Chang, UI; Chung, WC; Jung, SH; Kim, JD; Kwak, JW; Lee, KM; Paik, CN; Yang, JM, 2010) |
| "Another patient, a 36-year-old man with Crohn's disease, developed extensive granulomatous nephritis with stable moderate renal function." | 1.36 | [Tubulo-interstitial nephritis in inflammatory bowel disease: extra-intestinal manifestation or drug toxicity?]. ( Groeneveld, JH; Heidt, J; Ooms, EC; van der Werf, SD, 2010) |
| "We herein report a case of ulcerative colitis who experienced clinical remission after appendectomy for acute appendicitis." | 1.36 | [Remission of ulcerative colitis after appendectomy: a case report]. ( Cheung, DY; Cho, SH; Han, JY; Jun, EJ; Kim, JI; Kim, JK; Kim, TH; Lee, IK; Noh, CH; Park, SH, 2010) |
| "MMX mesalamine was the first 5-ASA to receive US FDA approval in a once daily regimen." | 1.36 | Does treatment schedule matter? Once daily versus divided doses of 5-ASAs. ( Kane, S, 2010) |
| "He had been diagnosed as ulcerative colitis (UC) and taking mesalazine for two months." | 1.36 | [A case of inferior vena cava thrombosis and acute pancreatitis in a patient with ulcerative colitis]. ( Chang, DK; Kim, CH; Kim, KH; Lee, JK; Lee, KH; Lee, KT; Park, SH; Shin, DH, 2010) |
| " These patients frequently fail to receive the full benefit from this treatment, often as a result of nonadherence to complex dosing regimens." | 1.36 | Oral 5-aminosalicylic acid therapy for mild-to-moderate ulcerative colitis. ( Olmstead, J, 2010) |
| "Patients prescribed mesalamine for ulcerative colitis prospectively received either a 23 week, nurse-delivered, patient support program (PSP) by phone, or standard care (SC)." | 1.36 | Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis--a prospective study. ( Chaudhary, N; Cheifetz, AS; Cury, D; Falchuk, KR; Junior, J; Moss, AC; Tukey, M, 2010) |
| " In addition, topical rectal steroids were considered as effective as topical mesalazine by 48% of the GGs vs 31% of the GSIBDs, indefinite treatment with 5-ASA was prescribed by only 26% of the GGs vs 41% of the GSIBDs, and the once daily dosing of 5-ASA was generally used by 46% of the GGs vs 51% of the GSIBDs." | 1.36 | Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on ulcerative colitis: a real-life survey in Spain. ( Gisbert, JP; Gomollón, F; Hinojosa, J; López San Román, A, 2010) |
| "We report a case of unilateral eosinophilic pneumonia secondary to balsalazide monotherapy for ulcerative colitis." | 1.36 | Unilateral balsalazide-induced eosinophilic pneumonia in an ulcerative colitis patient. ( Candlish, W; Gravil, J; McGrane, J; Paravasthu, M, 2010) |
| "Past medical history is significant for ulcerative colitis (UC) diagnosed at 9 years of age." | 1.35 | Severe chest pain in a pediatric ulcerative colitis patient after 5-aminosalicylic acid therapy. ( Arruda, J; Atay, O; Radhakrishnan, K; Wyllie, R, 2008) |
| "Since about 20 % of patients with ulcerative colitis (UC) are children and adolescents there is a need for therapeutic options custom-tailored to the children's needs." | 1.35 | Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study. ( Henker, J; Laass, MW; Müller, S; Schreiner, A; Schulze, J, 2008) |
| "To describe the long-term prognosis of ulcerative colitis (UC) and to establish whether a correlation exists between the different anatomic locations of the disease and the risk of relapse in a homogeneous cohort of patients with UC in clinical remission, all treated with fixed doses of oral mesalamine from the date of enrollment to the appearance of the first relapse." | 1.35 | Duration of remission and long-term prognosis according to the extent of disease in patients with ulcerative colitis on continuous mesalamine treatment. ( Bresci, G; Capria, A; Parisi, G, 2008) |
| "Acute pancreatitis is a serious disease with fatality rate up to 15%." | 1.35 | [A case of acute pancreatitis induced by multiple drugs in a patient with ulcerative colitis]. ( Choi, HS; Hahm, JS; Han, DS; Joo, YW; Lee, HL; Lee, OY; Son, CN; Yoon, BC, 2008) |
| " Once daily dosing may improve patient adherence." | 1.35 | A dynamic model of colonic concentrations of delayed-release 5-aminosalicylic acid (Asacol). ( Ehrenpreis, ED; Hannon, B; Putt, KS; Thorpe, MP, 2009) |
| " However, poor adherence due to frequent daily dosing and a large number of tablets has been shown to be an important barrier to successful management of patients with UC." | 1.35 | Use of new once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis: Is there anything new under the sun? ( Lakatos, PL, 2009) |
| "The incidence of PPI in patients with ulcerative colitis/indeterminate colitis is 5." | 1.35 | Incidence and short-term implications of prepouch ileitis following restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis. ( Bell, AJ; Ciclitira, PJ; Clark, SK; McLaughlin, SD; Nicholls, RJ; Tekkis, PP, 2009) |
| "We present a case of ulcerative colitis in a pediatric liver transplant recipient." | 1.35 | De novo inflammatory bowel disease after pediatric orthotopic liver transplant: a case report. ( Bahador, A; Dehghani, SM; Eshraghian, A; Geramizadeh, B; Kakaei, F; Malek-Hosseini, SA, 2009) |
| "Therapy of uncomplicated nonspecific ulcerative colitis with artrofoon effectively reduces the duration and number of relapses." | 1.35 | Artrofoon as alternative preparation in the treatment of uncomplicated forms of nonspecific ulcerative colitis. ( Osadchuk, AM; Osadchuk, MA, 2009) |
| "Myocarditis was diagnosed and balsalazide therapy was withdrawn, resulting in a full recovery and resolution of abnormalities." | 1.35 | Balsalazide-induced myocarditis. ( Austin, D; Hogg, KJ; Jamieson, N; Robertson, E, 2008) |
| "A total of 58 patients with ulcerative colitis (UC, N = 37) or Crohn's disease (CD, N = 21) together with 11 healthy controls were included in this study." | 1.35 | Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease. ( Hanai, H; Hirayama, K; Iida, T; Iwaoka, Y; Kikuyama, M; Maruyama, Y; Nagata, S; Takai, K; Takeuchi, K; Watanabe, F; Yamada, M, 2008) |
| "Children with newly diagnosed ulcerative colitis were evaluated prospectively at three time points: within 1 month, 6 months and 1 year after diagnosis." | 1.34 | Altered intestinal permeability is predictive of early relapse in children with steroid-responsive ulcerative colitis. ( Giannetti, E; Greco, L; Miele, E; Pascarella, F; Quaglietta, L; Staiano, A; Troncone, R, 2007) |
| "A 15-year-old female with ulcerative colitis developed polyuria, polydipsia, vomiting, and fatigue." | 1.34 | Acute tubular injury associated with mesalazine therapy in an adolescent girl with inflammatory bowel disease. ( Demir, H; Gürakan, F; Saltik-Temizel, IN; Topaloğlu, R; Uslu, N; Yüce, A, 2007) |
| "Human colon cancer cells were treated with vehicle or mesalazine (4 mm or 40 mm)." | 1.34 | Mesalazine downregulates c-Myc in human colon cancer cells. A key to its chemopreventive action? ( Ahluwalia, A; Chai, J; Chu, EC; Tarnawski, AS, 2007) |
| " Nonadherence to therapy can be associated with several other factors, including forgetfulness, male sex, complicated dosing regimens, treatment delivery methods (oral vs." | 1.34 | Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs. ( Boltri, JM; Tindall, WN; Wilhelm, SM, 2007) |
| "8 g per day of the active 5-aminosalicylate moiety, rather than starting at a lower dosage and increasing if treatment fails." | 1.34 | Ulcerative colitis: responding to the challenges. ( Achkar, JP, 2007) |
| "The risk of colorectal cancer is increased in patients with inflammatory bowel diseases, especially those with ulcerative colitis (UC)." | 1.34 | 5-aminosalicylic acid given in the remission stage of colitis suppresses colitis-associated cancer in a mouse colitis model. ( Endo, H; Fujisawa, T; Fujita, K; Ikeda, I; Inamori, M; Kubota, K; Nagashima, Y; Nakagama, H; Nakajima, A; Nozaki, Y; Saito, S; Takahashi, H; Tomimoto, A; Wada, K; Yoneda, M; Yonemitsu, K, 2007) |
| "We recently experienced a case of acute pancreatitis caused by 5-ASA suppositories in a patient with ulcerative colitis." | 1.34 | [A case of acute pancreatitis caused by 5-aminosalicylic acid suppositories in a patient with ulcerative colitis]. ( Jang, BI; Kim, KH; Kim, TN, 2007) |
| "Two years after being diagnosed with ulcerative colitis, a 57-year-old man taking oral mesalamine experienced severe respiratory distress due to left lung pleuropneumonitis." | 1.33 | Mesalamine-induced lung injury in a patient with ulcerative colitis and a confounding autoimmune background: a case report. ( Actis, GC; Baldi, S; Fusaro, E; Mengozzi, G; Modena, V; Ottobrelli, A; Rizzetto, M; Scappaticci, E, 2005) |
| "Prevention strategies for colorectal cancer in chronic ulcerative colitis (UC) are currently based on the identification of neoplasia by surveillance colonoscopy, but there is a great interest in the possibility of primary chemoprevention." | 1.33 | Will a 5-ASA a day keep the cancer (and dysplasia) away? ( Lashner, BA; Rubin, DT, 2005) |
| "Systemic lupus erythematosus is frequently accompanied by gastrointestinal symptoms, but colonic lesions are quite rare, and the regular treatment is not fixed yet." | 1.33 | Two cases of systemic lupus erythematosus complicated with colonic ulcers. ( Chino, Y; Goto, D; Hayashi, T; Ito, S; Matsumoto, I; Miyahara, S; Soeda, A; Sumida, T; Takahashi, R; Tsutsumi, A, 2005) |
| "Microproteinuria is mainly associated with UC and its activity but not affected by 5-ASA." | 1.33 | Microproteinuria in patients with inflammatory bowel disease: is it associated with the disease activity or the treatment with 5-aminosalicylic acid? ( Archimandritis, A; Dandakis, DC; Georgouli, A; Goumas, KE; Panagiotaki, M; Poulou, AC; Soutos, DC; Tyrmpas, I, 2006) |
| "Moderate-to-severe active extensive ulcerative colitis, unresponsive to mesalazine at 3." | 1.33 | Combined oral and topical mesalazine treatment for extensive ulcerative colitis. ( Cheifetz, AS; Moss, AC; Peppercorn, MA, 2006) |
| "Interestingly, treatment of ulcerative colitis with mesalazine, which displays few side effects during long-term treatment, is associated with a reduced incidence of colorectal cancer, but its molecular mechanism is not known." | 1.33 | Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. ( Bos, CL; Diks, SH; Hardwick, JC; Peppelenbosch, MP; Richel, DJ; Walburg, KV, 2006) |
| "Firstly we used ciprofloxacin to treat pouchitis." | 1.33 | Diffuse gastroduodenitis and pouchitis associated with ulcerative colitis. ( Hori, K; Ikeuchi, H; Kaibe, N; Nakamura, M; Nakano, H; Nishigami, T; Noda, M; Uchino, M; Yamamura, T; Yanagi, H, 2006) |
| "Mesalazine is released in the rectum of patients, with a bioavailability of about 40%." | 1.32 | Rectal tissue, plasma and urine concentrations of mesalazine after single and multiple administrations of 500 mg suppositories to healthy volunteers and ulcerative proctitis patients. ( Aumais, G; Bitton, A; Giard, A; Lefebvre, M; Madi, M; Martin, F; Spénard, J; Tremblay, C, 2003) |
| "The primary outcome was clinical recurrence of ulcerative colitis." | 1.32 | Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis. ( Aikens, J; Hanauer, S; Huo, D; Kane, S, 2003) |
| "A 50 years old male with a diagnosis of ulcerative colitis treated with mesalazine, developed after 2 months of treatment, cough, fever and progressive dyspnea." | 1.32 | [Eosinophilic pneumonia caused by mesalazine. Report of one case]. ( Brockmann, P; Cofré, C; Errázuriz, I; González, S; Pérez, C, 2003) |
| "Prednisolone (40 mg) was prescribed to 15 patients with severe disease activity." | 1.32 | Correlation between circulating soluble ICAM-1 and prednisolone-induced amelioration of ulcerative colitis. ( Nielsen, OH; Vainer, B, 2003) |
| "A 69-year-old man with ulcerative colitis (UC) developed sensorimotor polyneuropathy." | 1.32 | Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report. ( Iwasa, K; Ono, K; Shirasaki, H; Takamori, M, 2003) |
| "A 29-year-old male patient with ulcerative colitis, who underwent haemodialysis thrice a week because of severe renal dysfunction." | 1.32 | Sulphasalazine-induced leucopenia in a patient with renal dysfunction. ( Hino, B; Iida, M; Itoh, Y; Joh, Y; Makino, K; Oishi, R; Teshima, D; Yano, T, 2003) |
| "To report a case of benign intracranial hypertension related to mesalazine use." | 1.32 | Mesalazine-associated benign intracranial hypertension in a patient with ulcerative colitis. ( Giamundo, A; Iaccarino, G; Jura, A; Romano, A; Rosa, N, 2003) |
| "Potential biomarkers for Crohn's disease (CD) and ulcerative colitis (UC) were identified from two sets of full thickness pathologic samples utilizing DermArray and PharmArray DNA microarrays relative to uninvolved (Un) colon or normal colon." | 1.32 | Regulation of gene expression in inflammatory bowel disease and correlation with IBD drugs: screening by DNA microarrays. ( Curto, EV; Davis, RL; Dooley, TP; Elson, CO; Lambert, GW; Reddy, SP; Wilborn, TW, 2004) |
| " The need for site-specific dosage medications has led to the use of enteric coatings that allow the release of the active ingredients into the small intestine or in the colon." | 1.32 | Medications as a source of human exposure to phthalates. ( Calafat, AM; Duty, S; Godfrey-Bailey, L; Hauser, R, 2004) |
| "Coincidence of salmonellosis and ulcerative colitis is a rare clinical problem." | 1.32 | Salmonellosis and ulcerative colitis. A causal relationship or just a coincidence. ( Erkus, M; Ertem, GT; Karaoglu, AO; Yukselen, V, 2004) |
| "Colitis was induced by intrarectal administration of OXA solution (7." | 1.32 | Oxazolone-induced colitis in BALB/C mice: a new method to evaluate the efficacy of therapeutic agents for ulcerative colitis. ( Hatakeyama, S; Kojima, R; Kuroda, S; Nakamaru, K; Ohkishi, T, 2004) |
| "We report a case of ulcerative colitis (UC) that occurred during the course of rheumatoid arthritis (RA)." | 1.32 | Ulcerative colitis occurring in the course of rheumatoid arthritis: a case successfully treated with mesalamine enema. ( Fukaya, E; Honma, F; Iwadate, H; Kobayashi, H; Orikasa, H; Saito, H; Sato, K; Sato, Y; Sekine, H; Shio, K; Shioya, Y; Sugisaki, K; Watanabe, H, 2004) |
| "Relapse was defined as an increase in Clinical Activity Index and Endoscopic Index, of more than 6 and 4, respectively." | 1.31 | Long-term maintenance treatment in ulcerative colitis: a 10-year follow-up. ( Bertoni, M; Bresci, G; Capria, A; Parisi, G, 2002) |
| "All controls and patients with active ulcerative colitis carried SRB and total viable counts were significantly related to the clinical severity grade." | 1.31 | The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis. ( Beatty, ER; Cummings, JH; Pitcher, MC, 2000) |
| "The risk of colorectal cancer (CRC) in ulcerative colitis (UC) increases with extent and duration of disease." | 1.31 | Colorectal cancer prevention in ulcerative colitis: a case-control study. ( Abrams, K; Eaden, J; Ekbom, A; Jackson, E; Mayberry, J, 2000) |
| "A young man with ulcerative colitis who developed recurrent chest pain and electrocardiographic changes while on mesalamine is presented." | 1.31 | Mesalamine-induced chest pain: a case report. ( Amin, HE; Della Siega, AJ; Munt, B; Whittaker, JS, 2000) |
| "Pre-treatment with prednisolone decreased the cell attracting effect of ICAM-1 in a dose-dependent manner to 72% of the basal migration (P<0." | 1.31 | Chemotactic properties of ICAM-1 and PECAM-1 on neutrophil granulocytes in ulcerative colitis: effects of prednisolone and mesalazine. ( Nielsen, OH; Vainer, B, 2000) |
| "The treatment of ulcerative colitis (UC) with 5-aminosalicylic acid (5-ASA) does not have the same therapeutic effect in all patients." | 1.31 | Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. ( Caprilli, R; Frieri, G; Giacomelli, R; Palumbo, G; Pantaleoni, G; Passacantando, A; Pimpo, M, 2000) |
| "Ursodeoxycholic acid (UDCA) treatment for primary sclerosing cholangitis (PSC) has been considered a rational therapy, though its effectiveness in the clinical course is still open to discussion." | 1.31 | Paradoxical progression of biliary strictures against recovery of biochemical parameters under ursodeoxycholic acid treatment in a case of primary sclerosing cholangitis with ulcerative colitis. ( Kikuchi, S; Kisara, N; Komatsu, K; Maruhama, Y; Shimosegawa, T; Toyota, T; Uchi, M; Ueno, Y, 2000) |
| "Interstitial nephritis is a recognized side effect." | 1.31 | Interstitial nephritis in patients with inflammatory bowel disease treated with mesalamine. ( Alexopoulou, I; Churchill, DN; Margetts, PJ, 2001) |
| "This report presents two cases of ulcerative colitis in which lymph folliculitis and lymphoid hyperplasia were observed." | 1.31 | Lymph folliculitis in ulcerative colitis. ( Abe, T; Chiba, M; Fujiwara, K; Iizuka, M; Watanabe, S; Yamano, H, 2001) |
| "The aim of the present study was to develop a multi-unit dosage form containing 5-aminosalicylic acid (5-ASA) for the treatment of ulcerative colitis (UC), optimised on the basis of recent studies indicating that UC patients have higher intestinal pH than was previously thought to be the case." | 1.31 | A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis. ( Beckert, TE; Dressman, JB; Klein, S; Petereit, H; Rudolph, MW, 2001) |
| "We have developed a new experimental ulcerative colitis model in rats." | 1.31 | [The new experimental ulcerative colitis model in rats induced by subserosal injection of acetic acid]. ( Hamamoto, S; Iwadate, K; Kojima, R; Moriwaki, M; Ohwaki, T, 2001) |
| "Ulcerative colitis is a chronic inflammatory bowel disorder of unknown etiology." | 1.31 | Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial. ( Alexandrowitz, A; Arber, N; Brazowski, E; Dotan, I; Hallak, A; Halpern, Z; Hershkoviz, R; Knaani, Y; Santo, M, 2001) |
| "An 18-year-old woman with ulcerative colitis (UC) developed diffuse pulmonary infiltrates and hypoxemia three months after reinstitution of oral mesalamine." | 1.31 | Bronchiolitis obliterans in a patient with ulcerative colitis receiving mesalamine. ( Gil, J; Haralambou, G; Present, DH; Teirstein, AS, 2001) |
| "Outpatients with clinically quiescent ulcerative colitis for >6 months on maintenance mesalamine (Asacol, Procter and Gamble, Cincinnati, OH) were eligible." | 1.31 | Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis. ( Aikens, JE; Cohen, RD; Hanauer, SB; Kane, SV, 2001) |
| "Use of sulphasalazine in ulcerative colitis patients is hampered by a variety of side-effects, including male infertility." | 1.31 | Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerance and side-effects. ( Crispino, P; Di Paolo, MC; Iacopini, F; Paoluzi, OA; Paoluzi, P; Pica, R; Rivera, M; Spera, G, 2001) |
| "Physical examination suggested constrictive pericarditis." | 1.31 | Constrictive pericarditis in chronic ulcerative colitis. ( Danielson, GK; Loftus, EV; Mangan, TF; Oh, JK; Oxentenko, AS, 2002) |
| "Pancreatitis was significantly more frequent in girls as compared to boys (P = 0." | 1.31 | [Pancreatic involvement in inflammatory bowel diseases in children]. ( Cézard, JP; Faure, C; Hugot, JP; Le Large-Guiheneuf, C; Mougenot, JF; Munck, A; Navarro, J, 2002) |
| "We present a case of fulminant ulcerative colitis with associated extraintestinal manifestations, including upper airway obstruction from acute laryngotracheitis." | 1.30 | Airway obstruction in ulcerative colitis. ( Cross, DL; Scudder, DD, 1997) |
| "Hospitalizations for ulcerative colitis occurred with similar frequency (about 15 hospitalizations per 100 patients per year) among users of those drugs." | 1.30 | 5-Aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis. ( Bianchi, LA; Dreyer, NA; Field, LG; Sutherland, LR; Szneke, P; Walker, AM, 1997) |
| "Of 112 cases of ulcerative colitis observed, 95 showed no change in extent and were studied as examples of non-progressive UC, and in this group the extension of the disease was: pancolitis in 19%, left-sided colitis in 39%, proctosigmoiditis in 17% and proctitis in 25%." | 1.30 | Evaluation of clinical patterns in ulcerative colitis: a long-term follow-up. ( Banti, S; Bertoni, M; Bresci, G; Capria, A; Gambardella, L; Parisi, G; Rindi, G, 1997) |
| " The bioavailability of these drugs depends on their coating." | 1.30 | Gastrointestinal pH profiles in patients with inflammatory bowel disease. ( Ewe, K; Fuchs, B; Fuchs, M; Hauptmann, IA; Hauptmann, L; Press, AG; Ramadori, G, 1998) |
| "A 42-yr-old man with ulcerative colitis was admitted for investigation of prolonged fever associated with cholestatic liver tests." | 1.30 | Mesalamine-induced granulomatous hepatitis. ( Braun, M; Fraser, GM; Kunin, M; Salamon, F; Tur-Kaspa, R, 1999) |
| "After 12 months recurrences were observed in 14 of 15 patients initially treated with steroids and in 7 of 15 subjects who were had received transdermal nicotine (P = 0." | 1.30 | Long-term effects of a single course of nicotine treatment in acute ulcerative colitis: remission maintenance in a 12-month follow-up study. ( Guslandi, M, 1999) |
| "Our results show that, in Crohn's disease patients, the expression of E-selectin was up-regulated 5." | 1.29 | Up-regulation of E-selectin and intercellular adhesion molecule-1 differs between Crohn's disease and ulcerative colitis. ( Ghosh, L; Pooley, N; Sharon, P, 1995) |
| "Severe acute inflammation in ulcerative colitis is often associated with major intestinal blood loss." | 1.29 | [Substitution of factor XIII concentrate in treatment refractory ulcerative colitis. A prospective pilot study]. ( Born, P; Classen, M; Lorenz, R, 1994) |
| "Mesalamine sensitivity was documented endoscopically and histologically by evaluating mucosal changes after two mesalamine enemas during a 24-hour period." | 1.29 | Exacerbation of chronic ulcerative colitis with mesalamine. ( Bhatia, P; Hermens, D; Miner, PB; Sturgeon, JB, 1995) |
| "2." | 1.29 | Intraluminal colonic release of immunoreactive tumour necrosis factor in chronic ulcerative colitis. ( Antolín, M; Armengol, JR; Casellas, F; Guarner, F; Malagelada, JR; Papo, M, 1994) |
| "In Crohn's disease as well as in ulcerative colitis steroids are of major importance in the treatment of active disease." | 1.29 | [Current therapeutic possibilities in chronic inflammatory intestinal diseases]. ( Schölmerich, J, 1995) |
| "Nine patients with distal ulcerative colitis refractory to standard therapy were treated with intrarectal instillation of a sodium butyrate solution and 5-ASA." | 1.29 | Topical treatment of refractory distal ulcerative colitis with 5-ASA and sodium butyrate. ( Caprilli, R; Cittadini, M; Torsoli, A; Vernia, P, 1995) |
| "Acute pericarditis is rarely associated with inflammatory bowel disease." | 1.29 | [Pericarditis during inflammatory bowel diseases. Extra-intestinal or iatrogenic complication?]. ( Bretagne, JF; Génetet, N; Gosselin, M; Heresbach, D; Marteau, P; Rabot, A; Stéphan, C, 1994) |
| " The tissue level of 5-ASA had a significant correlation to the dosage of 5-ASA." | 1.29 | [Localization of salazopyrin in colonic mucosa patients with ulcerative colitis]. ( Fukushima, R; Kashima, K; Kitano, A; Nakagawa, M; Nakamura, S; Obayashi, M; Okabe, H; Tabata, A; Tomobuchi, M; Yasuda, K, 1993) |
| "Ulcerative colitis is a chronic inflammatory disease and the most common form of inflammatory bowel disease, which is a debilitating and unpredictable group of illnesses affecting the gastrointestinal tracts of over 2 million Americans." | 1.29 | Pentasa (Mesalamine). ( Claussen, DW, 1993) |
| "Of 12 patients with active ulcerative colitis (UC), 4 patients were without treatment, 4 were on prednisone and 4 on mesalazine." | 1.29 | Serum angiotensin converting enzyme activity in Crohn's disease and ulcerative colitis. ( Agostini, D; Boirivant, M; Corsi, A; D'Ambrosio, C; Letizia, C; Pallone, F; Scavo, D, 1993) |
| " Available evidence indicates that 5-aminosalicylic acid is beneficial in this role, although high dosage is needed." | 1.29 | Maintenance strategies in Crohn's disease. ( Sachar, DB, 1996) |
| "Twenty children with active ulcerative colitis were assessed before and after 8 weeks of medical therapy with 5-aminosalicylic acid (5-ASA) derivatives and corticosteroids." | 1.29 | Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. ( Beattie, RM; Domizio, P; Nicholls, SW; Walker-Smith, JA; Williams, CB, 1996) |
| "To determine the long term outcome of ulcerative colitis in patients treated with 6-MP." | 1.29 | The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. ( Bodian, C; George, J; Pou, R; Present, DH; Rubin, PH, 1996) |
| "The treatment of pneumothorax is difficult if the ulcerative colitis requires corticosteroids." | 1.29 | [Bilateral pneumothorax and hemorrhagic rectocolitis]. ( David, V; Heloury, Y; Nomballais, MF; Plattner, V, 1996) |
| "In patients with Crohn's disease with ileal involvement, relapse rates were sulphasalazine 9/28 (32." | 1.28 | Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis? ( Duncan, A; Nakshabendi, IM; Russell, RI, 1992) |
| "A regional inception cohort of 1161 ulcerative colitis (UC) patients was followed up from diagnosis to the end of 1987." | 1.28 | Colorectal cancer risk and mortality in patients with ulcerative colitis. ( Binder, V; Davidsen, M; Langholz, E; Munkholm, P, 1992) |
| "In active ulcerative colitis, A23187 and antihuman IgE induced significantly higher stimulation of PAF synthesis compared to their effects on normal mucosa." | 1.28 | Cytokines and platelet-activating factor in human inflamed colonic mucosa. ( Eliakim, R; Karmeli, F; Ligumsky, M; Rachmilewitz, D; Simon, P, 1992) |
| "Treatment with mesalamine enemas allowed patients to decrease or discontinue glucocorticoid treatment." | 1.28 | Long-term use of mesalamine enemas to induce remission in ulcerative colitis. ( Biddle, WL; Miner, PB, 1990) |
| " Our data suggest that both the route of drug administration and dosing regimen employed affect the antiinflammatory potency and/or efficacy of compounds on colitis induced by acetic acid in the rat." | 1.28 | Antiinflammatory effects of various drugs on acetic acid induced colitis in the rat. ( Bostwick, JS; Decktor, DL; Fitzpatrick, LR; Pendleton, RG; Renzetti, M, 1990) |
| "Sixteen patients with flare-ups of ulcerative colitis were studied." | 1.28 | [Cryptogenetic ulcerative colitis. Our clinical experience with new therapeutic approaches]. ( Cigala, O; Della Valle, M; Marasco, A; Pancallo, MT, 1990) |
| "The local and systemic bioavailability of a mesalazine enema (Pentasa, Ferring A/S, Denmark) and a mesalazine suppository (Pentasa, Ferring) was assessed during steady-state conditions." | 1.28 | Availability of mesalazine (5-aminosalicylic acid) from enemas and suppositories during steady-state conditions. ( Abildgaard, K; Christensen, LA; Fallingborg, J; Hansen, SH; Jacobsen, BA; Rasmussen, HH; Rasmussen, SN, 1991) |
| " The purpose of this study was to compare the pharmacokinetic profile of this drug between two patient groups, with either inflamed small or large bowel and with volunteers." | 1.28 | Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet in patients with Crohn's disease or ulcerative colitis and in healthy volunteers. ( Gotthard, R; Norlander, B; Ström, M, 1990) |
| "A male patient suffering from ulcerative colitis, presented with primary infertility due to sulphasalazine therapy." | 1.28 | Sulphasalazine-induced reversible male infertility. ( Delaere, KP; Meuleman, EJ; Strijbos, WE, 1989) |
| "In patients with left-sided ulcerative colitis, small volume [99mTc]5-ASA enemas reliably reach the area of inflammation." | 1.28 | Quantitative distribution of radiolabeled 5-aminosalicylic acid enemas in patients with left-sided ulcerative colitis. ( Fisher, RS; Knight, LC; Malmud, LS; Meyers, F; Siegel, JA; Vitti, RA, 1989) |
| " A pharmacokinetic comparison of polymer and SASP showed similar deliveries of 5-ASA and metabolites to the lower bowel, blood, and urine of orally dosed rats." | 1.27 | A polymeric drug for treatment of inflammatory bowel disease. ( Brown, JP; McGarraugh, GV; Onderdonk, AB; Parkinson, TM; Wingard, RE, 1983) |
| "Miniaturised methods have been used to construct dose-response curves for the effects of inhibitory drugs on prostaglandin synthesis using individual rectal biopsies obtained from patients with ulcerative colitis." | 1.27 | Inhibition of prostaglandin synthetase in human rectal mucosa. ( Hawkey, CJ; Lo Casto, M, 1983) |
| "In treatment of Crohn's disease, sulfasalazine has been shown to be effective when disease involves the colon or the colon and small intestine." | 1.27 | Pharmacotherapy of inflammatory bowel disease. Part 1. Sulfasalazine. ( Das, KM, 1983) |
| "Olsalazine is a very effective means of delivery of 5-aminosalicylic acid to the colonic mucosa in active disease." | 1.27 | Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis. ( Bukhave, K; Lauritsen, K; Rask-Madsen, J; Staerk Laursen, L, 1988) |
| "Sixteen patients with quiescent ulcerative colitis were studied." | 1.27 | Sulphasalazine induced seminal abnormalities in ulcerative colitis: results of mesalazine substitution. ( Goodman, MJ; Lecarpentier, J; Mandal, BK; Mani, V; Riley, SA; Turnberg, LA, 1987) |
| "We report the case of a man with ulcerative colitis in whom infertility and a markedly abnormal SPA were demonstrated while he was taking sulfasalazine." | 1.27 | Sulfasalazine-induced abnormal sperm penetration assay reversed on changing to 5-aminosalicylic acid enemas. ( Batzer, FR; Chatzinoff, M; Corson, SL; Friedman, LS; Guarino, JM, 1988) |
| " This suggests that, at least in some patients, the adverse effects of sulfasalazine are due to 5-aminosalicylic acid rather than sulfapyridine." | 1.27 | Adverse effects with oral 5-aminosalicyclic acid. ( Fardy, JM; Lloyd, DA; Reynolds, RP, 1988) |
| "Prednisone treatment can sometimes reverse this condition when combined with parenteral nutrition." | 1.27 | [Acute manifestations in Crohn disease and ulcerative colitis. Conservative treatment of acute situations]. ( Goebell, H, 1988) |
| " The mean plasma levels and AUC values confirmed that the active substance is poorly absorbed by rectal route." | 1.27 | 5-Aminosalicylic acid in patients with ulcerative colitis in remission: plasma levels after administration of a new rectal enema. ( Barbara, L; Belluzzi, A; Brignola, C; Campieri, M; Gionchetti, P; Miglioli, M; Tabanelli, GM; Torresan, F, 1988) |
| "According to Truelove and Witts, ulcerative colitis has been rated only by clinical classification without taking into account morphological alterations, and so far (in contrast to Crohn's disease) no activity index has been available for clinical studies." | 1.27 | [Ulcerative colitis. Activity index for the clinical and histological classification of inflammatory activity]. ( Kraus, B; Maier, K; von Gaisberg, U, 1988) |
| "Apart from two patients with Crohn's disease the antiphlogistic effect of 5-ASA could be proven by endoscopy, histomorphology and (or) radiography with an 86% remission rate and by the improved faecal quality (n = 12)." | 1.26 | [5-Aminosalicylic acid in ulcerative colitis and Crohn's disease (author's transl)]. ( Fischer, C; Heinkel, K; Klotz, U; Maier, K, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 128 (7.46) | 18.7374 |
| 1990's | 298 (17.38) | 18.2507 |
| 2000's | 436 (25.42) | 29.6817 |
| 2010's | 628 (36.62) | 24.3611 |
| 2020's | 225 (13.12) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, JP | 1 |
| McGarraugh, GV | 1 |
| Parkinson, TM | 1 |
| Wingard, RE | 1 |
| Onderdonk, AB | 1 |
| Li, F | 4 |
| Wu, G | 1 |
| Zheng, H | 1 |
| Wang, L | 3 |
| Zhao, Z | 2 |
| Zhu, S | 1 |
| Yang, C | 1 |
| Zhang, L | 6 |
| Wang, S | 3 |
| Ma, M | 1 |
| Zhao, J | 1 |
| Song, Z | 1 |
| Wang, F | 3 |
| Qu, X | 1 |
| Li, W | 4 |
| Chang, L | 1 |
| Zhang, Q | 4 |
| Tang, Y | 3 |
| Fang, Y | 1 |
| Dou, R | 1 |
| Chu, Y | 2 |
| Xia, Y | 1 |
| Wei, Z | 1 |
| Chen, L | 5 |
| Dai, Y | 1 |
| Jampala, N | 1 |
| Jain, A | 1 |
| Herfarth, HH | 1 |
| Long, MD | 3 |
| Weaver, KN | 1 |
| Barnes, EL | 1 |
| Shimodaira, Y | 1 |
| Watanabe, K | 8 |
| Iijima, K | 1 |
| Wu, YB | 1 |
| Dai, YK | 1 |
| Liu, Q | 2 |
| Ren, YJ | 1 |
| Xu, SJ | 1 |
| Pan, HG | 1 |
| Chen, WJ | 1 |
| Li, RL | 1 |
| Hu, L | 1 |
| Kido, M | 1 |
| Tamura, R | 1 |
| Yasui, Y | 1 |
| Okajima, H | 1 |
| Nunes, VRT | 1 |
| Vidigal, PVT | 1 |
| Pereira, MT | 1 |
| Ladeira, LCD | 1 |
| Caliari, MV | 1 |
| Oliveira, FMS | 1 |
| Cesar, ALA | 2 |
| Faraco, AAG | 2 |
| Barbuto, RC | 1 |
| Duval-Araujo, I | 1 |
| Velayos, FS | 4 |
| Lee, JK | 2 |
| Akbar, A | 1 |
| Arnott, I | 1 |
| Kennedy, NA | 1 |
| Nolan, J | 1 |
| Peake, S | 1 |
| Whiteoak, SR | 1 |
| Probert, C | 3 |
| Fraser, A | 1 |
| Cheshire, A | 1 |
| Lewis, A | 1 |
| Sugrue, K | 1 |
| Laird, S | 1 |
| Scott, G | 1 |
| Sriram, A | 1 |
| Tangirala, S | 1 |
| Atmakuri, S | 1 |
| Hoque, S | 1 |
| Modani, S | 1 |
| Srivastava, S | 1 |
| Mahajan, S | 1 |
| Maji, I | 1 |
| Kumar, R | 2 |
| Khatri, D | 1 |
| Madan, J | 1 |
| Singh, PK | 1 |
| Jena, A | 1 |
| Singh, AK | 2 |
| Siddharda, BV | 1 |
| Panda, P | 1 |
| Sharma, V | 2 |
| Shahdadi Sardou, H | 2 |
| Akhgari, A | 3 |
| Mohammadpour, AH | 3 |
| Beheshti Namdar, A | 1 |
| Kamali, H | 2 |
| Jafarian, AH | 2 |
| Afrasiabi Garekani, H | 2 |
| Sadeghi, F | 3 |
| Singh, A | 2 |
| Mandal, UK | 1 |
| Narang, RK | 1 |
| Tian, W | 1 |
| Xu, X | 2 |
| Zheng, Z | 1 |
| Liu, S | 1 |
| Ying, J | 1 |
| Zhang, X | 2 |
| Kjeldsen, S | 1 |
| Nielsen, J | 3 |
| Mertz Nørgård, B | 1 |
| Kjeldsen, J | 4 |
| Caron, B | 6 |
| Sandborn, WJ | 47 |
| Panaccione, R | 3 |
| Schreiber, S | 15 |
| Hart, A | 2 |
| Solitano, V | 1 |
| Danese, S | 19 |
| Peyrin-Biroulet, L | 20 |
| Dignass, AU | 4 |
| Paridaens, K | 5 |
| Al Awadhi, S | 3 |
| Begun, J | 2 |
| Cheon, JH | 7 |
| Fullarton, JR | 1 |
| Louis, E | 6 |
| Magro, F | 6 |
| Marquez, JR | 2 |
| Moschen, AR | 2 |
| Narula, N | 7 |
| Rydzewska, G | 2 |
| Travis, SPL | 2 |
| Adamowicz, M | 1 |
| Milkiewicz, P | 1 |
| Kempinska-Podhorodecka, A | 1 |
| Sedano, R | 2 |
| Jairath, V | 11 |
| Ma, C | 5 |
| Garrido, I | 1 |
| Santos, AL | 1 |
| Lopes, J | 1 |
| Lopes, S | 1 |
| Macedo, G | 2 |
| Song, HY | 1 |
| Seo, GS | 3 |
| Alhalabi, M | 2 |
| Eddin, KA | 1 |
| Ali, F | 2 |
| Abbas, A | 2 |
| Vaezi, Z | 1 |
| Asadzadeh Aghdaei, H | 1 |
| Sedghi, M | 1 |
| Mahdavian, R | 1 |
| Molakarimi, M | 1 |
| Hashemi, N | 1 |
| Naderi-Manesh, H | 1 |
| Kozhakhmetov, S | 1 |
| Babenko, D | 1 |
| Kozhakhmetova, S | 1 |
| Tuyakova, A | 1 |
| Nurgaziyev, M | 1 |
| Nurgozhina, A | 1 |
| Muhanbetganov, N | 1 |
| Chulenbayeva, L | 1 |
| Sergazy, S | 1 |
| Gulyayev, A | 1 |
| Aljofan, M | 1 |
| Kushugulova, A | 1 |
| Bai, B | 1 |
| Li, H | 3 |
| Han, L | 1 |
| Mei, Y | 1 |
| Hu, C | 1 |
| Mei, Q | 3 |
| Xu, J | 2 |
| Liu, X | 3 |
| Freddi, MJ | 1 |
| Travis, SP | 8 |
| Kucharzik, T | 4 |
| Banerjee, R | 2 |
| Pal, P | 2 |
| Hilmi, I | 1 |
| Ghoshal, UC | 1 |
| Desai, DC | 1 |
| Rahman, MM | 1 |
| Dutta, U | 3 |
| Mohiuddin, SA | 1 |
| Al Mohannadi, M | 1 |
| Philip, M | 1 |
| Ramesh, GN | 1 |
| Niriella, MA | 1 |
| De Silva, AP | 1 |
| de Silva, HJ | 1 |
| Pisespongsa, P | 1 |
| Limsrivilai, J | 1 |
| Aniwan, S | 1 |
| Nawarathne, M | 1 |
| Fernandopulle, N | 1 |
| Aye, TT | 1 |
| Ni, N | 1 |
| Joshi, N | 2 |
| Ngoc, PTV | 1 |
| Kieu, TV | 1 |
| Nguyen, AD | 1 |
| Abdullah, M | 1 |
| Ali, E | 1 |
| Zeid, A | 1 |
| Sollano, JD | 1 |
| Saberi, B | 1 |
| Omar, M | 1 |
| Mohsin, MN | 1 |
| Aftab, H | 1 |
| Wai, TM | 1 |
| Shastri, YM | 1 |
| Chaudhuri, S | 1 |
| Ahmed, F | 1 |
| Bhatia, SJ | 1 |
| Gardiner, LJ | 1 |
| Carrieri, AP | 1 |
| Bingham, K | 1 |
| Macluskie, G | 1 |
| Bunton, D | 1 |
| McNeil, M | 1 |
| Pyzer-Knapp, EO | 1 |
| Aparicio Serrano, A | 1 |
| Gallego Jiménez, E | 1 |
| Castro Rodríguez, J | 1 |
| Soto Escribano, P | 1 |
| Iglesias Flores, E | 1 |
| Marín Pedrosa, S | 1 |
| Benítez, JM | 2 |
| Kanazawa, M | 3 |
| Tominaga, K | 5 |
| Kanamori, A | 1 |
| Tanaka, T | 5 |
| Masuyama, S | 1 |
| Watanabe, S | 3 |
| Abe, K | 1 |
| Yamamiya, A | 2 |
| Goda, K | 2 |
| Irisawa, A | 3 |
| Zgheib, O | 1 |
| Trombert, V | 1 |
| Jandus, P | 1 |
| Serratrice, C | 1 |
| Jiao, C | 1 |
| Yang, M | 1 |
| Ma, J | 2 |
| Zhao, X | 3 |
| Tang, N | 1 |
| Dai, M | 1 |
| Li, Q | 2 |
| Jiang, Z | 1 |
| Huang, X | 2 |
| Zhang, H | 3 |
| Sun, L | 1 |
| Ashour, RH | 1 |
| Hazem, NM | 1 |
| AbdElfattah, AA | 1 |
| El-Kady, RA | 1 |
| Elmasry, A | 1 |
| Ben-Horin, S | 7 |
| Har-Noy, O | 4 |
| Katsanos, KH | 6 |
| Roblin, X | 4 |
| Chen, M | 2 |
| Gao, X | 1 |
| Schwartz, D | 4 |
| Cesarini, M | 2 |
| Bojic, D | 1 |
| Protic, M | 3 |
| Theodoropoulou, A | 1 |
| Abu-Kaf, H | 1 |
| Engel, T | 2 |
| Tang, J | 2 |
| Veyrard, P | 2 |
| Lin, X | 1 |
| Mao, R | 3 |
| Christodoulou, D | 1 |
| Karmiris, K | 3 |
| Knezevic-Ivanovski, T | 1 |
| Ruiz-Cerulla, A | 1 |
| Rodríguez-Alonso, L | 1 |
| Rodríguez-Moranta, F | 1 |
| Guardiola, J | 2 |
| Su, XL | 1 |
| Zhang, T | 1 |
| Guo, S | 1 |
| Wang, X | 8 |
| Wei, W | 1 |
| Wakai, M | 2 |
| Hayashi, R | 2 |
| Ueno, Y | 3 |
| Onishi, K | 2 |
| Takasago, T | 1 |
| Uchida, T | 1 |
| Takigawa, H | 2 |
| Yuge, R | 1 |
| Urabe, Y | 1 |
| Oka, S | 3 |
| Kitadai, Y | 1 |
| Tanaka, S | 3 |
| West, R | 2 |
| Russel, M | 1 |
| Bodelier, A | 1 |
| Kuijvenhoven, J | 1 |
| Bruin, K | 1 |
| Jansen, J | 2 |
| Van der Meulen, A | 1 |
| Keulen, E | 1 |
| Wolters, L | 1 |
| Ouwendijk, R | 1 |
| Bezemer, G | 1 |
| Koussoulas, V | 1 |
| Tang, T | 2 |
| Van Dobbenburgh, A | 1 |
| Van Nistelrooy, M | 1 |
| Minderhoud, I | 2 |
| Vandebosch, S | 1 |
| Lubbinge, H | 1 |
| Mak, JWY | 2 |
| Yuen, NTK | 1 |
| Yip, TCF | 2 |
| Lam, RHM | 1 |
| Lam, BKH | 1 |
| Cheng, CTY | 1 |
| Wong, GLH | 1 |
| Chan, FKL | 2 |
| Ng, SC | 5 |
| Matsuoka, K | 4 |
| Watanabe, M | 8 |
| Ohmori, T | 2 |
| Nakajima, K | 2 |
| Ishida, T | 1 |
| Ishiguro, Y | 2 |
| Kanke, K | 2 |
| Kobayashi, K | 5 |
| Hirai, F | 2 |
| Mizusawa, H | 1 |
| Kishida, S | 1 |
| Miura, Y | 1 |
| Ohta, A | 1 |
| Kajioka, T | 1 |
| Hibi, T | 17 |
| Zhang, Y | 12 |
| Wo, SK | 1 |
| Leng, W | 1 |
| Gao, F | 1 |
| Yan, X | 1 |
| Zuo, Z | 1 |
| Cao, QR | 1 |
| Ling, C | 1 |
| Liu, MJ | 1 |
| Deng, SF | 1 |
| Giri, S | 1 |
| Angadi, S | 1 |
| Jadhav, R | 1 |
| Gordon, M | 3 |
| Sinopoulou, V | 3 |
| Grafton-Clarke, C | 1 |
| Akobeng, AK | 3 |
| Clarkston, K | 1 |
| Karns, R | 3 |
| Jegga, AG | 1 |
| Sharma, M | 1 |
| Fox, S | 1 |
| Ojo, BA | 1 |
| Minar, P | 1 |
| Walters, TD | 3 |
| Griffiths, AM | 8 |
| Mack, DR | 5 |
| Boyle, B | 5 |
| LeLeiko, NS | 6 |
| Markowitz, J | 10 |
| Rosh, JR | 3 |
| Patel, AS | 3 |
| Shah, S | 3 |
| Baldassano, RN | 6 |
| Pfefferkorn, M | 7 |
| Sauer, C | 3 |
| Kugathasan, S | 7 |
| Haberman, Y | 4 |
| Hyams, JS | 10 |
| Denson, LA | 8 |
| Rosen, MJ | 2 |
| Li, Z | 2 |
| Ma, S | 1 |
| Wang, Y | 9 |
| Yan, R | 1 |
| Wang, J | 7 |
| Xu, Z | 1 |
| Feng, Y | 4 |
| Yang, P | 1 |
| Liu, L | 2 |
| Kruis, W | 23 |
| Siegmund, B | 4 |
| Lesniakowski, K | 1 |
| Simanenkov, V | 1 |
| Khimion, L | 1 |
| Sobon, M | 1 |
| Delmans, G | 1 |
| Maksyashina, SV | 1 |
| Sablin, OA | 1 |
| Pokrotnieks, J | 6 |
| Mostovoy, Y | 2 |
| Datsenko, O | 2 |
| Abdulkhakov, S | 2 |
| Dorofeyev, A | 1 |
| Levchenko, O | 3 |
| Alexeeva, O | 1 |
| Andreev, P | 2 |
| Kolesnik, IP | 1 |
| Mihaly, E | 1 |
| Abrahamovych, O | 1 |
| Baluta, M | 1 |
| Kharchenko, N | 2 |
| Viacheslav, N | 1 |
| Uspenskiy, Y | 1 |
| Vieth, M | 6 |
| Mohrbacher, R | 3 |
| Mueller, R | 8 |
| Greinwald, R | 16 |
| Vazirian, F | 1 |
| Samadi, S | 1 |
| Abbaspour, M | 2 |
| Taleb, A | 1 |
| Bagherhosseini, H | 1 |
| Mozaffari, HM | 1 |
| Emami, SA | 1 |
| Hogan, M | 2 |
| Zou, G | 4 |
| Singh, S | 10 |
| Feagan, BG | 17 |
| Miyazaki, R | 1 |
| Sakurai, T | 1 |
| Shimada, M | 2 |
| Iwashita, Y | 1 |
| Shibuya, N | 1 |
| Akita, Y | 1 |
| Miyashita, H | 1 |
| Maruyama, Y | 4 |
| Saruta, M | 3 |
| Huang, Y | 3 |
| Wu, M | 1 |
| Xiao, H | 1 |
| Liu, H | 1 |
| Yang, G | 1 |
| Guo, X | 1 |
| Liu, C | 1 |
| Varum, F | 1 |
| Thorne, H | 1 |
| Bravo, R | 1 |
| Gilgen, D | 3 |
| Hartig, C | 1 |
| Nicolas, GP | 1 |
| Wild, D | 1 |
| Liakoni, E | 1 |
| Haschke, M | 1 |
| Bauer, M | 1 |
| Baholli, L | 1 |
| Uflacker, L | 1 |
| Rolffs, S | 1 |
| Ohtaki, Y | 1 |
| Uchiyama, K | 2 |
| Kamiya, H | 1 |
| Moriizumi, E | 1 |
| Yamada, M | 3 |
| Aoki, Y | 1 |
| Watanabe, T | 4 |
| Kiryu, S | 1 |
| Suzuki, S | 4 |
| Matsumoto, Y | 1 |
| Ito, Z | 1 |
| Ohkusa, T | 1 |
| Koido, S | 1 |
| D'Amico, F | 3 |
| Nørgård, BM | 2 |
| Friedman, S | 1 |
| Huang, S | 2 |
| Xie, X | 1 |
| Su, Y | 2 |
| Pan, Z | 1 |
| Li, Y | 10 |
| Liang, J | 2 |
| Zhang, M | 3 |
| Pan, S | 1 |
| Xu, B | 2 |
| Li, L | 3 |
| Chen, J | 4 |
| Luo, X | 1 |
| Zhou, L | 2 |
| Ali Deeb, S | 1 |
| Mahmoud, R | 1 |
| Savelkoul, EHJ | 1 |
| Mares, W | 1 |
| Goetgebuer, R | 1 |
| Witteman, BJM | 1 |
| de Koning, DB | 1 |
| van Tuyl, SAC | 1 |
| Lutgens, MWMD | 1 |
| Akol-Simsek, D | 1 |
| van Schaik, FDM | 1 |
| Fidder, HH | 3 |
| Jansen, JM | 1 |
| van Boeckel, PGA | 1 |
| Mahmmod, N | 1 |
| Horjus-Talabur Horje, CS | 1 |
| Römkens, TEH | 2 |
| Colombel, JF | 8 |
| Hoentjen, F | 3 |
| Jharap, B | 1 |
| Oldenburg, B | 5 |
| Yaguchi, K | 1 |
| Matsune, Y | 1 |
| Kunisaki, R | 2 |
| Araki, K | 1 |
| Kimura, H | 2 |
| Inayama, Y | 1 |
| Kumagai, J | 1 |
| Maeda, S | 2 |
| Park, SK | 2 |
| Kang, SB | 3 |
| Kim, S | 1 |
| Kim, TO | 2 |
| Cha, JM | 1 |
| Im, JP | 1 |
| Choi, CH | 3 |
| Kim, ES | 2 |
| Eun, CS | 1 |
| Han, DS | 3 |
| Park, DI | 3 |
| Cheng, C | 1 |
| Hu, J | 4 |
| Ji, Y | 1 |
| Lian, Z | 1 |
| Au, R | 1 |
| Xu, F | 1 |
| Shen, H | 6 |
| Zhu, L | 4 |
| Yao, LY | 1 |
| Shao, BL | 1 |
| Tian, F | 1 |
| Ye, M | 1 |
| Li, YQ | 1 |
| Wang, XL | 1 |
| Yang, SQ | 1 |
| Lv, XP | 2 |
| Jia, Y | 2 |
| Wang, XH | 1 |
| Zhang, XQ | 1 |
| Wei, YL | 1 |
| Cao, Q | 1 |
| Choi, SY | 2 |
| Choi, S | 1 |
| Kang, B | 2 |
| Choe, BH | 1 |
| Lee, YJ | 1 |
| Park, JH | 2 |
| Kim, YB | 1 |
| Kim, JY | 3 |
| Lee, K | 1 |
| Lee, KJ | 2 |
| Kang, KS | 1 |
| Lee, YM | 1 |
| Kim, HJ | 2 |
| Kang, Y | 1 |
| Jang, HJ | 2 |
| Yi, DY | 1 |
| Hong, SJ | 1 |
| Choi, YJ | 1 |
| Hong, J | 1 |
| Kim, SC | 1 |
| Paupard, T | 1 |
| Gonzalez, F | 1 |
| Siproudhis, L | 1 |
| Xia, S | 2 |
| Zhou, Y | 1 |
| Sun, S | 2 |
| Shao, J | 1 |
| Zhang, Z | 2 |
| Kong, D | 1 |
| Zhang, F | 1 |
| Zheng, S | 1 |
| Liu, Y | 5 |
| Sun, Y | 2 |
| Wang, D | 1 |
| Zeng, L | 1 |
| Lu, Q | 1 |
| Xie, F | 1 |
| Li, S | 3 |
| Fan, Y | 1 |
| Lv, Q | 1 |
| Sun, X | 1 |
| Chen, Y | 7 |
| Yang, X | 3 |
| Chen, K | 1 |
| Shang, S | 1 |
| Yu, S | 1 |
| Cui, L | 1 |
| He, N | 1 |
| Mikami, Y | 2 |
| Tsunoda, J | 1 |
| Mizushima, I | 1 |
| Kiyohara, H | 2 |
| Kanai, T | 4 |
| Johnsen, KM | 3 |
| Florholmen, J | 5 |
| Moe, ØK | 3 |
| Gundersen, M | 3 |
| Beilfuss, J | 3 |
| Kileng, H | 3 |
| Sørbye, SW | 3 |
| Goll, R | 3 |
| Pengbo, S | 3 |
| Wang, P | 4 |
| Du, XY | 3 |
| Zhang, YJ | 3 |
| Liu, YH | 2 |
| Rong, ZL | 2 |
| Zhu, HY | 2 |
| Li, YT | 2 |
| You, Y | 2 |
| Lee, MH | 3 |
| Li, HJ | 2 |
| Wasuwanich, P | 2 |
| Kim, SE | 3 |
| Jeong, GH | 2 |
| Park, S | 2 |
| Yang, JW | 2 |
| Kim, MS | 2 |
| Yon, DK | 2 |
| Lee, SW | 2 |
| Koyanagi, A | 2 |
| Jacob, L | 2 |
| Kim, EY | 2 |
| Shin, JI | 2 |
| Smith, L | 2 |
| Chung, KS | 1 |
| Park, SE | 1 |
| Lee, JH | 2 |
| Kim, SY | 1 |
| Han, HS | 1 |
| Lee, YS | 1 |
| Jung, SH | 2 |
| Jang, E | 1 |
| Lee, S | 1 |
| Lee, KT | 2 |
| Pituch-Zdanowska, A | 1 |
| Dembiński, Ł | 1 |
| Banaszkiewicz, A | 1 |
| Abdelsameea, AA | 1 |
| Alsemeh, AE | 1 |
| Alabassery, N | 1 |
| Samy, W | 1 |
| Fawzy, A | 1 |
| Abbas, NAT | 1 |
| Mansuri, I | 1 |
| Rufo, PA | 3 |
| Liu, E | 1 |
| Chan, C | 1 |
| Bousvaros, A | 4 |
| Seishima, R | 1 |
| Okabayashi, K | 1 |
| Ikeuchi, H | 3 |
| Uchino, M | 2 |
| Futami, K | 1 |
| Noguchi, T | 1 |
| Ohge, H | 1 |
| Iseki, Y | 1 |
| Itabashi, M | 1 |
| Okamoto, K | 1 |
| Toiyama, Y | 1 |
| Ogino, T | 1 |
| Nakamura, M | 2 |
| Yamada, K | 1 |
| Wakai, T | 1 |
| Sato, Y | 3 |
| Takahashi, K | 3 |
| Hida, K | 1 |
| Kinugasa, Y | 1 |
| Ishida, F | 1 |
| Okuda, J | 1 |
| Daito, K | 1 |
| Koyama, F | 1 |
| Ueno, H | 1 |
| Yamamoto, T | 10 |
| Yamamoto, S | 3 |
| Hanai, T | 1 |
| Maemoto, A | 1 |
| Arakaki, J | 1 |
| Komori, K | 1 |
| Akagi, Y | 1 |
| Shida, D | 1 |
| Yamaguchi, S | 1 |
| Matsuda, K | 1 |
| Maeda, K | 1 |
| Noake, T | 1 |
| Nezu, R | 1 |
| Sasaki, S | 1 |
| Hasegawa, J | 1 |
| Sunami, E | 1 |
| Kanemitsu, Y | 1 |
| Katsumata, K | 1 |
| Uehara, K | 1 |
| Kiyomatsu, T | 1 |
| Suto, T | 1 |
| Kazama, S | 1 |
| Yamada, T | 1 |
| Goi, T | 1 |
| Ishihara, S | 3 |
| Ajioka, Y | 2 |
| Sugihara, K | 1 |
| Yue, LI | 1 |
| Shuting, W | 1 |
| Runyuan, Z | 1 |
| Dongmei, F | 1 |
| Dike, Z | 1 |
| Fengbin, L | 1 |
| Hong, MI | 1 |
| Kayal, M | 1 |
| Posner, H | 1 |
| Spencer, E | 1 |
| Stalgis, C | 1 |
| Ungaro, RC | 3 |
| Gantzel, RH | 1 |
| Vesterdal, JD | 1 |
| Haase, AM | 1 |
| Petersen, AJ | 1 |
| Grønbæk, H | 1 |
| Pedersen, ML | 1 |
| Bhandari, A | 1 |
| Basnet, BK | 1 |
| Liu, MR | 1 |
| Wei, LF | 1 |
| Liu, XT | 1 |
| An, ZT | 1 |
| Gu, LM | 1 |
| Tian, YZ | 1 |
| Cordesse, A | 1 |
| Delbet, JD | 1 |
| Lemoine, A | 1 |
| Dubern, B | 1 |
| Tounian, P | 1 |
| Lemale, J | 1 |
| van de Meeberg, MM | 2 |
| Verheij, ER | 1 |
| Bouma, G | 1 |
| Huitema, ADR | 2 |
| Löwenberg, M | 3 |
| Volkers, A | 1 |
| van Gennep, S | 1 |
| Mookhoek, A | 1 |
| Montazeri, N | 1 |
| Clasquin, E | 1 |
| Duijvestein, M | 1 |
| van Bodegraven, A | 1 |
| Rietdijk, S | 1 |
| van Asseldonk, D | 1 |
| van der Zanden, E | 1 |
| Dijkgraaf, M | 1 |
| de Boer, N | 1 |
| D'Haens, G | 11 |
| Sun, Q | 1 |
| Dai, L | 1 |
| Tang, Z | 2 |
| Zhou, W | 1 |
| Wu, T | 1 |
| Ji, G | 1 |
| Mouhtar El Hálabi, S | 1 |
| Valdés Delgado, T | 1 |
| Maldonado Pérez, B | 1 |
| Belvis Jiménez, M | 1 |
| Argüelles Arias, F | 1 |
| Gn, D | 1 |
| Patil, M | 1 |
| Shafiq, S | 1 |
| Jing, C | 1 |
| Shangbin, L | 1 |
| Yi, Z | 1 |
| Shuangyuan, HU | 1 |
| Pengfei, W | 1 |
| Wenhua, Z | 1 |
| Junfeng, S | 1 |
| Allegretti, JR | 1 |
| Mitsialis, V | 1 |
| Canavan, JB | 1 |
| Snapper, SB | 1 |
| Zegers, FD | 1 |
| Knudsen, T | 1 |
| Lund, K | 1 |
| Brodersen, JB | 1 |
| Sardou, HS | 1 |
| Garekani, HA | 1 |
| Hossein Jafarian, A | 1 |
| Nokhodchi, A | 1 |
| Mahami, S | 1 |
| Salehi, M | 1 |
| Mehrabi, M | 1 |
| Vahedi, H | 1 |
| Hassani, MS | 1 |
| Bitaraf, FS | 1 |
| Omri, A | 1 |
| Lee, AA | 1 |
| Gupta, S | 1 |
| Labban, M | 1 |
| Cao, FT | 1 |
| Trinh, QD | 1 |
| McNabb-Baltar, J | 1 |
| Wei, M | 1 |
| Liu, D | 1 |
| Xie, H | 1 |
| Du, L | 1 |
| Jin, Y | 1 |
| Słoka, J | 1 |
| Madej, M | 1 |
| Strzalka-Mrozik, B | 1 |
| Meszaros, S | 1 |
| Wehrum, S | 2 |
| Nacak, T | 2 |
| Gomes, L | 1 |
| Marques, MA | 1 |
| Ferreira, PG | 1 |
| Wada, H | 1 |
| Miyoshi, J | 1 |
| Kuronuma, S | 2 |
| Nishinarita, Y | 1 |
| Oguri, N | 1 |
| Hibi, N | 1 |
| Takeuchi, O | 2 |
| Akimoto, Y | 1 |
| Lee, STM | 1 |
| Matsuura, M | 3 |
| Kobayashi, T | 8 |
| Hisamatsu, T | 5 |
| Le Berre, C | 2 |
| Honap, S | 1 |
| Aruljothy, A | 2 |
| Moran, GW | 2 |
| Vuyyuru, SK | 1 |
| Zayadi, A | 1 |
| MacDonald, JK | 17 |
| Peyrin Biroulet, L | 1 |
| Jaramillo, AP | 1 |
| Castells, J | 1 |
| Ibrahimli, S | 1 |
| Siegel, S | 1 |
| Jayasooriya, N | 1 |
| Pollok, RC | 3 |
| Blackwell, J | 1 |
| Bottle, A | 1 |
| Petersen, I | 1 |
| Creese, H | 1 |
| Saxena, S | 3 |
| Ikehata, A | 1 |
| Honta, S | 1 |
| Sekino, Y | 1 |
| Masuo, T | 1 |
| Eizuka, K | 1 |
| Inomata, N | 1 |
| Ono, S | 1 |
| Gros, B | 1 |
| Kaplan, GG | 1 |
| Rana, VS | 1 |
| Mahajan, G | 1 |
| Patil, AN | 1 |
| Jearth, V | 1 |
| Sekar, A | 1 |
| Singh, H | 1 |
| Saroch, A | 1 |
| Do, HJ | 1 |
| Kim, YS | 4 |
| Oh, TW | 1 |
| Ma, JL | 1 |
| Zhang, HJ | 1 |
| Zhang, CF | 1 |
| Zhang, YY | 1 |
| Wang, GM | 1 |
| Joo, H | 1 |
| Lee, CS | 2 |
| Joe, S | 1 |
| Han, J | 1 |
| Kim, HK | 1 |
| Cho, H | 1 |
| Ali, NM | 1 |
| Shehab, MA | 1 |
| Fang, XH | 1 |
| Huang, YB | 1 |
| Ke, ZL | 1 |
| Zhang, YF | 1 |
| Zhou, JH | 1 |
| Su, HT | 1 |
| Chen, N | 1 |
| Liu, YL | 1 |
| Choi, YI | 1 |
| Kim, TJ | 1 |
| Park, DK | 1 |
| Chung, JW | 1 |
| Kim, KO | 2 |
| Kwon, KA | 1 |
| Kim, YJ | 1 |
| Thakur, V | 1 |
| Mishra, N | 1 |
| Roda, G | 4 |
| Nedeljkovic Protic, M | 1 |
| Kaimakliotis, P | 1 |
| Ramadugu, A | 1 |
| Kang, J | 1 |
| Trivedi, I | 1 |
| D'Haens, GR | 4 |
| Stitt, LW | 2 |
| Ananthakrishnan, AN | 3 |
| Dulai, PS | 5 |
| Khanna, R | 2 |
| Lie, MRKL | 1 |
| Kreijne, JE | 1 |
| Dijkstra, G | 3 |
| van Assche, G | 4 |
| West, RL | 1 |
| van Noord, D | 1 |
| van der Meulen-de Jong, AE | 2 |
| Zaal, RJ | 1 |
| Hansen, BE | 1 |
| de Vries, AC | 1 |
| Janneke van der Woude, C | 1 |
| Xu, L | 1 |
| Xue, X | 2 |
| Liu, J | 1 |
| Li, ZS | 2 |
| Yang, GY | 2 |
| Song, Y | 1 |
| Pan, Y | 1 |
| Ma, Y | 1 |
| Hu, S | 1 |
| Wen, A | 1 |
| Rodriguez, LM | 1 |
| Tull, MB | 1 |
| Benante, K | 1 |
| Khan, SA | 1 |
| Cao, Y | 2 |
| Jovanovic, B | 1 |
| Richmond, E | 1 |
| Umar, A | 1 |
| Bergan, R | 1 |
| Wu, K | 2 |
| Menon, S | 1 |
| Bressler, B | 2 |
| Reolid, A | 1 |
| Rodríguez-Jiménez, P | 1 |
| Llamas-Velasco, M | 1 |
| Chicharro, P | 1 |
| Fraga, J | 1 |
| Aragüés, M | 1 |
| Viscido, A | 4 |
| Latella, G | 4 |
| Frieri, G | 6 |
| Langhorst, J | 3 |
| Koch, AK | 1 |
| Voiss, P | 1 |
| Dobos, GJ | 3 |
| Rueffer, A | 2 |
| Maconi, G | 3 |
| Mezzina, N | 1 |
| Landi, S | 1 |
| Grillo, S | 1 |
| Bezzio, C | 3 |
| Bosani, M | 1 |
| Pastorelli, L | 1 |
| Dell'Era, A | 1 |
| Chibbar, R | 2 |
| Carmagnola, S | 1 |
| Molteni, P | 4 |
| Cassinotti, A | 2 |
| Massari, A | 1 |
| Ardizzone, S | 14 |
| Dignass, A | 7 |
| Fiorino, G | 5 |
| Bonovas, S | 5 |
| Dotan, I | 3 |
| Rogler, G | 7 |
| Fukunaga, S | 1 |
| Kusaba, Y | 1 |
| Tsuruta, O | 2 |
| Jun, X | 1 |
| Ning, C | 1 |
| Yang, S | 2 |
| Zhe, W | 1 |
| Na, W | 1 |
| Yifan, Z | 1 |
| Xinhua, R | 1 |
| Yulan, L | 1 |
| Ginard, D | 1 |
| Marín-Jiménez, I | 3 |
| Barreiro-de Acosta, M | 2 |
| Ricart, E | 3 |
| Domènech, E | 8 |
| Gisbert, JP | 10 |
| Esteve, M | 2 |
| Mínguez, M | 3 |
| Dal Buono, A | 1 |
| Argollo, M | 1 |
| Din, H | 1 |
| Anderson, AJ | 1 |
| Ramos Rivers, C | 1 |
| Proksell, S | 1 |
| Koutroumpakis, F | 1 |
| Salim, T | 1 |
| Babichenko, D | 1 |
| Tang, G | 1 |
| Koutroubakis, IE | 3 |
| Schwartz, M | 1 |
| Johnston, E | 1 |
| Barrie, A | 1 |
| Harrison, J | 1 |
| Hashash, J | 1 |
| Dunn, MA | 1 |
| Hartman, DJ | 1 |
| Binion, DG | 3 |
| Ogawa, K | 1 |
| Sakaguchi, K | 1 |
| Nagamoto, S | 1 |
| Kurosawa, K | 1 |
| Urakami, S | 1 |
| Okaneya, T | 1 |
| Jiang, XE | 1 |
| Yang, SM | 1 |
| Zhou, XJ | 1 |
| Niu, R | 1 |
| Zheng, J | 1 |
| Ding, D | 1 |
| Kuang, W | 1 |
| Lu, F | 1 |
| Yin, X | 1 |
| Ley, D | 1 |
| Martin, B | 1 |
| Caldera, F | 1 |
| So, J | 1 |
| Tang, W | 2 |
| Leung, WK | 2 |
| Li, M | 4 |
| Lo, FH | 2 |
| Ng, KM | 1 |
| Sze, SF | 2 |
| Leung, CM | 2 |
| Tsang, SWC | 1 |
| Shan, EHS | 1 |
| Chan, KH | 2 |
| Lam, BCY | 1 |
| Hui, AJ | 2 |
| Chow, WH | 2 |
| Iheozor-Ejiofor, Z | 2 |
| Kaur, L | 2 |
| Baines, PA | 2 |
| Hanauer, SB | 22 |
| Barrett, K | 6 |
| Naito, T | 2 |
| Kumada, J | 1 |
| Nomura, M | 1 |
| Ito, M | 1 |
| Chayama, K | 1 |
| Mazza, S | 1 |
| Sorce, A | 1 |
| Peyvandi, F | 1 |
| Vecchi, M | 5 |
| Caprioli, F | 1 |
| Watanabe, C | 1 |
| Nagahori, M | 3 |
| Fujii, T | 3 |
| Yokoyama, K | 2 |
| Yoshimura, N | 2 |
| Yamagami, H | 1 |
| Kitamura, K | 2 |
| Takashi, K | 1 |
| Nakamura, S | 4 |
| Naganuma, M | 7 |
| Esaki, M | 2 |
| Yonezawa, M | 1 |
| Sakuraba, A | 1 |
| Kuji, N | 1 |
| Miura, S | 1 |
| Suzuki, Y | 8 |
| Hokari, R | 2 |
| Fukuda, T | 2 |
| Takabayashi, K | 1 |
| Hagihara, Y | 1 |
| Tanemoto, S | 1 |
| Nomura, E | 1 |
| Yoshimatsu, Y | 1 |
| Sugimoto, S | 2 |
| Nanki, K | 2 |
| Mizuno, S | 2 |
| Fukuhara, K | 1 |
| Sujino, T | 1 |
| Mutaguchi, M | 2 |
| Inoue, N | 4 |
| Ogata, H | 6 |
| Iwao, Y | 5 |
| Abe, T | 4 |
| Al-Abcha, A | 1 |
| Raziq, F | 1 |
| Kherallah, S | 1 |
| Alratroot, A | 1 |
| El-Mahdy, NA | 1 |
| El-Sayad, ME | 1 |
| El-Kadem, AH | 1 |
| Abu-Risha, SE | 1 |
| Chen, YM | 1 |
| Deng, JM | 1 |
| Wen, Y | 2 |
| Chen, B | 1 |
| Hou, JT | 1 |
| Peng, B | 1 |
| Zhang, SJ | 1 |
| Mi, H | 1 |
| Jiang, QL | 1 |
| Wu, XL | 1 |
| Liu, FB | 1 |
| Chen, XL | 1 |
| Sehgal, P | 2 |
| Scrivo, B | 1 |
| Renna, S | 2 |
| Casà, A | 2 |
| Monachino, N | 1 |
| Macaluso, FS | 1 |
| Orlando, A | 6 |
| Iwamoto, M | 1 |
| Kato, K | 1 |
| Moriyama, M | 1 |
| Yamaguchi, K | 2 |
| Takahashi, S | 3 |
| Siegel, CA | 7 |
| Yang, F | 1 |
| Eslava, S | 1 |
| Cai, Z | 1 |
| Hiraoka, S | 4 |
| Fujiwara, A | 2 |
| Toyokawa, T | 1 |
| Higashi, R | 1 |
| Moritou, Y | 1 |
| Takagi, S | 2 |
| Matsueda, K | 1 |
| Miyaike, J | 1 |
| Inokuchi, T | 1 |
| Takahara, M | 1 |
| Kato, J | 5 |
| Okada, H | 5 |
| El-Baz, AM | 1 |
| Khodir, AE | 1 |
| Adel El-Sokkary, MM | 1 |
| Shata, A | 1 |
| Kim, J | 2 |
| Zhu, W | 1 |
| Dubois, E | 1 |
| Moens, A | 1 |
| Geelen, R | 1 |
| Sabino, J | 1 |
| Ferrante, M | 3 |
| Vermeire, S | 6 |
| Cordeiro, G | 1 |
| Dias, AM | 2 |
| Estevinho, MM | 1 |
| Vande Casteele, N | 3 |
| Jakate, A | 1 |
| McNamee, B | 1 |
| Akkol, EK | 1 |
| Karpuz, B | 1 |
| Sobarzo-Sánchez, E | 1 |
| Khan, H | 1 |
| Ungar, B | 2 |
| Kopylov, U | 4 |
| Murray, A | 2 |
| Nguyen, TM | 2 |
| Parker, CE | 7 |
| Yasuda, T | 1 |
| Takagi, T | 1 |
| Hasegawa, D | 1 |
| Hirose, R | 1 |
| Inoue, K | 1 |
| Dohi, O | 1 |
| Yoshida, N | 1 |
| Kamada, K | 1 |
| Ishikawa, T | 1 |
| Konishi, H | 1 |
| Naito, Y | 1 |
| Itoh, Y | 2 |
| Arai, Y | 1 |
| Ogawa, M | 1 |
| Yamane, F | 1 |
| Sumiyoshi, N | 1 |
| Arimoto, R | 1 |
| Ando, Y | 1 |
| Endo, D | 1 |
| Nakada, T | 1 |
| Sugawara, I | 1 |
| Yokoyama, H | 2 |
| Shimoyama, K | 1 |
| Inomata, H | 1 |
| Kawahara, Y | 2 |
| Kato, M | 1 |
| Arihiro, S | 1 |
| Hokari, A | 1 |
| Moreno Moraleda, I | 1 |
| Lázaro Sáez, M | 2 |
| Diéguez Castillo, C | 1 |
| Hernández Martínez, Á | 2 |
| Penmetsa, A | 1 |
| Kathi, P | 1 |
| Girish, G | 1 |
| Goren, I | 2 |
| Reddy, DN | 1 |
| Lan, D | 1 |
| Dong, X | 1 |
| Yang, Q | 1 |
| Wang, K | 2 |
| Miao, Y | 1 |
| Jansen, FM | 1 |
| Vavricka, SR | 4 |
| den Broeder, AA | 1 |
| de Jong, EM | 1 |
| van Dop, WA | 1 |
| Shaffer, SR | 1 |
| Huang, E | 1 |
| Patel, S | 1 |
| Rubin, DT | 12 |
| Fellermann, K | 2 |
| Schiefke, I | 1 |
| Rácz, I | 4 |
| Derova, J | 2 |
| Jonaitis, L | 3 |
| Brenner, EJ | 1 |
| Pigneur, B | 1 |
| Focht, G | 2 |
| Turner, D | 7 |
| Kappelman, MD | 5 |
| Ruemmele, FM | 4 |
| Naessens, D | 1 |
| Cameron, C | 1 |
| Hoaglin, DC | 1 |
| Yao, CK | 1 |
| Burgell, RE | 1 |
| Taylor, KM | 1 |
| Ward, MG | 1 |
| Friedman, AB | 1 |
| Barrett, JS | 1 |
| Muir, JG | 1 |
| Gibson, PR | 5 |
| Moss, AC | 14 |
| Alshahrani, AA | 1 |
| Fadida, M | 1 |
| Al-Saedi, M | 1 |
| Marshall, JK | 8 |
| Christensen, B | 2 |
| Koletzko, S | 2 |
| Kannengiesser, K | 1 |
| Hibiya, S | 1 |
| Matsuyama, Y | 1 |
| Maeyashiki, C | 1 |
| Saito, E | 1 |
| Ito, K | 1 |
| Shimizu, H | 4 |
| Kawamoto, A | 1 |
| Motobayashi, M | 1 |
| Takenaka, K | 2 |
| Kurosaki, M | 1 |
| Yauchi, T | 1 |
| Ohtsuka, K | 1 |
| Fujiwara, T | 1 |
| Okamoto, R | 1 |
| Kojimahara, S | 1 |
| Sugaya, T | 2 |
| Majima, Y | 1 |
| Iijima, M | 1 |
| Balram, B | 1 |
| Joshi, H | 1 |
| Wong, K | 1 |
| Kroeker, KI | 1 |
| Dieleman, LA | 2 |
| Halloran, BP | 1 |
| Baumgart, DC | 3 |
| Peerani, F | 1 |
| Toychiev, A | 1 |
| Navruzov, B | 1 |
| Pazylova, D | 1 |
| Davis, N | 1 |
| Badalova, N | 1 |
| Osipova, S | 1 |
| Ezquerra, A | 1 |
| Resina, E | 1 |
| Montes, Á | 1 |
| Álvarez-Malé, T | 1 |
| P Gisbert, J | 1 |
| Zhong, C | 1 |
| Cheng, X | 1 |
| Jia, B | 2 |
| Xiong, P | 1 |
| Lu, J | 2 |
| Zhang, P | 1 |
| Hegyi, PJ | 1 |
| Szakács, Z | 1 |
| Faluhelyi, N | 1 |
| Németh, BC | 1 |
| Bajor, J | 1 |
| Hegyi, P | 1 |
| Weislinger, L | 1 |
| Guillo, L | 2 |
| Achit, H | 2 |
| Ayav, C | 2 |
| Guillemin, F | 2 |
| Frimat, L | 2 |
| Jeličić, ML | 1 |
| Brusač, E | 1 |
| Klarić, DA | 1 |
| Nigović, B | 1 |
| Turk, N | 1 |
| Mornar, A | 1 |
| Tavares Junior, AG | 1 |
| de Araújo, JTC | 1 |
| Meneguin, AB | 1 |
| Chorilli, M | 1 |
| Dias, E | 1 |
| Santos-Antunes, J | 1 |
| Stange, EF | 4 |
| Jeyarajah, J | 1 |
| Guizzetti, L | 2 |
| Koh, Y | 1 |
| Nagaya, T | 1 |
| Saegusa, H | 1 |
| Kodama, R | 1 |
| Ushimaru, H | 1 |
| Ahmad, A | 1 |
| Ansari, MM | 1 |
| Mishra, RK | 1 |
| Kumar, A | 2 |
| Vyawahare, A | 1 |
| Verma, RK | 1 |
| Raza, SS | 1 |
| Khan, R | 1 |
| Liu, K | 2 |
| Xing, L | 1 |
| Wu, L | 1 |
| Guan, S | 1 |
| Huang, BB | 1 |
| Han, LC | 1 |
| Liu, GF | 1 |
| Lv, XD | 1 |
| Gu, GL | 1 |
| Li, SQ | 1 |
| Wang, HQ | 1 |
| Zhan, LL | 1 |
| von Bünau, R | 1 |
| Erhardt, A | 1 |
| Barberio, B | 1 |
| Segal, JP | 1 |
| Quraishi, MN | 1 |
| Black, CJ | 1 |
| Savarino, EV | 1 |
| Ford, AC | 8 |
| Shen, Z | 3 |
| Zheng, K | 4 |
| Zou, J | 2 |
| Gu, P | 2 |
| Xing, J | 1 |
| Rizzello, F | 9 |
| Calabrese, C | 2 |
| Salice, M | 2 |
| Calandrini, L | 1 |
| Privitera, H | 1 |
| Melotti, L | 1 |
| Peruzzi, G | 1 |
| Dussias, N | 1 |
| Belluzzi, A | 14 |
| Scaioli, E | 1 |
| Decorato, A | 1 |
| Siniscalchi, A | 1 |
| Filippone, E | 1 |
| Laureti, S | 1 |
| Rottoli, M | 1 |
| Poggioli, G | 2 |
| Gionchetti, P | 24 |
| Morikubo, H | 1 |
| Ozaki, R | 1 |
| Okabayashi, S | 1 |
| Shiba, T | 1 |
| Matsubayashi, M | 1 |
| Sagami, S | 1 |
| Nakano, M | 3 |
| Ikezaki, O | 1 |
| Tanaka, Y | 1 |
| Koslowsky, B | 1 |
| Orlev, A | 1 |
| Suzuki, K | 4 |
| Kakuta, Y | 1 |
| Takagawa, T | 1 |
| Hanai, H | 7 |
| Araki, H | 1 |
| Sasaki, Y | 1 |
| Sakuraba, H | 2 |
| Sasaki, M | 2 |
| Motoya, S | 2 |
| Matsumoto, T | 8 |
| Onodera, M | 1 |
| Nakase, H | 5 |
| Andoh, A | 3 |
| Shinozaki, M | 1 |
| Katsurada, T | 1 |
| Fujiya, M | 1 |
| Otsuka, T | 1 |
| Oshima, N | 2 |
| Noguchi, M | 1 |
| Ohta, Y | 1 |
| Kawai, Y | 1 |
| Tokunaga, K | 1 |
| Nagasaki, M | 1 |
| Kudo, H | 1 |
| Minegishi, N | 1 |
| Okamoto, D | 1 |
| Shimoyama, Y | 1 |
| Moroi, R | 1 |
| Kuroha, M | 1 |
| Shiga, H | 1 |
| Li, D | 1 |
| McGovern, DPB | 1 |
| Kinouchi, Y | 2 |
| Masamune, A | 1 |
| Han, Z | 1 |
| Wang, H | 2 |
| Guo, D | 1 |
| Zhang, J | 1 |
| Martí-Aguado, D | 2 |
| Ballester, MP | 3 |
| Wang, T | 1 |
| Lu, H | 1 |
| Céruti, H | 1 |
| Kayem, G | 1 |
| Guilbaud, L | 1 |
| Dussaux, C | 1 |
| Gervais, A | 1 |
| Beaufrère, A | 1 |
| Coffin, B | 1 |
| Mandelbrot, L | 1 |
| Maisonneuve, E | 1 |
| Zhou, C | 2 |
| Zheng, X | 2 |
| Su, J | 1 |
| Chen, Z | 2 |
| Chi, H | 1 |
| Montenegro, ML | 1 |
| Corral, JE | 1 |
| Lukens, FJ | 1 |
| Ji, B | 1 |
| Kröner, PT | 1 |
| Farraye, FA | 1 |
| Bi, Y | 1 |
| Yarlas, A | 5 |
| Willian, MK | 2 |
| Nag, A | 1 |
| Correia, JP | 1 |
| Ponte, AI | 1 |
| Silva, JC | 1 |
| Gomes, AC | 1 |
| Afecto, E | 1 |
| Attauabi, M | 1 |
| Seidelin, J | 1 |
| Burisch, J | 7 |
| Caio, G | 1 |
| Lungaro, L | 1 |
| Caputo, F | 1 |
| Muccinelli, M | 1 |
| Marcello, MC | 1 |
| Zoli, E | 1 |
| Volta, U | 1 |
| De Giorgio, R | 1 |
| Zoli, G | 1 |
| Tursi, A | 8 |
| Nenna, R | 2 |
| Musci, G | 1 |
| Elisei, W | 4 |
| Picchio, M | 2 |
| Smets, G | 1 |
| Grosber, M | 1 |
| Gutermuth, J | 1 |
| Bravenboer, B | 1 |
| Velkeniers, B | 1 |
| Yen, HH | 1 |
| Hsu, TC | 2 |
| Chen, MW | 1 |
| Su, PY | 1 |
| Chen, YY | 1 |
| Makadia, R | 1 |
| Knoll, C | 1 |
| Hardin, J | 1 |
| Voss, EA | 1 |
| Fife, D | 1 |
| Davis, K | 1 |
| Sloan, S | 1 |
| Xu, W | 1 |
| Su, W | 2 |
| Xue, Z | 1 |
| Pu, F | 1 |
| Xie, Z | 1 |
| Jin, K | 1 |
| Polyakov, NE | 1 |
| Dushkin, AV | 1 |
| Barber, GE | 1 |
| Hendler, S | 1 |
| Choe, M | 1 |
| Keyashian, K | 1 |
| Lechner, S | 1 |
| Limketkai, BN | 2 |
| Limsui, D | 1 |
| Dixon, SW | 1 |
| Collard, TJ | 1 |
| Mortensson, EMH | 1 |
| Legge, DN | 1 |
| Chambers, AC | 1 |
| Greenhough, A | 1 |
| Creed, TJ | 1 |
| Williams, AC | 1 |
| Miao, RR | 1 |
| Zhan, S | 1 |
| Hu, XT | 1 |
| Yuan, WM | 1 |
| Wu, LJ | 1 |
| Cui, SX | 1 |
| Qu, XJ | 1 |
| Zhang, S | 2 |
| Zhao, W | 1 |
| Ren, S | 1 |
| Ke, X | 1 |
| Gu, Q | 1 |
| Xie, J | 1 |
| Chen, S | 1 |
| Cheng, J | 2 |
| Nii, K | 1 |
| Okazaki, K | 2 |
| Kuboi, T | 1 |
| Brimacombe, M | 1 |
| Walters, T | 4 |
| Gibson, G | 3 |
| Mo, A | 3 |
| Mack, D | 4 |
| Griffiths, A | 4 |
| LeLeiko, N | 4 |
| Rosh, J | 6 |
| Patel, A | 3 |
| Baldassano, R | 2 |
| Dailey, J | 1 |
| Venkateswaran, S | 3 |
| Chen, PY | 1 |
| Yuan, C | 1 |
| Hong, ZC | 1 |
| Ke, XG | 1 |
| Yu, B | 1 |
| Wang, C | 3 |
| Xiao, XC | 1 |
| Wu, HZ | 1 |
| Yang, YF | 1 |
| Madarame, A | 1 |
| Fukuzawa, M | 1 |
| Yamauchi, Y | 1 |
| Kono, S | 1 |
| Sugimoto, A | 1 |
| Yamaguchi, H | 1 |
| Morise, T | 1 |
| Koyama, Y | 1 |
| Uchida, K | 2 |
| Suguro, M | 1 |
| Yasuyuki, K | 1 |
| Kawai, T | 1 |
| Itoi, T | 1 |
| Yin, Y | 1 |
| Xiao, D | 1 |
| Zou, Y | 4 |
| Sato, T | 1 |
| Tagawa, M | 1 |
| Izumi, I | 1 |
| Kiwamoto, T | 1 |
| Sumazaki, R | 1 |
| Nancey, S | 2 |
| Krishnakumar, C | 1 |
| Boyle, BM | 2 |
| Markowitz, JF | 1 |
| Sauer, CG | 4 |
| Bonkowski, E | 2 |
| Kilincalp, S | 1 |
| Ustun, Y | 1 |
| Şimşek, Z | 1 |
| Rocci, E | 1 |
| Park, K | 1 |
| Hutchens, K | 1 |
| Winterfield, L | 1 |
| Cohen, RD | 12 |
| Lichtenstein, GR | 22 |
| Axler, J | 1 |
| Riddell, RH | 1 |
| Zhu, C | 1 |
| Barrett, AC | 5 |
| Bortey, E | 8 |
| Forbes, WP | 9 |
| Iida, M | 6 |
| Ito, H | 4 |
| Nishino, H | 3 |
| Arai, T | 1 |
| Yokoyama, T | 2 |
| Okubo, T | 1 |
| Levine, A | 3 |
| Yerushalmi, B | 2 |
| Kori, M | 2 |
| Broide, E | 2 |
| Mozer-Glassberg, Y | 2 |
| Shaoul, R | 3 |
| Kolho, KL | 2 |
| Shteyer, E | 2 |
| Shamaly, H | 2 |
| Ledder, O | 2 |
| Cohen, S | 2 |
| Peleg, S | 2 |
| Shabat, CS | 1 |
| Shachmon, E | 1 |
| Boaz, M | 1 |
| On, A | 2 |
| Kochi, S | 1 |
| Omuro, S | 1 |
| Uygun, A | 1 |
| Ozturk, K | 1 |
| Demirci, H | 1 |
| Oger, C | 1 |
| Avci, IY | 1 |
| Turker, T | 1 |
| Gulsen, M | 1 |
| Dai, YC | 3 |
| Zheng, L | 2 |
| Zhang, YL | 3 |
| Chen, X | 3 |
| Chen, DL | 2 |
| Tang, ZP | 3 |
| Zhu, Y | 3 |
| Sun, M | 2 |
| Ma, H | 1 |
| Kim, B | 2 |
| Haiat, R | 1 |
| Eliakim, R | 8 |
| Ho Kim, W | 1 |
| Hee Cheon, J | 1 |
| Nikolaus, S | 1 |
| Bokemeyer, B | 4 |
| Bästlein, E | 1 |
| Bachmann, O | 2 |
| Görlich, D | 1 |
| Hofmann, U | 1 |
| Schwab, M | 1 |
| Lytras, T | 3 |
| Nikolopoulos, G | 2 |
| Collins, PD | 1 |
| Kokkinidis, DG | 1 |
| Bosdelekidou, EE | 1 |
| Iliopoulou, SM | 1 |
| Tassos, AG | 1 |
| Texakalidis, PT | 1 |
| Economopoulos, KP | 1 |
| Kousoulis, AA | 1 |
| Harbord, M | 2 |
| Bettenworth, D | 1 |
| Katsanos, K | 1 |
| Molnár, T | 3 |
| Raine, T | 1 |
| Sebastian, S | 4 |
| de Sousa, HT | 1 |
| Carbonnel, F | 3 |
| Andrews, JM | 1 |
| Rieder, F | 2 |
| Steinwurz, F | 1 |
| Stone, CD | 1 |
| Chen, MH | 1 |
| Bernstein, CN | 5 |
| Rutgeerts, PJ | 1 |
| Hindryckx, P | 2 |
| Shackelton, LM | 2 |
| Vandervoort, MK | 3 |
| Muller, C | 1 |
| Pai, RK | 1 |
| Marakhouski, Y | 3 |
| Horynski, M | 3 |
| Mikhailova, E | 1 |
| Pimanov, S | 1 |
| Rolandsdotter, H | 2 |
| Eberhardson, M | 2 |
| Fagerberg, UL | 1 |
| Finkel, Y | 2 |
| Marchetti, F | 1 |
| Mainetti, M | 1 |
| Giovannini, M | 1 |
| Morelli, C | 1 |
| Derwa, Y | 1 |
| Gracie, DJ | 1 |
| Hamlin, PJ | 2 |
| Kim, SH | 1 |
| Jang, S | 1 |
| Sung, Y | 1 |
| Park, JK | 1 |
| Park, Y | 3 |
| Yun, J | 1 |
| Izquierdo Romero, M | 1 |
| Varela Trastoy, P | 1 |
| Mancebo Mata, A | 1 |
| Eriksson, C | 2 |
| Rundquist, S | 1 |
| Zhulina, Y | 1 |
| Henriksson, I | 1 |
| Montgomery, S | 1 |
| Halfvarson, J | 2 |
| Miyake, M | 1 |
| Fujishima, M | 1 |
| Nakai, D | 1 |
| Jönsson-Videsäter, K | 1 |
| L Fagerberg, U | 1 |
| Hosseinpour, Z | 1 |
| Salehi, Z | 1 |
| Talesh Sasani, S | 1 |
| Aminian, K | 1 |
| Ashton, JJ | 1 |
| Beattie, RM | 3 |
| Davis, S | 1 |
| Keljo, DJ | 2 |
| Baker, SS | 4 |
| Otley, A | 5 |
| Heyman, M | 3 |
| Noe, J | 3 |
| Oliva-Hemker, M | 5 |
| Rufo, P | 2 |
| Strople, J | 2 |
| Ziring, D | 2 |
| Guthery, SL | 2 |
| Sudel, B | 4 |
| Benkov, K | 2 |
| Wali, P | 2 |
| Moulton, D | 2 |
| Evans, J | 4 |
| Marquis, A | 2 |
| Sylvester, FA | 2 |
| Collins, MH | 3 |
| Dubinsky, M | 3 |
| Tangpricha, V | 2 |
| Spada, KL | 2 |
| Britt, A | 1 |
| Saul, B | 2 |
| Gotman, N | 3 |
| Serrano, J | 2 |
| Abrantes, FA | 1 |
| Farah, L | 1 |
| Castilho, RO | 1 |
| Cardoso, V | 1 |
| Fernandes, SO | 1 |
| Araújo, ID | 1 |
| Doherty, G | 1 |
| Allez, M | 2 |
| Papamichael, K | 1 |
| Stallmach, A | 2 |
| Berset, IP | 1 |
| Kierkus, J | 3 |
| Lopetuso, L | 1 |
| Szymanska, E | 1 |
| Te Morsche, R | 1 |
| Peters, W | 1 |
| Burger, DM | 1 |
| Drenth, JPH | 1 |
| Nakazato, Y | 1 |
| López-Iñiguez, A | 1 |
| Pérez-Gutiérrez, MT | 1 |
| Lambraño-Castillo, D | 1 |
| Sierra-Madero, JG | 1 |
| Garcia-Planella, E | 3 |
| Mañosa, M | 6 |
| Chaparro, M | 2 |
| Beltrán, B | 2 |
| Barreiro-de-Acosta, M | 2 |
| Gordillo, J | 2 |
| Bermejo, F | 4 |
| García-Sánchez, V | 2 |
| Piqueras, M | 1 |
| Llaó, J | 2 |
| Cabré, E | 4 |
| Ribaldone, DG | 1 |
| Vernero, M | 1 |
| Saracco, GM | 1 |
| Pellicano, R | 3 |
| Finocchiaro, F | 1 |
| Caviglia, GP | 1 |
| Astegiano, M | 1 |
| Cuomo, A | 1 |
| Sgambato, D | 1 |
| D'Auria, MV | 1 |
| Miranda, A | 1 |
| Ferrante, E | 1 |
| Romano, M | 2 |
| Teynor, M | 1 |
| Kato, S | 2 |
| Ishibashi, A | 1 |
| Kani, K | 2 |
| Yakabi, K | 2 |
| Zhu, Z | 1 |
| Shu, X | 1 |
| Long, S | 1 |
| Jiang, X | 1 |
| Lu, N | 1 |
| Zhu, X | 1 |
| Liao, W | 1 |
| Salman, A | 1 |
| Seckin Gencosmanoglu, D | 1 |
| Alahdab, YO | 1 |
| Giménez-Arnau, AM | 1 |
| Borges, AS | 1 |
| Valejo Coelho, MM | 1 |
| Fernandes, C | 1 |
| Brasileiro, A | 1 |
| Gonçalo, M | 1 |
| Yoshida, T | 4 |
| Kitano, M | 1 |
| Festa, S | 2 |
| Zerboni, G | 1 |
| Papi, C | 4 |
| Manes, G | 1 |
| Saibeni, S | 4 |
| Lin, Z | 1 |
| Zhu, B | 2 |
| Jin, X | 1 |
| Keil, R | 1 |
| Wasserbauer, M | 1 |
| Zádorová, Z | 1 |
| Kojecký, V | 1 |
| Hlava, Š | 1 |
| Št'ovíček, J | 1 |
| Chudý, J | 1 |
| Roznětinská, M | 1 |
| Drábek, J | 1 |
| Kubišová, N | 1 |
| Lochmannová, J | 1 |
| Moran, CJ | 1 |
| Huang, H | 1 |
| Rivas, M | 1 |
| Kaplan, JL | 1 |
| Daly, MJ | 1 |
| Winter, HS | 2 |
| Loos, E | 1 |
| Lemkens, P | 1 |
| Poorten, VV | 1 |
| Humblet, E | 1 |
| Laureyns, G | 1 |
| Ray, G | 1 |
| Chen, YL | 1 |
| Kamimura, K | 1 |
| Yokoyama, J | 1 |
| Terai, S | 1 |
| Kluthe, C | 1 |
| Tsui, J | 1 |
| Spady, D | 1 |
| Carroll, M | 1 |
| Wine, E | 1 |
| Huynh, HQ | 1 |
| Neshta, V | 1 |
| Pesegova, M | 1 |
| Alekseeva, O | 1 |
| Lozynskyy, Y | 1 |
| Soloviev, K | 1 |
| Dorofeyev, AE | 4 |
| Stiess, M | 1 |
| Boeing, T | 1 |
| de Souza, P | 1 |
| Bonomini, TJ | 1 |
| Mariano, LNB | 1 |
| Somensi, LB | 1 |
| Lucinda, RM | 1 |
| Malheiros, A | 1 |
| da Silva, LM | 1 |
| Andrade, SF | 1 |
| Angelidou, I | 1 |
| Chrysanthopoulou, A | 1 |
| Mitsios, A | 1 |
| Arelaki, S | 1 |
| Arampatzioglou, A | 1 |
| Kambas, K | 1 |
| Ritis, D | 1 |
| Tsironidou, V | 1 |
| Moschos, I | 1 |
| Dalla, V | 1 |
| Stakos, D | 1 |
| Kouklakis, G | 2 |
| Mitroulis, I | 1 |
| Ritis, K | 1 |
| Skendros, P | 1 |
| Aboubakr, A | 1 |
| Wang, HG | 1 |
| Liu, SP | 1 |
| Ma, TH | 1 |
| Yan, W | 2 |
| Zhou, JF | 1 |
| Shi, YT | 1 |
| Shen, P | 1 |
| Yang, XZ | 1 |
| Wu, SN | 1 |
| Berends, SE | 1 |
| Strik, AS | 1 |
| Mathôt, RAA | 1 |
| Hirono, H | 1 |
| Hasegawa, K | 2 |
| Honma, T | 1 |
| Ohkoshi, S | 1 |
| Costa, JM | 1 |
| Carvalho, SD | 1 |
| Soares, JB | 1 |
| Guilcher, K | 1 |
| Fournier, N | 3 |
| Schoepfer, A | 1 |
| Schibli, S | 1 |
| Spalinger, J | 1 |
| Braegger, C | 1 |
| Nydegger, A | 1 |
| Jean, L | 1 |
| Audrey, M | 1 |
| Beauchemin, C | 2 |
| Consortium, OBOTI | 1 |
| Mazza, M | 1 |
| Calafiore, A | 1 |
| Campieri, M | 30 |
| Nguyen, NH | 1 |
| Fumery, M | 3 |
| Prokop, LJ | 1 |
| Murad, MH | 1 |
| Masoodi, M | 1 |
| Mahdiabadi, MA | 1 |
| Mokhtare, M | 1 |
| Agah, S | 1 |
| Kashani, AHF | 1 |
| Rezadoost, AM | 1 |
| Sabzikarian, M | 1 |
| Talebi, A | 1 |
| Sahebkar, A | 1 |
| Yamauchi, R | 1 |
| Araki, T | 1 |
| Mitsuyama, K | 4 |
| Tokito, T | 1 |
| Ishii, H | 4 |
| Yoshioka, S | 1 |
| Kuwaki, K | 1 |
| Mori, A | 1 |
| Yoshimura, T | 1 |
| Torimura, T | 1 |
| Nakagawa, S | 1 |
| Okaniwa, N | 1 |
| Mizuno, M | 3 |
| Sugiyama, T | 1 |
| Yamaguchi, Y | 1 |
| Tamura, Y | 1 |
| Izawa, S | 1 |
| Hijikata, Y | 1 |
| Ebi, M | 1 |
| Ogasawara, N | 1 |
| Funaki, Y | 1 |
| Kasugai, K | 1 |
| Minacapelli, CD | 2 |
| Bajpai, M | 2 |
| Geng, X | 2 |
| Van Gurp, J | 2 |
| Poplin, E | 2 |
| Amenta, PS | 2 |
| Brant, SR | 1 |
| Das, KM | 5 |
| Pereira, MS | 1 |
| Maia, L | 1 |
| Azevedo, LF | 1 |
| Campos, S | 1 |
| Carvalho, S | 1 |
| Albergaria, A | 1 |
| Lima, J | 1 |
| Marcos-Pinto, R | 1 |
| Lago, P | 1 |
| Pinho, SS | 1 |
| Yetto, T | 1 |
| Burns, C | 1 |
| Fehily, SR | 1 |
| Partsanis, NM | 1 |
| Bar Yehuda, S | 1 |
| Axlerod, R | 1 |
| Toker, O | 1 |
| Zigman, N | 1 |
| Mourad, V | 1 |
| Lederman, N | 1 |
| Cohen, N | 1 |
| Matz, E | 1 |
| Dushnitzky, D | 1 |
| Gavish, M | 1 |
| Borovsky, N | 1 |
| Schwarts, D | 1 |
| Schirmer, M | 3 |
| Denson, L | 1 |
| Vlamakis, H | 1 |
| Franzosa, EA | 1 |
| Thomas, S | 2 |
| Gotman, NM | 1 |
| Keljo, D | 3 |
| Huttenhower, C | 2 |
| Hyams, J | 2 |
| Xavier, RJ | 3 |
| Tsuboi, R | 1 |
| Matsumoto, S | 1 |
| Miyatani, H | 1 |
| Mashima, H | 1 |
| Iqbal, U | 1 |
| Anwar, H | 1 |
| Quadri, AA | 1 |
| Yamamoto, Y | 1 |
| Masuda, S | 1 |
| Maruyama, S | 1 |
| Matsubara, K | 2 |
| Gu, Y | 1 |
| Cao, XC | 1 |
| Wang, BM | 1 |
| Cao, HL | 1 |
| Meng, X | 1 |
| Dunsmore, G | 1 |
| Koleva, P | 1 |
| Elloumi, Y | 1 |
| Wu, RY | 1 |
| Sutton, RT | 1 |
| Ambrosio, L | 1 |
| Hotte, N | 1 |
| Nguyen, V | 1 |
| Madsen, KL | 1 |
| Chen, H | 1 |
| Huang, V | 1 |
| Elahi, S | 1 |
| Jensen, CB | 1 |
| Allin, KH | 1 |
| Agrawal, M | 1 |
| Ullman, T | 2 |
| Jess, T | 5 |
| Stokkeland, K | 1 |
| Höijer, J | 1 |
| Bottai, M | 1 |
| Söderberg-Löfdal, K | 1 |
| Bergquist, A | 1 |
| Seril, DN | 1 |
| Alvarez, J | 1 |
| Gorin, S | 1 |
| Das, KK | 1 |
| Huang, PH | 1 |
| Kuo, CJ | 1 |
| Lin, CW | 1 |
| Cheng, YM | 1 |
| Hu, HC | 1 |
| Lin, CY | 2 |
| Su, MY | 1 |
| Chiu, CT | 1 |
| Leoncini, G | 1 |
| Villanacci, V | 1 |
| Marin, MG | 1 |
| Crisafulli, V | 1 |
| Cadei, M | 1 |
| Antonelli, E | 1 |
| Leoci, C | 1 |
| Bassotti, G | 1 |
| Khanna, RK | 1 |
| Hage, R | 1 |
| Hage, A | 1 |
| Polin, V | 1 |
| Sené, T | 1 |
| Vignal-Clermont, C | 1 |
| Zammit, SC | 1 |
| Ellul, P | 1 |
| Turcan, S | 2 |
| Duricova, D | 3 |
| Bortlik, M | 2 |
| Andersen, KW | 1 |
| Andersen, V | 1 |
| Kaimakliotis, IP | 1 |
| Gower-Rousseau, C | 2 |
| Girardin, G | 1 |
| Valpiani, D | 6 |
| Goldis, A | 2 |
| Brinar, M | 1 |
| Čuković-Čavka, S | 1 |
| Oksanen, P | 1 |
| Collin, P | 1 |
| Barros, L | 1 |
| Misra, R | 1 |
| Arebi, N | 1 |
| Kievit, HAL | 1 |
| Pedersen, N | 5 |
| Myers, S | 1 |
| Christodoulou, DK | 1 |
| Midjord, J | 1 |
| Nielsen, KR | 2 |
| Kiudelis, G | 3 |
| Kupcinskas, L | 5 |
| Nikulina, I | 1 |
| Belousova, E | 2 |
| Odes, S | 2 |
| Salupere, R | 1 |
| Carmona, A | 1 |
| Pineda, JR | 2 |
| Vegh, Z | 3 |
| Lakatos, PL | 7 |
| Langholz, E | 8 |
| Munkholm, P | 12 |
| Arisaka, T | 1 |
| Takahashi, F | 1 |
| Arisaka, O | 1 |
| Hiraishi, H | 2 |
| Mohanta, S | 1 |
| Singh, SK | 2 |
| Kumar, B | 1 |
| Gulati, M | 2 |
| Yadav, AK | 1 |
| Wadhwa, S | 1 |
| Jyoti, J | 1 |
| Som, S | 1 |
| Dua, K | 1 |
| Pandey, NK | 1 |
| Feuerstein, JD | 3 |
| Tremaine, WJ | 5 |
| Ko, CW | 2 |
| Falck-Ytter, C | 1 |
| Falck-Ytter, Y | 1 |
| Cross, RK | 1 |
| Tomoda, Y | 1 |
| Kagawa, S | 1 |
| Kurata, S | 1 |
| Tanaka, K | 1 |
| Dexheimer, PJ | 1 |
| Somekh, J | 1 |
| Jurickova, I | 1 |
| Braun, T | 1 |
| Novak, E | 1 |
| Bauman, L | 1 |
| Nistel, M | 1 |
| Pfefferkorn, MD | 1 |
| Heyman, MB | 4 |
| Grifiths, AM | 1 |
| Noe, JD | 1 |
| Aronow, BJ | 1 |
| Thomas, SD | 1 |
| Mollen, K | 1 |
| Shen-Orr, S | 1 |
| Todo, K | 1 |
| Osamura, T | 1 |
| Imashuku, S | 1 |
| Huang, M | 3 |
| Lang, C | 1 |
| Yang, B | 2 |
| Xue, L | 1 |
| Chen, D | 2 |
| Li, X | 1 |
| Jiang, M | 2 |
| Wang, W | 2 |
| Shen, J | 1 |
| Cross, R | 2 |
| Gupta, N | 1 |
| Dias, T | 1 |
| Santos, A | 1 |
| Santos, RM | 1 |
| Carvalho, A | 1 |
| Anindya, AL | 1 |
| Oktaviani, RD | 1 |
| Praevina, BR | 1 |
| Damayanti, S | 1 |
| Kurniati, NF | 1 |
| Riani, C | 1 |
| Rachmawati, H | 1 |
| Sceats, LA | 1 |
| Morris, AM | 1 |
| Bundorf, MK | 1 |
| Park, KT | 2 |
| Kin, C | 1 |
| Sauer, BG | 1 |
| Olaisen, M | 2 |
| Spigset, O | 1 |
| Flatberg, A | 1 |
| Granlund, AVB | 1 |
| Brede, WR | 1 |
| Albrektsen, G | 1 |
| Røyset, ES | 1 |
| Gilde, B | 1 |
| Sandvik, AK | 1 |
| Martinsen, TC | 2 |
| Fossmark, R | 2 |
| Lee, J | 2 |
| Jee, SR | 1 |
| Kim, HW | 1 |
| Baek, DH | 1 |
| Song, GA | 1 |
| Moon, W | 3 |
| Park, SJ | 3 |
| Kikuchi, H | 1 |
| Akemoto, Y | 1 |
| Murai, Y | 1 |
| Fukutoku, Y | 1 |
| Asari, T | 1 |
| Tatsuta, T | 1 |
| Hasui, K | 1 |
| Hiraga, H | 1 |
| Sawaya, M | 1 |
| Chinda, D | 1 |
| Mikami, T | 1 |
| Tanaka, M | 2 |
| Fukuda, S | 1 |
| Davis Thomas, S | 1 |
| Marquis, MA | 1 |
| Hommel, K | 1 |
| Marigorta, UM | 1 |
| Wang, B | 1 |
| Li, J | 2 |
| Qiu, C | 1 |
| Fullana, M | 1 |
| Bosca-Watts, MM | 1 |
| Tosca, J | 2 |
| Romero, E | 1 |
| Sanchez, A | 1 |
| Navarro-Cortes, P | 1 |
| Anton, R | 1 |
| Mora, F | 1 |
| Bolia, R | 1 |
| Rajanayagam, J | 1 |
| Hardikar, W | 1 |
| Alex, G | 2 |
| Schultheiss, JPD | 1 |
| Park, M | 1 |
| Soga, K | 1 |
| Itani, K | 1 |
| Ishikawa, H | 1 |
| Mutoh, M | 1 |
| Nakajima, T | 2 |
| Takeuchi, Y | 1 |
| Ezoe, Y | 1 |
| Wakabayashi, K | 1 |
| Doyama, H | 1 |
| Sakai, T | 1 |
| Krums, LM | 1 |
| Babaian, AF | 1 |
| Bykova, SV | 1 |
| Lishchinskaia, AA | 1 |
| Khomeriki, SG | 2 |
| Gudkova, RB | 1 |
| Sabel'nikova, EA | 1 |
| Kniazev, OV | 2 |
| Parfenov, AI | 4 |
| Lin, WC | 1 |
| Chang, CW | 1 |
| Chen, MJ | 1 |
| Wang, HY | 1 |
| Buchner, AM | 2 |
| Sturniolo, GC | 5 |
| Bossa, F | 2 |
| di Sabatino, A | 2 |
| Giuffrida, P | 1 |
| Petruzzelli, MG | 1 |
| Margari, L | 1 |
| Ivagnes, S | 1 |
| Palumbi, R | 1 |
| Margari, F | 1 |
| León-Rendón, JL | 1 |
| Jiménez-Bobadilla, B | 1 |
| López-Pérez, RY | 1 |
| Gracida-Mancilla, NI | 1 |
| Alarcón-Bernés, L | 1 |
| Villanueva Herrero, JA | 1 |
| Nikolopoulos, GK | 1 |
| Piovani, D | 1 |
| González-Lorenzo, M | 1 |
| Pantavou, K | 1 |
| Hokkanen, SRK | 1 |
| Boxall, N | 1 |
| Campbell-Hill, S | 1 |
| Patel, H | 2 |
| Milanesi, E | 1 |
| Dobre, M | 1 |
| Manuc, TE | 1 |
| Becheanu, G | 1 |
| Tieranu, CG | 1 |
| Ionescu, EM | 1 |
| Manuc, M | 1 |
| Xie, C | 1 |
| Quan, R | 1 |
| Hong, F | 1 |
| Zou, K | 1 |
| Fu, Y | 1 |
| Sato, M | 2 |
| Hirata, J | 1 |
| Shibahara, Y | 1 |
| Carmody, JK | 1 |
| Plevinsky, J | 1 |
| Peugh, JL | 1 |
| Lobato, D | 1 |
| Hommel, KA | 2 |
| Tang, JH | 1 |
| Wen, JJ | 1 |
| Zhu, JQ | 1 |
| Sacks, A | 1 |
| Davis, MK | 1 |
| Chang, WC | 1 |
| Zenser, TV | 1 |
| Cooper, HS | 1 |
| Clapper, ML | 1 |
| Flourié, B | 2 |
| Hagège, H | 1 |
| Tucat, G | 1 |
| Maetz, D | 2 |
| Hébuterne, X | 3 |
| Kuyvenhoven, JP | 2 |
| Tan, TG | 2 |
| Pierik, MJ | 1 |
| Masclee, AA | 1 |
| Dewit, O | 3 |
| Probert, CS | 6 |
| Aoucheta, D | 1 |
| Slim, R | 1 |
| Amara, J | 1 |
| Nasnas, R | 1 |
| Honein, K | 1 |
| Jaoude, JB | 1 |
| Yaghi, C | 1 |
| Daniel, F | 1 |
| Sayegh, R | 1 |
| He, HH | 1 |
| Khan, N | 2 |
| Abbas, AM | 2 |
| Koleva, YN | 2 |
| Bazzano, LA | 2 |
| Pola, S | 1 |
| McDonald, JWD | 1 |
| Rutgeerts, P | 6 |
| Mittmann, U | 1 |
| King, D | 1 |
| Wong, CJ | 1 |
| Donner, A | 1 |
| Nelson, S | 2 |
| Fahmy, M | 1 |
| Loftus, EV | 8 |
| Van Assche, GA | 1 |
| Levesque, BG | 2 |
| Graham, PM | 1 |
| Li, JZ | 1 |
| Dou, X | 1 |
| Zhu, H | 1 |
| Misra, HP | 1 |
| Jia, Z | 1 |
| Hasan, MN | 1 |
| Tiselius, HG | 1 |
| Seibold, F | 2 |
| Beglinger, C | 5 |
| Mottet, C | 3 |
| Pittet, V | 1 |
| Yönal, O | 1 |
| Hatemi, G | 1 |
| Kaymakoğlu, S | 1 |
| Papiamonis, N | 1 |
| Terada, T | 1 |
| Hernández, V | 2 |
| Myrelid, P | 2 |
| Kariv, R | 1 |
| Tsianos, E | 1 |
| Toruner, M | 1 |
| Marti-Gallostra, M | 1 |
| Spinelli, A | 1 |
| Yuksel, ES | 1 |
| Gasche, C | 2 |
| Sedano Casas, A | 1 |
| Gato Díez, A | 1 |
| Mora Escudero, I | 1 |
| García Ángel, RD | 1 |
| Xue, LY | 1 |
| Ouyang, Q | 2 |
| Zhou, XG | 1 |
| Huang, ZH | 1 |
| Chen, W | 2 |
| Yu, LM | 1 |
| Sameshima, Y | 1 |
| Ota, A | 1 |
| Jayan, JB | 1 |
| Habeeb, MA | 1 |
| Tantry, VB | 1 |
| Yarlagadda, N | 1 |
| Koshy, A | 1 |
| Dhus, U | 1 |
| Krishnankutty, B | 1 |
| Moodahadu, LS | 1 |
| Vegter, S | 1 |
| Tolley, K | 1 |
| Wilson Waterworth, T | 1 |
| Jones, H | 1 |
| Jones, S | 1 |
| Jewell, D | 1 |
| Mukherjee, N | 1 |
| Pandya, N | 1 |
| Bhaduri, B | 1 |
| Bala, K | 1 |
| Criscuoli, V | 1 |
| Modesto, I | 3 |
| Cottone, M | 6 |
| Qanneta, R | 1 |
| García Pardo, G | 1 |
| Florit Serra, L | 1 |
| Choi, YS | 1 |
| Lee, IT | 1 |
| Cho, KR | 1 |
| Kim, JK | 2 |
| Suh, JP | 1 |
| Lee, DS | 1 |
| Co, ML | 1 |
| Gorospe, EC | 2 |
| Chande, N | 4 |
| Varnhagen, I | 1 |
| Schneider, SB | 1 |
| Albrecht, U | 1 |
| Stange, R | 1 |
| Michalsen, A | 1 |
| Managlia, E | 2 |
| Katzman, RB | 1 |
| Brown, JB | 2 |
| Barrett, TA | 2 |
| Pagoldh, M | 1 |
| Hultgren, E | 1 |
| Arnell, P | 1 |
| Eriksson, A | 1 |
| Selinger, CP | 2 |
| Eaden, J | 2 |
| Jones, DB | 2 |
| Katelaris, P | 2 |
| Chapman, G | 2 |
| McDonald, C | 2 |
| Smith, P | 1 |
| Lal, S | 2 |
| Leong, RW | 2 |
| McLaughlin, J | 2 |
| Robinson, A | 3 |
| Katz, S | 4 |
| Waljee, AK | 4 |
| Stidham, RW | 1 |
| Higgins, PD | 6 |
| Vijan, S | 1 |
| Saini, SD | 2 |
| Sugiyama, S | 1 |
| Goishi, H | 1 |
| Kajihara, T | 1 |
| Akagi, M | 1 |
| Miura, T | 1 |
| Abraham, A | 1 |
| Karakurum, A | 1 |
| Patuto, N | 1 |
| Jilani, JA | 1 |
| Shomaf, M | 1 |
| Alzoubi, KH | 1 |
| Singla, V | 1 |
| Pratap Mouli, V | 1 |
| Garg, SK | 1 |
| Rai, T | 1 |
| Choudhury, BN | 1 |
| Verma, P | 1 |
| Deb, R | 1 |
| Tiwari, V | 1 |
| Rohatgi, S | 1 |
| Dhingra, R | 1 |
| Kedia, S | 1 |
| Sharma, PK | 1 |
| Makharia, G | 1 |
| Ahuja, V | 2 |
| Lindgren, S | 2 |
| Oudkerk Pool, M | 1 |
| Marteau, P | 10 |
| Fascì-Spurio, F | 2 |
| Rogai, F | 1 |
| Settesoldi, A | 1 |
| Margagnoni, G | 2 |
| Annese, V | 7 |
| Eaton, JE | 1 |
| Smyrk, TC | 1 |
| Imam, M | 1 |
| Pardi, DS | 1 |
| Owens, VL | 1 |
| Talwalkar, JA | 1 |
| D'Incà, R | 5 |
| Paccagnella, M | 1 |
| Cardin, R | 1 |
| Pathak, S | 1 |
| Baldo, V | 1 |
| Giron, MC | 1 |
| Rungoe, C | 1 |
| Andersson, M | 2 |
| Basit, S | 1 |
| Nielsen, NM | 1 |
| Wohlfahrt, J | 1 |
| Connolly, MP | 3 |
| Postma, MJ | 1 |
| Nielsen, SK | 2 |
| Wolff, S | 1 |
| Terheggen, G | 1 |
| Franklin, J | 1 |
| Sun, H | 1 |
| Lee, JJ | 1 |
| Papadopoulos, EJ | 1 |
| Nelson, RM | 1 |
| Sachs, HC | 1 |
| Rodriguez, WJ | 1 |
| Mulberg, AE | 1 |
| Kong, LM | 1 |
| Fok, KC | 1 |
| Tsui, A | 1 |
| Qian, C | 1 |
| Fisher, L | 1 |
| Cravo, ML | 1 |
| Ferreira, PA | 1 |
| Sousa, P | 1 |
| Moura-Santos, P | 1 |
| Velho, S | 1 |
| Tavares, L | 1 |
| de Deus, JR | 1 |
| Ministro, P | 1 |
| Peixe, P | 1 |
| Correia, LA | 1 |
| Velosa, JF | 1 |
| Maio, RF | 1 |
| Brito, M | 1 |
| Pagnini, C | 1 |
| Menasci, F | 1 |
| Delle Fave, G | 1 |
| Herrlinger, KR | 1 |
| Xia, A | 1 |
| Stempak, JM | 1 |
| Grist, J | 1 |
| Silverberg, MS | 1 |
| Bach, H | 1 |
| Gillespie, D | 3 |
| Hood, K | 3 |
| Farewell, D | 2 |
| Stenson, R | 3 |
| Hawthorne, AB | 7 |
| Blonski, W | 1 |
| Andersson, P | 1 |
| Norblad, R | 1 |
| Söderholm, JD | 1 |
| Calafat, M | 1 |
| Shiraki, M | 1 |
| Bamba, T | 3 |
| Umegae, S | 3 |
| Matsumoto, K | 5 |
| Mayberry, J | 3 |
| Galatola, M | 1 |
| Miele, E | 3 |
| Strisciuglio, C | 1 |
| Paparo, L | 1 |
| Rega, D | 1 |
| Delrio, P | 1 |
| Duraturo, F | 1 |
| Martinelli, M | 1 |
| Rossi, GB | 1 |
| Staiano, A | 2 |
| Izzo, P | 1 |
| De Rosa, M | 1 |
| Fan, HY | 1 |
| Zhang, ZL | 1 |
| Yang, MY | 1 |
| Lv, WH | 1 |
| Che, X | 1 |
| Xu, H | 1 |
| Song, WW | 1 |
| Gilardi, D | 1 |
| Naccarato, P | 1 |
| Sociale, OR | 1 |
| Vishwakarma, N | 1 |
| Ganeshpurkar, A | 1 |
| Pandey, V | 1 |
| Dubey, N | 1 |
| Bansal, D | 1 |
| MacFie, TS | 1 |
| Poulsom, R | 1 |
| Parker, A | 1 |
| Warnes, G | 1 |
| Boitsova, T | 1 |
| Nijhuis, A | 1 |
| Suraweera, N | 1 |
| Poehlmann, A | 1 |
| Szary, J | 1 |
| Feakins, R | 1 |
| Jeffery, R | 1 |
| Harper, RW | 1 |
| Jubb, AM | 1 |
| Lindsay, JO | 1 |
| Silver, A | 1 |
| Chen, C | 2 |
| Cao, XN | 1 |
| Wang, GH | 1 |
| Hu, JB | 1 |
| Russo, L | 1 |
| Schneider, G | 1 |
| Gardiner, MH | 1 |
| Lanes, S | 1 |
| Streck, P | 2 |
| Rosen, S | 1 |
| Subramaniam, K | 1 |
| Richardson, A | 1 |
| Dodd, J | 1 |
| Platten, J | 1 |
| Shadbolt, B | 1 |
| Pavli, P | 1 |
| O'Connor, A | 1 |
| Ye, BD | 3 |
| Yang, SK | 2 |
| Kim, SO | 1 |
| Kim, JW | 2 |
| Park, SH | 4 |
| Yang, DH | 2 |
| Jung, KW | 2 |
| Kim, KJ | 2 |
| Byeon, JS | 2 |
| Myung, SJ | 2 |
| Kim, JH | 5 |
| Snipelisky, DF | 1 |
| Cable, CA | 1 |
| Maniaci, MJ | 1 |
| Coman, RM | 1 |
| Glover, SC | 1 |
| Gjymishka, A | 1 |
| Mody, R | 1 |
| Davis, KL | 2 |
| Wang, CC | 1 |
| Ding, H | 1 |
| Liu, XC | 1 |
| Xu, JM | 1 |
| Hu, XY | 1 |
| Zhao, LN | 1 |
| Li, JY | 1 |
| Yu, T | 1 |
| Chen, GC | 1 |
| Yuan, YH | 1 |
| Chen, QK | 1 |
| Xu, M | 1 |
| Qiao, H | 1 |
| Ping, Q | 1 |
| Elamin, ES | 1 |
| Kume, K | 1 |
| Oshima, J | 1 |
| Yoshikawa, I | 1 |
| Harada, M | 1 |
| Osterman, MT | 1 |
| Aberra, FN | 2 |
| Liakos, S | 1 |
| McCabe, R | 1 |
| Shafran, I | 1 |
| Wolf, D | 1 |
| Hardi, R | 2 |
| Nessel, L | 1 |
| Brensinger, C | 2 |
| Gilroy, E | 1 |
| Lewis, JD | 2 |
| Karner, M | 1 |
| Kocjan, A | 2 |
| Stein, J | 3 |
| von Boyen, G | 1 |
| Uebel, P | 1 |
| Schmidt, C | 1 |
| Dina, I | 1 |
| Zuelch, F | 1 |
| Keilhauer, G | 1 |
| Stremmel, W | 1 |
| Gecse, KB | 1 |
| Inoue, M | 2 |
| Horita, N | 1 |
| Kimura, N | 1 |
| Kojima, R | 3 |
| Miyazawa, N | 1 |
| Gruenhagen, B | 1 |
| Alraies, MC | 1 |
| Vakil, KP | 1 |
| March, SK | 1 |
| Pierce, D | 2 |
| Corcoran, M | 1 |
| Martin, P | 2 |
| Inglis, S | 2 |
| Preston, P | 1 |
| Thompson, TN | 1 |
| Willsie, SK | 1 |
| Paterson, C | 4 |
| Lillis, Y | 1 |
| Edwards George, JB | 1 |
| Choudhry, NK | 1 |
| Berg, AH | 2 |
| Cheifetz, AS | 6 |
| Horowitz, G | 2 |
| Leffler, DA | 1 |
| Ando, T | 2 |
| Sitkin, SI | 1 |
| Tkachenko, EI | 1 |
| Vakhitov, TIa | 1 |
| Oreshko, LS | 1 |
| Zhigalova, TN | 1 |
| Safina, DD | 1 |
| Abdulkhakov, RA | 1 |
| Abdulkhakov, SR | 1 |
| Odintsova, AKh | 1 |
| Cheremina, NA | 1 |
| Ninan, S | 1 |
| Hamlin, J | 1 |
| Kacprzak, A | 1 |
| Siemion-Szcześniak, I | 1 |
| Szturmowicz, M | 1 |
| Bestry, I | 1 |
| Langfort, R | 1 |
| Kuś, J | 1 |
| Hojsak, I | 2 |
| Pavić, AM | 1 |
| Kolaček, S | 2 |
| Chapuy, L | 1 |
| Bsat, M | 1 |
| Mehta, H | 1 |
| Rubio, M | 1 |
| Wakahara, K | 1 |
| Van, VQ | 1 |
| Baba, N | 1 |
| Cheong, C | 1 |
| Yun, TJ | 1 |
| Panzini, B | 1 |
| Wassef, R | 1 |
| Richard, C | 1 |
| Tamaz, R | 1 |
| Soucy, G | 1 |
| Delespesse, G | 1 |
| Sarfati, M | 1 |
| Kaimakliotis, I | 2 |
| Avnstrøm, S | 3 |
| Vinding, KK | 1 |
| Olsen, J | 1 |
| Tsianos, EV | 2 |
| Lakatos, L | 5 |
| Lupinacci, G | 1 |
| De Padova, A | 1 |
| Tighineanu, O | 1 |
| Mihu, I | 1 |
| Barros, LF | 1 |
| Lazar, D | 1 |
| Fernandez, A | 1 |
| Niewiadomski, O | 1 |
| Bell, S | 2 |
| Zezos, P | 1 |
| Patsiaoura, K | 1 |
| Nakos, A | 1 |
| Mpoumponaris, A | 1 |
| Vassiliadis, T | 1 |
| Giouleme, O | 1 |
| Pitiakoudis, M | 1 |
| Evgenidis, N | 1 |
| Takeshima, F | 1 |
| Matsumura, M | 1 |
| Makiyama, K | 2 |
| Ohba, K | 1 |
| Yamakawa, M | 1 |
| Nishiyama, H | 1 |
| Yamao, T | 1 |
| Akazawa, Y | 1 |
| Yamaguchi, N | 1 |
| Ohnita, K | 1 |
| Ichikawa, T | 1 |
| Isomoto, H | 1 |
| Nakao, K | 1 |
| Shin, T | 1 |
| Kobori, Y | 1 |
| Iwahata, T | 1 |
| Yagi, H | 1 |
| Soh, S | 1 |
| Arai, G | 1 |
| Frede, A | 1 |
| Knott, M | 1 |
| Pastille, E | 1 |
| Buer, J | 1 |
| Westendorf, AM | 1 |
| McDonald, JW | 3 |
| Chae, HB | 1 |
| Jung, YS | 1 |
| Lee, CK | 1 |
| Huh, KC | 1 |
| Shin, JE | 1 |
| Jung, Y | 2 |
| Jung, SA | 2 |
| Song, HJ | 1 |
| Hong, SN | 1 |
| Kim, YH | 2 |
| Kashkooli, SB | 1 |
| Rouhani, M | 1 |
| Saibil, F | 2 |
| Tack, GJ | 1 |
| Waayenberg, P | 1 |
| de Boer, NK | 1 |
| D'Ovidio, V | 1 |
| Meo, D | 1 |
| Gozer, M | 1 |
| Bazuro, ME | 1 |
| Vernia, P | 4 |
| Pontes, C | 2 |
| Vives, R | 1 |
| Torres, F | 1 |
| Panés, J | 4 |
| Yen, L | 7 |
| Hodgkins, P | 7 |
| Thielsen, P | 1 |
| Martinsen, L | 1 |
| Bennedsen, M | 1 |
| Haaber, A | 1 |
| Park, MI | 1 |
| Ku, KH | 1 |
| Song, SE | 1 |
| Chang, HK | 1 |
| Chhaya, V | 2 |
| Cecil, E | 2 |
| Chatu, S | 1 |
| Subramanian, V | 2 |
| Curcin, V | 2 |
| Majeed, A | 2 |
| Yamada, S | 1 |
| Koyama, T | 1 |
| Noguchi, H | 1 |
| Ueda, Y | 1 |
| Kitsuyama, R | 1 |
| Tanimoto, A | 1 |
| Wang, KY | 1 |
| Nawata, A | 1 |
| Nakayama, T | 1 |
| Sasaguri, Y | 1 |
| Satoh, T | 1 |
| Krzeski, P | 2 |
| Ibarguen-Secchia, E | 1 |
| Iwanczak, B | 1 |
| Kaczmarski, M | 1 |
| Osuntokun, B | 1 |
| Quiros, JA | 2 |
| Shah, M | 1 |
| Yacyshyn, B | 3 |
| Dunnmon, PM | 1 |
| Kawashima, K | 1 |
| Yuki, T | 1 |
| Kushiyama, Y | 1 |
| Fujishiro, H | 1 |
| Miyaoka, Y | 1 |
| Yuki, M | 1 |
| Komazawa, Y | 1 |
| Tanimura, T | 1 |
| Sonoyama, H | 1 |
| Tada, Y | 1 |
| Kusunoki, R | 1 |
| Oka, A | 1 |
| Fukuba, N | 1 |
| Moriyama, I | 1 |
| Kinoshita, Y | 1 |
| Nomoto, H | 1 |
| Hayashi, Y | 1 |
| Shinozaki, S | 1 |
| Yano, T | 2 |
| Sunada, K | 1 |
| Sasao, W | 1 |
| Kitamura, A | 1 |
| Ohashi, M | 1 |
| Hiyama, S | 1 |
| Lefor, AK | 1 |
| Yamamoto, H | 1 |
| Lu, YL | 1 |
| Yao, HF | 1 |
| Yamamoto-Furusho, JK | 1 |
| Jacintez-Cazares, M | 1 |
| Furuzawa-Carballeda, J | 1 |
| Fonseca-Camarillo, G | 1 |
| Jiang, XL | 2 |
| Wang, HH | 1 |
| Cui, HF | 1 |
| Moro, L | 2 |
| Jones, R | 2 |
| Bagin, R | 2 |
| David Ballard, E | 1 |
| Masure, J | 1 |
| Travis, S | 3 |
| Bendezú García, RA | 1 |
| Patrón Román, GO | 1 |
| Buurman, DJ | 1 |
| De Monchy, JG | 1 |
| Schellekens, RC | 1 |
| van der Waaij, LA | 1 |
| Kleibeuker, JH | 1 |
| Maaser, C | 1 |
| Bai, XY | 1 |
| Yan, Y | 1 |
| Zhao, LG | 1 |
| Lang, A | 3 |
| Salomon, N | 3 |
| Wu, JC | 2 |
| Lahat, A | 1 |
| Ching, JY | 2 |
| Cheong, PK | 1 |
| Avidan, B | 1 |
| Gamus, D | 2 |
| Hauso, Ø | 1 |
| Waldum, H | 1 |
| Ouakaa-Kchaou, A | 1 |
| Gargouri, D | 1 |
| Kochlef, A | 1 |
| Bibani, N | 1 |
| Elloumi, H | 1 |
| Trad, D | 1 |
| Kharrat, J | 1 |
| Brand, S | 1 |
| Fleming, K | 1 |
| Ashcroft, A | 1 |
| Alexakis, C | 1 |
| Tzias, D | 1 |
| Groves, C | 1 |
| Poullis, A | 2 |
| Safroneeva, E | 1 |
| Straumann, A | 1 |
| Schoepfer, AM | 1 |
| Stocco, G | 2 |
| Cuzzoni, E | 1 |
| De Iudicibus, S | 1 |
| Favretto, D | 1 |
| Malusà, N | 1 |
| Martelossi, S | 2 |
| Pozzi, E | 1 |
| Lionetti, P | 1 |
| Ventura, A | 3 |
| Decorti, G | 2 |
| Ferrusquía, J | 1 |
| Pérez-Martínez, I | 2 |
| Gómez de la Torre, R | 1 |
| Fernández-Almira, ML | 1 |
| de Francisco, R | 1 |
| Rodrigo, L | 1 |
| Riestra, S | 1 |
| Schorr, M | 1 |
| Vaidya, A | 1 |
| Schulte, S | 1 |
| Todd, DJ | 1 |
| Conant, A | 1 |
| Song, G | 1 |
| Shi, L | 1 |
| Casanova, MJ | 2 |
| Santander, C | 1 |
| Magalhães-Costa, P | 1 |
| Matos, L | 1 |
| Chagas, C | 1 |
| Neto, R | 1 |
| Raul, N | 1 |
| Ferdinande, L | 1 |
| Liesbeth, F | 1 |
| Pieter, H | 1 |
| Abinusawa, A | 2 |
| Tenjarla, S | 2 |
| Zhang, HX | 1 |
| Fu, XX | 1 |
| Zeng, JC | 1 |
| Zhang, JA | 1 |
| Wang, WD | 1 |
| Kong, B | 1 |
| Xiang, WY | 1 |
| Zhong, J | 1 |
| Wang, CY | 1 |
| Zheng, XB | 2 |
| Xu, JF | 1 |
| Jang, BI | 3 |
| Stiefelhagen, P | 3 |
| Meini, S | 1 |
| Laureano, R | 1 |
| Fani, L | 1 |
| Tascini, C | 1 |
| Galano, A | 1 |
| Antonelli, A | 1 |
| Rossolini, GM | 1 |
| Gomollón, F | 5 |
| Méndez, I | 1 |
| Agilli, M | 1 |
| Dogan, T | 1 |
| Ergin, G | 1 |
| Mellinger, JL | 1 |
| Pletneva, M | 1 |
| Fontana, RJ | 1 |
| Stelzer, T | 1 |
| Kohler, S | 1 |
| Marques Maggio, E | 1 |
| Heuss, LT | 1 |
| Solberg, IC | 1 |
| Høivik, ML | 1 |
| Cvancarova, M | 1 |
| Moum, B | 3 |
| Shimoyama, T | 3 |
| Navas-López, VM | 1 |
| Blasco-Alonso, J | 1 |
| Girón Fernández-Crehuet, F | 1 |
| Serrano Nieto, MJ | 1 |
| Gallego-Gutiérrez, S | 1 |
| Luque Pérez, S | 1 |
| Sierra Salinas, C | 1 |
| Franco, AI | 1 |
| Escobar, L | 1 |
| García, XA | 1 |
| Van Domselaar, M | 3 |
| Achecar, LM | 1 |
| Luján, DR | 1 |
| García, MJ | 1 |
| Calcagno, GP | 1 |
| Bagattini, JC | 1 |
| Forster, TA | 1 |
| Chiarella, M | 1 |
| Cohen, H | 2 |
| Crispino, P | 5 |
| Pica, R | 6 |
| Unim, H | 1 |
| Rivera, M | 4 |
| Cassieri, C | 2 |
| Zippi, M | 2 |
| Paoluzi, P | 7 |
| Vandermeer, B | 1 |
| El-Matary, W | 1 |
| Boyle, M | 1 |
| Ting, A | 1 |
| Cury, DB | 1 |
| Nanda, K | 1 |
| Moss, A | 1 |
| Iwakiri, R | 3 |
| Lee, MN | 1 |
| Kim, MJ | 2 |
| Woo, SY | 1 |
| Choe, YH | 1 |
| Lee, SY | 1 |
| Holt, PR | 1 |
| Moeser, A | 1 |
| Pletz, MW | 1 |
| Hagel, S | 1 |
| Kroegel, C | 1 |
| Gordon, GL | 6 |
| Zakko, S | 4 |
| Murthy, U | 5 |
| Sedghi, S | 5 |
| Pruitt, R | 8 |
| Singer, AAM | 1 |
| Adler, J | 1 |
| Zou, GY | 1 |
| Stitt, L | 1 |
| Mosli, M | 1 |
| Cocco, A | 1 |
| Marcheggiano, A | 4 |
| De Nitto, D | 1 |
| Avallone, EV | 1 |
| Occhigrossi, G | 1 |
| Yamamoto, R | 1 |
| Nagoshi, S | 1 |
| Torii, Y | 1 |
| Katano, Y | 1 |
| Yoshino, J | 1 |
| Inui, K | 1 |
| Wakabayasi, T | 1 |
| Kosaka, T | 1 |
| Ashizuka, S | 1 |
| Inatsu, H | 2 |
| Kita, T | 1 |
| Sherlock, ME | 2 |
| Steinhart, AH | 6 |
| Seow, CH | 3 |
| Bollen, L | 1 |
| Ballet, V | 2 |
| Gils, A | 1 |
| Cavey, T | 1 |
| Peltier, L | 1 |
| Bendavid, C | 1 |
| Bouguen, G | 1 |
| Li, YH | 1 |
| Xiao, HT | 1 |
| Fu, HB | 1 |
| Ho, A | 1 |
| Lin, G | 1 |
| Bian, ZX | 1 |
| Eliadou, E | 1 |
| Day, AS | 1 |
| Thompson-Fawcett, MW | 1 |
| Gearry, RB | 2 |
| Rowbotham, DS | 1 |
| Walmsley, R | 1 |
| Schultz, M | 2 |
| Inns, SJ | 1 |
| Losurdo, G | 1 |
| Iannone, A | 1 |
| Contaldo, A | 1 |
| Ierardi, E | 2 |
| Di Leo, A | 1 |
| Principi, M | 1 |
| Choi, KC | 1 |
| Cho, SW | 2 |
| Kook, SH | 1 |
| Chun, SR | 1 |
| Bhattarai, G | 1 |
| Poudel, SB | 1 |
| Kim, MK | 1 |
| Lee, KY | 1 |
| Lee, JC | 1 |
| Akiyama, N | 1 |
| Yokomura, K | 1 |
| Nozue, T | 1 |
| Matsui, T | 1 |
| Suda, T | 1 |
| Michelini, Z | 1 |
| Baroncelli, S | 1 |
| Fantauzzi, A | 1 |
| Pasquale, C | 1 |
| Galluzzo, CM | 1 |
| Sanchez, M | 1 |
| Gatto, M | 1 |
| Amici, R | 1 |
| Franco, M | 1 |
| d'Ettorre, G | 1 |
| Fimiani, C | 1 |
| Mezzaroma, I | 1 |
| Vullo, V | 1 |
| Merli, M | 1 |
| Palmisano, L | 1 |
| Zhai, H | 1 |
| Liu, A | 1 |
| Huang, W | 1 |
| Feng, S | 1 |
| Wu, J | 2 |
| Yao, Y | 1 |
| Hao, Q | 1 |
| Coenen, S | 1 |
| Weyts, E | 1 |
| Noman, M | 1 |
| Van Emelen, J | 1 |
| Balaha, M | 1 |
| Kandeel, S | 1 |
| Elwan, W | 1 |
| Jiang, Y | 1 |
| Gao, P | 1 |
| Prosberg, MV | 1 |
| Vester-Andersen, MK | 1 |
| Andersen, JT | 1 |
| Vind, I | 1 |
| Bendtsen, F | 1 |
| Zakko, SF | 1 |
| Bernardo, S | 1 |
| Fernandes, SR | 1 |
| Araújo-Correia, L | 1 |
| Prado Mel, E | 1 |
| Gil López, M | 1 |
| Cuffari, C | 2 |
| Korczowski, B | 1 |
| Fyderek, K | 1 |
| Van Heusen, H | 1 |
| Hossack, S | 1 |
| Wan, H | 1 |
| Edwards, AY | 1 |
| Lee, HJ | 2 |
| Kim, TI | 1 |
| Kim, WH | 2 |
| Sun, J | 2 |
| Yuan, Y | 2 |
| Bradette, M | 1 |
| Gabalec, L | 3 |
| Dobru, D | 1 |
| Márquez, J | 1 |
| Magee, E | 1 |
| Solomon, D | 6 |
| Karstensen, JG | 1 |
| Săftoiu, A | 1 |
| Brynskov, J | 3 |
| Hendel, J | 1 |
| Ciocalteu, A | 1 |
| Klausen, P | 1 |
| Klausen, TW | 1 |
| Riis, LB | 1 |
| Vilmann, P | 1 |
| Gasparetto, M | 1 |
| Guariso, G | 1 |
| Pozza, LV | 1 |
| Ross, A | 1 |
| Heuschkel, R | 1 |
| Zilbauer, M | 1 |
| Geisz, M | 1 |
| Ha, C | 1 |
| Martin, CF | 1 |
| Anton, K | 1 |
| Sandler, RS | 1 |
| Knyazev, OV | 2 |
| Konoplyannikov, AG | 2 |
| Boldyreva, ON | 1 |
| Puga, M | 1 |
| Carpio, D | 1 |
| Sampil, M | 1 |
| Zamora, MJ | 1 |
| Fernandez-Salgado, E | 1 |
| Zenda, T | 1 |
| Araki, I | 1 |
| Nakamiya, O | 1 |
| Tokuumi, Y | 1 |
| Shimada, Y | 1 |
| Komai, K | 1 |
| Taniuchi, Y | 1 |
| Hvas, CL | 1 |
| Dige, A | 1 |
| Bendix, M | 1 |
| Wernlund, PG | 1 |
| Christensen, LA | 4 |
| Dahlerup, JF | 1 |
| Agnholt, J | 1 |
| Bhanji, T | 1 |
| Rutka, M | 1 |
| Bálint, A | 1 |
| Farkas, K | 1 |
| Palatka, K | 1 |
| Lakner, L | 1 |
| Miheller, P | 1 |
| Hegede, G | 1 |
| Vincze, Á | 1 |
| Horváth, G | 1 |
| Szabó, A | 1 |
| Nagy, F | 3 |
| Szepes, Z | 1 |
| Gábor, Z | 1 |
| Zsigmond, F | 1 |
| Zsóri, Á | 1 |
| Juhász, M | 1 |
| Csontos, Á | 1 |
| Szűcs, M | 1 |
| Bor, R | 1 |
| Milassin, Á | 1 |
| Fischer, S | 1 |
| Neurath, MF | 2 |
| Atreya, R | 2 |
| Lopez, A | 1 |
| Collet-Fenetrier, B | 1 |
| Belle, A | 1 |
| Aloi, M | 1 |
| Birimberg-Schwartz, L | 1 |
| Buderus, S | 1 |
| Fell, JM | 1 |
| Bronsky, J | 1 |
| Veereman, G | 1 |
| Russell, RK | 2 |
| Abdalla, MI | 1 |
| Herfarth, H | 5 |
| Tziatzios, G | 1 |
| Polymeros, D | 1 |
| Spathis, A | 1 |
| Triantafyllou, M | 1 |
| Gkolfakis, P | 1 |
| Karakitsos, P | 1 |
| Dimitriadis, G | 1 |
| Triantafyllou, K | 1 |
| Timmer, A | 3 |
| Patton, PH | 1 |
| Zhang, ZM | 1 |
| Razik, R | 1 |
| Rumman, A | 1 |
| Bahreini, Z | 1 |
| McGeer, A | 1 |
| Nguyen, GC | 1 |
| Roose, L | 1 |
| D'cunja, J | 1 |
| Biedermann, L | 2 |
| Wiese, DM | 1 |
| Horst, SN | 2 |
| Brown, CT | 1 |
| Allaman, MM | 1 |
| Hodges, ME | 1 |
| Slaughter, JC | 1 |
| Druce, JP | 1 |
| Beaulieu, DB | 1 |
| Schwartz, DA | 1 |
| Wilson, KT | 1 |
| Coburn, LA | 1 |
| Grimstad, T | 1 |
| Norheim, KB | 1 |
| Kvaløy, JT | 1 |
| Isaksen, K | 1 |
| Leitao, K | 1 |
| Carlsen, A | 1 |
| Karlsen, LN | 1 |
| Aabakken, L | 1 |
| Omdal, R | 1 |
| Zhao, HM | 1 |
| Xu, R | 1 |
| Huang, XY | 1 |
| Cheng, SM | 1 |
| Huang, MF | 1 |
| Yue, HY | 1 |
| Lu, AP | 1 |
| Liu, DY | 1 |
| de Lima-Karagiannis, A | 1 |
| Zelinkova-Detkova, Z | 1 |
| van der Woude, CJ | 1 |
| Scaldaferri, F | 2 |
| Gerardi, V | 1 |
| Mangiola, F | 1 |
| Lopetuso, LR | 1 |
| Pizzoferrato, M | 1 |
| Petito, V | 1 |
| Papa, A | 2 |
| Stojanovic, J | 1 |
| Poscia, A | 1 |
| Cammarota, G | 1 |
| Gasbarrini, A | 3 |
| Rönnblom, A | 1 |
| Holmström, T | 1 |
| Tanghöj, H | 1 |
| Karlbom, U | 1 |
| Thörn, M | 1 |
| Sjöberg, D | 1 |
| Maxwell, EC | 1 |
| Grossman, AB | 1 |
| Shi, HY | 1 |
| Li, MK | 1 |
| Ng, CK | 1 |
| Hui, YT | 1 |
| Tsang, SW | 1 |
| Chan, YK | 1 |
| Loo, CK | 1 |
| Lee, M | 1 |
| Chan, V | 1 |
| Hung, IF | 1 |
| Ho, J | 2 |
| Lao, WC | 1 |
| Wong, MT | 1 |
| Shan, EH | 1 |
| Lam, BC | 1 |
| Tong, RW | 1 |
| Mak, LY | 1 |
| Wong, SH | 1 |
| Chan, FK | 1 |
| Sung, JJ | 2 |
| Matthis, AL | 1 |
| Zhang, B | 1 |
| Yacyshyn, BR | 1 |
| Aihara, E | 1 |
| Montrose, MH | 1 |
| Bosworth, BP | 1 |
| Harper, JR | 1 |
| Sameshima, S | 1 |
| Koketsu, S | 1 |
| Okuyama, T | 1 |
| Kubota, Y | 1 |
| Ono, Y | 1 |
| Noie, T | 1 |
| Oya, M | 1 |
| Cheddani, H | 1 |
| Dauchet, L | 1 |
| Charpentier, C | 1 |
| Marie Bouvier, A | 1 |
| Dupas, JL | 1 |
| Pariente, B | 1 |
| Savoye, G | 2 |
| Izzo, R | 1 |
| Figliuzzi, MM | 1 |
| Monteleone, G | 3 |
| Li, N | 1 |
| Ren, Y | 1 |
| Ma, T | 1 |
| You, S | 1 |
| Wada, S | 1 |
| Kumagai, H | 1 |
| Ito, T | 2 |
| Miyauchi, A | 1 |
| Sakamoto, S | 1 |
| Imagawa, T | 1 |
| Tulyeu, J | 1 |
| Yamagata, T | 1 |
| Ali, HS | 1 |
| Hanafy, AF | 1 |
| El Achy, SN | 1 |
| Jegadeesan, R | 1 |
| Navaneethan, U | 2 |
| Gutierrez, NG | 1 |
| Venkatesh, PG | 2 |
| Hammel, JP | 1 |
| Sanaka, MR | 1 |
| Shen, B | 4 |
| Mutneja, HR | 1 |
| Arora, S | 3 |
| Vij, A | 1 |
| Horton, N | 1 |
| Wu, X | 1 |
| Philpott, J | 1 |
| Garber, A | 2 |
| Achkar, JP | 5 |
| Brzezinski, A | 2 |
| Lashner, BA | 6 |
| Palumbo, VD | 1 |
| Romeo, M | 2 |
| Marino Gammazza, A | 2 |
| Carini, F | 1 |
| Damiani, P | 3 |
| Damiano, G | 1 |
| Buscemi, S | 1 |
| Lo Monte, AI | 1 |
| Gerges-Geagea, A | 1 |
| Jurjus, A | 1 |
| Tomasello, G | 3 |
| Zhao, WZ | 1 |
| Diao, N | 1 |
| Gu, YX | 1 |
| Zhu, XT | 1 |
| Li, MS | 1 |
| Seth, AK | 1 |
| Rawal, P | 1 |
| Bagga, R | 1 |
| Jain, P | 1 |
| Latushko, A | 1 |
| Ghazi, LJ | 1 |
| Cappello, M | 2 |
| Licata, A | 1 |
| Calvaruso, V | 1 |
| Bravatà, I | 1 |
| Aiello, A | 1 |
| Torres, D | 1 |
| Della Corte, V | 1 |
| Tuttolomondo, A | 1 |
| Perticone, M | 1 |
| Licata, G | 1 |
| Craxì, A | 1 |
| Cammà, C | 1 |
| Subramanian, S | 1 |
| Ekbom, A | 2 |
| Rhodes, JM | 3 |
| Viganò, C | 1 |
| Meucci, G | 3 |
| Manguso, F | 3 |
| Bennato, R | 2 |
| Lombardi, G | 2 |
| Riccio, E | 1 |
| Costantino, G | 1 |
| Fries, W | 2 |
| Kaur, R | 1 |
| Aktaş Karabay, E | 1 |
| Aksu Cerman, A | 1 |
| Kıvanc Altunay, İ | 1 |
| Yalçın, Ö | 1 |
| Ungaro, R | 1 |
| Mehandru, S | 1 |
| Allen, PB | 2 |
| Sonnenberg, E | 1 |
| Nantes, O | 1 |
| Leo, E | 1 |
| Rojas-Feria, M | 1 |
| Jauregui-Amezaga, A | 1 |
| García-López, S | 1 |
| Huguet, JM | 1 |
| Arguelles-Arias, F | 1 |
| Aicart, M | 1 |
| Gómez-García, M | 1 |
| Muñoz, F | 1 |
| Bujanda, L | 1 |
| Cortés, X | 1 |
| Muñoz, C | 2 |
| González-Lama, Y | 1 |
| Hinojosa, J | 3 |
| Vázquez, JM | 1 |
| Martinez-Montiel, MP | 1 |
| Rodríguez, GE | 1 |
| Pajares, R | 1 |
| García-Sepulcre, MF | 1 |
| Hernández-Martínez, A | 1 |
| Pérez-Calle, JL | 3 |
| Busquets, D | 2 |
| Ramos, L | 1 |
| Barrio, J | 1 |
| Roncedo, O | 1 |
| Calvet, X | 1 |
| Hervías, D | 1 |
| Domínguez-Antonaya, M | 1 |
| Alcaín, G | 1 |
| Sicilia, B | 1 |
| Dueñas, C | 1 |
| Gutiérrez, A | 1 |
| Lorente-Poyatos, R | 1 |
| Domínguez, M | 1 |
| Khorrami, S | 1 |
| Taxonera, C | 1 |
| Rodríguez-Pérez, A | 1 |
| Ponferrada, A | 1 |
| Arias-Rivera, ML | 1 |
| Merino, O | 1 |
| Castro, E | 1 |
| Marrero, JM | 1 |
| Martín-Arranz, M | 1 |
| Botella, B | 1 |
| Fernández-Salazar, L | 1 |
| Monfort, D | 1 |
| Opio, V | 1 |
| García-Herola, A | 1 |
| Menacho, M | 1 |
| Ramírez-de la Piscina, P | 1 |
| Ceballos, D | 1 |
| Almela, P | 1 |
| Navarro-Llavat, M | 1 |
| Robles-Alonso, V | 1 |
| Vega-López, AB | 1 |
| Moraleja, I | 1 |
| Novella, MT | 1 |
| Castaño-Milla, C | 1 |
| Sánchez-Torres, A | 1 |
| Rodríguez, C | 1 |
| Castro, L | 1 |
| Garrido, E | 2 |
| Monteserín, L | 1 |
| Jiménez, M | 1 |
| Molina, G | 1 |
| Reyes, N | 1 |
| Hernando, M | 1 |
| Sierra, M | 1 |
| Vaquero, L | 1 |
| Algaba, A | 1 |
| Guerra, I | 1 |
| García García de Paredes, A | 1 |
| Hernández Tejero, M | 1 |
| Ferre, C | 1 |
| Bonillo, D | 1 |
| Aguilera, L | 1 |
| López-Sanromán, A | 1 |
| Arai, K | 1 |
| Hosoi, K | 1 |
| Funayama, R | 1 |
| Jia, J | 1 |
| Lu, Y | 1 |
| Dahl, JU | 1 |
| Gray, MJ | 1 |
| Bazopoulou, D | 1 |
| Beaufay, F | 1 |
| Lempart, J | 1 |
| Koenigsknecht, MJ | 1 |
| Baker, JR | 1 |
| Hasler, WL | 1 |
| Young, VB | 1 |
| Sun, D | 1 |
| Jakob, U | 1 |
| Moussata, D | 1 |
| Cazals-Hatem, D | 1 |
| Treton, X | 1 |
| Laharie, D | 1 |
| Reimund, JM | 1 |
| Bertheau, P | 1 |
| Bourreille, A | 1 |
| Lavergne-Slove, A | 1 |
| Brixi, H | 1 |
| Branche, J | 1 |
| Gornet, JM | 1 |
| Stefanescu, C | 1 |
| Moreau, J | 1 |
| Pelletier, AL | 1 |
| Seksik, P | 2 |
| Simon, M | 1 |
| Fléjou, JF | 1 |
| Charlois, AL | 1 |
| Bouhnik, Y | 1 |
| Berger, F | 1 |
| Ong, SS | 1 |
| Walter, SD | 1 |
| Vora, GK | 1 |
| Daluvoy, M | 1 |
| Proia, AD | 1 |
| Mruthyunjaya, P | 1 |
| Lee, BI | 2 |
| Yoon, YS | 1 |
| Lee, H | 2 |
| Wargo, JJ | 1 |
| Adams, M | 1 |
| Trevino, J | 1 |
| Tang, H | 1 |
| Xiang, D | 1 |
| Mao, J | 1 |
| Tan, X | 1 |
| Rassokhina, OA | 1 |
| Dorofeyeva, AA | 1 |
| Markovic, S | 1 |
| Tarabar, D | 1 |
| Dijkstra, A | 1 |
| Touw, DJ | 1 |
| van Rheenen, PF | 1 |
| Sato, H | 2 |
| Umemura, K | 1 |
| Marti Aguado, D | 1 |
| Bosca Watts, MM | 1 |
| Barrett-Lee, P | 1 |
| Casbard, A | 1 |
| Hurt, C | 1 |
| Murray, N | 1 |
| Dai, YT | 1 |
| Heath, JL | 1 |
| Heath, RD | 1 |
| Tamboli, C | 1 |
| Johnson, L | 1 |
| Wilson, AS | 1 |
| Chervinskiy, S | 1 |
| Bell, MC | 1 |
| Kennedy, JL | 1 |
| Kamm, MA | 14 |
| Miller, V | 1 |
| Whorwell, PJ | 1 |
| Nakao, S | 1 |
| Suzuki, A | 1 |
| Inamori, M | 3 |
| Iida, H | 1 |
| Endo, H | 3 |
| Akiyama, T | 1 |
| Yoneda, K | 1 |
| Fujita, K | 2 |
| Takahashi, H | 4 |
| Yoneda, M | 3 |
| Abe, Y | 1 |
| Kobayashi, N | 1 |
| Kubota, K | 3 |
| Saito, S | 2 |
| Nakajima, A | 3 |
| Assisi, RF | 1 |
| Tozzi, A | 1 |
| Biagini, MR | 1 |
| Rastelli, C | 1 |
| Galli, A | 1 |
| Baldi, D | 1 |
| Milani, S | 1 |
| Atay, O | 1 |
| Radhakrishnan, K | 1 |
| Arruda, J | 1 |
| Wyllie, R | 2 |
| Lees, K | 3 |
| Joseph, R | 3 |
| Rahimi, R | 1 |
| Nikfar, S | 1 |
| Rezaie, A | 1 |
| Abdollahi, M | 1 |
| Latiano, A | 1 |
| Rossi, L | 1 |
| Magnani, M | 1 |
| Palmieri, O | 1 |
| Dallapiccola, B | 1 |
| Serafini, S | 1 |
| Damonte, G | 1 |
| De Santo, E | 1 |
| Andriulli, A | 1 |
| Hirotani, Y | 1 |
| Mikajiri, K | 1 |
| Ikeda, K | 1 |
| Myotoku, M | 1 |
| Kurokawa, N | 1 |
| Yen, EF | 1 |
| Kane, SV | 9 |
| Ladabaum, U | 2 |
| Tripodi Cutrì, F | 1 |
| Salerno, R | 1 |
| Lo Schiavo, A | 1 |
| Gravina, AG | 1 |
| Ruocco, E | 1 |
| Buckland, A | 1 |
| Bodger, K | 2 |
| Irvine, EJ | 5 |
| Yeh, CH | 2 |
| Ramsey, D | 3 |
| Stirling, AL | 1 |
| Henker, J | 1 |
| Müller, S | 1 |
| Laass, MW | 1 |
| Schreiner, A | 1 |
| Schulze, J | 2 |
| Porro, GB | 1 |
| Burakoff, R | 1 |
| MacDermott, RP | 3 |
| Green, JA | 1 |
| Ashley, CC | 1 |
| Bresci, G | 6 |
| Parisi, G | 4 |
| Mazzoni, A | 1 |
| Scatena, F | 1 |
| Capria, A | 4 |
| Gorelov, IA | 1 |
| Batovsky, M | 4 |
| Kykal, J | 1 |
| Boehm, S | 1 |
| Mayberry, H | 1 |
| Moshkovska, T | 6 |
| Mayberry, JF | 5 |
| Croog, V | 1 |
| Harpaz, N | 1 |
| Hossain, S | 1 |
| Kornbluth, A | 3 |
| Bodian, C | 2 |
| Itzkowitz, S | 1 |
| Matsuda, R | 1 |
| Koide, T | 1 |
| Tokoro, C | 1 |
| Godai, T | 1 |
| Morohashi, T | 1 |
| Fujita, Y | 1 |
| Takahashi, D | 1 |
| Kawana, I | 1 |
| Umemura, S | 1 |
| Kaulback, K | 1 |
| Schoenfield, PS | 1 |
| Taniguchi, T | 1 |
| Maejima, H | 1 |
| Saito, N | 1 |
| Katsuoka, K | 1 |
| Haruki, S | 1 |
| Rangwalla, SC | 1 |
| Moran, G | 1 |
| Dillon, J | 1 |
| Green, J | 1 |
| Patil, SA | 1 |
| Park, BJ | 1 |
| Hwang, JC | 1 |
| Sin, SJ | 1 |
| Chung, JY | 1 |
| Son, CN | 1 |
| Lee, HL | 1 |
| Joo, YW | 1 |
| Lee, OY | 1 |
| Yoon, BC | 1 |
| Choi, HS | 1 |
| Hahm, JS | 1 |
| Kounis, GN | 2 |
| Kouni, SA | 2 |
| Hahalis, G | 1 |
| Kounis, NG | 2 |
| Cortot, A | 1 |
| Degoutte, E | 1 |
| Delette, O | 1 |
| Meunier, P | 1 |
| Tan, G | 2 |
| Cazals, JB | 1 |
| Beorchia, S | 1 |
| Grunberg, B | 1 |
| Leprince, E | 1 |
| Forestier, S | 1 |
| Idier, I | 1 |
| Lémann, M | 1 |
| Prieto, G | 1 |
| Pérez-Moneo, B | 1 |
| Molina, M | 1 |
| Ramos, E | 1 |
| Sarría, J | 1 |
| Larrauri, J | 1 |
| Tovar, JA | 1 |
| Chiladakis, JA | 1 |
| Bosque López, MJ | 1 |
| Garrido Durán, C | 1 |
| Ginard Vicens, D | 1 |
| Munar Vila, MA | 1 |
| Vanrell Garau, M | 1 |
| Mariño Méndez, Z | 1 |
| Gayà Cantallops, J | 1 |
| Bakulin, IG | 2 |
| Stanke, DA | 2 |
| Law, JK | 1 |
| Salh, B | 1 |
| Yoshida, EM | 1 |
| Thorpe, MP | 2 |
| Ehrenpreis, ED | 3 |
| Putt, KS | 2 |
| Hannon, B | 3 |
| Donnellan, F | 1 |
| Cullen, G | 1 |
| Murray, FE | 2 |
| Barr, A | 1 |
| Jeejeebhoy, KN | 1 |
| Actis, GC | 4 |
| Rizzetto, M | 3 |
| Ayoubi, M | 1 |
| Leone, N | 1 |
| Tappero, G | 1 |
| Pazienza, P | 2 |
| Rosina, F | 2 |
| Belousova, EA | 2 |
| Golovenko, OV | 1 |
| Mikhailova, TL | 4 |
| Adamek, H | 1 |
| Mross, M | 1 |
| Vinter-Jensen, L | 1 |
| Börner, N | 1 |
| Silvennoinen, J | 2 |
| Pool, MO | 1 |
| Stijnen, T | 1 |
| Dietel, P | 1 |
| Klugmann, T | 1 |
| Bhatt, A | 1 |
| Veerman, H | 1 |
| Caponi, A | 1 |
| Roda, E | 1 |
| Martín, M | 1 |
| Santamarta, E | 1 |
| de la Iglesia, JM | 1 |
| Saiz, A | 1 |
| Bousseaden, A | 1 |
| Ajana, FZ | 1 |
| Essamri, W | 1 |
| Benelbarhdadi, I | 1 |
| Afifi, R | 1 |
| Benazzouz, M | 1 |
| Essaid, A | 1 |
| Rubenstein, JH | 1 |
| Jeter, JM | 1 |
| Scherl, EJ | 1 |
| Lamet, M | 1 |
| Shaw, A | 2 |
| Mareya, S | 1 |
| McLaughlin, SD | 1 |
| Clark, SK | 1 |
| Bell, AJ | 1 |
| Tekkis, PP | 1 |
| Ciclitira, PJ | 1 |
| Nicholls, RJ | 1 |
| Huang, XF | 1 |
| Elkjaer, M | 4 |
| Lynge, E | 2 |
| Zimmerer, T | 1 |
| Siegmund, SV | 1 |
| Singer, MV | 1 |
| Goel, A | 1 |
| Mittal, A | 1 |
| Evstatiev, R | 1 |
| Nemeth, M | 1 |
| Stolte, M | 8 |
| Boland, CR | 1 |
| Kane, S | 11 |
| Shimizu, T | 1 |
| Hayashi, M | 1 |
| Shimizu, N | 1 |
| Kinebuchi, S | 1 |
| Toyama, J | 1 |
| Pohl, JF | 1 |
| Attard, TM | 1 |
| Pieniaszek, HJ | 1 |
| Walker, K | 1 |
| Tabata, N | 1 |
| Sugimoto, K | 1 |
| Ueda, S | 1 |
| Sakata, N | 1 |
| Okada, M | 2 |
| Miyake, T | 1 |
| Shinohara, T | 2 |
| Yagi, M | 1 |
| Satou, T | 1 |
| Takemura, T | 1 |
| Prantera, C | 6 |
| Kohn, A | 1 |
| Caprilli, R | 8 |
| Pallone, F | 5 |
| Savarino, V | 1 |
| Ardia, A | 1 |
| Bellinvia, S | 1 |
| Viazis, N | 1 |
| Vlachogiannakos, J | 1 |
| Georgiou, O | 1 |
| Rodias, M | 1 |
| Georgiadis, D | 1 |
| Papastamopoulos, V | 1 |
| Baraboutis, IG | 1 |
| Karamanolis, DG | 2 |
| Skoutelis, A | 1 |
| Dehghani, SM | 1 |
| Eshraghian, A | 1 |
| Bahador, A | 1 |
| Kakaei, F | 1 |
| Geramizadeh, B | 1 |
| Malek-Hosseini, SA | 1 |
| Furuta, S | 1 |
| Sasaki, H | 2 |
| Takano, Y | 3 |
| Wiggins, JB | 1 |
| Rajapakse, R | 1 |
| Fujiyama, Y | 3 |
| Oshitani, N | 1 |
| Oga, T | 1 |
| Nonomura, K | 1 |
| Matsuoka, T | 1 |
| Esaki, Y | 1 |
| Murayama, T | 1 |
| Teramukai, S | 1 |
| Chiba, T | 2 |
| Narumiya, S | 1 |
| Deng, X | 1 |
| Tolstanova, G | 1 |
| Khomenko, T | 1 |
| Tarnawski, A | 1 |
| Szabo, S | 1 |
| Sandor, Z | 1 |
| Rizzi, M | 1 |
| Regula, J | 1 |
| Jojic, N | 1 |
| Lukas, M | 5 |
| Messer, CA | 1 |
| Stone, MA | 2 |
| Clatworthy, J | 1 |
| Smith, RM | 2 |
| Bankart, J | 2 |
| Baker, R | 3 |
| Horne, R | 1 |
| Poole, CD | 1 |
| Currie, CJ | 1 |
| Lee, G | 2 |
| Grimm, GR | 1 |
| Dirisina, R | 1 |
| Goretsky, T | 1 |
| Cheresh, P | 1 |
| Blatner, NR | 1 |
| Khazaie, K | 1 |
| Sierra Ausín, M | 1 |
| Rascarachi, G | 1 |
| Díez Rodríguez, R | 1 |
| Arias Rodríguez, L | 1 |
| Del Pozo Maroto, E | 1 |
| Muñoz Núñez, F | 1 |
| Parakkal, D | 1 |
| Aida, Y | 1 |
| Iida, T | 3 |
| Takeuchi, K | 4 |
| Arai, O | 1 |
| Watanabe, F | 3 |
| Abe, J | 1 |
| Oohata, A | 1 |
| Ikeya, K | 1 |
| Kageoka, M | 1 |
| Miwa, I | 1 |
| Yoshirou, S | 1 |
| Hosoda, Y | 2 |
| Kubota, T | 1 |
| Da-Silva, N | 1 |
| Arasaradnam, R | 1 |
| Getliffe, K | 1 |
| Sung, E | 1 |
| Oo, Y | 1 |
| Nwokolo, C | 1 |
| Korzenik, J | 1 |
| Lashner, B | 1 |
| Leighton, JA | 1 |
| Mahadevan, U | 1 |
| Marion, JF | 1 |
| Safdi, M | 7 |
| Sninsky, CA | 4 |
| Patel, RM | 1 |
| Friedenberg, KA | 1 |
| Dunnmon, P | 1 |
| Cook, PF | 1 |
| Emiliozzi, S | 1 |
| El-Hajj, D | 1 |
| McCabe, MM | 1 |
| Pitchumoni, CS | 1 |
| Rubin, A | 1 |
| Das, K | 1 |
| Pedersen, G | 1 |
| Raithel, M | 2 |
| Nägel, A | 1 |
| Zopf, Y | 1 |
| deRossi, T | 1 |
| Stengel, Ch | 1 |
| Hagel, A | 1 |
| Kressel, J | 1 |
| Hahn, EG | 2 |
| Konturek, P | 1 |
| Dubey, R | 2 |
| Omrey, P | 1 |
| Vyas, SP | 1 |
| Jain, SK | 1 |
| Thabane, M | 2 |
| Newman, JR | 2 |
| Anand, A | 2 |
| Länger, F | 1 |
| Rademacher, J | 1 |
| Brereton, N | 1 |
| Yan, S | 1 |
| Akehurst, R | 1 |
| Iacucci, M | 1 |
| de Silva, S | 1 |
| Ghosh, S | 5 |
| Plamondon, S | 1 |
| Hart, AL | 1 |
| Al-Hassi, HO | 1 |
| Guenther, T | 1 |
| Stagg, AJ | 1 |
| Knight, SC | 1 |
| Ohtsuka, T | 1 |
| Romano, C | 1 |
| Famiani, A | 1 |
| Comito, D | 1 |
| Rossi, P | 1 |
| Raffa, V | 1 |
| López-Serrano, P | 1 |
| Fernández-Rodríguez, C | 1 |
| Andrejic, J | 1 |
| Rojas-Balcazar, J | 1 |
| Dennis, M | 1 |
| Berkelhammer, C | 1 |
| Lamsiah, T | 1 |
| Moudden, K | 1 |
| Baaj, M | 1 |
| Hadri, L | 1 |
| Bischoff, A | 1 |
| Andus, T | 2 |
| Müser, M | 1 |
| Baranovsky, A | 1 |
| Zvyagintseva, TD | 1 |
| Lozynskyy, YS | 1 |
| Cascorbi, I | 2 |
| Dilger, K | 5 |
| Osadchuk, AM | 1 |
| Osadchuk, MA | 1 |
| Varshosaz, J | 1 |
| Emami, J | 1 |
| Ahmadi, F | 1 |
| Tavakoli, N | 1 |
| Minaiyan, M | 1 |
| Fassihi, A | 1 |
| Mahzouni, P | 1 |
| Dorkoosh, F | 1 |
| Sposato, B | 1 |
| Allegri, MP | 1 |
| Riccardi, MP | 1 |
| Chigiotti, S | 1 |
| Nencioni, C | 1 |
| Ricciardi, B | 1 |
| Carli, T | 1 |
| Cresti, A | 1 |
| Perari, MG | 1 |
| Migliorini, MG | 1 |
| Toti, M | 1 |
| Hartmann, F | 6 |
| Kao, J | 1 |
| Kwok, K | 1 |
| Lazebnik, LB | 2 |
| Ruchkina, IN | 2 |
| Rogozina, VA | 2 |
| Konopliannikov, AG | 1 |
| Jain, N | 1 |
| Petruff, C | 1 |
| Bandyopadhyay, T | 1 |
| Brandimarte, G | 4 |
| Giglio, A | 1 |
| Giorgetti, GM | 3 |
| Forti, G | 2 |
| Morini, S | 1 |
| Hassan, C | 1 |
| Pistoia, MA | 1 |
| Modeo, ME | 2 |
| Rodino', S | 1 |
| D'Amico, T | 1 |
| Sebkova, L | 1 |
| Sacca', N | 1 |
| Di Giulio, E | 2 |
| Luzza, F | 1 |
| Imeneo, M | 1 |
| Larussa, T | 1 |
| Di Rosa, S | 1 |
| Murphy, SJ | 1 |
| Mayer, L | 1 |
| Abreu, MT | 1 |
| Hatemi, I | 1 |
| Goksu, A | 1 |
| Dobrucali, A | 1 |
| Lawlor, G | 1 |
| Ahmed, A | 1 |
| Bernick, SJ | 1 |
| Djurić, M | 1 |
| Povazan, D | 1 |
| Secen, S | 1 |
| Jović, J | 1 |
| Kitayama, A | 1 |
| Misago, N | 1 |
| Okawa, T | 1 |
| Narisawa, Y | 1 |
| Michetti, P | 4 |
| Koseoglu, Z | 1 |
| Satar, S | 1 |
| Kara, B | 1 |
| Sebe, A | 1 |
| Kosenli, O | 1 |
| Kwak, JW | 1 |
| Lee, KM | 2 |
| Chung, WC | 1 |
| Paik, CN | 1 |
| Chang, UI | 1 |
| Kim, JD | 1 |
| Yang, JM | 1 |
| Heidt, J | 1 |
| Ooms, EC | 1 |
| van der Werf, SD | 1 |
| Groeneveld, JH | 1 |
| Barollo, M | 1 |
| Scarpa, M | 1 |
| Grillo, AR | 1 |
| Brun, P | 1 |
| Vettorato, MG | 1 |
| Castagliuolo, I | 1 |
| De Cruz, P | 1 |
| Desmond, PV | 1 |
| Noh, CH | 1 |
| Cheung, DY | 1 |
| Kim, TH | 1 |
| Jun, EJ | 1 |
| Lee, IK | 1 |
| Kim, JI | 1 |
| Cho, SH | 1 |
| Han, JY | 1 |
| Spénard, J | 3 |
| Shbaklo, H | 1 |
| Giguere, M | 1 |
| Harbaum, L | 1 |
| Siebert, F | 1 |
| Langner, C | 1 |
| Oustamanolakis, P | 1 |
| Fowler, BT | 1 |
| Gupta, T | 1 |
| Bilal, M | 1 |
| Hiwatashi, N | 4 |
| Munakata, A | 3 |
| Merchant, K | 2 |
| Shin, DH | 1 |
| Lee, KH | 1 |
| Kim, CH | 1 |
| Kim, KH | 2 |
| Chang, DK | 1 |
| Olmstead, J | 1 |
| Shuhaibar, M | 1 |
| Bailey, Y | 1 |
| Scherfig, H | 1 |
| Laugesen, B | 1 |
| O'Morain, C | 1 |
| Tai, WP | 1 |
| Hu, PJ | 1 |
| Lin, XC | 1 |
| Targan, SR | 5 |
| Xu, C | 1 |
| Byers, VS | 1 |
| Pimpo, MT | 2 |
| Galletti, B | 3 |
| Palumbo, G | 3 |
| Gentile, P | 1 |
| Chaudhary, N | 1 |
| Tukey, M | 1 |
| Junior, J | 1 |
| Cury, D | 1 |
| Falchuk, KR | 2 |
| López San Román, A | 4 |
| McGrane, J | 1 |
| Paravasthu, M | 1 |
| Candlish, W | 1 |
| Gravil, J | 1 |
| Lozynsky, YS | 1 |
| Zakharash, Y | 1 |
| Kull, K | 1 |
| Vcev, A | 1 |
| Faszczyk, M | 2 |
| Yoshida, A | 1 |
| Ueno, F | 1 |
| Yoshimatsu, E | 1 |
| Matsui, K | 1 |
| Fujikawa, T | 1 |
| Takatsuka, K | 1 |
| Iwabuchi, S | 1 |
| Benchimol, EI | 1 |
| Langer, JC | 1 |
| Shamberger, R | 1 |
| Cucchiara, S | 1 |
| Escher, JC | 1 |
| Wilson, DC | 1 |
| Lerer, T | 3 |
| Stephens, M | 1 |
| Kay, M | 2 |
| Saeed, S | 2 |
| Crandall, W | 1 |
| Michail, S | 1 |
| Grossman, A | 2 |
| Samson, C | 1 |
| Loew, BJ | 1 |
| Yang, LP | 1 |
| McCormack, PL | 2 |
| Qualtrough, D | 1 |
| Smallwood, K | 1 |
| Littlejohns, D | 1 |
| Pignatelli, M | 1 |
| Jackson, EL | 1 |
| Harris, MS | 1 |
| Orchard, TR | 1 |
| van der Geest, SA | 1 |
| Nugent, Z | 1 |
| Blanchard, JF | 1 |
| Khan, KJ | 4 |
| Talley, NJ | 1 |
| Moayyedi, P | 4 |
| Kisiel, JB | 1 |
| Harmsen, WS | 2 |
| Zinsmeister, AR | 4 |
| Rodolico, V | 2 |
| Zerilli, M | 2 |
| Martorana, A | 2 |
| Bucchieri, F | 1 |
| Pitruzzella, A | 1 |
| David, S | 1 |
| Rappa, F | 2 |
| Zummo, G | 2 |
| Accomando, S | 1 |
| Rizzo, M | 1 |
| de Macario, EC | 1 |
| Macario, AJ | 2 |
| Cappello, F | 2 |
| Oliveira, L | 1 |
| Gross, V | 5 |
| Bunganic, I | 1 |
| Tulassay, Z | 3 |
| Hattar, LN | 1 |
| Abraham, BP | 1 |
| Malaty, HM | 1 |
| Smith, EO | 1 |
| Ferry, GD | 2 |
| Zhou, N | 1 |
| Chen, WX | 1 |
| Chen, SH | 1 |
| Xu, CF | 1 |
| Li, YM | 1 |
| Burger, D | 1 |
| Levy, LC | 1 |
| Wakabayashi, M | 1 |
| Fujimoto, N | 1 |
| Uenishi, T | 1 |
| Danno, K | 1 |
| Bello, C | 1 |
| Belaiche, J | 1 |
| Reenaers, C | 1 |
| Blumenstein, I | 1 |
| Herrmann, E | 1 |
| Filmann, N | 1 |
| Zosel, C | 1 |
| Tacke, W | 1 |
| Bock, H | 2 |
| Zeuzem, S | 1 |
| Schröder, O | 1 |
| Zelante, A | 1 |
| Borgoni, R | 1 |
| Galuppi, C | 1 |
| Cifalà, V | 1 |
| Melchiorri, L | 1 |
| Gullini, S | 2 |
| Baricordi, O | 1 |
| Rizzo, R | 1 |
| Carrascosa, MF | 1 |
| Salcines-Caviedes, JR | 1 |
| Millán, MV | 1 |
| Martín, MC | 1 |
| Murguiondo, MZ | 1 |
| Gutiérrez, PG | 1 |
| Lavín, AC | 1 |
| Rivero, JG | 1 |
| Martin, D | 1 |
| Handler, T | 1 |
| McDermott, J | 1 |
| Perez, F | 1 |
| Tsai, R | 1 |
| Honkanen, A | 1 |
| Bass, D | 1 |
| Prenzler, A | 1 |
| Mittendorf, T | 1 |
| von der Schulenburg, JM | 1 |
| Jakobsen, C | 1 |
| Paerregaard, A | 1 |
| Wewer, V | 1 |
| Kevans, D | 1 |
| Greene, J | 1 |
| Galvin, L | 1 |
| Morgan, R | 1 |
| Scherer, M | 1 |
| Hardt, J | 1 |
| Blozik, E | 1 |
| Preiss, JC | 1 |
| Hüppe, A | 1 |
| Raspe, H | 1 |
| Samnaliev, M | 1 |
| Lightdale, JR | 1 |
| Giorgetti, G | 1 |
| Aiello, F | 1 |
| Fasoli, R | 1 |
| Gullotta, R | 1 |
| Colombo, E | 2 |
| Terpin, M | 1 |
| Jamal, MM | 1 |
| Dolin, B | 1 |
| Palmen, M | 3 |
| Machida, H | 1 |
| Hatakeyama, N | 1 |
| Inayama, M | 1 |
| Hosokawa, E | 1 |
| Ogushi, F | 1 |
| Hanauer, S | 6 |
| Edeline, M | 1 |
| Scott Harris, M | 1 |
| Sumner, M | 1 |
| Jenkins, M | 1 |
| Dai, SX | 1 |
| Feng, YL | 1 |
| Liu, HB | 1 |
| Chojnacki, C | 1 |
| Wisniewska-Jarosinska, M | 1 |
| Walecka-Kapica, E | 1 |
| Klupinska, G | 1 |
| Jaworek, J | 1 |
| Chojnacki, J | 1 |
| Moerike, M | 1 |
| Gong, Y | 1 |
| Zha, Q | 1 |
| Lu, A | 1 |
| Lin, Y | 1 |
| Meier, J | 1 |
| Sturm, A | 1 |
| Leifeld, L | 2 |
| Pfützer, R | 2 |
| Morgenstern, J | 2 |
| Pan, A | 1 |
| Schlup, M | 1 |
| Lubcke, R | 1 |
| Funato, M | 1 |
| Fukao, T | 1 |
| Sasai, H | 1 |
| Hori, T | 2 |
| Terazawa, D | 1 |
| Ozeki, M | 1 |
| Orii, K | 1 |
| Kaneko, H | 1 |
| Kondo, N | 1 |
| Liu, M | 1 |
| Lii, S | 1 |
| Gao, C | 1 |
| Xinmei, Z | 1 |
| Yan, C | 1 |
| Higurashi, T | 1 |
| Hosono, K | 1 |
| Sakai, E | 1 |
| Uchiyama, S | 1 |
| Kojima, T | 1 |
| Kawana, K | 1 |
| Natsumeda, Y | 1 |
| Nagase, H | 1 |
| Pérez-Pampín, E | 1 |
| Campos-Franco, J | 1 |
| Losada-Ares, L | 1 |
| Biancheri, P | 1 |
| Rovedatti, L | 1 |
| Macdonald, TT | 2 |
| Corazza, GR | 1 |
| Rosen, D | 1 |
| Bao, R | 1 |
| Tomaino, J | 1 |
| Ceballos, C | 1 |
| Russell, GJ | 1 |
| Benkov, KJ | 1 |
| Swinburn, P | 1 |
| Dewilde, S | 1 |
| Lloyd, A | 1 |
| Zabana, Y | 2 |
| Swarbrick, ET | 4 |
| Dhar, A | 1 |
| Kapur, KC | 2 |
| Williet, N | 1 |
| Pillot, C | 1 |
| Oussalah, A | 1 |
| Billioud, V | 1 |
| Chevaux, JB | 1 |
| Bresler, L | 1 |
| Bigard, MA | 1 |
| Gueant, JL | 1 |
| Brooks, AJ | 1 |
| Lobo, AJ | 4 |
| Shindoh, Y | 1 |
| Horaguchi, R | 1 |
| Hayashi, K | 2 |
| Suda, Y | 1 |
| Iijima, H | 1 |
| Shindoh, C | 1 |
| Gifford, A | 1 |
| Naves, JE | 1 |
| Lorenzo-Zúñiga, V | 1 |
| Marín, L | 1 |
| Oller, B | 1 |
| Moreno, V | 1 |
| Boix, J | 1 |
| Munding, J | 1 |
| Ziebarth, W | 1 |
| Pox, CP | 1 |
| Ladigan, S | 1 |
| Reiser, M | 1 |
| Hüppe, D | 3 |
| Brand, L | 1 |
| Schmiegel, W | 1 |
| Tannapfel, A | 1 |
| Reinacher-Schick, AC | 1 |
| Sciumé, C | 1 |
| Cicero, G | 1 |
| De Luca, R | 1 |
| Accardo, FM | 1 |
| Farina, F | 1 |
| Bonaventura, G | 1 |
| Modica, G | 1 |
| Conway de Macario, E | 1 |
| Velciov, S | 1 |
| Gluhovschi, G | 1 |
| Sporea, I | 1 |
| Trandafirescu, V | 1 |
| Petrica, L | 1 |
| Bozdog, G | 1 |
| Gluhovschi, C | 1 |
| Bob, F | 1 |
| Gădălean, F | 1 |
| Buzaş, R | 1 |
| Bobu, M | 1 |
| Voicu, L | 1 |
| Masoodi, I | 1 |
| Kochhar, R | 1 |
| Vaishnavi, C | 1 |
| Prasad, KK | 1 |
| Vaiphei, K | 1 |
| Hussain, S | 1 |
| Singh, K | 1 |
| Ham, M | 1 |
| Hommes, D | 2 |
| Gill, I | 1 |
| Broberg, P | 1 |
| Karrasch, T | 1 |
| Schirbel, A | 1 |
| Ehehalt, R | 1 |
| Wehkamp, J | 1 |
| de Haar, C | 1 |
| Velin, D | 1 |
| Higgins, P | 2 |
| Sans, M | 1 |
| Römkens, TE | 1 |
| Kampschreur, MT | 1 |
| Drenth, JP | 1 |
| van Oijen, MG | 1 |
| de Jong, DJ | 1 |
| Choudhary, M | 1 |
| Remzi, FH | 2 |
| Kiran, RP | 1 |
| Tong, JL | 1 |
| Huang, ML | 1 |
| Xu, XT | 1 |
| Qiao, YQ | 1 |
| Ran, ZH | 1 |
| Tang, RK | 1 |
| Zhao, P | 1 |
| Zhu, SS | 1 |
| Li, YG | 1 |
| Li, JB | 1 |
| Voulgari, PV | 1 |
| Sabatini, T | 1 |
| Filippini, A | 1 |
| Nicosia, F | 1 |
| Preti, S | 1 |
| Bertoli, M | 1 |
| Karlstadt, R | 2 |
| Hodgson, I | 1 |
| Kelly, S | 1 |
| Román, J | 1 |
| Planell, N | 1 |
| Lozano, JJ | 1 |
| Aceituno, M | 1 |
| Esteller, M | 1 |
| Balsa, D | 1 |
| Merlos, M | 2 |
| Salas, A | 1 |
| Geyshis, B | 1 |
| Katz, G | 1 |
| Stobaugh, DJ | 1 |
| Deepak, P | 1 |
| Thorpe, M | 1 |
| Suárez, J | 1 |
| Romero-Zerbo, Y | 1 |
| Márquez, L | 1 |
| Rivera, P | 1 |
| Iglesias, M | 1 |
| Bermúdez-Silva, FJ | 1 |
| Andreu, M | 1 |
| Rodríguez de Fonseca, F | 1 |
| Leggett, CL | 1 |
| Bollegala, N | 1 |
| Brill, H | 1 |
| Inchingolo, CD | 1 |
| Giorgio, F | 1 |
| Schmidt, FM | 1 |
| Tennert, C | 1 |
| Teupser, D | 1 |
| Himmerich, H | 1 |
| Richter, JM | 2 |
| Kushkuley, S | 1 |
| Barrett, JA | 1 |
| Oster, G | 1 |
| Pichai, MV | 1 |
| Ferguson, LR | 1 |
| Fernández Salazar, LI | 1 |
| Borrego Pintado, H | 1 |
| Velayos Jiménez, B | 1 |
| González Hernández, JM | 1 |
| Marsh, AM | 1 |
| Buczyński, J | 1 |
| Spychalski, M | 1 |
| Ławska-Wierzchniewska, A | 1 |
| Dziki, A | 1 |
| Zeisler, B | 1 |
| Kappelman, M | 1 |
| Carvalho, R | 1 |
| Faubion, W | 1 |
| Ashai-Khan, F | 1 |
| Boersma, C | 1 |
| Lipka, S | 1 |
| Kaur, N | 1 |
| Krousel-Wood, M | 1 |
| Gautille, T | 1 |
| Yeung, P | 1 |
| Ballard, ED | 1 |
| Ordás, I | 1 |
| Eckmann, L | 1 |
| Talamini, M | 1 |
| Braun, S | 1 |
| Budak, K | 1 |
| Vavricka, S | 1 |
| Holley, D | 1 |
| Buch, M | 1 |
| Zvidi, I | 1 |
| Fraser, GM | 2 |
| Niv, Y | 2 |
| Birkenfeld, S | 1 |
| Reimers, B | 1 |
| Ceplis-Kastner, S | 1 |
| Neumann, H | 1 |
| Tsoulis, DJ | 1 |
| Shcherbakov, PL | 1 |
| Mitra, D | 1 |
| Frei, P | 1 |
| Manser, CN | 1 |
| Wilk, M | 1 |
| Manz, M | 1 |
| Suskind, DL | 1 |
| Wahbeh, G | 1 |
| Burpee, T | 1 |
| Cohen, M | 1 |
| Christie, D | 1 |
| Weber, W | 1 |
| Kumar, S | 1 |
| Sankar, MJ | 1 |
| Love, BL | 1 |
| Miller, AD | 1 |
| Nogami, K | 1 |
| Ramadass, SK | 1 |
| Perumal, S | 1 |
| Jabaris, SL | 1 |
| Madhan, B | 1 |
| Martínez González, J | 1 |
| Busto Bea, V | 1 |
| Mesonero Gismero, F | 1 |
| Parejo Carbonell, S | 1 |
| Aldeguer, X | 1 |
| Kinjo, Y | 1 |
| Gifford, AE | 1 |
| Lahiff, C | 1 |
| Cheng, SX | 1 |
| Raizner, A | 1 |
| Phatak, UP | 1 |
| Cho, JH | 1 |
| Pashankar, DS | 1 |
| Frattini, F | 1 |
| Crestani, S | 1 |
| Vescovi, PP | 1 |
| Franchini, M | 1 |
| Nakano, R | 1 |
| Ikeda, Y | 1 |
| Kishi, T | 1 |
| Tsuruoka, N | 1 |
| Shimoda, R | 1 |
| Sakata, Y | 1 |
| Fujimoto, K | 1 |
| Sonu, I | 1 |
| Wong, R | 1 |
| Rothenberg, ME | 1 |
| Armuzzi, A | 2 |
| Felice, C | 1 |
| Lachaine, J | 1 |
| Rajilić-Stojanović, M | 1 |
| Shanahan, F | 3 |
| Guarner, F | 3 |
| de Vos, WM | 1 |
| Muijsers, RB | 1 |
| Goa, KL | 1 |
| Bertoni, M | 2 |
| Taylor, WR | 1 |
| O'Kane, D | 1 |
| Weinshilboum, RM | 1 |
| Podolsky, DK | 1 |
| Frandsen, NE | 1 |
| Saugmann, S | 1 |
| Marcussen, N | 1 |
| Schroeder, KW | 5 |
| Felley, C | 2 |
| Piodi, LP | 2 |
| Bardella, M | 1 |
| Rocchia, C | 1 |
| Cesana, BM | 2 |
| Baldassarri, A | 1 |
| Quatrini, M | 1 |
| Hanson, J | 1 |
| Wruble, L | 3 |
| Johanson, J | 1 |
| Koval, G | 3 |
| Riff, D | 1 |
| Winston, B | 1 |
| Cross, A | 1 |
| Doty, P | 1 |
| Johnson, LK | 3 |
| Aumais, G | 2 |
| Lefebvre, M | 2 |
| Tremblay, C | 2 |
| Bitton, A | 4 |
| Martin, F | 4 |
| Giard, A | 1 |
| Madi, M | 1 |
| Sutherland, L | 4 |
| Roth, D | 1 |
| Beck, P | 1 |
| May, G | 1 |
| Tanaka, H | 1 |
| Katoh, D | 1 |
| Shimizu, M | 1 |
| Ohno, T | 1 |
| Kanda, Y | 1 |
| Nørgård, B | 1 |
| Fonager, K | 1 |
| Pedersen, L | 1 |
| Jacobsen, BA | 2 |
| Sørensen, HT | 1 |
| Herrlinger, K | 1 |
| Castro Fernández, M | 1 |
| García Díaz, E | 1 |
| Romero, M | 1 |
| Galán Jurado, V | 1 |
| Rodríguez Alonso, C | 1 |
| Pruitt, RE | 3 |
| Green, JR | 7 |
| Huo, D | 2 |
| Aikens, J | 1 |
| D'Albasio, G | 10 |
| Pera, A | 3 |
| Bianchi Porro, G | 11 |
| Paoluzi, OA | 4 |
| Miglioli, M | 15 |
| Sturniolo, G | 1 |
| Giaccari, S | 1 |
| Ingrosso, M | 1 |
| Mansi, C | 1 |
| Riegler, G | 3 |
| Pérez, C | 1 |
| Errázuriz, I | 1 |
| Brockmann, P | 1 |
| González, S | 1 |
| Cofré, C | 1 |
| Rumiantsev, VG | 2 |
| Wiercińska-Drapało, A | 1 |
| Flisiak, R | 1 |
| Prokopowicz, D | 1 |
| Rammert, Ch | 1 |
| Kullak-Ublick, GA | 1 |
| Jo, Y | 2 |
| Yada, S | 1 |
| Fujisawa, K | 1 |
| Onai, N | 1 |
| Matsushima, K | 1 |
| Jani, AL | 1 |
| Hamilos, D | 1 |
| Vainer, B | 2 |
| Nielsen, OH | 9 |
| Forbes, A | 5 |
| Cartwright, A | 1 |
| Marchant, S | 1 |
| McIntyre, P | 1 |
| Newton, M | 1 |
| Ono, K | 1 |
| Iwasa, K | 1 |
| Shirasaki, H | 1 |
| Takamori, M | 1 |
| Devani, M | 1 |
| Rondonotti, E | 1 |
| De Franchis, R | 2 |
| Teshima, D | 1 |
| Hino, B | 1 |
| Makino, K | 1 |
| Joh, Y | 1 |
| Oishi, R | 1 |
| Awakawa, T | 1 |
| Hirohashi, S | 1 |
| Tsukuda, H | 1 |
| Ibayashi, Y | 1 |
| Hirane, T | 1 |
| Bekki, E | 1 |
| Imai, K | 1 |
| Rosa, N | 1 |
| Giamundo, A | 1 |
| Jura, A | 1 |
| Iaccarino, G | 1 |
| Romano, A | 1 |
| Guslandi, M | 6 |
| Giollo, P | 1 |
| Testoni, PA | 2 |
| Toubanakis, C | 1 |
| Batziou, E | 1 |
| Sipsas, N | 1 |
| Galanopoulos, G | 1 |
| Tzivras, M | 2 |
| Archimandritis, A | 3 |
| Kishikawa, H | 1 |
| Nishida, J | 1 |
| Hirano, E | 1 |
| Morishita, T | 1 |
| Sewitch, MJ | 1 |
| Abrahamowicz, M | 1 |
| Barkun, A | 1 |
| Wild, GE | 1 |
| Cohen, A | 1 |
| Dobkin, PL | 1 |
| Sinha, A | 1 |
| Nightingale, J | 1 |
| West, KP | 1 |
| Berlanga-Acosta, J | 1 |
| Playford, RJ | 2 |
| Farrell, RJ | 4 |
| Croog, VJ | 1 |
| Ullman, TA | 1 |
| Itzkowitz, SH | 1 |
| Fujimaru, K | 1 |
| Taneichi, H | 1 |
| Takebe, N | 1 |
| Ishida, W | 1 |
| Kaneko, Y | 1 |
| Sawada, A | 1 |
| Fukusima, A | 1 |
| Syouji, T | 1 |
| Isurugi, C | 1 |
| Kawahara, T | 1 |
| Seki, H | 1 |
| Oikawa, N | 1 |
| Foster, RA | 1 |
| Zander, DS | 1 |
| Mergo, PJ | 1 |
| Valentine, JF | 1 |
| Kolyvanos Naumann, U | 1 |
| Kaser, L | 1 |
| Vetter, W | 1 |
| Habal, F | 1 |
| Morselli, C | 1 |
| Amadini, C | 2 |
| Romagnoli, R | 1 |
| Vuotila, M | 1 |
| Ikäheimo, R | 1 |
| Pietiläinen, T | 1 |
| Bjorkman, DJ | 1 |
| Aqel, B | 1 |
| Bishop, M | 1 |
| Krishna, M | 2 |
| Cangemi, J | 1 |
| Bjorkman, D | 1 |
| Holtmann, MH | 1 |
| Galle, PR | 1 |
| Rutter, M | 1 |
| Saunders, B | 1 |
| Wilkinson, K | 1 |
| Rumbles, S | 1 |
| Schofield, G | 1 |
| Kamm, M | 1 |
| Williams, C | 1 |
| Price, A | 1 |
| Talbot, I | 1 |
| Swan, CH | 2 |
| Gibson, JA | 5 |
| Kerr, GD | 5 |
| Thornton, PC | 4 |
| Bilker, WB | 1 |
| Strom, BL | 1 |
| Elseviers, MM | 1 |
| Lerebours, E | 1 |
| Plane, C | 1 |
| Stolear, JC | 1 |
| Capasso, G | 1 |
| Van Outryve, M | 1 |
| Mishevska-Mukaetova, P | 1 |
| Djuranovic, S | 1 |
| Pelckmans, P | 1 |
| De Broe, ME | 1 |
| Ulivieri, FM | 1 |
| Cermesoni, L | 1 |
| Arend, LJ | 1 |
| Springate, JE | 1 |
| Magnanti, K | 1 |
| Bickston, SJ | 1 |
| Cominelli, F | 1 |
| Bar-Meir, S | 2 |
| Feher, J | 2 |
| Mickisch, O | 1 |
| Mlitz, H | 1 |
| Chowers, Y | 1 |
| Lengyele, G | 1 |
| Kovacs, A | 2 |
| Dooley, TP | 1 |
| Curto, EV | 1 |
| Reddy, SP | 1 |
| Davis, RL | 1 |
| Lambert, GW | 1 |
| Wilborn, TW | 1 |
| Elson, CO | 1 |
| Kanauchi, O | 1 |
| Takayuki, I | 1 |
| Araki, Y | 1 |
| Toyonaga, A | 1 |
| Sata, M | 2 |
| Kojima, A | 1 |
| Fukuda, M | 1 |
| Hauser, R | 1 |
| Duty, S | 1 |
| Godfrey-Bailey, L | 1 |
| Calafat, AM | 1 |
| Kühbacher, T | 1 |
| Fölsch, UR | 1 |
| Hakoda, Y | 1 |
| Aoshima, M | 1 |
| Kinoshita, M | 1 |
| Sakurai, M | 1 |
| Ohyashiki, K | 1 |
| Haghighi, DB | 1 |
| Baker, DE | 2 |
| Bennett, AE | 1 |
| Bast, J | 1 |
| Bambrick, ML | 1 |
| Fazio, VW | 1 |
| Lim, WC | 1 |
| Hoyas-Pablos, E | 1 |
| Castro-Fernández, M | 1 |
| Rodríguez-Alonso, C | 1 |
| Guerrero, P | 1 |
| Escudero-Ordóñez, J | 1 |
| Reissmann, A | 1 |
| Bischoff, SC | 1 |
| Fleig, W | 1 |
| Matthes, H | 1 |
| Moser, G | 1 |
| Jantschek, G | 1 |
| Díaz Rodríguez, C | 1 |
| Granja, E | 1 |
| Vázquez Martul, E | 1 |
| Sacristán, F | 1 |
| Moreno Fernández, A | 1 |
| González Rivero, C | 1 |
| del Río Romero, D | 1 |
| Trinidad, JC | 1 |
| Inatsuchi, S | 1 |
| Yoshio, Y | 1 |
| Entani, A | 1 |
| Okada, K | 1 |
| Fric, P | 2 |
| Fixa, B | 4 |
| Kascák, M | 1 |
| Weismueller, J | 1 |
| Wolff, C | 1 |
| Doering, J | 1 |
| Begue, B | 1 |
| Lentze, MJ | 1 |
| Rieux-Laucat, F | 1 |
| Goulet, O | 1 |
| Schmitz, J | 1 |
| Cerf-Bensussan, N | 1 |
| Karaoglu, AO | 1 |
| Yukselen, V | 1 |
| Ertem, GT | 1 |
| Erkus, M | 1 |
| Gigliobianco, A | 1 |
| Kuroda, S | 1 |
| Ohkishi, T | 1 |
| Nakamaru, K | 1 |
| Hatakeyama, S | 1 |
| Raedler, A | 2 |
| Behrens, C | 1 |
| Bias, P | 1 |
| Sugisaki, K | 1 |
| Honma, F | 1 |
| Iwadate, H | 1 |
| Shio, K | 1 |
| Shioya, Y | 1 |
| Fukaya, E | 1 |
| Sato, K | 1 |
| Saito, H | 1 |
| Sekine, H | 1 |
| Kobayashi, H | 2 |
| Orikasa, H | 1 |
| Watanabe, H | 1 |
| Winther, KV | 1 |
| Binder, V | 9 |
| Iacopini, F | 3 |
| Bella, A | 1 |
| Consolazio, A | 2 |
| Lucci, E | 1 |
| Lattuneddu, A | 1 |
| Ricci, E | 1 |
| Dubini, A | 1 |
| Garcea, D | 1 |
| Hoffmann, JC | 1 |
| Zeitz, M | 1 |
| Holomán, J | 1 |
| Hulek, P | 1 |
| Rumyantsev, VG | 1 |
| Grigoryeva, G | 1 |
| Doganay, L | 1 |
| Akinci, B | 1 |
| Pekel, N | 1 |
| Simsek, I | 1 |
| Akpinar, H | 1 |
| Pimpo, M | 2 |
| Corrao, G | 1 |
| Chiaramonte, M | 1 |
| Kles, KA | 1 |
| Turner, JR | 1 |
| Musch, MW | 1 |
| Chang, EB | 1 |
| D'Arienzo, A | 4 |
| Maieron, R | 1 |
| Lecis, PE | 1 |
| Iaquinto, G | 2 |
| Balzano, A | 1 |
| Varoli, G | 1 |
| Ottobrelli, A | 1 |
| Baldi, S | 1 |
| Scappaticci, E | 1 |
| Modena, V | 1 |
| Fusaro, E | 1 |
| Mengozzi, G | 1 |
| Cima, RR | 1 |
| Pemberton, JH | 1 |
| Massicotte, J | 1 |
| Kasbo, J | 1 |
| Brunet, JS | 1 |
| Cardinal, C | 1 |
| Grace, M | 1 |
| Vetter, C | 1 |
| Al-Damluji, A | 1 |
| Ashworth, S | 1 |
| Bramble, M | 1 |
| Herbert, K | 1 |
| Kang, JY | 2 |
| Przemioslo, R | 1 |
| Shetty, A | 1 |
| Iser, J | 1 |
| Biancone, L | 2 |
| Francavilla, A | 1 |
| Giglio, L | 1 |
| Tadic, M | 1 |
| Grgurevic, I | 1 |
| Scukanec-Spoljar, M | 1 |
| Bozic, B | 1 |
| Marusic, S | 1 |
| Horvatic, I | 1 |
| Galesic, K | 1 |
| Furuta, R | 1 |
| Kusugami, K | 2 |
| Goto, H | 1 |
| Tomomasa, T | 1 |
| Terdiman, JP | 1 |
| Walsh, JM | 1 |
| Mahmood, A | 1 |
| Melley, L | 1 |
| Fitzgerald, AJ | 1 |
| Gassul, M | 1 |
| Befrits, R | 1 |
| Midhagen, G | 1 |
| Rademaker, J | 1 |
| Foldager, M | 1 |
| Russo, A | 1 |
| Imbesi, V | 3 |
| Carrera, E | 1 |
| Pérez-Abad, M | 1 |
| Boixeda, D | 1 |
| van Staa, TP | 1 |
| Card, T | 1 |
| Logan, RF | 1 |
| Leufkens, HG | 1 |
| Ono, M | 1 |
| Murakami, K | 1 |
| Oda, M | 1 |
| Miyajima, H | 1 |
| Sato, R | 1 |
| Nasu, M | 1 |
| Kashima, K | 2 |
| Nakashima, T | 1 |
| Maeda, T | 1 |
| Nagamoto, H | 1 |
| Kumakura, T | 1 |
| Takai, M | 1 |
| Mori, T | 1 |
| Yamauchi, K | 1 |
| Takeda, H | 1 |
| Machida, Y | 1 |
| Suzuki, H | 1 |
| Baenkler, HW | 1 |
| Naegel, A | 1 |
| Buchwald, F | 1 |
| Schultis, HW | 1 |
| Backhaus, B | 1 |
| Kimpel, S | 1 |
| Koch, H | 1 |
| Mach, K | 1 |
| Konturek, PC | 1 |
| Ingram, JR | 1 |
| Thomas, GA | 1 |
| Rhodes, J | 8 |
| Green, JT | 1 |
| Hawkes, ND | 1 |
| Swift, JL | 1 |
| Srivastava, ED | 1 |
| Evans, BK | 8 |
| Williams, GT | 3 |
| Newcombe, RG | 1 |
| Courtney, E | 1 |
| Pillai, S | 1 |
| Woogen, S | 1 |
| Regalli, G | 2 |
| Yeh, C | 2 |
| Smith-Hall, N | 2 |
| Ajayi, F | 1 |
| Ferris, LK | 1 |
| Jukic, D | 1 |
| English, JC | 1 |
| Zirwas, MJ | 1 |
| Choi, SC | 1 |
| Oh, HM | 1 |
| Choi, EY | 1 |
| Choi, EJ | 1 |
| Yun, KJ | 1 |
| Kim, SW | 1 |
| Lee, JG | 1 |
| Han, WC | 1 |
| Park, KI | 1 |
| Jun, CD | 1 |
| D'Argenio, G | 1 |
| Valenti, M | 1 |
| Scaglione, G | 2 |
| Cosenza, V | 1 |
| Sorrentini, I | 2 |
| Di Marzo, V | 1 |
| Miyahara, S | 1 |
| Ito, S | 1 |
| Soeda, A | 1 |
| Chino, Y | 1 |
| Hayashi, T | 1 |
| Takahashi, R | 1 |
| Goto, D | 1 |
| Matsumoto, I | 1 |
| Tsutsumi, A | 1 |
| Sumida, T | 1 |
| Guyot, J | 1 |
| Hess, J | 1 |
| Delarive, J | 1 |
| Adam, B | 1 |
| Liebregts, T | 1 |
| Holtmann, G | 1 |
| Poulou, AC | 1 |
| Goumas, KE | 1 |
| Dandakis, DC | 1 |
| Tyrmpas, I | 1 |
| Panagiotaki, M | 1 |
| Georgouli, A | 1 |
| Soutos, DC | 1 |
| Fägerstam, JP | 1 |
| Whiss, PA | 1 |
| Bergman, R | 1 |
| Parkes, M | 1 |
| Pekárková, B | 1 |
| Radford-Smith, G | 2 |
| Tibitanzl, J | 1 |
| Florin, TH | 1 |
| Gorgulu, S | 1 |
| Yagci, G | 1 |
| Kaymakcioglu, N | 1 |
| Ozkara, M | 1 |
| Kurt, B | 1 |
| Ozcan, A | 1 |
| Kaya, O | 1 |
| Sadir, S | 1 |
| Tufan, T | 1 |
| Allgayer, H | 3 |
| García-Morán, S | 1 |
| Sáez-Royuela, F | 1 |
| Pérez-Alvarez, JC | 1 |
| Gento, E | 1 |
| Téllez, J | 1 |
| Miner, PB | 5 |
| Wedel, MK | 1 |
| Baker, BF | 1 |
| Peppercorn, MA | 10 |
| Zocco, MA | 1 |
| dal Verme, LZ | 1 |
| Cremonini, F | 1 |
| Piscaglia, AC | 1 |
| Nista, EC | 1 |
| Candelli, M | 1 |
| Novi, M | 1 |
| Rigante, D | 1 |
| Cazzato, IA | 1 |
| Ojetti, V | 1 |
| Gasbarrini, G | 1 |
| Bos, CL | 1 |
| Diks, SH | 1 |
| Hardwick, JC | 1 |
| Walburg, KV | 1 |
| Peppelenbosch, MP | 1 |
| Richel, DJ | 1 |
| Thomsen, OO | 1 |
| Fallingborg, JF | 1 |
| Pierik, M | 1 |
| Vlietinck, R | 1 |
| Picco, MF | 1 |
| Cangemi, JR | 1 |
| Shelton, D | 1 |
| Takenaka, R | 2 |
| Makidono, C | 2 |
| Hori, S | 1 |
| Okazaki, H | 1 |
| Kawamoto, H | 2 |
| Shiratori, Y | 2 |
| Tekin, F | 1 |
| Ozütemiz, O | 1 |
| Ilter, T | 1 |
| Cohen, HD | 1 |
| Sands, BE | 1 |
| Kilgore, KM | 1 |
| Bloomfeld, RS | 1 |
| Blaszyk, H | 1 |
| Hyman, NH | 1 |
| Cooper, K | 1 |
| Desreumaux, P | 2 |
| Orchard, T | 1 |
| Keshav, S | 1 |
| Ginsburg, PM | 1 |
| Dassopoulos, T | 1 |
| Menzies, O | 1 |
| Colls, B | 1 |
| Tjaden, C | 1 |
| Obermeier, F | 1 |
| Müller, R | 1 |
| Schölmerich, J | 9 |
| Engels, L | 1 |
| Baert, F | 2 |
| van der Waaij, L | 1 |
| Connor, P | 1 |
| Ramage, J | 1 |
| Stephenson, D | 2 |
| Böhm, S | 1 |
| Hori, K | 1 |
| Nishigami, T | 1 |
| Nakano, H | 1 |
| Kaibe, N | 1 |
| Noda, M | 1 |
| Yanagi, H | 1 |
| Yamamura, T | 1 |
| Regueiro, M | 2 |
| Iemoli, E | 1 |
| Piconi, S | 1 |
| Raimond, F | 1 |
| Scimeca, D | 1 |
| Buschhausen, L | 1 |
| Aymaz, S | 1 |
| Weber, M | 1 |
| Krakamp, B | 3 |
| Imai, T | 1 |
| Kikumori, T | 1 |
| Shibata, A | 1 |
| Horiba, T | 1 |
| Sawaki, M | 1 |
| Watanabe, R | 1 |
| Nakao, A | 1 |
| Kiuchi, T | 1 |
| Tsujikawa, T | 1 |
| Iwaoka, Y | 2 |
| Hirayama, K | 2 |
| Arai, H | 1 |
| Yoshii, S | 1 |
| Uchijima, M | 1 |
| Nagata, T | 1 |
| Koide, Y | 1 |
| Mackowiak, JI | 1 |
| Hagymási, K | 2 |
| Ikeda, H | 1 |
| Ishimaru, Y | 1 |
| Takayasu, H | 1 |
| Fujino, J | 1 |
| Kisaki, Y | 1 |
| Otani, Y | 1 |
| Yamagishi, J | 1 |
| Tahara, K | 1 |
| Zwolińska-Wcisło, M | 1 |
| Budak, A | 1 |
| Trojanowska, D | 1 |
| Mach, T | 1 |
| Rudnicka-Sosin, L | 1 |
| Galicka-Latała, D | 1 |
| Nowak, P | 1 |
| Cibor, D | 1 |
| Neĭman, KP | 1 |
| Menees, S | 1 |
| Korsnes, S | 1 |
| Elta, G | 1 |
| Swidsinski, A | 1 |
| Loening-Baucke, V | 1 |
| Bengmark, S | 1 |
| Lochs, H | 1 |
| Dörffel, Y | 1 |
| Boddu, P | 1 |
| Gubergrits, N | 1 |
| Lyne, A | 4 |
| Butler, T | 3 |
| Joseph, RE | 4 |
| Markiewicz, M | 1 |
| Suresh, L | 1 |
| Margarone, J | 1 |
| Aguirre, A | 1 |
| Brass, C | 1 |
| Gassull, M | 1 |
| Jackowski, L | 1 |
| Radwan, P | 1 |
| łupina, T | 1 |
| Radwan-Kwiatek, K | 1 |
| Milanowski, J | 1 |
| Vrij, AA | 1 |
| Oberndorff-Klein-Woolthuis, A | 1 |
| de Jong, AE | 1 |
| Wagenvoord, R | 1 |
| Hemker, HC | 1 |
| Stockbrügger, RW | 1 |
| Fukunaga, K | 1 |
| Ohda, Y | 1 |
| Inoue, T | 1 |
| Kono, T | 1 |
| Miwa, H | 1 |
| Banks, C | 1 |
| Price, LC | 1 |
| Grubnic, S | 1 |
| Rayner, CF | 1 |
| Munck, LK | 1 |
| Blanco, Gdel V | 1 |
| Sostegni, R | 1 |
| Petruzziello, C | 1 |
| Sica, G | 1 |
| Calabrese, E | 1 |
| Oxelmark, L | 1 |
| Hillerås, P | 1 |
| Mössner, J | 1 |
| Löfberg, R | 2 |
| Pascarella, F | 1 |
| Quaglietta, L | 1 |
| Giannetti, E | 1 |
| Greco, L | 1 |
| Troncone, R | 1 |
| Uslu, N | 1 |
| Demir, H | 1 |
| Saltik-Temizel, IN | 1 |
| Topaloğlu, R | 1 |
| Gürakan, F | 1 |
| Yüce, A | 1 |
| Martín Rodríguez, MM | 1 |
| Ruiz-Cabello Jiménez, M | 1 |
| Gómez García, M | 1 |
| Vega Villaamil, P | 1 |
| González Castillo, S | 1 |
| Perrot, S | 1 |
| Aslangul, E | 1 |
| Szwebel, T | 1 |
| Gadhoum, H | 1 |
| Romnicianu, S | 1 |
| Le Jeunne, C | 1 |
| Kuriyama, S | 1 |
| Iwabuchi, M | 1 |
| Tsuji, I | 1 |
| Shimosegawa, T | 2 |
| Chu, EC | 1 |
| Chai, J | 1 |
| Ahluwalia, A | 1 |
| Tarnawski, AS | 1 |
| Trenk, D | 1 |
| Rössle, M | 1 |
| Cap, M | 1 |
| Zähringer, A | 1 |
| Wacheck, V | 1 |
| Remmler, C | 1 |
| Kreisel, W | 2 |
| Novacek, G | 1 |
| Tindall, WN | 1 |
| Boltri, JM | 1 |
| Wilhelm, SM | 2 |
| Robertson, E | 1 |
| Austin, D | 1 |
| Jamieson, N | 1 |
| Hogg, KJ | 1 |
| Oka, M | 1 |
| Safdi, AV | 1 |
| Adamonis, K | 1 |
| Lavy, A | 1 |
| Chermesh, I | 1 |
| Henriksen, M | 1 |
| Howarth, LJ | 1 |
| Wiskin, AE | 1 |
| Griffiths, DM | 1 |
| Afzal, NA | 1 |
| Ikeda, I | 1 |
| Tomimoto, A | 1 |
| Wada, K | 1 |
| Fujisawa, T | 1 |
| Yonemitsu, K | 1 |
| Nozaki, Y | 1 |
| Nagashima, Y | 1 |
| Nakagama, H | 1 |
| Robinson, DM | 1 |
| Perry, CM | 1 |
| Nilsson, A | 2 |
| Dallaire, C | 1 |
| Archambault, A | 1 |
| Musch, E | 1 |
| Malek, M | 1 |
| Chrissafidou, A | 1 |
| Schulz, M | 1 |
| Kim, TN | 1 |
| Liang, HL | 1 |
| Kikuyama, M | 1 |
| Nagata, S | 1 |
| Takai, K | 1 |
| Kale-Pradhan, PB | 1 |
| Pradhan, RS | 1 |
| Stone, M | 1 |
| James, SL | 1 |
| Irving, PM | 1 |
| Hausmann, M | 1 |
| Paul, G | 1 |
| Menzel, K | 1 |
| Brunner-Ploss, R | 1 |
| Falk, W | 1 |
| Davis, CM | 1 |
| Marzano, A | 1 |
| Hu, MY | 1 |
| Swaminath, A | 1 |
| Rubin, G | 1 |
| Stelts, S | 1 |
| Taylor, MH | 1 |
| Nappi, J | 1 |
| Van Bakel, AB | 1 |
| Nayar, M | 1 |
| Cunliffe, W | 1 |
| Cross, P | 1 |
| Oppong, K | 1 |
| Malusa', N | 1 |
| Marino, S | 1 |
| Bartoli, F | 1 |
| Guijarro, LG | 1 |
| Mate, J | 2 |
| Arriaza, E | 1 |
| Olleros, T | 1 |
| Delgado, M | 1 |
| Castillejo, MS | 1 |
| Prieto-Merino, D | 1 |
| Gonzalez Lara, V | 1 |
| Pena, AS | 2 |
| Sabesin, SM | 1 |
| Vitat, P | 1 |
| Fernandez-Becker, NQ | 1 |
| Lanfranchi, GA | 5 |
| Bazzocchi, G | 6 |
| Brignola, C | 17 |
| Sarti, F | 1 |
| Franzin, G | 1 |
| Battocchia, A | 1 |
| Labo, G | 3 |
| Dal Monte, PR | 1 |
| Bartholomew, TC | 1 |
| Jewell, DP | 4 |
| Fischer, C | 3 |
| Maier, K | 6 |
| Klotz, U | 6 |
| Holdstock, G | 1 |
| Chastenay, BF | 1 |
| Krawitt, EL | 1 |
| Heinkel, K | 1 |
| Goldman, P | 1 |
| Dew, MJ | 6 |
| Hughes, P | 1 |
| Harries, AD | 3 |
| Williams, G | 1 |
| Hawkey, CJ | 6 |
| Lo Casto, M | 1 |
| Sircar, JC | 1 |
| Schwender, CF | 1 |
| Carethers, ME | 1 |
| Azad Khan, AK | 1 |
| Nurazzaman, M | 1 |
| Truelove, SC | 1 |
| Evans, N | 2 |
| Stumpf, E | 1 |
| von Gaisberg, U | 4 |
| Minguzzi, MR | 4 |
| Calari, MT | 1 |
| Austin, CA | 1 |
| Cann, PA | 4 |
| Jones, TH | 1 |
| Holdsworth, CD | 7 |
| Ebden, P | 1 |
| Kidwai, NS | 1 |
| McIntyre, PB | 3 |
| Lennard-Jones, JE | 6 |
| Chan, RP | 1 |
| Pope, DJ | 1 |
| Gilbert, AP | 1 |
| Sacra, PJ | 1 |
| Baron, JH | 3 |
| Bertoni, F | 1 |
| Bondesen, S | 7 |
| Jacobsen, O | 1 |
| Rasmussen, SN | 8 |
| Hansen, SH | 9 |
| Halskov, S | 2 |
| Hvidberg, EF | 4 |
| Eisenburg, J | 1 |
| Paumgartner, G | 1 |
| Ryder, RE | 1 |
| Flachs, H | 1 |
| Miles, AM | 1 |
| Grisham, MB | 1 |
| Pooley, N | 1 |
| Ghosh, L | 1 |
| Sharon, P | 1 |
| Karvonen, AL | 2 |
| Matikainen, M | 1 |
| Turunen, U | 3 |
| Wilding, IR | 1 |
| Kenyon, CJ | 1 |
| Chauhan, S | 1 |
| Hooper, G | 1 |
| Marshall, S | 1 |
| McCracken, JS | 1 |
| Staab, HJ | 1 |
| Armbrecht, J | 1 |
| Anderson, FH | 1 |
| Halphen, M | 1 |
| Farup, PG | 2 |
| Hovde, O | 1 |
| Halvorsen, FA | 1 |
| Raknerud, N | 1 |
| Brodin, U | 1 |
| Petrillo, M | 3 |
| Fasoli, A | 1 |
| Lorenz, R | 1 |
| Born, P | 1 |
| Classen, M | 1 |
| Casellas, F | 3 |
| Papo, M | 2 |
| Antolín, M | 2 |
| Segura, RM | 1 |
| Armengol, JR | 2 |
| Malagelada, JR | 3 |
| Sturgeon, JB | 1 |
| Bhatia, P | 1 |
| Hermens, D | 1 |
| Loizeau, E | 2 |
| Engelhardt, K | 1 |
| Mohr, K | 1 |
| Cuende, JI | 1 |
| Gómez, MT | 1 |
| García, M | 1 |
| Pérez, IJ | 1 |
| Grassi, M | 1 |
| Raffa, S | 1 |
| Damiani, VC | 1 |
| Fontana, M | 1 |
| Trallori, G | 7 |
| Messori, A | 3 |
| Scuffi, C | 1 |
| Bardazzi, G | 5 |
| Silvano, R | 1 |
| Pacini, F | 5 |
| Veligotskiĭ, NN | 1 |
| Parkhomenko, LK | 1 |
| Simeunovich, S | 1 |
| Skopichenko, SV | 1 |
| Bonanomi, AG | 3 |
| Amorosi, A | 3 |
| Bartoletti, L | 1 |
| Morettini, A | 3 |
| Smilde, TJ | 1 |
| van Liebergen, FJ | 1 |
| Koolen, MI | 1 |
| Gerlag, PG | 1 |
| Assmann, KJ | 1 |
| Berden, JH | 1 |
| Miner, P | 1 |
| Robinson, M | 5 |
| Schwartz, J | 2 |
| Cittadini, M | 1 |
| Torsoli, A | 2 |
| Boschi, S | 4 |
| Barbara, L | 12 |
| Heresbach, D | 1 |
| Rabot, A | 1 |
| Génetet, N | 1 |
| Stéphan, C | 1 |
| Bretagne, JF | 1 |
| Gosselin, M | 1 |
| Nikolopoulou, V | 1 |
| Katsakoulis, E | 1 |
| Tsiotos, P | 1 |
| Thomopoulos, K | 1 |
| Salsaa, B | 1 |
| Zoumbos, N | 1 |
| Roediger, WE | 3 |
| Millard, S | 2 |
| Carpani de Kaski, M | 1 |
| Hodgson, HJ | 2 |
| Abboudi, ZH | 1 |
| Marsh, JC | 1 |
| Smith-Laing, G | 1 |
| Gordon-Smith, EC | 1 |
| Laidlaw, ST | 1 |
| Reilly, JT | 1 |
| Järvinen, HJ | 1 |
| Gendre, JP | 1 |
| Andreoli, A | 1 |
| Spinella, S | 1 |
| Levenstein, S | 1 |
| Ament, ME | 1 |
| Vargas, JH | 1 |
| van Hogezand, RA | 1 |
| Thuluvath, PJ | 1 |
| Ninkovic, M | 1 |
| Calam, J | 1 |
| Anderson, M | 1 |
| Del Carlo, P | 1 |
| Palli, D | 1 |
| Galli, M | 1 |
| Petillo, FE | 1 |
| Berardesca, G | 1 |
| Braegger, CP | 1 |
| Torresani, T | 1 |
| Murch, SH | 1 |
| Savage, MO | 1 |
| Walker-Smith, JA | 3 |
| Sutherland, LR | 6 |
| May, GR | 1 |
| Shaffer, EA | 1 |
| Schmassmann, A | 1 |
| Halter, F | 1 |
| Kitano, A | 2 |
| Tabata, A | 1 |
| Obayashi, M | 1 |
| Nakagawa, M | 1 |
| Yasuda, K | 1 |
| Fukushima, R | 1 |
| Okabe, H | 1 |
| Tomobuchi, M | 1 |
| Scheppach, W | 1 |
| Kornbluth, AA | 1 |
| Salomon, P | 1 |
| Sacks, HS | 1 |
| Mitty, R | 1 |
| Janowitz, HD | 2 |
| Ohara, M | 1 |
| Takaishi, H | 1 |
| Hayashi, A | 1 |
| Aiso, S | 1 |
| Harings-Kaim, A | 1 |
| Abdullah, AM | 1 |
| Scott, RB | 1 |
| Martin, SR | 1 |
| Hallak, A | 2 |
| Baratz, M | 1 |
| Santo, M | 2 |
| Halpern, Z | 2 |
| Rabau, M | 1 |
| Werbin, N | 1 |
| Gilat, T | 1 |
| Hoop, R | 1 |
| Zbrozek, A | 1 |
| Wilkinson, C | 1 |
| Batts, KP | 1 |
| Lawson, GM | 2 |
| Steiner, BL | 1 |
| Harrison, JM | 1 |
| Faber, SM | 1 |
| Korelitz, BI | 1 |
| Sciarretta, G | 1 |
| Furno, A | 1 |
| Mazzoni, M | 1 |
| Ferrieri, A | 1 |
| Malaguti, P | 1 |
| Gait, JE | 2 |
| Powell, JH | 1 |
| Claussen, DW | 1 |
| Mantzaris, GJ | 1 |
| Hatzis, A | 1 |
| Petraki, K | 1 |
| Spiliadi, C | 1 |
| Triantaphyllou, G | 1 |
| Zijlstra, FJ | 1 |
| van Dijk, AP | 1 |
| Ouwendijk, RJ | 1 |
| van Riemsdijk-Overbeeke, IC | 1 |
| Wilson, JH | 2 |
| Roufail, W | 1 |
| Cello, J | 1 |
| Odze, R | 1 |
| Antonioli, D | 1 |
| Peppercorn, M | 1 |
| Goldman, H | 1 |
| Letizia, C | 1 |
| D'Ambrosio, C | 1 |
| Agostini, D | 1 |
| Corsi, A | 1 |
| Boirivant, M | 1 |
| Scavo, D | 1 |
| Jensen, J | 1 |
| Cornett, C | 1 |
| Olsen, CE | 1 |
| Christensen, J | 1 |
| Tjørnelund, J | 1 |
| Brunetti, G | 3 |
| Chakravarty, BJ | 1 |
| Pullan, RD | 1 |
| Ganesh, S | 1 |
| Mani, V | 6 |
| Morris, J | 1 |
| Chaussade, S | 1 |
| Sogni, P | 1 |
| Wiita, B | 2 |
| Demestihas, E | 1 |
| Allison, MC | 1 |
| Yoshida, Y | 2 |
| Muto, T | 1 |
| Tsuchiya, S | 1 |
| Fukushima, T | 1 |
| Nakajima, H | 1 |
| Desideri, S | 1 |
| Sachar, DB | 1 |
| Gujral, N | 1 |
| Friedenberg, F | 1 |
| Friedenberg, J | 1 |
| Gabriel, G | 1 |
| Kotler, M | 1 |
| Levine, G | 1 |
| Hanrahan, JP | 1 |
| Upton, MP | 1 |
| Bonner, GF | 2 |
| Rebocho, L | 1 |
| Lucas, M | 1 |
| Victorino, RM | 1 |
| Lizasoain, J | 1 |
| Rubio, FA | 1 |
| Erdozain, JC | 1 |
| Olveira, A | 1 |
| Conde, P | 1 |
| Pérez de Llano, LA | 1 |
| Lancho, A | 1 |
| Soilán del Cerro, JL | 1 |
| López-Róses, L | 1 |
| Kam, L | 1 |
| Dooley, C | 1 |
| Rubin, P | 1 |
| Orchard, J | 1 |
| Fockens, P | 1 |
| Mulder, CJ | 6 |
| Tytgat, GN | 6 |
| Blok, P | 2 |
| Ferwerda, J | 1 |
| Meuwissen, SG | 1 |
| Tuynman, HA | 2 |
| Dekker, W | 3 |
| Gasthuis, K | 1 |
| van Hees, PA | 2 |
| Ewe, K | 4 |
| Becker, K | 1 |
| Ueberschaer, B | 1 |
| Nicholls, SW | 1 |
| Domizio, P | 1 |
| Williams, CB | 1 |
| Vallano, A | 1 |
| Davis, P | 1 |
| Grancher, K | 1 |
| Justinich, CJ | 1 |
| Wareing, M | 1 |
| Mitchell, D | 1 |
| Singhal, A | 1 |
| Kar, P | 1 |
| van Bodegraven, AA | 1 |
| Boer, RO | 1 |
| Lourens, J | 1 |
| Sindram, JW | 1 |
| Peppercom, MA | 1 |
| George, J | 1 |
| Present, DH | 2 |
| Pou, R | 1 |
| Rubin, PH | 1 |
| Lee, FI | 1 |
| Keighley, MR | 1 |
| Kingston, RD | 1 |
| Record, CO | 5 |
| Grace, RH | 1 |
| Daniels, S | 1 |
| Patterson, J | 1 |
| Smith, K | 1 |
| Dipaolo, MC | 1 |
| McGowan, I | 1 |
| Tittobello, A | 2 |
| Venturi, A | 5 |
| Ferretti, M | 3 |
| Sharma, BC | 1 |
| Yachha, SK | 1 |
| Mishra, RN | 1 |
| Gupta, D | 1 |
| McCaulley, ME | 1 |
| Papatheodoridis, GV | 1 |
| Xourgias, V | 1 |
| Heloury, Y | 1 |
| Plattner, V | 1 |
| David, V | 1 |
| Nomballais, MF | 1 |
| Millar, AD | 1 |
| Rampton, DS | 1 |
| Chander, CL | 1 |
| Claxson, AW | 1 |
| Blades, S | 1 |
| Coumbe, A | 1 |
| Panetta, J | 1 |
| Morris, CJ | 1 |
| Blake, DR | 1 |
| Stretch, GL | 1 |
| Campbell, BJ | 1 |
| Dwarakanath, AD | 1 |
| Yaqoob, M | 1 |
| Stevenson, A | 1 |
| Morris, AI | 1 |
| Plaisier, PW | 1 |
| Fornaciari, G | 2 |
| Maccari, S | 1 |
| Borgatti, PP | 1 |
| Rustichelli, R | 1 |
| Amelio, N | 1 |
| Lattuada, I | 1 |
| Plancher, AC | 1 |
| Dube, LM | 1 |
| Rountree, LV | 1 |
| Linnen, PJ | 1 |
| Lancaster, JF | 1 |
| Cross, DL | 1 |
| Scudder, DD | 1 |
| Lázaro, MT | 1 |
| García-Tejero, MT | 1 |
| Díaz-Lobato, S | 1 |
| Björck, S | 1 |
| Jennische, E | 1 |
| Dahlström, A | 1 |
| Ahlman, H | 1 |
| Walker, AM | 1 |
| Szneke, P | 1 |
| Bianchi, LA | 1 |
| Field, LG | 1 |
| Dreyer, NA | 1 |
| Galofre, N | 1 |
| Fuste, L | 1 |
| Oriol, A | 1 |
| Grau, J | 1 |
| Kimura, I | 4 |
| Nagahama, S | 2 |
| Kawasaki, M | 3 |
| Kataoka, M | 4 |
| Camarri, E | 1 |
| Milla, M | 2 |
| Ferrero, S | 1 |
| Biagini, M | 1 |
| Quaranta, S | 1 |
| Rückert, Y | 1 |
| Odes, HS | 1 |
| Konstandinidis, A | 1 |
| Hatzis, G | 1 |
| Paraskeva, K | 1 |
| Skandalis, N | 1 |
| Corbelli, C | 3 |
| Fanti, S | 1 |
| Manenti, L | 1 |
| De Rosa, A | 1 |
| Buzio, C | 1 |
| Khatchatourian, M | 1 |
| Seaton, TL | 1 |
| Schütz, E | 3 |
| Judmaier, G | 2 |
| Bollani, S | 2 |
| DeMicco, M | 1 |
| Sninsky, C | 1 |
| Banks, P | 1 |
| Deren, J | 1 |
| Nichols, T | 1 |
| Targan, S | 2 |
| Fleishman, C | 1 |
| Fernández, J | 1 |
| Sala, M | 1 |
| Feu, F | 1 |
| Navarro, S | 1 |
| Terés, J | 1 |
| Gambardella, L | 2 |
| Banti, S | 1 |
| Rindi, G | 1 |
| Leicester, RJ | 1 |
| Parkins, KJ | 1 |
| Taylor, MD | 2 |
| Botoman, VA | 1 |
| Botoman, DA | 1 |
| Tzanakis, N | 1 |
| Samiou, M | 1 |
| Bouros, D | 1 |
| Mouzas, J | 1 |
| Kouroumalis, E | 1 |
| Siafakas, NM | 1 |
| Asirvatham, S | 1 |
| Sebastian, C | 1 |
| Thadani, U | 1 |
| Crand, J | 1 |
| Foucault, M | 1 |
| Rambaud, JC | 2 |
| Muraoka, M | 1 |
| Kimura, G | 1 |
| Zhaopeng, H | 1 |
| Takada, K | 1 |
| Goebell, H | 6 |
| Prakash, A | 2 |
| Spencer, CM | 1 |
| Howard, G | 1 |
| Lynn, KL | 1 |
| Sarigol, S | 1 |
| Riley, SA | 6 |
| Steinberg, H | 1 |
| Press, AG | 1 |
| Hauptmann, IA | 1 |
| Hauptmann, L | 1 |
| Fuchs, B | 1 |
| Fuchs, M | 1 |
| Ramadori, G | 1 |
| Brandes, JW | 2 |
| Theuer, D | 2 |
| Otto, P | 1 |
| Lorenz-Mayer, H | 1 |
| Sentongo, TA | 1 |
| Piccoli, DA | 1 |
| Popoola, J | 1 |
| Muller, AF | 1 |
| Pollock, L | 1 |
| O'Donnell, P | 1 |
| Carmichael, P | 1 |
| Stevens, P | 1 |
| Castiglione, GN | 1 |
| Vicinanza, G | 1 |
| Sanges, M | 1 |
| Mazzacca, G | 2 |
| Asakura, H | 1 |
| Hussain, FN | 1 |
| Ajjan, RA | 1 |
| Moustafa, M | 1 |
| Anderson, JC | 1 |
| Kumamoto, T | 1 |
| Matsuda, A | 3 |
| Kokuba, Y | 2 |
| Sesin, GP | 1 |
| Mucciardi, N | 1 |
| Almeida, S | 1 |
| Crowe, JP | 1 |
| Schofield, KJ | 1 |
| Kokurba, Y | 1 |
| Tanigawa, K | 1 |
| Sugiyama, K | 1 |
| Matsuyama, H | 1 |
| Nakao, H | 1 |
| Kohno, K | 1 |
| Komuro, Y | 1 |
| Iwanaga, Y | 1 |
| Eguchi, K | 1 |
| Kitaichi, M | 1 |
| Takagi, H | 2 |
| Fernández-Bañares, F | 1 |
| Sánchez-Lombraña, JL | 1 |
| Navarro, E | 1 |
| Martínez-Salmerón, JF | 1 |
| García-Pugés, A | 1 |
| González-Huix, F | 1 |
| Riera, J | 1 |
| González-Lara, V | 1 |
| Domínguez-Abascal, F | 1 |
| Giné, JJ | 1 |
| Moles, J | 1 |
| Gassull, MA | 1 |
| Ogino, H | 1 |
| Tachibana, Y | 1 |
| Yonejima, H | 1 |
| Satomura, Y | 1 |
| Unoura, M | 1 |
| Miwa, A | 1 |
| Marí, B | 1 |
| Brullet, E | 1 |
| Campo, R | 1 |
| Bustamante, E | 1 |
| Bombardó, J | 1 |
| Soriano, ML | 1 |
| Martínez, N | 1 |
| Grilli, R | 1 |
| Fariña, MC | 1 |
| Martín, L | 1 |
| Requena, L | 1 |
| Støa-Birketvedt, G | 1 |
| Cerutti, R | 1 |
| Benvenuti, ME | 1 |
| Biasco, G | 1 |
| Cesari, P | 1 |
| Ranzi, T | 3 |
| Markham, A | 2 |
| Pohl, C | 1 |
| Hôgye, M | 1 |
| Lonovics, J | 1 |
| Morice, AH | 1 |
| Kumwenda, J | 1 |
| Qureshi, N | 1 |
| Curran, A | 1 |
| Regueiro, MD | 1 |
| Blázovics, A | 1 |
| Lugasi, A | 1 |
| Bíró, L | 1 |
| Masutani, M | 1 |
| Matsuda, T | 1 |
| Ohira, K | 1 |
| Nomura, A | 1 |
| Sadaoka, K | 1 |
| Douchin, A | 1 |
| Suzuki, J | 1 |
| Kawakami, Y | 1 |
| Agharazii, M | 1 |
| Marcotte, J | 1 |
| Boucher, D | 1 |
| Noël, R | 1 |
| Lebel, M | 1 |
| Braun, M | 1 |
| Kunin, M | 1 |
| Salamon, F | 1 |
| Tur-Kaspa, R | 1 |
| Schenck, B | 1 |
| Tromm, A | 2 |
| Hoshino, J | 1 |
| Sugawara, K | 1 |
| Ishikawa, S | 1 |
| Hayami, Y | 1 |
| Sakurazawa, T | 1 |
| Yamamoto, N | 1 |
| Hashimoto, M | 1 |
| Hoshihara, Y | 1 |
| Fine, SN | 1 |
| Adachi, E | 1 |
| Matsushima, Y | 1 |
| Seno, H | 1 |
| Kawanami, C | 1 |
| Nakamura, T | 1 |
| Rembacken, BJ | 1 |
| Snelling, AM | 1 |
| Hawkey, PM | 1 |
| Chalmers, DM | 1 |
| Axon, AT | 1 |
| Facchini, S | 1 |
| Candusso, M | 1 |
| Zennaro, F | 1 |
| Johansson, R | 1 |
| Zucconi, E | 1 |
| Brigidi, P | 1 |
| Matteuzzi, D | 1 |
| Bonet, J | 1 |
| Vaquero, M | 1 |
| Bayés, B | 1 |
| Romero, R | 1 |
| Lisciandrano, D | 1 |
| Benti, R | 1 |
| Baldassarri, AR | 1 |
| Bruno, A | 1 |
| Bianchi, PA | 1 |
| Gerundini, P | 1 |
| Barnett, JL | 1 |
| Kleer, CG | 1 |
| Appelman, HD | 1 |
| Horiuchi, Y | 1 |
| Shimakura, S | 1 |
| Palumbo, GC | 1 |
| Onori, L | 1 |
| Pantaleoni, GC | 1 |
| Motegi, K | 1 |
| Nagasako, K | 1 |
| Nogawa, H | 1 |
| Akiya, T | 1 |
| Kon, Y | 1 |
| Sawada, T | 1 |
| Aihara, H | 1 |
| Sakai, K | 1 |
| Nakajima, S | 1 |
| Fujinuma, S | 1 |
| Sakai, Y | 1 |
| Iizuka, B | 1 |
| Yamagishi, N | 1 |
| Honma, N | 1 |
| Hayashi, N | 1 |
| Nishiyama, Y | 1 |
| Ida, A | 1 |
| Koyama, K | 1 |
| Kougo, Y | 1 |
| Parente, F | 1 |
| Geboes, K | 1 |
| Jouret, A | 1 |
| Ectors, N | 1 |
| Pitcher, MC | 1 |
| Beatty, ER | 1 |
| Cummings, JH | 1 |
| Langman, MJ | 1 |
| Allan, RN | 1 |
| Thomson, AB | 2 |
| Williams, CN | 2 |
| Abrams, K | 1 |
| Jackson, E | 1 |
| Faubion, WA | 2 |
| Doldo, P | 1 |
| Giglio, LA | 1 |
| Gaia, E | 1 |
| Valentini, M | 1 |
| Massa, P | 1 |
| Del Piano, M | 1 |
| Rossini, F | 1 |
| Guidetti, CS | 1 |
| Pearce, CB | 1 |
| Duncan, HD | 1 |
| Timmis, L | 1 |
| Grandinetti, G | 1 |
| Villotti, G | 1 |
| Clemett, D | 1 |
| Woseth, DM | 1 |
| Thisted, RA | 1 |
| Rufle, W | 1 |
| Frühmorgen, P | 2 |
| Huber, W | 1 |
| Kimmig, JM | 2 |
| Amin, HE | 1 |
| Della Siega, AJ | 1 |
| Whittaker, JS | 1 |
| Munt, B | 1 |
| Folwaczny, C | 1 |
| Good, LI | 1 |
| Goodman, MW | 1 |
| Pizinger, RJ | 1 |
| Strum, WB | 1 |
| Lyss, C | 1 |
| Haber, G | 1 |
| Miyata, Y | 1 |
| Hasuike, S | 1 |
| Ideguchi, T | 1 |
| Minami, H | 1 |
| Hirono, S | 1 |
| Tsubouchi, H | 1 |
| Giacomelli, R | 1 |
| Passacantando, A | 1 |
| Pantaleoni, G | 1 |
| Rowe, FA | 1 |
| Walker, JH | 1 |
| Karp, LC | 2 |
| Vasiliauskas, EA | 1 |
| Plevy, SE | 1 |
| Zamir, D | 1 |
| Weizman, J | 1 |
| Zamir, C | 1 |
| Fireman, Z | 1 |
| Weiner, P | 1 |
| Järnerot, G | 2 |
| Ström, M | 4 |
| Danielsson, A | 1 |
| Kilander, A | 1 |
| Lööf, L | 1 |
| Hultcrantz, R | 1 |
| Florén, C | 1 |
| Broström, O | 1 |
| Marlicz, K | 1 |
| Paradowski, L | 1 |
| Margus, B | 1 |
| Zaborowski, P | 1 |
| Bielecki, JW | 1 |
| Avar, S | 1 |
| Joss, R | 1 |
| De Vos, M | 1 |
| Surawicz, CM | 1 |
| Seror, P | 1 |
| Sáez, J | 1 |
| Martínez, J | 1 |
| García, C | 1 |
| Griñó, P | 1 |
| Pérez-Mateo, M | 1 |
| Beltrami, M | 1 |
| Di Maurizio , P | 1 |
| Beretta, L | 1 |
| Ganio, E | 1 |
| Usai, P | 1 |
| de Franchis , R | 1 |
| Birketvedt, GS | 1 |
| Berg, KJ | 1 |
| Fausa, O | 1 |
| Bantel, H | 1 |
| Berg, C | 1 |
| Schulze-Osthoff, K | 1 |
| Komatsu, K | 1 |
| Kikuchi, S | 1 |
| Uchi, M | 1 |
| Maruhama, Y | 1 |
| Kisara, N | 1 |
| Toyota, T | 1 |
| Margetts, PJ | 1 |
| Churchill, DN | 1 |
| Alexopoulou, I | 1 |
| Goldstein, F | 1 |
| Fleig, WE | 1 |
| Schwetz, BA | 1 |
| Funakoshi, S | 2 |
| Hitotsumatsu, O | 1 |
| Ezaki, T | 1 |
| Chiba, M | 1 |
| Yamano, H | 1 |
| Fujiwara, K | 1 |
| Iizuka, M | 1 |
| Kondo, H | 1 |
| Watanabe, J | 1 |
| Iwasaki, H | 1 |
| Rudolph, MW | 1 |
| Klein, S | 1 |
| Beckert, TE | 1 |
| Petereit, H | 1 |
| Dressman, JB | 1 |
| Musil, D | 1 |
| Katz, JA | 1 |
| Pore, G | 1 |
| Parlak, E | 1 |
| Dağli, U | 1 |
| Ulker, A | 1 |
| Alkim, C | 1 |
| Sahin, B | 1 |
| Mavrogiannis, C | 1 |
| Papanikolaou, IS | 1 |
| Elefsiniotis, IS | 1 |
| Psilopoulos, DI | 1 |
| Karameris, A | 1 |
| Karvountzis, G | 1 |
| Nomura, S | 1 |
| Tahara, M | 1 |
| Haneda, M | 1 |
| Kikkawa, R | 1 |
| Nakamura, Y | 1 |
| Hinterleitner, TA | 1 |
| Rachmilewitz, D | 6 |
| Meier, R | 1 |
| Keller, R | 1 |
| Rathbone, B | 1 |
| Oddsson, E | 1 |
| Carceller, E | 1 |
| Salas, J | 1 |
| Giral, M | 1 |
| Ferrando, R | 1 |
| Escamilla, I | 1 |
| Ramis, J | 1 |
| García-Rafanell, J | 1 |
| Forn, J | 1 |
| Hamamoto, S | 1 |
| Moriwaki, M | 1 |
| Iwadate, K | 1 |
| Ohwaki, T | 1 |
| Ragunath, K | 1 |
| Williams, JG | 2 |
| Bahrani, O | 1 |
| Ishikawa, N | 1 |
| Imamura, T | 1 |
| Yamaga, J | 1 |
| Yuchi, H | 1 |
| Ootsuka, M | 1 |
| Aoki, T | 1 |
| Eto, T | 1 |
| Thompson, DG | 1 |
| Wilkin, D | 1 |
| Roberts, C | 1 |
| Wiedemann, B | 1 |
| Arber, N | 1 |
| Alexandrowitz, A | 1 |
| Knaani, Y | 1 |
| Hershkoviz, R | 1 |
| Brazowski, E | 1 |
| Haralambou, G | 1 |
| Teirstein, AS | 1 |
| Gil, J | 1 |
| Sossai, P | 1 |
| Cappellato, MG | 1 |
| Stefani, S | 1 |
| Campbell, S | 1 |
| Aikens, JE | 1 |
| Howaldt, S | 1 |
| Hämling, J | 1 |
| Mönnikes, H | 1 |
| Koop, I | 1 |
| Pallant, D | 1 |
| Ewald, U | 1 |
| Gibbon, KL | 1 |
| Bewley, AP | 1 |
| Thomas, K | 1 |
| Oshimoto, H | 1 |
| Okamura, S | 1 |
| Onozato, Y | 1 |
| Ishihara, H | 1 |
| Mori, M | 1 |
| Goto, M | 1 |
| Okamoto, Y | 1 |
| Yamamoto, M | 1 |
| Aki, H | 1 |
| Di Paolo, MC | 1 |
| Spera, G | 1 |
| Ina, K | 1 |
| Tsuzuki, T | 1 |
| Nishio, Y | 1 |
| Imada, A | 1 |
| Mansfield, JC | 2 |
| Giaffer, MH | 2 |
| McKenna, D | 1 |
| Van Nueten, L | 1 |
| Van De Velde, I | 1 |
| Joslyn, A | 1 |
| Mahmud, N | 1 |
| O'Toole, D | 1 |
| O'Hare, N | 1 |
| Freyne, PJ | 1 |
| Weir, DG | 2 |
| Kelleher, D | 1 |
| Sule, A | 1 |
| Gaitonde, S | 1 |
| Bhojani, K | 1 |
| Mittal, G | 1 |
| Balakrishnan, C | 1 |
| Gurmeet, M | 1 |
| Deshpande, RB | 1 |
| Joshi, VR | 1 |
| Oxentenko, AS | 1 |
| Oh, JK | 1 |
| Danielson, GK | 1 |
| Mangan, TF | 1 |
| Malchow, H | 2 |
| Gertz, B | 1 |
| Pajares, JM | 1 |
| van Bergeijk, JD | 1 |
| von Tirpitz, C | 2 |
| Lygren, I | 1 |
| Rädler, A | 1 |
| Waldum, HL | 1 |
| Friis, S | 1 |
| Tefera, S | 1 |
| Hoogkamer, JF | 1 |
| Rösch, M | 1 |
| Leidl, R | 1 |
| Reinshagen, M | 1 |
| Adler, G | 1 |
| König, HH | 1 |
| Niemelä, S | 1 |
| Frego, R | 1 |
| Viale, E | 1 |
| Le Large-Guiheneuf, C | 1 |
| Hugot, JP | 1 |
| Faure, C | 1 |
| Munck, A | 1 |
| Mougenot, JF | 1 |
| Navarro, J | 1 |
| Cézard, JP | 1 |
| Ohya, M | 1 |
| Otani, H | 1 |
| Kimura, K | 1 |
| Kodama, N | 1 |
| Minami, Y | 1 |
| Liang, XM | 1 |
| Maeshima, E | 1 |
| Yamada, Y | 1 |
| Mune, M | 1 |
| Yukawa, S | 1 |
| Levine, DS | 1 |
| Riff, DS | 1 |
| Sales, D | 1 |
| Bell, JK | 1 |
| Tozaki, H | 1 |
| Odoriba, T | 1 |
| Okada, N | 1 |
| Fujita, T | 1 |
| Terabe, A | 1 |
| Suzuki, T | 1 |
| Okabe, S | 1 |
| Muranishi, S | 1 |
| Yamamoto, A | 1 |
| Kapaniris, O | 1 |
| Eigler, FW | 1 |
| Courtney, MG | 1 |
| Nunes, DP | 1 |
| Bergin, CF | 1 |
| O'Driscoll, M | 1 |
| Trimble, V | 1 |
| Keeling, PW | 1 |
| Fischbach, W | 1 |
| Nakshabendi, IM | 1 |
| Duncan, A | 1 |
| Russell, RI | 1 |
| Daneshmend, TK | 1 |
| Everitt, SJ | 1 |
| Holmes, GK | 1 |
| Malkinson, C | 1 |
| Shaheen, MZ | 1 |
| Willars, JE | 1 |
| Simerl, NA | 1 |
| Maier, KP | 1 |
| Goldman, DH | 1 |
| Perrault, J | 1 |
| Rodrigues, CA | 2 |
| Manjunatha, S | 1 |
| Barrison, IG | 2 |
| Polson, RJ | 1 |
| Hoare, AM | 1 |
| Davidsen, M | 1 |
| Mahida, YR | 2 |
| Simon, P | 1 |
| Ligumsky, M | 2 |
| Karmeli, F | 3 |
| Macrae, K | 1 |
| Thau, I | 1 |
| Schwegler, U | 1 |
| Kuntz, HD | 1 |
| Krieg, M | 1 |
| May, B | 3 |
| Lagler, U | 1 |
| Schulthess, HK | 1 |
| Kuhn, M | 2 |
| Rowlinson, A | 1 |
| Brown, P | 1 |
| Thornton, P | 1 |
| Barrow, S | 1 |
| Rees, SH | 1 |
| Lloyd, DR | 1 |
| Chorev, M | 1 |
| Okon, E | 1 |
| Di Febo, G | 2 |
| Zagni, P | 1 |
| Ngô, Y | 1 |
| Gélinet, JM | 1 |
| Ivanovic, A | 1 |
| Kac, J | 1 |
| Schénowitz, G | 1 |
| Vilotte, J | 1 |
| Ottonello, L | 2 |
| Dapino, P | 1 |
| Pastorino, G | 1 |
| Vitale, E | 1 |
| Dallegri, F | 2 |
| Claussen, D | 1 |
| Almer, S | 2 |
| Ekberg, S | 1 |
| Chapman, NJ | 1 |
| Brown, ML | 1 |
| Phillips, SF | 1 |
| Dewanjee, MK | 1 |
| Reinoso, MA | 1 |
| Pisani, RJ | 1 |
| Segars, LW | 1 |
| Gales, BJ | 1 |
| Hayllar, J | 1 |
| Bjarnason, I | 1 |
| Fitzgerald, JM | 1 |
| Marsh, TD | 1 |
| Alstead, EM | 1 |
| Wilson, AG | 1 |
| Farthing, MJ | 1 |
| Welte, T | 1 |
| Hamm, H | 1 |
| Fabel, H | 1 |
| Rothbart, D | 1 |
| Kölbel, C | 1 |
| Feurle, GE | 2 |
| Eckardt, VF | 1 |
| Kanzler, G | 1 |
| Rieder, H | 1 |
| Gavazzi, O | 1 |
| Vannozzi, G | 1 |
| Frittelli, G | 1 |
| Cini, E | 1 |
| Falai, T | 1 |
| Varini, C | 1 |
| Cobden, I | 2 |
| al-Mardini, H | 1 |
| Zaitoun, A | 1 |
| le Gros, V | 1 |
| Saveuse, H | 1 |
| Lesur, G | 1 |
| Brion, N | 1 |
| Lamming, CE | 1 |
| Gallagher, A | 1 |
| Norlander, B | 2 |
| Osterwald, H | 1 |
| Rasenack, J | 1 |
| Cort, DH | 1 |
| Powers, BJ | 1 |
| Sessions, JT | 1 |
| Jacobs, WH | 1 |
| Lo, SK | 1 |
| Cerda, JJ | 1 |
| Zaitoun, AM | 1 |
| al Mardini, H | 1 |
| Tampieri, M | 5 |
| Iannone, P | 5 |
| Pinnau, R | 1 |
| Bertovich, MJ | 1 |
| Nash, GS | 1 |
| Wengrower, D | 1 |
| Ahnfelt-Rønne, I | 1 |
| Christensen, A | 1 |
| Riis, P | 1 |
| Ghetti, A | 1 |
| Nucci, A | 1 |
| Biddle, WL | 2 |
| Fitzpatrick, LR | 1 |
| Bostwick, JS | 1 |
| Renzetti, M | 1 |
| Pendleton, RG | 1 |
| Decktor, DL | 1 |
| Bruckstein, AH | 1 |
| Aparicio-Pagés, MN | 1 |
| Verspaget, HW | 1 |
| Hafkenscheid, JC | 1 |
| Crama-Bohbouth, GE | 1 |
| Weterman, IT | 2 |
| Lamers, HW | 1 |
| Cigala, O | 1 |
| Pancallo, MT | 1 |
| Marasco, A | 1 |
| Della Valle, M | 1 |
| Carrai, M | 1 |
| Venturini, G | 1 |
| Pacheco, S | 1 |
| Hillier, K | 1 |
| Smith, CL | 1 |
| Tiel-van Buul, MM | 1 |
| van Royen, EA | 1 |
| Wiltink, EH | 2 |
| Hesselmann, J | 1 |
| Ostendorf, PC | 1 |
| Huep, WW | 1 |
| Abildgaard, K | 1 |
| Rasmussen, HH | 1 |
| Fallingborg, J | 1 |
| Gremillion, DE | 1 |
| Herring, RW | 1 |
| Bailey, AH | 1 |
| Faust, TW | 1 |
| Potter, M | 1 |
| Long, KM | 1 |
| Fedorak, RN | 1 |
| Empey, LR | 1 |
| MacArthur, C | 1 |
| Jewell, LD | 1 |
| Gotthard, R | 1 |
| Ireland, A | 1 |
| Ballestrero, A | 1 |
| Bogliolo, F | 1 |
| Ferrando, F | 1 |
| Patrone, F | 1 |
| Panarese, A | 1 |
| D'Armiento, FP | 1 |
| Lancia, C | 1 |
| Quattrone, P | 1 |
| Giannattasio, F | 1 |
| Boscaino, A | 1 |
| Mehta, RP | 1 |
| Dybdahl, JH | 1 |
| Staerk Laursen, L | 2 |
| Stokholm, M | 1 |
| Bukhave, K | 4 |
| Rask-Madsen, J | 5 |
| Lauritsen, K | 6 |
| Plauth, M | 1 |
| Balfour, TW | 1 |
| Long, RG | 1 |
| Jenss, H | 1 |
| Weber, P | 1 |
| Healey, JN | 2 |
| Petronelli, A | 1 |
| Fiorentini, MT | 1 |
| Fracchia, M | 1 |
| Galatola, G | 1 |
| Barlotta, A | 1 |
| de la Pierre, M | 1 |
| Ciarleglio, CA | 1 |
| Breuer, N | 1 |
| Deakin, EJ | 1 |
| Walker, G | 1 |
| Nance, SH | 1 |
| Ginsberg, AL | 1 |
| Friedman, LS | 4 |
| Delaere, KP | 1 |
| Strijbos, WE | 1 |
| Meuleman, EJ | 1 |
| Kjaergaard, N | 1 |
| Lauritsen, JG | 1 |
| Greenwell, BE | 1 |
| Dölle, W | 2 |
| Barden, L | 1 |
| Lipson, A | 1 |
| Pert, P | 1 |
| Vitti, RA | 1 |
| Meyers, F | 1 |
| Knight, LC | 1 |
| Siegel, JA | 1 |
| Malmud, LS | 1 |
| Fisher, RS | 1 |
| Robinson, MG | 1 |
| Ruf-Ballauf, W | 1 |
| Hofstädter, F | 1 |
| Krentz, K | 1 |
| Torresan, F | 2 |
| Henning, HV | 1 |
| Meinhold, J | 1 |
| Eisenhauer, T | 1 |
| Scheler, F | 1 |
| Gröne, HJ | 1 |
| Donowitz, M | 1 |
| Bode, JC | 1 |
| Heller, T | 1 |
| Banatwala, N | 1 |
| Barber, GB | 1 |
| Lee, DE | 1 |
| Antonioli, DA | 1 |
| Boughton-Smith, NK | 1 |
| Whittle, BJ | 1 |
| Friedman, G | 1 |
| Donald, IP | 1 |
| Wilkinson, SP | 1 |
| Helmstädter, V | 1 |
| Schou, JB | 1 |
| Jensen, PH | 1 |
| Lassen, LB | 1 |
| Krasilnikoff, PA | 1 |
| Danø, P | 1 |
| Peskar, BM | 3 |
| Dreyling, KW | 2 |
| Peskar, BA | 1 |
| Cooper, BT | 1 |
| Gerok, W | 1 |
| Puleo, A | 1 |
| Calabrese, A | 1 |
| Cipolla, C | 1 |
| Gatto, G | 1 |
| Oliva, L | 1 |
| Rao, SS | 2 |
| Goerg, KJ | 1 |
| Wanitschke, R | 1 |
| Gabbert, H | 1 |
| Breiling, J | 1 |
| Franke, M | 1 |
| Meyer zum Büschenfelde, KH | 1 |
| Sullivan, SN | 1 |
| Lecarpentier, J | 1 |
| Goodman, MJ | 3 |
| Mandal, BK | 1 |
| Turnberg, LA | 3 |
| Elomaa, I | 1 |
| Anttila, VJ | 1 |
| Seppälä, K | 1 |
| Schaarschmidt, K | 1 |
| Habal, FM | 1 |
| Greenberg, GR | 1 |
| Chatzinoff, M | 2 |
| Guarino, JM | 1 |
| Corson, SL | 1 |
| Batzer, FR | 1 |
| Herd, ME | 2 |
| Dutt, S | 2 |
| Terpstra, IJ | 1 |
| Schrijver, M | 1 |
| van der Heide, H | 1 |
| Daiss, W | 1 |
| Rijk, MC | 1 |
| van Schaik, A | 1 |
| van Tongeren, JH | 1 |
| Fardy, JM | 1 |
| Lloyd, DA | 1 |
| Reynolds, RP | 1 |
| Walker, JG | 1 |
| Gozzetti, G | 1 |
| Lauri, A | 1 |
| Paganelli, GM | 1 |
| Santucci, R | 1 |
| von Mühlendahl, KE | 1 |
| Winther, K | 1 |
| Grøn, I | 1 |
| Winther, A | 1 |
| Hardy, JG | 1 |
| Reynolds, JR | 1 |
| Laursen, LS | 2 |
| Houthoff, HJ | 1 |
| Powell-Tuck, J | 1 |
| MacRae, KD | 1 |
| Healy, MJ | 1 |
| Parkins, RA | 1 |
| Novis, BH | 1 |
| Korzets, Z | 1 |
| Chen, P | 1 |
| Bernheim, J | 1 |
| Yao, T | 1 |
| Benedittini, N | 1 |
| Farinotti, R | 1 |
| Rene, E | 1 |
| Likforman, J | 1 |
| Dauphin, A | 1 |
| Mignon, M | 1 |
| Tabanelli, GM | 3 |
| Greenberger, NJ | 1 |
| Swan, JT | 1 |
| McPhee, MS | 1 |
| Meyers, S | 1 |
| Ilstrup, DM | 1 |
| Maier, KE | 1 |
| Migaldi, M | 1 |
| Fahrländer, H | 1 |
| Schuman, BM | 1 |
| Bayerdörffer, E | 1 |
| Kraus, B | 2 |
| Guarino, J | 1 |
| Berk, T | 1 |
| Kirkham, SE | 1 |
| DeMonaco, HJ | 1 |
| May, RJ | 1 |
| Tippmann, P | 1 |
| Gerhard, F | 1 |
| Lepiorz, P | 1 |
| Greer, S | 1 |
| Greenberger, N | 1 |
| Martin, T | 1 |
| Sparr, J | 1 |
| Prokipchuk, E | 1 |
| Borgen, L | 1 |
| Chakraborty, TK | 1 |
| Bhatia, D | 1 |
| Heading, RC | 1 |
| Ford, MJ | 1 |
| Mardini, HA | 1 |
| Lindsay, DC | 1 |
| Deighton, CM | 1 |
| Kandel, G | 1 |
| Prokipchuk, EJ | 1 |
| Cappello, IP | 1 |
| Fedotin, MS | 1 |
| Hvidberg, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Combination Corticosteroids + 5-aminosalicylic Acids Compared to Corticosteroids Alone in the Treatment of Moderate-severe Active Ulcerative Colitis.[NCT01941589] | Phase 4 | 149 participants (Actual) | Interventional | 2013-09-30 | Completed | ||
| [NCT02261636] | 150 participants (Actual) | Observational | 2015-01-31 | Completed | |||
| Phase III Study of AJM300 in Patients With Active Ulcerative Colitis[NCT03531892] | Phase 3 | 198 participants (Actual) | Interventional | 2018-06-06 | Completed | ||
| A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Effect of Mutaflor in Patients With Mild-to-moderate Ulcerative Colitis on 5-ASA Treatment.[NCT04969679] | Phase 4 | 134 participants (Actual) | Interventional | 2018-03-16 | Completed | ||
| QUality of Life in pAtients With Mild to modeRate Active procTitis Treated by mesalaZine (Pentasa®)[NCT02368743] | 117 participants (Actual) | Observational | 2015-12-31 | Completed | |||
| A Randomised, Active-Controlled, Double-Blind and Open Label Extensions Study to Evaluate the Efficacy, Long-Term Safety and Tolerability of TP05 3.2g/Day for the Treatment of Active Ulcerative Colitis[NCT01903252] | Phase 3 | 817 participants (Actual) | Interventional | 2013-07-31 | Completed | ||
| A Prospective Multi-centre Observational Cohort Study Assessing the Effectiveness of Cortiment® for the Treatment of Mild-to-moderate Active Ulcerative Colitis in Routine Clinical Practice[NCT02586259] | 378 participants (Actual) | Observational | 2015-12-31 | Completed | |||
| A Randomized, Open-label, Multiple Dose, Parallel Group Study to Evaluate 5 ASA and N Ac 5 ASA Pharmacokinetics Following Administration of Oral Doses of Asacol 2.4 g/Day and Lialda 2.4 g/Day for 7 Days in Healthy Volunteers[NCT00751699] | Phase 1 | 37 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| The Efficacy and Tolerability of Bio-enhanced Curcumin (Diferuloylmethane) in the Induction of Remission in Patients With Mild to Moderate Ulcerative Colitis[NCT02683733] | Phase 3 | 50 participants (Anticipated) | Interventional | 2016-02-29 | Recruiting | ||
| Open-label, Multi-centre, Proof of Concept Phase IIa Clinical Trial on the Efficacy and Tolerability of an 8 Week Oral Treatment With Once Daily 9 mg Budesonide in Patients With Active Ulcerative Colitis[NCT02550418] | Phase 2 | 60 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| Monitoring Serologic Response to SARS-COV-2 / Coronavirus Disease 2019 (COVID-19) in Children, Adolescents, and Young Adults Receiving Biologic Therapies (RECONN)[NCT04838834] | 472 participants (Actual) | Observational | 2020-05-15 | Active, not recruiting | |||
| Role of Intestinal Protozoa and Helminths in the Course of Ulcerative Colitis[NCT03441893] | Phase 1/Phase 2 | 300 participants (Anticipated) | Interventional | 2015-01-01 | Active, not recruiting | ||
| A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Budesonide MMX® 9 mg Extended-release Tablets as Add-on Therapy in Patients With Active, Mild or Moderate Ulcerative Colitis Not Adequately Controlled on a Ba[NCT01532648] | Phase 3 | 510 participants (Actual) | Interventional | 2012-01-27 | Completed | ||
| Observational Study on Clinical Practice in the Management of Ulcerative Colitis With Oral 5-Aminosalicylic Acid in Japan[NCT01654783] | 5,704 participants (Actual) | Observational | 2012-09-30 | Completed | |||
| Efficacy of Fecal Microbiota Transplantation for Refractory Inflammatory Bowel Disease[NCT02575040] | Phase 3 | 60 participants (Anticipated) | Interventional | 2015-05-31 | Recruiting | ||
| Fecal Microbiota Transplantation (FMT) of FMP30 in Relapsing-Remitting Multiple Sclerosis: A Phase 1b Clinical Trial to Evaluate Feasibility, Safety, Tolerability and Effects on Immune Function[NCT03594487] | Phase 1 | 30 participants (Anticipated) | Interventional | 2018-11-16 | Active, not recruiting | ||
| Reduction in Length of Hospitalization in Patients With Acute Severe Ulcerative Colitis Treated With Rescue Therapy With Infliximab by the Use of Web-app Constant-Care. One Year Follow-up, Inclusive Colectomy Rate.[NCT04165265] | 28 participants (Anticipated) | Interventional | 2019-12-03 | Recruiting | |||
| Clinical Trial to Assess the Efficacy and Safety of Adding GMA to Infliximab in Paediatric Patients With Steroid-refractory Ulcerative Colitis[NCT05430412] | 15 participants (Anticipated) | Interventional | 2022-01-11 | Recruiting | |||
| The Role of Lactobacillus Rhamnosus GG (ATCC 53103) in the Modulation of the Inflammatory Process in the Mucosa of Ulcerative Colitis (UC) Patients With Mild-moderate Clinical Activity[NCT04102852] | Phase 1/Phase 2 | 76 participants (Actual) | Interventional | 2019-09-30 | Completed | ||
| Multicenter Open-label Study Evaluating the Safety and Efficacy of Standardized Initial Therapy Using Either Mesalamine or Corticosteroids Then Mesalamine to Treat Children and Adolescents With Newly Diagnosed Ulcerative Colitis.[NCT01536535] | Phase 4 | 431 participants (Actual) | Interventional | 2012-07-10 | Completed | ||
| A Phase 4, Open-label, Multicenter, Prospective Study to Evaluate the Effect of Remission Status on the Ability to Maintain or Achieve Clinical and Endoscopic Remission During a 12-Month, Long-term Maintenance Phase With 2.4g/Day MMX Mesalamine/Mesalazine[NCT01124149] | Phase 4 | 759 participants (Actual) | Interventional | 2010-06-29 | Completed | ||
| Randomized, Double-blind, Multicentre Study to Compare the Efficacy and Safety of Budesonide Versus Mesalazine Suppository Versus a Combination Therapy of Budesonide/Mesalazine Suppositories in Patients With Acute Ulcerative Proctitis[NCT01966783] | Phase 2 | 320 participants (Anticipated) | Interventional | 2013-09-30 | Completed | ||
| Relationship Between Baseline Burden of Disease and Anti-TNF Drug Trough Levels in Ulcerative Colitis.[NCT03808506] | 0 participants (Actual) | Observational | 2019-09-01 | Withdrawn (stopped due to no recruitment during COVID pandemic) | |||
| A Multicentered Prospective Cohort Study of Chinese IBD Patients Concerning Cost-effectiveness Analysis, Therapeutic Effect Predictor Exploration and Gut Microbiota Analysis[NCT05386290] | 200 participants (Anticipated) | Observational | 2020-07-09 | Enrolling by invitation | |||
| "A Phase 1b/2 Study to Demonstrate the Safety and Efficacy of EXE-346 Live Biotherapeutic to Reduce High Bowel Movement Frequency in Subjects With an Ileal Pouch-Anal Anastomosis (PROF). The PROF Study."[NCT05938465] | Phase 1/Phase 2 | 50 participants (Anticipated) | Interventional | 2023-10-11 | Recruiting | ||
| Nicotinamide Riboside in Ulcerative Colitis[NCT05561738] | 40 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | |||
| Multicentre, Controlled, Randomised, Investigator-Blinded, Comparative Study of Oral Mesalazine 4g Once Daily Versus Mesalazine 4g in Two Divided Doses in Patients With Active Ulcerative Colitis.[NCT00737789] | Phase 3 | 206 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| Responsiveness of Endoscopic Evaluation of Ulcerative Colitis Using a Central Reader Based Image Management System[NCT01960439] | 194 participants (Actual) | Observational | 2013-07-31 | Completed | |||
| A Randomized Placebo-Controlled Double-Blind Study to Evaluate the Efficacy and Safety of Asacol™ 4.8 g/Day (800 mg Tablets) for the Treatment of Active Ulcerative Colitis[NCT01059344] | Phase 3 | 281 participants (Actual) | Interventional | 2009-11-30 | Completed | ||
| Test Treat Strategy to Prevent Ulcerative Colitis Relapse[NCT00652145] | Phase 4 | 119 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| [NCT01011322] | Phase 2 | 156 participants (Actual) | Interventional | 2009-12-31 | Active, not recruiting | ||
| A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Amoxicillin Administered Alone and in Combination With MMX® Mesalazine/Mesalamine in Healthy Adult Subjects[NCT01442688] | Phase 1 | 62 participants (Actual) | Interventional | 2011-10-07 | Completed | ||
| A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Sulfamethoxazole Administered Alone and in Combination With MMX® Mesalazine/Mesalamine in Healthy Adult Subjects[NCT01469637] | Phase 1 | 44 participants (Actual) | Interventional | 2011-11-07 | Completed | ||
| A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Ciprofloxacin XR Administered Alone and in Combination With MMX® Mesalazine/Mesalamine in Healthy Adult Subjects[NCT01402947] | Phase 1 | 30 participants (Actual) | Interventional | 2011-07-25 | Completed | ||
| A Phase 1, Randomized, Open-label, Crossover, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of Metronidazole Administered Alone and in Combination With MMX® Mesalazine/Mesalamine in Healthy Adult Subjects[NCT01418365] | Phase 1 | 30 participants (Actual) | Interventional | 2011-08-22 | Completed | ||
| Adherence to Mesalamine Profile for Patients With Inflammatory Bowel Disease[NCT01349504] | 106 participants (Actual) | Observational | 2011-04-30 | Completed | |||
| "Prospective and Multicenter Study About the Epidemiology and the Characteristics Omics in Patients Recently Diagnosed of Inflammatory Bowel Disease in Spain"[NCT03689257] | 376 participants (Actual) | Observational | 2017-10-01 | Completed | |||
| A Double-blind, Randomised, Placebo and Mesalazine Controlled Phase II Study to Explore the Safety and Activity of Dersalazine in Patients With Mild to Moderate Active Colitis[NCT00808977] | Phase 2 | 80 participants (Anticipated) | Interventional | 2008-12-31 | Completed | ||
| A Phase IV, Multi-center, Open-label Study to Assess Clinical Recurrence Related to Compliance With Treatment With MMX Mesalamine 2.4g/Day Given Once Daily for the Maintenance of Quiescent Ulcerative Colitis (UC)[NCT00446849] | Phase 4 | 290 participants (Actual) | Interventional | 2007-05-01 | Completed | ||
| Clinical Study to Evaluate the Possible Efficacy and Safety of Roflumilast in Patients With Ulcerative Colitis.[NCT05684484] | Phase 4 | 52 participants (Anticipated) | Interventional | 2023-02-01 | Not yet recruiting | ||
| An Evaluation of Clinical Study Experiences of Patients With Ulcerative Colitis[NCT05737836] | 500 participants (Anticipated) | Observational | 2024-03-31 | Not yet recruiting | |||
| Role of Information and Communication Technologies for Health Support in Inflammatory Bowel Diseases: The DAMASCO Trial (Stage I)[NCT04893928] | 351 participants (Anticipated) | Observational | 2021-05-03 | Recruiting | |||
| Individualization of Oral Mesalazine Treatment Through a Self-managed Web-based Solution in Mild-to-moderate Ulcerative Colitis: A Pilot Study[NCT03604536] | 1 participants (Actual) | Observational | 2019-12-02 | Terminated (stopped due to not able to recruit patients) | |||
| Study to Assess the Safety and Efficacy of Asacol® (1.2 to 4.8 g/Day) Administered as 400 mg Delayed-release Tablets Given Every 12 Hours for 6 Weeks to Children and Adolescents With Mildly-to-Moderately Active Ulcerative Colitis[NCT00713310] | Phase 3 | 83 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| Randomized, Double-blind, Placebo-controlled Study to Evaluated the Efficacy of Combining Curcumin+5ASA Medication Versus 5ASA Medication Alone on Active Mild to Moderate Ulcerative Colitis Patients[NCT01320436] | Phase 3 | 50 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| Investigation of the Effects of Curcumin and Resveratrol Supplements Added to the Mediterranean Diet on Disease Severity and Inflammatory Biomarkers in Patients With Ulcerative Colitis[NCT05761327] | 45 participants (Anticipated) | Interventional | 2022-06-03 | Recruiting | |||
| Mesalazine and Compound Glutamin Enema for the Treatment of Ulcerative Colitis Through Colonic Transendoscopic Enteral Tubing: A Multicenter, Randomized, Controlled Trail[NCT03917095] | 75 participants (Anticipated) | Interventional | 2019-05-15 | Recruiting | |||
| Investigation of the Faecal Loss of Vedolizumab and Its Role in Influencing Serum Drug Levels, Outcomes and Response in Ulcerative Colitis[NCT04006080] | Phase 4 | 30 participants (Anticipated) | Interventional | 2019-07-01 | Recruiting | ||
| A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Use of Mesalamine Pellet Formulation 1.5G QD to Maintain Remission From Mild to Moderate Ulcerative Colitis[NCT00744016] | Phase 3 | 305 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Use of Mesalamine Pellet Formulation 1.5G QD to Maintain Remission From Mild to Moderate Ulcerative Colitis[NCT00767728] | Phase 3 | 256 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| A Multicenter, Open-Label, Treatment Extension Trial to Evalaute the Long-Term Safety and Tolerability of Mesalamine Pellet Formulation[NCT00326209] | Phase 3 | 393 participants (Actual) | Interventional | 2005-12-22 | Completed | ||
| A Phase 1, Multicenter, Open-label Study to Determine the Safety and Pharmacokinetics of MMX Mesalamine Following Administration in Children and Adolescents With Ulcerative Colitis[NCT01130844] | Phase 1 | 52 participants (Actual) | Interventional | 2010-10-08 | Completed | ||
| Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis[NCT01257386] | Phase 3 | 251 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase[NCT01257399] | Phase 3 | 251 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| Confocal Laser Endomicroscopy Findings in Patients With Proctosigmoiditis Before and After Initiation of Treatment[NCT01684514] | 29 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| Risk of Hepatitis Flare in Patients With Previous Hepatitis B Virus Exposure Amongst Patients on Immunosuppressive and Biological Modifier Therapies Exposure[NCT04356404] | 68 participants (Actual) | Observational | 2020-05-01 | Terminated (stopped due to No suitable case identified) | |||
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Budesonide Foam (2 mg/25 mL BID for 2 Weeks, Followed by 2 mg/25 mL QD for 4 Weeks) Versus Placebo in Subjects With Active Mild to Moderate Ulc[NCT01008410] | Phase 3 | 265 participants (Actual) | Interventional | 2009-11-17 | Completed | ||
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Budesonide Foam (2 mg/25 mL BID for 2 Weeks, Followed by 2 mg/25 mL QD for 4 Weeks) Versus Placebo in Subjects With Active Mild to Moderate Ulc[NCT01008423] | Phase 3 | 281 participants (Actual) | Interventional | 2009-11-20 | Completed | ||
| Assessing the Prevalence of Respiratory Impairment in Chronic Inflammatory Bowel Diseases[NCT04225650] | 480 participants (Anticipated) | Observational | 2020-05-01 | Not yet recruiting | |||
| Study of the Impact of a Physical Activity Programme on the Quality of Life of Patients With Inflammatory Bowel Disease[NCT05099653] | 30 participants (Anticipated) | Interventional | 2020-02-20 | Recruiting | |||
| Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events[NCT05313620] | Phase 4 | 30 participants (Anticipated) | Interventional | 2022-04-01 | Recruiting | ||
| Prevalance of non_ Alcoholic Fatty Liver Diseases in Patient With Inflammatory Bowel Diseases Attending Assiut University Hospitals[NCT04328259] | 30 participants (Anticipated) | Observational | 2020-10-01 | Not yet recruiting | |||
| Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: Multicentre, Prospective, Randomized Clinical Trial and Economic Evaluation[NCT02994836] | Phase 4 | 139 participants (Actual) | Interventional | 2017-04-21 | Completed | ||
| Zoledronate Versus Ibandronate Comparative Evaluation: A Randomized Phase III, Open-Label, Multicenter, Parallel Group Clinical Trial to Evaluate and Compare the Efficacy, Safety Profile and Tolerability of Oral Ibandronate Versus Intravenous Zoledronate [NCT00326820] | Phase 3 | 1,404 participants (Actual) | Interventional | 2006-01-31 | Active, not recruiting | ||
| A Randomized, Single-Blind Study to Assess Efficacy and Safety of Dosing Mesalazine 800 mg Tablets (Asacol®) at 2.4 g Once Daily Versus Divided Doses 3 Times Daily for 12 Months in Maintenance of Remission of Ulcerative Colitis.[NCT00708656] | Phase 3 | 213 participants (Actual) | Interventional | 2006-10-31 | Completed | ||
| A Phase III, Randomized, Multi-center, Open-label, 12 to 14 Month Extension Study to Evaluate the Safety and Tolerability of SPD476 (Mesalazine) Given Once Daily vs. Twice Daily for the Maintenance of Ulcerative Colitis in Remission.[NCT00151944] | Phase 3 | 400 participants | Interventional | 2003-11-26 | Completed | ||
| Double-blind, Double-dummy, Randomised, Multicentre, Comparative Study of the Efficacy and Tolerability of Once Daily 3.0 g Mesalazine Granules Versus Three Times Daily 1.0 g Mesalazine Granules in Patients With Active Ulcerative Colitis[NCT00449722] | Phase 3 | 380 participants | Interventional | 2005-07-31 | Completed | ||
| PhaRmacOkinetics and PHarmacodynamic BiomarkErs of Janus Kinase Inhibitor Therapy in PatIents With Ulcerative Colitis (PROPHETIC)[NCT04576000] | 3 participants (Actual) | Observational | 2020-08-25 | Terminated (stopped due to Not able to meet recruitment targets) | |||
| "Azione Chemiopreventiva Della Mesalazina Sul Cancro Del Colon-retto: Studio Pilota Per la Valutazione Degli Effetti Molecolari in Vivo Sulla Via di Segnalazione Proliferativa Della β-catenina (Official Title in Italian Language)"[NCT02077777] | Phase 2 | 21 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| A Multi-center, Investigator-blinded, Randomized, 12-month, Parallel-group, Non-inferiority Study to Compare the Efficacy of 1.6 to 2.4 g Asacol® Therapy QD Versus Divided Dose (BID) in the Maintenance of Remission of Ulcerative Colitis[NCT00505778] | Phase 3 | 1,027 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Counseling to Optimize Medication Adherence in Expectant Mothers With Inflammatory Bowel Disease (COACH-IBD)[NCT03091309] | 220 participants (Anticipated) | Interventional | 2017-10-01 | Recruiting | |||
| Controlled, Randomized, Double-blind Clinical Trial, 24 Months Duration, to Compare the Efficacy, Safety and Tolerability of Andrographolide Versus Placebo in Patients With Progressive Forms of Multiple Sclerosis[NCT02273635] | Phase 1/Phase 2 | 68 participants (Anticipated) | Interventional | 2014-09-30 | Recruiting | ||
| Double-blind, Double-dummy, Randomised, Multicentre, 12-months, Comparative Study of the Efficacy and Tolerability of Once Daily 3.0 g Mesalazine Granules vs. Once Daily 1.5 g Mesalazine Granules vs. Three Times Daily 0.5 g Mesalazine Granules for Mainten[NCT00746447] | Phase 3 | 648 participants (Actual) | Interventional | 2005-05-31 | Completed | ||
| Managing Pediatric Acute Severe Colitis According to the 2011 ECCO-ESPGHAN Guidelines: Efficacy of Infliximab as a Rescue Therapy[NCT02170714] | 31 participants (Actual) | Observational | 2010-05-31 | Completed | |||
| The Effect of Therapeutic Fecal Transplant on the Gut Microbiome in Children With Ulcerative Colitis[NCT02291523] | Phase 1 | 101 participants (Anticipated) | Interventional | 2016-11-01 | Active, not recruiting | ||
| A Double-blind, Randomized, 6 Week, Parallel-group Design Clinical Trial in Patients With Mildly to Moderately Active Ulcerative Colitis to Assess the Safety and Efficacy of Asacol 4.8 g/Day Versus Asacol 2.4 g/Day[NCT00577473] | Phase 3 | 301 participants (Actual) | Interventional | 2001-02-28 | Completed | ||
| A Double-Blind, Randomized, 6-Week, Parallel-Group Design Clinical Trial to Assess Safety and Efficacy of Asacol 4.8 g/Day (800 mg Tablet) Versus Asacol 2.4 g/Day (400 mg Tablet) for the Treatment of Moderately Active Ulcerative Colitis[NCT00073021] | Phase 3 | 386 participants (Actual) | Interventional | 2000-09-30 | Completed | ||
| Manitoba Inflammatory Bowel Disease Cohort Study[NCT03262649] | 388 participants (Actual) | Observational | 2002-03-01 | Completed | |||
| Double-blind, Double-dummy, Randomised, Multi-centre, Comparative Phase III Clinical Study on the Efficacy and Tolerability of an 8 Week Oral Treatment With 9 mg Budesonide or 3 g Mesalazine in Patients With Active Ulcerative Colitis[NCT00747110] | Phase 3 | 343 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| Efficacy of High-dose Corticosteroid Pulses Added to Conventional Oral Corticosteroid Course for Moderate Flares of Ulcerative Colitis.[NCT02921555] | Phase 4 | 75 participants (Actual) | Interventional | 2018-10-11 | Completed | ||
| Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease by Proteomic and Mass Cytometry Approaches[NCT03885713] | Phase 4 | 180 participants (Anticipated) | Interventional | 2019-09-10 | Recruiting | ||
| Measurement of Rectal Levels of 5-aminosalicylic Acid (5-ASA) Using a Novel In-vivo Rectal Dialysis Technique in Healthy Volunteers on Asacol[NCT04032652] | Phase 2 | 2 participants (Actual) | Interventional | 2012-12-31 | Terminated (stopped due to Insufficient enrollment) | ||
| Improving OutcoMes in the Pediatric to Adult Care Transition in Inflammatory Bowel Disease[NCT02085083] | 150 participants (Actual) | Interventional | 2014-07-31 | Completed | |||
| Efficacy and Safety of New Oral Budesonide-MMX™ (CB-01-02) 6 mg and 9 mg Extended Release Tablet Formulations in Patients With Mild or Moderate, Active Ulcerative Colitis. A Multicenter, Randomized, Double-blind, Double Dummy Comparative Study Versus Plac[NCT00679432] | Phase 3 | 510 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Curcumin in Pediatric Inflammatory Bowel Disease: A Forced Dose Titration Study[NCT00889161] | Phase 1 | 11 participants (Actual) | Interventional | 2009-05-31 | Completed | ||
| Non-Pharmacologic Alternatives for the Treatment of Childhood Obesity in Mexico[NCT03670875] | 300 participants (Actual) | Interventional | 2021-07-31 | Completed | |||
| Phase 2a Randomised Double-blind Placebo-controlled Trial to Assess Safety, Efficacy of Artesunate & Curcumin in Crohn's Disease Patients, Who Continue to Have Mild to Moderate Disease Activity on an Adequate Dose of Azathioprine[NCT04713631] | Phase 2 | 40 participants (Anticipated) | Interventional | 2021-01-21 | Recruiting | ||
| Pro-active Fecal Calprotectin Monitoring to Improve Patient Outcomes in Ulcerative Colitis: A Prospective Randomised Control Trial[NCT03549988] | 654 participants (Anticipated) | Observational | 2018-12-01 | Recruiting | |||
| A Double-blind, Randomized, Placebo-Controlled Trial of Curcumin Versus Placebo for Prevention of Relapse in Patients With Ulcerative Colitis[NCT03122613] | 29 participants (Actual) | Interventional | 2017-06-19 | Terminated (stopped due to Decision made by team of investigators) | |||
| The Effects of Daily Anti-inflammatory Supplementation on Foundation Pain Index Scores in Chronic Opiate Patients[NCT05896878] | 20 participants (Anticipated) | Interventional | 2023-07-10 | Enrolling by invitation | |||
| The Correlation Between Anemia of Chronic Diseases, Hepcidin and Vitamin D in IBD Patients[NCT03145896] | 40 participants (Anticipated) | Interventional | 2017-06-01 | Not yet recruiting | |||
| Effect of Aloe Vera in the Inflammation of Patients With Mild Ulcerative Colitis[NCT01783119] | Early Phase 1 | 60 participants (Anticipated) | Interventional | 2012-08-31 | Recruiting | ||
| The Effect of Sulfasalazine on CRH Levels in Pregnant Women With a History of Pre-Term Birth: A Randomized Controlled Trial[NCT05703425] | Phase 2 | 50 participants (Anticipated) | Interventional | 2023-03-01 | Recruiting | ||
| Decisional Influences and IBD Patients' Medication Use[NCT00968721] | 55 participants (Actual) | Observational | 2010-06-30 | Terminated (stopped due to lack of support) | |||
| A Pilot Study to Evaluate the Applicability of the Crohn's Disease Endoscopy Index of Severity to Data Obtained by the Colonic Capsule Endoscopy in Ileocolonic Crohn's Disease[NCT01183845] | Phase 4 | 24 participants (Actual) | Interventional | 2009-04-30 | Completed | ||
| Association of Golimumab Trough Levels With Endoscopic and Histologic Healing in Patients With Ulcerative Colitis[NCT03773445] | 52 participants (Actual) | Observational | 2019-03-01 | Completed | |||
| A Pilot Study of the Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis[NCT00583531] | Phase 2 | 2 participants (Actual) | Interventional | 2007-03-31 | Terminated (stopped due to Lack of enrollment) | ||
| Safety of BB-12 Supplemented Strawberry Yogurt For Healthy Adults on Antibiotics[NCT00848003] | Phase 1 | 40 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Hypnotherapy for Prevention of Relapse in Ulcerative Colitis: a Randomised, Single-blind, Controlled Clinical Trial[NCT00553163] | 26 participants (Actual) | Interventional | 2007-10-31 | Terminated (stopped due to Unable to recruit sufficient numbers of patinets in the time available) | |||
| A Randomized, Multicenter Open Label Study Comparing Cyclosporine With Infliximab in Steroid-refractory Severe Attacks of Ulcerative Colitis[NCT00542152] | Phase 4 | 115 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| An Observational Study of the Immunopathogenesis of and Response to Step-Up Inflammatory Bowel Disease Therapy for Hermansky-Pudlak Syndrome-Associated Colitis[NCT00514982] | Phase 2 | 0 participants (Actual) | Interventional | 2007-08-07 | Withdrawn | ||
| A Phase II, Randomized, Multi-centre, Double-blind, Parallel-group, Dose-ranging, Exploratory Study in Subjects With Mild to Moderate Ulcerative Colitis Treated With SPD476 (Mesalazine) Once Daily[NCT00545389] | Phase 2 | 38 participants (Actual) | Interventional | 2003-02-10 | Completed | ||
| A Phase III, Randomized, Multi-Centre, Double-Blind, Parallel Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SPD476 (Mesalazine) Given Twice Daily (2.4 g/Day) Versus SPD476 Given as a Single Dose (4.8 g/Day) in Subjects With Acute [NCT00503243] | Phase 3 | 280 participants (Actual) | Interventional | 2003-09-30 | Completed | ||
| A Phase III, Randomized, Multi-Centre, Double-blind, Double Dummy, Parallel Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Two Doses of SPD476 (Mesalazine) 2.4g and 4.8g Once Daily, With Reference to ASACOL 0.8g Three Times Daily, [NCT00548574] | Phase 3 | 343 participants (Actual) | Interventional | 2003-12-04 | Completed | ||
| A Randomized Open-label Two-arm Pilot Study to Assess the Safety and Efficacy of Trichuris Suis Ova for the Treatment of Moderate to Severe Chronic Plaque Psoriasis. Protocol: Psoriasis IIT[NCT01836939] | Phase 1 | 8 participants (Actual) | Interventional | 2013-03-31 | Completed | ||
| An Open-label Pilot Study to Assess the Safety and Efficacy of Trichuris Suis Ova for the Treatment of Moderate to Severe Chronic Plaque Psoriasis[NCT01948271] | Phase 1 | 3 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to lack of efficacy) | ||
| Use of Autologous Adult Adipose-Derived Stem/Stromal Cells in Inflammatory Bowel Disease[NCT02952131] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2016-11-30 | Enrolling by invitation | ||
| NIH SUBSTUDY:Randomized, Double-blind, Placebo-controlled, Parallel-group Proof-of-concept Study to Assess the Efficacy, Safety and Tolerability of Two Single Infusions of AIN457 in Patients With Moderate to Severe Active Crohn's Disease[NCT00936585] | 2 participants (Actual) | Interventional | 2009-07-31 | Terminated (stopped due to Study halted by the sponsor) | |||
| An Investigator Initiated Study of Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With Apremilast[NCT03442088] | Phase 2 | 28 participants (Actual) | Interventional | 2018-06-01 | Completed | ||
| Valutazione Dell'Efficacia Di Una Preparazione Commerciale A Base Di Lactobacillus Casei Dg Nella Riduzione Della Sintomatologia Dolorosa Associata Alla Sindrome Dell' Intestino Irritabile (Sii). Studio Clinico Pilota. (Official Title in Italian Language)[NCT02077699] | Phase 4 | 10 participants (Actual) | Interventional | 2012-03-31 | Completed | ||
| Antimicrobial Therapy for Ulcerative Colitis : Evaluation of Two Antibiotic Combinations for Refractory Ulcerative Colitis[NCT03986996] | Phase 2 | 20 participants (Actual) | Interventional | 2019-07-25 | Terminated (stopped due to There is no feasibility to conduct the study) | ||
| Pharmacokinetics of Infliximab and Tumor Necrosis Factor Concentrations in Serum, Stool, and Colonic Mucosa in Acute Severe Ulcerative Colitis[NCT03765450] | 18 participants (Actual) | Observational | 2018-12-21 | Active, not recruiting | |||
| Electronic Linkage for Inflammatory Bowel Disease to Deliver Joint Access to Health Reports[NCT02985476] | 61 participants (Actual) | Interventional | 2010-05-31 | Completed | |||
| Randomized, Double-Blind, Placebo-Controlled Study of VSL#3 Versus Placebo in the Maintenance of Remission in Crohn's Disease[NCT00114465] | Phase 4 | 38 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Supplementation of Extra Virgin Olive Oil Monocultivar Coratina in Patients With Active Ulcerative Colitis[NCT03408847] | 30 participants (Anticipated) | Interventional | 2017-11-20 | Recruiting | |||
| A Cluster Randomized Controlled Trial of a Care-Path for the Management of Ulcerative Colitis[NCT01882426] | Phase 4 | 192 participants (Actual) | Interventional | 2014-05-31 | Terminated | ||
| Low Dose IL-2 for the Treatment of Crohn's Disease[NCT04263831] | Phase 1/Phase 2 | 30 participants (Anticipated) | Interventional | 2021-03-11 | Recruiting | ||
| A Phase I Study of Low Dose Subcutaneous Interleukin-2 (IL-2) For The Treatment of Ulcerative Colitis.[NCT02200445] | Phase 1 | 26 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| Phase 3: Randomised Controlled Trial of Rituximab in Active Ulcerative Colitis[NCT00261118] | Phase 2/Phase 3 | 24 participants (Actual) | Interventional | 2004-04-30 | Completed | ||
| A Randomized, Double-Blind, Comparative Trial of the Safety and Efficacy of Famotidine vs Placebo for the Treatment of Non-Hospitalized Symptomatic Adults With COVID-19[NCT04724720] | Phase 2 | 56 participants (Actual) | Interventional | 2021-01-19 | Active, not recruiting | ||
| New Insight and Knowledge on Anti-inflammatory Effectiveness of Dietary Phenolics (NIKE)[NCT03000101] | 18 participants (Actual) | Interventional | 2017-01-19 | Active, not recruiting | |||
| Pilot Study for the Evaluation of Food Choices and Exclusion of Gluten From the Diet in Patients With Inflammatory Bowel Diseases[NCT05079932] | 45 participants (Anticipated) | Observational | 2021-04-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Between-Group Difference of Endoscopic Score, Change from Baseline. The changes from baseline to week 8 values in sigmoidoscopic (mucosal) appearance scores will be compared between the two treatment groups. A value of 0 in the endoscopic score means normal or inactive disease and a value of 3 means severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between baseline to week 8 indicates treatment success. (NCT01903252)
Timeframe: Baseline and Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| TP05 (Mesalazine) | 0.5 |
| Asacol (Mesalazine) | 0.6 |
"Between-Group Difference of Mayo Score, Change from Baseline The changes from baseline to week 8 values in Mayo scores are compared between the two treatment groups.~The Mayo scoring system is a well-established tool for assessing UC disease activity. The Mayo score is the sum of 4 component sub-scores, each scored on a scale ranging from 0 representing no pathology to 3 for severe disease. The 4 component sub-scores consist of, 1) stool frequency, 2) rectal bleeding, 3) flexible sigmoidoscopy scores, and 4) physician's global assessment. A Mayo score of 0 indicates no pathology and a score of 12, severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A larger change in Mayo score from baseline when patients experienced acute disease, indicates improvement and treatment success." (NCT01903252)
Timeframe: Baseline and Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| TP05 (Mesalazine) | 3.1 |
| Asacol (Mesalazine) | 3.2 |
Between-Group Difference of Partial Mayo Score, Change from Baseline to Week 8 The Partial Mayo Score is the sum of the component sub-scores, 1) stool frequency, 2) rectal bleeding and 3) physician's global assessment. A partial Mayo Score of 0 indicates no disease and a maximum score of 9 indicates severe symptoms. Change from Baseline is calculated Baseline-score minus week 8-score. A larger change in Partial Mayo Score from Baseline where patients experienced acute disease, indicates improvement and treatment success. (NCT01903252)
Timeframe: Baseline and Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| TP05 (Mesalazine) | 2.5 |
| Asacol (Mesalazine) | 2.5 |
"Between-Group Difference of Physician Global Assessment Score, Change from Baseline.~The changes from baseline to week 8 values in the Physician Global Assessment score will be compared between the two treatment groups. A value of 0 means no pathology and a value of 3 means severe disease. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between baseline to week 8 indicates treatment success." (NCT01903252)
Timeframe: Baseline and Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| TP05 (Mesalazine) | 0.6 |
| Asacol (Mesalazine) | 0.7 |
Between-Group Difference of Rectal Bleeding Score, Change from Baseline The changes from baseline to week 8 values in rectal bleeding scores will be compared between the two treatment groups. A value of 0 indicates no rectal bleeding, a value of 3 indicates only blood is passing. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference at week 8 compared to baseline is indicative of treatment success. (NCT01903252)
Timeframe: Baseline and Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| TP05 (Mesalazine) | 0.9 |
| Asacol (Mesalazine) | 1.0 |
Between-Group Difference of Stool Frequency Score, Change from Baseline The changes from baseline to week 8 values in stool frequency will be compared between the two treatment groups. Values for stool frequency range between 0 and 3. A value of 0 indicates normal stool frequency, a value of 3 indicates 5 or more stools than normal. Change from Baseline is calculated Baseline-score minus week 8-score. A large difference between week 8 values and baselines indicates treatment success. (NCT01903252)
Timeframe: Baseline and Week 8
| Intervention | units on a scale (Mean) |
|---|---|
| TP05 (Mesalazine) | 0.9 |
| Asacol (Mesalazine) | 0.9 |
Mayo Score of <= 2 points with no individual sub-score > 1 (NCT01903252)
Timeframe: Week 8
| Intervention | Participants (Count of Participants) |
|---|---|
| TP05 (Mesalazine) | 87 |
| Asacol (Mesalazine, Tillotts Pharma AG) | 95 |
Clinical and Endoscopic Response was defined as a decrease in the Mayo score of ≥3 points from baseline and a reduction of ≥ 30% from baseline with either an accompanying decrease in the rectal bleeding sub-score of at least 1 point or an absolute rectal bleeding sub-score of 0 or 1 at the Week 8 visit. If a subject withdrew from the study prior to Week 8 or their response status was not evaluable due to incomplete and/or invalid data, the subject was considered a non-responder. (NCT01903252)
Timeframe: Week 8
| Intervention | Participants (Count of Participants) |
|---|---|
| TP05 (Mesalazine) | 221 |
| Asacol (Mesalazine) | 236 |
Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS) (NCT01903252)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| TP05 (Mesalazine) | 93 |
| Asacol (Mesalazine, Tillotts Pharma AG) | 113 |
Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS) (NCT01903252)
Timeframe: Week 8
| Intervention | Participants (Count of Participants) |
|---|---|
| TP05 (Mesalazine) | 92 |
| Asacol (Mesalazine, Tillotts Pharma AG) | 110 |
Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS) (NCT01903252)
Timeframe: Week 8 and week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| TP05 (Mesalazine) | 66 |
| Asacol (Mesalazine, Tillotts Pharma AG) | 80 |
A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0. (NCT01903252)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| TP05 (Mesalazine) | 223 |
| Asacol (Mesalazine, Tillotts Pharma AG) | 233 |
A decrease in the Partial Mayo Score of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0. (NCT01903252)
Timeframe: Week 8 and Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| TP05 (Mesalazine) | 216 |
| Asacol (Mesalazine, Tillotts Pharma AG) | 230 |
Endoscopic remission was defined as a Mayo endoscopy subscore of 0 (NCT01903252)
Timeframe: Week 8
| Intervention | Participants (Count of Participants) |
|---|---|
| TP05 (Mesalazine) | 36 |
| Asacol (Mesalazine, Tillotts Pharma AG) | 44 |
Endoscopic response was define as a reduction in the Mayo endoscopic sub score of at least one. (NCT01903252)
Timeframe: Week 8
| Intervention | Participants (Count of Participants) |
|---|---|
| TP05 (Mesalazine) | 185 |
| Asacol (Mesalazine, Tillotts Pharma AG) | 196 |
Rectal bleeding sub-score of 0 was defined as a sub score on the rectal bleeding component of the Mayo score (NCT01903252)
Timeframe: Week 12
| Intervention | Participants (Count of Participants) |
|---|---|
| TP05 (Mesalazine) | 193 |
| Asacol (Mesalazine, Tillotts Pharma AG) | 205 |
Rectal bleeding sub-score of 0 was defined as a sub score on the rectal bleeding component of the Mayo score (NCT01903252)
Timeframe: Week 8
| Intervention | Participants (Count of Participants) |
|---|---|
| TP05 (Mesalazine) | 212 |
| Asacol (Mesalazine, Tillotts Pharma AG) | 226 |
Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS) (NCT01903252)
Timeframe: Week 16
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended Induction | 53 |
A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0. (NCT01903252)
Timeframe: Week 16
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended Induction | 183 |
Percentage of patients achieving the endpoint rectal bleeding sub-score of 0 (NCT01903252)
Timeframe: Week 16
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended Induction | 146 |
Percentage of patients achieving the endpoint stool frequency sub-score of 0 (NCT01903252)
Timeframe: Week 16
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended Induction | 64 |
Percentage of Patients Experiencing Complications related to UC (NCT01903252)
Timeframe: Week 16
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended Induction | 0.0 |
Percentage of patients achieving an Urgency Score of 0. A score of 0 indicates no urgency reported in any of the three days prior to the visit at week 16. A score of 1 indicates urgency reported in any of the three days prior to the visits. (NCT01903252)
Timeframe: Week 16
| Intervention | Participants (Count of Participants) |
|---|---|
| Extended Induction | 109 |
Mayo Score of <= 2 points with no individual sub-score > 1 (NCT01903252)
Timeframe: Week 38
| Intervention | percentage of participants (Number) |
|---|---|
| 1.6g/Day Maintenance Open-Label | 65.8 |
| 3.2/Day Maintenance Open-Label | 39.4 |
| 4.8g/Day Maintenance Open-Label | 29.6 |
Both has to be achieved, Clinical and Endoscopic Response which is defined by a decrease from baseline in the Mayo score of ≥ 3 points and > 30% of the baseline score, with an accompanying decrease in the rectal bleeding sub-score of ≥ 1 point or an absolute rectal bleeding sub-score of 0 or 1. (NCT01903252)
Timeframe: Week 38
| Intervention | percentage of participants (Number) |
|---|---|
| 1.6g/Day Maintenance Open-Label | 89.6 |
| 3.2/Day Maintenance Open-Label | 78.1 |
| 4.8g/Day Maintenance Open-Label | 69.3 |
Clinical Remission was defined as a score of 0 points for both stool frequency and rectal bleeding on the Partial Mayo Clinic Score (PMCS) (NCT01903252)
Timeframe: Week 38
| Intervention | percentage of participant (Number) |
|---|---|
| 1.6g/Day Maintenance Open-Label | 70.3 |
| 3.2/Day Maintenance Open-Label | 33.9 |
| 4.8g/Day Maintenance Open-Label | 30.7 |
A decrease in the PMCS of ≥ 2 points and ≥ 30% from baseline, with a decrease in the rectal bleeding sub-score of ≥ 1 point or absolute rectal bleeding sub-score of 1 or 0. (NCT01903252)
Timeframe: Week 38
| Intervention | percentage of participants (Number) |
|---|---|
| 1.6g/Day Maintenance Open-Label | 94.1 |
| 3.2/Day Maintenance Open-Label | 83.9 |
| 4.8g/Day Maintenance Open-Label | 78.4 |
Percentage of each dose group achieving an endoscopy sub score of 0 (NCT01903252)
Timeframe: Week 38
| Intervention | percentage of participants (Number) |
|---|---|
| 1.6g/Day Maintenance Open-Label | 37.6 |
| 3.2/Day Maintenance Open-Label | 32.4 |
| 4.8g/Day Maintenance Open-Label | 13.6 |
Endoscopic response was define as a reduction in the Mayo endoscopic sub score of at least one. (NCT01903252)
Timeframe: Week 38
| Intervention | percentage of participants (Number) |
|---|---|
| 1.6g/Day Maintenance Open-Label | 73.8 |
| 3.2/Day Maintenance Open-Label | 58.8 |
| 4.8g/Day Maintenance Open-Label | 53.3 |
No urgency is a score of 0 and indicates that patients did not report urgency during any of the three days prior to the visit at week 38. A score of 1 indicates that urgency was reported during any of these three days. (NCT01903252)
Timeframe: Week 38
| Intervention | Participants (Count of Participants) |
|---|---|
| 1.6g/Day Maintenance Open-Label | 161 |
| 3.2/Day Maintenance Open-Label | 173 |
| 4.8g/Day Maintenance Open-Label | 109 |
Percentage of each dose group achieving the endpoint rectal bleeding subscore 0 (NCT01903252)
Timeframe: Week 38
| Intervention | percentage of participants (Number) |
|---|---|
| 1.6g/Day Maintenance Open-Label | 88.1 |
| 3.2/Day Maintenance Open-Label | 76.3 |
| 4.8g/Day Maintenance Open-Label | 74.9 |
Patients achieving a Stool Frequency sub-score of 0 (NCT01903252)
Timeframe: Week 38
| Intervention | Participants (Count of Participants) |
|---|---|
| 1.6g/Day Maintenance Open-Label | 148 |
| 3.2/Day Maintenance Open-Label | 101 |
| 4.8g/Day Maintenance Open-Label | 66 |
Percentage of Patients with Complications related to UC (NCT01903252)
Timeframe: Week 38
| Intervention | Participants (Count of Participants) |
|---|---|
| 1.6g/Day Maintenance Open-Label | 3 |
| 3.2/Day Maintenance Open-Label | 2 |
| 4.8g/Day Maintenance Open-Label | 1 |
Clinical response defined as an improvement in UCDAI from Baseline of ≥3 points with a rectal bleeding score ≤1. UCDAI is the sum (0 to 12) of 4 severity scores (0 to 3). Rectal bleeding was based on information recorded in daily participant diaries. The diary entries were averaged for rectal bleeding for 3 days prior to (and closest to) Day 56 with non-missing diary data, within 5 days prior to (and closest to) Day 56. The 5 days did not include any days of the flexible sigmoidoscopy (or colonoscopy) or the preparation for the flexible sigmoidoscopy (or colonoscopy). These averages were rounded to integer values. If either subscore could not be calculated because of missing data, the score for that UCDAI component was set to missing. Participants with insufficient data at Day 56 were excluded from the analysis. (NCT01532648)
Timeframe: Baseline up to Day 56
| Intervention | Participants (Count of Participants) |
|---|---|
| Budesonide MMX | 101 |
| Placebo | 86 |
Clinical remission defined as a score of 0 for rectal bleeding and 0 for stool frequency components from the Ulcerative Colitis Disease Activity Index (UCDAI). UCDAI is the sum (0 to 12) of 4 severity scores (0 to 3). Stool frequency and rectal bleeding were based on information recorded in daily participant diaries. The diary entries were averaged for rectal bleeding and stool frequency for 3 days prior to (and closest to) Day 56 with non-missing diary data, within 5 days prior to (and closest to) Day 56. The 5 days did not include any days of the flexible sigmoidoscopy (or colonoscopy) or the preparation for the flexible sigmoidoscopy (or colonoscopy). These averages were rounded to integer values. If either subscore could not be calculated because of missing data, the score for that UCDAI component was set to missing. Participants with insufficient data at Day 56 were excluded from the analysis. Participants who had clinical remission at Baseline were classified as non-responders. (NCT01532648)
Timeframe: Baseline up to Day 56
| Intervention | Participants (Count of Participants) |
|---|---|
| Budesonide MMX | 56 |
| Placebo | 52 |
Endoscopic remission was defined as a score of 0 in the mucosal appearance component subscore of the UCDAI at Day 56. UCDAI is the sum (0 to 12) of 4 severity scores (0 to 3). Mucosal appearance was based on endoscopy results. If the mucosal appearance subscore could not be calculated because of missing data, endoscopic remission was set to missing. Participants with insufficient data at Day 56 were excluded from the analysis. (NCT01532648)
Timeframe: Screening and Day 56
| Intervention | Participants (Count of Participants) |
|---|---|
| Budesonide MMX | 46 |
| Placebo | 28 |
Participants achieved histologic healing if histologic assessments of all biopsy specimens were graded as 0 (normal mucosa). If the score for ≥1 sample was missing, the overall score at that visit was set to missing. Participants with insufficient data at Day 56 were excluded from analysis. (NCT01532648)
Timeframe: Baseline and Day 56
| Intervention | Participants (Count of Participants) |
|---|---|
| Budesonide MMX | 62 |
| Placebo | 40 |
UCDAI remission was defined as a total UCDAI score ≤1 with subscores of 0 for rectal bleeding, stool frequency, and mucosal appearance of the colon. UCDAI is the sum (0 to 12) of 4 severity scores (0 to 3). Stool frequency and rectal bleeding were based on information recorded in daily participant diaries and mucosal appearance was based on endoscopy results. The diary entries were averaged for rectal bleeding and stool frequency for 3 days prior to (and closest to) Day 56 with non-missing diary data, within 5 days prior to (and closest to) Day 56. The 5 days did not include any days of the flexible sigmoidoscopy (or colonoscopy) or the preparation for the flexible sigmoidoscopy (or colonoscopy). These averages were rounded to integer values. If the subscore could not be calculated because of missing data, the score for that UCDAI component was set to missing. Participants with insufficient data at Day 56 were excluded from the analysis. (NCT01532648)
Timeframe: Baseline up to Day 56
| Intervention | Participants (Count of Participants) |
|---|---|
| Budesonide MMX | 30 |
| Placebo | 17 |
Treatment failure was defined as an unchanged, worsened, or missing UCDAI score at Day 56. UCDAI is the sum (0 to 12) of 4 severity scores (0 to 3). Stool frequency and rectal bleeding was based on information recorded in daily participant diaries and mucosal appearance was based on endoscopy results. The diary entries were averaged for rectal bleeding and stool frequency for 3 days prior to (and closest to) Day 56 with non-missing diary data, within 5 days prior to (and closest to) Day 56. The 5 days did not include any days of the flexible sigmoidoscopy (or colonoscopy) or the preparation for the flexible sigmoidoscopy (or colonoscopy). These averages were rounded to integer values. If the subscore could not be calculated because of missing data, the score for that UCDAI component was set to missing. Participants with insufficient data at Day 56 were excluded from the analysis. (NCT01532648)
Timeframe: Baseline up to Day 56
| Intervention | Participants (Count of Participants) |
|---|---|
| Budesonide MMX | 45 |
| Placebo | 61 |
The IBD-QoL questionnaire was self-completed by the participant. The IBD-QoL is a disease-specific instrument to evaluate the quality of life of participants with UC. This 32-item questionnaire has 4 dimensions: bowel function, emotional function, systemic symptoms, and social function. The total score is presented, which ranges from 32 to 224, with higher scores indicating a better quality of life. The scores of participants in remission usually range from 170 to 190. If >50% of the questionnaire answers for a particular dimension were missing, this dimension score was set to missing. The total score for the IBD-QoL was the sum of the domain scores, however, if any dimension score was missing, the total IBD-QoL score was set to missing. (NCT01532648)
Timeframe: Baseline, Days 14, 28, and 56
| Intervention | scores on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline | Change at Day 14 | Change at Day 28 | Change at Day 56 | |
| Budesonide MMX | 132.8 | 24.4 | 31.8 | 31.1 |
| Placebo | 134.1 | 21.3 | 25.7 | 31.7 |
Number of participants who received a colectomy within 52 weeks (NCT01536535)
Timeframe: Within 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Mild UC Disease | 2 |
| Moderate to Severe UC | 23 |
Number of participants who needed additional therapy or colectomy. Additional therapy included Anti-Tumour Necrosis Factor alpha (TNFα), Calcineurin inhibitor, Immunomodulator (NCT01536535)
Timeframe: Within 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Mild UC Disease | 46 |
| Moderate to Severe UC | 151 |
"Week 52 CS-free remission: Number of participants with a PUCAI < 10 and no corticosteroids (CS) for 28 days without additional therapy or colectomy. Participants in both groups received corticosteroids, biologics, or colectomies, if symptomatic.~The Pediatric Ulcerative Colitis Activity Index (PUCAI) is a non-invasive disease activity index. The index measures include abdominal pain, rectal bleeding, stool consistency, number of stools per 24 hours, nocturnal stools, and activity level. A total score less than 10 indicates remission, Mild disease activity is 10-30, Moderate 35-60, Severe disease activity 65-85." (NCT01536535)
Timeframe: 52 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Mild UC | 80 |
| Moderate to Severe UC | 70 |
Clinical remission was defined as a score of 0 for rectal bleeding and stool frequency. Rectal bleeding is assessed on a scale from 0-3 (0 = no rectal bleeding, 1 = streaks of blood, 2 = obvious blood, 3 = mostly blood). Stool frequency is assessed on a scale of 0-2 (0 = 0-1 more than normal per day, 1 = 2-3 more than normal per day, 2 = 4 or more than normal per day). (NCT01124149)
Timeframe: 12 months
| Intervention | percentage of subjects (Number) |
|---|---|
| MMX Mesalamine/ Mesalazine (Complete Remission Acute Phase) | 58.8 |
| MMX Mesalamine/ Mesalazine (Partial Remission Acute Phase) | 40.4 |
Complete remission was defined as a modified Ulcerative Colitis Disease Activity Index (UC-DAI) <=1 with a score of 0 for rectal bleeding and stool frequency and at least a 1-point reduction in endoscopy score from baseline. The modified UC-DAI score is the sum of the scores of 4 parameters (stool frequency, rectal bleeding, endoscopy score, and physician global assessment), each scoring between 0 and 3, making 12 the worst score. Endoscopy score (mucosal appearance) ranges from 0-3 (0 = normal, 1 = mild , 2 = moderate, 3 = severe). Rectal bleeding is assessed on a scale from 0-3 (0 = no rectal bleeding, 1 = streaks of blood, 2 = obvious blood, 3 = mostly blood). Stool frequency is assessed on a scale of 0-2 (0 = 0-1 more than normal per day, 1 = 2-3 more than normal per day, 2 = 4 or more than normal per day). (NCT01124149)
Timeframe: 12 months
| Intervention | percentage of subjects (Number) |
|---|---|
| MMX Mesalamine/ Mesalazine (Complete Remission Acute Phase) | 47.8 |
| MMX Mesalamine/ Mesalazine (Partial Remission Acute Phase) | 26.0 |
Complete (clinical and endoscopic) remission was defined as a modified UC-DAI <=1 with a score of 0 for rectal bleeding and stool frequency and at least a 1-point reduction in endoscopy score from baseline. The modified UC-DAI score is the sum of the scores of 4 parameters (stool frequency, rectal bleeding, endoscopy score, and physician global assessment), each scoring between 0 and 3, making 12 the worst score. Endoscopy score (mucosal appearance) ranges from 0-3 (0 = normal, 1 = mild , 2 = moderate, 3 = severe). Rectal bleeding is assessed on a scale from 0-3 (0 = no rectal bleeding, 1 = streaks of blood, 2 = obvious blood, 3 = mostly blood). Stool frequency is assessed on a scale of 0-2 (0 = 0-1 more than normal per day, 1 = 2-3 more than normal per day, 2 = 4 or more than normal per day). (NCT01124149)
Timeframe: 8 Weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| MMX Mesalamine/ Mesalazine | 25.9 |
Partial remission was defined as a modified UC-DAI <=3 with a combined stool frequency and rectal bleeding score of <=1 and not in complete remission. The modified UC-DAI score is the sum of the scores of 4 parameters (stool frequency, rectal bleeding, endoscopy score, and physician global assessment), each scoring between 0 and 3, making 12 the worst score. Endoscopy score (mucosal appearance) ranges from 0-3 (0 = normal, 1 = mild , 2 = moderate, 3 = severe). Rectal bleeding is assessed on a scale from 0-3 (0 = no rectal bleeding, 1 = streaks of blood, 2 = obvious blood, 3 = mostly blood). Stool frequency is assessed on a scale of 0-2 (0 = 0-1 more than normal per day, 1 = 2-3 more than normal per day, 2 = 4 or more than normal per day). (NCT01124149)
Timeframe: 8 weeks
| Intervention | percentage of subjects (Number) |
|---|---|
| MMX Mesalamine/ Mesalazine | 39.3 |
Subjects with mucosal healing were defined as subjects who had an endoscopy score <=1. Endoscopy score (mucosal appearance) ranges from 0-3 (0 = normal, 1 = mild , 2 = moderate, 3 = severe). (NCT01124149)
Timeframe: 12 months
| Intervention | percentage of subjects (Number) |
|---|---|
| MMX Mesalamine/ Mesalazine (Complete Remission Acute Phase) | 76.4 |
| MMX Mesalamine/ Mesalazine (Partial Remission Acute Phase) | 63.5 |
Relapse was defined in the Maintenance Phase as the need for alternative treatment for UC (including surgery); subjects were classified as having a relapse if they had withdrawn from the study due to a lack of efficacy. (NCT01124149)
Timeframe: 12 months
| Intervention | percentage of subjects (Number) |
|---|---|
| MMX Mesalamine/ Mesalazine (Complete Remission Acute Phase) | 6.0 |
| MMX Mesalamine/ Mesalazine (Partial Remission Acute Phase) | 10.5 |
Improvement was defined as at least a 1-point reduction in the rectal bleeding score from baseline at each assessment point. Rectal bleeding is assessed on a scale from 0-3 (0 = no rectal bleeding, 1 = streaks of blood, 2 = obvious blood, 3 = mostly blood). (NCT01124149)
Timeframe: 3 and 8 weeks
| Intervention | percentage of subjects (Number) | |
|---|---|---|
| Week 3 | Week 8 | |
| MMX Mesalamine/ Mesalazine | 42.4 | 59.8 |
Improvement was defined as at least a 1-point reduction in the stool frequency score from baseline at each assessment point. Stool frequency is assessed on a scale of 0-2 (0 = 0-1 more than normal per day, 1 = 2-3 more than normal per day, 2 = 4 or more than normal per day). (NCT01124149)
Timeframe: 3 and 8 weeks
| Intervention | percentage of subjects (Number) | |
|---|---|---|
| 3 Weeks | 8 Weeks | |
| MMX Mesalamine/ Mesalazine | 38.5 | 58.9 |
Clinical remission defined as a score of 0 for stool frequency, 0 for rectal bleeding and no urgency (NCT01059344)
Timeframe: 10 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Mesalamin | 57 |
| Placebo | 30 |
Endoscopic remission is defined as a sigmoidoscopy score of 1 or less (NCT01059344)
Timeframe: 10 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Mesalamin | 73 |
| Placebo | 52 |
Endoscopic remission is defined as a sigmoidoscopy score of 1 or less (NCT01059344)
Timeframe: 6 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Mesalamin | 64 |
| Placebo | 35 |
Improvement is defined as a reduction of at least 3 points from baseline in the modified UC-DAI score. (minumum 3, maximum 7, higher absolute UC-DAI scores indicate more severe disease) (NCT01059344)
Timeframe: 10 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Mesalamin | 88 |
| Placebo | 57 |
Improvement is defined as a reduction of at least 3 points from baseline in the modified UC-DAI score. (minumum 3, maximum 7, higher absolute UC-DAI scores indicate more severe disease) (NCT01059344)
Timeframe: 6 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Mesalamin | 83 |
| Placebo | 47 |
Clinical remission defined as stool frequency score of 0, rectal bleeding score of 0, no urgency (NCT01059344)
Timeframe: 6 weeks
| Intervention | participants (Number) |
|---|---|
| Mesalamin | 42 |
| Placebo | 29 |
Clinical Remission, defined as stool frequency score of 0, rectal bleeding score of 0 and absence of urgency in subjects with adequate disease extent at baseline confirmed by central reading. (NCT01059344)
Timeframe: 6 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Mesalamin | 31 |
| Placebo | 12 |
(NCT00652145)
Timeframe: at 6 weeks after randomization
| Intervention | participants (Number) |
|---|---|
| Increase Dose of Mesalamine | 10 |
| Maintain Baseline Mesalamine Dose | 2 |
(NCT00652145)
Timeframe: at 6 weeks after randomization
| Intervention | participants (Number) |
|---|---|
| Increase Dose of Mesalamine | 10 |
| Maintain Baseline Mesalamine Dose | 3 |
(NCT00652145)
Timeframe: 6 weeks after randomization
| Intervention | participants (Number) |
|---|---|
| Increase Mesalamine Dose by 2.4g/Day | 7 |
| Maintain Mesalmine Dose | 1 |
AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body. (NCT01442688)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4
| Intervention | h*ug/ml (Mean) |
|---|---|
| Amoxicillin + MMX Placebo | 27.8 |
| Amoxicillin + MMX Mesalazine/Mesalamine | 28.3 |
Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated. (NCT01442688)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4
| Intervention | ug/ml (Mean) |
|---|---|
| Amoxicillin + MMX Placebo | 10.3 |
| Amoxicillin + MMX Mesalazine/Mesalamine | 10.2 |
AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure of how much and how long a drug stays in a body. (NCT01469637)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4
| Intervention | h*ug/ml (Mean) |
|---|---|
| Sulfamethoxazole + MMX Placebo | 786 |
| Sulfamethoxazole + MMX Mesalazine/Mesalamine | 909 |
Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated. (NCT01469637)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4
| Intervention | ug/ml (Mean) |
|---|---|
| Sulfamethoxazole + MMX Placebo | 89.1 |
| Sulfamethoxazole + MMX Mesalazine/Mesalamine | 100 |
AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body. (NCT01402947)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4
| Intervention | ng*h/ml (Mean) |
|---|---|
| MMX Placebo + Ciprofloxacin | 7805 |
| MMX Mesalazine/Mesalamine + Ciprofloxacin | 7934 |
Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated. (NCT01402947)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4
| Intervention | ng/ml (Mean) |
|---|---|
| MMX Placebo + Ciprofloxacin | 1455 |
| MMX Mesalazine/Mesalamine + Ciprofloxacin | 1433 |
AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body. (NCT01418365)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4
| Intervention | ng*h/ml (Mean) |
|---|---|
| Metronidazole + MMX Placebo | 217686 |
| Metronidazole + MMX Mesalazine/Mesalamine | 215809 |
Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated. (NCT01418365)
Timeframe: Assessed over a 24-hour period starting post-dose on day 4
| Intervention | ng/ml (Mean) |
|---|---|
| Metronidazole + MMX Placebo | 28193 |
| Metronidazole + MMX Mesalazine/Mesalamine | 28057 |
Endoscopic remission is defined as an endoscopy score of less than or equal to 1. Endoscopy score (mucosal appearance) ranges from 0-3 (0 = normal [intact vascular pattern; no friability or granulation], 1 = mild [erythema; decreased vascular pattern; minimal granularity], 2 = moderate [marked erythema; granularity; friability; absent vascular pattern; bleeding with minimal trauma; no ulcerations], 3 = severe [ulceration; spontaneous bleeding]. (NCT00446849)
Timeframe: 12 Months
| Intervention | Participants (Number) |
|---|---|
| MMX Mesalamine (Maintenance Phase) | 124 |
Quiescent UC is defined as scores of 0 for both rectal bleeding and bowel movements. Rectal bleeding is assessed on a scale from 0-3 (0 = no rectal bleeding, 1 = streaks of blood, 2 = obvious blood, 3 = mostly blood). Bowel movements are assessed on a scale of 0-2 (0 = 0-1 more than normal per day, 1 = 2-3 more than normal per day, 2 = 4 or more than normal per day). (NCT00446849)
Timeframe: 12 Months
| Intervention | Participants (Number) |
|---|---|
| MMX Mesalamine (Maintenance Phase) | 101 |
Clinical recurrence is defined as 4 or more bowel movements per day above the subject's normal frequency and associated with any of the following: urgency, abdominal pain, or rectal bleeding. Compliance is a subject's adherence to a recommended course of treatment and for this study is calculated: (Sum of days' supplies dispensed) divided by (Sum of days in all refill intervals) x 100. (NCT00446849)
Timeframe: 12 months
| Intervention | Percent of participants (Number) | |
|---|---|---|
| < 80% Compliant (n = 40) | 80-120% Compliant (n = 154) | |
| MMX Mesalamine (Maintenance Phase) | 52.5 | 31.2 |
Clinical recurrence is defined as 4 or more bowel movements per day above the subject's normal frequency and associated with any of the following: urgency, abdominal pain, or rectal bleeding. Compliance is a subject's adherence to a recommended course of treatment and for this study is calculated: [(Sum of days' supplies dispensed) divided by (Sum of days in all refill intervals)] x 100. (NCT00446849)
Timeframe: 6 Months
| Intervention | Percent of participants (Number) | ||
|---|---|---|---|
| < 80% Compliant (n = 36) | 80-120% Compliant (n = 158) | > 120% Compliant (n = 2) | |
| MMX Mesalamine (Maintenance Phase) | 36.1 | 20.9 | 0 |
Clinical recurrence is defined as 4 or more bowel movements per day above the subject's normal frequency and associated with any of the following: urgency, abdominal pain, or rectal bleeding. (NCT00446849)
Timeframe: 12 Months
| Intervention | participants (Number) | ||
|---|---|---|---|
| Yes | No | Missing | |
| MMX Mesalamine (Maintenance Phase) | 69 | 125 | 13 |
Clinical recurrence is defined as 4 or more bowel movements per day above the subject's normal frequency and associated with any of the following: urgency, abdominal pain, or rectal bleeding. (NCT00446849)
Timeframe: 6 months
| Intervention | participants (Number) | ||
|---|---|---|---|
| Yes | No | Missing | |
| MMX Mesalamine (Maintenance Phase) | 46 | 150 | 11 |
PUCAI 0-85, abdominal pain (no pain/0, pain ignored/5, pain not ignored/10), rectal bleeding (none/0, small <50% stool/10, small with most stools/20, large >50% stool/30), stool consistency (formed/0, partially/5, unformed/10), # per 24 hrs (0-2/0, 3-5/5, 6-8/10, >8/15), nocturnal bowel movements (no/0, yes/10), activity level (no limitation/0, occasional limitation/5, severely restricted/10) Remission <10, Mild 10-34, Moderate 35-64, Severe 65-85, Success score<10 at Wk 6 (complete) or reduction of >=20 points baseline to Wk 6 with Wk 6 score>=10 (partial) (NCT00713310)
Timeframe: Baseline and 6 weeks
| Intervention | % participants with treatment success (Number) |
|---|---|
| Low Dose | 56.1 |
| High Dose | 55.0 |
PUCAI 0-85, abdominal pain amended (no pain/0, very mild/2.5, mild/5, moderate/7.5, severe/10), rectal bleeding (none/0, small <50% stool/10, small with most stools/20, large >50% stool/30), stool consistency (formed/0, partially/5, unformed/10), # per 24 hrs (0-2/0, 3-5/5, 6-8/10, >8/15), nocturnal bowel movements (no/0, yes/10), activity level (no limitation/0, occasional limitation/5, severely restricted/10) Remission <10, Mild 10-34, Moderate 35-64, Severe 65-85, Success score<10 at Wk 6 (complete) or reduction of >=20 points baseline to Wk 6 with Wk 6 score>=10 (partial) (NCT00713310)
Timeframe: Baseline and Week 6
| Intervention | % participants with treatment success (Number) |
|---|---|
| Low Dose | 56.1 |
| High Dose | 57.5 |
Number of participants who prematurely discontinued treatment due to any reason were reported. (NCT00326209)
Timeframe: Baseline up to Month 24
| Intervention | Participants (Count of Participants) |
|---|---|
| Encapsulated Mesalamine Granules (eMG) | 282 |
Vital signs included systolic and diastolic blood pressure, pulse rate, body temperature, or body weight. (NCT00326209)
Timeframe: Baseline, up to follow-up visit (Month 24.5)
| Intervention | Participants (Count of Participants) |
|---|---|
| Encapsulated Mesalamine Granules (eMG) | 0 |
An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A TEAE was defined as any event with a start date occurring on or after treatment Day 1 or, if pre-existing, worsening after treatment Day 1. Serious AEs were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section. (NCT00326209)
Timeframe: Baseline (Day 1) up to follow-up (24.5 months)
| Intervention | Participants (Count of Participants) |
|---|---|
| Encapsulated Mesalamine Granules (eMG) | 280 |
Criteria for potentially clinically significant abnormal hematology and blood chemistry values included: hemoglobin (grams/deciliter [g/dL]): <10 and ≥3 decrease, or >20; hematocrit (%): <30 and ≥10 decrease, or >60; platelets (*10^9 cells/liter): <100 or >700 (normal: 150-400); white blood cells (*10^9 cells/liter): <2.3 or >16.2 (normal: 3.5-11.1); alanine aminotransferase (units/liter [U/L]): ≥3 * upper limit of normal (ULN) (normal range 0-47 U/L); aspartate aminotransferase (U/L): ≥3 * ULN (normal range 0-37 U/L); total bilirubin (micromoles/liter [µmol/L]): >2 times; and calcium creatinine clearance (milliliters/minute [mL/min]): ≤50. (NCT00326209)
Timeframe: Baseline up to follow-up (24.5 months)
| Intervention | Participants (Count of Participants) | |||||||
|---|---|---|---|---|---|---|---|---|
| Hemoglobin (g/dL) | Hematocrit (%) | Platelets (*10^9 cells/L) | White blood cells (*10^9 cells/L) | Alanine aminotransferase (U/L) | Aspartate aminotransferase (U/L) | Total bilirubin (µmol/L) | Calcium creatinine clearance (mL/min) | |
| Encapsulated Mesalamine Granules (eMG) | 8 | 7 | 5 | 13 | 3 | 3 | 6 | 2 |
AUC can be used as a measure of drug exposure. It is derived from drug concentration and time so it gives a measure how much and how long a drug stays in a body. (NCT01130844)
Timeframe: 2, 4, 6, 9, 12, 16, and 24 hours post-dose on day 7
| Intervention | ug*h/L (Mean) |
|---|---|
| MMX Mesalamine (30mg/kg) | 21411 |
| MMX Mesalamine (60 mg/kg) | 46173 |
| MMX Mesalamine (100 mg/kg) | 49213 |
(NCT01130844)
Timeframe: 2, 4, 6, 9, 12, 16, and 24 hours post-dose on day 7
| Intervention | ug*h/L (Mean) |
|---|---|
| MMX Mesalamine Metabolite (30mg/kg) | 30942 |
| MMX Mesalamine Metabolite (60 mg/kg) | 58119 |
| MMX Mesalamine Metabolite (100 mg/kg) | 63067 |
(NCT01130844)
Timeframe: Over a 24-hour period starting on day 7
| Intervention | L/h (Mean) |
|---|---|
| MMX Mesalamine Metabolite (30mg/kg) | 16.2 |
| MMX Mesalamine Metabolite (60 mg/kg) | 12.2 |
| MMX Mesalamine Metabolite (100 mg/kg) | 10.0 |
(NCT01130844)
Timeframe: Over a 24-hour period starting on day 7
| Intervention | ug/L (Mean) |
|---|---|
| MMX Mesalamine Metabolite (30mg/kg) | 2396 |
| MMX Mesalamine Metabolite (60 mg/kg) | 4113 |
| MMX Mesalamine Metabolite (100 mg/kg) | 4968 |
(NCT01130844)
Timeframe: Over a 24-hour period starting on day 7
| Intervention | mg (Mean) |
|---|---|
| MMX Mesalamine (30mg/kg) | 162 |
| MMX Mesalamine (60 mg/kg) | 298 |
| MMX Mesalamine (100 mg/kg) | 235 |
(NCT01130844)
Timeframe: Over a 24-hour period starting on day 7
| Intervention | mg (Mean) |
|---|---|
| MMX Mesalamine Metabolite (30mg/kg) | 532 |
| MMX Mesalamine Metabolite (60 mg/kg) | 708 |
| MMX Mesalamine Metabolite (100 mg/kg) | 593 |
Cmax is a term that refers to the maximum (or peak) concentration that a drug achieves in the body after the drug has been administrated. (NCT01130844)
Timeframe: Over a 24-hour period starting on day 7
| Intervention | ug/L (Mean) |
|---|---|
| MMX Mesalamine (30mg/kg) | 1884 |
| MMX Mesalamine (60 mg/kg) | 3825 |
| MMX Mesalamine (100 mg/kg) | 4314 |
The percentage of the dose absorbed was calculated as: 100 x (Xu0-24h 5-ASA + [0.7847* Xu0-24h Ac-5-ASA])/dose, where 0.7847 is the ratio of the molecular weight of 5-ASA (153.14) to the molecular weight of Ac-5-ASA (195.15). Xu0-24h is equal to the cumulative amount recovered in urine in the time interval of 0 to 24 hours. (NCT01130844)
Timeframe: Over a 24-hour period starting on day 7
| Intervention | percentage of dose absorbed (Mean) |
|---|---|
| MMX Mesalamine (30mg/kg) | 29.4 |
| MMX Mesalamine (60 mg/kg) | 27.0 |
| MMX Mesalamine (100 mg/kg) | 22.1 |
Tmax is the time after administration of a drug when the maximum plasma concentration in the body is reached. (NCT01130844)
Timeframe: Over a 24-hour period starting on day 7
| Intervention | hours (Median) |
|---|---|
| MMX Mesalamine (30mg/kg) | 6.00 |
| MMX Mesalamine (60 mg/kg) | 8.98 |
| MMX Mesalamine (100 mg/kg) | 1.98 |
(NCT01130844)
Timeframe: Over a 24-hour period starting on day 7
| Intervention | hours (Median) |
|---|---|
| MMX Mesalamine Metabolite (30mg/kg) | 9.00 |
| MMX Mesalamine Metabolite (60 mg/kg) | 7.48 |
| MMX Mesalamine Metabolite (100 mg/kg) | 1.98 |
Clearance of a substance from the blood by the kidneys. (NCT01130844)
Timeframe: Over a 24-hour period starting on day 7
| Intervention | L/h (Mean) |
|---|---|
| MMX Mesalamine (30mg/kg) | 6.48 |
| MMX Mesalamine (60 mg/kg) | 5.94 |
| MMX Mesalamine (100 mg/kg) | 4.95 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. BF subscore ranged from 0-3, where 0 indicated normal number of stools per day and 3 indicated 5 or more stools than normal. PGA subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. Endoscopy subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. MMDAI total score ranged from 0-12, where higher score indicated severe disease. Missing data was imputed using LOCF method. (NCT01008410)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 52.6 |
| Placebo | 37.9 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices:stool frequency, rectal bleeding, physician's global assessment and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding MMDAI subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. Missing data was imputed using LOCF method. (NCT01008410)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 46.6 |
| Placebo | 28.0 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. Bowel frequency (BF) subscore ranged from 0-3, where 0 indicated normal number of stools per day and 3 indicated 5 or more stools than normal. PGA subscore ranged from 0-3, where 0 indicated normal disease and 3 indicated severe disease. Missing data was imputed using LOCF method. (NCT01008410)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 41.4 |
| Placebo | 25.8 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, physician's global assessment and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Endoscopy subscale ranged from 0-3, where 0 = normal or inactive disease, 1 = mild disease, 2 = moderate disease and 3 = severe disease (spontaneous bleeding, ulceration). Percentage of participants with normal or mild disease have been presented in this outcome measure. Missing data was imputed using LOCF method. (NCT01008410)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 55.6 |
| Placebo | 43.2 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, physician's global assessment and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. BF subscore ranged from 0-3, where 0 indicated normal number of stools per day and 3 indicated 5 or more stools than normal. Physician global assessment (PGA) subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. Endoscopy subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. MMDAI total score ranged from 0-12, where higher score indicated severe disease. Missing data was imputed using LOCF method. (NCT01008410)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 45.9 |
| Placebo | 30.3 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Endoscopy subscore ranged from 0-3, where 0 = normal or inactive disease, 1 = mild disease (erythema, decreased vascular pattern), 2 = moderate disease (marked erythema, absent vascular pattern, friability, erosions), and 3 = severe disease (spontaneous bleeding, ulceration). Missing data was imputed using LOCF method. (NCT01008410)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 57.1 |
| Placebo | 47.7 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding MMDAI subscore ranged from 0-3, where 0 = no blood seen, 1 = streaks of blood with stool less than half the time, 2 = obvious blood with stool most of the time, and 3 indicated blood alone passed. Missing data was imputed using LOCF method. (NCT01008410)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 70.7 |
| Placebo | 53.0 |
Remission was a combined assessment of clinical and endoscopic variables, defined as an endoscopy score of less than or equal to (<=) 1, a rectal bleeding score of 0, and an improvement or no change from baseline in stool frequency subscales of the Modified Mayo Disease Activity Index (MMDAI) at the end of 6 weeks of treatment. MMDAI was used to assess the overall disease activity for each participant. MMDAI evaluated 4 indices: stool frequency, rectal bleeding, physician's global assessment (PGA) and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Stool frequency MMDAI subscore ranged from 0-3, where 0 indicated normal number of stools per day and 3 indicated 5 or more stools than normal. Rectal bleeding MMDAI subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. Endoscopy MMDAI subscore ranged from 0-3, where 0 indicated normal or inactive disease and 3 indicated severe disease (spontaneous bleeding, ulceration). (NCT01008410)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 38.3 |
| Placebo | 25.8 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. BF subscore ranged from 0-3, where 0 indicated normal number of stools per day and 3 indicated 5 or more stools than normal. PGA subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. Endoscopy subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. MMDAI total score ranged from 0-12, where higher score indicated severe disease. Missing data was imputed using LOCF method. (NCT01008410)
Timeframe: Baseline, Week 6
| Intervention | unit on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Bowel frequency score: Baseline | Bowel frequency score: Change at Week 6 | Rectal Bleeding score:Baseline | Rectal Bleeding score: Change at Week 6 | PGA score:Baseline | PGA score: Change at Week 6 | Endoscopy score:Baseline | Endoscopy score: Change at Week 6 | Total score:Baseline | Total score: Change at Week 6 | |
| Budesonide | 1.8 | -0.7 | 2.1 | -1.2 | 1.8 | -0.8 | 2.1 | -0.8 | 7.8 | -3.5 |
| Placebo | 1.9 | -0.5 | 2.1 | -0.8 | 1.8 | -0.5 | 2.1 | -0.5 | 7.9 | -2.4 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, physician's global assessment and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding MMDAI subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. Percentage of participants who were rectal bleeding responder at scheduled assessments were reported. Rectal bleeding responders were defined as those participants who achieved a rectal bleeding MMDAI subscale score of 0 during the treatment period. Missing data was imputed using LOCF method. (NCT01008410)
Timeframe: Weeks 1, 2, 4, and 6
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Responder at 1 Assessment | Responder at 2 Assessment | Responder at 3 Assessment | Responder at 4 Assessment | |
| Budesonide | 12.0 | 18.8 | 21.1 | 6.0 |
| Placebo | 13.6 | 13.6 | 10.6 | 1.5 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. BF subscore ranged from 0-3, where 0 indicated normal number of stools per day and 3 indicated 5 or more stools than normal. PGA subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. Endoscopy subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. MMDAI total score ranged from 0-12, where higher score indicated severe disease. Missing data was imputed using LOCF method. (NCT01008423)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 53.7 |
| Placebo | 34.0 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices:stool frequency, rectal bleeding, physician's global assessment and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding MMDAI subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. Missing data was imputed using LOCF method. (NCT01008423)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 50.0 |
| Placebo | 28.6 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. BF subscore ranged from 0-3, where 0 indicated normal number of stools per day and 3 indicated 5 or more stools than normal. PGA subscore ranged from 0-3, where 0 indicated normal disease and 3 indicated severe disease. Missing data was imputed using LOCF method. (NCT01008423)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 46.3 |
| Placebo | 23.8 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, physician's global assessment and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Endoscopy subscale ranged from 0-3, where 0 = normal or inactive disease, 1 = mild disease, 2 = moderate disease and 3 = severe disease (spontaneous bleeding, ulceration). Percentage of participants with normal or mild disease have been presented in this outcome measure. Missing data was imputed using LOCF method. (NCT01008423)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 56.0 |
| Placebo | 36.7 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. BF subscore ranged from 0-3, where 0 indicated normal number of stools per day and 3 indicated 5 or more stools than normal. PGA subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. Endoscopy subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. MMDAI total score ranged from 0-12, where higher score indicated severe disease. Missing data was imputed using LOCF method. (NCT01008423)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 49.3 |
| Placebo | 28.6 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Endoscopy subscore ranged from 0-3, where 0 = normal or inactive disease, 1 = mild disease (erythema, decreased vascular pattern), 2 = moderate disease (marked erythema, absent vascular pattern, friability, erosions), and 3 = severe disease (spontaneous bleeding, ulceration). Missing data was imputed using LOCF method. (NCT01008423)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 57.5 |
| Placebo | 38.8 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding MMDAI subscore ranged from 0-3, where 0 = no blood seen, 1 = streaks of blood with stool less than half the time, 2 = obvious blood with stool most of the time, and 3 indicated blood alone passed. Missing data was imputed using LOCF method. (NCT01008423)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 72.4 |
| Placebo | 56.5 |
Remission was a combined assessment of clinical and endoscopic variables, defined as an endoscopy score of less than or equal to (<=) 1, a rectal bleeding score of 0, and an improvement or no change from baseline in stool frequency subscales of the Modified Mayo Disease Activity Index (MMDAI) at the end of 6 weeks of treatment. MMDAI was used to assess the overall disease activity for each participant. MMDAI evaluated 4 indices: stool frequency, rectal bleeding, physician's global assessment (PGA) and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Stool frequency MMDAI subscore ranged from 0-3, where 0 indicated normal number of stools per day and 3 indicated 5 or more stools than normal. Rectal bleeding MMDAI subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. Endoscopy MMDAI subscore ranged from 0-3, where 0 indicated normal or inactive disease and 3 indicated severe disease (spontaneous bleeding, ulceration). (NCT01008423)
Timeframe: Week 6
| Intervention | percentage of participants (Number) |
|---|---|
| Budesonide | 44.0 |
| Placebo | 22.4 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. BF subscore ranged from 0-3, where 0 indicated normal number of stools per day and 3 indicated 5 or more stools than normal. PGA subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. Endoscopy subscore ranged from 0-3, where 0 indicated normal and 3 indicated severe disease. MMDAI total score ranged from 0-12, where higher score indicated severe disease. Missing data was imputed using LOCF method. (NCT01008423)
Timeframe: Baseline, Week 6
| Intervention | unit on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Bowel frequency score: Baseline | Bowel frequency score: Change at Week 6 | Rectal Bleeding score:Baseline | Rectal Bleeding score: Change at Week 6 | PGA score:Baseline | PGA score: Change at Week 6 | Endoscopy score:Baseline | Endoscopy score: Change at Week 6 | Total score:Baseline | Total score: Change at Week 6 | |
| Budesonide | 1.7 | -0.8 | 2.1 | -1.3 | 2.0 | -0.9 | 2.1 | -0.9 | 7.9 | -3.8 |
| Placebo | 1.8 | -0.5 | 2.1 | -0.9 | 2.0 | -0.6 | 2.1 | -0.5 | 8.0 | -2.5 |
The MMDAI was used to assess the overall disease activity for each participant. The MMDAI evaluated 4 indices: stool frequency, rectal bleeding, PGA and endoscopy findings each on a scale of 0 to 3 with a maximum total score of 12. Rectal bleeding MMDAI subscore ranged from 0-3, where 0 indicated no blood seen and 3 indicated blood alone passed. Percentage of participants who were rectal bleeding responder at scheduled assessments were reported. Rectal bleeding responders were defined as those participants who achieved a rectal bleeding MMDAI subscale score of 0 during the treatment period. Missing data was imputed using LOCF method. (NCT01008423)
Timeframe: Weeks 1, 2, 4, and 6
| Intervention | percentage of participants (Number) | |||
|---|---|---|---|---|
| Responder at 1 assessment | Responder at 2 assessment | Responder at 3 assessment | Responder at 4 assessment | |
| Budesonide | 8.2 | 16.4 | 21.6 | 13.4 |
| Placebo | 18.4 | 17.0 | 7.5 | 2.0 |
Relapse/flare is defined as SCCAI >= 5. Simple Clinical Colitis Activity Index: minimum score 0, maximum score 19, reflects disease activity over the 24 hours prior to completion. Composite Score: bowel frequency (day, 0-3) (night, 0-2), defecation urgency (0-3), blood in stool (0-3), general well being (0-4), extracolonic features (arthritis, pyoderma gangrenosum, erythema nodosum, uveitis - 1 per manifestation). (NCT00505778)
Timeframe: 6 months
| Intervention | Participants (Number) |
|---|---|
| Mesalamine Once-Daily | 45 |
| Mesalamine Twice-Daily | 39 |
Is your ulcerative colitis in remission (not active)? Y/N (NCT00505778)
Timeframe: 6 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Mesalamine Once-Daily | 83.1 |
| Mesalamine Twice-Daily | 86.6 |
Remission defined as SCCAI score < 5. Simple Clinical Colitis Activity Index: minimum score 0, maximum score 19, reflects disease activity over the 24 hours prior to completion. Composite Score: bowel frequency (day, 0-3) (night, 0-2), defecation urgency (0-3), blood in stool (0-3), general well being (0-4), extracolonic features (arthritis, pyoderma gangrenosum, erythema nodosum, uveitis - 1 per manifestation). (NCT00505778)
Timeframe: 12 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Mesalamine Once-Daily | 85.4 |
| Mesalamine Twice-Daily | 85.4 |
Remission defined as SCCAI < 5. Simple Clinical Colitis Activity Index: minimum score 0, maximum score 19, reflects disease activity over the 24 hours prior to completion. Composite Score: bowel frequency (day, 0-3) (night, 0-2), defecation urgency (0-3), blood in stool (0-3), general well being (0-4), extracolonic features (arthritis, pyoderma gangrenosum, erythema nodosum, uveitis - 1 per manifestation). (NCT00505778)
Timeframe: 3 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Mesalamine Once-Daily | 94.8 |
| Mesalamine Twice-Daily | 95.6 |
Remission defined as SCCAI <5. Simple Clinical Colitis Activity Index: minimum score 0, maximum score 19, reflects disease activity over the 24 hours prior to completion. Composite Score: bowel frequency (day, 0-3) (night, 0-2), defecation urgency (0-3), blood in stool (0-3), general well being (0-4), extracolonic features (arthritis, pyoderma gangrenosum, erythema nodosum, uveitis - 1 per manifestation). (NCT00505778)
Timeframe: 6 months
| Intervention | Percentage of Participants (Number) |
|---|---|
| Mesalamine Once-Daily | 90.5 |
| Mesalamine Twice-Daily | 91.8 |
MARS: Composite score for the following statements: I change how many times per day I take my medicine, I forget to use it, I stop taking it for a while, I only use it when I am having active symptoms, I decide to miss out on a dose, I take less than instructed, I take more than instructed, I avoid using it if I can, I use it regularly every day (reverse scored): 5-never, 4-rarely, 3-sometimes, 2-often, 1-very often. Minimum score 9, maximum score 45. (NCT00505778)
Timeframe: 6 months
| Intervention | MARS Score (Mean) |
|---|---|
| Mesalamine Once-Daily | 42.3 |
| Mesalamine Twice-Daily | 41.8 |
0-generally well, 1-fair, 2-poor, 3-terrible (NCT00577473)
Timeframe: Week 3
| Intervention | Percentage of Participants (Number) |
|---|---|
| Asacol 2.4 g/Day | 42.2 |
| Asacol 4.8 g/Day | 49.6 |
0-generally well, 1-fair, 2-poor, 3-terrible (NCT00577473)
Timeframe: Week 6
| Intervention | Percentage of Participants (Number) |
|---|---|
| Asacol 2.4 g/Day | 54.1 |
| Asacol 4.8 g/Day | 60.7 |
0-normal (intact vascular pattern, no friability or granularity), 1-mild (erythema; diminished or absent vascular markings; mild granularity; friability), 2-moderate (marked erythema, granularity; absent vascular markings; bleeds with minimal trauma; no ulcerations), 3-severe (spontaneous bleeding, ulcerations). Scoring Scale: 0-good thru 3-worse. (NCT00577473)
Timeframe: Week 3
| Intervention | Percentage of Participants (Number) |
|---|---|
| Asacol 2.4 g/Day | 51.5 |
| Asacol 4.8 g/Day | 52.0 |
0-normal (intact vascular pattern, no friability or granularity), 1-mild (erythema; diminished or absent vascular markings; mild granularity; friability), 2-moderate (marked erythema, granularity; absent vascular markings; bleeds with minimal trauma; no ulcerations), 3-severe (spontaneous bleeding, ulcerations). Scoring Scale: 0-good thru 3-worse. (NCT00577473)
Timeframe: Week 6
| Intervention | Percentage of Participants (Number) |
|---|---|
| Asacol 2.4 g/Day | 66.7 |
| Asacol 4.8 g/Day | 73.2 |
Treatment Success - complete or partial response; Complete = complete resolution of clinical assessments (stool frequency, rectal bleeding, PFA [patient's functional assessment], sigmoidoscopy) and PGA (physician global assessment) = 0, Partial = improvement from baseline PGA score and improvement in at least 1 of the clinical assessments [decrease of at least 1 on scale] and no worsening [no score increases] of remaining clinical assessments. Each clinical assessment graded using scale 0/normal, better thru 3/severe, worse. (NCT00577473)
Timeframe: 3 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Asacol 2.4 g/Day | 42.0 |
| Asacol 4.8 g/Day | 38.7 |
Treatment Success - complete or partial response; Complete = complete resolution of clinical assessments (stool frequency, rectal bleeding, PFA [patient's functional assessment], sigmoidoscopy) and PGA (physician global assessment) = 0, Partial = improvement from baseline PGA score and improvement in at least 1 of the clinical assessments [decrease of at least 1 on scale] and no worsening [no score increases] of remaining clinical assessments. Each clinical assessment graded using scale 0/normal, better thru 3/severe, worse. (NCT00577473)
Timeframe: 6 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Asacol 2.4 g/Day | 51.3 |
| Asacol 4.8 g/Day | 55.9 |
PGA - 0-quiescent disease activity (all 0's) , 1-mild (mostly 1's), 2-moderate (mostly 2's), 3-severe (mostly 3's) based upon on scoring for stool frequency, rectal bleeding, PFR (patient's functional assessment - 0-well, 1-fair, 2-poor, 3-terrible), sigmoidoscopy findings. Improvement defined as either complete response (remission, score = 0) or partial response (improvement on treatment). Scoring Scale: 0-good thru 3-worse. (NCT00577473)
Timeframe: Week 3
| Intervention | Percentage of Participants (Number) |
|---|---|
| Asacol 2.4 g/Day | 49.3 |
| Asacol 4.8 g/Day | 44.8 |
PGA - 0-quiescent disease activity (all 0's) , 1-mild (mostly 1's), 2-moderate (mostly 2's), 3-severe (mostly 3's) based upon on scoring for stool frequency, rectal bleeding, PFR (patient's functional assessment - 0-well, 1-fair, 2-poor, 3-terrible), sigmoidoscopy findings. Improvement defined as complete response (remission, score = 0) or partial response (improvement on treatment). Scoring Scale: 0-good thru 3-worse. (NCT00577473)
Timeframe: Week 6
| Intervention | Percentage of Participants (Number) |
|---|---|
| Asacol 2.4 g/Day | 61.4 |
| Asacol 4.8 g/Day | 64.8 |
0: no blood seen, 1: streaks of blood with stool less than half of the time, 2: obvious blood with stool most of the time, 3: blood alone passed, Scoring Scale: 0-good thru 3-worse. (NCT00577473)
Timeframe: Week 3
| Intervention | Percentage of Participants (Number) |
|---|---|
| Asacol 2.4 g/Day | 48.1 |
| Asacol 4.8 g/Day | 59.1 |
0-no blood seen, 1- streaks of blood with stool less than half of the time, 2- obvious blood with stool most of the time, 3- blood alone passed. Scoring Scale: 0-good thru 3-worse. (NCT00577473)
Timeframe: Week 6
| Intervention | Percentage of Participants (Number) |
|---|---|
| Asacol 2.4 g/Day | 60.2 |
| Asacol 4.8 g/Day | 71.5 |
0: normal stool frequency per day, 1: 1-2 stools greater than normal per day, 2: 3-4 stools greater than normal per day, 3: 5 or more stools greater than normal per day, Scoring Scale: 0-good thru 3-worse. (NCT00577473)
Timeframe: Week 3
| Intervention | Percentage of Participants (Number) |
|---|---|
| Asacol 2.4 g/Day | 46.7 |
| Asacol 4.8 g/Day | 54.3 |
0: normal stool frequency per day, 1: 1-2 stools greater than normal per day, 2: 3-4 stools greater than normal per day, 3: 5 or more stools greater than normal per day, Scoring Scale: 0-good thru 3-worse. (NCT00577473)
Timeframe: Week 6
| Intervention | Percentage of Participants (Number) |
|---|---|
| Asacol 2.4 g/Day | 63.2 |
| Asacol 4.8 g/Day | 66.7 |
UCDAI - sum of clinical assessment scores (stool frequency score [0=normal, 1=1-2 stools > normal/day, 2=3-4 stools > normal/day, 3=5 or more stools > normal/day], rectal bleeding score [0=no blood seen, 1=streaks of blood with stool less than half of the time, 2=obvious blood with stool most of the time, 3=blood alone passed and PGA score [0=quiescent disease, 1=mild, 2=moderate, 3=severe]) and sigmoidoscopy score [0=normal, 1=mild, 2=moderate, 3=severe] (NCT00073021)
Timeframe: 6 weeks
| Intervention | Scores on a Scale (Mean) |
|---|---|
| Asacol 2.4 g/Day | -3.2 |
| Asacol 4.8 g/Day | -3.7 |
IBDQ-32 questions divided into 4 categories: bowel, systemic, emotional and social. Each question graded with the following responses: 1-more than ever before, 2-extremely frequently, 3-very frequently, 4-moderate increase in frequency, 5-some increase in frequency, 6-slight increase in frequency or 7-not at all/normal; 1/worst thru 7/best. Scoring 32 - 224 - higher score better. (NCT00073021)
Timeframe: 3 Weeks
| Intervention | Scores on a Scale (Mean) |
|---|---|
| Asacol 2.4 g/Day | 30.4 |
| Asacol 4.8 g/Day | 29.8 |
IBDQ-32 questions divided into 4 categories: bowel, systemic, emotional and social. Each question graded with the following responses: 1-more than ever before, 2-extremely frequently, 3-very frequently, 4-moderate increase in frequency, 5-some increase in frequency, 6-slight increase in frequency or 7-not at all/normal; 1/worst thru 7/best. Scoring 32-224 - higher score better. (NCT00073021)
Timeframe: 6 Weeks
| Intervention | Scores on a Scale (Mean) |
|---|---|
| Asacol 2.4 g/Day | 43.1 |
| Asacol 4.8 g/Day | 40.4 |
Rectal Bleeding - 0=no blood seen, 1=streaks of blood w/stool less than half of the time, 2=obvious blood w/stool most of the time, 3=blood alone passed Sigmoidoscopy Assessment Score - 0=normal (intact vascular pattern, no friability or granularity), 1=mild (erythema, diminished or absent vascular markings; mild granularity; friability), 2=moderate (marked erythema, granularity; absent vascular markings; bleeds with minimal trauma; no ulcerations) 3=severe (spontaneous bleeding, ulcerations) (NCT00073021)
Timeframe: 6 Weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Asacol 2.4 g/Day | 59.8 |
| Asacol 4.8 g/Day | 63.6 |
Sigmoidoscopy Assessment Score (0=normal intact vascular pattern, no friability or granularity, 1=mild erythema; diminished or absent vascular markings; mild granularity; friability, 2=moderate marked erythema, granularity; absent vascular markings; bleeds with minimal trauma; no ulcerations, 3=severe spontaneous bleeding, ulcerations) (NCT00073021)
Timeframe: 6 Weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Asacol 2.4 g/Day | 69.0 |
| Asacol 4.8 g/Day | 75.2 |
0=Normal stool frequency per day, 1=1-2 stools greater than normal per day, 2=3-4 stools greater than normal per day, 3=5 or more stools greater than normal per day (NCT00073021)
Timeframe: 6 Weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Asacol 2.4 g/Day | 71.3 |
| Asacol 4.8 g/Day | 74.0 |
PFA - 0=generally well, 1=fair, 2=poor, 3=terrible (NCT00073021)
Timeframe: 6 Weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Asacol 2.4 g/Day | 70.5 |
| Asacol 4.8 g/Day | 69.6 |
PGA -Physician's Global Assessment - 0=quiescent disease (all parameters 0), 1=mild disease (parameters mostly 1's) 2=moderate (parameters mostly 2's), 3=severe (parameters mostly 3's) [parameters: combination of stool frequency, rectal bleeding, PFA & sigmoidoscopy findings] If scoring equal default to physician judgement. (NCT00073021)
Timeframe: 6 Weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Asacol 2.4 g/Day | 73.5 |
| Asacol 4.8 g/Day | 83.2 |
Rectal Bleeding (0=no blood seen, 1=streaks of blood with stool less than half of the time, 2=obvious blood with stool most of the time, 3=blood alone passed) (NCT00073021)
Timeframe: 6 Weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Asacol 2.4 g/Day | 77.5 |
| Asacol 4.8 g/Day | 78.5 |
Treatment success defined as complete response (PGA score 0 and complete resolution of stool frequency, rectal bleeding, PFA (patient's functional assessment), normal sigmoidoscopy) or partial response (improvement from baseline PGA and improvement in 1 clinical assessment [stool frequency, rectal bleeding, PFA, sigmoidoscopy] and no worsening in any other clinical assessments) (NCT00073021)
Timeframe: 6 Weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Asacol 2.4 g/Day | 60.0 |
| Asacol 4.8 g/Day | 71.1 |
Treatment success defined as complete response (PGA score 0 and complete resolution of stool frequency, rectal bleeding, PFA (patient's functional assessment), normal sigmoidoscopy) or partial response (improvement from baseline PGA and improvement in 1 clinical assessment [stool frequency, rectal bleeding, PFA, sigmoidoscopy] and no worsening in any other clinical assessments) (NCT00073021)
Timeframe: 3 Weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Asacol 2.4 g/Day | 51.5 |
| Asacol 4.8 g/Day | 61.3 |
Treatment success defined as complete response (PGA score 0 and complete resolution of stool frequency, rectal bleeding, PFA (patient's functional assessment), normal sigmoidoscopy) or partial response (improvement from baseline PGA and improvement in 1 clinical assessment [stool frequency, rectal bleeding, PFA, sigmoidoscopy] and no worsening in any other clinical assessments) (NCT00073021)
Timeframe: 6 Weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Asacol 2.4 g/Day | 59.2 |
| Asacol 4.8 g/Day | 71.8 |
Clinical and endoscopic remission defined as a Ulcerative Colitis Disease Activity Index (UCDAI) score ≤ 1, with subscores of 0 for rectal bleeding, stool frequency, and mucosal appearance and with a ≥ 1 point reduction in the endoscopic index score. (NCT00679432)
Timeframe: 8 weeks
| Intervention | percentage of patients (Number) |
|---|---|
| 1: Budesonide-MMX® 6 mg | 13.2 |
| 2: Budesonide-MMX® 9 mg | 17.9 |
| 3: Placebo | 7.4 |
| 4: Asacol® 400 mg | 12.1 |
Clinical improvement, defined as a ≥ 3-point improvement in UCDAI from baseline to the end of Week 8. (NCT00679432)
Timeframe: 8 weeks
| Intervention | percentage of patients (Number) |
|---|---|
| 1: Budesonide-MMX® 6 mg | 30.6 |
| 2: Budesonide-MMX® 9 mg | 33.3 |
| 3: Placebo | 24.8 |
| 4: Asacol® 400 mg | 33.9 |
"Greater or equal to a 1 point improvement in the mucosal appearance subscore of the UCDAI, from baseline to week 8.~As per the hierarchical testing procedure for secondary endpoints, because clinical improvement was not statistically significant in the ITT population, formal statistical comparisons for endoscopic improvement between the 2 budesonide MMX groups and placebo were not conducted." (NCT00679432)
Timeframe: 8 weeks
| Intervention | percentage of patients (Number) |
|---|---|
| 1: Budesonide-MMX® 6 mg | 35.5 |
| 2: Budesonide-MMX® 9 mg | 41.5 |
| 3: Placebo | 33.1 |
| 4: Asacol® 400 mg | 33.1 |
Measure of anxiety, HADS Hospital anxiety and depression scale. HADS questionnaire consists of a 14 question validated questionnaire, developed to measure anxiety and depression in the hospital setting. Each item is answered by the patient on a four point (0-3) response category so the possible scores range from 0 (minimum) to 21 (maximum) for anxiety and 0 (minimum) to 21 (maximum) for depression. Higher scores indicate worse outcome, (NCT00553163)
Timeframe: 13 weeks
| Intervention | score on a scale (Median) |
|---|---|
| UC Patients Given Gut-focussed Hpynotherapy | 7 |
| UC Patients Given Control Educational Sessions | 10 |
Measure of depression. Each item is answered by the patient on a four point (0-3) response category so the possible scores range from 0 to 21 for anxiety and 0 to 21 for depression. Each item is answered by the patient on a four point (0-3) response category so the possible scores range from 0 (minimum) to 21 (maximum) for anxiety and (minimum) to 21 (maximum) for depression. Higher scores worse outcome. (NCT00553163)
Timeframe: 13 weeks
| Intervention | units on a scale (Median) |
|---|---|
| UC Patients Given Gut-focussed Hypnotherapy | 1.5 |
| UC Patients Given Control Educational Sessions | 4 |
IBDQ (standard measure of IBD patients' Quality of life (QoL) (Irvine et al 1982 approx). The IBDQ is a validated and reliable tool to measure of health-related quality of life in adult patients with IBD. The questionnaire consists of 32 questions scored in four domains: bowel symptoms, emotional health, systemic systems and social function. Scores range from 1 (poorest QoL) to 7 (best QoL). Higher scores indicate better QoL. Lowest score 7, highest score 224. (NCT00553163)
Timeframe: 13 weeks
| Intervention | units on a scale (Median) |
|---|---|
| UC Patients Given Gut-focussed Hypnotherapy | 195 |
| UC Patients Given Control Educational Sessions | 192 |
Measure of recent psychological stress. THE PSQ R consists of a 30 question questionnaires: recent, in which the statements used apply to the last month in which used statements apply to the last two years (Appendix 1.3). The score for both recent and general stress levels were stated as the PSQ index ranging from 0 (non-stressed) to 0.99 (highly stressed). Higher scores indicate worse outcome. (NCT00553163)
Timeframe: 13 weeks
| Intervention | units on a scale (Median) |
|---|---|
| UC Patients Given Gut-focussed Hypnotherapy | 0.3 |
| UC Patients Given Control Educational Sessions | 0.4 |
The number of patients suffering a relapse was compared between the two treatment groups, and was the primary outcome parameter of this study. (NCT00553163)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| UC Patients Given Gut-focussed Hypnotherapy | 8 |
| UC Patients Given Control Educational Sessions | 7 |
To assess change in IL-17 in the identified patient AM-endotype computing relative percent reduction for each subject being treated and serum marker. The median and other summary statistics of these percent change values will be computed (NCT03442088)
Timeframe: Baseline, Week 16
| Intervention | Pg/mL (Mean) | |
|---|---|---|
| Baseline | Week 16 | |
| Apremilast for Treatment of Psoriasis With the AM-endotype | 1.513 | -0.8315 |
To assess change in serum myeloperoxidase in the identified patient AM-endotype computing relative percent reduction for each subject being treated and serum marker. The median and other summary statistics of these percent change values will be computed (NCT03442088)
Timeframe: Baseline, Week 16
| Intervention | Pg/mL (Mean) | |
|---|---|---|
| Baseline | Week 16 | |
| Apremilast for Treatment of Psoriasis With the AM-endotype | 24198 | 24294 |
To assess change in Tissue Factor in the identified patient AM-endotype computing relative percent reduction for each subject being treated and serum marker. The median and other summary statistics of these percent change values will be computed (NCT03442088)
Timeframe: Baseline, Week 16
| Intervention | Pg/mL (Mean) | |
|---|---|---|
| Baseline | Week 16 | |
| Apremilast for Treatment of Psoriasis With the AM-endotype | 72.28 | 75.52 |
To assess change in in the identified patient AM-endotype computing relative percent reduction for each subject being treated and serum marker. The median and other summary statistics of these percent change values will be computed (NCT03442088)
Timeframe: Baseline, Week 16
| Intervention | Pg/mL (Mean) | |
|---|---|---|
| Baseline | Week 16 | |
| Apremilast for Treatment of Psoriasis With the AM-endotype | 14.95 | 14.26 |
For each subject, we will identify a target biomarker of abnormally elevated monocytes, among 1.) intermediate, or 2.) doublets, or 3.) platelet doubles. Each subject will thus have one identified monocyte biomarker for which relative percent change will be its basis for analysis in the primary outcome measure. We will specifically assess change from baseline to 16 weeks by computing relative percent reduction for each subject being treated. Note for example that a change of 1.5% to 1.2% is (1 - (1.2/1.5))*100% = 20% reduction. The median and other summary statistics of these percent change values will be computed. Wilcoxon's signed rank test will be used to evaluate the null hypothesis of the median percent change being 0. (NCT03442088)
Timeframe: Baseline, Week 16
| Intervention | Percent change (Mean) | |
|---|---|---|
| Baseline | Week 16 | |
| Apremilast for Treatment of Psoriasis With the AM-endotype | 0.5665 | 0.1715 |
Enumeration of the serious and non-serious adverse events seen in the study. Enumeration of any dose limiting toxicity seen in the study. (NCT02200445)
Timeframe: 8 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Interleukin-2 Dose A | 0 |
| Interleukin-2 Dose B | 0 |
| Interleukin-2 Dose C | 0 |
370 reviews available for mesalamine and Colitis, Ulcerative
| Article | Year |
|---|---|
Efficacy and safety of Qingre-Chushi therapies in active ulcerative colitis: A network meta-analysis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Databases, Factu | 2021 |
Budding Multi-matrix Technology-a Retrospective Approach, Deep Insights, and Future Perspectives.
Topics: Anti-Inflammatory Agents; Budesonide; Colitis, Ulcerative; Humans; Mesalamine; Retrospective Studies | 2021 |
Efficacy of Pharmacological Agents for Ulcerative Proctitis: A Systematic Literature Review.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Mesalamine; Observation | 2022 |
[Living guideline on ulcerative colitis].
Topics: Colitis, Ulcerative; Glucocorticoids; Humans; Immunosuppressive Agents; Mesalamine; Proctocolectomy, | 2022 |
Antibiotics for the induction and maintenance of remission in ulcerative colitis.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Mesalam | 2022 |
Efficacy and Safety of Vitamin D Adjuvant Therapy for Ulcerative Colitis: A Meta-Analysis.
Topics: Colitis, Ulcerative; Humans; Mesalamine; Treatment Outcome; Vitamin D; Vitamins | 2022 |
Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review.
Topics: Budesonide; Colitis, Ulcerative; Humans; Mesalamine | 2022 |
Efficacy and Safety of Bifidobacterium Quadruple Viable Bacteria Combined with Mesalamine against UC Management: A Systematic Review and Meta-Analysis.
Topics: Bifidobacterium; C-Reactive Protein; Colitis, Ulcerative; Humans; Interleukin-4; Interleukin-8; Mesa | 2022 |
Significance of 5-Aminosalicylic Acid Intolerance in the Clinical Management of Ulcerative Colitis.
Topics: Abdominal Pain; Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; | 2023 |
COVID-19 susceptibility and clinical outcomes in inflammatory bowel disease: An updated systematic review and meta-analysis.
Topics: Adrenal Cortex Hormones; Colitis, Ulcerative; COVID-19; Crohn Disease; Humans; Inflammatory Bowel Di | 2023 |
COVID-19 susceptibility and clinical outcomes in inflammatory bowel disease: An updated systematic review and meta-analysis.
Topics: Adrenal Cortex Hormones; Colitis, Ulcerative; COVID-19; Crohn Disease; Humans; Inflammatory Bowel Di | 2023 |
COVID-19 susceptibility and clinical outcomes in inflammatory bowel disease: An updated systematic review and meta-analysis.
Topics: Adrenal Cortex Hormones; Colitis, Ulcerative; COVID-19; Crohn Disease; Humans; Inflammatory Bowel Di | 2023 |
COVID-19 susceptibility and clinical outcomes in inflammatory bowel disease: An updated systematic review and meta-analysis.
Topics: Adrenal Cortex Hormones; Colitis, Ulcerative; COVID-19; Crohn Disease; Humans; Inflammatory Bowel Di | 2023 |
Old but Fancy: Curcumin in Ulcerative Colitis-Current Overview.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Curcumin; Humans; Inflammation; Mesala | 2022 |
Molecular Mechanisms of the Antitumor Effects of Mesalazine and Its Preventive Potential in Colorectal Cancer.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Crohn Disease; H | 2023 |
Ulcerative colitis.
Topics: Adrenal Cortex Hormones; Colitis, Ulcerative; Humans; Mesalamine | 2023 |
Systematic review with meta-analysis: Medical therapies for treatment of ulcerative proctitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerativ | 2023 |
Ulcerative Colitis in Adults: A Review.
Topics: Adult; Antibodies, Monoclonal; Colitis, Ulcerative; Colorectal Neoplasms; Female; Humans; Inflammati | 2023 |
Upadacitinib as a Rescue Therapy in Acute Severe Ulcerative Colitis: A Case Report and Review of the Literature.
Topics: Adolescent; Adult; Colitis, Ulcerative; Female; Heterocyclic Compounds, 3-Ring; Humans; Infliximab; | 2023 |
Modern use of 5-aminosalicylic acid compounds for ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Colitis, Ulcerative; Gastrointestin | 2020 |
Leukemic Vasculitis: Case Report and Review of the Literature.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Bone Marrow Transplantation; | 2019 |
Histological healing: should it be considered as a new outcome for ulcerative colitis?
Topics: Antibodies, Monoclonal; Colitis, Ulcerative; Colonoscopy; Humans; Intestinal Mucosa; Mesalamine; Rem | 2020 |
Probiotics for maintenance of remission in ulcerative colitis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans | 2020 |
Probiotics for induction of remission in ulcerative colitis.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Bias; Child; Colitis, Ulcerative; Combin | 2020 |
Time to Symptom Resolution in Ulcerative Colitis With Multimatrix Mesalazine Treatment: A Pooled Analysis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonoscopy; Dose-Response Rela | 2020 |
Inflammatory Bowel Disease - Non-biological treatment.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Colitis, Ulcerative; Crohn Disease; Cyclosporine; | 2020 |
A phytopharmacological overview of medicinal plants used for prophylactic and treatment of colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Gastrointestinal Microbiome; Humans; M | 2020 |
Solving the questions regarding 5-aminosalitylate formulation in the treatment of ulcerative colitis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Dose-Response Re | 2020 |
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Bias; Colitis, Ulcerative; Drug Admin | 2020 |
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Topics: Administration, Oral; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Bias; Colitis, | 2020 |
Clinical management of the most common extra-intestinal manifestations in patients with inflammatory bowel disease focused on the joints, skin and eyes.
Topics: Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Arthralgia; | 2020 |
Mesalamine in the Initial Therapy of Ulcerative Colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Dibutyl Phthalate; Drug Compounding; E | 2020 |
Ulcerative Colitis-Diagnostic and Therapeutic Algorithms.
Topics: Adolescent; Algorithms; Biosimilar Pharmaceuticals; Child; Colitis, Ulcerative; Germany; Humans; Mes | 2020 |
Characteristics, Properties and Analytical/Bioanalytical Methods of 5-Aminosalicylic Acid: A Review.
Topics: Colitis, Ulcerative; Crohn Disease; Feces; Humans; Mesalamine | 2022 |
Efficacy of Oral, Topical, or Combined Oral and Topical 5-Aminosalicylates, in Ulcerative Colitis: Systematic Review and Network Meta-analysis.
Topics: Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc | 2021 |
Genetic Background of Mesalamine-induced Fever and Diarrhea in Japanese Patients with Inflammatory Bowel Disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Diarrhea; Genetic Background; Genome-W | 2022 |
Kidney function monitoring to prevent 5-aminosalicylic acid nephrotoxicity: What the gastroenterologist should know.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Creatinine; Glomerular Filtration Rate | 2021 |
Risk factors and management strategies associated with non-response to aminosalicylates as a maintenance treatment in ulcerative colitis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Mesalami | 2021 |
Pancreatic Disorders in Patients with Inflammatory Bowel Disease.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Autoimmune Pancreatitis; Azathioprin | 2022 |
Recurrent myocarditis in a patient with active ulcerative colitis: a case report and review of the literature.
Topics: Adult; Colitis, Ulcerative; Humans; Inflammatory Bowel Diseases; Male; Mesalamine; Myocarditis | 2021 |
Mesalazine-induced eosinophilic glossitis and hypereosinophilia in a patient with ulcerative colitis: a case report and review of literature.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Eosinophilia; Glossitis; Humans; Mesal | 2021 |
Drug development for ulcerative proctitis: current concepts.
Topics: Administration, Oral; Administration, Rectal; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Ant | 2021 |
Efficacy and safety of rectal 5-aminosalicylic acid versus corticosteroids in active distal ulcerative colitis: a systematic review and network meta-analysis.
Topics: Administration, Rectal; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Colitis, U | 2017 |
Emerging treatments for ulcerative colitis: a systematic review.
Topics: Andrographis paniculata; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies | 2017 |
Systematic review with meta-analysis: the efficacy of probiotics in inflammatory bowel disease.
Topics: Adult; Colitis, Ulcerative; Crohn Disease; Humans; Mesalamine; Probiotics; Randomized Controlled Tri | 2017 |
European Crohn's and Colitis Organisation Topical Review on Treatment Withdrawal ['Exit Strategies'] in Inflammatory Bowel Disease.
Topics: Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Colitis, Ulcerative; Conse | 2018 |
Optimized Management of Ulcerative Proctitis: When and How to Use Mesalazine Suppository.
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Consensus; Di | 2018 |
A safety evaluation of budesonide MMX for the treatment of ulcerative colitis.
Topics: Administration, Oral; Anti-Inflammatory Agents; Biological Availability; Budesonide; Colitis, Ulcera | 2018 |
Laryngeal Manifestations of Inflammatory Bowel Disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Laryngeal Diseases; Me | 2019 |
Systematic review: safety of mesalazine in ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Mesalamine; Randomized | 2018 |
Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis.
Topics: Adrenal Cortex Hormones; Animals; Antibodies, Monoclonal; Biological Factors; Calcineurin Inhibitors | 2019 |
Economic Evaluations of Treatments for Inflammatory Bowel Diseases: A Literature Review.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Colitis, Ulcerative; Cost-Benefit Anal | 2018 |
The safety of beclomethasone dipropionate in the treatment of ulcerative colitis.
Topics: Administration, Oral; Administration, Topical; Algorithms; Anti-Inflammatory Agents; Beclomethasone; | 2018 |
Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses.
Topics: Administration, Oral; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; C | 2018 |
The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antineoplastic Agents; Coliti | 2018 |
Refocusing IBD Patient Management: Personalized, Proactive, and Patient-Centered Care.
Topics: Biological Factors; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Drug Therapy, Comb | 2018 |
Use of Curcumin in Achieving Clinical and Endoscopic Remission in Ulcerative Colitis: A Systematic Review and Meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Curcumin; Endoscopy; Humans; Mesalamin | 2018 |
AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Disease Management; Disease Pro | 2019 |
AGA Clinical Practice Guidelines on the Management of Mild-to-Moderate Ulcerative Colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Disease Management; Female; Humans; Ma | 2019 |
Efficacy and safety of once daily versus twice daily mesalazine for mild-to-moderate ulcerative colitis: A meta-analysis of randomized controlled trials.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Administration Schedule; Humans; | 2019 |
Does the 5-Aminosalicylate Concentration Correlate with the Efficacy of Oral 5-Aminosalicylate and Predict Response in Patients with Inflammatory Bowel Disease? A Systematic Review.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; Colitis, Ulc | 2020 |
Comparative assessment of budesonide-MMX and mesalamine in active, mild-to-moderate ulcerative colitis: A systematic review and network meta-analysis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Delayed-Action Prep | 2019 |
The culprit of mesalamine intolerance: case series and literature review.
Topics: Abdominal Pain; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Diarrhea; Drug Eruptio | 2019 |
[Practice Examples of Academic Detailing -Prescription Support Based on Basic Pharmaceutical Science and Evidence].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biopharmaceutics; Clinical Trials as Topic; Colitis, | 2019 |
Differential response of flat and polypoid colitis-associated colorectal neoplasias to chemopreventive agents and heterocyclic amines.
Topics: Amines; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Carcinogens; Cell Proliferation | 2013 |
Should maintenance therapy be performed in ulcerative proctitis? How long should it be continued?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Enema; Humans; Mesalamine; Proctocolit | 2012 |
Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I).
Topics: Age of Onset; Anticarcinogenic Agents; Cholangitis, Sclerosing; Colitis, Ulcerative; Colorectal Neop | 2014 |
Meta-analysis using individual patient data: efficacy and durability of topical alicaforsen for the treatment of active ulcerative colitis.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Enema; | 2013 |
Mesalazine for the treatment of inflammatory bowel disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Crohn Disease; H | 2013 |
Pediatric case of mesalazine-induced interstitial nephritis with literature review.
Topics: Adolescent; Biopsy; Colitis, Ulcerative; Creatinine; Dose-Response Relationship, Drug; Drug Administ | 2013 |
Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviews.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutical; Clinical T | 2013 |
[Inflammatory bowel disease].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Colitis, Ulcerative; Crohn Disease; Humans; Immun | 2013 |
Mucosal healing in inflammatory bowel disease: treatment efficacy and predictive factors.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Biomarkers; Blood Component Removal; C-Reactive P | 2013 |
Critical review of the evidence on 5-aminosalicilate for chemoprevention of colorectal cancer in ulcerative colitis: a methodological question.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chemoprevention; Colitis, Ulcerative; Colorectal Neoplasms; | 2014 |
Differences between treatment guidelines--Germany.
Topics: Antibodies, Monoclonal; Colitis, Ulcerative; Crohn Disease; Germany; Humans; Infliximab; Mesalamine; | 2013 |
Treatment of ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colitis, Ulcerative; Cyclosporine; Gastrointe | 2014 |
Review article: integrating budesonide-MMX into treatment algorithms for mild-to-moderate ulcerative colitis.
Topics: Algorithms; Anti-Inflammatory Agents; Budesonide; Chemistry, Pharmaceutical; Colitis, Ulcerative; De | 2014 |
Current and emerging maintenance therapies for ulcerative colitis.
Topics: Adalimumab; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclona | 2014 |
37-year-old man with abdominal pain.
Topics: Abdominal Pain; Adult; Colitis, Ulcerative; Colonoscopy; Emergency Service, Hospital; Follow-Up Stud | 2014 |
Febrile pleuropericarditis, a potentially life-threatening adverse event of balsalazide--case report and literature review of the side effects of 5-aminosalicylates.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Fever; Humans; Male; Mesalamine | 2014 |
5-Aminosalicylates reduce the risk of colorectal neoplasia in patients with ulcerative colitis: an updated meta-analysis.
Topics: Colitis, Ulcerative; Colorectal Neoplasms; Humans; Mesalamine; Risk | 2014 |
Ulcerative proctitis: an update on the pharmacotherapy and management.
Topics: Anti-Inflammatory Agents; Colitis, Ulcerative; Disease Management; Humans; Mesalamine; Prednisolone; | 2014 |
Pulmonary pathology in patients with ulcerative colitis treated with mesalazine--a challenging and complex diagnostic problem. Case series and literature review.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Lung Dise | 2014 |
Methotrexate for induction of remission in ulcerative colitis.
Topics: Administration, Oral; Anti-Inflammatory Agents; Colitis, Ulcerative; Humans; Immunosuppressive Agent | 2014 |
Ulcerative colitis: epidemiology, diagnosis, and management.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Colectomy; Colitis, Ulcerative; Co | 2014 |
Ulcerative colitis: epidemiology, diagnosis, and management.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Colectomy; Colitis, Ulcerative; Co | 2014 |
Ulcerative colitis: epidemiology, diagnosis, and management.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Colectomy; Colitis, Ulcerative; Co | 2014 |
Ulcerative colitis: epidemiology, diagnosis, and management.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Colectomy; Colitis, Ulcerative; Co | 2014 |
[Mesalazine old and new].
Topics: Administration, Oral; Administration, Rectal; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-St | 2011 |
[New therapeutic strategies in chronic inflammatory bowel disease].
Topics: Adrenal Cortex Hormones; Biological Products; Biosimilar Pharmaceuticals; Colitis, Ulcerative; Crohn | 2015 |
5-Aminosalicylic acid, a specific drug for ulcerative colitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colon; Humans; Inflammation; | 2015 |
[Medical therapy of ulcerative colitis].
Topics: Algorithms; Antibodies, Monoclonal, Humanized; Colitis, Ulcerative; Colonoscopy; Drug Therapy, Combi | 2015 |
[Changing paradigm in the management of inflammatory bowel disease].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Colitis, Ulcerative; Crohn Disease; | 2015 |
Breakthrough Lactobacillus rhamnosus GG bacteremia associated with probiotic use in an adult patient with severe active ulcerative colitis: case report and review of the literature.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents; Bacteremia; Candidemia; Co | 2015 |
Mesalazine-induced eosinophilic pneumonia in a patient with ulcerative colitis disease: a case report and literature review.
Topics: Adult; Colitis, Ulcerative; Female; Humans; Mesalamine; Pulmonary Eosinophilia | 2016 |
Methotrexate for maintenance of remission in ulcerative colitis.
Topics: Administration, Oral; Colitis, Ulcerative; Humans; Immunosuppressive Agents; Maintenance Chemotherap | 2015 |
Lung disease and ulcerative colitis--mesalazine-induced bronchiolitis obliterans with organizing pneumonia or pulmonary manifestation of inflammatory bowel disease?
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Cryptogenic Organizing Pneumoni | 2015 |
Oral budesonide for induction of remission in ulcerative colitis.
Topics: Administration, Oral; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; | 2015 |
New Applications for Traditional Drugs in Inflammatory Bowel Disease: What Do Cochrane Reviews Tell Us?
Topics: Anti-Inflammatory Agents; Azathioprine; Budesonide; Colitis, Ulcerative; Congresses as Topic; Crohn | 2015 |
Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Clinical Trials, Phase III as Topic; Colit | 2016 |
Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Clinical Trials, Phase III as Topic; Colit | 2016 |
Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Clinical Trials, Phase III as Topic; Colit | 2016 |
Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Clinical Trials, Phase III as Topic; Colit | 2016 |
Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Clinical Trials, Phase III as Topic; Colit | 2016 |
Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Clinical Trials, Phase III as Topic; Colit | 2016 |
Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Clinical Trials, Phase III as Topic; Colit | 2016 |
Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Clinical Trials, Phase III as Topic; Colit | 2016 |
Long-Term Benefit of Mesalamine Granules for Patients Who Achieved Corticosteroid-Induced Ulcerative Colitis Remission.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Clinical Trials, Phase III as Topic; Colit | 2016 |
Escherichia coli Nissle 1917 in Ulcerative Colitis Treatment: Systematic Review and Meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chi-Square Distribution; Colitis, Ulcerative; Colon; Escher | 2015 |
Oral or Topical 5-ASA in Ulcerative Colitis.
Topics: Administration, Oral; Administration, Topical; Clinical Trials as Topic; Colitis, Ulcerative; Humans | 2016 |
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Inductio | 2016 |
[Colitis ulcerosa - a diagnostic and therapeutic update].
Topics: Administration, Oral; Administration, Rectal; Algorithms; Colitis, Ulcerative; Colonoscopy; Dipyrone | 2016 |
Budesonide for the treatment of ulcerative colitis.
Topics: Administration, Oral; Administration, Rectal; Animals; Anti-Inflammatory Agents; Biological Availabi | 2016 |
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Topics: Administration, Oral; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcera | 2016 |
Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Azathioprine; Colitis, Ulcerative; | 2016 |
Once daily vs multiple daily mesalamine therapy for mild to moderate ulcerative colitis: a meta-analysis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Administrat | 2016 |
[Ulcerative colitis].
Topics: Administration, Rectal; Adrenal Cortex Hormones; Algorithms; Colitis, Ulcerative; Colonoscopy; Diagn | 2016 |
Role and mechanisms of action of Escherichia coli Nissle 1917 in the maintenance of remission in ulcerative colitis patients: An update.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Escherichia coli; Humans; Maintenance | 2016 |
Advances in Pediatric Inflammatory Bowel Disease.
Topics: Adalimumab; Adolescent; Adrenal Cortex Hormones; Anti-Bacterial Agents; Antibodies, Monoclonal, Huma | 2016 |
Efficacy and Safety of Beclomethasone Dipropionate versus 5-Aminosalicylic Acid in the Treatment of Ulcerative Colitis: A Systematic Review and Meta-Analysis.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Beclomethasone; Colitis, Ulcerati | 2016 |
Recent advances in clinical practice: a systematic review of isolated colonic Crohn's disease: the third IBD?
Topics: Adalimumab; Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; | 2017 |
The problem of adherence to therapy in ulcerative colitis and the potential utility of multi-matrix system (MMX) technology.
Topics: Anti-Inflammatory Agents; Budesonide; Colitis, Ulcerative; Delayed-Action Preparations; Drug Carrier | 2017 |
Efficacy and Safety of Oral Beclomethasone Dipropionate in Ulcerative Colitis: A Systematic Review and Meta-Analysis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Beclomethasone; Colitis, Ulcerative; | 2016 |
Ulcerative colitis.
Topics: Colectomy; Colitis, Ulcerative; Colonoscopy; Diagnosis, Differential; Glucocorticoids; Humans; Immun | 2017 |
Ulcerative colitis.
Topics: Colectomy; Colitis, Ulcerative; Colonoscopy; Diagnosis, Differential; Glucocorticoids; Humans; Immun | 2017 |
Ulcerative colitis.
Topics: Colectomy; Colitis, Ulcerative; Colonoscopy; Diagnosis, Differential; Glucocorticoids; Humans; Immun | 2017 |
Ulcerative colitis.
Topics: Colectomy; Colitis, Ulcerative; Colonoscopy; Diagnosis, Differential; Glucocorticoids; Humans; Immun | 2017 |
Ulcerative colitis.
Topics: Colectomy; Colitis, Ulcerative; Colonoscopy; Diagnosis, Differential; Glucocorticoids; Humans; Immun | 2017 |
Ulcerative colitis.
Topics: Colectomy; Colitis, Ulcerative; Colonoscopy; Diagnosis, Differential; Glucocorticoids; Humans; Immun | 2017 |
Ulcerative colitis.
Topics: Colectomy; Colitis, Ulcerative; Colonoscopy; Diagnosis, Differential; Glucocorticoids; Humans; Immun | 2017 |
Ulcerative colitis.
Topics: Colectomy; Colitis, Ulcerative; Colonoscopy; Diagnosis, Differential; Glucocorticoids; Humans; Immun | 2017 |
Ulcerative colitis.
Topics: Colectomy; Colitis, Ulcerative; Colonoscopy; Diagnosis, Differential; Glucocorticoids; Humans; Immun | 2017 |
Ulcerative colitis.
Topics: Colectomy; Colitis, Ulcerative; Colonoscopy; Diagnosis, Differential; Glucocorticoids; Humans; Immun | 2017 |
Ulcerative colitis.
Topics: Colectomy; Colitis, Ulcerative; Colonoscopy; Diagnosis, Differential; Glucocorticoids; Humans; Immun | 2017 |
Ulcerative colitis.
Topics: Colectomy; Colitis, Ulcerative; Colonoscopy; Diagnosis, Differential; Glucocorticoids; Humans; Immun | 2017 |
Ulcerative colitis.
Topics: Colectomy; Colitis, Ulcerative; Colonoscopy; Diagnosis, Differential; Glucocorticoids; Humans; Immun | 2017 |
Ulcerative colitis.
Topics: Colectomy; Colitis, Ulcerative; Colonoscopy; Diagnosis, Differential; Glucocorticoids; Humans; Immun | 2017 |
Ulcerative colitis.
Topics: Colectomy; Colitis, Ulcerative; Colonoscopy; Diagnosis, Differential; Glucocorticoids; Humans; Immun | 2017 |
Ulcerative colitis.
Topics: Colectomy; Colitis, Ulcerative; Colonoscopy; Diagnosis, Differential; Glucocorticoids; Humans; Immun | 2017 |
[Second Korean Guideline for the Management of Ulcerative Colitis].
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; C-Reactive Pr | 2017 |
Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Crohn Disease; H | 2017 |
Review article: 5-aminosalicylate formulations for the treatment of ulcerative colitis--methods of comparing release rates and delivery of 5-aminosalicylate to the colonic mucosa.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; Colitis, Ulcerative; Dialys | 2008 |
Comparison of mesalazine and balsalazide in induction and maintenance of remission in patients with ulcerative colitis: a meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Male; Mesalamine; Phen | 2009 |
Balsalazide plus high-potency probiotic preparation (VSL[sharp]3) in the treatment of acute mild-to-moderate ulcerative colitis and uncomplicated diverticulitis of the colon.
Topics: Clinical Trials as Topic; Colitis, Ulcerative; Diverticulitis, Colonic; Drug Therapy, Combination; G | 2008 |
Systematic review: impact of non-adherence to 5-aminosalicylic acid products on the frequency and cost of ulcerative colitis flares.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Cost-Benefit Analys | 2009 |
Voting With their Feet (VWF) endpoint: a meta-analysis of an alternative endpoint in clinical trials, using 5-ASA induction studies in ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Colitis, Ulcerative; Humans; Mesa | 2009 |
Balsalazide disodium for the treatment of ulcerative colitis.
Topics: Colitis, Ulcerative; Gastrointestinal Agents; Humans; Mesalamine; Phenylhydrazines | 2008 |
Mesalamine with MMX technology for the treatment of ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Mesalamine; Remission Inductio | 2008 |
[Contemporary views on non-specific ulcerative colitis and conservative methods of its treatment ].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Budesonide; Colitis, Ulcerative; Ga | 2008 |
[Effectiveness of new, once-daily 5-aminosalicylic acid in the treatment of ulcerative colitis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Administration Schedule; Humans; | 2009 |
Individually administered or co-prescribed thiopurines and mesalamines for inflammatory bowel disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; Drug Synergism; Humans; | 2009 |
Encapsulated mesalamine granules (Apriso) for ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Colitis, Ulcerative; Drug Interac | 2009 |
[The problems of compliance and adherence, using the example of chronic inflammatory bowel disease].
Topics: Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colitis, Ulcerative; Gluc | 2009 |
Importance of mucosal healing in ulcerative colitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodi | 2010 |
Balsalazide in treating colonic diseases.
Topics: Colitis, Ulcerative; Colonic Diseases; Gastrointestinal Agents; Humans; Mesalamine; Phenylhydrazines | 2009 |
Balsalazide: a novel 5-aminosalicylate prodrug for the treatment of active ulcerative colitis.
Topics: Clinical Trials as Topic; Colitis, Ulcerative; Delayed-Action Preparations; Gastrointestinal Agents; | 2009 |
5-ASA in ulcerative colitis: improving treatment compliance.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Colitis, Ulcerative; Drug Adminis | 2009 |
[For treatment decision the age to be taken into account. In Crohn's disease and ulcerative colitis attention to be paid to the age at manifestation].
Topics: Adolescent; Adult; Age Factors; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroi | 2009 |
Pancreatitis in inflammatory bowel diseases.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colitis, Ulcerative; Crohn Dis | 2010 |
Rectal 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Mesala | 2010 |
[Pulmonary manifestations of inflammatory bowel disease].
Topics: Antibodies, Monoclonal; Antirheumatic Agents; Bronchoscopy; Chest Pain; Colitis, Ulcerative; Cough; | 2010 |
Mesalazine in inflammatory bowel disease: a trendy topic once again?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Crohn Disease; H | 2010 |
Inducing and maintaining remission in ulcerative colitis: role of high-dose, extended-release mesalamine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-Action Preparations; Dose-Resp | 2010 |
Insight into the widespread problem of nonadherence to therapy in ulcerative colitis patients.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Mesalamine; Patient Compliance | 2010 |
Best practice in the management of mild-to-moderately active ulcerative colitis and achieving maintenance of remission using mesalazine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Health Care Costs; Humans; Mesalamine; | 2010 |
Dysplastic lesions in ulcerative colitis: changing paradigms.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colectomy; Colitis, Ulcerative; Colonic Polyps; Colonoscopy | 2010 |
Oral budesonide for induction of remission in ulcerative colitis.
Topics: Administration, Oral; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; | 2010 |
Consensus for managing acute severe ulcerative colitis in children: a systematic review and joint statement from ECCO, ESPGHAN, and the Porto IBD Working Group of ESPGHAN.
Topics: Acute Disease; Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroid | 2011 |
Foam preparations for the treatment of ulcerative colitis.
Topics: Administration, Rectal; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Clinical T | 2012 |
Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc | 2011 |
Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc | 2011 |
Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc | 2011 |
Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc | 2011 |
MMX® Mesalazine: a review of its use in the management of mild to moderate ulcerative colitis.
Topics: Chemistry, Pharmaceutical; Clinical Trials as Topic; Colitis, Ulcerative; Delayed-Action Preparation | 2011 |
Review article: delivery and efficacy of topical 5-aminosalicylic acid (mesalazine) therapy in the treatment of ulcerative colitis.
Topics: Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc | 2011 |
Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Dose-Response Relationship, Drug; Huma | 2011 |
Maintaining remission in ulcerative colitis--role of once daily extended-release mesalamine.
Topics: Colitis, Ulcerative; Delayed-Action Preparations; Humans; Medication Adherence; Mesalamine; Remissio | 2011 |
Is 5-ASA still the treatment of choice for ulcerative colitis?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Colitis, Ulcerative; Humans; Mesa | 2011 |
Conventional medical management of inflammatory bowel disease.
Topics: Adrenal Cortex Hormones; Algorithms; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroid | 2011 |
Pulmonary nodules as respiratory manifestation of inflammatory bowel disease: case report and review.
Topics: Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Col | 2011 |
Cost-effectiveness analysis of adjunct VSL#3 therapy versus standard medical therapy in pediatric ulcerative colitis.
Topics: Antibodies, Monoclonal; Azathioprine; Child; Colectomy; Colitis, Ulcerative; Combined Modality Thera | 2011 |
Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Administration Schedule; H | 2011 |
Current treatment of ulcerative colitis.
Topics: Adrenal Cortex Hormones; Antibodies, Monoclonal; Azathioprine; Colitis, Ulcerative; Cyclosporine; En | 2011 |
Fulminant ulcerative colitis despite maximal immunosuppression following liver transplantation: a case report and literature review.
Topics: Cholangitis, Sclerosing; Colectomy; Colitis, Ulcerative; Drug Therapy, Combination; Female; Humans; | 2011 |
Recent advances in understanding ulcerative colitis.
Topics: Biopsy, Needle; Colectomy; Colitis, Ulcerative; Colorectal Neoplasms; Combined Modality Therapy; Dis | 2012 |
Efficacy of topical 5-aminosalicylates in preventing relapse of quiescent ulcerative colitis: a meta-analysis.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Colit | 2012 |
[Topical therapy of ulcerative colitis].
Topics: Administration, Rectal; Adrenal Cortex Hormones; Algorithms; Anti-Inflammatory Agents, Non-Steroidal | 2011 |
Efficacy of oral vs. topical, or combined oral and topical 5-aminosalicylates, in Ulcerative Colitis: systematic review and meta-analysis.
Topics: Administration, Cutaneous; Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colitis, U | 2012 |
Mesalamine in the treatment and maintenance of remission of ulcerative colitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, P | 2012 |
Results of the 2nd scientific workshop of the ECCO (III): basic mechanisms of intestinal healing.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2012 |
High mucosal healing rates in 5-ASA-treated ulcerative colitis patients: results of a meta-analysis of clinical trials.
Topics: Clinical Trials as Topic; Colitis, Ulcerative; Humans; Intestinal Mucosa; Mesalamine; Wound Healing | 2012 |
Once-daily versus multiple-daily mesalamine for patients with ulcerative colitis: a meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Administration Schedule; Humans; | 2012 |
Can oral 5-aminosalicylic acid be administered once daily in the treatment of mild-to-moderate ulcerative colitis? A meta-analysis of randomized-controlled trials.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-Action P | 2012 |
Inflammatory bowel disease and lupus: a systematic review of the literature.
Topics: Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, | 2012 |
Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Dose-Response Re | 2012 |
Potential prospects of nanomedicine for targeted therapeutics in inflammatory bowel diseases.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; Cyclin D1; Gen | 2012 |
E-health: Web-guided therapy and disease self-management in ulcerative colitis. Impact on disease outcome, quality of life and compliance.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Benchmarking; Colitis, Ulcerative; | 2012 |
Ulcerative colitis.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonic Pouches; Humans; M | 2012 |
[Rational treatment of ulcerative colitis--local or systemic therapy? Surgery?].
Topics: Administration, Oral; Administration, Rectal; Adrenal Cortex Hormones; Algorithms; Anti-Inflammatory | 2012 |
Multi-Matrix System (MMX®) mesalamine for the treatment of mild-to-moderate ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Mesalamine; Product Surveillan | 2012 |
Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Azathioprine; Colitis, Ulcerative; Humans; | 2012 |
Topical therapies in inflammatory bowel disease.
Topics: Administration, Rectal; Anti-Inflammatory Agents; Budesonide; Colitis, Ulcerative; Drug Therapy, Com | 2012 |
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Inductio | 2012 |
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Topics: Administration, Oral; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcera | 2012 |
Curcumin for maintenance of remission in ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Curcumin; Drug Therapy, Combination; H | 2012 |
Extended-release mesalamine granules for ulcerative colitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-Action Preparations; | 2012 |
Rectal 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Topics: Administration, Oral; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulce | 2012 |
The role of chemoprevention of colorectal cancer with 5-aminosalicylates in ulcerative colitis.
Topics: Adenocarcinoma; Adenoma; Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colo | 2012 |
Topical therapy.
Topics: Administration, Topical; Adrenal Cortex Hormones; Budesonide; Colitis, Ulcerative; Humans; Mesalamin | 2012 |
Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.
Topics: Aminosalicylic Acids; Anti-Ulcer Agents; Colitis, Ulcerative; Databases, Bibliographic; Female; Huma | 2002 |
Inflammatory bowel disease.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ul | 2002 |
Inflammatory bowel disease.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ul | 2002 |
Inflammatory bowel disease.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ul | 2002 |
Inflammatory bowel disease.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ul | 2002 |
Role of mesalazine in acute and long-term treatment of ulcerative colitis and its complications.
Topics: Acute Disease; Administration, Oral; Administration, Rectal; Aminosalicylic Acids; Anti-Inflammatory | 2002 |
Evolving medical therapies for ulcerative colitis.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antineopl | 2002 |
Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutical; Colitis, U | 2002 |
Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Feces; Humans; M | 2003 |
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Topics: Administration, Oral; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcera | 2002 |
[Standard therapy of ulcerative colitis. Evidence- and consensus-based recommendations].
Topics: Acute Disease; Administration, Rectal; Adrenal Cortex Hormones; Colectomy; Colitis, Ulcerative; Croh | 2002 |
[Conservative therapy of inflammatory bowel diseases].
Topics: Acute Disease; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Chro | 2002 |
[Management of ulcerative colitis].
Topics: Administration, Oral; Adrenal Cortex Hormones; Aminosalicylic Acids; Anemia; Anti-Inflammatory Agent | 2003 |
Review article: Oral, modified-release mesalazine formulations--proprietary versus generic.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; D | 2003 |
Review article: diagnosis, monitoring and treatment of distal colitis.
Topics: Acute Disease; Administration, Oral; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal | 2003 |
[A case of acute phase ulcerative colitis like colitis developed by the interferon-beta therapy for chronic hepatitis C].
Topics: Acute-Phase Reaction; Anti-Inflammatory Agents, Non-Steroidal; Colitis; Colitis, Ulcerative; Colonos | 2003 |
Chemoprevention of colorectal cancer in ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Calcium, Dietary; Chemoprevention; Cholagogues and Choleret | 2003 |
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Mesalamine; Randomized Control | 2003 |
The efficacy of oral 5-ASAs in the treatment of active ulcerative colitis: a systematic review.
Topics: Administration, Oral; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agen | 2003 |
[5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; Humans; Mesalamine; Rec | 2003 |
Collagenous colitis evolving into ulcerative colitis: a case report and review of the literature.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis; Colitis, Ulcerative; Colonoscopy; Diagnosis, Diffe | 2003 |
Systematic review: short-term adverse effects of 5-aminosalicylic acid agents in the treatment of ulcerative colitis.
Topics: Administration, Oral; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agen | 2004 |
Current concept of pathophysiological understanding and natural course of ulcerative colitis.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Colect | 2004 |
[Pathophysiology of inflammatory bowel diseases and the therapeutic strategy].
Topics: Adrenal Cortex Hormones; Antibodies; Antigen Presentation; Autoimmunity; Colitis, Ulcerative; Colon; | 2004 |
Ulcerative colitis: conservative management and long-term effects.
Topics: Administration, Oral; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2004 |
[A case of eosinophilic pneumonia possibly associated with 5-aminosalicylic acid (5-ASA)].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Male; Mesalamine; Pulmo | 2004 |
Left-sided ulcerative colitis.
Topics: Administration, Cutaneous; Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colitis, U | 2004 |
The short- and long-term safety of 5-aminosalicylate products in the treatment of ulcerative colitis.
Topics: Adolescent; Adult; Aminosalicylic Acids; Child; Clinical Trials as Topic; Colitis, Ulcerative; Dose- | 2004 |
Controversies with aminosalicylates in inflammatory bowel disease.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Chemopreventi | 2004 |
Ulcerative colitis with low-grade dysplasia.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cell Transformation, Neoplastic; Colectomy; Colitis, | 2004 |
[Association between membranous glomerulonephritis and Crohn's disease].
Topics: Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Autoimmune Diseases; Child; Colitis, Ul | 2004 |
[S3 guideline by the German Society of Digestive and Metabolic Diseases and the Competence Network of Chronic Inflammatory Bowel diseases on diagnosis and therapy of ulcerative colitis. An update].
Topics: Administration, Oral; Administration, Rectal; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non | 2005 |
Medical and surgical management of chronic ulcerative colitis.
Topics: Anastomosis, Surgical; Antibodies, Monoclonal; Chronic Disease; Colectomy; Colitis, Ulcerative; Colo | 2005 |
Inflammatory bowel disease.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonoscopy; | 2005 |
[Drug therapy for ulcerative colitis: salazosulfapyridine and 5-ASA].
Topics: Administration, Oral; Colitis, Ulcerative; Drug Administration Schedule; Enema; Humans; Mesalamine; | 2005 |
[Enema therapy for ulcerative colitis patients].
Topics: Abietanes; Alanine; Anesthetics, Local; Betamethasone; Colitis, Ulcerative; Enema; Fatty Acids, Vola | 2005 |
[Guidelines for treatment of ulcerative colitis in children].
Topics: Azathioprine; Child; Colitis, Ulcerative; Contraindications; Cyclosporins; Growth Disorders; Humans; | 2005 |
Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Colitis, Ulcerative; Color | 2005 |
Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Colitis, Ulcerative; Color | 2005 |
Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Colitis, Ulcerative; Color | 2005 |
Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Colitis, Ulcerative; Color | 2005 |
[Ulcerative colitis and Crohn's disease].
Topics: Animals; Anti-Bacterial Agents; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Fungal; Antibodi | 2005 |
5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control St | 2005 |
[A case of simple ulcer with ulcerative colitis].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Behcet Syndrome; Cecal Diseases; Colit | 2005 |
Systematic review: adherence issues in the treatment of ulcerative colitis.
Topics: Administration, Oral; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Attitude to H | 2006 |
[Inflammatory diseases of the intestines].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Colitis, U | 2006 |
Systematic review: the use of mesalazine in inflammatory bowel disease.
Topics: Acute Disease; Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroida | 2006 |
Systematic review: the use of mesalazine in inflammatory bowel disease.
Topics: Acute Disease; Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroida | 2006 |
Systematic review: the use of mesalazine in inflammatory bowel disease.
Topics: Acute Disease; Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroida | 2006 |
Systematic review: the use of mesalazine in inflammatory bowel disease.
Topics: Acute Disease; Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroida | 2006 |
What's new: innovative concepts in inflammatory bowel disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Colitis, Ulcerative; | 2006 |
New lessons: classic treatments, expanding options in ulcerative colitis.
Topics: Anti-Inflammatory Agents; Chemistry, Pharmaceutical; Clinical Trials as Topic; Colitis, Ulcerative; | 2006 |
Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Mesalami | 2006 |
Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis.
Topics: Administration, Oral; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcera | 2006 |
Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention.
Topics: Administration, Oral; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Phar | 2006 |
[Does 5-ASA prevent development of colon cancer in ulcerative colitis?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonic Neoplasms; Humans; Mesalamine; | 2006 |
Pharmacogenetics in inflammatory bowel disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; Colitis, Ulcerative; | 2006 |
Inflammatory bowel disease in children: a pediatrician's perspective.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Child; Colitis, Ulcerative; Environment; G | 2006 |
The metabolism of mesalamine and its possible use in colonic diverticulitis as an anti-inflammatory agent.
Topics: Acute Disease; Administration, Oral; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal | 2006 |
Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence.
Topics: Acetylation; Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colon; Delayed-A | 2006 |
Review article: induction therapy for patients with active ulcerative colitis.
Topics: Administration, Oral; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulce | 2006 |
Review article: maintenance therapy in patients with ulcerative colitis.
Topics: Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc | 2006 |
MMX mesalamine.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-Action P | 2006 |
Review article: high-dose aminosalicylates to induce and maintain remissions in ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Administration Schedule; Humans; | 2006 |
[Probiotics in chronic inflammatory bowel disease].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bifidobacterium; Colitis, Ulcerative; Crohn Disease; Escher | 2006 |
Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, | 2006 |
[Inflammatory bowel disease and colorectal cancer].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cholangitis, Sclerosing; Colitis, Ulcerative; Colonoscopy; | 2006 |
[Ulcerous colitis and Crohn's disease in members of one family: case description and review of literature].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonoscopy; Crohn Disease; Humans; Ma | 2006 |
Drug insight: aminosalicylates for the treatment of IBD.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Chemoprevention; Colitis, Ulcerative; | 2007 |
[Treatment of inflammatory bowel disease].
Topics: Anti-Inflammatory Agents; Biological Products; Colitis, Ulcerative; Crohn Disease; Humans; Mesalamin | 2007 |
The risks and the benefits of mesalazine as a treatment for ulcerative colitis.
Topics: Animals; Colitis, Ulcerative; Humans; Mesalamine; Risk Factors | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
Inflammatory bowel disease: clinical aspects and established and evolving therapies.
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Croh | 2007 |
[Medical therapy of inflammatory bowel diseases: ulcerative colitis].
Topics: Administration, Oral; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, | 2007 |
MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind Method; Drug Admin | 2007 |
Duration of treatment with 5-aminosalicylic acid compounds.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Colitis, Ulcerative; Dose-Respons | 2007 |
Review article: increasing the dose of oral mesalazine therapy for active ulcerative colitis does not improve remission rates.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-Action Preparat | 2007 |
[Colorectal cancer in inflammatory bowel disease].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonoscopy; Colorectal Neoplasms; Cro | 2007 |
Delayed-release Multi Matrix System (MMX) mesalazine in ulcerative colitis: a viewpoint by Cosimo Prantera.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-Action Preparations; Drug-Rela | 2007 |
Delayed-release Multi Matrix System (MMX) mesalazine: in ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-Action Preparations; Drug Tole | 2007 |
Delayed-release Multi Matrix System (MMX) mesalazine in ulcerative colitis: a viewpoint by Ake Nilsson.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-Action Preparations; Humans; M | 2007 |
Multi-matrix system mesalamine: to use or not to use.
Topics: Chemistry, Pharmaceutical; Colitis, Ulcerative; Drug Delivery Systems; Humans; Mesalamine | 2008 |
Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutical; Colitis, Ulcerative; Drug Admini | 2008 |
Management of distal ulcerative colitis: frequently asked questions analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutical; Colitis, Ulcerative; Drug Admini | 2008 |
Review article: evolving concepts in treatment and disease modification in ulcerative colitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Biological Therapy; | 2008 |
Ulcerative proctitis: a review of pharmacotherapy and management.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Controlled Clini | 2008 |
MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis.
Topics: Clinical Trials as Topic; Colitis, Ulcerative; Delayed-Action Preparations; Gastrointestinal Agents; | 2008 |
Optimizing drug therapy in inflammatory bowel disease.
Topics: Absorptiometry, Photon; Adalimumab; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal | 2007 |
Review article: medication non-adherence in ulcerative colitis--strategies to improve adherence with mesalazine and other maintenance therapies.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Health Care Costs; Huma | 2008 |
Mesalamine for inflammatory bowel disease: recent reappraisals.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; Humans; Mesalamine; PPA | 2008 |
Maximizing patient adherence and clinical outcomes with mesalamine in mildly-to-moderately active ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Mesalamine; Recurrence; Risk F | 2008 |
Improving delivery of aminosalicylates in ulcerative colitis: effect on patient outcomes.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Delivery Sy | 2008 |
Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development.
Topics: Aminosalicylic Acids; Animals; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Drug In | 1984 |
Medical treatment of ulcerative colitis.
Topics: Administration, Oral; Administration, Topical; Adrenocorticotropic Hormone; Aminosalicylic Acids; Az | 1984 |
Antioxidant properties of 5-aminosalicylic acid: potential mechanism for its protective effect in ulcerative colitis.
Topics: Aminosalicylic Acids; Antioxidants; Colitis, Ulcerative; Colon; Free Radical Scavengers; Humans; In | 1995 |
[Changing treatment of inflammatory bowel diseases].
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, N | 1994 |
A mesalazine enema for ulcerative colitis.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Enema; Mesalamin | 1994 |
[False melanuria in a female patient treated with 5-ASA for ulcerative colitis].
Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; False Pos | 1995 |
[Current orientation in medical management of ulcerative colitis].
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc | 1995 |
5-Aminosalicylic acid enemas to maintain remission in left-sided ulcerative colitis: a meta- and economic analysis.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Cost of Illness; | 1995 |
Rolling review: inflammatory bowel disease.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents; Clinical Trials as Topic; Colitis, Ulcerative; Crohn | 1993 |
Fatal aplastic anaemia after mesalazine.
Topics: Aged; Aminosalicylic Acids; Anemia, Aplastic; Colitis, Ulcerative; Fatal Outcome; Humans; Male; Mesa | 1994 |
[The treatment of ulcerative colitis].
Topics: Acute Disease; Adrenal Cortex Hormones; Aminosalicylic Acids; Colitis, Ulcerative; Humans; Mesalamin | 1993 |
[Current medical treatment of hemorrhagic rectocolitis].
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-Bacterial Agents; Azathioprine; Colitis, Ulcerat | 1994 |
Medical therapy for ulcerative colitis in childhood.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Child; Child, Preschool; Clinical Trials as Topic; Co | 1994 |
Medical management of patients with difficult-to-treat inflammatory bowel disease.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine | 1994 |
Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment of ulcerative colitis.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Humans; Mesalamine; Odds Ratio; Randomized Controlled Tri | 1993 |
[Local or systemic treatment of inflammatory bowel diseases?].
Topics: Administration, Oral; Administration, Rectal; Administration, Topical; Adrenal Cortex Hormones; Amin | 1993 |
[The local therapy of distal colitis and ulcerative proctitis].
Topics: Administration, Rectal; Aminosalicylic Acids; Colitis; Colitis, Ulcerative; Cromolyn Sodium; Fatty A | 1993 |
Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents; Colitis, Ulcerative; Humans; Mesalamine; Placebo Eff | 1993 |
Acute pancreatitis secondary to 5-aminosalicylic acid in a child with ulcerative colitis.
Topics: Aminosalicylic Acids; Child; Colitis, Ulcerative; Humans; Male; Mesalamine; Pancreatitis | 1993 |
A rational approach to 5-aminosalicylic acid therapy in ulcerative colitis.
Topics: Administration, Oral; Administration, Rectal; Administration, Topical; Adult; Aged; Aminosalicylic A | 1993 |
[Treatment and recurrence prevention ulcerative colitis].
Topics: Acute Disease; Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroida | 1995 |
Pleuropericarditis related to the use of mesalamine.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Hypersensit | 1996 |
Mesalamine-induced lung toxicity.
Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; H | 1996 |
Current medical therapy for inflammatory bowel disease.
Topics: Administration, Topical; Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Anti-In | 1996 |
Clinical pharmacology in gastroenterology: development of new forms of treatment of inflammatory bowel disease.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Colitis, Ul | 1996 |
Medical treatment of inflammatory bowel disease.
Topics: Aminosalicylic Acids; Anti-Bacterial Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non | 1995 |
[Drug therapy of ulcerative colitis].
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-Inflammatory Agents; Clinical Trials as Topic; C | 1997 |
Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta-analysis.
Topics: Administration, Oral; Administration, Rectal; Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-I | 1997 |
[Indications for immunosuppressive therapy of chronic inflammatory bowel diseases].
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc | 1997 |
Guidelines for the treatment of ulcerative colitis in remission.
Topics: Adrenal Cortex Hormones; Colitis, Ulcerative; Humans; Immunosuppressive Agents; Mesalamine; Sulfasal | 1997 |
Management of inflammatory bowel disease.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ul | 1998 |
[Therapy of chronic inflammatory bowel diseases].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Diseas | 1997 |
[Ulcerative colitis--colon delivery of 5-aminosalicylic acid].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Capsules; Cellulose; Colitis, Ulcerative; Colon; D | 1998 |
A practical guide to the management of distal ulcerative colitis.
Topics: Administration, Oral; Administration, Topical; Adrenal Cortex Hormones; Anti-Inflammatory Agents, No | 1998 |
[Management of the chronically ill patient with Crohn disease and ulcerative colitis].
Topics: Colitis, Ulcerative; Colon; Combined Modality Therapy; Crohn Disease; Glucocorticoids; Humans; Mesal | 1998 |
Balsalazide.
Topics: Aminosalicylic Acids; Anti-Ulcer Agents; Colitis, Ulcerative; Drug Tolerance; Humans; Mesalamine; Ph | 1998 |
The treatment of inflammatory bowel disease in children.
Topics: Adrenocorticotropic Hormone; Anti-Inflammatory Agents; Child; Colitis, Ulcerative; Crohn Disease; Fe | 1998 |
Recurrent pericarditis due to mesalamine hypersensitivity: a pediatric case report and review of the literature.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Hypersensitivity; Hum | 1998 |
[Ulcerative colitis and intestinal bleeding].
Topics: Anti-Infective Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Colitis, U | 1998 |
Mesalazine-induced eosinophilic pneumonia.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Lymphocyte Acti | 1999 |
[A case of ulcerative colitis associated with interstitial pneumonitis during administration of 5-aminosalicylic acid].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Lung Diseases, Interstitial; M | 1999 |
[5-Aminosalicylic acid-induced acute pancreatitis].
Topics: Acute Disease; Adult; Colitis, Ulcerative; Female; Humans; Mesalamine; Pancreatitis | 1999 |
Pyodermatitis-pyostomatitis vegetans: report of a case and review of the literature.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Carboxymethylcellulose Sodium; Cl | 1999 |
Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Colitis, Ulcerative | 1999 |
[Clinical effect of various 5-ASA preparations in ulcerative colitis].
Topics: Clinical Trials as Topic; Colitis, Ulcerative; Delayed-Action Preparations; Drug Delivery Systems; H | 1999 |
[Acute myocarditis due to mesalazine in a patient with ulcerative colitis].
Topics: Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Male; Me | 1999 |
[A case of ulcerative colitis with folate deficient megaloblastic anemia induced by sulfasalazine].
Topics: Adult; Anemia, Megaloblastic; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Folic Ac | 1999 |
Acute pancreatitis secondary to 5-aminosalicylic acid therapy in a patient with ulcerative colitis.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Hypersensit | 1999 |
[Renal involvement in patients with chronic inflammatory intestinal disease treated with mesalazine. How to prevent its nephrotoxicity?].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Colitis, Ulcerative; Humans; Kidney | 1999 |
New strategies in the management of inflammatory bowel disease.
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprin | 1999 |
[Medical therapy in ulcerative colitis].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Colectomy; Colitis, Ulcerative; D | 1999 |
[Salazosulfapyridine and 5-aminosalicylic acid agents for the treatment of ulcerative colitis].
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Cytokines; Depression, Chemic | 1999 |
[Treatment of mild and moderate ulcerative colitis].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Betamethasone; Colitis, Ulcerativ | 1999 |
[Cardio vascular disease associated with ulcerative colitis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; HLA-B Antigens; HLA-B52 Antige | 1999 |
[Clinical features and management of the elderly patients with ulcerative colitis].
Topics: Age of Onset; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; | 1999 |
[Ulcerative colitis and pregnancy].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Fertility; Humans; Immu | 1999 |
[Recent progress in therapy of inflammatory bowel diseases].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colitis, Ulcerative | 1999 |
[Histopathologic diagnosis of the activity of chronic inflammatory bowel disease. Evaluation of the effect of drug treatment. Use of histological scores].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Biopsy; Colitis, Ulc | 1999 |
Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; Delayed-Action | 2000 |
A meta-analysis and overview of the literature on treatment options for left-sided ulcerative colitis and ulcerative proctitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Glucocorticoids; Humans; Mesalamine; P | 2000 |
Putting rectal 5-aminosalicylic acid in its place: the role in distal ulcerative colitis.
Topics: Administration, Oral; Administration, Rectal; Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-In | 2000 |
Clinical pharmacokinetics of slow release mesalazine.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; Digestive Syst | 2000 |
Ulcerative colitis and cytomegaloviral esophagitis: two diseases, two randomized, controlled trials.
Topics: Antiviral Agents; Ciprofloxacin; Colitis, Ulcerative; Cytomegalovirus Infections; Drug Therapy, Comb | 1999 |
Clinical pharmacology of inflammatory bowel disease therapies.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Biomarkers; Colitis, | 2000 |
[Guidelines of the DGVS. Acute process. German Society of Digestive and Metabolic Diseases].
Topics: Acute Disease; Administration, Oral; Administration, Rectal; Anti-Inflammatory Agents; Anti-Inflamma | 2001 |
[Guidelines of DGVS. Remission. German Society of Digestive and Metabolic Diseases].
Topics: Anti-Inflammatory Agents; Colitis, Ulcerative; Combined Modality Therapy; Dose-Response Relationship | 2001 |
Inflammatory bowel disease and pregnancy.
Topics: Adult; Aminosalicylic Acids; Anti-Bacterial Agents; Colitis, Ulcerative; Crohn Disease; Female; Fert | 2001 |
Review article: balsalazide therapy in ulcerative colitis.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clinical Trials as | 2001 |
[Therapeutic principles for chronic inflammatory bowel disease].
Topics: Adjuvants, Immunologic; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colectomy; Colitis; C | 2001 |
Can a drug-induced pulmonary hypersensitivity reaction be dose-dependent? A case with mesalamine.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Dose-Response Relationship, Drug | 2001 |
Medical management of ulcerative proctitis, proctosigmoiditis, and left-sided colitis.
Topics: Administration, Oral; Administration, Rectal; Administration, Topical; Adult; Anti-Inflammatory Agen | 2001 |
Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease: a systematic review.
Topics: Acute Disease; Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroida | 2002 |
[Drug therapy of inflammatory bowel diseases].
Topics: Adjuvants, Immunologic; Anti-Bacterial Agents; Anti-Inflammatory Agents; Anti-Inflammatory Agents, N | 1999 |
Review article: treatment of mild to moderate ulcerative colitis and pouchitis.
Topics: Administration, Oral; Administration, Rectal; Anti-Infective Agents; Anti-Inflammatory Agents; Anti- | 2002 |
Review article: maintenance of remission in ulcerative colitis.
Topics: Administration, Oral; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; | 2002 |
[Interstitial nephritis induced by mesalazine].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Mesalamine; Nep | 2002 |
Equimolar doses of balsalazide and mesalamine: are we comparing apples and oranges?
Topics: Aminosalicylic Acids; Anti-Ulcer Agents; Colitis, Ulcerative; Dose-Response Relationship, Drug; Huma | 2002 |
[Long-term therapy and timing of surgical intervention in ulcerative colitis and Crohn disease].
Topics: Acute Disease; Aminosalicylic Acids; Colitis, Ulcerative; Combined Modality Therapy; Crohn Disease; | 1992 |
[Drug therapy of chronic inflammatory bowel disease--reliable standards and new developments].
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Azathioprine; Colitis, Ulcerative; Crohn Disease; Hum | 1992 |
Sulfasalazine and 5-ASA compounds.
Topics: Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Drug Combination | 1992 |
Therapeutic interventions in gastrointestinal disease based on an understanding of inflammatory mediators.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Cytokines; Eicosapentaenoic Acid; Fish Oil | 1992 |
Medical treatment of inflammatory bowel disease.
Topics: Adjuvants, Immunologic; Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-Inflammatory Agents; Ant | 1992 |
Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.
Topics: Administration, Oral; Administration, Rectal; Aminosalicylic Acids; Chemistry, Pharmaceutical; Clini | 1992 |
Choosing an oral 5-aminosalicylic acid preparation for ulcerative colitis.
Topics: Administration, Oral; Aminosalicylic Acids; Colitis, Ulcerative; Humans; Mesalamine | 1992 |
Sulphasalazine in ulcerative colitis: in memoriam?
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Dose-Response Relationship, Drug; Humans; Mesalamine; Neu | 1991 |
Mesalamine in ulcerative colitis.
Topics: Administration, Rectal; Adrenal Cortex Hormones; Aminosalicylic Acids; Colitis, Ulcerative; Costs an | 1991 |
[Conservative therapy of ulcerative colitis--long-term experience].
Topics: Aminosalicylic Acids; Azathioprine; Colitis, Ulcerative; Glucocorticoids; Humans; Immunosuppressive | 1991 |
[New developments in the treatment of inflammatory bowel diseases. What is certain?].
Topics: Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Humans; Immunosu | 1990 |
[New developments in therapy with 5-aminosalicylic acid preparations in ulcerative colitis and Crohn disease].
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Dose-Response Relationship, Drug; Humans; | 1991 |
Review article: new developments in the use of 5-aminosalicylic acid in patients with inflammatory bowel disease.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Humans; Inflammatory Bowel Diseases; Mesal | 1991 |
[Conservative therapy of ulcerative colitis and Crohn disease].
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Humans; Immunosup | 1991 |
Topical treatment of ulcerative colitis.
Topics: Absorption; Administration, Topical; Adrenal Cortex Hormones; Aminosalicylic Acids; Colitis, Ulcerat | 1990 |
Phagocytes, toxic oxygen metabolites and inflammatory bowel disease: implications for treatment.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Colon; Crohn Disease; Humans; Mesalamine; Oxygen; Phagocy | 1990 |
New salicylate therapies for ulcerative colitis.
Topics: Administration, Oral; Administration, Rectal; Aminosalicylic Acid; Aminosalicylic Acids; Colitis, Ul | 1990 |
Mechanism of action of 5-aminosalicylic acid and its derivatives.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Colon; Humans; Mesalamine | 1990 |
[Aminosalicylates in the treatment of chronic inflammatory bowel diseases].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Humans; Mesalamine; R | 1990 |
Topical salicylate therapy (4-ASA and 5-ASA enemas).
Topics: Administration, Topical; Aminosalicylic Acid; Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disea | 1989 |
Drug treatment and formation of eicosanoids in patients with chronic inflammatory bowel disease.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Humans; Inflammatory Bowel Diseases; Leuko | 1989 |
[Prevention of recurrence of chronic inflammatory bowel diseases].
Topics: Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Humans; Immunosu | 1989 |
New oral salicylates in the therapy of chronic idiopathic inflammatory bowel disease.
Topics: Administration, Oral; Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Humans; Mesalamine | 1989 |
5-ASA enema therapy.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Enema; Humans; M | 1989 |
Salazopyrin and its newer analogues in the treatment of inflammatory bowel disease.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Double-Blind Method; Drug Combinations; Dr | 1985 |
Sulfasalazine and new analogues.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Animals; Clinical Trials as Topic; Colitis, Ulcerative; C | 1986 |
Oral 5-aminosalicylic acid preparations in treatment of inflammatory bowel disease. An update.
Topics: Administration, Oral; Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Dis | 1987 |
Medical treatment of inflammatory bowel disease: new therapies, new drugs.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; F | 1987 |
[Therapy of chronic inflammatory bowel diseases. Clinical aspects and therapy of drug-induced side effects].
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Glucocorticoids; Humans; Immunosuppressive | 1988 |
[Inhibition of intestinal leukotriene formation as a possible mechanism of action of sulfasalazine, 5-aminosalicylic acid and 4-aminosalicylic acid].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Animals; Colitis, Ulcerative; Crohn Disease; Humans; Inte | 1988 |
Clinical tolerance of olsalazine.
Topics: Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Diarrhea; Humans; Mesalamine | 1988 |
5-Aminosalicylic acid in the treatment of inflammatory bowel disease.
Topics: Administration, Oral; Administration, Rectal; Aminosalicylic Acids; Animals; Chemical Phenomena; Che | 1987 |
Pharmacology and pharmacokinetics of 5-aminosalicylic acid.
Topics: Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Humans; Mesalami | 1987 |
[Drug treatment of chronic inflammatory intestinal diseases with special reference to 5-azosalicylic acid].
Topics: Administration, Oral; Aminosalicylic Acids; Anti-Inflammatory Agents; Colitis, Ulcerative; Crohn Dis | 1987 |
331 trials available for mesalamine and Colitis, Ulcerative
| Article | Year |
|---|---|
Corticosteroids and Mesalamine Versus Corticosteroids for Acute Severe Ulcerative Colitis: A Randomized Controlled Trial.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Coliti | 2022 |
AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
Topics: Colitis, Ulcerative; Humans; Induction Chemotherapy; Integrin alpha4; Mesalamine; Nasopharyngitis; P | 2022 |
Novel Budesonide Suppository and Standard Budesonide Rectal Foam Induce High Rates of Clinical Remission and Mucosal Healing in Active Ulcerative Proctitis: a Randomised, Controlled, Non-inferiority Trial.
Topics: Budesonide; Colitis, Ulcerative; Double-Blind Method; Humans; Mesalamine; Proctitis; Quality of Life | 2022 |
Evaluation of the efficacy of Thymus kotschyanus extract as an additive treatment in patients with ulcerative colitis: a randomized double-blind placebo-controlled trial.
Topics: Colitis, Ulcerative; Double-Blind Method; Humans; Leukocyte L1 Antigen Complex; Mesalamine; Plant Ex | 2022 |
Additive effect of probiotics (Mutaflor) on 5-aminosalicylic acid therapy in patients with ulcerative colitis.
Topics: Colitis, Ulcerative; Double-Blind Method; Escherichia coli; Escherichia coli Infections; Humans; Mes | 2022 |
Efficacy of the Panax Notoginseng Ejiao Suppository in the Treatment of Patients with Ulcerative Proctitis and Its Effect on Inflammatory Response and Immune Function.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Gelatin; Humans; Immunity; Inflammatio | 2022 |
Mercaptopurine for the Treatment of Ulcerative Colitis: A Randomized Placebo-Controlled Trial.
Topics: Colitis, Ulcerative; Humans; Mercaptopurine; Mesalamine; Prospective Studies; Remission Induction | 2023 |
No Superiority of Tacrolimus Suppositories vs Beclomethasone Suppositories in a Randomized Trial of Patients With Refractory Ulcerative Proctitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Beclomethasone; Colitis, Ulcerative; Female; Humans; Male; | 2020 |
A Phase I Trial of Berberine in Chinese with Ulcerative Colitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Berberine; Biopsy; China; Coli | 2020 |
Distinct patterns of short-chain fatty acids during flare in patients with ulcerative colitis under treatment with mesalamine or a herbal combination of myrrh, chamomile flowers, and coffee charcoal: secondary analysis of a randomized controlled trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chamomile; Charcoal; Coffee; Colitis, Ulcerative; Double-Bl | 2020 |
Use of an iPhone Application to Increase Adherence in Patients With Ulcerative Colitis in Remission: A Randomized Controlled Trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cell Phone; Colitis, Ulcerative; Female; Humans; Mai | 2020 |
Modified Sijunzi decoction in the treatment of ulcerative colitis in the remission phase: study protocol for a series of N-of-1 double-blind, randomised controlled trials.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind Method; Drug | 2020 |
Similar pharmacokinetics of three dosing regimens comprising two oral delayed-release mesalamine formulations in healthy adult volunteers: Randomised, open-label, parallel-group study.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Clinical Protocols; Colitis, U | 2021 |
Novel Bioenhanced Curcumin With Mesalamine for Induction of Clinical and Endoscopic Remission in Mild-to-Moderate Ulcerative Colitis: A Randomized Double-Blind Placebo-controlled Pilot Study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Curcumin; Double-Blind Method; Humans; | 2021 |
Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1).
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, N | 2020 |
Intestinal protozoa and helminths in ulcerative colitis and the influence of anti-parasitic therapy on the course of the disease.
Topics: Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antiparasitic Agents; Blastocystis; Blastoc | 2021 |
Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis.
Topics: Adult; Colitis, Ulcerative; Endoscopy; Feces; Humans; Leukocyte L1 Antigen Complex; Mesalamine; Remi | 2022 |
Chinese herbal extract granules combined with 5-aminosalicylic acid for patients with moderately active ulcerative colitis: study protocol for a multicenter randomized double-blind placebo-controlled trial.
Topics: China; Colitis, Ulcerative; Double-Blind Method; Drugs, Chinese Herbal; Humans; Mesalamine; Multicen | 2021 |
Effect of Kangfuxin Liquid enema combined with mesalazine on gestational outcomes and quality of life in child-bearing female with active ulcerative colitis: A protocol for randomized, double-blind, controlled trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind Method; Enema; Fem | 2021 |
Randomised clinical trial: Efficacy and safety of Qing-Chang-Hua-Shi granules in a multicenter, randomized, and double-blind clinical trial of patients with moderately active ulcerative colitis.
Topics: Adult; Anti-Ulcer Agents; Colitis, Ulcerative; Double-Blind Method; Drugs, Chinese Herbal; Female; H | 2021 |
Budesonide Multimatrix Is Efficacious for Mesalamine-refractory, Mild to Moderate Ulcerative Colitis: A Randomised, Placebo-controlled Trial.
Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcer | 2017 |
2.4 g Mesalamine (Asacol 400 mg tablet) Once Daily is as Effective as Three Times Daily in Maintenance of Remission in Ulcerative Colitis: A Randomized, Noninferiority, Multi-center Trial.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Bl | 2017 |
Mesalamine Enemas for Induction of Remission in Oral Mesalamine-refractory Pediatric Ulcerative Colitis: A Prospective Cohort Study.
Topics: Adolescent; Child; Child, Preschool; Colitis, Ulcerative; Enema; Female; Humans; Male; Mesalamine; P | 2017 |
Fecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonoscopy; Fecal Microbiota T | 2017 |
Fecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonoscopy; Fecal Microbiota T | 2017 |
Fecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonoscopy; Fecal Microbiota T | 2017 |
Fecal microbiota transplantation is a rescue treatment modality for refractory ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonoscopy; Fecal Microbiota T | 2017 |
Effects of Jianpi Qingchang decoction on the quality of life of patients with ulcerative colitis: A randomized controlled trial.
Topics: Adult; Colitis, Ulcerative; Drugs, Chinese Herbal; Female; Gastrointestinal Agents; Health Status; H | 2017 |
Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Colitis, Ulcerative; D | 2017 |
Patient Education in a 14-month Randomised Trial Fails to Improve Adherence in Ulcerative Colitis: Influence of Demographic and Clinical Parameters on Non-adherence.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcera | 2017 |
Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, P | 2017 |
Granulocyte and Monocyte Apheresis for Induction of Remission in Children With New-Onset Inflammatory Bowel Colitis.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Combined Modality T | 2018 |
Urinalysis of MMX-mesalazine as a tool to monitor 5-ASA adherence in daily IBD practice.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Chromatography, High Pressure Liquid; Colitis, | 2018 |
Health-Related Quality of Life and Work-Related Outcomes for Patients With Mild-to-Moderate Ulcerative Colitis and Remission Status Following Short-Term and Long-Term Treatment With Multimatrix Mesalamine: A Prospective, Open-Label Study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Administration Schedule; F | 2018 |
Genetic variants in cellular transport do not affect mesalamine response in ulcerative colitis.
Topics: Adult; Biological Transport, Active; Colitis, Ulcerative; Female; Humans; Male; Mesalamine; Middle A | 2018 |
Budesonide Suppositories Are Effective and Safe for Treating Acute Ulcerative Proctitis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Budesonide; Colitis, Ulcerative; Double-Blind Met | 2019 |
The efficacy of curcuminoids in improvement of ulcerative colitis symptoms and patients' self-reported well-being: A randomized double-blind controlled trial.
Topics: Adult; Colitis, Ulcerative; Curcumin; Double-Blind Method; Female; Humans; Male; Mesalamine; Micelle | 2018 |
Efficacy of mesalazine in combination with bifid triple viable capsules on ulcerative colitis and the resultant effect on the inflammatory factors.
Topics: Adult; Bifidobacterium; Colitis, Ulcerative; Drug Therapy, Combination; Enterococcus; Female; Humans | 2018 |
Clinical and biological predictors of response to standardised paediatric colitis therapy (PROTECT): a multicentre inception cohort study.
Topics: Adolescent; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Child; Chi | 2019 |
Utility of Mesalazine in Familial Adenomatous Polyposis: Clinical Report of Reduction of Polyp Size in Patients with Ulcerative Colitis, and Safety Examination in Familial Adenomatous Polyposis Patients.
Topics: Adenomatous Polyposis Coli; Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Co | 2019 |
A Phase 2a, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Trial of IBD98-M Delayed-Release Capsules to Induce Remission in Patients with Active and Mild to Moderate Ulcerative Colitis.
Topics: Adult; Capsules; Colitis, Ulcerative; Delayed-Action Preparations; Double-Blind Method; Endoscopy; F | 2019 |
Longitudinal non-adherence predicts treatment escalation in paediatric ulcerative colitis.
Topics: Adolescent; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Calcineurin Inhibitors | 2019 |
Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcera | 2013 |
[Observation of the curative effect of qingchang huashi recipe for treating active ulcerative colitis of inner-accumulation of damp-heat syndrome].
Topics: Adult; Colitis, Ulcerative; Drugs, Chinese Herbal; Female; Humans; Male; Mesalamine; Middle Aged; Ph | 2012 |
The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind | 2013 |
The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind | 2013 |
The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind | 2013 |
The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind | 2013 |
Comparison of QD and TID oral mesalazine for maintenance of remission in quiescent ulcerative colitis: a double-blind, double-dummy, randomized multicenter study.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Bl | 2013 |
Randomised clinical trial: evaluation of the efficacy of mesalazine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation -- a placebo-controlled study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Asian People; Colitis, Ulcerative; | 2013 |
Randomised clinical trial: a herbal preparation of myrrh, chamomile and coffee charcoal compared with mesalazine in maintaining remission in ulcerative colitis--a double-blind, double-dummy study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chamomile; Charcoal; Coffee; Colitis, Ulcerative; Do | 2013 |
Hyperbaric oxygen therapy does not improve the effects of standardized treatment in a severe attack of ulcerative colitis: a prospective randomized study.
Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Betamethasone; Colectomy; | 2013 |
Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis - a randomized, placebo-controlled, pilot study.
Topics: Administration, Rectal; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Curcumi | 2014 |
Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life.
Topics: Administration, Oral; Administration, Rectal; Adult; Anti-Inflammatory Agents, Non-Steroidal; Coliti | 2014 |
Electronic monitoring of medication adherence in a 1-year clinical study of 2 dosing regimens of mesalazine for adults in remission with ulcerative colitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Dose-Resp | 2014 |
Mesalamine dose escalation reduces fecal calprotectin in patients with quiescent ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Feces; Humans; Leukocyte L1 Ant | 2014 |
First multicenter study of modified release phosphatidylcholine "LT-02" in ulcerative colitis: a randomized, placebo-controlled trial in mesalazine-refractory courses.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind Method; Female; Ge | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials.
Topics: Adult; Amoxicillin; Ciprofloxacin; Colitis, Ulcerative; Cross-Over Studies; Drug Interactions; Femal | 2014 |
Long-term safety and tolerability of once-daily mesalamine granules in the maintenance of remission of ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind Method; Female; Follow-Up | 2014 |
A randomized clinical trial of mesalazine suppository: the usefulness and problems of central review of evaluations of colonic mucosal findings.
Topics: Adolescent; Adult; Advisory Committees; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulce | 2014 |
[Serum metabolome by gas chromatography-mass spectrometry (GC-MS) in patients with ulcerative colitis and celiac disease].
Topics: Adolescent; Adult; Carboxylic Acids; Celiac Disease; Colitis, Ulcerative; Combined Modality Therapy; | 2013 |
Efficacy of long-term 4.0 g/day mesalazine (Pentasa) for maintenance therapy in ulcerative colitis.
Topics: Cohort Studies; Colitis, Ulcerative; Dose-Response Relationship, Drug; Humans; Japan; Kaplan-Meier E | 2014 |
Safety and activity of dersalazine sodium in patients with mild-to-moderate active colitis: double-blind randomized proof of concept study.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Azo Compound | 2014 |
The relationship among multiple patient-reported outcomes measures for patients with ulcerative colitis receiving treatment with MMX ® formulated delayed-release mesalamine.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Health Status; Health S | 2015 |
High- and low-dose oral delayed-release mesalamine in children with mild-to-moderately active ulcerative colitis.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Colitis, Ulcerative; D | 2014 |
Combined diosmectite and mesalazine treatment for mild-to-moderate ulcerative colitis: a randomized, placebo-controlled study.
Topics: Adolescent; Adult; Aged; Blood Sedimentation; C-Reactive Protein; Colitis, Ulcerative; Defecation; D | 2015 |
Ulcerative colitis patients with an inflammatory response upon mesalazine cannot be desensitized: a randomized study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; C-Reactive Protein; Colitis, Ulcerative; Cross-Over | 2015 |
Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc | 2015 |
Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc | 2015 |
Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc | 2015 |
Curcumin in Combination With Mesalamine Induces Remission in Patients With Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc | 2015 |
Efficacy of mesalazine or beclomethasone dipropionate enema or their combination in patients with distal active ulcerative colitis.
Topics: Adult; Aged; Anti-Inflammatory Agents; Beclomethasone; Colitis, Ulcerative; Drug Therapy, Combinatio | 2015 |
Once-daily Mesalamine Formulation for Maintenance of Remission in Ulcerative Colitis: A Randomized, Placebo-controlled Clinical Trial.
Topics: Adult; Anti-Inflammatory Agents; Colitis, Ulcerative; Double-Blind Method; Drug Administration Sched | 2016 |
Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials.
Topics: Adult; Colitis, Ulcerative; Double-Blind Method; Endoscopy; Female; Gastrointestinal Hemorrhage; Hum | 2015 |
A randomized trial comparing 4.8 vs. 2.4 g/day of oral mesalazine for maintenance of remission in ulcerative colitis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Biops | 2015 |
Reduced Plasma Levels of sCD14 and I-FABP in HIV-infected Patients with Mesalazine-treated Ulcerative Colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Colitis, Ulcerative; Cross-Sectional Stu | 2016 |
Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Capsules; Colitis, Ulcerative; Double-Blind Method; | 2016 |
Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Capsules; Colitis, Ulcerative; Double-Blind Method; | 2016 |
Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Capsules; Colitis, Ulcerative; Double-Blind Method; | 2016 |
Once-daily mesalamine granules for maintaining remission of ulcerative colitis: pooled analysis of efficacy, safety, and prognostic factors.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Capsules; Colitis, Ulcerative; Double-Blind Method; | 2016 |
Randomized clinical trial: pharmacokinetics and safety of multimatrix mesalamine for treatment of pediatric ulcerative colitis.
Topics: Adolescent; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Child; | 2016 |
Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Active Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; China; Colitis, Ulcerative; De | 2016 |
Mesalazine Modified-Release Tablet in the Treatment of Ulcerative Colitis in the Remission Phase: A Chinese, Multicenter, Single-Blind, Randomized Controlled Study.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; China; Colitis, Ulcerative; De | 2016 |
Ulcerative Colitis Remission Status After Induction With Mesalazine Predicts Maintenance Outcomes: the MOMENTUM Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcera | 2016 |
Casein glycomacropeptide for active distal ulcerative colitis: a randomized pilot study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Caseins; Colitis, Ulcerative; Dietary Suppleme | 2016 |
[Long-term adalimumab therapy in ulcerative colitis in clinical practice: result of the Hungarian multicenter prospective study].
Topics: Adalimumab; Adolescent; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Azathioprine; Chil | 2016 |
Serum Fatty Acids Are Correlated with Inflammatory Cytokines in Ulcerative Colitis.
Topics: Adult; Aged; Colitis, Ulcerative; Colon; Cytokines; Fatty Acids, Unsaturated; Female; Humans; Inflam | 2016 |
Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.
Topics: Administration, Oral; Administration, Rectal; Adult; Anti-Inflammatory Agents, Non-Steroidal; Budeso | 2016 |
Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.
Topics: Administration, Oral; Administration, Rectal; Adult; Anti-Inflammatory Agents, Non-Steroidal; Budeso | 2016 |
Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.
Topics: Administration, Oral; Administration, Rectal; Adult; Anti-Inflammatory Agents, Non-Steroidal; Budeso | 2016 |
Baseline Oral 5-ASA Use and Efficacy and Safety of Budesonide Foam in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis: Analysis of 2 Phase 3 Studies.
Topics: Administration, Oral; Administration, Rectal; Adult; Anti-Inflammatory Agents, Non-Steroidal; Budeso | 2016 |
The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study.
Topics: Adult; Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Bifidobacterium bifidum; | 2016 |
[Efficacy of Yunnan Baiyao as an adjuvant treatment for active ulcerative colitis: an open-label randomized controlled study].
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drugs, Chines | 2016 |
Traditional Chinese medicine combination therapy for patients with steroid-dependent ulcerative colitis: study protocol for a randomized controlled trial.
Topics: Azathioprine; Clinical Protocols; Colitis, Ulcerative; Drugs, Chinese Herbal; Humans; Medicine, Chin | 2017 |
Are random biopsies still useful for the detection of neoplasia in patients with IBD undergoing surveillance colonoscopy with chromoendoscopy?
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Colitis, Ulcerative; Colonoscopy; Colorectal | 2018 |
Simple Urine Test to Evaluate Adherence to Oral 5-ASA in Teenagers With Ulcerative Colitis: Proof of Concept.
Topics: Administration, Oral; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Chi | 2017 |
Combined butyric acid/mesalazine treatment in ulcerative colitis with mild-moderate activity. Results of a multicentre pilot study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Butyric Acid; Colitis, Ulcerative; | 2008 |
Effect of extended MMX mesalamine therapy for acute, mild-to-moderate ulcerative colitis.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-Action P | 2009 |
Erythrocyte-mediated delivery of dexamethasone in patients with mild-to-moderate ulcerative colitis, refractory to mesalamine: a randomized, controlled study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonoscopy; Dexamethason | 2008 |
The effect of mesalazine therapy on quality of life in patients with mildly and moderately active ulcerative colitis.
Topics: Administration, Oral; Adult; Colitis, Ulcerative; Delayed-Action Preparations; Double-Blind Method; | 2008 |
Granulocytapheresis versus methylprednisolone in patients with acute ulcerative colitis: 12-month follow up.
Topics: Acute Disease; Administration, Oral; Adult; Anti-Inflammatory Agents; Colitis, Ulcerative; Colonosco | 2008 |
Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chi-Square Distribution; Colitis, Ulcerative; Colono | 2009 |
Mesalamine foam enema versus mesalamine liquid enema in active left-sided ulcerative colitis.
Topics: Administration, Rectal; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-St | 2008 |
[Activity indices--objective criteria of the estimation of severity level of ulcerous colitis].
Topics: Adolescent; Adult; Aged; Colitis, Ulcerative; Colonoscopy; Drug Administration Schedule; Female; Hum | 2008 |
Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Ster | 2009 |
Safety and efficacy of a new 3.3 g b.i.d. tablet formulation in patients with mild-to-moderately-active ulcerative colitis: a multicenter, randomized, double-blind, placebo-controlled study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Disease Progression; Dose | 2009 |
In vivo effects of mesalazine or E. coli Nissle 1917 on microsatellite instability in ulcerative colitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Colitis, Ulcerative; Colon; Double-Bli | 2009 |
Safety, efficacy, and pharmacokinetics of balsalazide in pediatric patients with mild-to-moderate active ulcerative colitis: results of a randomized, double-blind study.
Topics: Adolescent; Aminosalicylic Acids; Anti-Inflammatory Agents; Child; Colitis, Ulcerative; Colon; Doubl | 2009 |
Clinical trial: ulcerative colitis maintenance treatment with 5-ASA: a 1-year, randomized multicentre study comparing MMX with Asacol.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-Actio | 2009 |
Pharmacokinetics and safety of single and multiple doses of Asacol tablets in Japanese healthy volunteers.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Colitis, Ulc | 2009 |
Effect of EP4 agonist (ONO-4819CD) for patients with mild to moderate ulcerative colitis refractory to 5-aminosalicylates: a randomized phase II, placebo-controlled trial.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind Method; Drug Resistance; | 2010 |
Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis.
Topics: Administration, Oral; Aged; Anti-Inflammatory Agents, Non-Steroidal; Canada; Colitis, Ulcerative; De | 2009 |
Quality of life improvements attributed to combination therapy with oral and topical mesalazine in mild-to-moderately active ulcerative colitis.
Topics: Administration, Oral; Administration, Rectal; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non | 2009 |
Direct comparison of two different mesalamine formulations for the maintenance of remission in patients with ulcerative colitis: a double-blind, randomized study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutical; Colitis | 2010 |
Thiopurine maintenance therapy for ulcerative colitis: the clinical significance of monitoring 6-thioguanine nucleotide.
Topics: Adolescent; Adult; Aged; Bone Marrow; Bone Marrow Diseases; Colitis, Ulcerative; Drug Monitoring; Er | 2010 |
Direct comparison of two different mesalamine formulations for the induction of remission in patients with ulcerative colitis: a double-blind, randomized study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutical; Colitis | 2010 |
Once-daily dosing of delayed-release oral mesalamine (400-mg tablet) is as effective as twice-daily dosing for maintenance of remission of ulcerative colitis.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Del | 2010 |
Topical rosiglitazone treatment improves ulcerative colitis by restoring peroxisome proliferator-activated receptor-gamma activity.
Topics: Administration, Topical; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Blotting, Wes | 2010 |
Plasma histamine levels (H) during adjunctive H1-receptor antagonist treatment with loratadine in patients with active inflammatory bowel disease (IBD).
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Diseas | 2010 |
Immunosuppressive effects via human intestinal dendritic cells of probiotic bacteria and steroids in the treatment of acute ulcerative colitis.
Topics: Acute Disease; Adrenal Cortex Hormones; Adult; Aged; Azathioprine; B7-2 Antigen; CD40 Antigens; Coli | 2010 |
Oral beclomethasone dipropionate in pediatric active ulcerative colitis: a comparison trial with mesalazine.
Topics: Administration, Oral; Anti-Inflammatory Agents; Beclomethasone; Blood Sedimentation; C-Reactive Prot | 2010 |
Clinical trial: a novel high-dose 1 g mesalamine suppository (Salofalk) once daily is as efficacious as a 500-mg suppository thrice daily in active ulcerative proctitis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Administ | 2010 |
Clinical trial: controlled, open, randomized multicentre study comparing the effects of treatment on quality of life, safety and efficacy of budesonide or mesalazine enemas in active left-sided ulcerative colitis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Budesonide; Colitis, Ulcerative; Enema; Female; H | 2010 |
Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study.
Topics: Adult; Azathioprine; Bifidobacterium; Colitis, Ulcerative; Combined Modality Therapy; Double-Blind M | 2010 |
Rectal administration of Lactobacillus casei DG modifies flora composition and Toll-like receptor expression in colonic mucosa of patients with mild ulcerative colitis.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colon; Humans; | 2011 |
Efficacy and safety of mesalamine suppositories for treatment of ulcerative proctitis in children and adolescents.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschool; Colitis, Ulcerative; F | 2010 |
Clinical trial: Effects of an oral preparation of mesalazine at 4 g/day on moderately active ulcerative colitis. A phase III parallel-dosing study.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Dose-Response Relat | 2011 |
Clinical trial: once-daily mesalamine granules for maintenance of remission of ulcerative colitis - a 6-month placebo-controlled trial.
Topics: Adult; Colitis, Ulcerative; Double-Blind Method; Female; Hemorrhage; Humans; Male; Mesalamine; Middl | 2010 |
E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Denmark; Feas | 2010 |
E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Denmark; Feas | 2010 |
E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Denmark; Feas | 2010 |
E-health empowers patients with ulcerative colitis: a randomised controlled trial of the web-guided 'Constant-care' approach.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Denmark; Feas | 2010 |
Randomised clinical trial: herbal extract HMPL-004 in active ulcerative colitis - a double-blind comparison with sustained release mesalazine.
Topics: Acanthaceae; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; China; Colitis, Ulcer | 2011 |
Randomised clinical trial: a comparative dose-finding study of three arms of dual release mesalazine for maintaining remission in ulcerative colitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Dose-Resp | 2011 |
High-dose mesalazine treatment for ulcerative colitis patients who relapse under low-dose maintenance therapy.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonoscopy; Female; Humans; Ma | 2011 |
Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc | 2011 |
Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc | 2011 |
Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc | 2011 |
Randomised clinical trial: delayed-release oral mesalazine 4.8 g/day vs. 2.4 g/day in endoscopic mucosal healing--ASCEND I and II combined analysis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc | 2011 |
Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis - new light on a familiar question.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind Method; Female; Humans; M | 2011 |
Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis - new light on a familiar question.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind Method; Female; Humans; M | 2011 |
Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis - new light on a familiar question.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind Method; Female; Humans; M | 2011 |
Randomised clinical trial: early assessment after 2 weeks of high-dose mesalazine for moderately active ulcerative colitis - new light on a familiar question.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind Method; Female; Humans; M | 2011 |
Changes in immunohistochemical levels and subcellular localization after therapy and correlation and colocalization with CD68 suggest a pathogenetic role of Hsp60 in ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Bi | 2011 |
3g mesalazine granules are superior to 9mg budesonide for achieving remission in active ulcerative colitis: a double-blind, double-dummy, randomised trial.
Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Chi-Square Dis | 2011 |
Impact of a tailored patient preference intervention in adherence to 5-aminosalicylic acid medication in ulcerative colitis: results from an exploratory randomized controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Case-Control St | 2011 |
Strategies in maintenance for patients receiving long-term therapy (SIMPLE): a study of MMX mesalamine for the long-term maintenance of quiescent ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Administration Schedule; F | 2012 |
Evaluation of melatonin effectiveness in the adjuvant treatment of ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; C-Reactive Protein; Colitis, Ulcerativ | 2011 |
Efficacy and safety of Fufangkushen colon-coated capsule in the treatment of ulcerative colitis compared with mesalazine: a double-blinded and randomized study.
Topics: Administration, Oral; Adult; Analysis of Variance; Anti-Inflammatory Agents; Capsules; Chi-Square Di | 2012 |
Capsule-endoscopic findings of ulcerative colitis patients.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Capsule Endoscopy; Case-Control Studies; Colitis, Ul | 2011 |
One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Administrat | 2012 |
Mesalazine in left-sided ulcerative colitis: efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Colitis, Ulcerative; Colon; Female | 2012 |
Once-daily MMX(®) mesalamine for endoscopic maintenance of remission of ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Confidence Intervals; Double-Blind Met | 2012 |
Evaluation of responsive gene expression as a sensitive and specific biomarker in patients with ulcerative colitis.
Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Antigens, Differentiation; Azo | 2013 |
Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Dose-R | 2012 |
Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Dose-R | 2012 |
Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Dose-R | 2012 |
Mesalazine granules 1.5 g once-daily maintain remission in patients with ulcerative colitis who switch from other 5-ASA formulations: a pooled analysis from two randomised controlled trials.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Dose-R | 2012 |
Impact of MMX® mesalamine on improvement and maintenance of health-related quality of life in patients with ulcerative colitis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Cost o | 2013 |
"One more time" 5-ASA retrial after a glucocorticosteroid induced remission in moderate to severe ulcerative colitis: a prospective community practice experience.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc | 2013 |
Once-daily budesonide MMX® extended-release tablets induce remission in patients with mild to moderate ulcerative colitis: results from the CORE I study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesoni | 2012 |
The effect of third-party reporting on adoption of evidence-based mesalazine regimens in ulcerative colitis: an observational study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Attitude of Health Personne | 2013 |
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Combined Modality T | 2013 |
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Combined Modality T | 2013 |
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Combined Modality T | 2013 |
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Combined Modality T | 2013 |
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Combined Modality T | 2013 |
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Combined Modality T | 2013 |
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Combined Modality T | 2013 |
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Combined Modality T | 2013 |
Tolerability of curcumin in pediatric inflammatory bowel disease: a forced-dose titration study.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Combined Modality T | 2013 |
Factors affecting short- and long-term effects of leukocyte removal therapy in active ulcerative colitis.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Child | 2013 |
Balsalazide is superior to mesalamine in the time to improvement of signs and symptoms of acute mild-to-moderate ulcerative colitis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Aminosalicylic Acids; Anti-Inflammatory A | 2002 |
Oral and topical 5-aminosalicylic acid (mesalazine) in inducing and maintaining remission in mild-moderate relapse of ulcerative colitis: one-year randomised multicentre trial.
Topics: Administration, Oral; Administration, Topical; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colit | 2002 |
Topical butyrate improves efficacy of 5-ASA in refractory distal ulcerative colitis: results of a multicentre trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Butyrates; Chronic Disease; Colit | 2003 |
[Comparative efficacy of mezakol and sulfasalazine in treating chronic relapsing ulcerative colitis].
Topics: Adult; Colitis, Ulcerative; Female; Humans; Male; Mesalamine; Recurrence; Sulfasalazine; Treatment O | 2003 |
A pilot trial of Saccharomyces boulardii in ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Combined Modality Therapy; Fema | 2003 |
Epidermal growth factor enemas with oral mesalamine for mild-to-moderate left-sided ulcerative colitis or proctitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Bl | 2003 |
Patient-led variable dosing with balsalazide as long-term therapy for maintenance in ulcerative colitis: a 3-year prospective observational study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminosalicylic Acids; Cohort Studies; Colitis, Ulcerativ | 2004 |
Long-term intermittent treatment with low-dose 5-aminosalicylic enemas is efficacious for remission maintenance in ulcerative colitis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Colitis, Ulc | 2004 |
A pilot feasibility study of once daily versus conventional dosing mesalamine for maintenance of ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Administration Schedule; F | 2003 |
The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Dose-Response Relationshi | 2003 |
Germinated barley foodstuff prolongs remission in patients with ulcerative colitis.
Topics: Adult; Colitis, Ulcerative; Dietary Fiber; Female; Germination; Hordeum; Humans; Male; Mesalamine; P | 2004 |
Treatment of rectal cuff inflammation (cuffitis) in patients with ulcerative colitis following restorative proctocolectomy and ileal pouch-anal anastomosis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonic Pouches; Female; Humans | 2004 |
Maintaining remission of ulcerative colitis with the probiotic Escherichia coli Nissle 1917 is as effective as with standard mesalazine.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double | 2004 |
Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis.
Topics: Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Drug Therapy, Combination; Female; Humans; M | 2004 |
Mesalazine (5-aminosalicylic acid) micropellets show similar efficacy and tolerability to mesalazine tablets in patients with ulcerative colitis--results from a randomized-controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc | 2004 |
A double-blind dose-escalating trial comparing novel mesalazine pellets with mesalazine tablets in active ulcerative colitis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind | 2005 |
Long-term oral plus topical mesalazine in frequently relapsing ulcerative colitis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colit | 2005 |
Topical treatment of distal active ulcerative colitis with beclomethasone dipropionate or mesalamine: a single-blind randomized controlled trial.
Topics: Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Beclometh | 2005 |
Multicentre randomized-controlled clinical trial of Ipocol, a new enteric-coated form of mesalazine, in comparison with Asacol in the treatment of ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Male; Mesalamine; Midd | 2005 |
Comparison of two different daily dosages (2.4 vs. 1.2 g) of oral mesalazine in maintenance of remission in ulcerative colitis patients: 1-year follow-up study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc | 2005 |
A new oral delivery system for 5-ASA: preliminary clinical findings for MMx.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonosco | 2005 |
Trial of trefoil factor 3 enemas, in combination with oral 5-aminosalicylic acid, for the treatment of mild-to-moderate left-sided ulcerative colitis.
Topics: Administration, Oral; Adult; Colitis, Ulcerative; Double-Blind Method; Drug Therapy, Combination; En | 2005 |
Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study.
Topics: Administration, Oral; Administration, Rectal; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non | 2005 |
Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colitis, Ulcerative; | 2006 |
Significance of salicylate intolerance in diseases of the lower gastrointestinal tract.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colitis, Ulcerative; Crohn Disease; Diet; Drug Hyp | 2005 |
A randomized trial of nicotine enemas for active ulcerative colitis.
Topics: Adult; Aged; Aged, 80 and over; Colitis, Ulcerative; Double-Blind Method; Enema; Female; Humans; Mal | 2005 |
Delayed-release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc | 2005 |
Comparison of the efficacy and safety of Eudragit-L-coated mesalazine tablets with ethylcellulose-coated mesalazine tablets in patients with mild to moderately active ulcerative colitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Ster | 2006 |
Safety and efficacy of two dose formulations of alicaforsen enema compared with mesalazine enema for treatment of mild to moderate left-sided ulcerative colitis: a randomized, double-blind, active-controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcera | 2006 |
Efficacy of Lactobacillus GG in maintaining remission of ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Therapy, Combination; Fema | 2006 |
Centrifugal leukocytapheresis therapy for ulcerative colitis without concurrent corticosteroid administration.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Colitis, Ulcerative; Contraindications; Endoscopy, | 2006 |
Steroid dependent ulcerative colitis: azathioprine use is finally "evidence-based".
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colitis, Ulcerative; Humans; Mesalamine; Sing | 2006 |
Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose-ranging study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind | 2006 |
Leukocytapheresis in patients with moderate-severe steroid-dependant ulcerative colitis: clinical response without endoscopic response.
Topics: Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclon | 2006 |
[Characterization of proteinuria in patients with ulcerative colitis and therapy with aminosalicylates].
Topics: Acute Disease; Adolescent; Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Col | 2006 |
Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc | 2006 |
Effect of once- or twice-daily MMX mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Dose-Response Relationship, Dru | 2007 |
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-A | 2007 |
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-A | 2007 |
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-A | 2007 |
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-A | 2007 |
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-A | 2007 |
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-A | 2007 |
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-A | 2007 |
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-A | 2007 |
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-A | 2007 |
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-A | 2007 |
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-A | 2007 |
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-A | 2007 |
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-A | 2007 |
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-A | 2007 |
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-A | 2007 |
Once-daily, high-concentration MMX mesalamine in active ulcerative colitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-A | 2007 |
Thrombin generation in mesalazine refractory ulcerative colitis and the influence of low molecular weight heparin.
Topics: Adult; Colitis, Ulcerative; Double-Blind Method; Female; Hemostasis; Heparin, Low-Molecular-Weight; | 2007 |
Beclomethasone dipropionate versus mesalazine in distal ulcerative colitis: a multicenter, randomized, double-blind study.
Topics: Adult; Aged; Anti-Inflammatory Agents; Beclomethasone; Colitis, Ulcerative; Colonoscopy; Diarrhea; D | 2007 |
Quality of life in patients with active ulcerative colitis treated with selective leukocyte apheresis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Gluco | 2007 |
Effect of weekend 5-aminosalicylic acid (mesalazine) enema as maintenance therapy for ulcerative colitis: results from a randomized controlled study.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Admi | 2007 |
A clinical trial on absorption and N-acetylation of oral and rectal mesalazine.
Topics: Administration, Oral; Administration, Rectal; Adult; Anti-Inflammatory Agents, Non-Steroidal; Coliti | 2007 |
Clinical trial: randomized-controlled clinical study comparing the efficacy and safety of a low-volume vs. a high-volume mesalazine foam in active distal ulcerative colitis.
Topics: Administration, Rectal; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, U | 2007 |
Delayed-release oral mesalamine 4.8 g/day (800 mg tablets) compared to 2.4 g/day (400 mg tablets) for the treatment of mildly to moderately active ulcerative colitis: The ASCEND I trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc | 2007 |
Successful treatment of steroid refractory active ulcerative colitis with natural interferon-beta--an open long-term trial.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Colitis, Ulcerative; Dose-Response Relationship, D | 2007 |
A clinical trial of combined use of rosiglitazone and 5-aminosalicylate for ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Therapy, Combination; Fema | 2008 |
Randomised trial of once- or twice-daily MMX mesalazine for maintenance of remission in ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutical; Colitis, Ulcerative; Dela | 2008 |
MMX mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient subpopulations.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind Method; Female; Hu | 2008 |
N-acetyl-L-cysteine combined with mesalamine in the treatment of ulcerative colitis: randomized, placebo-controlled pilot study.
Topics: Acetylcysteine; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Chemokine CCL2; Colitis, Ulcer | 2008 |
Treatment of ulcerative colitis with high-dose 5-aminosalicylic acid enemas.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Child; Clinical Trials as Topic; Colitis, Ulcerative; | 1981 |
Maintenance of remission in ulcerative colitis with oral preparation of 5-aminosalicylic acid.
Topics: Acrylic Resins; Administration, Oral; Adult; Aminosalicylic Acids; Clinical Trials as Topic; Colitis | 1982 |
The effect of the acetylator phenotype on the metabolism of sulphasalazine in man.
Topics: Acetylation; Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Humans; Mesalamine | 1983 |
Maintenance of remission in ulcerative colitis with 5-amino salicylic acid in high doses by mouth.
Topics: Administration, Oral; Adult; Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Do | 1983 |
Disposition of 5-aminosalicylic acid, the active metabolite of sulphasalazine, in man.
Topics: Adult; Aged; Aminosalicylic Acids; Bile; Biliary Tract Diseases; Colitis, Ulcerative; Crohn Disease; | 1983 |
Sulfasalazine. Pharmacology, clinical use, toxicity, and related new drug development.
Topics: Aminosalicylic Acids; Animals; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Drug In | 1984 |
Studies of two novel sulfasalazine analogs, ipsalazide and balsalazide.
Topics: Aminosalicylic Acids; Animals; Chemical Phenomena; Chemistry; Clinical Trials as Topic; Colitis, Ulc | 1983 |
A double-blind clinical trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Biopsy; Clinical Trials as Topic; Colitis, Ulcerative; Co | 1984 |
5-Aminosalicylic acid enemas in patients with active ulcerative colitis. Influence of acidity on the kinetic pattern.
Topics: Adolescent; Adult; Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Enema; Femal | 1984 |
[Comparative randomized open study of the efficacy and tolerance of enemas with 2 gr of 4-amino-salicylic acid (4-ASA) and 1 gr of 5-amino-salicylic acid (5-ASA) in distal forms of hemorrhagic rectocolitis].
Topics: Adult; Aminosalicylic Acid; Aminosalicylic Acids; Colitis, Ulcerative; Endoscopy, Gastrointestinal; | 1995 |
Mesalazine suppositories versus hydrocortisone foam in patients with distal ulcerative colitis. A comparison of the efficacy and practicality of two topical treatment regimens.
Topics: Administration, Rectal; Administration, Topical; Adult; Aminosalicylic Acids; Anti-Inflammatory Agen | 1995 |
Low Pentasa dosage versus hydrocortisone in the topical treatment of active ulcerative colitis: a randomized, double-blind study.
Topics: Administration, Rectal; Adolescent; Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Stero | 1995 |
Intermittent versus continuous 5-aminosalicylic acid treatment for maintaining remission in ulcerative colitis.
Topics: Administration, Oral; Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, | 1994 |
Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group.
Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Capsules; Colitis, Ulcerative; | 1995 |
5-ASA enema versus oral sulphasalazine in maintaining remission in ulcerative colitis.
Topics: Administration, Oral; Adult; Aminosalicylic Acids; Colitis, Ulcerative; Drug Administration Schedule | 1994 |
5-Aminosalicylic acid in pregnancy: clinical report.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Female; Fetus; Humans; Mesalamine; Pregnancy; Preg | 1994 |
Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents; Colitis, Ulcerative; Humans; Mesalamine; Placebo Eff | 1993 |
Mesalamine capsules enhance the quality of life for patients with ulcerative colitis.
Topics: Administration, Oral; Adult; Aminosalicylic Acids; Capsules; Colitis, Ulcerative; Data Collection; D | 1994 |
A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis.
Topics: Administration, Oral; Administration, Topical; Adrenal Cortex Hormones; Adult; Aged; Aminosalicylic | 1994 |
Experience with Eudragit-S-coated mesalamine (Asacol) in inflammatory bowel disease. An open study.
Topics: Acrylic Resins; Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Gels; Humans; Mesalamine; | 1993 |
Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission in ulcerative proctitis and proctosigmoiditis.
Topics: Administration, Oral; Administration, Rectal; Adolescent; Adult; Aged; Aminosalicylic Acids; Colitis | 1994 |
IBD: which 5-ASA drug works where?
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Humans; Mesalamine; Recurrence | 1993 |
Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.
Topics: Adult; Aminosalicylic Acids; Biopsy; Capsules; Colitis, Ulcerative; Colon; Delayed-Action Preparatio | 1993 |
Effect of topical 5-aminosalicylic acid (5-ASA) therapy on rectal mucosal biopsy morphology in chronic ulcerative colitis.
Topics: Administration, Topical; Adult; Aged; Aminosalicylic Acids; Biopsy; Colitis, Ulcerative; Female; Hum | 1993 |
Better quality of therapy with 5-ASA colonic foam in active ulcerative colitis. A multicenter comparative trial with 5-ASA enema.
Topics: Administration, Rectal; Adult; Aminosalicylic Acids; Colitis, Ulcerative; Enema; Female; Humans; Mal | 1993 |
Comparison of bismuth citrate and 5-aminosalicylic acid enemas in distal ulcerative colitis: a controlled trial.
Topics: Adult; Aminosalicylic Acids; Anti-Ulcer Agents; Colitis, Ulcerative; Double-Blind Method; Enema; Fem | 1993 |
An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial. The Mesalamine Study Group.
Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Bl | 1996 |
Double-blind comparative study of sulfasalazine and controlled-release mesalazine tablets in the treatment of active ulcerative colitis.
Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Coli | 1995 |
Adverse effects of sulfasalazine and treatment of ulcerative colitis with mesalazine.
Topics: Adverse Drug Reaction Reporting Systems; Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflam | 1995 |
Coated oral 5-aminosalicylic acid (Claversal) is equivalent to sulfasalazine for remission maintenance in ulcerative colitis. A double-blind study.
Topics: Acrylic Resins; Adult; Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non | 1995 |
A comparison of mesalamine suspension enema and oral sulfasalazine for treatment of active distal ulcerative colitis in adults.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aminosalicylic Acids; Analysis of Variance; Anti-Infl | 1996 |
Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa Study Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-S | 1995 |
Systemic uptake of 5-aminosalicylic acid from olsalazine and eudragit L coated mesalazine in patients with ulcerative colitis in remission.
Topics: Adult; Aged; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Biotransformation; Colit | 1996 |
Distribution of mesalazine enemas in active and quiescent ulcerative colitis.
Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colon; Co | 1996 |
A randomised trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis.
Topics: Acute Disease; Administration, Rectal; Adolescent; Adult; Aged; Aged, 80 and over; Aminosalicylic Ac | 1996 |
Pilot trial of nicotine patches as an alternative to corticosteroids in ulcerative colitis.
Topics: Administration, Cutaneous; Adult; Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory | 1996 |
Systemic availability of 5-aminosalicylic acid: comparison of delayed release and an azo-bond preparation.
Topics: Adult; Aged; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; | 1996 |
Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aminosalicylic Acids; Analysis of Variance; Anti-Infl | 1996 |
5-amino salicylic acid absorption and metabolism in ulcerative colitis patients receiving maintenance sulphasalazine, olsalazine or mesalazine.
Topics: Absorption; Acetylation; Acetylglucosaminidase; Adult; Aged; Aminosalicylic Acids; Anti-Inflammatory | 1996 |
A trial of zileuton versus mesalazine or placebo in the maintenance of remission of ulcerative colitis. The European Zileuton Study Group For Ulcerative Colitis.
Topics: Adult; Aged; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Dou | 1997 |
Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double-blind study.
Topics: Administration, Oral; Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, | 1997 |
5-Aminosalicylic acid, 1,000-mg caplets versus 500-mg tablets, in maintenance of remission in ulcerative colitis.
Topics: Administration, Oral; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcera | 1997 |
Systemic absorption of 5-aminosalicylic acid in patients with inactive ulcerative colitis treated with olsalazine and mesalazine.
Topics: Administration, Oral; Adult; Aged; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Co | 1997 |
Retrograde colonic spread of a new mesalazine rectal enema in patients with distal ulcerative colitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colon; Enema; Female; Hum | 1997 |
Transdermal nicotine for ulcerative colitis.
Topics: Administration, Cutaneous; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, U | 1997 |
Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative colitis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double | 1997 |
A double-blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis.
Topics: Administration, Oral; Administration, Rectal; Adult; Anti-Inflammatory Agents, Non-Steroidal; Coliti | 1997 |
Balsalazide is more effective and better tolerated than mesalamine in the treatment of acute ulcerative colitis. The Abacus Investigator Group.
Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Colitis, Ul | 1998 |
Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis.
Topics: Administration, Oral; Administration, Rectal; Adult; Colitis, Ulcerative; Female; Humans; Male; Mesa | 1998 |
Use of mesalazine slow release suppositories 1 g three times per week to maintain remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-Action Preparations; Do | 1998 |
Dose-ranging study of mesalamine (PENTASA) enemas in the treatment of acute ulcerative proctosigmoiditis: results of a multicentered placebo-controlled trial. The U.S. PENTASA Enema Study Group.
Topics: Acute Disease; Adult; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcera | 1998 |
Olsalazine versus mesalazine in the treatment of mild to moderate ulcerative colitis.
Topics: Adult; Aged; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Dou | 1998 |
Beclomethasone dipropionate (3 mg) enemas combined with oral 5-ASA (2.4 g) in the treatment of ulcerative colitis not responsive to oral 5-ASA alone.
Topics: Administration, Oral; Administration, Topical; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Ag | 1998 |
Maintenance of remission of ulcerative colitis: a comparison between balsalazide 3 g daily and mesalazine 1.2 g daily over 12 months. ABACUS Investigator group.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Anti-Ulcer Agents; Colitis, Ulcerative; Delayed-Actio | 1998 |
Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study of Crohn's Disease and Ulcerative Colitis (GETECCU).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cathartics; Colitis, Ulcerative; Dietary Fiber; Fatt | 1999 |
Double therapy for IBD better than single therapy? The issue is not how but how much.
Topics: Administration, Oral; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulce | 1999 |
Balsalazide led to greater remission rates and tolerance than mesalamine in acute ulcerative colitis.
Topics: Acute Disease; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; F | 1999 |
The systemic load and efficient delivery of active 5-aminosalicylic acid in patients with ulcerative colitis on treatment with olsalazine or mesalazine.
Topics: Adult; Aged; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Chromatography, | 1999 |
Is maintenance therapy always necessary for patients with ulcerative colitis in remission?
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-Actio | 1999 |
A new mesalazine gel enema in the treatment of left-sided ulcerative colitis: a randomized controlled multicentre trial.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind | 1999 |
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind Method; Escherichi | 1999 |
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind Method; Escherichi | 1999 |
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind Method; Escherichi | 1999 |
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomised trial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind Method; Escherichi | 1999 |
Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis.
Topics: Adult; Aged; Bifidobacterium; Colitis, Ulcerative; Feces; Female; Humans; Hydrogen-Ion Concentration | 1999 |
Scintigraphic imaging and absorption of a 5-aminosalicylic acid enema in patients with ileorectal anastomosis.
Topics: Adult; Aged; Anastomosis, Surgical; Colitis, Ulcerative; Enema; Female; Humans; Ileum; Intestinal Ab | 1999 |
Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment.
Topics: Administration, Oral; Administration, Topical; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colit | 1999 |
Probiotic therapy with E. coli for ulcerative colitis: take the good with the bad.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind Method; Escherichia coli; | 2000 |
Mesalazine foam (Salofalk foam) in the treatment of active distal ulcerative colitis. A comparative trial vs Salofalk enema. The SAF-3 study group.
Topics: Administration, Topical; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Cross- | 1999 |
Assessment of the prevalence of infection with Helicobacter pylori in patients with inflammatory bowel disease.
Topics: Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Breath Tests; Colitis, Ulcera | 2000 |
Combined oral sodium butyrate and mesalazine treatment compared to oral mesalazine alone in ulcerative colitis: randomized, double-blind, placebo-controlled pilot study.
Topics: Administration, Oral; Adult; Butyrates; Colitis, Ulcerative; Colonoscopy; Double-Blind Method; Drug | 2000 |
[Budesonide foam as a new therapeutic principle in distal ulcerative colitis in comparison with mesalazine enema. An open, controlled, randomized and prospective multicenter pilot study].
Topics: Administration, Rectal; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Bu | 2000 |
[Chronic inflammatory bowel diseases. Do antihistaminics reduce the need for steroids?].
Topics: Anti-Inflammatory Agents; Colitis, Ulcerative; Crohn Disease; Drug Therapy, Combination; Histamine H | 2000 |
[Probiotics for prevention of ulcerative colitis recurrence: alternative medicine added to standard treatment?].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcera | 2000 |
Long-term use of mesalamine (Rowasa) suppositories in remission maintenance of ulcerative proctitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind Method; Fema | 2000 |
Allopurinol in addition to 5-aminosalicylic acid based drugs for the maintenance treatment of ulcerative colitis.
Topics: Adult; Aged; Allopurinol; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Colitis, Ulcerat | 2000 |
Efficacy and tolerability of mesalazine foam enema (Salofalk foam) for distal ulcerative colitis: a double-blind, randomized, placebo-controlled study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind Method; Drug | 2000 |
Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study.
Topics: Administration, Oral; Administration, Topical; Adolescent; Adult; Aged; Anti-Inflammatory Agents, No | 2001 |
Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Colitis, Ulcerative; Double-Blind Meth | 2000 |
Comparison of 5-amino salicylic acid plus glucocorticosteroid with metronidazole and ciprofloxacin in patients with active ulcerative colitis.
Topics: Adult; Ciprofloxacin; Colitis, Ulcerative; Drug Therapy, Combination; Female; Glucocorticoids; Human | 2001 |
Mesalazine 4 g daily given as prolonged-release granules twice daily and four times daily is at least as effective as prolonged-release tablets four times daily in patients with ulcerative colitis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Delayed-Actio | 2001 |
Guided self-management and patient-directed follow-up of ulcerative colitis: a randomised trial.
Topics: Administration, Topical; Adolescent; Adult; Aged; Ambulatory Care; Anti-Inflammatory Agents; Anti-In | 2001 |
Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily) maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice daily) was superior in preventing relapses.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colon; Double-Bl | 2001 |
A double-blind comparison of balsalazide, 6.75 g daily, and sulfasalazine, 3 g daily, in patients with newly diagnosed or relapsed active ulcerative colitis.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Aged; Aminosalicylic Acids; Anti-Ulcer Agents; | 2002 |
A double-blind comparison of balsalazide, 6.75 g, and sulfasalazine, 3 g, as sole therapy in the management of ulcerative colitis.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Aminosalicylic Acids; Anti-Ulcer Agents; Colit | 2002 |
Efficacy and safety of oral ridogrel in the treatment of ulcerative colitis: two multicentre, randomized, double-blind studies.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colit | 2002 |
Evaluation of renal function following treatment with 5-aminosalicylic acid derivatives in patients with ulcerative colitis.
Topics: Adult; Albuminuria; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerati | 2002 |
A new mesalazine foam enema (Claversal Foam) compared with a standard liquid enema in patients with active distal ulcerative colitis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Dosage Forms; | 2002 |
Octreotide in patients with active ulcerative colitis treated with high dose corticosteroids (OPUS 1).
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double-Blind Method; Drug Admin | 2002 |
Distal ulcerative colitis refractory to rectal mesalamine: role of transdermal nicotine versus oral mesalamine.
Topics: Administration, Cutaneous; Administration, Oral; Administration, Rectal; Adult; Anti-Inflammatory Ag | 2002 |
A randomized, double blind, dose-response comparison of balsalazide (6.75 g), balsalazide (2.25 g), and mesalamine (2.4 g) in the treatment of active, mild-to-moderate ulcerative colitis.
Topics: Adult; Aged; Aged, 80 and over; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Anti- | 2002 |
Randomised comparison of olsalazine and mesalazine in prevention of relapses in ulcerative colitis.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Female; Humans; Life Tables; Mal | 1992 |
Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Drug Therapy, Combination; Eicos | 1992 |
Improved maintenance of remission in ulcerative colitis by balsalazide 4 g/day compared with 2 g/day.
Topics: Adult; Aged; Aged, 80 and over; Aminosalicylic Acids; Colitis, Ulcerative; Dose-Response Relationshi | 1992 |
Short report: comparison of two doses of balsalazide in maintaining ulcerative colitis in remission over 12 months.
Topics: Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Dose-Response Relationship, Drug; Double-Bli | 1992 |
Spread and distribution of 5-ASA colonic foam and 5-ASA enema in patients with ulcerative colitis.
Topics: Administration, Topical; Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Colon; Dosage Forms | 1992 |
[Efficacy of a daily application of mesalazine (Pentasa) suppository with progressive release, in the treatment of ulcerative proctitis. A double-blind versus placebo randomized trial].
Topics: Adult; Aged; Aged, 80 and over; Aminosalicylic Acids; Colitis, Ulcerative; Dose-Response Relationshi | 1992 |
[New developments in the treatment of inflammatory bowel diseases. What is certain?].
Topics: Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Humans; Immunosu | 1990 |
Is topical therapy necessary in acute distal colitis? Double-blind comparison of high-dose oral mesalazine versus steroid enemas in the treatment of active distal ulcerative colitis.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerat | 1991 |
Steady-state pharmacokinetics of a new 4-gram 5-aminosalicylic acid retention enema in patients with ulcerative colitis in remission.
Topics: Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Enema; Female; Humans; Male; Mesalamine; Mid | 1991 |
Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.
Topics: Administration, Oral; Adult; Aged; Aminosalicylic Acids; Chi-Square Distribution; Colitis, Ulcerativ | 1991 |
Morphometric studies in rectal biopsy specimens from patients with ulcerative colitis: effect of oral 5 amino salicylic acid and rectal prednisolone treatment.
Topics: Aminosalicylic Acids; Biopsy; Colitis, Ulcerative; Diagnosis, Computer-Assisted; Double-Blind Method | 1991 |
Optimum dosage of 5-aminosalicylic acid as rectal enemas in patients with active ulcerative colitis.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Colon; Double-Blind Method; Drug Administration Sc | 1991 |
Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission in ulcerative proctosigmoiditis.
Topics: Administration, Oral; Adult; Aminosalicylic Acids; Colitis, Ulcerative; Double-Blind Method; Enema; | 1990 |
Inhibition of cell mediated cytotoxicity by sulphasalazine: effect of in vivo treatment with 5-aminosalicylic acid and sulphasalazine on in vitro natural killer cell activity.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Cytotoxicity Tests, Immunologic; Cytotoxic | 1990 |
Therapeutic effectiveness and tolerance of 5-aminosalicylic acid in short term treatment of patients with ulcerative colitis at a low or medium phase of activity.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Gastroscopy; Humans; Mesalamine; Stomach; Sulfasalazine; | 1990 |
Oral asacol in the treatment of mild to moderate ulcerative colitis: the Nashville experience.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Double-Blind Method; Drug Administration Schedule; Drug E | 1991 |
Topical treatment with 5-aminosalicylic in distal ulcerative colitis by using a new suppository preparation. A double-blind placebo controlled trial.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Double-Blind Method; Drug Administration Schedule; | 1990 |
5-Aminosalicylic acid suppositories in the maintenance of remission in idiopathic proctitis or proctosigmoiditis: a double-blind placebo-controlled clinical trial.
Topics: Administration, Rectal; Adult; Aminosalicylic Acids; Colitis, Ulcerative; Double-Blind Method; Drug | 1990 |
Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion.
Topics: Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Colon; Delayed-Action Preparations; Drug Car | 1990 |
Gastrointestinal transit and release of mesalazine tablets in patients with inflammatory bowel disease.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Colon; Crohn Disease; Delayed-Action Preparations; Gastri | 1990 |
[5-aminosalicylic acid in the long-term treatment of ulcerative colitis].
Topics: Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Double-Blind Method; Female; Hu | 1989 |
Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Double | 1989 |
Effects of mesalazine substitution on salicylazosulfapyridine-induced seminal abnormalities in men with ulcerative colitis.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Delayed-Action Preparations; Humans; Male; Mesalam | 1989 |
[Prevention of recurrence of chronic inflammatory bowel diseases].
Topics: Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Humans; Immunosu | 1989 |
Comparative efficacy of coated, oral 5-aminosalicylic acid (Claversal) and sulphasalazine for maintaining remission of ulcerative colitis. International Study Group.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Double-Bli | 1989 |
5-ASA enema therapy.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Enema; Humans; M | 1989 |
[Successful acute treatment of chronic inflammatory intestinal diseases with oral 5-aminosalicylic acid].
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Female; Humans; M | 1985 |
Refractory distal ulcerative colitis responsive to 5-aminosalicylate enemas.
Topics: Administration, Oral; Adult; Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; En | 1985 |
Sulfasalazine and new analogues.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Animals; Clinical Trials as Topic; Colitis, Ulcerative; C | 1986 |
[Drug therapy of chronic inflammatory intestinal diseases--current status of 5-aminosalicylic acid].
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Azathioprine; Clinical Trials as Topic; Colitis, Ulce | 1986 |
Clinical experience of the tolerance of mesalazine and olsalazine in patients intolerant of sulphasalazine.
Topics: Adult; Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Female; Humans; Male; Me | 1987 |
Mesalazine tolerance in patients with inflammatory bowel disease and previous intolerance or allergy to sulphasalazine or sulphonamides.
Topics: Adolescent; Adult; Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Diseas | 1987 |
Oral 5-aminosalicylic acid preparations in treatment of inflammatory bowel disease. An update.
Topics: Administration, Oral; Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Dis | 1987 |
Treatment of ulcerative colitis with oral 5-aminosalicylic acid including patients with adverse reactions to sulfasalazine.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Aminosalicylic Acids; Clinical Tri | 1988 |
Comparison of delayed-release 5-aminosalicylic acid (mesalazine) and sulfasalazine as maintenance treatment for patients with ulcerative colitis.
Topics: Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Delayed-Action Preparations; Female; Humans; | 1988 |
Comparison of delayed release 5 aminosalicylic acid (mesalazine) and sulphasalazine in the treatment of mild to moderate ulcerative colitis relapse.
Topics: Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Delayed-Action Pre | 1988 |
Double-blind comparison of slow-release 5-aminosalicylate and sulfasalazine in remission maintenance in ulcerative colitis.
Topics: Actuarial Analysis; Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Delayed-Action Preparati | 1988 |
Balsalazide in the maintenance treatment of patients with ulcerative colitis, a double-blind comparison with sulphasalazine.
Topics: Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Double-Blind Method; Female; Humans; Male; M | 1988 |
Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis.
Topics: Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Dialysis; Dinopros | 1986 |
Comparison of 5-aminosalicylic acid (3 g) and prednisolone phosphate sodium enemas (30 mg) in the treatment of distal ulcerative colitis. A prospective, randomized, double-blind trial.
Topics: Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Double-Blind Metho | 1988 |
Clinical tolerance of olsalazine.
Topics: Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Diarrhea; Humans; Mesalamine | 1988 |
Colonic prostaglandin E2 levels and olsalazine metabolism in relapsing ulcerative colitis: implications for controlled trials in the long term.
Topics: Adult; Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Colon; Dinoprostone; Fem | 1988 |
A defence of the small clinical trial: evaluation of three gastroenterological studies.
Topics: Adult; Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Colonic Diseases, Functi | 1986 |
5-Aminosalicylic acid enemas in distal colitis.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Enema; Humans; Mesalamine | 1988 |
New enema treatments for inflammatory bowel disease.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents; Clinical Trials as Topic; Colitis, Ulcerative; Enema | 1988 |
5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis.
Topics: Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Double-Blind Method; Enema; Fem | 1988 |
Mesalamine for ulcerative colitis.
Topics: Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Dose-Response Relationship, Dru | 1988 |
5-ASA for ulcerative colitis.
Topics: Administration, Oral; Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Humans; M | 1988 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Aminosalicylic Acids; Clinical Trials as Topic; Co | 1987 |
Pharmacology and pharmacokinetics of 5-aminosalicylic acid.
Topics: Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Humans; Mesalami | 1987 |
5-Aminosalicylic acid enemas in treatment of distal ulcerative colitis and proctitis in Canada.
Topics: Adult; Aminosalicylic Acids; Canada; Clinical Trials as Topic; Colitis, Ulcerative; Double-Blind Met | 1987 |
Efficacy of 5-aminosalicylic acid enemas versus hydrocortisone enemas in ulcerative colitis.
Topics: Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Double-Blind Method; Enema; Hum | 1987 |
5-Aminosalicylic acid as enemas or suppositories in distal ulcerative colitis?
Topics: Administration, Rectal; Aminosalicylic Acids; Colitis, Ulcerative; Enema; Humans; Mesalamine; Self A | 1988 |
[5-Aminosalicylic acid--a new therapeutic possibility in chronic inflammatory bowel disease].
Topics: Administration, Oral; Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Dis | 1986 |
5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: a randomized, controlled trial.
Topics: Adult; Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Double-Blind Method; Dru | 1986 |
5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis.
Topics: Adult; Aminosalicylic Acids; Colitis; Colitis, Ulcerative; Enema; Female; Humans; Male; Mesalamine; | 1987 |
1024 other studies available for mesalamine and Colitis, Ulcerative
| Article | Year |
|---|---|
A polymeric drug for treatment of inflammatory bowel disease.
Topics: Aminosalicylic Acid; Animals; Biotransformation; Colitis, Ulcerative; Guinea Pigs; Intestines; Polym | 1983 |
Synthesis, colon-targeted studies and pharmacological evaluation of an anti-ulcerative colitis drug 4-Aminosalicylic acid-β-O-glucoside.
Topics: Animals; Colitis, Ulcerative; Colon; Dose-Response Relationship, Drug; Glucosides; Male; Molecular S | 2016 |
Development of M10, myricetin-3-O-β-d-lactose sodium salt, a derivative of myricetin as a potent agent of anti-chronic colonic inflammation.
Topics: Animals; Anti-Inflammatory Agents; Colitis, Ulcerative; Colon; Dextran Sulfate; Drug Stability; Fema | 2019 |
Synthesis of norisoboldine derivatives and bioactivity assay for inducing the generation of regulatory T cells.
Topics: Alkaloids; Animals; Cell Differentiation; Cell Survival; Colitis, Ulcerative; Dextran Sulfate; Dose- | 2021 |
Personalized Best: Toward Improving Care in Ulcerative Colitis.
Topics: Adalimumab; Anti-Inflammatory Agents; Antibodies; Colitis, Ulcerative; Female; Humans; Mesalamine; P | 2021 |
Clinical Course of Ulcerative Colitis Associated with an Age at Diagnosis: A Recent Japanese Database Survey.
Topics: Adolescent; Adult; Age of Onset; Aged; Child; Child, Preschool; Colitis, Ulcerative; Databases, Fact | 2021 |
Novel application of infliximab for diversion colitis.
Topics: Adult; Colectomy; Colitis; Colitis, Ulcerative; Humans; Infliximab; Male; Mesalamine; Treatment Outc | 2021 |
Evaluation of mesalazine polymeric conjugate in the treatment of actinic proctitis in rats.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; | 2021 |
Endoscopic Surveillance and Dysplasia Management in IBD: Plus Ça Change, Plus C'est la Même Chose.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonoscopy; Early Detection of Cancer | 2022 |
Recommendations for the optimal use of mesalazine in the management of patients with mild to moderate ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Inflammatory Bowel Diseases; M | 2021 |
Mesalamine-Induced Perimyocarditis: Rare Adverse Event in a Patient With Acute Severe Ulcerative Colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Mesalamine; Remission Inductio | 2022 |
Optimization study of combined enteric and time-dependent polymethacrylates as a coating for colon targeted delivery of 5-ASA pellets in rats with ulcerative colitis.
Topics: Animals; Colitis, Ulcerative; Colon; Drug Delivery Systems; Hydrogen-Ion Concentration; Mesalamine; | 2022 |
Development and
Topics: Animals; Caco-2 Cells; Colitis, Ulcerative; Humans; Mesalamine; Pectins; Rats; Rats, Wistar; Sacchar | 2022 |
Effects of jianguiqre decotion combined with mesalazine enteriic-coated tablets and bifid triple capsule dissolving at testines on the efficacy, TCM scores and inflammatory factors of patients with severe chronic colitis.
Topics: Colitis; Colitis, Ulcerative; Humans; Mesalamine; Tablets | 2022 |
Mesalazine in Inflammatory Bowel Disease and COVID-19: Hospitalization and Adverse In-Hospital Outcomes Based on Nationwide Data.
Topics: Colitis, Ulcerative; COVID-19; Crohn Disease; Hospitalization; Hospitals; Humans; Inflammatory Bowel | 2022 |
Multinational evaluation of clinical decision-making in the treatment and management of mild-to-moderate ulcerative colitis.
Topics: Clinical Decision-Making; Colitis, Ulcerative; Humans; Leukocyte L1 Antigen Complex; Mesalamine; Mut | 2022 |
5-aminosalicylic acid inhibits the expression of oncomiRs and pro-inflammatory microRNAs: an in vitro study.
Topics: Caco-2 Cells; Colitis, Ulcerative; Gene Expression Regulation; Humans; Mesalamine; MicroRNAs | 2021 |
Design of Clinical Trials for Mild to Moderate Ulcerative Colitis.
Topics: Colitis, Ulcerative; Humans; Mesalamine; Sulfasalazine | 2022 |
"Hepatotoxicity in inflammatory bowel disease: mesalazine, the forgotten drug".
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chemical and Drug Induced Liver Injury; Cholestasis; Coliti | 2021 |
5-Aminosalicylic Acid-induced Myocarditis in a Patient with Atypical Ulcerative Colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chest Pain; Colitis, Ulcerative; Dyspnea; Humans; Ma | 2022 |
SARS-CoV-2 (COVID-19) pneumonia patient treated with two doses of infliximab within 2 weeks for acute severe ulcerative colitis: A case report.
Topics: Adult; Azathioprine; Colitis, Ulcerative; COVID-19; COVID-19 Drug Treatment; Humans; Infliximab; Mal | 2022 |
Hemoglobin bio-adhesive nanoparticles as a colon-specific delivery system for sustained release of 5-aminosalicylic acid in the effective treatment of inflammatory bowel disease.
Topics: Adhesives; Animals; Anti-Inflammatory Agents, Non-Steroidal; Caco-2 Cells; Colitis, Ulcerative; Colo | 2022 |
Therapeutic Potential of Metabolites from
Topics: Animals; Colitis, Ulcerative; Cytokines; Dextran Sulfate; Disease Models, Animal; Dysbiosis; Gastroi | 2022 |
Molecular mechanism of the TGF‑β/Smad7 signaling pathway in ulcerative colitis.
Topics: Animals; Cadherins; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Models, Animal; Female; Int | 2022 |
Modelling the benefits of an optimised treatment strategy for 5-ASA in mild-to-moderate ulcerative colitis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Colitis, Ulcerat | 2022 |
Emerging inflammatory bowel disease demographics, phenotype, and treatment in South Asia, South-East Asia, and Middle East: Preliminary findings from the Inflammatory Bowel Disease-Emerging Nations' Consortium.
Topics: Aged; Asia, Eastern; Asia, Southeastern; Colitis, Ulcerative; Crohn Disease; Cross-Sectional Studies | 2022 |
Combining explainable machine learning, demographic and multi-omic data to inform precision medicine strategies for inflammatory bowel disease.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease | 2022 |
Mesalazine induced interstitial pneumonitis in the COVID era.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; COVID-19; Humans; Lung Diseases, Inter | 2022 |
A Case of Stevens-Johnson Syndrome Complicated with Multimatrix System Mesalamine in Ulcerative Colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Male; Mesalamine; Remis | 2022 |
Drug-induced hypersensitivity syndrome with lupus manifestations due to mesalazine in a patient with ulcerative colitis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Hypersensitivity Syndrome; | 2022 |
Shenling Baizhu San ameliorates ulcerative colitis by regulating the gut microbiota and its tryptophan metabolites: A complementary medicine to mesalamine.
Topics: Chromatography, Liquid; Colitis, Ulcerative; Complementary Therapies; Drugs, Chinese Herbal; Gastroi | 2022 |
Pentosan Polysulfate Sodium augments the therapeutic effect of 5-Aminosalicylic Acid in DSS colitis model; the role of IL-35 expression.
Topics: Animals; Colitis; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Models, Animal; Female; Inter | 2022 |
A high adalimumab induction dosing regimen achieves clinical and endoscopic remission in super-refractory ulcerative colitis.
Topics: Adalimumab; Colitis, Ulcerative; Humans; Mesalamine; Remission Induction; Sulfasalazine; Treatment O | 2022 |
Efficacy of Wumei Baijiang prescription on regulatory T cells / helper T cells Immune balance in mice with ulcerative coliti.
Topics: Animals; Body Weight; Colitis, Ulcerative; Colon; Disease Models, Animal; Drugs, Chinese Herbal; Int | 2022 |
Promoting mechanism of serum amyloid a family expression in mouse intestinal epithelial cells.
Topics: Animals; Colitis, Ulcerative; Epithelial Cells; Flagellin; Humans; Inflammation; Mesalamine; Mice; N | 2022 |
Lower Risk of Recurrence with a Higher Induction Dose of Mesalazine and Longer Duration of Treatment in Ulcerative Colitis: Results from the Dutch, Non-Interventional, IMPACT Study.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Duration | 2022 |
No increased risk of flare in ulcerative colitis patients in corticosteroid-free remission after stopping 5-aminosalicylic acid: A territory-wide population-based study.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Mesal | 2022 |
Population pharmacokinetics and IVIVC for mesalazine enteric-coated tablets.
Topics: Biological Availability; Colitis, Ulcerative; Humans; Intestine, Small; Mesalamine; Solubility; Tabl | 2022 |
[Electroacupuncture of "Shangjuxu"(ST37) and "Tianshu"(ST25) reduces colonic injury by suppressing NF-κB/NLRP3 signaling in rats with ulcerative colitis].
Topics: Animals; Colitis, Ulcerative; Electroacupuncture; Inflammasomes; Male; Mesalamine; NF-kappa B; NLR F | 2022 |
Stopping rules for 5-ASA in UC need to be redefined.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Mesalamine | 2022 |
Targeted Assessment of Mucosal Immune Gene Expression Predicts Clinical Outcomes in Children with Ulcerative Colitis.
Topics: Adrenal Cortex Hormones; Adult; Child; Colitis, Ulcerative; Gene Expression; Humans; Mesalamine; Muc | 2022 |
Pharmacokinetic and gut microbiota analyses revealed the effect of Lactobacillus acidophilus on the metabolism of Olsalazine in ulcerative colitis rats.
Topics: Aminosalicylic Acids; Animals; Colitis, Ulcerative; Gastrointestinal Microbiome; Lactobacillus acido | 2022 |
Comparison of the Relative Sensitivity of Clinical, Endoscopic, and Histologic Remission for Detection of Treatment Efficacy in Ulcerative Colitis Trials.
Topics: Colitis, Ulcerative; Humans; Mesalamine; Remission Induction; Sulfasalazine; Treatment Outcome | 2023 |
Bowel frequency (night) and urgent defecation are improved by budesonide foam in patients with ulcerative colitis: a retrospective observational study.
Topics: Budesonide; Colitis, Ulcerative; Defecation; Humans; Mesalamine; Quality of Life; Treatment Outcome | 2022 |
Mesalamine-Mediated Amelioration of Experimental Colitis in Piglets Involves Gut Microbiota Modulation and Intestinal Immune Cell Infiltration.
Topics: Animals; Colitis; Colitis, Ulcerative; Dextran Sulfate; Gastrointestinal Microbiome; Mesalamine; Swi | 2022 |
Targeted colonic release formulations of mesalazine - A clinical pharmaco-scintigraphic proof-of-concept study in healthy subjects and patients with mildly active ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Healthy Volunteers; Humans; Mesalamine | 2022 |
[Perimyocarditis as a complication of a multiple drug therapy in the treatment of a severe ulcerative colitis episode].
Topics: Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; | 2022 |
The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Mesalamine; Retrospective Stud | 2022 |
The safety of paternal and maternal use of 5-aminosalicylic acid during conception and pregnancy: a nationwide cohort study.
Topics: Child; Cohort Studies; Colitis, Ulcerative; Crohn Disease; Fathers; Female; Humans; Infant, Newborn; | 2022 |
Dahuang Mudan decoction repairs intestinal barrier in chronic colitic mice by regulating the function of ILC3.
Topics: Animals; Body Weight; Caco-2 Cells; Claudin-1; Colitis; Colitis, Ulcerative; Culture Media, Conditio | 2022 |
Ulcerative colitis-associated bronchiectasis: A rare extraintestinal manifestation of inflammatory bowel disease: A case report.
Topics: Adult; Azathioprine; Bronchiectasis; Chronic Disease; Colitis, Ulcerative; Cough; Female; Humans; In | 2022 |
Complete Endoscopic Healing Is Associated With Lower Relapse Risk After Anti-TNF Withdrawal in Inflammatory Bowel Disease.
Topics: Adult; Chronic Disease; Colitis, Ulcerative; Crohn Disease; Humans; Inflammatory Bowel Diseases; Inf | 2023 |
Progression of ulcerative colitis following diversion colitis.
Topics: Colitis; Colitis, Ulcerative; Colonoscopy; Diverticulum, Colon; Humans; Male; Mesalamine; Middle Age | 2022 |
Qing-Chang-Hua-Shi granule ameliorates DSS-induced colitis by activating NLRP6 signaling and regulating Th17/Treg balance.
Topics: Animals; Colitis; Colitis, Ulcerative; Colon; Dextran Sulfate; Drugs, Chinese Herbal; Inflammasomes; | 2022 |
Trends in medication use and treatment patterns in Chinese patients with inflammatory bowel disease.
Topics: Adrenal Cortex Hormones; China; Chronic Disease; Colitis, Ulcerative; Crohn Disease; Humans; Immunos | 2022 |
Epidemiological Trends of Pediatric Inflammatory Bowel Disease in Korea: A Multicenter Study of the Last 3 Years Including the COVID-19 Era.
Topics: Azathioprine; Colitis, Ulcerative; COVID-19; Crohn Disease; Humans; Inflammatory Bowel Diseases; Inf | 2022 |
Real-world evidence of quality of life improvement in patients with distal ulcerative colitis treated by mesalazine: the Quartz study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Inflammatory Bowel Diseases; M | 2022 |
Qingchang Wenzhong Decoction reduce ulcerative colitis in mice by inhibiting Th17 lymphocyte differentiation.
Topics: Animals; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Models, Animal; Inflammation; Interleu | 2022 |
Identification and exploration of pharmacological pyroptosis-related biomarkers of ulcerative colitis.
Topics: Animals; Biomarkers, Pharmacological; Colitis; Colitis, Ulcerative; Dextran Sulfate; Mesalamine; Mic | 2022 |
Prediction of long-term remission in patients following discontinuation of anti-TNF therapy in ulcerative colitis: a 10 year follow up study.
Topics: Colitis, Ulcerative; Follow-Up Studies; Humans; Mesalamine; Recurrence; Remission Induction; Tumor N | 2022 |
Prediction of long-term remission in patients following discontinuation of anti-TNF therapy in ulcerative colitis: a 10 year follow up study.
Topics: Colitis, Ulcerative; Follow-Up Studies; Humans; Mesalamine; Recurrence; Remission Induction; Tumor N | 2022 |
Prediction of long-term remission in patients following discontinuation of anti-TNF therapy in ulcerative colitis: a 10 year follow up study.
Topics: Colitis, Ulcerative; Follow-Up Studies; Humans; Mesalamine; Recurrence; Remission Induction; Tumor N | 2022 |
Prediction of long-term remission in patients following discontinuation of anti-TNF therapy in ulcerative colitis: a 10 year follow up study.
Topics: Colitis, Ulcerative; Follow-Up Studies; Humans; Mesalamine; Recurrence; Remission Induction; Tumor N | 2022 |
Prediction of long-term remission in patients following discontinuation of anti-TNF therapy in ulcerative colitis: a 10 year follow up study.
Topics: Colitis, Ulcerative; Follow-Up Studies; Humans; Mesalamine; Recurrence; Remission Induction; Tumor N | 2022 |
Prediction of long-term remission in patients following discontinuation of anti-TNF therapy in ulcerative colitis: a 10 year follow up study.
Topics: Colitis, Ulcerative; Follow-Up Studies; Humans; Mesalamine; Recurrence; Remission Induction; Tumor N | 2022 |
Prediction of long-term remission in patients following discontinuation of anti-TNF therapy in ulcerative colitis: a 10 year follow up study.
Topics: Colitis, Ulcerative; Follow-Up Studies; Humans; Mesalamine; Recurrence; Remission Induction; Tumor N | 2022 |
Prediction of long-term remission in patients following discontinuation of anti-TNF therapy in ulcerative colitis: a 10 year follow up study.
Topics: Colitis, Ulcerative; Follow-Up Studies; Humans; Mesalamine; Recurrence; Remission Induction; Tumor N | 2022 |
Prediction of long-term remission in patients following discontinuation of anti-TNF therapy in ulcerative colitis: a 10 year follow up study.
Topics: Colitis, Ulcerative; Follow-Up Studies; Humans; Mesalamine; Recurrence; Remission Induction; Tumor N | 2022 |
A New Evaluation Method for Remission of Ulcerative Colitis.
Topics: Causality; Colitis, Ulcerative; Humans; Mesalamine; Remission Induction | 2023 |
A New Evaluation Method for Remission of Ulcerative Colitis.
Topics: Causality; Colitis, Ulcerative; Humans; Mesalamine; Remission Induction | 2023 |
A New Evaluation Method for Remission of Ulcerative Colitis.
Topics: Causality; Colitis, Ulcerative; Humans; Mesalamine; Remission Induction | 2023 |
A New Evaluation Method for Remission of Ulcerative Colitis.
Topics: Causality; Colitis, Ulcerative; Humans; Mesalamine; Remission Induction | 2023 |
A New Evaluation Method for Remission of Ulcerative Colitis.
Topics: Causality; Colitis, Ulcerative; Humans; Mesalamine; Remission Induction | 2023 |
A New Evaluation Method for Remission of Ulcerative Colitis.
Topics: Causality; Colitis, Ulcerative; Humans; Mesalamine; Remission Induction | 2023 |
A New Evaluation Method for Remission of Ulcerative Colitis.
Topics: Causality; Colitis, Ulcerative; Humans; Mesalamine; Remission Induction | 2023 |
A New Evaluation Method for Remission of Ulcerative Colitis.
Topics: Causality; Colitis, Ulcerative; Humans; Mesalamine; Remission Induction | 2023 |
A New Evaluation Method for Remission of Ulcerative Colitis.
Topics: Causality; Colitis, Ulcerative; Humans; Mesalamine; Remission Induction | 2023 |
Comparison of effects of aminosalicylic acid, glucocorticoids and immunosuppressive agents on the expression of multidrug-resistant genes in ulcerative colitis.
Topics: Aminosalicylic Acid; ATP Binding Cassette Transporter, Subfamily B, Member 1; Colitis, Ulcerative; G | 2022 |
Comparison of effects of aminosalicylic acid, glucocorticoids and immunosuppressive agents on the expression of multidrug-resistant genes in ulcerative colitis.
Topics: Aminosalicylic Acid; ATP Binding Cassette Transporter, Subfamily B, Member 1; Colitis, Ulcerative; G | 2022 |
Comparison of effects of aminosalicylic acid, glucocorticoids and immunosuppressive agents on the expression of multidrug-resistant genes in ulcerative colitis.
Topics: Aminosalicylic Acid; ATP Binding Cassette Transporter, Subfamily B, Member 1; Colitis, Ulcerative; G | 2022 |
Comparison of effects of aminosalicylic acid, glucocorticoids and immunosuppressive agents on the expression of multidrug-resistant genes in ulcerative colitis.
Topics: Aminosalicylic Acid; ATP Binding Cassette Transporter, Subfamily B, Member 1; Colitis, Ulcerative; G | 2022 |
[Mechanism of Shenling Baizhu Powder on treatment of ulcerative colitis based on NLRP3 inflammatory].
Topics: Animals; Caspase 1; Colitis; Colitis, Ulcerative; Colon; Cytokines; Dextran Sulfate; Disease Models, | 2022 |
[Mechanism of Shenling Baizhu Powder on treatment of ulcerative colitis based on NLRP3 inflammatory].
Topics: Animals; Caspase 1; Colitis; Colitis, Ulcerative; Colon; Cytokines; Dextran Sulfate; Disease Models, | 2022 |
[Mechanism of Shenling Baizhu Powder on treatment of ulcerative colitis based on NLRP3 inflammatory].
Topics: Animals; Caspase 1; Colitis; Colitis, Ulcerative; Colon; Cytokines; Dextran Sulfate; Disease Models, | 2022 |
[Mechanism of Shenling Baizhu Powder on treatment of ulcerative colitis based on NLRP3 inflammatory].
Topics: Animals; Caspase 1; Colitis; Colitis, Ulcerative; Colon; Cytokines; Dextran Sulfate; Disease Models, | 2022 |
Protective effect of 7-hydroxyl-1-methylindole-3-acetonitrile on the intestinal mucosal damage response to inflammation in mice with DSS-induced colitis.
Topics: Animals; Colitis; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Models, Animal; Drinking Wate | 2023 |
Icosapent ethyl alleviates acetic acid-induced ulcerative colitis via modulation of SIRT1 signaling pathway in rats.
Topics: Acetic Acid; Animals; Caspase 3; Colitis; Colitis, Ulcerative; Collagen; Colon; Eicosapentaenoic Aci | 2023 |
Efficacy and Safety of Sulfasalazine Suspension in Children With Ulcerative Colitis.
Topics: Adolescent; Azathioprine; Child; Colitis, Ulcerative; Humans; Immunosuppressive Agents; Infliximab; | 2023 |
Effect of Biologics on the Risk of Advanced-Stage Inflammatory Bowel Disease-Associated Intestinal Cancer: A Nationwide Study.
Topics: Biological Products; Colitis, Ulcerative; Crohn Disease; Humans; Immunologic Factors; Inflammatory B | 2023 |
Efficacy of active ingredients in Qingdai on ulcerative colitis: a network pharmacology-based evaluation.
Topics: Animals; Colitis; Colitis, Ulcerative; Colon; Disease Models, Animal; Glycogen Synthase Kinase 3; Me | 2023 |
Net Remission Rates with Biologic and Small Molecule Treatment in Ulcerative Colitis: A Reappraisal of the Clinical Trial Data.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Colitis, Ulcerative; Humans; Mesalamin | 2023 |
The Prevalence of Inflammatory Bowel Disease in Greenland.
Topics: Colitis, Ulcerative; Crohn Disease; Cross-Sectional Studies; Greenland; Humans; Inflammatory Bowel D | 2023 |
Use of Novel Biological Agent in Severe Ulcerative Colitis with Poor Response to Initial Therapy: A Case Report.
Topics: Adalimumab; Azathioprine; Biological Factors; Colitis, Ulcerative; Humans; Inflammation; Mesalamine | 2022 |
[Effects of Huangqin Tang on NLRP3/Caspase-1 pathway in mice model of ulcerative colitis].
Topics: Animals; Caspase 1; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Models, Animal; Drugs, Chin | 2023 |
Prevalence and Etiologies of Renal and Urinary Manifestations in a Large Cohort of Children With Inflammatory Bowel Disease.
Topics: Adolescent; Child; Colitis, Ulcerative; Crohn Disease; Humans; Inflammatory Bowel Diseases; Kidney; | 2023 |
Potential of Mesalazine Therapeutic Drug Monitoring by Measuring Fecal Excretion in Patients With Ulcerative Colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Cross-Sectional Studies; Drug M | 2023 |
Serum Bile Acid Metabolites Predict the Therapeutic Effect of Mesalazine in Patients with Ulcerative Colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bile Acids and Salts; Biomarkers; Colitis, Ulcerative; Huma | 2023 |
Severe outbreak of ulcerative colitis and cerebral neoplasia. Difficult management in COVID time.
Topics: Colitis, Ulcerative; COVID-19; Disease Outbreaks; Humans; Male; Mesalamine; Middle Aged; Neoplasms | 2023 |
Drug-induced bradycardia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bradycardia; Colitis, Ulcerative; Female; Humans; Mesalamin | 2023 |
Efficacy of Qifu Lizhong enema prescription on intestinal mucosal tight junction function modulation of ulcerative colitis rat model.
Topics: Actins; Animals; Claudin-1; Claudin-2; Colitis, Ulcerative; Enema; Intestinal Mucosa; Male; Mesalami | 2023 |
Low-Dose Interleukin 2 for the Treatment of Moderate to Severe Ulcerative Colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Interleukin-2; Mesalamine | 2023 |
Patients with elderly onset inflammatory bowel disease have a decreased chance of initiation of all types of medications and increased risk of surgeries-A nationwide cohort study.
Topics: Adrenal Cortex Hormones; Adult; Aged; Cohort Studies; Colitis, Ulcerative; Crohn Disease; Humans; Im | 2023 |
Comparison of 5-ASA layered or matrix pellets coated with a combination of ethylcellulose and eudragits L and s in the treatment of ulcerative colitis in rats.
Topics: Animals; Colitis, Ulcerative; Colon; Drug Delivery Systems; Drug Implants; Mesalamine; Rats; Solubil | 2023 |
Ulcerative proctitis: Challenges for clinical management.
Topics: Colitis, Ulcerative; Humans; Mesalamine; Proctitis | 2023 |
pH-sensitive HPMCP-chitosan nanoparticles containing 5-aminosalicylic acid and berberine for oral colon delivery in a rat model of ulcerative colitis.
Topics: Animals; Berberine; Chitosan; Colitis, Ulcerative; Hydrogen-Ion Concentration; Mesalamine; Nanoparti | 2023 |
Drug-induced acute pancreatitis due to medications used for inflammatory bowel disease: A VigiBase pharmacovigilance database study.
Topics: Acute Disease; Arthritis, Rheumatoid; Biological Products; Colitis, Ulcerative; Crohn Disease; Human | 2023 |
Mesalazine hollow suppositories based on 3D printing for treatment of ulcerative colitis.
Topics: Animals; Colitis, Ulcerative; Humans; Inflammation; Mesalamine; Printing, Three-Dimensional; Rats; S | 2023 |
Mesalazine granules promote disease clearance in patients with mild-to-moderate ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Endoscopy; Humans; Mesalamine; Remissi | 2023 |
Fulminant organizing pneumonia in a patient with ulcerative colitis on mesalamine and infliximab: striving to identify the cause!
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Infliximab; Mesalamine; Organi | 2023 |
5-Aminosalicylic acid alters the gut microbiota and altered microbiota transmitted vertically to offspring have protective effects against colitis.
Topics: Animals; Anti-Inflammatory Agents; Colitis; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Mod | 2023 |
Recurrent Multidrug-Resistant
Topics: Adalimumab; Anti-Bacterial Agents; Clostridium Infections; Colitis, Ulcerative; Female; Humans; Mesa | 2023 |
Adherence to 5-aminosalicylic acid maintenance treatment in young people with ulcerative colitis: a retrospective cohort study in primary care.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Humans; Mesalamine; | 2023 |
[A case of ulcerative colitis with mesalazine intolerance complicated with agranulocytosis and septic shock during salazosulfapyridine administration].
Topics: Aged; Agranulocytosis; Colitis, Ulcerative; Female; Humans; Mesalamine; Shock, Septic; Sulfasalazine | 2023 |
Factors contributing to flares of ulcerative colitis in North India- a case-control study.
Topics: Adult; Anti-Bacterial Agents; Case-Control Studies; Colitis; Colitis, Ulcerative; Female; Humans; In | 2023 |
Effect of Polycan, a β-Glucan from
Topics: Animals; beta-Glucans; Colitis; Colitis, Ulcerative; Colon; Dextran Sulfate; Dextrans; Disease Model | 2023 |
Construction of molecular subgroups of ulcerative colitis.
Topics: Colitis, Ulcerative; Gene Expression Profiling; Humans; Intracellular Signaling Peptides and Protein | 2023 |
Bickerstaff's brainstem encephalitis: a rare case of neurologic complication in Ulcerative Colitis.
Topics: Ataxia; Autoimmune Diseases of the Nervous System; Brain Stem; Colitis, Ulcerative; Encephalitis; Ga | 2023 |
The oral bacterial microbiota facilitates the stratification for ulcerative colitis patients with oral ulcers.
Topics: Bacteria; Colitis, Ulcerative; Feces; Gastrointestinal Microbiome; Humans; Inflammatory Bowel Diseas | 2023 |
Comparison of outcomes of continuation/discontinuation of 5-aminosalicylic acid after initiation of anti-tumor necrosis factor-alpha therapy in patients with inflammatory bowel disease.
Topics: Adult; Colitis, Ulcerative; Crohn Disease; Female; Humans; Inflammatory Bowel Diseases; Kaplan-Meier | 2019 |
Spray dried formulation of mesalamine embedded with probiotic biomass for the treatment of ulcerative colitis:
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzenesulfonates; Caco-2 Cells; Colitis, Ulcerati | 2019 |
Comment on: "Improving the Quality of Inpatient Ulcerative Colitis Management: Promoting Evidence-Based Practice and Reducing Care Variation With an Inpatient Protocol".
Topics: Colitis, Ulcerative; Evidence-Based Practice; Humans; Inpatients; Mesalamine | 2019 |
Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis.
Topics: Adult; Colitis, Ulcerative; Gastrointestinal Hemorrhage; Humans; Inflammation; Mesalamine; Patient R | 2020 |
Editorial: aminosalicylates and nephrotoxicity-an issue put to rest.
Topics: Case-Control Studies; Cohort Studies; Colitis, Ulcerative; Humans; Mesalamine; Renal Insufficiency | 2019 |
Topical Aminosalicylates and Histologic Healing in Ulcerative Colitis.
Topics: Aminosalicylic Acid; Colitis, Ulcerative; Humans; Mesalamine; Randomized Controlled Trials as Topic; | 2019 |
Use, effectiveness and tolerability of budesonide-MMX in ulcerative colitis: A real-life experience.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Budesonide; Colitis, Ulcerative; | 2019 |
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Cohort Studies; Colitis, Ulcerative; Dos | 2019 |
Use of Endocytoscopy for Ulcerative Colitis Surveillance: A Case Study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Colitis, Ulcerative; Colonic Neoplasms; Colo | 2020 |
Alteration of Fungal Microbiota After 5-ASA Treatment in UC Patients.
Topics: Adult; Colitis, Ulcerative; DNA, Fungal; Dysbiosis; Feces; Female; Fungi; Gastrointestinal Tract; Hu | 2020 |
Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on topical therapy in ulcerative colitis.
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Glucocorticoi | 2020 |
Disease Characteristics and Severity in Patients With Inflammatory Bowel Disease With Coexistent Diabetes Mellitus.
Topics: Adult; Aged; Biological Products; Colitis, Ulcerative; Crohn Disease; Diabetes Mellitus, Type 1; Dia | 2020 |
[DRUG-INDUCED BILATERAL NEPHROLITHIASIS IN AN ULCERATIVE COLITIS PATIENT: A CASE REPORT].
Topics: Colitis, Ulcerative; Female; Humans; Lithotripsy; Mesalamine; Middle Aged; Nephrolithiasis; Sulfasal | 2019 |
Effects of mesalazine combined with bifid triple viable on intestinal flora, immunoglobulin and levels of cal, MMP-9, and MPO in feces of patients with ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Combined Modality Therapy; Fece | 2020 |
Giant pyoderma gangrenosum in a patient with ulcerative colitis: A case report.
Topics: Adult; Anti-Inflammatory Agents; Colitis, Ulcerative; Diagnosis, Differential; Drug Therapy, Combina | 2020 |
Cancer risk and chemoprevention in Chinese inflammatory bowel disease patients: a population-based cohort study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; China; Cohort Studies; Colitis, Ulcerative; | 2020 |
Serum amyloid A is a better predictive biomarker of mucosal healing than C-reactive protein in ulcerative colitis in clinical remission.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biologica | 2020 |
A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis.
Topics: Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Betacoronavirus; Clini | 2020 |
Non-adherence to Medications in Pregnant Ulcerative Colitis Patients Contributes to Disease Flares and Adverse Pregnancy Outcomes.
Topics: Abortion, Spontaneous; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; | 2021 |
Mucosal concentrations of N-acetyl-5-aminosalicylic acid related to endoscopic activity in ulcerative colitis patients with mesalamine.
Topics: Adult; Aminosalicylic Acids; Biomarkers; Colitis, Ulcerative; Colon, Sigmoid; Cross-Sectional Studie | 2020 |
Mesalamine-induced eosinophilic pleural effusion.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Diagnosis, Differential; Eosinophilia; | 2020 |
Targeting IL-10, ZO-1 gene expression and IL-6/STAT-3 trans-signaling by a combination of atorvastatin and mesalazine to enhance anti-inflammatory effects and attenuates progression of oxazolone-induced colitis.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Colitis, Ulcerative; Colon; Drug Therapy, Combinati | 2021 |
Letter: mesalazine-a safe drug with rare serious adverse events? Authors' reply.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Mesalamine | 2020 |
Letter: mesalazine-a safe drug with rare serious adverse events.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Mesalamine | 2020 |
Remission of ulcerative colitis flare-up induced by nivolumab.
Topics: Aged; Colitis, Ulcerative; Humans; Inflammation; Male; Mesalamine; Middle Aged; Nivolumab | 2020 |
Treatment Pathways Leading to Biologic Therapies for Ulcerative Colitis and Crohn's Disease in the United States.
Topics: Administrative Claims, Healthcare; Biological Products; Colitis, Ulcerative; Critical Pathways; Croh | 2020 |
Multicenter survey on mesalamine intolerance in patients with ulcerative colitis.
Topics: Abdominal Pain; Administration, Oral; Adult; Colitis, Ulcerative; Diarrhea; Disease Progression; Fem | 2021 |
The protective effect of Lactobacillus versus 5-aminosalicylic acid in ulcerative colitis model by modulation of gut microbiota and Nrf2/Ho-1 pathway.
Topics: Animals; Antioxidants; Colitis, Ulcerative; Escherichia coli; Fusobacterium; Gastrointestinal Microb | 2020 |
No benefit of continuing vs stopping 5-aminosalicylates in patients with ulcerative colitis escalated to anti-metabolite therapy.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Biological | 2020 |
Long-term outcomes of patients with ulcerative proctitis: Analysis from a large referral centre cohort.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Biological Factors; Colitis, Ulcerative; Drug Resista | 2020 |
Long-term outcome of ulcerative proctitis.
Topics: Cohort Studies; Colitis, Ulcerative; Humans; Mesalamine; Proctitis; Referral and Consultation | 2020 |
Multiple Cerebral Infarction Associated with Cerebral Vasculitis in a Patient with Ulcerative Colitis.
Topics: Adult; Cerebral Infarction; Colitis, Ulcerative; Humans; Male; Mesalamine; Prednisolone; Vasculitis, | 2021 |
Mesalazine formulation intolerance due to suspected excipient allergy in the treatment of ulcerative colitis: a case report.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Excipients; Humans; Hypersensitivity; | 2020 |
Inflammatory bowel disease and inherited colorectal cancer: Is there a genetic link?
Topics: Adenocarcinoma; Adult; Age of Onset; Anti-Inflammatory Agents; Azathioprine; Breast Neoplasms; Colit | 2021 |
The endogenous ligand for guanylate cyclase-C activation reliefs intestinal inflammation in the DSS colitis model.
Topics: Animals; Colitis, Ulcerative; Colon; Cytokines; Dextran Sulfate; Disease Models, Animal; Enzyme Acti | 2020 |
Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Biological Products; Col | 2021 |
Benign Evolution of SARS-Cov2 Infections in Children With Inflammatory Bowel Disease: Results From Two International Databases.
Topics: Adolescent; Ambulatory Care; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Co | 2021 |
Network Meta-analysis of Ulcerative Colitis Pharmacotherapies: Carryover Effects From Induction and Bias of the Results.
Topics: Colitis, Ulcerative; Drug-Related Side Effects and Adverse Reactions; Humans; Mesalamine; Network Me | 2021 |
Effects of fiber intake on intestinal pH, transit, and predicted oral mesalamine delivery in patients with ulcerative colitis.
Topics: Administration, Oral; Adult; Aged; Colitis, Ulcerative; Dietary Fiber; Drug Liberation; Eating; Fema | 2021 |
Histologic remission does not offer additional benefit for ulcerative colitis patients in endoscopic remission.
Topics: Adolescent; Adult; Colitis, Ulcerative; Colonoscopy; Female; Humans; Intestinal Mucosa; Mesalamine; | 2020 |
5-aminosalicylate-intolerant patients are at increased risk of colectomy for ulcerative colitis.
Topics: Colectomy; Colitis, Ulcerative; Humans; Japan; Mesalamine; Retrospective Studies; Risk Factors | 2021 |
A Case of Lung Abscess Caused by Double Immunosuppressive Therapy to Treat Ulcerative Colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Immunosuppressive Agent | 2020 |
Concomitant 5-Aminosalicylate Therapy in Moderate-to-Severe Ulcerative Colitis Patients Escalated to Infliximab Is Not Beneficial.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Colitis, Ulcerative; Drug Therapy, C | 2021 |
Pericardial effusion associated with mesalamine treatment in a patient with ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Mesalamine; Middle Age | 2021 |
Gancao Xiexin decoction combined with mesalazine in the treatment of ulcerative colitis: A protocol for a systematic review and meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Therapy, Combination; Drugs, Chin | 2020 |
Recurrent acute pancreatitis induced by 5-ASA and azathioprine in ulcerative colitis.
Topics: Acute Disease; Adult; Azathioprine; Colitis, Ulcerative; Humans; Male; Mesalamine; Pancreatitis; Rec | 2020 |
Knowledge of 5-aminosalicylic acid nephrotoxicity and adherence to kidney function monitoring of patients with inflammatory bowel disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Inflammatory Bowel Diseases; K | 2021 |
A chromatographic approach to development of 5-aminosalicylate/folic acid fixed-dose combinations for treatment of Crohn's disease and ulcerative colitis.
Topics: Chromatography; Colitis, Ulcerative; Crohn Disease; Drug Combinations; Folic Acid; Humans; Inflammat | 2020 |
A case of severe diverticulosis in a patient with ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colitis, Ulcerative; Colonoscopy; Diverticulu | 2021 |
A new kid on the budesonide block.
Topics: Budesonide; Colitis, Ulcerative; Humans; Mesalamine | 2020 |
[Mesalazine-induced myocarditis].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Fever; Humans; Male; Mesalamine | 2020 |
Enteric-coated gelatin nanoparticles mediated oral delivery of 5-aminosalicylic acid alleviates severity of DSS-induced ulcerative colitis.
Topics: Administration, Oral; Animals; Colitis, Ulcerative; Colon; Drug Delivery Systems; Gelatin; Mesalamin | 2021 |
Ultraperformance Liquid Chromatography Coupled with Quadrupole Time-of-Flight Mass Spectrometry-Based Metabolomics and Lipidomics Identify Biomarkers for Efficacy Evaluation of Mesalazine in a Dextran Sulfate Sodium-Induced Ulcerative Colitis Mouse Model.
Topics: Animals; Biomarkers; Chromatography, Liquid; Colitis, Ulcerative; Dextran Sulfate; Lipidomics; Mass | 2021 |
Infliximab is effective in the treatment of ulcerative colitis with dermatomyositis: A case report.
Topics: Colitis, Ulcerative; Dermatomyositis; Female; Humans; Infliximab; Mesalamine; Middle Aged | 2020 |
Ulcerative colitis-Maintanance of Remission With the Probiotic Escherichia coli Strain Nissle 1917.
Topics: Colitis, Ulcerative; Escherichia coli; Escherichia coli Infections; Humans; Mesalamine; Probiotics | 2021 |
COVID-19 in IBD: The experience of a single tertiary IBD center.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Biological Products; | 2021 |
Differential effects of mesalazine formulations on thiopurine metabolism through thiopurine S-methyltransferase inhibition.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colitis, Ulcerative; Humans; Mercaptopurine; | 2021 |
Peri-myocarditis caused by topical rectal mesalamine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Male; Mesalamine; Middle Aged; | 2021 |
Integrative transcriptomic and metabonomic profiling analyses reveal the molecular mechanism of Chinese traditional medicine huankuile suspension on TNBS-induced ulcerative colitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Cytokines; Disease Models, An | 2021 |
Application of inulin/Eudragit RS in 5-ASA pellet coating with tuned, sustained-release feature in an animal model of ulcerative colitis.
Topics: Acrylic Resins; Animals; Colitis, Ulcerative; Delayed-Action Preparations; Inulin; Mesalamine; Model | 2021 |
Intrahepatic cholestasis of pregnancy associated with azathioprine: A case series.
Topics: Adult; Azathioprine; Bile Acids and Salts; Cholagogues and Choleretics; Cholestasis, Intrahepatic; C | 2021 |
[
Topics: Animals; Cell Count; Colitis, Ulcerative; Immunity, Innate; Male; Mesalamine; Mice; Scutellaria baic | 2021 |
The impact of clinical symptoms and endoscopic and histologic disease activity on health-related quality of life in patients with ulcerative colitis following treatment with multimatrix mesalazine.
Topics: Adult; Colitis, Ulcerative; Endoscopy; Female; Humans; Male; Mesalamine; Quality of Life; Severity o | 2021 |
Mesalazine-induced acute pancreatitis: a rare adverse reaction but with important therapeutic implications in ulcerative colitis.
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Mesalamine; Pan | 2021 |
Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology?
Topics: Colitis, Ulcerative; COVID-19; Humans; Mesalamine; Research Design; SARS-CoV-2 | 2021 |
Histological Remission in Ulcerative Colitis in Deep Remission under Treatment with Adalimumab.
Topics: Adalimumab; Adult; Biopsy; Colitis, Ulcerative; Colon; Colonoscopy; Female; Follow-Up Studies; Human | 2021 |
Clinical features and treatment of inflammatory bowel disease in a low-incidence area: A hospital-based retrospective cohort study in Taiwan.
Topics: Adult; Age Factors; Biological Factors; Colectomy; Colitis, Ulcerative; Crohn Disease; Databases, Fa | 2021 |
Understanding patient journey in ulcerative colitis prior to biologic initiation: a 5-year exploration.
Topics: Biological Products; Colitis, Ulcerative; Crohn Disease; Humans; Immunologic Factors; Mesalamine | 2021 |
Research on Preparation of 5-ASA Colon-Specific Hydrogel Delivery System without Crosslinking Agent by Mechanochemical Method.
Topics: Administration, Oral; Alginates; Animals; Biological Availability; Chemistry, Pharmaceutical; Chitos | 2021 |
Thiopurine Monotherapy Is Effective in Maintenance of Mild-Moderate Inflammatory Bowel Disease.
Topics: Adult; Colitis, Ulcerative; Crohn Disease; Humans; Inflammatory Bowel Diseases; Mesalamine; Retrospe | 2022 |
5-Aminosalicylic acid inhibits stem cell function in human adenoma-derived cells: implications for chemoprophylaxis in colorectal tumorigenesis.
Topics: Adenoma; Carcinogenesis; Carcinoma; Cell Line, Tumor; Cell Transformation, Neoplastic; Chemopreventi | 2021 |
Myricetin and M10, a myricetin-3-O-β-d-lactose sodium salt, modify composition of gut microbiota in mice with ulcerative colitis.
Topics: Alanine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Bacteria; Colitis, Ulcerative; Dextran Su | 2021 |
Maternal mesalazine-induced neonatal gastrointestinal bleeding.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Gast | 2021 |
Clinical and Host Biological Factors Predict Colectomy Risk in Children Newly Diagnosed With Ulcerative Colitis.
Topics: Adolescent; Biological Factors; Child; Child, Preschool; Cohort Studies; Colectomy; Colitis, Ulcerat | 2022 |
Revealing the mechanism of "Huai Hua San" in the treatment of ulcerative colitis based on network pharmacology and experimental study.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Survival; Colitis, Ulcerative; Dose-Response | 2021 |
Predictive factors of relapse after dose reduction of oral 5-aminosalicylic acid in patients with ulcerative colitis in the remission phase.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colit | 2021 |
Supplemental bifid triple viable capsule treatment improves inflammatory response and T cell frequency in ulcerative colitis patients.
Topics: Colitis, Ulcerative; Humans; Mesalamine; Probiotics; T-Lymphocytes; Tumor Necrosis Factor-alpha | 2021 |
Mesalazine-induced lung injury in a child; the value of bronchoscopy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bronchoscopy; Child; Colitis, Ulcerative; Humans; Lung Inju | 2021 |
Stringent criteria for withdrawal of biologics in ulcerative colitis - Authors' reply.
Topics: Biological Products; Colitis, Ulcerative; Humans; Mesalamine | 2021 |
Editorial: 5-ASA in IBD patients on biologics-'stop or continue'?
Topics: Biological Products; Colitis, Ulcerative; Humans; Mesalamine | 2021 |
Early Change in Fecal Calprotectin Predicts One-Year Outcome in Children Newly Diagnosed With Ulcerative Colitis.
Topics: Biomarkers; Child; Colitis, Ulcerative; Feces; Humans; Leukocyte L1 Antigen Complex; Mesalamine; Rem | 2022 |
Letter: how to define remission in ulcerative colitis - histological remission should be considered.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Mesalamine; Remission Inductio | 2017 |
First report of mesalamine (5-aminosalicylic acid) as the causative agent in a case of acute generalized exanthamous pustulosis.
Topics: Acute Generalized Exanthematous Pustulosis; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, | 2017 |
Budesonide MMX Add-on to 5-Aminosalicylic Acid Therapy in Mild-to-Moderate Ulcerative Colitis: A Favourable Risk-Benefit Profile.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Budesonide; Colitis, Ulcerative; Drug Delivery Systems; Dru | 2017 |
Real life results in using 5-ASA for maintaining mild to moderate UC patients in Japan, a multi-center study, OPTIMUM Study.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Dru | 2017 |
Combination of Corticosteroids with 5-Aminosalicylic Acids Compared to Corticosteroids Alone for Hospitalized Patients with Active Ulcerative Colitis.
Topics: Administration, Oral; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colit | 2016 |
Editorial: evidence is growing for protective effects of 5-aminosalicylates against colitis-associated cancer-authors' reply.
Topics: Colitis; Colitis, Ulcerative; Humans; Mesalamine; Neoplasms | 2017 |
Editorial: evidence is growing for protective effects of 5-aminosalicylates against colitis-associated cancer.
Topics: Colitis; Colitis, Ulcerative; Humans; Mesalamine; Neoplasms | 2017 |
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Colitis, Ulce | 2017 |
Combination of corticosteroids and 5-aminosalicylates or corticosteroids alone for patients with moderate-severe active ulcerative colitis: A global survey of physicians' practice.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Asia; Australia; Brazil; Clinical | 2017 |
[Budd-Chiari syndrome and ulcerative colitis in an adolescent.]
Topics: Adolescent; Anti-Inflammatory Agents; Anticoagulants; Budd-Chiari Syndrome; Colitis, Ulcerative; Fem | 2017 |
Use of Novel Oral Anticoagulant to Treat Pulmonary Thromboembolism in Patient with Ulcerative Colitis Superinfected Cytomegalovirus Colitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Colitis, Ulcer | 2017 |
Fecal transplantation as a treatment for Clostridium difficile infection in patients with ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clostridioides difficile; Colitis, Ulcerative; Enterocoliti | 2017 |
Changes in medical management and colectomy rates: a population-based cohort study on the epidemiology and natural history of ulcerative colitis in Örebro, Sweden, 1963-2010.
Topics: Adolescent; Adult; Cohort Studies; Colectomy; Colitis, Ulcerative; Disease Progression; Female; Huma | 2017 |
Inhibitory Potency of Marketed Drugs for Ulcerative Colitis and Crohn's Disease on PEPT1.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Dipeptides; HEK293 Cells; Humans; Mesalami | 2017 |
Mucosal Cytokine Profiles After Induction Therapy With Granulocyte/Monocyte Apheresis in New-onset Inflammatory Colitis.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Colon; Cytokines; F | 2018 |
p53 and miR-34b/c genetic variation and their impact on ulcerative colitis susceptibility.
Topics: Adult; Alleles; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Colitis, Ulcerative; | 2018 |
Improving remission rates in newly diagnosed paediatric ulcerative colitis.
Topics: Child; Colitis, Ulcerative; Humans; Mesalamine | 2017 |
Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study.
Topics: Administration, Intravenous; Administration, Oral; Adolescent; Adrenal Cortex Hormones; Anti-Inflamm | 2017 |
New mesalamine polymeric conjugate for controlled release: Preparation, characterization and biodistribution study.
Topics: Biological Availability; Cell Line; Chondroitin Sulfates; Colitis, Ulcerative; Delayed-Action Prepar | 2018 |
The risk factor of clinical relapse in ulcerative colitis patients with low dose 5-aminosalicylic acid as maintenance therapy: A report from the IBD registry.
Topics: Adult; Colitis, Ulcerative; Female; Humans; Male; Mesalamine; Middle Aged; Prospective Studies; Recu | 2017 |
Necrotic lesion in an immunosuppressed patient.
Topics: Aged; Colitis, Ulcerative; Ecthyma; Fatal Outcome; Gangrene; Humans; Immunocompromised Host; Immunos | 2018 |
Serial semi-quantitative measurement of fecal calprotectin in patients with ulcerative colitis in remission.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Colitis, Ulcerative; Colonoscopy; Feces; | 2018 |
The adherence to the therapy in inflammatory bowel disease: beyond the number of the tablets.
Topics: Adolescent; Adult; Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerat | 2018 |
Multi Matrix System Mesalazine Plus Rectal Mesalazine in the Treatment of Mild to Moderately Active Ulcerative Proctitis.
Topics: Adolescent; Adult; Aged; Colitis, Ulcerative; Female; Humans; Male; Mesalamine; Middle Aged; Proctit | 2018 |
Ulcerative colitis followed by the development of typical intestinal Behçet disease: A case report.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Behcet Syndrome; Colitis, Ulce | 2018 |
Mesalazine-induced bullous fixed drug eruption.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Blister; Colitis, Ulcerative; Drug Eruptions; Foot D | 2018 |
Systemic allergic dermatitis caused by sodium metabisulfite in rectal enemas.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Colitis, Ulcerative; | 2018 |
Extensive colonic mucosal defect induced by mesalamine.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonoscopy; Drug Administratio | 2018 |
Onset of HLA-B27-associated diseases in diabetic patient during a period of religious fasting: A case report.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Diabetes Mellitus; Diagnostic Techniqu | 2018 |
Adherence, risk factors of non-adherence and patient's preferred treatment strategy of mesalazine in ulcerative colitis: multicentric observational study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcera | 2018 |
Long-term maintenance treatment of ulcerative colitis in eastern India: a 15-year follow-up.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colitis, Ulcerative; | 2018 |
Systems pharmacology approach reveals the antiinflammatory effects of
Topics: Ampelopsis; Animals; Anti-Inflammatory Agents; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease | 2018 |
A case of Behçet's disease with various gastrointestinal findings.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Behcet Syndrome; Colitis, U | 2018 |
The Frequency of Clinic Visits Was Not Associated with Medication Adherence or Outcome in Children with Inflammatory Bowel Diseases.
Topics: Adalimumab; Adolescent; Ambulatory Care Facilities; Analysis of Variance; Canada; Child; Cohort Stud | 2018 |
Antioxidant and anti-inflammatory effect of plumieride in dextran sulfate sodium-induced colitis in mice.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Apocynaceae; Cell Line; Colitis; Colitis, Ulcerativ | 2018 |
REDD1/Autophagy Pathway Is Associated with Neutrophil-Driven IL-1β Inflammatory Response in Active Ulcerative Colitis.
Topics: Adult; Autophagy; Colitis, Ulcerative; Colon; Crohn Disease; Extracellular Traps; Female; Humans; In | 2018 |
Fecal microbiota transplantation treatment for refractory ulcerative colitis with allergy to 5-aminosalicylic acid: A case report.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Hypersensitivity; Fecal Microbiot | 2018 |
A Case of Right-Sided Ulcerative Colitis with Mesalamine-Induced Hypersensitivity Reactions.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonoscopy; Drug Hypersensitivity; Fe | 2018 |
Mesalazine-induced Bronchiolitis Obliterans With Organising Pneumonia in a Young Patient With Ulcerative Colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bronchiolitis Obliterans; Colitis, Ulcerative; Female; Huma | 2018 |
Change of treatment modalities over the last 10 years in pediatric patients with inflammatory bowel disease in Switzerland.
Topics: Adolescent; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; C | 2018 |
Treatment Adherence in Patients with Ulcerative Colitis Is Dependent on the Formulation of 5-Aminosalicylic Acid.
Topics: Administration, Oral; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerativ | 2019 |
Methotrexate Monotherapy for Induction and Maintenance of Clinical Remission in Ulcerative Colitis: Dead on Arrival.
Topics: Colitis, Ulcerative; Humans; Mercaptopurine; Mesalamine; Methotrexate; Remission Induction | 2018 |
miR-206 as a Biomarker for Response to Mesalamine Treatment in Ulcerative Colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Colitis, Ulcerative; Female; Follow-Up S | 2019 |
A [Glyco]biomarker that Predicts Failure to Standard Therapy in Ulcerative Colitis Patients.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biomarker | 2019 |
Linear IgA bullous dermatosis associated with ulcerative proctitis: treatment challenge.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Immu | 2018 |
Cough in the Immunosuppressed Patient.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Cough; Female; Humans; Immunoco | 2019 |
The Association of Inflammatory Bowel Diseases with Autoimmune Disorders: A Report from the epi-IIRN.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Autoimmune Diseases; Biological Products; Case | 2019 |
Compositional and Temporal Changes in the Gut Microbiome of Pediatric Ulcerative Colitis Patients Are Linked to Disease Course.
Topics: Adolescent; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Preschoo | 2018 |
Crohn's Disease with Mesalazine Allergy that Was Difficult to Differentiate from Comorbid Ulcerative Colitis.
Topics: Adalimumab; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonoscopy; C | 2019 |
Towards more efficient assessment of ulcerative colitis drugs.
Topics: Colitis, Ulcerative; Drug Development; Humans; Mesalamine | 2019 |
Influence of Pharmaceutical Formulation on the Mucosal Concentration of 5-Aminosalicylic Acid and N-Acetylmesalamine in Japanese Patients with Ulcerative Colitis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Compound | 2019 |
Smoldering Multiple Myeloma Arising in Ulcerative Colitis.
Topics: Aged; Biopsy; C-Reactive Protein; Colitis, Ulcerative; Colonoscopy; gamma-Globulins; Humans; Immunog | 2018 |
The Profile of Human Milk Metabolome, Cytokines, and Antibodies in Inflammatory Bowel Diseases Versus Healthy Mothers, and Potential Impact on the Newborn.
Topics: Aminobutyrates; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; Case-Control Studies; | 2019 |
Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biological Therapy; Cohort Studies; Colitis, Ulcerat | 2019 |
Statin Use Is Associated With Improved Outcomes of Patients With Primary Sclerosing Cholangitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Cholagogues and Choleretics; Cholangit | 2019 |
Effect of Long-Term Mesalamine Therapy on Cancer-Associated Gene Expression in Colonic Mucosa of Patients with Ulcerative Colitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Biopsy; Cell Line, Tu | 2019 |
Mesalazine-related lung disease in a patient with ulcerative colitis: A case report.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Diagnosis, Differential; Female; | 2018 |
Colonic hypereosinophilia in ulcerative colitis may help to predict the failure of steroid therapy.
Topics: Adult; Anti-Inflammatory Agents; Colitis, Ulcerative; Colon; Colonic Diseases; Drug Therapy, Combina | 2018 |
Mesalazine treatment causing resolution of intracranial hypertension secondary to ulcerative colitis: A case report.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Diagnosis, Differential; Humans; Male; | 2018 |
Disease course of inflammatory bowel disease unclassified in a European population-based inception cohort: An Epi-IBD study.
Topics: Adult; Cohort Studies; Colectomy; Colitis, Ulcerative; Disease Progression; Europe; Female; Follow-U | 2019 |
Hematemesis due to Drug Allergy to Oral Prednisolone in a Patient with Ulcerative Colitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents; Colitis, Ulcerative; Drug Hypersensitivity; H | 2019 |
Efficacy of co-administration of modified apple polysaccharide and probiotics in guar gum-Eudragit S100 based mesalamine mini tablets: A novel approach in treating ulcerative colitis.
Topics: Animals; Body Weight; Colitis, Ulcerative; Colon; Drug Liberation; Galactans; Malus; Mannans; Mesala | 2019 |
Pyoderma gangrenosum of the breast.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Breast Diseases; Colitis, Ulcerative; Debridement; Fe | 2018 |
Ulcerative colitis mucosal transcriptomes reveal mitochondriopathy and personalized mechanisms underlying disease severity and treatment response.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Feces; Femal | 2019 |
Mesalazine-Induced Acute Focal Bacterial Nephritis-Like Features in Two Paediatric Patients with Ulcerative Colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Humans; Inflammatory Bowel Dise | 2019 |
Comparison of the efficiency of different enemas on patients with distal ulcerative colitis.
Topics: Adult; Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Enema; Female; Humans; | 2019 |
Management of Mild-to-Moderate Ulcerative Colitis: Patient Guide.
Topics: Colitis, Ulcerative; Comprehension; Disease Management; Drug Therapy, Combination; Female; Guideline | 2019 |
Mild-to-Moderate Ulcerative Colitis (UC) Clinical Decision Support Tool.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Decision Support Systems, Clini | 2019 |
Mild-to-Moderate Ulcerative Colitis Guideline.
Topics: Administration, Oral; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulce | 2019 |
Too Soon to Discard 5-ASAs?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biological Therapy; Colitis, Ulcerative; Humans; M | 2019 |
Recurrent mesalazine-induced myopericarditis in a patient with ulcerative colitis.
Topics: Colitis, Ulcerative; Drug Hypersensitivity; Humans; Male; Mesalamine; Myocarditis; Pericarditis; You | 2019 |
Xylan from Pineapple Stem Waste: a Potential Biopolymer for Colonic Targeting of Anti-inflammatory Agent Mesalamine.
Topics: Administration, Oral; Ananas; Animals; Anti-Inflammatory Agents, Non-Steroidal; Biopolymers; Chromat | 2019 |
Sex Differences in Treatment Strategies Among Patients With Ulcerative Colitis: A Retrospective Cohort Analysis of Privately Insured Patients.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Child; Cohort S | 2019 |
Response to Gupta and Hanauer.
Topics: Biological Therapy; Colitis, Ulcerative; Humans; Mesalamine | 2019 |
ACG Clinical Guideline: Ulcerative Colitis in Adults.
Topics: Adalimumab; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Budesonide; C | 2019 |
Mucosal 5-aminosalicylic acid concentration, drug formulation and mucosal microbiome in patients with quiescent ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arylamine N-Acetyltransferase; Colitis, Ulcerative; | 2019 |
Factors associated with low adherence to oral 5-aminosalicylic acid in patients with ulcerative colitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Cross-Sec | 2019 |
A case of nivolumab-associated colitis, which relapsed after mucosal healing and was then successfully treated with mesalazine.
Topics: Antineoplastic Agents, Immunological; Colitis, Ulcerative; Humans; Maintenance Chemotherapy; Male; M | 2019 |
Impact and risk factors of non-adherence to 5-aminosalicylates in quiescent ulcerative colitis evaluated by an electronic management system.
Topics: Adult; Colitis, Ulcerative; Electronic Prescribing; Female; Humans; Male; Medication Adherence; Mesa | 2019 |
Impact of Changing Treatment Strategies on Outcomes in Pediatric Ulcerative Colitis.
Topics: Adolescent; Australia; Child; Child, Preschool; Colectomy; Colitis, Ulcerative; Female; Gastrointest | 2019 |
Recurrent Eosinophilic Pneumonia Associated with Mesalazine Suppository in a Patient with Ulcerative Colitis.
Topics: Adult; Anti-Inflammatory Agents; Budesonide; Colitis, Ulcerative; Colonoscopy; Female; Humans; Mesal | 2019 |
Hyposensitization trial using salazosulfapyridine in a case of mesalamine intolerance.
Topics: Abdominal Pain; Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; | 2019 |
Celiac disease associated with ulcerative colitis.
Topics: Adalimumab; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Celiac Disease; Colit | 2019 |
Effectiveness of sigmoidoscopy for assessing ulcerative colitis disease activity and therapeutic response.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biologica | 2019 |
Editorial: mesalazine and mucosal microbiome in quiescent ulcerative colitis-what can we learn?
Topics: Aminosalicylic Acid; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Compounding; | 2019 |
Editorial: mesalamine and mucosal microbiome in quiescent ulcerative colitis-what can we learn? Authors' reply.
Topics: Aminosalicylic Acid; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Compounding; | 2019 |
Early onset first-episode psychosis during treatment with thalidomide for refractory ulcerative colitis: a case report.
Topics: Adolescent; Aftercare; Age of Onset; Anti-Inflammatory Agents, Non-Steroidal; Antipsychotic Agents; | 2019 |
Ulcerative colitis: epidemiology, clinical features and associated factors with surgical treatment in a tertiary hospital in Mexico.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Incidence | 2019 |
No increased risk of nephrotoxicity associated with 5-aminosalicylic acid in IBD: a population-based cohort and nested case-control study.
Topics: Aged; Aged, 80 and over; Case-Control Studies; Cohort Studies; Colitis, Ulcerative; Crohn Disease; D | 2019 |
Mucosal gene expression changes induced by anti-TNF treatment in inflammatory bowel disease patients.
Topics: Adult; ATP Binding Cassette Transporter, Subfamily B; Colitis, Ulcerative; Crohn Disease; Female; Ge | 2019 |
Regulatory mechanism of mesalazine on TLR4/MyD88-dependent pathway in mouse ulcerative colitis model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colitis, Ulcerative; Colon; Disease | 2019 |
A curious case of red-brown urine in a child taking mesalamine.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Color; Humans; Male; Mesal | 2013 |
Isolated fever induced by mesalamine treatment.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Fever; Gastrointestinal Agents; Humans | 2013 |
Long-term mesalamine maintenance in ulcerative colitis: which is more important? Adherence or daily dose.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Ster | 2013 |
Protection against peroxynitrite-induced DNA damage by mesalamine: implications for anti-inflammation and anti-cancer activity.
Topics: Anti-Inflammatory Agents; Anticarcinogenic Agents; Bacteriophage phi X 174; Colitis, Ulcerative; Col | 2013 |
Mesalamine: a rare constituent of urinary tract concretions.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Hydrogen-Ion Co | 2013 |
Topical therapy is underused in patients with ulcerative colitis.
Topics: Administration, Oral; Administration, Rectal; Administration, Topical; Adolescent; Adrenal Cortex Ho | 2014 |
Cornelia de Lange syndrome in association with ulcerative colitis: a case report.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Colitis, Ulcerative; De Lang | 2013 |
[Cholesterol emboli-induced ischemic colitis].
Topics: Aged; Anti-Inflammatory Agents; Colitis, Ischemic; Colitis, Ulcerative; Colonoscopy; Diagnostic Erro | 2013 |
What you see is not always what you get: raising the bar on clinical trial methodology in ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Male; Mesalamine | 2013 |
Bacterial immune interaction in experimental colitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Bacteria; Colitis, Ulcerative; Colon; Disease Mode | 2013 |
Letter: assessment of safety and efficacy of mesalazine in Indian patients with ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Male; Mesalamine | 2013 |
Chest pain in a 12-year-old girl with ulcerative colitis after therapy with mesalazine.
Topics: Anti-Inflammatory Agents; Cardiomegaly; Chest Pain; Child; Colitis, Ulcerative; Echocardiography; El | 2013 |
Acute pleuropericarditis in a patient with primary Sjögren's syndrome and quiescent ulcerative colitis in longstanding 5-aminosalicylic acid therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Mesalamine; Middle Age | 2013 |
Education and imaging. Gastrointestinal: Asymptomatic rectal perforation and massive pneumoretroperitoneum in patient with ulcerative colitis treated with mesalamine enemas.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Enema; Female; Humans; Intestina | 2013 |
Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells.
Topics: Adolescent; Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; beta Catenin; Blotting, | 2013 |
Modifiable factors associated with nonadherence to maintenance medication for inflammatory bowel disease.
Topics: Anxiety Disorders; Biological Factors; Cohort Studies; Colitis, Ulcerative; Crohn Disease; Depressiv | 2013 |
My treatment approach to the management of ulcerative colitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Colectomy; Colitis, Ul | 2013 |
Point-counterpoint: Are we overtreating patients with mild ulcerative colitis?
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colectomy; Colitis, Ulcerative; Colorectal Neoplasms | 2014 |
Treatment of children and adolescents with ulcerative colitis by adsorptive depletion of myeloid lineage leucocytes as monotherapy or in combination with low dose prednisolone after failure of first-line medications.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Blood Componen | 2013 |
Acute respiratory failure secondary to mesalamine-induced interstitial pneumonitis.
Topics: Acute Lung Injury; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Lung | 2013 |
Synthesis and evaluation of mutual azo prodrug of 5-aminosalicylic acid linked to 2-phenylbenzoxazole-2-yl-5-acetic acid in ulcerative colitis.
Topics: Acetates; Animals; Anti-Inflammatory Agents, Non-Steroidal; Benzoxazoles; Colitis, Ulcerative; Disea | 2013 |
The fate of indefinite and low-grade dysplasia in ulcerative colitis and primary sclerosing cholangitis colitis before and after liver transplantation.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cholangitis, Sclerosing; Colitis, Ulcerative; | 2013 |
5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colon; | 2013 |
Changes in medical treatment and surgery rates in inflammatory bowel disease: a nationwide cohort study 1979-2011.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Cohort Studies; Colitis, Ulcerative; Crohn | 2014 |
Cost and quality-adjusted life year differences in the treatment of active ulcerative colitis using once-daily 4 g or twice-daily 2g mesalazine dosing.
Topics: Administration, Oral; Colitis, Ulcerative; Cost-Benefit Analysis; Drug Administration Schedule; Gast | 2014 |
Are endoscopic endpoints reliable in therapeutic trials of ulcerative colitis?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Endoscopy, Gastrointestinal; Follow-Up | 2013 |
Alternate endpoints and clinical outcome assessments in pediatric ulcerative colitis registration trials.
Topics: Antibodies, Monoclonal; Colitis, Ulcerative; Humans; Infliximab; Mesalamine; Outcome Assessment, Hea | 2014 |
Peripheral T-cell lymphoma mimicking 5-aminosalicylate hypersensitivity in ulcerative colitis.
Topics: Adult; Colitis, Ulcerative; Diagnosis, Differential; Drug Hypersensitivity; Humans; Lymphoma, T-Cell | 2013 |
IL23R polymorphisms influence phenotype and response to therapy in patients with ulcerative colitis.
Topics: Adrenal Cortex Hormones; Adult; Age Factors; Anti-Inflammatory Agents; Antibodies, Monoclonal; Azath | 2014 |
Differences in the management of pediatric and adult onset ulcerative colitis--lessons from the joint ECCO and ESPGHAN consensus guidelines for the management of pediatric ulcerative colitis.
Topics: Adult; Age of Onset; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Az | 2014 |
Effect of inflammatory bowel disease therapies on immunogenicity of Mycobacterium paratuberculosis proteins.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non- | 2014 |
Ileorectal anastomosis in comparison with ileal pouch anal anastomosis in reconstructive surgery for ulcerative colitis--a single institution experience.
Topics: Abdominal Neoplasms; Adenocarcinoma; Adolescent; Adrenal Cortex Hormones; Adult; Anastomosis, Surgic | 2014 |
[Acute pericarditis associated with oral or topical mesalazine therapy in patients with ulcerative colitis].
Topics: Administration, Oral; Administration, Rectal; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agen | 2014 |
Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Colitis, Ulcerative; Feces; Female | 2014 |
The history of 5-ASA compounds and their use in ulcerative colitis--trailblazing discoveries in gastroenterology.
Topics: Animals; Anti-Inflammatory Agents; Colitis, Ulcerative; Diffusion of Innovation; Gastroenterology; G | 2013 |
Synergistic effect of interleukin-10-receptor variants in a case of early-onset ulcerative colitis.
Topics: Adenomatous Polyposis Coli; Age of Onset; Anti-Infective Agents; Azathioprine; beta Catenin; Biomark | 2013 |
Effectiveness of a hydroxynaphthoquinone fraction from Arnebia euchroma in rats with experimental colitis.
Topics: Animals; Anti-Inflammatory Agents; Boraginaceae; Colitis, Ulcerative; Colon; Disease Models, Animal; | 2013 |
Safety and efficacy of sodium hyaluronate (IBD98E) in the induction of clinical and endoscopic remission in subjects with distal ulcerative colitis.
Topics: Adjuvants, Immunologic; Administration, Topical; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aza | 2014 |
Mesalazine-probiotics beads for acetic acid experimental colitis: formulation and characterization of a promising new therapeutic strategy for ulcerative colitis.
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Survival; Colitis, Ulcerative; C | 2015 |
DUOX2 and DUOXA2 form the predominant enzyme system capable of producing the reactive oxygen species H2O2 in active ulcerative colitis and are modulated by 5-aminosalicylic acid.
Topics: Adenoma; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Cells, Cultured; Colitis, Ulcer | 2014 |
Efficacy of topical versus oral 5-aminosalicylate for treatment of 2,4,6-trinitrobenzene sulfonic acid-induced ulcerative colitis in rats.
Topics: Administration, Oral; Administration, Topical; Animals; Anti-Inflammatory Agents, Non-Steroidal; Col | 2014 |
Role of pharmacoepidemiology studies in addressing pharmacovigilance questions: a case example of pancreatitis risk among ulcerative colitis patients using mesalazine.
Topics: Acute Disease; Adverse Drug Reaction Reporting Systems; Anti-Inflammatory Agents, Non-Steroidal; Col | 2014 |
Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.
Topics: Adalimumab; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibo | 2014 |
Clinical features and course of ulcerative colitis diagnosed in asymptomatic subjects.
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Asymptomatic Diseases | 2014 |
Real-world assessment of therapy changes, suboptimal treatment and associated costs in patients with ulcerative colitis or Crohn's disease.
Topics: Adolescent; Adult; Anti-Inflammatory Agents; Colitis, Ulcerative; Crohn Disease; Female; Glucocortic | 2014 |
Ulcerative colitis flair induced by mesalamine suppositories hypersensitivity.
Topics: Abdominal Pain; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonoscopy; Di | 2014 |
Preparation and evaluation of colon adhesive pellets of 5-aminosalicylic acid.
Topics: Acrylic Resins; Adhesiveness; Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal | 2014 |
Rectal perforation caused by mesalazine enema in a patient with ulcerative colitis.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Enema; Female; | 2014 |
Three cases of mesalazine-induced pneumonitis with eosinophilia.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Lung; Mesa | 2014 |
Ulcerative colitis-induced myocarditis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Diagnosis, Differential; Drug Therapy, | 2014 |
Attitudes to mesalamine questionnaire: a novel tool to predict mesalamine nonadherence in patients with IBD.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Attitude to Health; Cohort Studies | 2014 |
[Clinical case of a combination of ulcerative colitis and alopecia areata].
Topics: Adult; Alopecia Areata; Anti-Inflammatory Agents, Non-Steroidal; Autoimmune Diseases; Colitis, Ulcer | 2013 |
The young patient with acute bloody diarrhoea.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathioprine; C-Reactive Pro | 2014 |
Fecal calprotectin-guided dosing of mesalamine in ulcerative colitis: concept proved but more data needed.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Feces; Humans; Leukocyte L1 Antigen Co | 2014 |
Mesalamine treatment mimicking relapse in a child with ulcerative colitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Drug T | 2014 |
Basophils increase in Crohn disease and ulcerative colitis and favor mesenteric lymph node memory TH17/TH1 response.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Basophils; Cell Movement; Cell Proliferation; Cell Survival | 2014 |
Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: results of the 2011 ECCO-EpiCom inception cohort.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Australia; Coho | 2014 |
Severe eosinophilic infiltration in colonic biopsies predicts patients with ulcerative colitis not responding to medical therapy.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Azathiopr | 2014 |
Inflammatory bowel disease in subfertile men and the effect of mesalazine on fertility.
Topics: Anti-Inflammatory Agents; Colitis, Ulcerative; Crohn Disease; Female; Fertility; Gastrointestinal Ag | 2014 |
Distinct kinetics in the frequency of peripheral CD4+ T cells in patients with ulcerative colitis experiencing a flare during treatment with mesalazine or with a herbal preparation of myrrh, chamomile, and coffee charcoal.
Topics: Adult; Aged; CD4-Positive T-Lymphocytes; Chamomile; Charcoal; Coffee; Colitis, Ulcerative; Female; F | 2014 |
[Differences in the prognosis according to the periods of diagnosis in ulcerative colitis].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Follow-Up Studies; Hosp | 2014 |
Ultra-high dose of mesalamine to treat steroid-dependent ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Dose-Response Relationship, Dru | 2014 |
Beneficial pharmacological interaction between thiopurine and mesalazine—never change a winning team.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Interactions; Erythrocytes | 2014 |
Ulcerative colitis and granulocyte-monocyte-apheresis: safety and efficacy of maintenance therapy during pregnancy.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Combined Modality Therapy; Fema | 2015 |
eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Computer-Assisted Instruc | 2014 |
eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Computer-Assisted Instruc | 2014 |
eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Computer-Assisted Instruc | 2014 |
eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Computer-Assisted Instruc | 2014 |
eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Computer-Assisted Instruc | 2014 |
eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Computer-Assisted Instruc | 2014 |
eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Computer-Assisted Instruc | 2014 |
eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Computer-Assisted Instruc | 2014 |
eHealth: individualization of mesalazine treatment through a self-managed web-based solution in mild-to-moderate ulcerative colitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Computer-Assisted Instruc | 2014 |
Protein-losing gastropathy caused by mesalamine in a patient with ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Endoscopy, Gastrointestinal; Female; H | 2014 |
[Chronic inflammatory bowel diseases. Strive for healing the mucosa, prevent overtreatment].
Topics: Budesonide; Clinical Trials as Topic; Colitis, Ulcerative; Crohn Disease; Dose-Response Relationship | 2014 |
The impact of timing and duration of thiopurine treatment on colectomy in ulcerative colitis: a national population-based study of incident cases between 1989-2009.
Topics: Adolescent; Adult; Aged; Colectomy; Colitis, Ulcerative; Drug Administration Schedule; Female; Gluco | 2015 |
Marine hydroquinone zonarol prevents inflammation and apoptosis in dextran sulfate sodium-induced mice ulcerative colitis.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Apoptosis; Cell Line; Colitis, Ulcerative; | 2014 |
Therapeutic efficacy of pH-dependent release formulation of mesalazine on active ulcerative colitis resistant to time-dependent release formulation: analysis of fecal calprotectin concentration.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutical; Col | 2014 |
Ulcerative colitis-associated pulmonary nodules with cavity formation successfully treated with mesalazine and granulocyte-monocyte apheresis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Diagnosis, Differential; Female; Granu | 2014 |
[Effect of qingchang huashi recipe on IL-17 in the plasma and colonic mucosa of patients with ulcerative colitis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drugs, Chinese Herbal; Humans; Immunol | 2014 |
Peroxisome proliferator-activated receptors family is involved in the response to treatment and mild clinical course in patients with ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Colitis, Ulcerative; Colon; Fe | 2014 |
Induction of clinical and colonoscopic remission of mild-to-moderate ulcerative colitis with budesonide MMX 9 mg: pooled analysis of two phase 3 studies.
Topics: Adolescent; Adult; Aged; Budesonide; Clinical Trials, Phase III as Topic; Colitis, Ulcerative; Colon | 2015 |
[Chemical proctitis due to ergotamine: «not always an ulcerative colitis»].
Topics: Acetaminophen; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Diagnosis, Differ | 2015 |
Novel pH-sensitive hydrogels for 5-aminosalicylic acid colon targeting delivery: in vivo study with ulcerative colitis targeting therapy in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colon; Drug Delivery Systems; | 2016 |
Acute pancreatitis secondary to long-term 5- aminosalicylic acid therapy in a patient with ulcerative colitis: a case-report.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Male; Me | 2014 |
[Favorable effects on health related quality of life].
Topics: Administration, Oral; Colitis, Ulcerative; Delayed-Action Preparations; Drug Administration Schedule | 2015 |
[Curcumin add-on therapy for ulcerative colitis].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Curcumin; Drug Therapy, Combina | 2015 |
Proposed case of mesalazine-induced cardiomyopathy in severe ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cardiomyopathies; Colitis, Ulcerative; Drug Substitu | 2015 |
Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-S | 2015 |
Thiopurine metabolites variations during co-treatment with aminosalicylates for inflammatory bowel disease: effect of N-acetyl transferase polymorphisms.
Topics: Adolescent; Anti-Inflammatory Agents; Arylamine N-Acetyltransferase; Azathioprine; Biotransformation | 2015 |
Gastroenterology case report of mesalazine-induced cardiopulmonary hypersensitivity.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Colitis, Ulcerative | 2015 |
Interactive medical case. A man with diarrhea and back pain.
Topics: Abdominal Pain; Adult; Anti-Inflammatory Agents; Back Pain; Colitis, Ulcerative; Colon; Colonoscopy; | 2015 |
Spicing up the Treatment of Mild to Moderate Ulcerative Colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Curcumin; Female; Humans; Male; Mesala | 2015 |
Combinatorial Intervention with Mesenchymal Stem Cells and Granulocyte Colony-Stimulating Factor in a Rat Model of Ulcerative Colitis.
Topics: Animals; Colitis, Ulcerative; Gene Expression Regulation; Granulocyte Colony-Stimulating Factor; Inf | 2015 |
Rectal hypersensitivity in patients with quiescent ulcerative colitis.
Topics: Adrenergic Uptake Inhibitors; Adult; Amitriptyline; Colitis, Ulcerative; Fecal Incontinence; Humans; | 2015 |
Chronic tubulointerstitial nephritis induced by 5-aminosalicylate in an ulcerative colitis patient: a rare but serious adverse event.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Colitis, Ulcerative; Humans; Kidney | 2015 |
Not a Usual Flare up of Ulcerative Colitis.
Topics: Anti-Inflammatory Agents; Biopsy; Colitis, Ulcerative; Colon; Eosinophilia; Gastrointestinal Agents; | 2015 |
Release of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various pH Levels.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutical; Colitis, U | 2015 |
BTLA associates with increased Foxp3 expression in CD4(+) T cells in dextran sulfate sodium-induced colitis.
Topics: Animals; CD4-Positive T-Lymphocytes; Colitis, Ulcerative; Colon; Dextran Sulfate; Disease Models, An | 2015 |
[What therapy for which patient?].
Topics: Azathioprine; Biological Products; Colitis, Ulcerative; Crohn Disease; Humans; Mesalamine; Precision | 2015 |
[Novaferon ameliorates dextran sulfate sodium-induced colitis and downregulates expression of TNF-α in mice].
Topics: Animals; Colitis, Ulcerative; Dextran Sulfate; Female; Interferons; Intestinal Mucosa; Mesalamine; M | 2015 |
[Cost-effectiveness assessment through theoretical cost-minimization analysis of the use of two gastro-resistant modified-release mesalazine formulations in the management of ulcerative colitis in Spain].
Topics: Colitis, Ulcerative; Cost-Benefit Analysis; Dosage Forms; Humans; Mesalamine; Models, Economic; Remi | 2016 |
Methodological Approach to Mesalazine Treatment in Patients with Mild-to-moderate Ulcerative Colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Internet; Male; Mesala | 2015 |
New Onset Bloody Diarrhea in a Liver Transplant Recipient. New Onset Bloody Diarrhea in a Liver Transplant Recipient.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Diarrhea; Gastrointestinal Hemorrhage; | 2015 |
Reply to Methodological Approach to Mesalazine Treatment in Patients with Mild-to-moderate Ulcerative Colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Internet; Male; Mesala | 2015 |
An unusual cause of febrile hepatitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Chemical and Drug Induced Liver Injury; Cholestasis | 2015 |
Risk matrix model for prediction of colectomy in a population-based study of ulcerative colitis patients (the IBSEN study).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biomarkers; Blood Sedimentation; C-Reactive Protein; Chi | 2015 |
Consecutive monitoring of faecal calprotectin during mesalazine suppository therapy for active rectal inflammation in ulcerative colitis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Colitis, Ulcerative; E | 2015 |
[Professional and private loadable -- despite ulcerative colitis: With Mezavant 1 × daily noticeable therapeutic success ].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Administration Schedule; Evidence | 2015 |
Successful treatment for ulcerative proctitis with rectal tacrolimus in an 8-year-old girl with intolerance to mesalamine.
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Female; | 2014 |
[Intracranial sinus venous thrombosis in ulcerative colitis. Report of one case].
Topics: Anti-Inflammatory Agents; Anticoagulants; Cerebral Infarction; Colitis, Ulcerative; Enoxaparin; Head | 2015 |
[The first oral budesonide: effective in an acute episode].
Topics: Acute Disease; Administration, Oral; Administration, Rectal; Budesonide; Colitis, Ulcerative; Drug A | 2015 |
Adherence to Rectal Mesalamine in Patients with Ulcerative Colitis.
Topics: Administration, Rectal; Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcera | 2015 |
Safety and Efficacy of AJM300, an Oral Antagonist of α4 Integrin, in Induction Therapy for Patients With Active Ulcerative Colitis.
Topics: Adrenal Cortex Hormones; Colitis, Ulcerative; Double-Blind Method; Humans; Integrin alpha4; Mesalami | 2015 |
Impact of Genetic Polymorphisms on 6-Thioguanine Nucleotide Levels and Toxicity in Pediatric Patients with IBD Treated with Azathioprine.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colitis, Ulcerative; Crohn Diseas | 2015 |
Curcumin for Inflammatory Bowel Disease: A Caution.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Curcumin; Female; Humans; Male; Mesala | 2016 |
What Role Do Immunomodulators Have in Assessing Response to Curcumin as an Add-on Therapy for Patients With Ulcerative Colitis?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Curcumin; Humans; Immunologic Factors; | 2016 |
Reply.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Curcumin; Female; Humans; Male; Mesala | 2016 |
[Adherence to oral 5-aminosalicylic acid by patients with quiescent ulcerative colitis: a questionnaire survey].
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; H | 2015 |
A case of diverticular colitis with lesions resembling ulcerative colitis and correlation of tumor necrosis factor-alpha staining with clinical manifestations.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis; Colitis, Ulcerative; Colonoscopy; Diverticulum, Co | 2015 |
Adrenomedullin Therapy in Patients with Refractory Ulcerative Colitis: A Case Series.
Topics: Adrenomedullin; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colitis, Ulcerat | 2016 |
Thromboembolism as an important complication of inflammatory bowel disease.
Topics: Adalimumab; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; C | 2016 |
EHealth: self-management in inflammatory bowel disease and in irritable bowel syndrome using novel constant-care web applications. EHealth by constant-care in IBD and IBS.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; Denmark; Diet Th | 2015 |
Letter: wide variation in faecal calprotectin values according to the assay.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Leukocyte L1 Antigen C | 2016 |
Letter: wide variation in faecal calprotectin values according to the assay - authors' reply.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Leukocyte L1 Antigen C | 2016 |
Addition of Berberine to 5-Aminosalicylic Acid for Treatment of Dextran Sulfate Sodium-Induced Chronic Colitis in C57BL/6 Mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Berberine; Cells, Cultured; Colitis, Ulcerative; C | 2015 |
New Zealand Society of Gastroenterology Guidelines for the Management of Refractory Ulcerative Colitis.
Topics: Adalimumab; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal, | 2015 |
Intestinal anti-inflammatory activity of the seeds of Raphanus sativus L. in experimental ulcerative colitis models.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Colitis, Ulcerative; Colon; Cytokines | 2016 |
[THREE CASES OF DRUG-INDUCED PNEUMONIA CAUSED BY MESALAZINE].
Topics: Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Mal | 2015 |
Increasing rate of inflammatory bowel disease: a 12-year retrospective study in NingXia, China.
Topics: Adolescent; Adult; Age Distribution; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; | 2016 |
Identifying predictors of low adherence in patients with inflammatory bowel disease.
Topics: Adult; Age Factors; Anti-Inflammatory Agents; Belgium; Case-Control Studies; Chi-Square Distribution | 2016 |
Garlic oil inhibits dextran sodium sulfate-induced ulcerative colitis in rats.
Topics: Allyl Compounds; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Antioxidants; | 2016 |
Circulating memory B cells and plasmablasts are associated with the levels of serum immunoglobulin in patients with ulcerative colitis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antigens, CD; B-Lymphocyte Subsets | 2016 |
Long-term Compliance with Oral 5-aminosalicylic Acid Therapy and Risk of Disease Recurrence in Patients with Ulcerative Colitis: A Population-based Cohort Study.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Colitis, | 2016 |
Mesalamine-induced myopericarditis - A case report.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Mesalamine; Pericardit | 2016 |
[Mesalazine-induced intersticial pneumonitis in patients with ulcerative colitis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Fibrosis; Humans; Lung Diseases, Inter | 2016 |
Effect of mucosal healing (Mayo 0) on clinical relapse in patients with ulcerative colitis in clinical remission.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; C | 2016 |
Confocal laser endomicroscopy in ulcerative colitis: a longitudinal study of endomicroscopic changes and response to medical therapy (with videos).
Topics: Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Case-Co | 2016 |
Clinical course and outcomes of diagnosing Inflammatory Bowel Disease in children 10 years and under: retrospective cohort study from two tertiary centres in the United Kingdom and in Italy.
Topics: Adalimumab; Adolescent; Adrenal Cortex Hormones; Age of Onset; Anti-Bacterial Agents; Anti-Inflammat | 2016 |
Medication Utilization and the Impact of Continued Corticosteroid Use on Patient-reported Outcomes in Older Patients with Inflammatory Bowel Disease.
Topics: Adrenal Cortex Hormones; Adult; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anxiety; | 2016 |
[Use of mesenchymal stem cells in the combination therapy of ulcerative colitis].
Topics: Adult; Anti-Inflammatory Agents; Colitis, Ulcerative; Colonoscopy; Combined Modality Therapy; Diseas | 2016 |
Ocular Toxoplasmosis Reactivation in a Patient With Inflammatory Bowel Disease Under Treatment With Azathioprine.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Chorioretinitis; Colitis, Ulcerative; | 2016 |
Achilles tendinitis as a rare extraintestinal manifestation of ulcerative colitis.
Topics: Achilles Tendon; Adult; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Colitis, Ulcerative; Colon, | 2016 |
Patients' knowledge and fear of colorectal cancer risk in inflammatory bowel disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Colectomy; Colitis, Ulcerat | 2016 |
Treatment Options and Outcomes of Pediatric IBDU Compared with Other IBD Subtypes: A Retrospective Multicenter Study from the IBD Porto Group of ESPGHAN.
Topics: Adolescent; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Biological Products; C | 2016 |
Increased levels of circulating platelet derived microparticles in Crohn's disease patients.
Topics: Adult; Annexin A5; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Cell-Derived Micro | 2016 |
Recurrence of Clostridium difficile Infection in Patients with Inflammatory Bowel Disease: The RECIDIVISM Study.
Topics: Adalimumab; Adult; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Clostridioides difficile; | 2016 |
Conventional treatment regimens for ulcerative colitis alleviate fatigue - an observational cohort study.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Biomarkers; C-Reactive Protein; Cohort Studies; Co | 2016 |
Curcumin improves regulatory T cells in gut-associated lymphoid tissue of colitis mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colon; Curcumin; Cytokines; D | 2016 |
The Effects of Active IBD During Pregnancy in the Era of Novel IBD Therapies.
Topics: Abortion, Spontaneous; Adult; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Colitis, Ulce | 2016 |
Low colectomy rate five years after diagnosis of ulcerative colitis. Results from a prospective population-based cohort in Sweden (ICURE) diagnosed during 2005-2009.
Topics: Adult; Aged; Aged, 80 and over; Colectomy; Colitis, Ulcerative; Disease Progression; Female; Humans; | 2016 |
Steroid dependency and trends in prescribing for inflammatory bowel disease - a 20-year national population-based study.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; Drug | 2016 |
Epidemiology of Inflammatory Bowel Disease from 1981 to 2014: Results from a Territory-Wide Population-Based Registry in Hong Kong.
Topics: Adolescent; Adult; Age of Onset; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn | 2016 |
Importance of the Evaluation of N-Acetyltransferase Enzyme Activity Prior to 5-Aminosalicylic Acid Medication for Ulcerative Colitis.
Topics: Adolescent; Adult; Aged; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arylamine N-Acetyltransfe | 2016 |
Ulcerative colitis associated with nephrotic syndrome after treatment with mesalazine developed into rectal carcinoma: a case study.
Topics: Adenocarcinoma; Adolescent; Antineoplastic Agents; Colitis, Ulcerative; Colonoscopy; Humans; Lymphat | 2016 |
Cancer in Elderly Onset Inflammatory Bowel Disease: A Population-Based Study.
Topics: Adrenal Cortex Hormones; Age of Onset; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroi | 2016 |
Sphingosine-1-phosphate receptor: a novel therapeutic target in ulcerative colitis.
Topics: Animals; Antibodies, Monoclonal; Colitis, Ulcerative; Disease Models, Animal; Humans; Mesalamine; Mi | 2016 |
Mesalazine allergy in a boy with ulcerative colitis: clinical usefulness of mucosal biopsy criteria.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Colitis, Ulcerative; Colon; Colonoscopy | 2016 |
Tailoring the mucoadhesive and sustained release characteristics of mesalamine loaded formulations for local treatment of distal forms of ulcerative colitis.
Topics: Adhesiveness; Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colon; Delayed- | 2016 |
Pattern of Inflammation on Surveillance Colonoscopy Does Not Predict Development of Colitis-associated Neoplasia.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Colitis, Ulcerative; Colonic N | 2016 |
Ozanimod Treatment for Ulcerative Colitis.
Topics: Colitis, Ulcerative; Humans; Mesalamine; Remission Induction; Sulfasalazine | 2016 |
Ozanimod Treatment for Ulcerative Colitis.
Topics: Colitis, Ulcerative; Humans; Mesalamine; Remission Induction; Sulfasalazine | 2016 |
Impact of Low Immunoglobulin G Levels on Disease Outcomes in Patients with Inflammatory Bowel Diseases.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Ste | 2016 |
Successful colonoscopic fecal microbiota transplantation for active ulcerative colitis: First report from India.
Topics: Adrenal Cortex Hormones; Adult; Azathioprine; Colitis, Ulcerative; Colonoscopy; Fecal Microbiota Tra | 2016 |
A Case of Thiopurine-Induced Acute Myocarditis in a Patient with Ulcerative Colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Atrial Fibrillation; Azathioprine; Cardiac Imaging Techniqu | 2016 |
Increased expression of markers of early atherosclerosis in patients with inflammatory bowel disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Atherosclerosis; Biomarkers; Carotid Arteries; Carot | 2017 |
Role of synbiotics in polysaccharide assisted colon targeted microspheres of mesalamine for the treatment of ulcerative colitis.
Topics: Animals; Body Weight; Colitis, Ulcerative; Colon; Diarrhea; Drug Carriers; Drug Liberation; Feces; F | 2017 |
Bullous Pyoderma Gangrenosum With Subungual Involvement Associated With Ulcerative Colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Colitis, Ulcerative; Gastrointestinal Agents | 2017 |
Ulcerative Colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Biosimilar Pharmaceutica | 2016 |
Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
Topics: Adalimumab; Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antirheumatic Agents; Colitis, | 2017 |
Colonic pseudopolyposis in inflammatory bowel disease.
Topics: Adult; Anemia, Iron-Deficiency; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Colitis, Ulcerative | 2017 |
What is the real-life maintenance mesalazine dose in ulcerative colitis?
Topics: Adult; Aged; Anti-Ulcer Agents; Colitis, Ulcerative; Drug Administration Schedule; Female; Humans; M | 2017 |
5-Aminosalicylate intolerance causing exacerbation in pediatric ulcerative colitis.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Disease Progression | 2017 |
The anti-inflammatory drug mesalamine targets bacterial polyphosphate accumulation.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biofilms; Cecum; Colitis, Ulcerative; Escherichia | 2017 |
Ocular Surface Epithelial Atypia Mimicking Squamous Neoplasia in Association With Ulcerative Colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Conjunctiva; Cornea; Diagnosis, | 2017 |
Subcorneal pustular dermatosis and episcleritis associated with poorly controlled ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colectomy; Colitis, Ulcerative; Disease Progression; Enema; | 2017 |
5-ASA-loaded SiO2 nanoparticles-a novel drug delivery system targeting therapy on ulcerative colitis in mice.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Cell Survival; Colitis, Ulcerative; Cyt | 2017 |
Late-Onset of Acute Severe Ulcerative Colitis: Clinical Case.
Topics: Acute Disease; Age of Onset; Azathioprine; Colitis, Ulcerative; Humans; Infliximab; Intestinal Mucos | 2017 |
Case Report: Acute Flair of Ulcerative Colitis during Pregnancy Is Still a Major Problem.
Topics: Adrenal Cortex Hormones; Adult; Colitis, Ulcerative; Disease Progression; Female; Humans; Infliximab | 2017 |
Interstitial nephritis associated with ulcerative colitis in monozygotic twins.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Diseases in Twins; Female; Humans; Mes | 2017 |
Invasive pulmonary aspergillosis in an immunocompromised patient with severe ulcerative colitis.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Immunocomp | 2017 |
The use of randomisation-based efficacy estimators in non-inferiority trials.
Topics: Administration, Intravenous; Administration, Oral; Anti-Inflammatory Agents; Bone Density Conservati | 2017 |
The use of randomisation-based efficacy estimators in non-inferiority trials.
Topics: Administration, Intravenous; Administration, Oral; Anti-Inflammatory Agents; Bone Density Conservati | 2017 |
The use of randomisation-based efficacy estimators in non-inferiority trials.
Topics: Administration, Intravenous; Administration, Oral; Anti-Inflammatory Agents; Bone Density Conservati | 2017 |
The use of randomisation-based efficacy estimators in non-inferiority trials.
Topics: Administration, Intravenous; Administration, Oral; Anti-Inflammatory Agents; Bone Density Conservati | 2017 |
Jianpi Qingchang decoction alleviates ulcerative colitis by inhibiting nuclear factor-κB activation.
Topics: Animals; Colitis; Colitis, Ulcerative; Colon; Dextran Sulfate; Drugs, Chinese Herbal; Inflammation; | 2017 |
Mesalamine desensitization in a patient with treatment refractory ulcerative colitis and aspirin and nonsteroidal anti-inflammatory drug hypersensitivity.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colitis, Ulcerative; Desensitization, Immun | 2017 |
[Treating distal ulcerative colitis intrarectally. Foam instead of enema, low volume rather than high volume].
Topics: Administration, Rectal; Budesonide; Colitis, Ulcerative; Enema; Humans; Hydrocortisone; Mesalamine; | 2008 |
Ulcerative colitis and PPAR gamma ligand. Is cardiac toxicity on the other side of the coin?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiovascular Diseases; Colitis, Ulcerative; Humans; Ligan | 2008 |
Treatment of inflammatory bowel disease: a role for hypnotherapy?
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; C | 2008 |
Ulcerative colitis with positivity for proteinase 3-antineutrophil cytoplasmic antibody.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antineutrophil Cytoplasmic; Colitis, Ulc | 2008 |
Mesalamine-induced pleuritis in a patient with ulcerative colitis.
Topics: Colitis, Ulcerative; Humans; Male; Mesalamine; Pleurisy; Young Adult | 2009 |
Severe chest pain in a pediatric ulcerative colitis patient after 5-aminosalicylic acid therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chest Pain; Child; Colitis, Ulcerative; Colonoscopy; Drug H | 2008 |
Mea culpa.
Topics: Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; | 2008 |
Changes of the peptide YY levels in the intestinal tissue of rats with experimental colitis following oral administration of mesalazine and prednisolone.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Co | 2008 |
Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Cost-Benefit Analysis; Humans; Markov | 2008 |
Ulcerative colitis associated with leukocytoclastic vasculitis of the skin.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Male; Mesalamine; Vascu | 2009 |
The cost-utility of high dose oral mesalazine for moderately active ulcerative colitis.
Topics: Administration, Oral; Colitis, Ulcerative; Cost-Benefit Analysis; Decision Trees; Drug Administratio | 2008 |
Probiotic Escherichia coli Nissle 1917 (EcN) for successful remission maintenance of ulcerative colitis in children and adolescents: an open-label pilot study.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Dose-Response Relat | 2008 |
What is the optimal maintenance treatment for ulcerative colitis?
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Colitis, U | 2008 |
How long is it advisable to prolong maintenance treatment of patients with ulcerative colitis?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Humans; Mesalami | 2008 |
Is it always therapeutically important to distinguish between Crohn's disease and ulcerative colitis?
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antibodies, Monoclonal; Az | 2008 |
What is the optimal therapy for severe ulcerative colitis?
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Colectomy; Colitis, | 2008 |
Duration of remission and long-term prognosis according to the extent of disease in patients with ulcerative colitis on continuous mesalamine treatment.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonosco | 2008 |
Co-prescribing azathiopurine or 6-mercaptopurine and 5-aminosalicylate compounds in ulcerative colitis.
Topics: Adult; Colitis, Ulcerative; Drug Therapy, Combination; Female; Humans; Immunosuppressive Agents; Mal | 2009 |
Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Chemoprevention; Child; Cohort Stu | 2008 |
Quantitive cytokine mRNA expression profiles in the colonic mucosa of patients with steroid naïve ulcerative colitis during active and quiescent disease.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Colitis, Ulcerative; C | 2009 |
Case of linear IgA bullous dermatosis-involved ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Autoantibodies; Autoimmune Diseases; Colitis, Ulcera | 2009 |
Crohn's disease, hepatosplenic T-cell lymphoma and no biological therapy: are we barking up the wrong tree?
Topics: Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug Therapy, Combination; Glucocorticoids; Humans | 2009 |
[Relapse rates of ulcerative colitis in remission and factors related to relapse].
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Azathioprine; Chronic Disease | 2008 |
[Relapse of ulcerative colitis in remission].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Azathioprine; Chronic Disease; Colitis, Ul | 2008 |
[A case of acute pancreatitis induced by multiple drugs in a patient with ulcerative colitis].
Topics: Acute Disease; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Azathioprine; Colitis, Ulce | 2008 |
Mesalamine hypersensitivity and Kounis syndrome in a pediatric ulcerative colitis patient.
Topics: Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Drug Hypersen | 2008 |
Fibrosing colonopathy associated with treatment with enteric-coated mesalazine pills.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Colon; Colonoscopy; Fibrosis; H | 2009 |
Comment: Mesalamine-associated hypersensitivity myocarditis in ulcerative colitis and the Kounis syndrome.
Topics: Colitis, Ulcerative; Coronary Vasospasm; Drug Hypersensitivity; Humans; Mesalamine; Myocarditis | 2009 |
[Severe tubulo-interstitial nephritis secondary to 5-ASA].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Kidney Failure, | 2009 |
Ulcerative colitis.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Causality; Colitis, Ulcerative; C | 2008 |
All that bleeds is not infliximab-refractory ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Monoclonal; Asian People; Colitis, Ulcerative; Drug Res | 2009 |
A dynamic model of colonic concentrations of delayed-release 5-aminosalicylic acid (Asacol).
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colon; Computer Simulation; Delayed-Ac | 2009 |
New-onset ulcerative colitis in a patient treated with the anti-CD11a monoclonal antibody efalizumab.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibo | 2009 |
Renal effects of long-term treatment with 5-aminosalicylic acid.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcera | 2009 |
Use of new once-daily 5-aminosalicylic acid preparations in the treatment of ulcerative colitis: Is there anything new under the sun?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Colitis, Ulcerative; Drug Adminis | 2009 |
Severe cholestatic acute hepatitis following azathioprine therapy in a patient with ulcerative pancolitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Cholestasis, Intrahepatic; Colitis, Ulcerativ | 2009 |
[Myopericarditis in a patient with ulcerative colitis treated with mesalazine].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Male; Mesalamine; Pericarditis | 2010 |
Mesalamine enema-induced exacerbation of ulcerative colitis.
Topics: Adult; Colitis, Ulcerative; Disease Progression; Enema; Female; Humans; Mesalamine | 2009 |
Cost effectiveness of ulcerative colitis surveillance in the setting of 5-aminosalicylates.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colono | 2009 |
Incidence and short-term implications of prepouch ileitis following restorative proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis.
Topics: Adult; Aged; Anti-Infective Agents; Anti-Inflammatory Agents; Budesonide; Ciprofloxacin; Colitis, Ul | 2009 |
Beta-catenin pathway in ulcerative colitis-associated colorectal cancer and therapeutic implication.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; beta Catenin; Cell Transformation, Neoplastic; Col | 2009 |
Development of a Web-based concept for patients with ulcerative colitis and 5-aminosalicylic acid treatment.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anxiety; Colitis, Ulcerative; Computer-Assiste | 2010 |
A 38-year-old with recurrent colitis. Is it noncompliance?
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Health Knowledge, Attitudes, Pr | 2009 |
[A case of mesalazine-induced lung injury improved by only discontinuation of mesalazine].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Lung Diseases; Mesalam | 2009 |
Severe skeletal muscle damage following the administration of mesalazine to a patient with ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Female; Humans; Mesalamine; Mus | 2009 |
Course of inflammatory bowel disease in patients infected with human immunodeficiency virus.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiretroviral Therapy, Highly Active; Azathioprine; | 2010 |
De novo inflammatory bowel disease after pediatric orthotopic liver transplant: a case report.
Topics: Adolescent; Anti-Inflammatory Agents; Biopsy; Chronic Disease; Colitis, Ulcerative; Colon; Colonosco | 2009 |
Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: novel molecular mechanism for therapeutic action of mesalamine.
Topics: Angiostatins; Animals; Anti-Inflammatory Agents, Non-Steroidal; Blotting, Western; Colitis, Ulcerati | 2009 |
An investigation of medication adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis, using self-report and urinary drug excretion measurements.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Colitis, Ulcerative; Female; Humans; In Vitro Techniques | 2009 |
Accidentally ASCENDing into comparative effective research for inflammatory bowel disease.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Comparative Effe | 2009 |
Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; beta Catenin; Biopsy; Cell Proliferation; Colitis, | 2010 |
Asian perspectives in the management of inflammatory bowel disease: findings from a recent survey.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Asia; Attitude of Health Personnel; Colitis, Ulce | 2010 |
[Mesalazine-induced acute pericarditis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chest Pain; Colitis, Ulcerative; Diagnosis, Differential; H | 2010 |
A dynamic model of once-daily 5-aminosalicylic acid predicts clinical efficacy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colon; Computer Simulation; Drug Admin | 2010 |
Altered mRNA expression of telomere binding proteins (TPP1, POT1, RAP1, TRF1 and TRF2) in ulcerative colitis and Crohn's disease.
Topics: Azathioprine; Biomarkers, Tumor; Chromosomal Instability; Colitis, Ulcerative; Colon; Colonic Neopla | 2010 |
Telephone nurse counseling for medication adherence in ulcerative colitis: a preliminary study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Cognition; Colitis, Ulcerative; Counseling; Em | 2010 |
Development and characterization of colon specific drug delivery system bearing 5-ASA and Camylofine dihydrochloride for the treatment of ulcerative colitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; Chitosan; Colitis, Ulcera | 2010 |
A cost-effectiveness analysis of MMX mesalazine compared with mesalazine in the treatment of mild-to-moderate ulcerative colitis from a UK perspective.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Confidence Intervals; Cost-Benefit Ana | 2010 |
Combinational effect of low-dose oral corticosteroid and mizoribine for ulcerative colitis in a patient with systemic sclerosis.
Topics: Adrenal Cortex Hormones; Antibodies, Antinuclear; Colitis, Ulcerative; Drug Therapy, Combination; Es | 2010 |
Ulcerative colitis in Madrid, Spain: current management.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Cohort Studies; Colectomy; Colitis, Ul | 2010 |
Azathioprine-induced hypersensitivity hepatitis: tolerance to 6-mercaptopurine.
Topics: Acute Disease; Azathioprine; Chemical and Drug Induced Liver Injury; Colitis, Ulcerative; Drug Hyper | 2010 |
[Interstitial pneumonia related to mesalamine].
Topics: Administration, Oral; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulce | 2010 |
[Drug therapy of Crohn's disease: slowly increase or start aggressively right away?].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathiopr | 2010 |
Artrofoon as alternative preparation in the treatment of uncomplicated forms of nonspecific ulcerative colitis.
Topics: Adolescent; Adult; Aged; Antibodies, Monoclonal; Colitis, Ulcerative; Female; Humans; Male; Mast Cel | 2009 |
Preparation of budesonide-dextran conjugates using glutarate spacer as a colon-targeted drug delivery system: in vitro/in vivo evaluation in induced ulcerative colitis.
Topics: Administration, Oral; Anhydrides; Animals; Anti-Inflammatory Agents; Budesonide; Colitis, Ulcerative | 2011 |
Mesalazine-induced multi-organ hypersensitivity.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Hypersensitivity; Humans; | 2010 |
[Transplantation of allogeneic mesenchymal stem cells from the bone marrow increases duration of remission and reduces the risk of ulcerative colitis relapse].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bone Marrow Cells; Colitis, Ulcerative; Female; Glucocortic | 2010 |
Mesalamine lung toxicity.
Topics: Alveolitis, Extrinsic Allergic; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Dyspne | 2010 |
Mesalamine (5-aminosalicylic acid) therapy well tolerated in a patient with aspirin hypersensitivity and ulcerative colitis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colitis, Ulcerative; Cross Reactions; Drug H | 2011 |
Mesalazine induced drug fever.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Fever; Gastrointestinal Agents; Humans | 2010 |
Once-daily mesalamine granules for ulcerative colitis.
Topics: Abdominal Pain; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Colitis, Ulcerati | 2010 |
[Differential diagnosis problem of pulmonary changes in ulcerative colitis].
Topics: Alveolitis, Extrinsic Allergic; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Diagno | 2010 |
Pyodermatitis-pyostomatitis vegetans after subtotal colectomy for ulcerative colitis.
Topics: Azathioprine; Colectomy; Colitis, Ulcerative; Colonoscopy; Cyclosporine; Diagnosis, Differential; Fe | 2010 |
An unusual case of mesalazine intoxication: oral and rectal overloading of the rectal suppository form.
Topics: Administration, Oral; Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Ag | 2011 |
[A case of ulcerative colitis found in a patient whose parent has Crohn's disease].
Topics: Colitis, Ulcerative; Colonoscopy; Crohn Disease; Female; Genetic Predisposition to Disease; Humans; | 2010 |
[Tubulo-interstitial nephritis in inflammatory bowel disease: extra-intestinal manifestation or drug toxicity?].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Colitis, Ulcerative; Crohn Disease; | 2010 |
[Remission of ulcerative colitis after appendectomy: a case report].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Appendectomy; Colitis, Ulcerative; Colonoscopy; Huma | 2010 |
Opportunistic streptococcal gastritis in a patient with ulcerative colitis mimicking gastric involvement by inflammatory bowel disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Azathioprine; Breath Tests; Colitis, Ulcerative; Dru | 2010 |
New desensitization regimen with mesalamine granules in a patient with ulcerative colitis and mesalamine intolerance.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Hypersensitivity; Humans; | 2011 |
Asacol®-induced neutropenia resolution without the use of granulocyte colony-stimulating factor.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Granulocyte Colony-Stimulating F | 2010 |
Does treatment schedule matter? Once daily versus divided doses of 5-ASAs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Colitis, Ulcerative; Dose-Respons | 2010 |
[A case of inferior vena cava thrombosis and acute pancreatitis in a patient with ulcerative colitis].
Topics: Acute Disease; Amylases; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Cholangiopancreato | 2010 |
Reporting of relapse rates in a trial of mesalazine for ulcerative colitis.
Topics: Colitis, Ulcerative; Humans; Mesalamine; Mucous Membrane; Randomized Controlled Trials as Topic | 2010 |
Oral 5-aminosalicylic acid therapy for mild-to-moderate ulcerative colitis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutical; Colitis, U | 2010 |
In-vitro characterization of 5-aminosalicylic acid release from MMX mesalamine tablets and determination of tablet coating thickness.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Gastrointestinal Motility; Gastrointes | 2011 |
Six ulcerative colitis patients with refractory symptoms co-infective with Blastocystis hominis in China.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antiprotozoal Agents; Blastocystis hominis; Blastocy | 2011 |
Mesalazine vanishing time from rectal mucosa following its topical administration.
Topics: Administration, Oral; Administration, Rectal; Adult; Anti-Inflammatory Agents, Non-Steroidal; Biopsy | 2010 |
Impact of a patient-support program on mesalamine adherence in patients with ulcerative colitis--a prospective study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Colitis, Ulcerative; Female; Humans; | 2010 |
Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on ulcerative colitis: a real-life survey in Spain.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Colitis, Ulcerative; Cross-Sectional Studies; Eur | 2010 |
Unilateral balsalazide-induced eosinophilic pneumonia in an ulcerative colitis patient.
Topics: Adult; Biopsy; Colitis, Ulcerative; Female; Gastrointestinal Agents; Humans; Mesalamine; Phenylhydra | 2010 |
Possible role of early transabdominal ultrasound in patients undergoing cytapheresis for active ulcerative colitis.
Topics: Adrenal Cortex Hormones; Adult; Aged; Colitis, Ulcerative; Colon; Cytapheresis; Female; Humans; Immu | 2011 |
[Gastroenterology and hepatology. Using established therapies].
Topics: Anti-Inflammatory Agents; Clinical Trials as Topic; Colitis, Ulcerative; Combined Modality Therapy; | 2010 |
Outcome following thiopurine use in children with ulcerative colitis: a prospective multicenter registry study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Child; Colitis, Ulcerative; Female; Humans; I | 2011 |
The actin-bundling protein fascin is overexpressed in inflammatory bowel disease and may be important in tissue repair.
Topics: Actins; Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Butyrates; Carrier Proteins; Cell L | 2011 |
VSL#3 and remission in active ulcerative colitis: larger studies required.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Bifidobacterium; Colitis, Ulcerative; Diet; D | 2011 |
5-aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Cohort Studies; Colitis, Ulcer | 2011 |
Outcome of sporadic adenomas and adenoma-like dysplasia in patients with ulcerative colitis undergoing polypectomy.
Topics: Adenoma; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Cell T | 2012 |
Inflammatory bowel disease characteristics in Hispanic children in Texas.
Topics: Adolescent; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Black or African American; Body Ma | 2012 |
Inflammatory bowel disease unclassified.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anastomosis, Surgical; Biopsy; Colitis, Ulcerative | 2011 |
Endoscopic mucosal healing in ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonoscopy; Dose-Response Relationshi | 2011 |
A case of acne fulminans in a patient with ulcerative colitis successfully treated with prednisolone and diaminodiphenylsulfone: a literature review of acne fulminans, rosacea fulminans and neutrophilic dermatoses occurring in the setting of inflammatory
Topics: Acne Vulgaris; Anti-Inflammatory Agents; Biopsy; Cefozopran; Cephalosporins; Colitis, Ulcerative; Da | 2011 |
Evolution and predictive factors of relapse in ulcerative colitis patients treated with mesalazine after a first course of corticosteroids.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Child; Co | 2011 |
Female patients suffering from inflammatory bowel diseases are treated less frequently with immunosuppressive medication and have a higher disease activity: a subgroup analysis of a large multi-centre, prospective, internet-based study.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; A | 2011 |
Therapy modifies HLA-G secretion differently in Crohn's disease and ulcerative colitis patients.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Biomarkers; Cells, C | 2011 |
Leucocytoclastic vasculitis in severe ulcerative colitis.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Col | 2011 |
Cost effectiveness of ulcerative colitis treatment in Germany: a comparison of two oral formulations of mesalazine.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Cost-Benefit Ana | 2011 |
Steroid dependency and pediatric inflammatory bowel disease in the era of immunomodulators--a population-based study.
Topics: Adolescent; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Child; C | 2011 |
Mesalazine-induced bronchiolitis obliterans organizing pneumonia (BOOP) in a patient with ulcerative colitis and primary sclerosing cholangitis.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Cholangitis, Sclerosing; Colitis, Ulcerative; C | 2011 |
[Pharmacotherapy in patients with ulcerative colitis].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Anti-Inflammatory Agents; Biological Products; Col | 2011 |
On the cost-effectiveness of the use of probiotics in inflammatory bowel disease.
Topics: Antibodies, Monoclonal; Azathioprine; Colectomy; Colitis, Ulcerative; Humans; Infliximab; Mesalamine | 2011 |
Role of fecal calprotectin in the diagnosis and treatment of segmental colitis associated with diverticulosis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Case-Control Studies; Colitis, Ulcerative | 2011 |
Prognostic significance of endoscopic remission in patients with active ulcerative colitis treated with oral and topical mesalazine: a prospective, multicenter study.
Topics: Administration, Oral; Administration, Topical; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; | 2012 |
[Two cases of drug-induced intrathoracic lesions caused by mesalazine in patients with ulcerative colitis].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Hypersensitivity; Female; | 2011 |
Early symptomatic response and mucosal healing with mesalazine rectal suspension therapy in active distal ulcerative colitis--additional results from two controlled studies.
Topics: Administration, Oral; Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infl | 2011 |
Twelve-month persistency with oral 5-aminosalicylic acid therapy for ulcerative colitis: results from a large pharmacy prescriptions database.
Topics: Administration, Oral; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Child; Child, Pres | 2011 |
Baicalin down-regulates the expression of macrophage migration inhibitory factor (MIF) effectively for rats with ulcerative colitis.
Topics: Animals; Chemokine CCL2; Chemokine CCL20; Colitis, Ulcerative; Drug Evaluation, Preclinical; Drugs, | 2012 |
Inaccuracies concerning Salofalk granules.
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Delivery | 2011 |
Mesalazine granules are superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis - a pooled analysis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; H | 2011 |
Successful treatment of pediatric immune thrombocytopenic purpura associated with ulcerative colitis.
Topics: Anemia; Child; Colitis, Ulcerative; Female; Gastrointestinal Hemorrhage; Humans; Mesalamine; Prednis | 2011 |
In vitro degradation and drug-release properties of water-soluble chitosan cross-linked oxidized sodium alginate core-shell microgels.
Topics: Administration, Oral; Alginates; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cell De | 2012 |
Nephrotic syndrome and Moya-moya syndrome in a patient with ulcerative colitis.
Topics: Anti-Inflammatory Agents; Colitis, Ulcerative; Cyclosporine; Fatal Outcome; Humans; Male; Mesalamine | 2012 |
Avascular necrosis of the knees and ulcerative colitis.
Topics: Adrenal Cortex Hormones; Adult; Aspirin; Cholecalciferol; Colitis, Ulcerative; Cyclosporine; Humans; | 2011 |
Analysis of current treatments used in clinical practice in a pediatric summer camp population for children with inflammatory bowel disease.
Topics: Adolescent; Adrenal Cortex Hormones; Child; Child, Preschool; Colitis, Ulcerative; Crohn Disease; Fe | 2012 |
Patient preferences for first-line oral treatment for mild-to-moderate ulcerative colitis: a discrete-choice experiment.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Choice Behavior; Colitis, Ulce | 2012 |
Long-term outcome of ulcerative colitis in patients who achieve clinical remission with a first course of corticosteroids.
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; A | 2012 |
Incidence of and impact of medications on colectomy in newly diagnosed ulcerative colitis in the era of biologics.
Topics: Adult; Colectomy; Colitis, Ulcerative; Combined Modality Therapy; Female; Follow-Up Studies; Humans; | 2012 |
Are mesalazine granules superior to Eudragit-L-coated mesalazine tablets for induction of remission in distal ulcerative colitis?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Male; Mesalamine; Poly | 2012 |
[A case of lung injury induced by long-term administration of mesalazine].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Male; Mesalamine; Middle Aged; | 2011 |
Comment on Moshkovska et al.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Male; Medication Adher | 2013 |
Response to the letter of Gifford and Moss.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Male; Medication Adher | 2013 |
Long-term outcome of patients with distal ulcerative colitis and inflammation of the appendiceal orifice.
Topics: Administration, Oral; Administration, Topical; Adult; Aged; Aminosalicylic Acids; Anti-Inflammatory | 2011 |
The influence of 5-aminosalicylic acid on the progression of colorectal adenomas via the β-catenin signaling pathway.
Topics: Adenoma; beta Catenin; Cadherins; Cell Line, Tumor; Colitis, Ulcerative; Colorectal Neoplasms; Cycli | 2012 |
Long term follow-up of appendiceal and distal right-sided colonic inflammation.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Appendicitis; Colitis, Ulcerative; Colonoscopy; Dise | 2012 |
Hsp10, Hsp70, and Hsp90 immunohistochemical levels change in ulcerative colitis after therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chaperonin 10; Colitis, Ulcerative; Down-Regulation; HSP70 | 2011 |
Asymptomatic urinary anomalies, hematuria and proteinuria, in patients with inflammatory bowel disease. Preliminary study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; Diagnosis, Diffe | 2011 |
[FAQs in chronic inflammatory bowel diseases. This way your patient stays in remission].
Topics: Anti-Inflammatory Agents; Antibodies, Monoclonal; Azathioprine; Colitis, Ulcerative; Colonoscopy; Cr | 2011 |
Evaluation of fecal myeloperoxidase as a biomarker of disease activity and severity in ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers; Biopsy; Colitis, Ulcerative; Colonoscopy | 2012 |
[Guidelines for the management of ulcerative colitis].
Topics: Administration, Oral; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Monoclonal; Ant | 2012 |
Long-term clinical impact of early introduction of granulocyte and monocyte adsorptive apheresis in new onset, moderately active, extensive ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Femal | 2012 |
The effects of liver transplantation on the clinical course of colitis in ulcerative colitis patients with primary sclerosing cholangitis.
Topics: Adult; Aged; Cholangitis, Sclerosing; Cohort Studies; Colectomy; Colitis, Ulcerative; Female; Follow | 2012 |
Recurrence of myocarditis after mesalazine treatment for ulcerative colitis: a case report.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Male; Mesalamine; Myocarditis; | 2013 |
The impact of MMX mesalazine on disease-specific health-related quality of life in ulcerative colitis patients.
Topics: Adult; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Coli | 2012 |
Ulcerative colitis.
Topics: Anecdotes as Topic; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Colitis, Ulcerative; D | 2012 |
Cost utility of inflammation-targeted therapy for patients with ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Health Care Costs; Humans; Infl | 2012 |
A patient with ulcerative colitis and central serous chorioretinopathy--a therapeutic dilemma.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Central Serous Chorioretinopathy; | 2013 |
Simulated comparison of topical and oral formulations of 5-aminosalicylate for the treatment of ulcerative colitis.
Topics: Administration, Oral; Administration, Topical; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colit | 2013 |
Ulcerative colitis impairs the acylethanolamide-based anti-inflammatory system reversal by 5-aminosalicylic acid and glucocorticoids.
Topics: Adolescent; Adult; Aged; Amidohydrolases; Anti-Inflammatory Agents; Colitis, Ulcerative; Colon; Etha | 2012 |
Mesalazine-induced interstitial nephritis in a patient with ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Kidney; Male; Mesalamin | 2012 |
Pill impaction mimicking appendicitis in ulcerative colitis.
Topics: Abdominal Pain; Appendicitis; Colitis, Ulcerative; Diagnosis, Differential; Endoscopy, Gastrointesti | 2012 |
Resource utilization during pediatric to adult transfer of care in IBD.
Topics: Adolescent; Ambulatory Care; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Azathi | 2013 |
Mucosal expression of basic fibroblastic growth factor, Syndecan 1 and tumor necrosis factor-alpha in diverticular disease of the colon: a case-control study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Case | 2012 |
[Optimizing antidepressant pharmacotherapy in a case of inflammatory bowel disease and major depression].
Topics: Alleles; Anti-Inflammatory Agents; Antidepressive Agents, Tricyclic; Colitis, Ulcerative; Combined M | 2012 |
Treatment of new-onset ulcerative colitis and ulcerative proctitis: a retrospective study.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Ster | 2012 |
Differential diagnosis and management of histologic eosinophilic colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Asthma; Blastocystis hominis; Blastocystis Infections; Coli | 2013 |
Commentary: impact of MMX mesalazine on health-related quality of life in ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Male; Mesalamine; Qual | 2012 |
Higher apoptosis index and proliferation index in colonocytes of patients with ulcerative colitis in remission.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; bcl-2-Associated X Protein; Cell Prolifera | 2012 |
Outcome following aminosalicylate therapy in children newly diagnosed as having ulcerative colitis.
Topics: Adolescent; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcera | 2013 |
The economics of mesalazine in active ulcerative colitis and maintenance in the Netherlands.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Mesalami | 2012 |
Long-term oral mesalazine adherence and the risk of disease flare in ulcerative colitis: nationwide 10-year retrospective cohort from the veterans affairs healthcare system.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Ster | 2012 |
[Probiotics in gastrointestinal diseases].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Combined Modality Therapy; Coop | 2012 |
National differences in ulcerative colitis experience and management among patients from five European countries and Canada: an online survey.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Attitude of Health Personnel; Attitude to Health; Ca | 2013 |
The prevalence of inflammatory bowel disease in an Israeli Arab population.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arabs; Arthralgia; Arthritis; Chil | 2013 |
Letter: real-life management of new onset ulcerative colitis and proctitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Glucocorticoids; Humans; Male; | 2012 |
[Optimization of cell therapy in patients with inflammatory bowel diseases].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cell Transplantation; Colitis, Ulcerative; Glucocort | 2012 |
Association between oral 5-ASA adherence and health care utilization and costs among patients with active ulcerative colitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcera | 2012 |
[A treatment indicator revision plan of the ulcerative colitis].
Topics: Blood Component Removal; Colitis, Ulcerative; Humans; Immunologic Factors; Mesalamine; Practice Guid | 2012 |
Preparation and evaluation of mesalamine collagen in situ rectal gel: a novel therapeutic approach for treating ulcerative colitis.
Topics: Administration, Rectal; Animals; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colla | 2013 |
[Rescue therapy with sulfasalazine prior to immunosuppressive or biological agents in ulcerative colitis poorly controlled with mesalazine].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biological Factors; Colitis, Ulcerative; Female; Humans; Im | 2013 |
Clinical experience with adalimumab in anti-TNF-naïve patients with ulcerative colitis.
Topics: Adalimumab; Adult; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal, Humanized; Azath | 2013 |
Conveying medication benefits to ulcerative colitis patients and effects on patient attitudes regarding thresholds for adherence.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Data Display; Female; Hea | 2013 |
A random urine test can identify patients at risk of mesalamine non-adherence: a prospective study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Area Under Curve; Biomarkers; Chromatography, | 2013 |
Celiac disease in a child with ulcerative colitis: a possible genetic association.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Celiac Disease; Child; Colitis, Ulcerative; Diet, Gluten-Fr | 2013 |
Pure white cell aplasia induced by mesalazine in a patient with ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Chemotherapy-Induced Febrile Neutropenia; Colitis, Ulcerati | 2013 |
5-ASA induced recurrent myopericarditis and cardiac tamponade in a patient with ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cardiac Tamponade; Colitis, Ulcerative; Female; Humans; Mes | 2013 |
Inducing remission of ulcerative colitis: are clinicians better equipped than ever?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Colitis, Ulcerative; Glucocorticoid | 2013 |
Medication adherence and persistence in the treatment of Canadian ulcerative colitis patients: analyses with the RAMQ database.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Canada; Coliti | 2013 |
Phylogenetic analysis of dysbiosis in ulcerative colitis during remission.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Cluster Analysis; | 2013 |
Long-term maintenance treatment in ulcerative colitis: a 10-year follow-up.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Follow-Up Studies; Huma | 2002 |
N-acetyltransferase 1 and 2 genotypes do not predict response or toxicity to treatment with mesalamine and sulfasalazine in patients with ulcerative colitis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Arylamine N-Acetyltransferase; Chi | 2002 |
Acute interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Male; Mesalamine; | 2002 |
Which 5-ASA?
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Enema; Humans; Inflammatory Bowel Diseases | 2002 |
[Ulcerative colitis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Colitis, Ulcerative; Colonoscopy; Diagnosis, Differ | 2002 |
Possible protective effect of 5-aminosalicylic acid on Helicobacter pylori infection in patients with inflammatory bowel disease.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; Female; He | 2003 |
Rectal tissue, plasma and urine concentrations of mesalazine after single and multiple administrations of 500 mg suppositories to healthy volunteers and ulcerative proctitis patients.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biological Availability; Colitis, Ulcerative; Female | 2003 |
[A case of neonatal severe hypereosinophilia associated with mesalazine administered during pregnancy].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Hypereosinophilic Synd | 2002 |
Birth outcome in women exposed to 5-aminosalicylic acid during pregnancy: a Danish cohort study.
Topics: Abnormalities, Drug-Induced; Adult; Anti-Inflammatory Agents, Non-Steroidal; Cohort Studies; Colitis | 2003 |
[Treatment of steroid-refractory ulcerative colitis with infliximab].
Topics: Adult; Anti-Bacterial Agents; Antibodies, Monoclonal; Azathioprine; Blood Transfusion; Budesonide; C | 2003 |
Caution in the interpretation of safety and efficacy differences in clinical trials comparing aminosalicylates for ulcerative colitis.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Clinical Trials as | 2003 |
Treatment of ulcerative colitis with balsalazide: response to editorial by Drs. Farrell and Peppercorn and letter to the editor by Dr. Hanauer.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Colitis, Ulcerativ | 2003 |
Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Human | 2003 |
Does length really matter? ... Oral and topical 5-aminosalicylic acid therapy for ulcerative colitis.
Topics: Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc | 2002 |
The mesalamine wars heat up-enter balsalazide.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Colitis, Ulcerativ | 2003 |
[Eosinophilic pneumonia caused by mesalazine. Report of one case].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Hydr | 2003 |
Treatment of ulcerative colitis with balsalazide: response to Drs Johnson, Green, and Pruitt.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Colitis, Ulcerativ | 2003 |
Effect of ulcerative colitis treatment on transforming growth factor beta(1) in plasma and rectal mucosa.
Topics: Administration, Oral; Adult; Aged; Colitis, Ulcerative; Female; Humans; Intestinal Mucosa; Male; Mes | 2003 |
CCR4 is an up-regulated chemokine receptor of peripheral blood memory CD4+ T cells in Crohn's disease.
Topics: Acute Disease; Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; CD4 | 2003 |
Bloody diarrhea, fever, and pancytopenia in a patient with active ulcerative colitis.
Topics: Antibodies, Antineutrophil Cytoplasmic; Antibodies, Antinuclear; Autoantigens; Autoimmune Diseases; | 2003 |
Correlation between circulating soluble ICAM-1 and prednisolone-induced amelioration of ulcerative colitis.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents; Biomarkers; Colitis, Ulcerative; Female | 2003 |
Sensorimotor polyneuropathy with 5-aminosalicylic acid: a case report.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Functional Laterality; Humans; M | 2003 |
Sulphasalazine-induced leucopenia in a patient with renal dysfunction.
Topics: Adult; Arylamine N-Acetyltransferase; Colitis, Ulcerative; Gastrointestinal Agents; Humans; Kidney D | 2003 |
Mesalazine-associated benign intracranial hypertension in a patient with ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Headache; Humans; Mesal | 2003 |
Acute pancreatitis after long-term therapy with mesalazine, and hyperamylasaemia associated with azathioprine in a patient with ulcerative colitis.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colitis, Ulcerative; Hu | 2003 |
Ulcerative colitis associated with aplastic anemia.
Topics: Adult; Anemia, Aplastic; Anti-Inflammatory Agents; Blood Transfusion; Bone Marrow Examination; Colit | 2003 |
Patient nonadherence to medication in inflammatory bowel disease.
Topics: Adult; Colitis, Ulcerative; Crohn Disease; Female; Humans; Intention; Male; Mesalamine; Middle Aged; | 2003 |
Patient nonadherence to medication in inflammatory bowel disease.
Topics: Adult; Colitis, Ulcerative; Crohn Disease; Female; Humans; Intention; Male; Mesalamine; Middle Aged; | 2003 |
Patient nonadherence to medication in inflammatory bowel disease.
Topics: Adult; Colitis, Ulcerative; Crohn Disease; Female; Humans; Intention; Male; Mesalamine; Middle Aged; | 2003 |
Patient nonadherence to medication in inflammatory bowel disease.
Topics: Adult; Colitis, Ulcerative; Crohn Disease; Female; Humans; Intention; Male; Mesalamine; Middle Aged; | 2003 |
Epidermal growth factor for ulcerative colitis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Therapy, Co | 2003 |
[Successful delivery in case of pregnancy with type 1 diabetes mellitus complicated by ulcerative colitis ].
Topics: Adult; Betamethasone; Colitis, Ulcerative; Diabetes Mellitus, Type 1; Diet, Diabetic; Female; Humans | 2003 |
Mesalamine-related lung disease: clinical, radiographic, and pathologic manifestations.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; Drug Hypersensit | 2003 |
[Crohn disease].
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn | 2003 |
Standard treatment of ulcerative colitis.
Topics: Administration, Oral; Administration, Topical; Adrenal Cortex Hormones; Anti-Inflammatory Agents, No | 2003 |
[Interstitial nephritis associated with mesalazine therapy].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Male; Mesalamine; Middl | 2003 |
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.
Topics: Adolescent; Adult; Case-Control Studies; Child; Colitis, Ulcerative; Colonoscopy; Colorectal Neoplas | 2004 |
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.
Topics: Adolescent; Adult; Case-Control Studies; Child; Colitis, Ulcerative; Colonoscopy; Colorectal Neoplas | 2004 |
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.
Topics: Adolescent; Adult; Case-Control Studies; Child; Colitis, Ulcerative; Colonoscopy; Colorectal Neoplas | 2004 |
Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis.
Topics: Adolescent; Adult; Case-Control Studies; Child; Colitis, Ulcerative; Colonoscopy; Colorectal Neoplas | 2004 |
Seasonal variation in flares of inflammatory bowel disease.
Topics: Adrenal Cortex Hormones; Adult; Cohort Studies; Colitis, Ulcerative; Crohn Disease; Drug Prescriptio | 2004 |
Renal impairment in patients with inflammatory bowel disease: association with aminosalicylate therapy?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcera | 2004 |
Interstitial nephritis from mesalazine: case report and literature review.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; Humans; Kid | 2004 |
Optimal dosing of 5-aminosalicylic acid: 5 decades of choosing between politicians.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Dose-Response Relationship, Drug; Huma | 2003 |
Regulation of gene expression in inflammatory bowel disease and correlation with IBD drugs: screening by DNA microarrays.
Topics: Adult; Aged; Azathioprine; Caco-2 Cells; Colitis, Ulcerative; Colon; Crohn Disease; DNA Primers; Fem | 2004 |
Medications as a source of human exposure to phthalates.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Body Burden; Chemistry, Pharmaceutical; Colitis, Ulc | 2004 |
You're the flight surgeon. Ulcerative colitis.
Topics: Adult; Aerospace Medicine; Anti-Inflammatory Agents, Non-Steroidal; Colic; Colitis, Ulcerative; Diag | 2004 |
[Colon carcinoma. Outlooks of prevention useful].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonic Neoplasms; Diet; Humans; Mesal | 2004 |
Ulcerative colitis that developed 8 years after human parvovirus B19 encephalopathy.
Topics: Adolescent; Anti-Inflammatory Agents; Brain Diseases; Colitis, Ulcerative; Erythema Infectiosum; Fem | 2004 |
[Mesalazine granules instead of tablets. New ulcerative colitis therapy confirmed also in general practice routine].
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Colitis, Ul | 2004 |
[Intestinal mucosa as the focal point. In distal ulcerative colitis relief with topical therapy].
Topics: Administration, Rectal; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Dosage Forms; | 2004 |
[Newcomer in ulcerative colitis: beclomethasone dipropionate: a corticoid with aim: colonic mucosa and colitis].
Topics: Administration, Oral; Administration, Rectal; Anti-Inflammatory Agents; Anti-Inflammatory Agents, No | 2004 |
[Ulcerative colitis and erythema multiforme].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Erythema Multiforme; Female; Gl | 2004 |
[Ulcerative colitis. Acute episode].
Topics: Acute Disease; Administration, Oral; Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-Inflammator | 2004 |
[Ulcerative colitis. Complementary therapies].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Complementary Therapies; | 2004 |
[Case of ulcerative colitis induced by mesalazine with acute aggravated colitis-like symptoms].
Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Betamethasone; Colitis, Ul | 2004 |
Induction of T lymphocyte apoptosis by sulphasalazine in patients with Crohn's disease.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Cells, Cultured; Child; Child | 2004 |
Salmonellosis and ulcerative colitis. A causal relationship or just a coincidence.
Topics: Abdomen, Acute; Adult; Biopsy, Needle; Colitis, Ulcerative; Colonoscopy; Drug Therapy, Combination; | 2004 |
Oxazolone-induced colitis in BALB/C mice: a new method to evaluate the efficacy of therapeutic agents for ulcerative colitis.
Topics: Animals; Colitis; Colitis, Ulcerative; Dose-Response Relationship, Drug; Drug Evaluation, Preclinica | 2004 |
Ulcerative colitis occurring in the course of rheumatoid arthritis: a case successfully treated with mesalamine enema.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Colitis, Ulcerative; Colon; C | 2004 |
Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; C | 2004 |
Oral mesalazine (5-ASA) treatment may protect against proximal extension of mucosal inflammation in ulcerative proctitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Disease-F | 2004 |
Skip lesion of the cecum associated with proctitis: an atypical case of ulcerative colitis.
Topics: Acute Disease; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Cecum; Colectomy; Colitis, Ulcer | 2004 |
Mesalazine-induced myopericarditis in a patient with ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Diagnosis, Differential; Echoca | 2006 |
Dose escalation of 5ASA: does it work?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Dose-Response Relationship, Drug; Huma | 2005 |
Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum.
Topics: Aminosalicylic Acids; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Colitis, | 2005 |
Mesalamine-induced lung injury in a patient with ulcerative colitis and a confounding autoimmune background: a case report.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Immunocompromised Host; Male; | 2005 |
Pharmacokinetics and pilot efficacy of a mesalazine rectal gel in distal ulcerative colitis.
Topics: Administration, Rectal; Adult; Anti-Inflammatory Agents, Non-Steroidal; Biotransformation; Chromatog | 2005 |
[Chronic inflammatory bowel diseases. Recurrence prevention = carcinoma prevention?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Cholangitis, Sclerosing; Colitis, Ulcerative; | 2005 |
Acute interstitial nephritis due to mesalazine.
Topics: Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Male; Me | 2005 |
[Chronic inflammatory bowel diseases. Update on evidence-based therapy].
Topics: Administration, Oral; Administration, Rectal; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Ant | 2005 |
Will a 5-ASA a day keep the cancer (and dysplasia) away?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Disease Progress | 2005 |
Adherence to treatment in inflammatory bowel disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; Female; Gastroin | 2005 |
Rebamipide enema is effective for treatment of experimental dextran sulfate sodium induced colitis in rats.
Topics: Alanine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Colitis, Ulcerative; D | 2005 |
[A case of mesalazine-induced pleuritis with hemophagocytic findings].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Mesalamine; Pha | 2005 |
Drug-induced bullous pemphigoid caused by a generic Canadian medication obtained over the internet.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutical; Colitis, Ulcerative; Diag | 2005 |
Increased expression of MIP-3alpha/CCL20 in peripheral blood mononuclear cells from patients with ulcerative colitis and its down-regulation by sulfasalazine and glucocorticoid treatment.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chemokine CCL20; Chemokines, CC; Colitis, Ulcerative | 2005 |
Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation.
Topics: Adult; Aged; Amidohydrolases; Animals; Arachidonic Acids; Benzenesulfonates; Colitis; Colitis, Ulcer | 2006 |
Two cases of systemic lupus erythematosus complicated with colonic ulcers.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Colitis, Ulcerative; Colonoscopy; Diagnosis, | 2005 |
Azathioprine versus mesalamine in steroid-dependent ulcerative colitis: long-awaited results?
Topics: Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites; Azathioprine; Colitis, Ulcerat | 2006 |
[Maintaining remission of ulcerative colitis with the probiotic Escherichia Coli Nissle 1917 is as effective as with standard mesalazine].
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Double | 2006 |
Microproteinuria in patients with inflammatory bowel disease: is it associated with the disease activity or the treatment with 5-aminosalicylic acid?
Topics: Adolescent; Adult; Aged; Colitis, Ulcerative; Creatinine; Crohn Disease; Female; Humans; Inflammator | 2006 |
Higher platelet P-selectin in male patients with inflammatory bowel disease compared to healthy males.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Blood Platelets; Colitis, Ulcerative; Crohn Di | 2006 |
Hyperbaric oxygen enhances the efficiency of 5-aminosalicylic acid in acetic acid-induced colitis in rats.
Topics: Acetic Acid; Animals; Colitis, Ulcerative; Combined Modality Therapy; Disease Models, Animal; Female | 2006 |
Chemoprevention of colorectal neoplasia in ulcerative colitis: the effect of 6-mercaptopurine.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimetabolites, Antineoplastic; Azathioprine; Colitis, Ulc | 2006 |
Myopericarditis and mitral insufficiency associated with ulcerative colitis treated with mesalazine.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Disease Progression; Humans; Ma | 2006 |
Combined oral and topical mesalazine treatment for extensive ulcerative colitis.
Topics: Administration, Oral; Administration, Topical; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colit | 2006 |
Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; beta Catenin; Cell Line, Tumor; Colitis, Ulcerative; Coloni | 2006 |
[5-aminosalicylic acid and cancer prophylaxis?].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Humans; Mesalami | 2006 |
Oral mesalamine and clinical remission are associated with a decrease in the extent of long-standing ulcerative colitis.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Colitis, Ulcerative; C | 2006 |
Acute tubulointerstitial nephritis due to 5-aminosalicylic acid in a patient with ulcerative colitis and chronic renal failure.
Topics: Acute Disease; Anti-Inflammatory Agents; Colitis, Ulcerative; Creatinine; Humans; Kidney Failure, Ch | 2006 |
[Chronic inflammatory bowel diseases. Proven and innovative in the treatment].
Topics: Administration, Oral; Administration, Rectal; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspi | 2006 |
Variation in severity assessment and initial mesalamine dose selection for ulcerative colitis in community practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcera | 2006 |
Herpes simplex virus colitis in ulcerative colitis, simulating malignancy.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis; Colitis, Ulcerative; Diagnosis, Differentia | 2006 |
Editorial: mesalazine in ulcerative colitis--is it time to revise treatment guidelines in the UK?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Mesalamine; Practice Guideline | 2006 |
Therapeutic efficacy of leukocytapheresis in a pregnant woman with severe active ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Combined Modality Therapy; Fema | 2006 |
Colitis and bronchiolitis obliterans organising pneumonia--the treatment or the disease?
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Bronchiolitis Obliterans; Colitis, Ulcerative; Femal | 2006 |
Adverse events in clinical trials with azathioprine and mesalamine for prevention of postoperative recurrence of Crohn's disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Colitis, Ulcerative; Humans; Immunosuppressiv | 2006 |
Diffuse gastroduodenitis and pouchitis associated with ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Duodenitis; Female; Gastritis; | 2006 |
Clinical guidelines for the medical management of left-sided ulcerative colitis and ulcerative proctitis: summary statement.
Topics: Adrenal Cortex Hormones; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; D | 2006 |
Erythroderma and toxic epidermal necrolysis caused by to 5-aminosalacylic acid.
Topics: Colitis, Ulcerative; Dermatitis, Exfoliative; Exanthema; Humans; Male; Mesalamine; Stevens-Johnson S | 2006 |
Adrenal incidentaloma: review of 197 patients and report of a drug-related false-positive urinary normetanephrine result.
Topics: Adrenal Gland Neoplasms; Adrenalectomy; Adult; Anti-Inflammatory Agents, Non-Steroidal; Biomarkers, | 2006 |
A two-stage decision analysis to assess the cost of 5-aminosalicylic acid failure and the economics of balsalazide versus mesalamine in the treatment of ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Decision Support Techniques; Humans; M | 2006 |
Efficacy of granulocyte apheresis in pediatric patients with ulcerative colitis: a pilot study.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Child; Colitis, Ulcerative; Female; Glucocortic | 2006 |
[The influence of Candida albicans on the course of ulcerative colitis].
Topics: Adolescent; Adult; Aged; Antifungal Agents; Biopsy; Candida albicans; Colitis, Ulcerative; Colonosco | 2006 |
Does colonoscopy cause increased ulcerative colitis symptoms?
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colonoscopy; Cross-Over Studies | 2007 |
Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Bacteria; Bacterial Adhesion; Colitis; | 2007 |
Pyostomatitis vegetans: A clinical marker of silent ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Diagnosis, Differential; Gastro | 2007 |
[Pulmonary complications in patient with ulcerative colitis, treated with 5-aminosalicylic preparations].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Colitis, Ulcerative; Humans; Lung | 2006 |
Toxic epidermal necrosis associated with mesalamine in a patient with ulcerative colitis.
Topics: Adolescent; Anti-Inflammatory Agents; Colitis, Ulcerative; Humans; Male; Mesalamine; Stevens-Johnson | 2007 |
Topical treatment of ulcerative colitis. Some reflections.
Topics: Anti-Inflammatory Agents; Beclomethasone; Colitis, Ulcerative; Enema; Humans; Mesalamine; Remission | 2007 |
Mesalazine-induced bronchiectasis and eosinophilia in a patient with ulcerative colitis: a case report.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Bronchiectasis; Colitis, Ulcerative; Eosinophilia; F | 2007 |
Once-daily mesalamine (Lialda) for ulcerative colitis.
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Administrat | 2007 |
Altered intestinal permeability is predictive of early relapse in children with steroid-responsive ulcerative colitis.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Antineutrophil Cytoplasmic; Cellobi | 2007 |
Acute tubular injury associated with mesalazine therapy in an adolescent girl with inflammatory bowel disease.
Topics: Acute Disease; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Diagnosis, | 2007 |
[Benign intracranial hypertension and ulcerative colitis].
Topics: Acetazolamide; Adult; Anti-Inflammatory Agents, Non-Steroidal; Carbonic Anhydrase Inhibitors; Coliti | 2007 |
Sulfasalazine-induced pericarditis in a patient with ulcerative colitis without recurrence when switching to mesalazine.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Humans; Male; Mesalamine; Middle Aged; Pericarditis; Recu | 2007 |
Curcumin for maintenance therapy in ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Bias; Colitis, Ulcerative; Curcumin; Humans; Mesalamine; Tr | 2007 |
[News from the Cochrane Library: Maintenance of remission in ulcerative colitis].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Clinical Trials as Topic; Colitis, Ulcerative | 2007 |
Mesalazine downregulates c-Myc in human colon cancer cells. A key to its chemopreventive action?
Topics: Annexin A5; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Blotting, Western; Colitis, Ulcerati | 2007 |
["Treatment refractory" ulcerative colitis].
Topics: Adrenal Cortex Hormones; Adult; Angiography; Angiomatosis; Biopsy; Colitis, Ischemic; Colitis, Ulcer | 2007 |
[Patients prefer foam].
Topics: Administration, Rectal; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonid | 2007 |
Parotitis and acute pancreatitis in a patient with ulcerative colitis.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Mesalamine | 2008 |
Mild-to-moderate ulcerative colitis: your role in patient compliance and health care costs.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colorectal Neoplasms; Controlled Clini | 2007 |
Ulcerative colitis: responding to the challenges.
Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents; Antibodies, Monoclonal; Colitis, Ulcerative; | 2007 |
Balsalazide-induced myocarditis.
Topics: Adult; Colitis, Ulcerative; Gastrointestinal Agents; Humans; Male; Mesalamine; Myocarditis; Phenylhy | 2008 |
Pyoderma gangrenosum and interleukin 8.
Topics: Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Breast Diseases; Colitis, Ulcerative; Fe | 2007 |
Outcome of childhood ulcerative colitis at 2 years.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Child; Child, Preschool; Colectom | 2007 |
5-aminosalicylic acid given in the remission stage of colitis suppresses colitis-associated cancer in a mouse colitis model.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Body Weight; Colitis; Colitis, Ulcerative; Disease | 2007 |
[A case of acute pancreatitis caused by 5-aminosalicylic acid suppositories in a patient with ulcerative colitis].
Topics: Acute Disease; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Male; Me | 2007 |
Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease.
Topics: Adolescent; Adult; Antigens, CD; Colitis, Ulcerative; Crohn Disease; Drug Therapy, Combination; Fema | 2008 |
Qualitative investigation of patient adherence to 5-aminosalicylic acid therapy in patients with ulcerative colitis.
Topics: Adolescent; Adult; Colitis, Ulcerative; Female; Humans; Interview, Psychological; Male; Mesalamine; | 2008 |
NAT1 genotypes do not predict response to mesalamine in patients with ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arylamine N-Acetyltransferase; Colitis, Ulcerative; Genetic | 2008 |
Medication adherence and quality of life in pediatric inflammatory bowel disease.
Topics: Adolescent; Anti-Inflammatory Agents; Azathioprine; Colitis, Ulcerative; Crohn Disease; Depression; | 2008 |
How important is mesalamine in the maintenance of steroid-refractory colitis?
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colectomy; Colitis, Ulcerative; Drug Resistance; Hum | 2008 |
Mesalamine-associated hypersensitivity myocarditis in ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Diagnosis, Differential; Drug H | 2008 |
[Once daily mesalazine for long-term remission. Ulcerative colitis: maintenance therapy becomes easier].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Dose-Response Relationship, Drug; Drug | 2008 |
Mesalazine-induced jaundice, eosonophilia, and thrombocytopenia.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Eosinophilia; Humans; Jaundice; Male; | 2008 |
Interruption of mesalamine and reduction of the blood concentration of the active metabolites of azathioprine: possible causes of ulcerative colitis relapse.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Child, Preschool; Colitis, Ulcerative; Drug I | 2008 |
Inhibition of leucocyte motility by drugs used in ulcerative colitis.
Topics: Aminosalicylic Acids; Cell Movement; Chemotaxis, Leukocyte; Colitis, Ulcerative; Dose-Response Relat | 1981 |
Simplified high-performance liquid chromatographic method for 5-aminosalicylic acid in plasma and urine.
Topics: Aminosalicylic Acids; Chromatography, High Pressure Liquid; Colitis, Ulcerative; Crohn Disease; Huma | 1981 |
Increased suppressor cell activity in inflammatory bowel disease.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Humans; Hydrocortisone; In Vitro Technique | 1981 |
[5-Aminosalicylic acid in ulcerative colitis and Crohn's disease (author's transl)].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Aminosalicylic Acids; Anti-Inflammatory Agents; Co | 1982 |
Will there be a next generation of sulfasalazine?
Topics: Administration, Oral; Aminosalicylic Acids; Animals; Colitis, Ulcerative; Crohn Disease; Delayed-Act | 1982 |
Inhibition of prostaglandin synthetase in human rectal mucosa.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents; Colitis, Ulcerative; Cyclooxygenase Inhibitors; Dose | 1983 |
Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Glycine max; Humans; Kinetics; Lipoxygenase Inhibitors; M | 1983 |
Treatment of ulcerative colitis with oral 5-aminosalicyclic acid in patients unable to take sulphasalazine.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aminosalicylic Acids; Child; Colitis, Ulcerative; Fem | 1983 |
Pharmacotherapy of inflammatory bowel disease. Part 1. Sulfasalazine.
Topics: Aminosalicylic Acids; Bacteria; Colitis, Ulcerative; Colon; Crohn Disease; Humans; Kinetics; Mesalam | 1983 |
5-aminosalicylic acid as rectal enema in ulcerative colitis patients unable to take sulphasalazine.
Topics: Acute Disease; Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Enema; Female; Humans; Male; | 1984 |
Exacerbation of diarrhoea and pain in patients treated with 5-aminosalicylic acid for ulcerative colitis.
Topics: Acute Disease; Adolescent; Adult; Aminosalicylic Acids; Colitis, Ulcerative; Diarrhea; Female; Human | 1984 |
Comparison of the absorption and metabolism of sulphasalazine and acrylic-coated 5-amino salicylic acid in normal subjects and patients with colitis.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Female; Humans; Intestinal Absorption; Male; Mesal | 1984 |
Reversal with balsalazide of infertility caused by sulphsalazine.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Humans; Infertility, Male; Male; Mesalamine; Pheny | 1984 |
Reversal of male infertility on changing treatment from sulphasalazine to 5-aminosalicylic acid.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Humans; Infertility, Male; Male; Mesalamine; Sulfa | 1984 |
Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Dose-Response Relationship, Drug; Glycine max; Humans; In | 1984 |
Colonic release of 5-amino salicylic acid from an oral preparation in active ulcerative colitis.
Topics: Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Colon; Female; Humans; Intestines; Male; Mes | 1983 |
5-Aminosalicylic acid for the treatment of inflammatory bowel disease.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Delayed-Action Preparations; Humans; Mesal | 1984 |
5-aminosalicylic acid in a slow-release preparation: bioavailability, plasma level, and excretion in humans.
Topics: Adult; Aminosalicylic Acids; Biological Availability; Chromatography, High Pressure Liquid; Colitis, | 1982 |
Up-regulation of E-selectin and intercellular adhesion molecule-1 differs between Crohn's disease and ulcerative colitis.
Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Cell Adhesion Molecules; Cells | 1995 |
Colonic spreading of a non-chlorofluorocarbon mesalazine rectal foam enema in patients with quiescent ulcerative colitis.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colon; Enema; Hu | 1995 |
The rectal approach to treatment in distal ulcerative colitis.
Topics: Absorption; Administration, Rectal; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; B | 1995 |
New salicylates as maintenance treatment in ulcerative colitis.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Humans; Kidney Diseases; Mesalamine | 1995 |
[Substitution of factor XIII concentrate in treatment refractory ulcerative colitis. A prospective pilot study].
Topics: Acute Disease; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; C | 1994 |
Effects of thromboxane synthase inhibition on in vivo release of inflammatory mediators in chronic ulcerative colitis.
Topics: Adult; Aged; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Colitis | 1995 |
Exacerbation of chronic ulcerative colitis with mesalamine.
Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Colitis, Ulce | 1995 |
[Discussion apropos of a case of ulcerative colitis].
Topics: Adrenal Cortex Hormones; Aged; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Coliti | 1995 |
[Mesalazine].
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Colitis, Ulcer | 1995 |
[Combined surgical and therapeutic treatment of complicated ulcerative necrotic enterocolitis on the background of scleroderma using Salofalk preparation].
Topics: Abdomen, Acute; Abdominal Injuries; Adolescent; Aminosalicylic Acids; Anti-Inflammatory Agents, Non- | 1994 |
[Tubulointerstitial nephritis caused by mesalazine (5-ASA) agents].
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Female; Humans; Kidney Tubules; Mal | 1994 |
Intraluminal colonic release of immunoreactive tumour necrosis factor in chronic ulcerative colitis.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Biomarkers; Colitis, Ulcerative; Colon; Colonic Disea | 1994 |
[Current therapeutic possibilities in chronic inflammatory intestinal diseases].
Topics: Aminosalicylic Acids; Chronic Disease; Colitis; Colitis, Ulcerative; Crohn Disease; Drug Therapy, Co | 1995 |
Topical treatment of refractory distal ulcerative colitis with 5-ASA and sodium butyrate.
Topics: Administration, Topical; Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Butyr | 1995 |
Bioavailability of single and multiple doses of a new oral formulation of 5-ASA in patients with inflammatory bowel disease and healthy volunteers.
Topics: Administration, Oral; Adult; Aged; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Bi | 1994 |
[Pericarditis during inflammatory bowel diseases. Extra-intestinal or iatrogenic complication?].
Topics: Adolescent; Adrenal Cortex Hormones; Aminosalicylic Acids; Colitis, Ulcerative; Humans; Lymphocyte A | 1994 |
Production of interleukin-1b and tumor necrosis factor--a by peripheral blood human mononuclear cells in active and inactive stages of ulcerative colitis.
Topics: Administration, Oral; Adolescent; Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroid | 1995 |
Selective inhibition of fatty acid oxidation in colonocytes by ibuprofen: a cause of colitis?
Topics: Aminosalicylic Acids; Animals; Butyrates; Butyric Acid; Carbon Dioxide; Cells, Cultured; Colitis, Ul | 1995 |
Antilymphocyte globulin for mesalazine-associated aplastic anaemia.
Topics: Aminosalicylic Acids; Anemia, Aplastic; Antilymphocyte Serum; Colitis, Ulcerative; Humans; Male; Mes | 1994 |
Mesalazine induced interstitial nephritis.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Humans; Male; Mesalamine; Nephritis, Interstitial | 1994 |
Pleuropericarditis in a patient with ulcerative colitis in longstanding 5-aminosalicylic acid therapy.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Female; Humans; Mesalamine; Pericarditis; Pleurisy | 1994 |
Urinary growth hormone in growth-impaired children with chronic inflammatory bowel disease.
Topics: Adolescent; Aminosalicylic Acids; Child; Colitis, Ulcerative; Creatinine; Crohn Disease; Enzyme-Link | 1993 |
[Localization of salazopyrin in colonic mucosa patients with ulcerative colitis].
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Colon; Female; Humans; Intestinal Mucosa; Male; Me | 1993 |
Interleukin 2 and interferon-gamma augment anticolon antibody dependent cellular cytotoxicity in ulcerative colitis.
Topics: Adolescent; Adult; Aminosalicylic Acids; Antibody-Dependent Cell Cytotoxicity; Autoantibodies; Colit | 1993 |
Negligible excretion of 5-aminosalicylic acid in breast milk.
Topics: Adult; Aminosalicylic Acids; Breast Feeding; Colitis, Ulcerative; Female; Humans; Infant, Newborn; M | 1993 |
Ileitis after colectomy for ulcerative colitis or carcinoma.
Topics: Adult; Aged; Aminosalicylic Acids; Azathioprine; Colectomy; Colitis, Ulcerative; Colonic Neoplasms; | 1994 |
Scintigraphic study of gastrointestinal transit and disintegration sites of mesalazine tablets labeled with technetium-99m.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Colonic Diseases, Functional; Crohn Disease; Diges | 1993 |
Use of mesalamine and olsalazine in ulcerative colitis.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Humans; Mesalamine | 1993 |
Pentasa (Mesalamine).
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Humans; Mesalamine | 1993 |
Eicosanoid production by the mucosa in inflammatory bowel disease after 5-ASA treatment.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Eicosanoids; Female; Humans; Hydroxyeicosatetraenoic Acid | 1993 |
Treatment of ulcerative colitis with 5-aminosalicylic acid.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Humans; Mesalamine; Meta-Analysis as Topic; Research Desi | 1993 |
Serum angiotensin converting enzyme activity in Crohn's disease and ulcerative colitis.
Topics: Adult; Aged; Aminosalicylic Acids; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Co | 1993 |
Identification of oxidation products of 5-aminosalicylic acid in faeces and the study of their formation in vitro.
Topics: Aminosalicylic Acids; Chromatography, High Pressure Liquid; Colitis, Ulcerative; Feces; Hemoglobins; | 1993 |
Predictors and the rate of medical treatment failure in ulcerative colitis.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Cyclosporine; Discriminant Analysis; Female; Human | 1993 |
Concentrations of 5-ASA and AC-5-ASA in human ileocolonic biopsy homogenates.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Humans; Intestinal Mucosa; Intestines; Mesalamine | 1993 |
[Ulcerative colitis and pericarditis. The role of mesalazine hypersensitivity].
Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Hype | 1995 |
Diluted effect from diluted mesalamine rectal suspension?
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Enema; Humans; M | 1995 |
Mesalazine induced exacerbation of ulcerative colitis.
Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Colon, Si | 1995 |
Maintenance strategies in Crohn's disease.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Combined Modalit | 1996 |
[Autoimmune hemolytic anemia and ulcerative colitis].
Topics: Adult; Aminosalicylic Acids; Anemia, Hemolytic, Autoimmune; Anti-Inflammatory Agents; Anti-Inflammat | 1995 |
Folliculitis and mesalamine.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Folliculitis; Hu | 1996 |
Cryptogenic fibrosing alveolitis predating ulcerative colitis.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Azathioprin | 1996 |
5-aminosalicylates in inflammatory bowel disease--the more the merrier?
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; H | 1995 |
Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis.
Topics: Adolescent; Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; | 1996 |
Leukopenia and thrombocytopenia as adverse effects of treatment with 5-aminosalicylic suppositories.
Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; H | 1996 |
Clinical outcome of ulcerative colitis in children.
Topics: Adolescent; Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; | 1996 |
Drug induced otalgia due to mesalazine and sulphasalazine.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents; Colitis, Ulcerative; Earache; Humans; Male; Mesalami | 1996 |
6-mercaptopurine for the management of ulcerative colitis: a concept whose time has come.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antimetabol | 1996 |
The long-term outcome of ulcerative colitis treated with 6-mercaptopurine.
Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti | 1996 |
Cytokine gene transcription of human colonic intraepithelial lymphocytes costimulated with epithelial cells bearing HLA-DR and its inhibition by 5-aminosalicylic acid.
Topics: Actins; Adult; Aged; Aged, 80 and over; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroida | 1996 |
Hypoplastic anemia associated with ulcerative colitis in a child.
Topics: Aminosalicylic Acids; Anemia, Aplastic; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Blood Trans | 1996 |
Immune thrombocytopenia and ulcerative colitis: response to nonoperative therapy.
Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Ther | 1996 |
[Bilateral pneumothorax and hemorrhagic rectocolitis].
Topics: Adolescent; Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; | 1996 |
Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis.
Topics: Acetic Acid; Aminosalicylic Acids; Animals; Antioxidants; Butylated Hydroxytoluene; Colitis; Colitis | 1996 |
Ulcerative colitis and renal cell carcinoma.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Carcinoma, Renal Cell; Colectomy; Col | 1996 |
Nephrotic syndrome from 5-ASA for ulcerative colitis? Complicated by carcinoma of the colon and sclerosing cholangitis.
Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Cholangitis, Sclerosing; Colit | 1997 |
Airway obstruction in ulcerative colitis.
Topics: Adult; Airway Obstruction; Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, U | 1997 |
Mesalamine-induced lung disease.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Male; Me | 1997 |
Influence of topical rectal application of drugs on dextran sulfate-induced colitis in rats.
Topics: Administration, Rectal; Aminosalicylic Acids; Anesthetics, Local; Animals; Anti-Inflammatory Agents; | 1997 |
5-Aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inf | 1997 |
[Peripheral eosinophilia in ulcerative colitis: apropos of a case].
Topics: Adult; Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Coli | 1997 |
[Pharmacological studies of BX661A. 5-[4-(2-carboxyethylcarbamoyl)-phenylazo]-salicylic acid disodium salt dihydrate (1). Therapeutic effects on dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) model in rats].
Topics: Administration, Oral; Aminosalicylic Acids; Animals; Anthracenes; Anti-Inflammatory Agents, Non-Ster | 1997 |
Mesalazine-associated interstitial nephritis: twice in the same patient.
Topics: Adult; Colitis, Ulcerative; Humans; Male; Mesalamine; Nephritis, Interstitial; Recurrence | 1997 |
An unusual complication of immunosuppressive therapy in inflammatory bowel disease.
Topics: Aged; Aminosalicylic Acids; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antim | 1997 |
Acute pancreatitis after long-term 5-aminosalicylic acid therapy.
Topics: Acute Disease; Adult; Amylases; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female | 1997 |
Evaluation of clinical patterns in ulcerative colitis: a long-term follow-up.
Topics: Administration, Oral; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Ene | 1997 |
Small airways function in patients with inflammatory bowel disease.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; Drug Thera | 1998 |
Severe symptomatic sinus bradycardia associated with mesalamine use.
Topics: Adult; Bradycardia; Colitis, Ulcerative; Electrocardiography; Female; Humans; Mesalamine | 1998 |
A 66-year-old woman with ulcerative colitis.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Decision Making; Diagnosis, Diff | 1998 |
Renal dysfunction and the treatment of inflammatory bowel disease (IBD): a case for monitoring.
Topics: Aged; Colitis, Ulcerative; Humans; Kidney Function Tests; Male; Mesalamine; Monitoring, Physiologic; | 1998 |
What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Dose-Response Relationship, Drug; Drug | 1998 |
Efficacy of treatment for ulcerative colitis.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents; Colitis, Ulcerative; Humans; Mesalamine; Sulfasalazi | 1998 |
Gastrointestinal pH profiles in patients with inflammatory bowel disease.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Colitis, Ulcerative; Crohn Dis | 1998 |
Late onset interstitial nephritis associated with mesalazine treatment.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Male; Mesalamine; Nephr | 1998 |
Efficacy of different mesalamine-releasing drugs.
Topics: Acute Disease; Aminosalicylic Acids; Anti-Ulcer Agents; Clinical Trials as Topic; Colitis, Ulcerativ | 1998 |
Simple method for the determination of 5-aminosalicylic and N-acetyl-5-aminosalicylic acid in rectal tissue biopsies.
Topics: Aminosalicylic Acids; Anhydrides; Biopsy; Chemical Precipitation; Chromatography, High Pressure Liqu | 1998 |
Effects of BX661A, a new therapeutic agent for ulcerative colitis, on reactive oxygen species in comparison with salazosulfapyridine and its metabolite sulfapyridine.
Topics: Aminosalicylic Acids; Anti-Ulcer Agents; Colitis, Ulcerative; Cytochrome c Group; Hydrogen Peroxide; | 1998 |
Mesalamine-associated pleural effusion with pulmonary infiltration.
Topics: Aged; Colitis, Ulcerative; Female; Humans; Lung Diseases; Mesalamine; Pleural Effusion | 1998 |
Determination of the active moiety of BX661A, a new therapeutic agent for ulcerative colitis, by studying its therapeutic effects on ulcerative colitis induced by dextran sulfate sodium in rats.
Topics: Alanine; Aminosalicylic Acids; Animals; Anti-Ulcer Agents; Colitis, Ulcerative; Colon; Dextran Sulfa | 1998 |
Effects of BX661A, a new therapeutic agent for ulcerative colitis, on chemotaxis and reactive oxygen species production in polymorphonuclear leukocytes in comparison with salazosulfapyridine and its metabolite sulfapyridine.
Topics: Aminosalicylic Acids; Animals; Anti-Ulcer Agents; Chemotaxis, Leukocyte; Colitis, Ulcerative; Guinea | 1998 |
Respiratory distress during mesalamine therapy.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Lung Diseases; | 1999 |
Placebos in medicine.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Cholelithiasis; Clinical Trials as Topic; Colitis, U | 1999 |
Pericarditis associated with inflammatory bowel disease: case report.
Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Femal | 1999 |
Mesalazine activation of eosinophil.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Churg-Strauss Syndrome; Colitis, Ulcerative; Eosinop | 1997 |
Will the real 5-aminosalicylic acid please stand up?
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Colitis, Ulcerativ | 1999 |
Antioxidant defense in erythrocytes and plasma of patients with active and quiescent Crohn disease and ulcerative colitis: a chemiluminescent study.
Topics: Adult; Antioxidants; Colitis, Ulcerative; Crohn Disease; Erythrocytes; Female; Free Radical Scavenge | 1999 |
Chronic interstitial nephritis due to 5-aminosalicylic acid.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Colitis, Ulcerative; Humans; Kidney; Kidney | 1999 |
Mesalamine-induced granulomatous hepatitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chemical and Drug Induced Liver Injury; Colitis, Ulc | 1999 |
[Extra-intestinal manifestations and complications in chronic active ulcerative colitis in childhood and adolescence].
Topics: Adolescent; Azathioprine; Budesonide; Child; Colitis, Ulcerative; Diagnosis, Differential; Drug Ther | 1999 |
Mesalamine-associated thrombocytopenia.
Topics: Adult; Colitis, Ulcerative; Diagnosis, Differential; Dose-Response Relationship, Drug; Female; Human | 1999 |
Clinical quiz. 5-ASA hypersensitivity lung disease.
Topics: Adolescent; Antibodies, Antineutrophil Cytoplasmic; Colitis, Ulcerative; Drug Hypersensitivity; Huma | 1999 |
Endoscopic and histological patchiness in treated ulcerative colitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Chi-Squ | 1999 |
Mesalazine and photosensitivity.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Exanthema; Hand Dermatoses; Humans; Ma | 1999 |
Ultrasonography in the evaluation of extension, activity, and follow-up of ulcerative colitis.
Topics: Adolescent; Adult; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Barium Sulfate; Bl | 1999 |
The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Dose-Response Relationship, Dru | 2000 |
Escherichia coli for ulcerative colitis.
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Escherichia c | 1999 |
Trends in inflammatory bowel disease therapy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; Humans; Mesalamine; Sig | 1999 |
Long-term effects of a single course of nicotine treatment in acute ulcerative colitis: remission maintenance in a 12-month follow-up study.
Topics: Administration, Cutaneous; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug | 1999 |
Colorectal cancer prevention in ulcerative colitis: a case-control study.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Colitis, Ulcerativ | 2000 |
Treatment of distal ulcerative colitis: now the patients have the choice.
Topics: Administration, Oral; Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulc | 1999 |
Mesalamine-induced chest pain: a case report.
Topics: Adult; Angina Pectoris; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Electrocardiog | 2000 |
Chemotactic properties of ICAM-1 and PECAM-1 on neutrophil granulocytes in ulcerative colitis: effects of prednisolone and mesalazine.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Cell Culture Techniques; Chemotax | 2000 |
[A case of left-sided ulcerative colitis successfully treated with mesalazine enema but not steroid suppository].
Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Betamethasone; Colitis, Ul | 2000 |
Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Biopsy; Chromatography, High Pressure Liquid; | 2000 |
Factors predictive of response to cyclosporin treatment for severe, steroid-resistant ulcerative colitis.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Child; Child | 2000 |
[Mesalamine-induced hypersensitivity pneumonitis].
Topics: Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug H | 1999 |
[Sulfasalazine-induced pulmonary infiltrates and Legionella pneumonia].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Diagnosis, Differential; Enema; | 2000 |
Oral mesalamine prodrug approved for active ulcerative colitis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Approval; Humans; Mesalamine; Pro | 2000 |
[Thrombopenia in treatment with mesalazine].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Mesalamine; Middle Age | 2000 |
Idiopathic pancreatitis associated with ulcerative colitis.
Topics: Adult; Colitis, Ulcerative; Drug Therapy, Combination; Humans; Male; Mesalamine; Pancreatic Function | 2000 |
[Ulcerative colitis. When is standard therapy enough?].
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Clinical Trials as Topic; Colitis | 2000 |
[Value of therapy with 5-aminosalicylic acid in chemoprevention of colorectal carcinoma in ulcerative colitis].
Topics: Case-Control Studies; Colitis, Ulcerative; Colorectal Neoplasms; Humans; Mesalamine; Retrospective S | 2000 |
Glomerular and tubular renal functions after long-term medication of sulphasalazine, olsalazine, and mesalazine in patients with ulcerative colitis.
Topics: Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Female; Gastrointestinal Agents; Humans; Kid | 2000 |
Progress in understanding the mechanisms of action of 5-aminosalicylic acid.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Mesalamine; NF-kappa B; Sulfas | 2000 |
Paradoxical progression of biliary strictures against recovery of biochemical parameters under ursodeoxycholic acid treatment in a case of primary sclerosing cholangitis with ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Antineutrophil Cytoplasmic; Autoimmune Diseases; Betame | 2000 |
Interstitial nephritis in patients with inflammatory bowel disease treated with mesalamine.
Topics: Adult; Biopsy; Colitis, Ulcerative; Crohn Disease; Female; Humans; Kidney; Mesalamine; Middle Aged; | 2001 |
Look out for toxic effects of mesalamines!
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Crohn Disease; Humans; Kidney Function | 2001 |
From the Food and Drug Administration.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Breast Neoplasms; Clinical Trials as | 2001 |
[Efficacy of mesalamine enema in the treatment of steroid-resistant or dependent distal ulcerative colitis].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Anti-Inflammatory Agents; Colitis, Ulcerative; Drug Resi | 2001 |
Lymph folliculitis in ulcerative colitis.
Topics: Adult; Biopsy, Needle; Colitis, Ulcerative; Colonoscopy; Follow-Up Studies; Gastrointestinal Hemorrh | 2001 |
T-large granular lymphocyte leukemia accompanied by an increase of natural killer cells (CD3-) and associated with ulcerative colitis and autoimmune hepatitis.
Topics: Anti-Inflammatory Agents; Colitis, Ulcerative; Gene Rearrangement; Genes, T-Cell Receptor beta; Hepa | 2001 |
A new 5-aminosalicylic acid multi-unit dosage form for the therapy of ulcerative colitis.
Topics: Acrylates; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutical; Colitis, Ulcerative; | 2001 |
[Early renal failure caused by mesalazine].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Male; Mesalamine; Renal | 2000 |
Ulcerative colitis associated with interferon treatment for chronic hepatitis C.
Topics: Adult; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Femal | 2001 |
[Interstitial nephritis after treatment with mesalazine in the patient with ulcerative colitis].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Humans; Male; Mesalamine; Nephr | 2001 |
Oral balsalazide (Colazal) for ulcerative colitis.
Topics: Abdominal Pain; Administration, Oral; Aminosalicylic Acids; Anti-Ulcer Agents; Colitis, Ulcerative; | 2001 |
Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis: comparison of orally administered mesalamine and sulfasalazine.
Topics: Administration, Oral; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; H | 2001 |
Novel azo derivatives as prodrugs of 5-aminosalicylic acid and amino derivatives with potent platelet activating factor antagonist activity.
Topics: Amines; Aminosalicylic Acids; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aza Compounds; Azo C | 2001 |
[The new experimental ulcerative colitis model in rats induced by subserosal injection of acetic acid].
Topics: Acetic Acid; Animals; Anti-Inflammatory Agents; Colitis, Ulcerative; Disease Models, Animal; Inflamm | 2001 |
The hair of the dog.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Escherichia coli; Humans; Mesalamine; | 2001 |
Acute pericarditis associated with 5-aminosalicylic acid (5-ASA) treatment for severe active ulcerative colitis.
Topics: Adolescent; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; | 2001 |
[Conservative therapy of severe ulcerative colitis. More effective than internists believe!].
Topics: Adrenal Cortex Hormones; Colitis, Ulcerative; Drug Therapy, Combination; Humans; Immunosuppressive A | 2001 |
Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Colitis, Ulcerative; Enoxapari | 2001 |
Bronchiolitis obliterans in a patient with ulcerative colitis receiving mesalamine.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Bronchiolitis Obliterans; Colitis, Ulcerative; | 2001 |
Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Colitis, Ulcerative; Crohn Disease; Drug T | 2001 |
Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Logistic | 2001 |
Mesalazine-induced pustular drug eruption.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Diagnosis, Differential; Drug E | 2001 |
Mesalazine for ulcerative colitis complicated with diabetic nephropathy.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Diabetic Nephropathies; Female; Humans | 2001 |
[Role of prebiotics and probiotics in therapeutic management of cryptogenetic inflammatory bowel disease].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Ciprofloxacin | 2001 |
Anti-inflammatory effects of 5-aminosalicylic acid conjugates with chenodeoxycholic acid and ursodeoxycholic acid on carrageenan-induced colitis in guinea-pigs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Chenodeoxycholic Acid; Colitis, Ulcer | 2001 |
Balsalazide disodium.
Topics: Aminosalicylic Acids; Anti-Ulcer Agents; Colitis, Ulcerative; Drug Interactions; Female; Humans; Mal | 2002 |
Sulphasalazine and 5-aminosalicylic acid in long-term treatment of ulcerative colitis: report on tolerance and side-effects.
Topics: Adolescent; Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Desensitization, Im | 2001 |
Suppressive effects of cyclosporine A on neutrophils and T cells may be related to therapeutic benefits in patients with steroid-resistant ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents; Child; Colitis, Ulcerative; Cyclosporine; Drug Resistance; Female; | 2002 |
Systemic hypersensitivity reaction to mesacol.
Topics: Biopsy, Needle; Colitis, Ulcerative; Drug Hypersensitivity; Follow-Up Studies; Humans; Kidney; Male; | 2001 |
Constrictive pericarditis in chronic ulcerative colitis.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Female; Humans; Mesalamine; Per | 2002 |
[Mesalazine in ulcerative colitis. Fewer cases of colorectal carcinoma].
Topics: Adolescent; Adult; Age Factors; Anti-Inflammatory Agents, Non-Steroidal; Case-Control Studies; Child | 2002 |
[Measurement of outpatient treatment costs of chronic inflammatory bowel diseases at a German university hospital].
Topics: Adult; Ambulatory Care; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Budesonid | 2002 |
[Patients need no longer plan meals. Colitis therapy is simplified].
Topics: Clinical Trials as Topic; Colitis, Ulcerative; Drug Administration Schedule; Humans; Mesalamine; Tab | 2002 |
[Pancreatic involvement in inflammatory bowel diseases in children].
Topics: Adolescent; Amylases; Anti-Inflammatory Agents, Non-Steroidal; Azathioprine; Child; Colitis, Ulcerat | 2002 |
Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Capsules; Carboxymethylcellu | 2002 |
Lipogenesis from n-butyrate in colonocytes. Action of reducing agent and 5-aminosalicylic acid with relevance to ulcerative colitis.
Topics: Aminosalicylic Acids; Animals; Butyrates; Colitis, Ulcerative; Colon; Lipids; Mesalamine; Rats; Rats | 1992 |
Is Asacol as effective as sulphasalazine in maintaining remission of Crohn's disease and ulcerative colitis?
Topics: Acrylic Resins; Adolescent; Adult; Aged; Aged, 80 and over; Aminosalicylic Acids; Colitis, Ulcerativ | 1992 |
Oral mesalamine for ulcerative colitis.
Topics: Administration, Oral; Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Humans; M | 1992 |
Comparisons of olsalazine and mesalazine in prevention of relapse in ulcerative colitis.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Humans; Mesalamine; Recurrence; Research Design | 1992 |
[Aminosalicylates in chronic inflammatory intestinal diseases and rheumatoid arthritis].
Topics: Aminosalicylic Acids; Arthritis, Rheumatoid; Colitis, Ulcerative; Crohn Disease; Humans; Mesalamine; | 1992 |
Measurement of colonic tissue cyclosporine concentration in children with severe ulcerative colitis.
Topics: Administration, Oral; Adolescent; Aminosalicylic Acids; Child; Colitis, Ulcerative; Colon; Cyclospor | 1992 |
Colorectal cancer risk and mortality in patients with ulcerative colitis.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminosalicylic Acids; Child; Cohort Studies; Colectomy; | 1992 |
Cytokines and platelet-activating factor in human inflamed colonic mucosa.
Topics: Aminosalicylic Acids; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Anti-Idiotypic; Calcimyci | 1992 |
Mesalazine versus olsalazine for prophylaxis of ulcerative colitis relapse.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Humans; Mesalamine; Recurrence | 1992 |
[Serum cholinesterases as activity parameters in chronic inflammatory bowel diseases].
Topics: Acute-Phase Proteins; Adolescent; Adult; Aged; Aminosalicylic Acids; Child; Cholinesterases; Colitis | 1992 |
[Acute alveolitis due to mesalazine].
Topics: Aged; Alveolitis, Extrinsic Allergic; Aminosalicylic Acids; Bronchiolitis; Colitis, Ulcerative; Huma | 1992 |
Drug management of ulcerative colitis.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Humans; Mesalamine | 1992 |
Tests of renal function in patients with quiescent colitis: effects of drug treatment.
Topics: Adult; Aged; Aged, 80 and over; Aminosalicylic Acids; Colitis, Ulcerative; Delayed-Action Preparatio | 1992 |
Effect of drugs on colonic eicosanoid accumulation in active ulcerative colitis.
Topics: Adult; Aged; Aged, 80 and over; Aminosalicylic Acid; Aminosalicylic Acids; Anti-Inflammatory Agents, | 1992 |
The drug 5-aminosalicylic acid rescues alpha 1-proteinase inhibitor from the neutrophil oxidative inactivation. A possible contribution to its therapeutic action in ulcerative colitis.
Topics: alpha 1-Antitrypsin; Aminosalicylic Acids; Colitis, Ulcerative; Humans; Male; Mesalamine; Neutrophil | 1992 |
Ulcerative colitis.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Humans; Mesalamine | 1992 |
Asacol (mesalamine).
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Humans; Mesalamine | 1992 |
Retrograde distribution of a new 5-aminosalicylic acid enema in patients with ulcerative colitis.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Diffusion; Enema; Female; Humans; Male; Mesalamine | 1992 |
Distribution of mesalamine enemas in patients with active distal ulcerative colitis.
Topics: Adolescent; Adult; Aminosalicylic Acids; Colitis, Ulcerative; Colon, Sigmoid; Enema; Female; Humans; | 1992 |
Lung disease associated with orally administered mesalamine for ulcerative colitis.
Topics: Administration, Oral; Aminosalicylic Acids; Colitis, Ulcerative; Female; Humans; Lung Diseases; Mesa | 1992 |
Lichen planus and mesalazine.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Female; Humans; Lichen Planus; Male; Mesalamine; M | 1991 |
Mesalazine alveolitis.
Topics: Aged; Alveolitis, Extrinsic Allergic; Aminosalicylic Acids; Colitis, Ulcerative; Humans; Male; Mesal | 1991 |
Comment: mesalamine in ulcerative colitis.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Colitis, Ulcerative; Enema; Humans; Mesalamine; Sulfa | 1991 |
[Pancreatitis associated with 5-aminosalicylic acid].
Topics: Acute Disease; Adult; Aminosalicylic Acids; Amylases; Clinical Enzyme Tests; Colitis, Ulcerative; Cr | 1991 |
Combined therapy with 5-aminosalicylic tablets and enemas for maintaining remission in ulcerative colitis.
Topics: Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Combined Modality Therapy; Enema; Female; Hu | 1991 |
Lung and skin hypersensitivity to 5-aminosalicylic acid.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Drug Eruptions; Drug Hypersensitivity; Female; Humans; Me | 1991 |
5-Aminosalicylic acid is a potent inhibitor of interleukin 1 beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease.
Topics: Adult; Aged; Aged, 80 and over; Aminosalicylic Acids; Colitis, Ulcerative; Colon; Crohn Disease; Dex | 1991 |
Increased activation of isolated intestinal lamina propria mononuclear cells in inflammatory bowel disease.
Topics: Aminosalicylic Acids; Antigens, Surface; Cell Separation; Colitis, Ulcerative; Crohn Disease; Flow C | 1991 |
Comparable efficacy of oral 5-aminosalicylic acid (Mesasal) and sulfasalazine in maintaining ulcerative colitis in remission.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Double-Bli | 1990 |
Clinical evidence supporting the radical scavenger mechanism of 5-aminosalicylic acid.
Topics: Adult; Aged; Aminosalicylic Acids; Biopsy; Colitis, Ulcerative; Colonic Diseases, Functional; Crohn | 1990 |
Long-term use of mesalamine enemas to induce remission in ulcerative colitis.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Drug Therapy, Combination; Enema | 1990 |
Platelet-activating factor--a possible mediator in the pathogenesis of ulcerative colitis.
Topics: Aminosalicylic Acids; Cells, Cultured; Colitis, Ulcerative; Dose-Response Relationship, Drug; Humans | 1990 |
Antiinflammatory effects of various drugs on acetic acid induced colitis in the rat.
Topics: Acetates; Acetic Acid; Aminosalicylic Acids; Animals; Anti-Inflammatory Agents; Colitis, Ulcerative; | 1990 |
[Cryptogenetic ulcerative colitis. Our clinical experience with new therapeutic approaches].
Topics: Adrenal Cortex Hormones; Adult; Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Diagnosis, | 1990 |
Prostaglandin catabolism and ulcerative colitis: effect of sulphasalazine, 5-aminosalicylic acid and other drugs.
Topics: Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Female; Humans; Intestinal Mucosa; Male; Mes | 1990 |
Retrograde spread of mesalazine (5-aminosalicylic acid)-containing enema in patients with ulcerative colitis.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Colon; Enema; Female; Humans; Ma | 1991 |
[Acute alveolitis in ulcerative colitis: extra-intestinal organ complication or drug side effect].
Topics: Adult; Aminosalicylic Acids; Bronchoalveolar Lavage Fluid; Colitis, Ulcerative; Diagnosis, Different | 1991 |
Availability of mesalazine (5-aminosalicylic acid) from enemas and suppositories during steady-state conditions.
Topics: Administration, Rectal; Adult; Aminosalicylic Acids; Biological Availability; Colitis, Ulcerative; D | 1991 |
Misoprostol provides a colonic mucosal protective effect during acetic acid-induced colitis in rats.
Topics: Acetates; Acetic Acid; Alprostadil; Aminosalicylic Acids; Animals; Anti-Ulcer Agents; Betamethasone; | 1990 |
Pharmacokinetics of a 5-aminosalicylic acid enteric-coated tablet in patients with Crohn's disease or ulcerative colitis and in healthy volunteers.
Topics: Adolescent; Adult; Aminosalicylic Acids; Chromatography, High Pressure Liquid; Colitis, Ulcerative; | 1990 |
Cytoprotection against neutrophil derived hypochlorous acid: a potential mechanism for the therapeutic action of 5-aminosalicylic acid in ulcerative colitis.
Topics: Aminosalicylic Acids; Cells, Cultured; Colitis, Ulcerative; Cytotoxicity Tests, Immunologic; Humans; | 1990 |
Acute interstitial nephritis due to 5-aminosalicylic acid.
Topics: Acute Disease; Adult; Aminosalicylic Acids; Colitis, Ulcerative; Humans; Male; Mesalamine; Nephritis | 1990 |
[Mesalazine (5-ASA) in ulcerative colitis].
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Humans; Mesalamine | 1990 |
Pentasa in maintenance treatment of ulcerative colitis.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Humans; Mesalamine | 1990 |
Inflammation in the rectal stump: the role of 5-amino salicylic acid suppositories.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Female; Humans; Inflammation; Male; Mesalamine; Po | 1990 |
5-Aminosalicylic acid and its metabolite in breast milk during lactation.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Female; Humans; Mesalamine; Milk, Human | 1990 |
Role of rectal formulations: enemas.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Enema; Humans; Mesalamine | 1990 |
Acute pancreatitis during oral 5-aminosalicylic acid therapy.
Topics: Acute Disease; Adult; Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Humans; Male; Mesala | 1990 |
Rowasa suspension enema (mesalamine, USP).
Topics: Administration, Rectal; Aminosalicylic Acids; Colitis, Ulcerative; Enema; Humans; Mesalamine | 1989 |
Assessment of salicylate derivatives for potential use in ulcerative colitis: proposal for a new action of 5-aminosalicylic acid?
Topics: Aminosalicylic Acids; Animals; Carbon Dioxide; Colitis, Ulcerative; Colon; Epithelial Cells; Fatty A | 1989 |
Male infertility related to 5-ASA enemas.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Enema; Humans; Infertility, Male; Male; Mesalamine; Sulfa | 1989 |
Sulphasalazine-induced reversible male infertility.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Follicle Stimulating Hormone; Humans; Infertility, | 1989 |
Active moiety of sulfasalazine.
Topics: Aminosalicylic Acids; Chemistry, Pharmaceutical; Colitis, Ulcerative; Humans; Mesalamine; Sulfasalaz | 1989 |
Mesalazine in childhood inflammatory bowel disease.
Topics: Adolescent; Aminosalicylic Acids; Child; Child, Preschool; Colitis, Ulcerative; Crohn Disease; Femal | 1989 |
Quantitative distribution of radiolabeled 5-aminosalicylic acid enemas in patients with left-sided ulcerative colitis.
Topics: Adult; Aged; Aminosalicylic Acids; Animals; Colitis, Ulcerative; Enema; Female; Humans; Male; Mesala | 1989 |
[Acute interstitial nephritis caused by 5-aminosalicylic acid?].
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Humans; Kidney; Kidney Function Tests; Male; Mesal | 1989 |
5-Aminosalicylic acid suppositories in the management of ulcerative colitis.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Drug Administration Schedule; Female; Humans; Male | 1989 |
[Chronic interstitial nephritis after treatment with 5-aminosalicylic acid].
Topics: Adult; Aminosalicylic Acids; Chronic Disease; Colitis, Ulcerative; Humans; Male; Mesalamine; Nephrit | 1989 |
Longterm olsalazine treatment: pharmacokinetics, tolerance and effects on local eicosanoid formation in ulcerative colitis and Crohn's colitis.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Dinoprostone; Fec | 1988 |
Arachidonic acid metabolites and their role in inflammatory bowel disease. An update requiring addition of a pathway.
Topics: Aminosalicylic Acids; Arachidonic Acid; Arachidonic Acids; Biological Transport; Bradykinin; Colitis | 1985 |
Modulation of human colonic arachidonic acid metabolism by sulfasalazine.
Topics: Aminosalicylic Acids; Arachidonic Acid; Arachidonic Acids; Autoradiography; Chromatography, Thin Lay | 1985 |
The value of 5-aminosalicylic acid in inflammatory bowel disease for patients intolerant or allergic to sulphasalazine.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Drug Hypersensitivity; Humans; Mesa | 1985 |
[Exacerbation of ulcerative colitis and Crohn's disease following a change-over from salazosulfapyridine to 5-aminosalicylic acid].
Topics: Adolescent; Adult; Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Female; Humans; Male; M | 1986 |
Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Female; Humans; Kinetics; Male; | 1986 |
Enhanced formation of sulfidopeptide-leukotrienes in ulcerative colitis and Crohn's disease: inhibition by sulfasalazine and 5-aminosalicylic acid.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Humans; Intestinal Mucosa; Kinetics; Leuko | 1986 |
Sulphasalazine in inflammatory bowel disease: recent advances.
Topics: Administration, Oral; Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Enema; Humans; Mesal | 1986 |
[Treatment of chronic inflammatory intestinal diseases with 5-aminosalicylic acid].
Topics: Administration, Oral; Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Enema; Humans; Mesal | 1987 |
Sulphasalazine: drug or pro-drug?
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Humans; Male; Mesalamine; Sulfasalazine | 1987 |
[5-aminosalicylic acid treatment of ulcerative colitis during the acute phase in patients resistant or intolerant to salazopyrine].
Topics: Acute Disease; Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Drug Combinations; Drug Erupt | 1987 |
[Salazosulfapyridine or 5-aminosalicylic acid].
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Enema; Humans; Mesalamine; Sulfasalazine; Suppositories | 1987 |
Azodisalicylate (azodisal sodium) causes intestinal secretion. Comparative study of the effect of azodisalicylate, sulfasalazine, 5-aminosalicylic acid and sulfapyridine on the water and electrolyte transfer and the morphology of the rat ileum and colon i
Topics: Aminosalicylic Acids; Animals; Colitis, Ulcerative; Colon; Ileum; Intestinal Absorption; Intestinal | 1987 |
Sulfasalazine lung. Desensitization to sulfasalazine and treatment with acrylic coated 5-ASA and azodisalicylate.
Topics: Adult; Aminosalicylic Acids; Bronchiolitis Obliterans; Colitis, Ulcerative; Desensitization, Immunol | 1987 |
Sulphasalazine induced seminal abnormalities in ulcerative colitis: results of mesalazine substitution.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Humans; Infertility, Male; Male; Mesalamine; Oligo | 1987 |
Possible mode of action of 5-aminosalicylic acid.
Topics: Aminosalicylic Acids; Arachidonic Acid; Arachidonic Acids; Arthritis, Rheumatoid; Colitis, Ulcerativ | 1987 |
Sulfasalazine-induced abnormal sperm penetration assay reversed on changing to 5-aminosalicylic acid enemas.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Enema; Female; Humans; Infant, Newborn; Infertilit | 1988 |
Pentasa in lieu of sulfasalazine.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Humans; Mesalamin | 1988 |
Disposition of 5-aminosalicylic acid by 5-aminosalicylic acid-delivering compounds.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Delayed-Action Preparations; Female | 1988 |
Adverse effects with oral 5-aminosalicyclic acid.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Desensitization, Immunologic; Drug Hypersensitivit | 1988 |
[Acute manifestations in Crohn disease and ulcerative colitis. Conservative treatment of acute situations].
Topics: Acute Disease; Aminosalicylic Acids; Colitis, Ulcerative; Combined Modality Therapy; Crohn Disease; | 1988 |
Topical administration of 5-aminosalicylic acid: a therapeutic proposal for the treatment of pouchitis.
Topics: Administration, Topical; Adolescent; Adult; Aminosalicylic Acids; Anal Canal; Anastomosis, Surgical; | 1989 |
[Nephritis from 5-aminosalicylic acid].
Topics: Adolescent; Aminosalicylic Acids; Colitis, Ulcerative; Drug Therapy, Combination; Humans; Male; Mesa | 1989 |
Lack of effect of 5-aminosalicylic acid on platelet aggregation and fibrinolytic activity in vivo and in vitro.
Topics: Adult; Aged; Aminosalicylic Acids; beta-Thromboglobulin; Colitis, Ulcerative; Crohn Disease; Fibrino | 1987 |
[Exanthema in 2 patients with ulcerative colitis treated with Pentasa].
Topics: Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Drug Eruptions; Exanthema; Humans; Male; Mes | 1988 |
Evaluation of an enteric-coated delayed-release 5-aminosalicylic acid tablet in patients with inflammatory bowel disease.
Topics: Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Female; Humans; Inflammatory | 1987 |
Nephrotic syndrome after treatment with 5-aminosalicylic acid.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Female; Humans; Mesalamine; Middle Aged; Nephrotic Syndro | 1988 |
[Inflammatory bowel disease; internal therapy].
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Drug Combinations | 1988 |
[Treatment of hemorrhagic rectocolitis with 5-aminosalicylic acid enema].
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Enema; Female; Humans; Male; Mesalamine | 1985 |
5-Aminosalicylic acid in patients with ulcerative colitis in remission: plasma levels after administration of a new rectal enema.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Enema; Female; Humans; Male; Mesalamine; Middle Ag | 1988 |
Inflammatory bowel disease. Options in office management.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acids; Anti-Bacterial Agents; Colitis, Ulcerative; Crohn Dis | 1988 |
[Drug safety, acceptance and effectiveness of 5-aminosalicylic acid (mesalazine) in the treatment of ulcerative colitis and Crohn disease].
Topics: Administration, Oral; Adolescent; Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Crohn Dise | 1988 |
[Ulcerative colitis. Activity index for the clinical and histological classification of inflammatory activity].
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Female; Humans; Inflammation; Male; Mesalamine; Pr | 1988 |
Hypersensitivity to 5-aminosalicylic acid in patients with ulcerative colitis.
Topics: Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Drug Hypersensitivity; Female; Humans; Male; | 1987 |
5-Aminosalicylic acid enemas in refractory distal ulcerative colitis: long-term results.
Topics: Adolescent; Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Drug Administration Schedule; En | 1987 |
[Ulcerative colitis. Evaluation of a newly developed activity index within the scope of a therapeutic study of mesalazin].
Topics: Adult; Aged; Aminosalicylic Acids; Colitis, Ulcerative; Colon; Colonoscopy; Female; Humans; Male; Me | 1987 |
Salicylate induced exacerbation of ulcerative colitis.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Female; Humans; Male; Mesalamine; Middle Aged | 1987 |
Effect of polymer coating on faecal recovery of ingested 5-amino salicylic acid in patients with ulcerative colitis.
Topics: Acrylic Resins; Aminosalicylic Acids; Colitis, Ulcerative; Feces; Humans; Mesalamine; Polymethacryli | 1987 |
5-ASA enemas for refractory distal ulcerative colitis. An open trial.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Drug Administration Schedule; Drug Therapy, Combin | 1987 |
Asacol: mesalazine for ulcerative colitis.
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Humans; Mesalamine | 1986 |
Retrograde spread of 5-aminosalicylic acid enemas in patients with active ulcerative colitis.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Enema; Female; Humans; Male; Mesalamine; Middle Ag | 1986 |
Topical administration of 5-aminosalicylic acid enemas in patients with ulcerative colitis. Studies on rectal absorption and excretion.
Topics: Administration, Topical; Aminosalicylic Acids; Colitis, Ulcerative; Enema; Humans; Intestinal Absorp | 1985 |
Five-aminosalicylic acid enemas in treatment of ulcerative colitis.
Topics: Adult; Aminosalicylic Acids; Colitis, Ulcerative; Enema; Female; Humans; Male; Mesalamine; Middle Ag | 1985 |
[5-amino-salicylic acid. A review of a new treatment of chronic inflammatory bowel disease].
Topics: Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Humans; Intestinal Diseases; Mesalamine | 1985 |